<SEC-DOCUMENT>0001193125-21-293688.txt : 20211007
<SEC-HEADER>0001193125-21-293688.hdr.sgml : 20211007
<ACCEPTANCE-DATETIME>20211007071248
ACCESSION NUMBER:		0001193125-21-293688
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20211007
DATE AS OF CHANGE:		20211007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		211311046

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d185056d20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:kzia="http://www.kaziatherapeutics.com/20210630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 20-F</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P07_01_2020To06_30_2021">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P07_01_2020To06_30_2021">FY</ix:nonNumeric><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" id="hidden26941597" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" sign="-">8810000</ix:nonFraction><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" id="hidden26941709" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" sign="-">9111000</ix:nonFraction><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P07_01_2020To06_30_2021">0001075880</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P07_01_2020To06_30_2021">--06-30</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941445" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-09-05</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941446" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-10-17</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941447" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-11-01</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941448" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-11-23</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941449" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2022-08-07</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941451" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941452" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941453" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941454" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-11-09</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941455" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-11-09</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941456" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-11-09</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941457" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-11-09</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941458" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941459" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941460" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941461" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941368" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941369" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941371" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941372" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941592" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2023-02-05</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941373" contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2020-11-16</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941375" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-10-17</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941376" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-11-01</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941377" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-11-23</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941378" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2022-08-07</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941379" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2023-02-05</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941380" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941381" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941382" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941383" contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941384" contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941385" contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941591" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-09-05</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941585" contextRef="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2023-02-05</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941586" contextRef="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941587" contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2024-01-04</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941588" contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2025-01-13</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941600" contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2019-12-16</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941602" contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2019-12-18</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941603" contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2020-06-30</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941605" contextRef="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2020-11-16</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941606" contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-02-01</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941607" contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-02-01</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941608" contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-02-01</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941609" contextRef="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-09-05</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941610" contextRef="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-10-17</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941611" contextRef="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-11-01</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941612" contextRef="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2021-11-23</ix:nonNumeric><ix:nonNumeric name="kzia:ShareBasedPaymentArrangementOptionsExpiryDate" id="hidden26941613" contextRef="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">2022-08-07</ix:nonNumeric><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" id="hidden26941594" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3">0.492</ix:nonFraction><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" id="hidden26941595" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3">0.492</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="kzia-20210630.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P07_01_2020To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_14_2016" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2016" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2016To06_30_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-07-01</xbrli:startDate> <xbrli:endDate>2017-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_AUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_LicensingRevenueMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >kzia:LicensingRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis" >ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >kzia:LicensingRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_SwedanMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >kzia:SwedanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To06_30_2019_CNifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CN</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_AUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaLaboratoriesPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaResearchPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:GlioblastPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:OtherTrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >kzia:ShortTermDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >kzia:CashAtBankAndInHandMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_IssueDateSixteenthAprilTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis" >kzia:IssueDateSixteenthAprilTwoThousandAndTwentyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_IssueDatedNovemberOneTwoThousandAndNineteenMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis" >kzia:IssueDatedNovemberOneTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ShareIssueTransactionCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheElevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_LicensingRevenueMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >kzia:LicensingRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis" >ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >kzia:LicensingRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_SwedanMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >kzia:SwedanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_CNifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CN</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAvailableforsaleCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaLaboratoriesPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaResearchPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:GlioblastPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis" >kzia:KaziaTherapeuticsHongKongLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:EVT801LicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_EvotechLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:EvotechLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_AUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_UnlistedOptionsMemberifrsfullClassesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis" >kzia:UnlistedOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TranchesTwoAndEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TranchesTwoAndEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TranchesTenAndTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TranchesTenAndTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_BottomOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >kzia:ShortTermDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis" >kzia:CashAtBankAndInHandMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:IssuedOnAchievementOfAMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis" >kzia:IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedFifteenthMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis" >kzia:IssueDatedFifteenthMarchTwoThousandTwentyOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedSecondMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis" >kzia:IssueDatedSecondMarchTwoThousandTwentyOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:RetailPlacementUnderAnreoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:InstitutionalPlacementUnderAnreoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDateTwentyEightAugustTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis" >kzia:IssueDateTwentyEightAugustTwoThousandAndTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >kzia:ResearchAndDevelopmentTaxIncentiveProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_TopOfRangeMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" >kzia:ResearchAndDevelopmentTaxIncentiveProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_LicenseAgreementForPaxalisibMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:LicenseAgreementForPaxalisibMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_LicensingAgreementForEvtEightZeroOneMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:LicensingAgreementForEvtEightZeroOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ShareIssueTransactionCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheElevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSeventeenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="kzia:FundingPurposeAxis" >kzia:ClinicalTrialsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kzia:UncertainityAxis" >kzia:CovidNinteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_LicensingRevenueMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >kzia:LicensingRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis" >ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis" >kzia:LicensingRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_SwedanMemberifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >kzia:SwedanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_CNifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:CN</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_MilestoneTwoMemberifrsfullClassesOfContingentLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis" >kzia:MilestoneTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >kzia:GlioblastPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_GenentechAgreementMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >kzia:GenentechAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_ResearchAndDevelopmentTaxRebateReceivableMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >kzia:ResearchAndDevelopmentTaxRebateReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:LicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >kzia:DepositsHeldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_InterestRateRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:DecreaseInMarketRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:IncreaseInMarketRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis" >kzia:ContingentConsiderationPaxalisibMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:LicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:LicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:LicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >ifrs-full:LicencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis" >ifrs-full:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >kzia:DepositsHeldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" >ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_InterestRateRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:InterestRateRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis" >ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis" >ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:DecreaseInMarketRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:DecreaseInMarketRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:IncreaseInMarketRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:IncreaseInMarketRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis" >currency:EUR</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis" >kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis" >ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheElevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ContingentConsiderationEvt801MemberifrsfullClassesOfContingentLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis" >kzia:ContingentConsiderationEvt801Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis" >kzia:ContingentConsiderationPaxalisibMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_USifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_AUifrsfullGeographicalAreasAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2017_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis" >kzia:GlioblastPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2019To11_01_2019_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-01</xbrli:startDate> <xbrli:endDate>2019-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_16_2020To04_16_2020_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-16</xbrli:startDate> <xbrli:endDate>2020-04-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_11_2020To05_11_2020_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-11</xbrli:startDate> <xbrli:endDate>2020-05-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_28_2020To08_28_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-08-28</xbrli:startDate> <xbrli:endDate>2020-08-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_12_2020To10_12_2020_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:InstitutionalPlacementUnderAnreoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-12</xbrli:startDate> <xbrli:endDate>2020-10-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_26_2020To10_26_2020_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:RetailPlacementUnderAnreoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-26</xbrli:startDate> <xbrli:endDate>2020-10-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_02_2021To03_02_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-02</xbrli:startDate> <xbrli:endDate>2021-03-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_15_2021To03_15_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-15</xbrli:startDate> <xbrli:endDate>2021-03-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_28_2021To04_28_2021_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:SharePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-28</xbrli:startDate> <xbrli:endDate>2021-04-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_21_2021To05_21_2021_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:IssuedOnAchievementOfAMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-21</xbrli:startDate> <xbrli:endDate>2021-05-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2021To06_30_2021_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ShareIssueTransactionCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-30</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2021To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:ConversionOfOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-30</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="kzia:FundingPurposeAxis" >kzia:ClinicalTrialsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kzia:UncertainityAxis" >kzia:CovidNinteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis" >ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheElevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheElevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFourteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSixteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis" >ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:EVT801LicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis" >kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheSeventeenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis" >kzia:TrancheNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherReservesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis" >ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001075880</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis" >ifrs-full:FinancialAssetsAvailableforsaleCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis" >ifrs-full:AtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_AUD" > <xbrli:measure>iso4217:AUD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segments" > <xbrli:measure>kzia:Segments</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_AUD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:AUD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Major_Customer" > <xbrli:measure>kzia:Major_Customer</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Milestone" > <xbrli:measure>kzia:Milestone</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">WASHINGTON, D.C. 20549 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P07_01_2020To06_30_2021">20-F</ix:nonNumeric></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Mark One) </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="P07_01_2020To06_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P07_01_2020To06_30_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P07_01_2020To06_30_2021" format="ixt:datemonthdayyearen">June 30, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P07_01_2020To06_30_2021">2021</ix:nonNumeric></ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P07_01_2020To06_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentShellCompanyReport" contextRef="P07_01_2020To06_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Date of event requiring this shell company report <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission file number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P07_01_2020To06_30_2021">0-29962</ix:nonNumeric></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P07_01_2020To06_30_2021">Kazia Therapeutics Limited</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">ACN 063 259 754 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not Applicable </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Translation of Registrant&#8217;s name into English) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New South Wales, <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2020To06_30_2021" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Jurisdiction of incorporation or organization) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P07_01_2020To06_30_2021">Three International Towers Level 24, 300 Barangaroo Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P07_01_2020To06_30_2021">Sydney</ix:nonNumeric>, New South Wales <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P07_01_2020To06_30_2021">2000</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P07_01_2020To06_30_2021" format="ixt-sec:countrynameen">Australia</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address of principal executive offices) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Gabrielle Heaton</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(e)<ix:nonNumeric name="dei:ContactPersonnelEmailAddress" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Gabrielle.Heaton@kaziatherapeutics.com</ix:nonNumeric> (t) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">+<ix:nonNumeric name="dei:CountryRegion" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">61</ix:nonNumeric>-<ix:nonNumeric name="dei:CityAreaCode" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">2</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">9472-4101</ix:nonNumeric></div></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Three International Towers Level 24, 300 Barangaroo Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Sydney</ix:nonNumeric>, New South Wales <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">2000</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:countrynameen">Australia</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(Name, Telephone, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-mail</div> and/or Facsimile number and Address of Company Contact Person) </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Symbol(s)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange on which registered</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P07_01_2020To06_30_2021">American Depositary Shares, each representing ten<br/> Ordinary Shares*</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P07_01_2020To06_30_2021">KZIA</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P07_01_2020To06_30_2021" format="ixt-sec:exchnameen">The NASDAQ Stock Market</ix:nonNumeric></div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not for trading, but only in connection with the registration of American Depositary Shares. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not Applicable </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of outstanding Ordinary Shares of the issuer as at June&#160;30, 2021, was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">132,012,209</ix:nonFraction>. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P07_01_2020To06_30_2021">No</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#9746;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P07_01_2020To06_30_2021">No</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#9746;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P07_01_2020To06_30_2021">Yes</ix:nonNumeric><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#9746; &#160; &#160; &#160; &#160; &#160; &#160;No &#160;&#9744;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P07_01_2020To06_30_2021">Yes</ix:nonNumeric><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#9746; &#160; &#160; &#160; &#160; &#160; &#160;No &#160;&#9744;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, or an emerging growth company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act: </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Large accelerated&#160;filer&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated&#160;filer&#160;&#160;&#9744;<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P07_01_2020To06_30_2021" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P07_01_2020To06_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P07_01_2020To06_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 67%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.&#160;GAAP&#160;&#160;&#9744;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentAccountingStandard" contextRef="P07_01_2020To06_30_2021">International Financial Reporting Standards</ix:nonNumeric> as issued</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by the International Accounting Standards Board&#160;&#160;&#9746;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:right;">Other&#160;&#160;&#9744;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If &#8216;Other&#8217; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 17&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;&#9744; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act). </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P07_01_2020To06_30_2021" format="ixt:booleanfalse">&#9746;</ix:nonNumeric> </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc185056_1">FORWARD-LOOKING STATEMENTS</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc185056_2">PART&#160;I</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;1.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_3">Identity of Directors, Senior Management and Advisors</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 2.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_4">Offer Statistics and Expected Timetable</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 3.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_5">Key Information</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 4.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_6">Information on the Company</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">11</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 4A.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_7">Unresolved Staff Comments</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">21</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 5.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_8">Operating and Financial Review and Prospects</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">21</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 6.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_9">Directors, Senior Management and Employees</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">25</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 7.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_10">Major Shareholders and Related Party Transactions</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">34</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 8.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_11">Financial Information</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">35</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 9.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_12">The Offer and Listing</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">35</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 10.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_13">Additional Information</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">35</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 11.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_14">Quantitative and Qualitative Disclosures about Market Risk</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">46</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 12.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_15">Description of Securities Other than Equity Securities</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">47</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc185056_16">PART II</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">48</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 13.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_17">Defaults, Dividend Arrearages and Delinquencies</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">48</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 14.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_18">Material Modifications to the Rights of Security Holders and the Use of Proceeds</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">48</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 15.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_19">Controls and Procedures</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">48</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 16.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_20">[Reserved]</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">48</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16A.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_21">Audit Committee Financial Expert</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">48</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16B.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_22">Code of Ethics</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">49</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16C.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_23">Principal Accounting Fees and Services</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">49</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16D.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_24">Exemptions from the Listing Standards for Audit Committees</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">49</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16E.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_25">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">49</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16F.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_26">Changes in registrant&#8217;s Certifying Accountant</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">49</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16G.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_27">Corporate Governance</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">50</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item&#160;16H.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_28">Mine Safety Disclosure</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc185056_29">PART III</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 17.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_30">Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 18.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_31">Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Item 19.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><a href="#toc185056_32">Exhibits</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">51</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc185056_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FORWARD-LOOKING STATEMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> includes forward-looking statements, which involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; or &#8220;opportunity,&#8221; the negative of these words or other similar words. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects and other statements that are not historical facts are also forward-looking statements. Discussions containing these forward-looking statements may be found, among other places, in &#8220;Business Overview&#8221; and &#8220;Operating and Financial Review and Prospects&#8221; in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995 and section 27A of the Securities Act and Section&#160;21E of the Exchange Act. Readers of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the time this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> was filed with the Securities and Exchange Commission, or SEC. These forward-looking statements are based largely on our expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, without limitation, those discussed in &#8220;Risk Factors&#8221; and in &#8220;Operating and Financial Review and Prospects&#8221; of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> In addition, past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Except as required by law, we undertake no obligation to update publicly or revise our forward-looking statements to reflect events or circumstances that arise after the filing of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F,</div> &#8220;Kazia,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Kazia Therapeutics Limited and its wholly owned subsidiaries on a consolidated basis, unless the context otherwise provides. </div> <div id="toc185056_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_3" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identity of Directors, Senior Management and Advisors </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 1 details are not required to be disclosed as part of the Annual Report. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_4" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offer Statistics and Expected Timetable </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 2 details are not required to be disclosed as part of the Annual Report. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_5" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key Information </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. Selected financial data </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">[Reserved] </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Capitalization and Indebtedness. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Reasons for the Offer and Use of Proceeds. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">D. Risk factors </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in our securities involves a high degree of risk. You should consider carefully the risks described below, together with other information in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> and our other public filings, before making investment decisions regarding our securities. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. Moreover, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Financial Condition and Capital Requirement </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have incurred significant net losses. We anticipate that we will continue to incur significant net losses for the foreseeable future and we may never achieve or maintain profitability. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a biotechnology company and have not yet generated significant revenue. We have incurred losses of A$10.3&#160;million, A$12.5&#160;million and A$8.4&#160;million for the fiscal years ended June&#160;30, 2019, 2020 and 2021, respectively. We have not generated any revenues from sales of any of our product candidates in prior financial years, however in the fiscal year ended June&#160;30, 2021 we did generate revenues of A$15.2&#160;million from the licensing of our drug products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we had accumulated losses of A$44.2&#160;million. We have devoted most of our financial resources to research and development, including our clinical development activities. To date, we have financed our operations primarily through the issuance of equity securities, research and development grants from the Australian government and payments from our collaboration partners. While we have generated significant revenue this fiscal year from license transactions, the nature of such revenue is irregular and unpredictable, and is based upon achievement of milestones over which we have limited or no control. As a consequence, we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development including clinical trials and the regulatory approval process for product candidates. The amount of our future net losses is uncertain and will depend, in part, on the rate of our future expenditures. Our ability to continue operations will depend on, among other things, our ability to obtain funding through equity or debt financings, strategic collaborations or grants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to continue to incur significant expenses and similar or increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continue our research and clinical development of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expand the scope of our current clinical studies for our product candidates or initiate additional clinical or other studies for product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">further develop the manufacturing process for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">change or add additional manufacturers or suppliers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek to identify and validate additional product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> other product candidates and technologies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain, protect and expand our intellectual property portfolio; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">create additional infrastructure to support our operations as a public company in the United States and our product development and future commercialization efforts; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">experience any delays or encounter issues with any of the above. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The net losses we incur may fluctuate significantly from year to year, such that a period <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to-period</div> comparison of our results of operations may not be a good indication of our future performance. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have never generated any revenue from product sales and may never be profitable. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to generate significant revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of and obtain the regulatory approvals for our product candidates, to manufacture sufficient supply of our product candidates, to establish a sales and marketing organization or suitable third-party alternative for the marketing of any approved products and to successfully commercialize any approved products on commercially reasonable terms. All of these activities will require us to raise sufficient funds to finance business activities. In addition, we do not anticipate generating revenue from commercializing product candidates for the foreseeable future, if ever. Our ability to generate future revenues from commercializing product candidates depends heavily on our success in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully initiating and completing clinical trials of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintaining, protecting and expanding our intellectual property portfolio, and avoiding infringing on intellectual property of third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing and maintaining successful licenses, collaborations and alliances with third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developing a sustainable, scalable, reproducible and transferable manufacturing process for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing and maintaining supply and manufacturing relationships with third parties that can provide products and services adequate, in amount and quality, to support clinical development and commercialization of our product candidates, if approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">launching and commercializing any product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining market acceptance of any product candidates that receive regulatory approval as viable treatment options; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining favorable coverage and reimbursement rates for our products from third-party payers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">addressing any competing technological and market developments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identifying and validating new product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if one or more of our product candidates is approved for commercial sale, we may incur significant costs associated with commercializing any approved product candidate. As one example, our expenses could increase beyond expectations if we are required by the Food and Drug Administration, or FDA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations, which could have an adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company is currently conducting clinical trials of two experimental therapies. Failure of one or both of these therapies to show benefit to patients could materially affect the continuity of our business and our financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s lead programs include paxalisib (formerly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GDC-0084),</div> a small molecule inhibitor of the PI3K/Akt/mTor pathway, and EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). However, even though progress has been made, such as the clinical validation of the PI3K/Akt/mTor pathway as a target for oncology therapies, developments of our product candidates may prove unsuccessful, after completion of clinical trials, due to any failure to provide any beneficial effect to cancer patients. It is possible that either or both agents may fail to show sufficient benefit as a treatment for cancer to become commercially viable products. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company has ongoing clinical trials in which experimental therapies are administered to human subjects. If profound and unexpected safety concerns are encountered in clinical trials, it may materially affect the continuity of our business and our financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite all applicable efforts to characterise the safety profile of our drug development candidates through animal studies and other mechanisms, the possibility of unexpected safety concerns remains. If one or both of our clinical stage candidates were found to be associated with profound and unexpected toxicity, Kazia may be required to cease development, and may additionally incur other impairments to the business including reputational damage. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise capital to support its R&amp;D programs. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has limited cash resources and will periodically need additional funds to maintain the planned level of R&amp;D activity. We expect to consume cash and incur operating losses for the foreseeable future as the Company continues developing its oncology drug candidates. The impact on cash resources and results from operations will vary with the extent and timing of future clinical trial programs. While it is not possible to make accurate predictions of future operating results, we expect existing cash and cash equivalents will be sufficient to enable us to continue our research and development activities until approximately the final quarter of calendar 2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at June&#160;30, 2021, we had cash in hand and at bank of A$27.6&#160;million. The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, our ability to continue as a going concern is dependent upon our ability to derive sufficient cash from investors, from licensing and partnering activities and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and are confident that the strategies in place are appropriate to generate sufficient funding to allow us to continue as a going concern. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to obtain additional funds on favorable terms or at all, it may be required to cease or reduce its operations. Also, if the Company raises more funds by selling additional securities, the ownership interests of holders of its securities will be diluted. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Negative global economic conditions may pose challenges to the Company&#8217;s business strategy, which relies on access to capital from the markets or collaborators. Failure to obtain sufficient funding on acceptable terms could have a material adverse effect on our business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Negative conditions in the global economy, including credit markets and the financial services industry, have generally made equity and debt financing more difficult to obtain, and may negatively impact the Company&#8217;s ability to complete financing transactions. For instance, the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic has negatively affected the global economy and has created uncertainties in the financial markets and volatility in stock markets, which increases the risk of capital raisings being unsuccessful for issuers that need funds to finance their business operations. The duration and severity of these conditions is uncertain, as is the extent to which they may adversely affect the Company&#8217;s business and the business of current and prospective vendors and collaborators. If negative global economic conditions persist or worsen, the Company may be unable to secure additional funding to sustain its operations or to find suitable collaborators to advance its internal programs, even if positive results are achieved from research and development efforts. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to raise sufficient funding on acceptable terms, we may be unable to continue to operate. There is no assurance that we will be successful in obtaining sufficient financing on acceptable terms and conditions to fund continuing operations, if at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not successfully engage in strategic transactions or enter into new collaborations, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">From time to time, we may consider additional strategic transactions, such as collaborations, acquisitions, asset purchases or sales <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;out-&#160;or&#160;in-licensing&#160;of</div></div> product candidates or technologies. In particular we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborators is significant, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new or existing collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator discontinues the collaboration. Any such collaboration, or other strategic transaction, may require us to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">incur&#160;non-recurring&#160;or</div> other charges, increase our expenditures, pose significant integration or implementation challenges or disrupt our management or business. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay and make more expensive the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success largely depends on the continued service of key management and other specialized personnel. The loss of one or more members of our management team or other key employees or advisors could delay or increase the cost of our research and development programs and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and the specialized nature of the regulatory approval process for our product candidates. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our collaborations with outside scientists and consultants may be subject to restriction and change. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We work with medical experts, chemists, biologists and other scientists at academic and other institutions, and consultants who assist us in our research, development and regulatory efforts, including the members of our scientific advisory board. In addition, these scientists and consultants have provided, and we expect that they will continue to provide, valuable advice regarding our programs and regulatory approval processes. These scientists and consultants are not our employees and may have other commitments that would limit their future availability to us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, we are limited in our ability to prevent them from establishing competing businesses or developing competing products. For example, if a key scientist acting as a principal investigator in any of our future clinical trials identifies a potential product or compound that is more scientifically interesting to his or her professional interests, his or her availability to remain involved in any future clinical trials could be restricted or eliminated. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The use of our product candidates in clinical trials and the sale of any products for which we may in the future obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impairment of our business reputation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of clinical trial participants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs due to related litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distraction of management&#8217;s attention from our primary business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to patients or other claimants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to commercialize our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for our product candidates, if approved for commercial sale; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased cost, or impairment of our ability, to obtain or maintain product liability insurance coverage. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may use our limited financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our internal computer and information technology systems, or those of our collaborators and other development partners, third-party Contract Research Organisations (CROs) or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our product development programs. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite the implementation of security measures, our internal computer and information technology systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cyber-attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. While we have not experienced any material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials or data from preclinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and will rely on third parties to conduct future clinical trials, and similar events relating to their computer systems could also have similar consequences to our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed and become more expensive. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ability to utilize our net operating losses and certain other tax attributes may be limited. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have substantial carried forward tax losses which may not be available to offset any future assessable income. In order for an Australian corporate taxpayer to carry forward and utilize tax losses, the taxpayer must pass either the continuity of ownership test, or, if it fails the COT, the same business test (&#8220;SBT&#8221;), or similar business test, in respect of relevant tax losses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not carried out any analysis as to whether we have met the COT or, failing the COT, the SBT or similar business test over relevant periods.&#160;In addition, future shareholding changes may result in a significant ownership change for us. It is therefore uncertain as to whether any of our tax losses carried forward as of June&#160;30, 2021 will be available to be carried forward and available to offset our assessable income, if any, in future periods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Product Development and Regulatory Approval of Our Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to obtain orphan drug exclusivity, where relevant, in all markets for our product candidates. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. The FDA may also designate a product as an orphan drug if it is intended to treat a disease or condition of more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product candidate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for such indication for that time period. The applicable period is seven years in the United States. Orphan drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2018, the FDA granted orphan drug designation status in the United States for paxalisib (formerly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GDC-0084)</div> for the treatment of glioblastoma, and in August 2020, the FDA granted orphan drug designation status in the United States for paxalisib (formerly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GDC-0084)</div> for the treatment of malignant glioma, which includes DIPG, a rare and highly aggressive childhood brain cancer. Even if we obtain orphan drug exclusivity for additional products in the United States or other jurisdictions, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition, and the same drug could be approved for a different condition. Moreover, even after an orphan drug is approved, the FDA can subsequently approve the same drug, made by a competitor, for the same condition if the FDA concludes that the competitive product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Positive results from preclinical studies of our product candidates are not necessarily predictive of the results of our planned clinical trials of our product candidates. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Positive results in preclinical proof of concept and animal studies of our product candidates may not result in positive results in clinical trials in humans. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical development or early stage clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory authority approval. If we fail to produce positive results in our clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be negatively impacted. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if the Company receives regulatory approval to commercialize its drug candidates, the ability to generate revenues from any resulting products will be subject to a variety of risks, many of which are out of the Company&#8217;s control. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regardless of regulatory approval, products arising from the development process may not gain market acceptance among physicians, patients, healthcare payers or the medical community. The Company believes that the degree of market acceptance and its ability to generate revenues from such products will depend on a number of factors, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advancements in the treatment of cancer that make our treatments obsolete; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market exclusivity and competitor products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">timing of market introduction of the Company&#8217;s drugs and competitive drugs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual and perceived efficacy and safety of the Company&#8217;s drug candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prevalence and severity of any side effects; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential or perceived advantages or disadvantages over alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">strength of sales, marketing and distribution support; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">price of future products, both in absolute terms and relative to alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effect of current and future healthcare laws on the Company&#8217;s drug candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability of coverage and reimbursement from government and other third-party payers. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the Company&#8217;s drugs are approved and fail to achieve market acceptance, the Company may not be able to generate significant revenue to achieve or sustain profitability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Commercialization of Our Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company may not be able to establish the contractual arrangements necessary to develop, market and distribute the product candidates. Our failure to do so may adversely affect our business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has been successful in executing contractual agreements with strategic partners. This remains a key part of the Company&#8217;s business plan and the Company must continue to partner with third parties to manufacture clinical grade drug product and conduct key <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical investigations. Strategic agreements around packaging, branding, market access and distribution for its drug products will also eventually be required. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, potential partners could be discouraged by the Company&#8217;s limited operating history. There is no assurance that the Company will be able to negotiate commercially acceptable licensing or other agreements for the future exploitation of its drug product candidates including continued clinical development, manufacture or marketing. If the Company is unable to successfully contract for these services, or if arrangements for these services are terminated, the Company may have to delay the commercialization program which will adversely affect its ability to generate operating revenues. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side effects or are less expensive than its drug candidates. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The development of drug candidates is highly competitive and is high risk. A number of other companies have products or drug candidates in various stages of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or clinical development that are intended for the same therapeutic indications for which the Company&#8217;s drug candidates are being developed. Some of these potential competing drugs are further advanced in development than the Company&#8217;s drug candidates and may be commercialized sooner. Even if the Company is successful in developing effective drugs, its compounds may not compete successfully with products produced by its competitors. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. In addition, companies active in different but related fields represent substantial competition. Many of the Company&#8217;s competitors developing oncology drugs have significantly greater capital resources, larger R&amp;D staff and facilities and greater experience in drug development, regulation, manufacturing and marketing. These organizations also compete with the Company and its service providers, to recruit qualified personnel, and to attract partners for joint ventures and to license technologies. As a result, the Company&#8217;s competitors may be able to develop technologies and products that would render the Company&#8217;s technologies or its drug candidates obsolete or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect intellectual property rights related to our product candidates, we may not be able to obtain exclusivity for our product candidates or prevent others from developing similar competitive products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We rely upon a combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">patents,&#160;know-how,&#160;trade</div> secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;in-license&#160;may</div> fail to result in issued patents with claims that cover our product candidates in the United States or other jurisdictions. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interference,&#160;re-examination,&#160;post-grant</div> review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Furthermore, even if our patents and patent applications are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the patent applications we hold or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">have&#160;in-licensed&#160;with</div> respect to our programs or product candidates fail to issue, or are revoked, if the breadth or strength of our patent protection is threatened, or if our patent portfolio fails to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates and threaten our ability to commercialize future products. Any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. This risk is material in light of the length of the development process of our products and lifespan of our current patent portfolio. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proprietary&#160;know-how&#160;that</div> is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proprietary&#160;know-how,&#160;information</div> or technology that is not covered by patents. However, trade secrets can be difficult to protect. What constitutes a trade secret and what protections are available for trade secrets varies from state to state in the United States and country by country worldwide. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. Security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various corresponding governmental patent agencies outside of the United States require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our success depends, in part, on our ability to protect our intellectual property and our technologies. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success depends, in part, on our ability to obtain and maintain patent and trade secret protection for our technologies, our traits, and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Filing, prosecuting and defending patents on product candidates in all countries around the world would be prohibitively expensive. In addition, we may at times <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> third-party technologies for which limited international patent protection exists and for which the time period for filing international patent applications has passed. Consequently, we may not be able to prevent third parties from practicing our inventions, or from selling or importing products made using our inventions. Potential competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement is difficult. These products may compete with our product candidates, if approved, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies have encountered significant problems in protecting and defending intellectual property rights around the world. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Reliance on Third Parties </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company relies on third parties to conduct its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies. If those parties do not successfully carry out their contractual duties or meet expected deadlines, the Company&#8217;s drug candidates may not advance in a timely manner or at all. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the course of discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing and clinical trials, the Company relies on third parties, including laboratories, investigators, clinical contract research organizations (&#8220;CROs&#8221;), and manufacturers, to perform critical services. For example, the Company relies on third parties to conduct all of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical studies. These third parties may not be available when the Company needs them or, if they are available, may not comply with all regulatory and contractual requirements or may not otherwise perform their services in a timely or acceptable manner, and the Company may need to enter into new arrangements with alternative third parties and the studies may be extended, delayed or terminated. These independent third parties may also have relationships with other commercial entities, some of which may compete with the Company. As a result of the Company&#8217;s dependence on third parties, it may face delays or failures outside of its direct control. These risks also apply to the development activities of collaborators, and the Company does not control their research and development, clinical trial or regulatory activities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company has no direct control over the cost of manufacturing its drug candidates. Increases in the cost of manufacturing the Company&#8217;s drug candidates would increase the costs of conducting clinical trials and could adversely affect future profitability. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company does not intend to manufacture the drug product candidates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house,</div> and it will rely on third parties for drug supplies both for clinical trials and for commercial quantities in the future. The Company has taken the strategic decision not to manufacture active pharmaceutical ingredients (&#8220;API&#8221;) for the drug candidates, as these can be more economically supplied by third parties with particular expertise in this area. The Company outsources the manufacture of its drug products and their testing to FDA requirements. The Company uses contract facilities that are registered with the FDA, have a track record of large-scale API manufacture, and have already invested in capital and equipment. The Company has no direct control over the cost of manufacturing its product candidates. If the cost of manufacturing increases, or if the cost of the materials used increases, these costs may be passed on, making the cost of conducting clinical trials more expensive. Increases in manufacturing costs could adversely affect the Company&#8217;s future profitability if it was unable to pass all of the increased costs along to its customers. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to our Securities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Enforceability of civil liabilities under the federal securities laws against the Company or the Company&#8217;s officers and directors may be difficult. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a public company limited by shares and is registered and operates under the Australian Corporations Act 2001. Some of the Company&#8217;s directors and officers reside outside of the United States. In addition, a substantial portion of the directly owned assets of the Company are located outside of the United States. As a result, it may be difficult or impossible for investors to effect service of process within the United States against the Company or its directors and officers or to enforce against them any of the judgments, including those obtained in original actions or in actions to enforce judgments of the U.S. courts, predicated upon the civil liability provisions of the federal or state securities laws of the United States. There is doubt as to the enforceability in the Commonwealth of Australia, in original actions or in actions for enforcement of judgments of U.S. courts, of civil liabilities predicated solely upon federal or state securities laws of the U.S., especially in the case of enforcement of judgments of U.S. courts where the defendant has not been properly served in Australia. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The trading price of the Company&#8217;s ordinary shares and American Depositary Shares (&#8220;ADSs&#8221;) is highly volatile. Your investment could decline in value and the Company may incur significant costs from class action litigations. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading price of the Company&#8217;s ordinary shares and ADSs is highly volatile in response to various factors, many of which are beyond the Company&#8217;s control, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unacceptable toxicity findings in animals and humans; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lack of efficacy in human trials at Phase II stage or beyond; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements of technological innovations by the Company and its competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">new products introduced or announced by the Company or its competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in financial estimates by securities analysts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual or anticipated variations in operating results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expiration or termination of licenses, research contracts or other collaboration agreements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conditions or trends in the regulatory climate in the biotechnology, pharmaceutical and genomics industries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in the market values of similar companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the liquidity of any market for the Company&#8217;s securities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional sales by the Company of its shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, equity markets in general and the market for biotechnology and life sciences companies in particular, have experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the companies traded in those markets. Further changes in economic conditions in Australia, the U.S., EU, or globally, could impact the Company&#8217;s ability to grow profitably. Adverse economic changes are outside the Company&#8217;s control and may result in material adverse effects on the Company&#8217;s business or results of operations. These broad market and industry factors may materially affect the market price of the Company&#8217;s ordinary shares and ADSs regardless of its development and operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted against that company. Such litigation, if instituted against the Company, could cause it to incur substantial costs and divert management&#8217;s attention and resources. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the market price of the Company&#8217;s ADSs falls and remains below US$5.00 per share, under stock exchange rules, the Company&#8217;s stockholders will not be able to use such ADSs as collateral for borrowing in margin accounts. This inability to use ADSs as collateral may depress demand as certain institutional investors are restricted from investing in securities priced below US$5.00 and may lead to sales of such ADSs, creating downward pressure on and increased volatility in the market price of the Company&#8217;s ordinary shares and ADSs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A decrease in the trading price of our ADSs could cause their delisting from NASDAQ. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under NASDAQ rules, companies listed on the NASDAQ Capital Market are required to maintain a share price of at least US$1.00 per share to avoid delisting of their shares. If the share price declines below US$1.00 for a period of 30 consecutive business days, then that listed company would have 180 days to regain compliance with the US$1.00 per share minimum. In the event that the Company&#8217;s share price declines below US$1.00, it may be required to take action, such as a reverse stock split, in order to comply with the NASDAQ rules that may be in effect at the time. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You are reliant on the depositary to exercise your voting rights and to receive distributions on ADSs and, as a result, you may be unable to exercise your voting rights on a timely basis or you may not receive certain distributions. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In certain circumstances, holders of ADSs may have limited rights relative to holders of ordinary shares. The rights of holders of ADSs with respect to the voting of ordinary shares and the right to receive certain distributions may be limited in certain respects by the deposit agreement entered into by us and The Bank of New York Mellon. For example, although ADS holders are entitled under the deposit agreement, subject to any applicable provisions of Australian law and of our Constitution, to instruct the depositary as to the exercise of the voting rights pertaining to the ordinary shares represented by the ADSs, and the depositary has agreed that it will try, as far as practical, to vote the ordinary shares so represented in accordance with such instructions, ADS holders may not receive notices sent by the depositary in time to ensure that the depositary will vote the ordinary shares. This means that, from a practical point of view, the holders of ADSs may not be able to exercise their right to vote. In addition, under the deposit agreement, the depositary has the right to restrict distributions to holders of the ADSs in the event that it is unlawful or impractical to make such distributions. We have no obligation to take any action to permit distributions to holders of our ADSs. As a result, holders of ADSs may not receive distributions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There is a risk that we are, or will become, a passive foreign investment company, or PFIC, which will subject our U.S. investors to adverse tax rules </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is a risk that we are, or will become, a passive foreign investment company, commonly referred to as a PFIC. Our treatment as a PFIC could result in a reduction in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> return to the U.S. holders of our ordinary shares or ADSs and would likely cause a reduction in the value of such ordinary shares or ADSs. For U.S. federal income tax purposes, we will be classified as a PFIC for any taxable year in which either (i) 75% or more of our gross income is passive income, or (ii)&#160;at least 50% of the average quarterly value of all of our assets for the taxable year produce or are held for the production of passive income. If we are classified as a PFIC for U.S. federal income tax purposes, highly complex rules will apply to U.S. holders owning ordinary shares or ADSs. Accordingly, you are urged to consult your tax advisors regarding the application of such rules. See Item 10 - Additional Information - Taxation, United States Federal Income Tax Consequences&#8221; for a more complete discussion of the U.S. federal income tax risks related to owning and disposing of our ordinary shares or ADSs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Currency fluctuations may adversely affect the price of our ordinary shares, ADSs. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ordinary shares are quoted in Australian dollars on the ASX and the ADSs are quoted in U.S. dollars on NASDAQ. Movements in the Australian dollar/U.S. dollar exchange rate may adversely affect the U.S. dollar price of the ADSs. In the past year the Australian dollar has generally weakened against the U.S. dollar. However, this trend may not continue and may be reversed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares and ADSs. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Australian Corporations Act 2001, or the Corporations Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in our issued voting shares if the acquisition of that interest will lead to a person&#8217;s voting power in us increasing to more than 20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares. This may have the ancillary effect of entrenching our board of directors and may deprive or limit our shareholders&#8217; and ADS holders&#8217; opportunity to sell their ordinary shares and ADSs and may further restrict the ability of our shareholders and ADS holders to obtain a premium from such transactions. See Item 10.B &#8220;Additional Information &#8211; Memorandum and Articles of Association.&#8221; </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_6" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information on the Company </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. History and development of the Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited (&#8220;Kazia&#8221;), a public company limited by shares, was incorporated in March 1994 under the laws of New South Wales, Australia. Kazia is registered and operates under the Australian Corporations Act 2001. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Kazia has its registered office at Three International Towers, Level&#160;24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia. Its telephone number and other contact details are: Phone <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">+61-2-9472</div></div> 4101; email info@kaziatherapeutics.com; and website, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.kaziatherapeutics.com</div> (the information contained in the website does not form part of the Annual Report). Our agent for service of process in the United States is Vcorp Services, LLC, 25 Robert Pitt Drive, Suite 204, Monsey, New York 10952.. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Ordinary Shares are listed on the Australian Securities Exchange (&#8220;ASX&#8221;) under the symbol &#8216;KZA&#8217; and its ADSs, each representing ten Ordinary Shares, trade on the NASDAQ Capital Market under the symbol &#8216;KZIA&#8217;. The Depositary for the Company&#8217;s ADSs is The Bank of New York Mellon, 240 Greenwich Street, New York, NY 10286. All information we file with the SEC is available through the SEC&#8217;s Electronic Data Gathering, Analysis and Retrieval system, which may be accessed through the SEC&#8217;s website at www.sec.gov. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Business overview </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ongoing principal business of the Company has been pharmaceutical drug development. The Company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. The lead drug candidate is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is involved in ten active trials as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Kazia-sponsored phase II clinical trial to examine paxalisib in newly diagnosed glioblastoma, the most common and most aggressive form of primary brain tumor in adults; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a phase II / III adaptive registrational study in glioblastoma, sponsored by the Global Coalition for Adaptive Research; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a phase I clinical trial being conducted by St Jude Children&#8217;s Hospital, examining paxalisib in diffuse intrinsic pontine glioma (DIPG), a rare but very aggressive form of childhood brain cancer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a phase II study being conducted at Dana-Farber Cancer Institute, examining HER2+ breast cancer brain metastases &#8211; breast cancer which has spread to the brain &#8211; in combination with Herceptin (trastuzumab); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an NCI funded multi-drug study of brain metastases &#8211; cancer which has spread to the brain from any primary tumor. This study is a phase II trial and is being conducted by the Alliance for Clinical Trials in Oncology; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Memorial Sloan Kettering Cancer Center is investigating the potential use of paxalisib in combination with radiotherapy in a phase I clinical trial for cancer which has spread to the brain; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A phase II clinical trial is being conducted by Weill Cornell Cancer Centre to examine the impact of a ketogenic diet on the use of paxalisib in glioblastoma; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dana-Farber Cancer Institute is conducting a phase II trial examining paxalisib in primary CNS lymphoma; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pacific Pediatric Neuro-Oncology Consortium is examining paxalisib in DIPG and DMGs (childhood brain cancer) in a phase&#160;II study; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A human &#8216;ADME&#8217; study (also called a &#8216;mass-balance&#8217; study), which is designed to better understand the elimination of paxalisib from the body, and which is required for eventual product approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following graphic illustrates the primary Kazia trials currently in progress. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g185056g185056g48n95.jpg" style="width: 720px; height: 498px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cantrixil (TRX-E-002-1) was previously under development by the Company as a potential therapy for ovarian cancer, and the Company has recently licensed the global rights to Oasmia Pharmaceutical AB (&#8220;Oasmia&#8221;), a Swedish company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EVT801 is the Company&#8217;s second clinical asset after the global rights were licensed from Evotec SE in a recent transaction which is detailed below. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Paxalisib (formerly GDC-0084) </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The company&#8217;s lead development candidate is paxalisib (formerly known as GDC-0084), a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTor pathway, that is being developed as a potential therapy for glioblastoma (GBM), the most common and most aggressive form of primary brain tumour in adults, as well as other forms of brain cancer. Paxalisib is orally administered and is presented in a 15mg capsule formulation. The development candidate is the subject of IND 112,608 with the US FDA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib was developed by Genentech, Inc (South San Francisco, California) and the company entered into a worldwide exclusive license for the asset in October 2016. Prior to this transaction, Genentech had completed an extensive preclinical development program that provided convincing validation for paxalisib as a potential drug for brain cancer. Genentech also completed a phase I clinical trial in 47 patients with advanced recurrent grade III and grade IV glioma (NCT01547546). The most common adverse events were oral mucositis and hyperglycemia. Per RANO criteria, 40% of patients exhibited a best observable response of stable disease, and 26% demonstrated a metabolic partial response on FDG-PET. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development candidate was granted the International Non-Proprietary Name (INN) &#8216;paxalisib&#8217; by the World Health Organisation in December 2019. This was confirmed as the United States Adopted Name (USAN) by the USAN Council in April 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib is a potent and selective inhibitor of all four isoforms of phosphoinositide-3-kinase (PI3K) and a moderate inhibitor of the mammalian target of rapamycin (mTOR). The PI3K / Akt / mTOR signaling axis has been shown to be dysregulated in approximately 85-90% of cases of glioblastoma, per Cancer Genome Atlas, and is considered a promising target in this disease. More generally, five PI3K inhibitors have thus far been approved by FDA, for a range of hematological malignancies and solid tumors, making this a well-validated target in cancer. Paxalisib is distinguished from these products by the fact that it is the only PI3K inhibitor in mainstream clinical development which is known to cross the blood-brain barrier, a crucial prerequisite for any novel treatment in brain cancer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib&#8217;s mechanism is therefore entirely distinct from that of temozolomide, the existing FDA-approved standard of care treatment. Temozolomide functions primarily by alkylating guanine residues in DNA, thereby inhibiting cell division in the rapidly-growing tumor. Paxalisib, by contrast, inhibits a biochemical control signal, and is therefore associated with a very different resistance and toxicity profile. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib is the subject of granted or pending composition-of-matter patents in all key territories. In general, the expiry of these patents is in December 2031. However, the company expects that it will be able to secure patent term extensions in the most substantial markets, including US, EU, China, Japan, and Korea, and that these extensions will provide effective protection until 2036. In addition, the company has recently received notice of grant for a patent protecting the manufacturing process associated with paxalisib, and this will provide an additional layer of protection in relevant territories until 2036. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib was granted orphan drug designation (ODD) by FDA for glioblastoma in February 2018, and for the broader indication of glioma in August 2020. The development candidate also received Fast Track designation (FTD) for glioblastoma in August 2020, and Rare Pediatric Disease Designation (RPDD) for diffuse midline gliomas in August 2020. Collectively, these special designations provide paxalisib with enhanced access to FDA, a waiver of PDUFA fees, a period of data exclusivity and, in the specific case of RPDD, the potential to secure a pediatric Priority Review Voucher (pPRV) should paxalisib be approved in this indication. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II Clinical Trial in Newly Diagnosed Glioblastoma with Unmethylated MGMT Status (NCT03522298) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company-sponsored phase II study of paxalisib in newly diagnosed patients with unmethylated MGMT promotor status (NCT03522298) remains ongoing. In November 2020, an interim analysis was presented at the Society for Neuro-Oncology (SNO) Annual Meeting. This analysis showed a median progression-free survival (PFS) of 8.4 months, and a median overall survival (OS) of 17.5 months, each of which compare favourably to the corresponding figures of 5.3 months and 12.7 months which are associated in this patient population with temozolomide, the existing standard of care. The safety profile of paxalisib continues to appear highly favourable, with rash, hyperglycemia, and oral mucositis representing the most common toxicities. In April 2021, the company presented additional interim data focusing on pharmacokinetics at the American Association for Cancer Research Annual Meeting. This data supported 60mg as the go-forward dose, and suggested no significant food effect, allowing for both fed and fasted administration in future studies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, the last patient in the phase II study experienced disease progression and came off study drug, after some 2.3 years of treatment. The study is now in survival follow-up, with final data expected by end of CY2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II / III Clinical Trial in Glioblastoma (GBM AGILE) (NCT03970447) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib commenced recruitment to GBM AGILE (NCT03970447), a phase II / III adaptive clinical trial in glioblastoma, in January 2021. GBM AGILE is sponsored by the Global Coalition for Adaptive Research, a US-based 501<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#169;</div>(3) non-profit organisation dedicated to advancing the development of new therapies via the application of cutting-edge statistical methodologies. The study is a platform study, or master protocol study, in which multiple experimental agents are evaluated in parallel, and are compared against a shared control arm. GBM AGILE uses an adaptive Bayesian statistical design to ensure that only the number of patients required to reach a definitive answer are enrolled. Three patient populations are included in the study: newly diagnosed patients with unmethylated MGMT promotor status, newly diagnosed patients with methylated MGMT promotor status, and recurrent patients. Paxalisib is participating in the first and third of these groups but will not examine patients with methylated MGMT promotor status in this study. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at 30 June 2021, three experimental agents are enrolling patients in GBM AGILE: Bayer&#8217;s regorafenib, Kazia&#8217;s paxalisib, and VAL-083, manufactured by Kintara Therapeutics. The study has screened approximately 650 patients, and approximately two-dozen study sites are open to the paxalisib arm, with more expected to open during 2H CY2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GBM AGILE is intended to serve as the registration study for paxalisib in glioblastoma. The study has been designed with registrational intent, and FDA has indicated that it considers the study suitable for this purpose. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II Study in Glioblastoma in Combination with Ketogenesis </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the company entered into an agreement with the Joan &amp; Sanford I Weill Medical College of Cornell University in New York, NY, known generally as Weill Cornell Medicine, for an investigator-initiated phase II clinical trial combining paxalisib with ketogenesis in patients with newly-diagnosed and recurrent glioblastoma. In addition to the general interest in ketogenic diets as a potential adjunct to treatment for various forms of cancer, research by Professor Lew Cantley and colleagues has demonstrated the potential for insulin to antagonise PI3K inhibition. Administering a PI3K inhibitor in the context of minimal insulin secretion should allow the drug to achieve its full potential, and a combination of ketogenic diet and metformin will be used in this study to achieve a hypoinsulinaemic state. Professor Cantley serves as a scientific advisor to the study, and Dr Howard Fine, a highly experienced neuro-oncologist, will serve as Principal Investigator. The study is expected to commence recruitment during 2H CY2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase I Study in Diffuse Intrinsic Pontine Glioma (DIPG) (NCT03696355) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An investigator-initiated phase I study of paxalisib in children with diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs) (NCT03696355), sponsored by St Jude Children&#8217;s Research Hospital in Memphis, TN, reported initial interim data in an oral presentation at the SNO Annual Meeting in November 2020. The study met its primary objective and determined a maximum tolerated dose for paediatric use of 27 mg/m2. 27 patients were recruited, of whom 24 received at least one dose of paxalisib. The safety profile and pharmacokinetics were highly consistent with the adult data. The study had not at that stage demonstrated a survival benefit. As at 30 June 2021, a number of patients remain in survival follow-up, and final data is expected during FY2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II Study in Diffuse Intrinsic Pontine Glioma (DIPG) (NCT05009992) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, the company entered into a letter of intent with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to execute an investigator-initiated phase II adaptive study of paxalisib in patients with DIPG and other DMGs (), a group which collectively constitutes one of the most aggressive childhood cancers. The study will explore paxalisib in combination with ONC-201, a small-molecule investigational new drug which targets dopamine receptor D2 (DRD2), and which is manufactured by Oncoceutics, Inc, a wholly-owned subsidiary of Chimerix, Inc. The St Jude phase I study in DIPG has already provided invaluable information regarding dosing and safety of paxalisib in a paediatric population, but it has always been assumed that combination therapy would be required to achieve meaningful efficacy in such an aggressive tumour. Research by Professor Matt Dun at the Hunter Medical Research Institute in Newcastle, Australia, has shown compelling evidence of combinatorial synergy between paxalisib and ONC-201, and so the PNOC study will investigate this combination, among others, in patients. The study is expected to commence recruitment in 2H CY2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II Study in Primary CNS Lymphoma (PCNSL) (NCT04906096) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, the company signed an agreement with Dana-Farber Cancer Institute in Boston, MA, for an investigator-initiated phase II clinical study of paxalisib in patients with primary CNS lymphoma (PCNSL) (NCT04906096). This study commenced recruitment in June 2021. Four of the five FDA-approved PI3K inhibitors are indicated for various forms of lymphoma, so this is considered a high-potential indication for paxalisib. The unique brain-penetrant qualities of paxalisib make it ideally suitable for investigation in this patient group. The study is expected to recruit around 25 patients, and to run for approximately two years. The Principal Investigator is Professor Lakshmi Nayak, a highly experienced clinical researcher in brain cancer, with a specialist interest in PCNSL. The study commenced recruitment in June 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase I Study in Brain Metastases in Combination with Radiotherapy (NCT04192981) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr T Jonathan Yang is the Principal Investigator to a phase I study in patients with brain metastases and leptomeningeal metastases, in which paxalisib is administered in combination with radiotherapy (NCT04192981), sponsored by Memorial Sloan-Kettering Cancer Center in New York, NY. This study is expected to provide initial interim data during FY2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II Study in HER2+ Breast Cancer Brain Metastases in Combination with Trastuzumab (NCT03765983) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr Jose Pablo Leone is the Principal Investigator to a phase II study in patients with HER2-positive breast cancer brain metastases, in which paxalisib is administered in combination with Herceptin (trastuzumab) (NCT03765983), sponsored by Dana-Farber Cancer Institute in Boston, MA. This study is expected to provide initial interim data during FY2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Phase II Genomically-Guided Study in Brain Metastases (NCT03994796) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Alliance for Clinical Trials in Oncology is sponsoring a phase II multi-drug study of multiple agents in the treatment of brain metastases from any primary tumour (NCT03994796). The study establishes a genomic profile for patients at entry and then assigns them, on the basis of the predominant mutational profile in their tumour, to receive either abemaciclib (CDK4/6 mutations), entrectanib (ROS/Trk mutations), or paxalisib (PI3K mutations). This study is expected to provide initial interim data during FY2022. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EVT801 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The company&#8217;s second development candidate is EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 was originally discovered by Sanofi SA and was licensed to Evotec SE as part of a broader transaction. Evotec conducted an extensive program of preclinical development, which showed compelling evidence of activity in a broad range of animal models. The drug was licensed to Kazia in April 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EVT801 is protected by granted or pending composition-of-matter patents in all key territories, with exclusivity generally through to the early 2030s. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For several decades, it has been clear that growing tumours require an extensive network of newly formed blood vessels and lymphatic vessels to satisfy their substantial nutrient requirements. Drugs which inhibit the formation of new blood vessels (angiogenesis inhibitors) have proven effective in a wide range of solid tumours, with Avastin (bevacizumab) being the best-known example of the class. However, the use of such drugs is limited by hypoxia-induced resistance mechanisms and, in the case of many small-molecule inhibitors, by toxicity. EVT801 has been designed to respond to these challenges by selectively targeting lymphangiogenesis, the formation of new lymphatic vessels. Doing so, and with a high degree of selectivity, is expected to provide many of the same benefits as inhibition of angiogenesis, but without the attendant problems of resistance and toxicity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, drugs which target VEGF receptors have shown the potential to alter the population of immune cells within the tumour micro-environment, thereby potentially making &#8216;cold&#8217; tumours more susceptible to immuno-oncology agents such as checkpoint inhibitors. A wealth of preclinical evidence supports this hypothesis with EVT801 and provides a second and almost entirely distinct mechanism of action through which the drug may provide benefit to cancer patients. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia has initiated work on a phase I clinical trial of EVT801, which will seek to explore both of these mechanisms (inhibition of lymphangiogenesis and modulation of tumour immune micro-environment), as well as provide critical information regarding the safety, tolerability, and pharmacokinetics of the drug. The planned phase I study will be initiated at two trial sites in France and will aim to recruit up to 96 patients with advanced cancer. The study is expected to commence recruitment by the end of CY2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a reasonable expectation that during fiscal 2022: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Final results will be reported from the phase II clinical trial of paxalisib in glioblastoma; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim results will be reported from the phase II clinical trial of paxalisib in combination with trastuzumab in breast cancer metastases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim results will be reported from the phase II genomically-guided study of paxalisib in brain metastases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim results will be reported from the phase I study of paxalisib in combination with radiotherapy in brain metastases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Final data will be reported from the phase I study of paxalisib in children with diffuse intrinsic pontine glioma (DIPG); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The phase II study of paxalisib in combination with a ketogenic diet in glioblastoma will commence recruitment; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The phase II study of paxalisib in combination with ONC-201 in DIPG and DMGs will commence recruitment; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The phase I study of EVT801 in patients with advanced solid tumours will commence recruitment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In parallel, the Company continues to actively explore licensing and partnering opportunities with other companies that have the potential to effect further refinements in the scope of the Company&#8217;s business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent Protection </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an aggressive global Intellectual Property (&#8220;IP&#8221;) strategy to protect its key assets and we have partnered with a global patent law firm to lodge patents that offer the best possible protection for our assets. The patent strategy is adapted for each technology platform and the principle mode of protection is through the patenting procedure, seeking to obtain exclusive licenses for all its key inventions and drug pipeline. The overarching strategy in the IP portfolio is to cover the three critical corner stones of pharmaceutical patent: composition of matter (the breadth structures covered in the patent), method of manufacture (the chemical processes used to manufacture the compounds disclosed in the patent) and method of use. Patents are submitted initially as provisional applications and after 12 months&#8217; progress through to a Patent Cooperation Treaty (&#8220;PCT&#8221;) application. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drug discovery/development efforts are contributing to our pipeline with our other technology platforms also delivering hit and lead drug candidates. As the research programs reveal new hit molecules, these are protected through lodging patents. The Company will continue to pursue a broad patent filing strategy based on multiple jurisdictions with a focus on those member countries offering the most significant market opportunities for future development. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulatory requirements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Australian Regulatory Requirements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Goods</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Act 1989</div></div> (&#8220;1989 Act&#8221;), sets out the legal requirements for the import, export, manufacture and supply of pharmaceutical products in Australia. The 1989 Act requires that all pharmaceutical products to be imported into, supplied in, manufactured in or exported from Australia be included in the Australian Register of Therapeutic Goods (&#8220;ARTG&#8221;), unless specifically exempted under the Act. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Medicines with a higher level of risk (prescription medicines, some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-prescription</div> medicines) are evaluated for quality, safety and efficacy and are registered on the ARTG. Medicines with a lower risk (many over the counter medicines including vitamins) are assessed only for quality and safety. Medicines included in the ARTG can be identified by the AUST R number (for registered medicines) or an AUST L number (for listed medicines) which appears on the packaging of the medicine. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In order to ensure that a product can be included in the ARTG, a sponsoring company must make an application to the Therapeutic Goods Administration (&#8220;TGA&#8221;). The application usually consists of a form accompanied by data (based on the EU requirements) to support the quality, safety and efficacy of the product for its intended use and payment of a fee. Application details are available on the TGA website <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.tga.gov.au</div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The first phase of evaluation, known as the Application Entry Process, is usually a short period during which an application is assessed at an administrative level to ensure that it complies with the basic guidelines. The TGA may request further details from the applicant and may agree with sponsors that additional data (which while not actually required by the application, could enhance the assessment outcome) may be submitted later at an agreed time. The TGA must decide within at least 40 working days whether it will accept the application for evaluation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Once an application is accepted for evaluation, aspects of the data provided are allocated to evaluators within the different relevant sections, who prepare clinical evaluation reports. Following evaluation, the chemistry, quality control bioavailability and pharmacokinetics aspects of a product may be referred to a Pharmaceutical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Sub-Committee</div> (&#8220;PSC&#8221;), which is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-committee</div> of the TGA prescription medicine expert advisory committee, the Advisory Committee on Prescriptive Medicines (&#8220;ACPM&#8221;) to review the relevant clinical evaluation reports. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The clinical evaluation reports (along with any resolutions of the ACPM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-committee)</div> are sent to the sponsoring company who then has the opportunity to comment on the views expressed within the evaluation report, provide corrections and to submit supplementary data to address any issues raised in the evaluation reports. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the evaluations are complete, the TGA prepares a summary document on the key issues on which advice will be sought from either the ACPM (for new medicines) or from the Peer Review Committee (&#8220;PRC&#8221;) for extensions to products which are already registered. This summary is sent to the sponsoring company, which is able to submit a response to the ACPM or PRC dealing with issues raised in the summary and those not previously addressed in the evaluation report. The ACPM/PRC provide independent advice on the quality, risk/benefit, effectiveness and access of the product and conduct medical and scientific evaluations of the application. The ACPM meets every two months to examine the applications referred by the TGA and its resolutions are provided to the sponsoring company within five working days after the ACPM meeting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The TGA takes into account the advice of the ACPM or PRC in reaching a decision to approve or reject a product. Any approval for registration on the ARTG may have conditions associated with it. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From the time that the TGA accepts the initial application for evaluation, the TGA must complete the evaluation and make a decision on the registration of the product within at least 255 working days. If not completed within 255 working days, the TGA forfeits 25% of the evaluation fee otherwise payable by the sponsor, but any time spent waiting for a response from the sponsor is not included in the 255 working days. The TGA also has a system of priority evaluation for products that meet certain criteria, including where the product is a new chemical entity that it is not otherwise available on the market as an approved product, and is for the treatment of a serious, life-threatening illness for which other therapies are either ineffective or not available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Regulatory Requirements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The FDA regulates and imposes substantial requirements upon the research, development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical testing, labelling, manufacture, quality control, storage, approval, advertising, promotion, marketing, distribution, import and export of pharmaceutical products including drugs and biologics, as well as significant reporting and record-keeping obligations. State governments may also impose obligations in these areas. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, pharmaceutical products are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and other laws in the case of biologics, the Public Health Service Act and other acts that implement regulations. The Company believes that the FDA will regulate its products as drugs. The process required by the FDA before drugs may be marketed in the United States generally involves the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> laboratory evaluations, including formulation and stability testing, and animal tests performed under the FDA&#8217;s Good Laboratory Practices regulations to assess pharmacological activity and toxicity potential; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">submission and approval of an IND Application, including results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, clinical experience, manufacturing information, and protocols for clinical tests, which must become effective before clinical trials may begin in the United States; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining approval of Institutional Review Boards (&#8220;IRBs&#8221;), to administer the products to human subjects in clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the product for the product&#8217;s intended use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">development of manufacturing processes which conform to FDA current Good Manufacturing Practices (&#8220;cGMPs&#8221;), as confirmed by FDA inspection; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">submission of results for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical studies, and chemistry, manufacture and control information on the product to the FDA in a New Drug Approval (&#8220;NDA&#8221;) Application; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of an NDA, prior to any commercial sale, promotion or shipment of a product. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The testing and approval process requires substantial time, effort, and financial resources, and the Company cannot be certain that any approval will be granted on a timely basis, if at all. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The results of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, clinical experience together with initial specified manufacturing information, the proposed clinical trial protocol, and information about the participating investigators are submitted to the FDA as part of an IND, which must become effective before the Company may begin human clinical trials in the U.S. Additionally, an independent IRB must review and approve each study protocol and oversee conduct of the trial. An IND becomes effective 30 days after receipt by the FDA, unless the FDA, within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period, raises concerns or questions about the conduct of the trials as outlined in the IND and imposes a clinical hold. If the FDA imposes a clinical hold, the IND sponsor must resolve the FDA&#8217;s concerns before clinical trials can begin. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> tests and studies can take several years to complete, and there is no guarantee that an IND submitted, based on such tests and studies, will become effective within any specific time period, if at all. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human clinical trials are typically conducted in three sequential phases that may overlap, which are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase I: </div></div>The drug is initially introduced into healthy human subjects or patients and tested for safety and dosage tolerance. For oncology medicines, patients with the target disease are used rather than healthy patients. Absorption, metabolism, distribution, and excretion testing, among other tests, are generally performed at this stage. These studies may also provide early evidence of effectiveness. The maximum tolerated dose of the drug may be calculated from Phase I studies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase II: </div></div>The drug is studied in controlled, exploratory therapeutic trials in a limited number of subjects with the disease or medical condition for which the new drug is intended to be used in order to identify possible adverse effects and safety risks, to determine the preliminary or potential efficacy of the product for specific targeted diseases or medical conditions, and to determine dosage tolerance and the optimal effective dose; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase III: </div></div>While Phase II studies demonstrate that a specific dosage range of the drug is likely to be effective and the drug has an acceptable safety profile, controlled, large-scale therapeutic, Phase III trials are undertaken at multiple study sites to demonstrate clinical efficacy and to further test for safety in an expanded patient population. These studies are used to evaluate the overall benefit &#8211; risk relationship of the drug and provide a basis for physician labelling. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company cannot be certain that it will successfully complete Phase I, Phase II or Phase III testing of its products within any specific time period, if at all. Furthermore, the FDA, the IRB or the Company may suspend or terminate clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, as well as detailed information about the manufacturing process, quality control methods, and product composition, among other things, are submitted to the FDA as part of an NDA seeking approval to market and commercially distribute the product on the basis of a determination that the product is safe and effective for its intended use. Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless GMP compliance is satisfactory. If applicable regulatory criteria are not satisfied, the FDA may deny the NDA or require additional testing or information. As a condition of approval, the FDA also may require post-marketing testing or surveillance to monitor the product&#8217;s safety or efficacy. Even after an NDA is approved, the FDA may impose additional obligations or restrictions (such as labelling changes), or even suspend or withdraw a product approval on the basis of data that arise after the product reaches the market, or if compliance with regulatory standards is not maintained. The Company cannot be certain that the FDA on a timely basis, if at all will approve any NDA it submits. Also, any such approval may limit the indicated uses for which the product may be marketed. Any refusal to approve, delay in approval, suspension or withdrawal of approval, or restrictions on indicated uses could have a material adverse impact on the Company&#8217;s business prospects. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A user fee, pursuant to the requirements of the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), and its amendments, applies to NDAs. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for prescription drugs and biologics, and an annual establishment fee on facilities used to manufacture prescription drugs and biologics. A written request can be submitted for a waiver under certain circumstances. Waivers may be possible for the application fee for the first human drug application that is filed by a small business, as defined by the FDCA, but there are no small business waivers for product or establishment fees. Waivers may also be possible for one or more fees, upon written request, when a waiver or reduction is necessary to protect the public health, the user fees would present a significant barrier to innovation, or the fees are anticipated to exceed the present or future costs incurred by FDA. The Company is not at the stage of development with its products where it is subject to these fees, but they are significant expenditures that may be incurred in the future and must be paid at the time of application submissions to FDA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Satisfaction of FDA requirements typically takes several years. The actual time required varies substantially, based upon the type, complexity, and novelty of the pharmaceutical product, among other things. Government regulation imposes costly and time-consuming requirements and restrictions throughout the product life cycle and may delay product marketing for a considerable period of time, limit product marketing, or prevent marketing altogether. Success in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or early stage clinical trials does not ensure success in later stage clinical trials. Data obtained from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit, or prevent marketing approval. Even if a product receives marketing approval, the approval is limited to specific clinical indications. Further, even after marketing approval is obtained, the discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After product approval, there are continuing significant regulatory requirements imposed by the FDA, including record-keeping requirements, obligations to report adverse events in patients using the products, and restrictions on advertising and promotional activities. Quality control and manufacturing procedures must continue to conform to GMPs, and the FDA periodically inspects facilities to assess GMP compliance. Additionally, post-approval changes in ingredient composition, manufacturing processes or facilities, product labelling, or other areas may require submission of an NDA Supplement to the FDA for review and approval. New indications will require additional clinical studies and submission of an NDA Supplement. Failure to comply with FDA regulatory requirements may result in an enforcement action by the FDA, including warning letters, product recalls, suspension or revocation of product approval, seizure of product to prevent distribution, impositions of injunctions prohibiting product manufacture or distribution, and civil and criminal penalties. Maintaining compliance is costly and time-consuming. The Company cannot be certain that it, or its present or future suppliers or third-party manufacturers, will be able to comply with all FDA regulatory requirements, and potential consequences of noncompliance could have a material adverse impact on its business prospects. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s policies may change, and additional governmental regulations may be enacted that could delay, limit, or prevent regulatory approval of the Company&#8217;s products or affect its ability to manufacture, market, or distribute its products after approval. Moreover, increased attention to the containment of healthcare costs in the U.S. and in foreign markets could result in new government regulations that could have a material adverse effect on the business. The Company&#8217;s failure to obtain coverage, an adequate level of reimbursement, or acceptable prices for future products could diminish any revenues the Company may be able to generate. The Company&#8217;s ability to commercialize future products will depend in part on the extent to which coverage and reimbursement for the products will be available from government and health administration authorities, private health insurers, and other third-party payers. EU member states and U.S. government and other third-party payers increasingly are attempting to contain healthcare costs by consideration of new laws and regulations limiting both coverage and the level of reimbursement for new drugs. The Company cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or abroad. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s activities may also be subject to state laws and regulations that affect its ability to develop and sell products. The Company is also subject to numerous federal, state, and local laws relating to such matters as safe working conditions, clinical, laboratory, and manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. The Company may incur significant costs to comply with such laws and regulations now or in the future, and the failure to comply may have a material adverse impact on the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDCA includes provisions designed to facilitate the development and expedite the review of drugs and biological products intended for treatment of serious or life-threatening conditions that demonstrate the potential to address unmet medical needs for such conditions. These provisions set forth a procedure for designation of a drug as a &#8220;fast track product&#8221;. The fast track designation applies to the combination of the product and specific indication for which it is being studied. A product designated as fast track is ordinarily eligible for additional programs for expediting development and review, but products that are not in fast-track drug development programs may also be able to take advantage of these programs if they meet the necessary requirements. These programs include priority review of NDAs and accelerated approval. Drug approval under the accelerated approval regulations may be based on evidence of clinical effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. A post-marketing clinical study will be required to verify clinical benefit, and other restrictions to assure safe use may be imposed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, a sponsor may obtain marketing exclusivity for a period of time following FDA approval of certain drug applications, regardless of patent status, if the drug is a new chemical entity or if new clinical studies were required to support the marketing application for the drug. This marketing exclusivity prevents a third party from obtaining FDA approval for an identical or nearly identical drug under an Abbreviated New Drug Application or a &#8220;505(b)(2) New Drug Application&#8221;. The statute also allows a patent owner to obtain an extension of applicable patent terms for a period equal to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> the period of time elapsed between the filing of an IND and the filing of the corresponding NDA plus the period of time between the filing of the NDA and FDA approval, with reductions taken for any time an applicant did not act with due diligence. There is a five-year maximum patent extension and a maximum of 14 years protection from product approval. The Company cannot be certain that it will be able to take advantage of either the patent term extension or marketing exclusivity provisions of these laws. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union Regulatory Requirements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Outside the United States, the Company&#8217;s ability to market its products will also be contingent upon receiving marketing authorizations from the appropriate regulatory authorities and compliance with applicable post-approval regulatory requirements. Although the specific requirements and restrictions vary from country to country, as a general matter, foreign regulatory systems include risks similar to those associated with FDA regulation, described above. Under EU regulatory systems, marketing authorizations may be submitted either under a centralized or a national procedure. Under the centralized procedure, a single application to the European Medicines Agency (&#8220;EMA&#8221;) leads to an approval granted by the European Commission that permits the marketing of the product throughout the EU. The centralized procedure is mandatory for certain classes of medicinal products, but optional for others. For example, all medicinal products developed by certain biotechnological means, and those developed for cancer and other specified diseases and disorders, must be authorized via the centralized procedure. The Company assumes that the centralized procedure will apply to its products that are developed by means of a biotechnology process. The national procedure is used for products not requiring authorization by the centralized procedure. Under the national procedure, an application for a marketing authorization is submitted to the competent authority of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-member</div> state of the EU. The holders of a national marketing authorization may submit further applications to the competent authorities of the remaining member states via either the decentralized or mutual recognition procedure. The decentralized procedure enables applicants to submit an identical application to the competent authorities of all member states where approval is sought at the same time as the first application, while under the mutual recognition procedure, products are authorized initially in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-member</div> state, and other member states where approval is sought are then requested to recognize the original authorization based upon an assessment report prepared by the original authorizing competent authority. Both the decentralized and mutual recognition procedures should take no longer than 90 days, but if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-member</div> state makes an objection, which under the legislation can only be based on a possible risk to human health, the application will be automatically referred to the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA. If a referral for arbitration is made, the procedure is suspended. However, member states that have already approved the application may, at the request of the applicant, authorize the product in question without waiting for the result of the arbitration. Such authorizations will be without prejudice to the outcome of the arbitration. For all other concerned member states, the opinion of the CHMP, which is binding, could support or reject the objection or alternatively could reach a compromise position acceptable to all EU countries concerned. The arbitration procedure may take an additional year before a final decision is reached and may require the delivery of additional data. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As with FDA approval, the Company may not be able to secure regulatory approvals in the EU in a timely manner, if at all. Additionally, as in the U.S., post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution, would apply to any product that is approved in the EU, and failure to comply with such obligations could have a material adverse effect on the Company&#8217;s ability to successfully commercialize any product. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The conduct of clinical trials in the EU is governed by the European Clinical Trials Directive (2001/20/EC), which was implemented in May 2004. This Directive governs how regulatory bodies in member states control clinical trials. No clinical trial may be started without a clinical trial authorization granted by the national competent authority and favorable ethics approval. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, there is a marked degree of change and uncertainty both in the regulation of clinical trials and in respect of marketing authorizations that face the Company or its products in the EU. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has met the compliance requirements for ASX listings and accordingly has not been in breach of those requirements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product and Corporate Developments during Fiscal 2021 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company continued to pursue its strategy of focusing resources on clinical programs, being those most likely to provide a return to shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In October 2020, the Company raised $23.6&#160;million (net of costs) from an accelerated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-renounceable</div> entitlement offer to industry investors, and in April 2021, raised US$4&#160;million as a result of a placement to Simcere. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2021, the Company partnered our legacy asset, Cantrixil <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TRX-E-002-1)</div></div></div> to Oasmia for US$4&#160;million up front, up to US$42&#160;million in contingent milestone payments and double-digit royalties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Also in March 2021, the Company partnered paxalisib for Greater China to Simcere for US$11&#160;million up front comprising US$7&#160;million in cash and US$4&#160;million in equity investment, and up to US$281&#160;million in contingent milestones and tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> royalties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2021, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> EVT801, a selective small-molecule inhibitor of VEGFR3 from Evotec SE of Germany for &#8364;1&#160;million up front, approximately &#8364;308&#160;million in contingent milestones and single-digit royalties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The funds supplied by the capital raises, as well as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments from the two licensing transactions, funded the operations of the Company for fiscal 2021 and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment for EVT801, and will provide funding for the ongoing studies being conducted for both assets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As well as our own ongoing clinical trials, paxalisib is now also involved in a further seven clinical trials, all being conducted by world renowned research organizations and principally funded by parties other than Kazia, giving us multiple opportunities to realise value from this drug. EVT801 is expected to enter the clinic later in 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has continued to make all efforts to improve operating efficiency and maintain the current low rate of G&amp;A costs, allowing the bulk of the company&#8217;s funds to be directed towards our research and development activities. Cash outlaid in relation to our clinical programs represented approximately 80% of the total cash outlay for the year, as compared to 72% in the prior fiscal period. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Organizational structure </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited is incorporated in Australia and has the following wholly-owned subsidiaries: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 67%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country of incorporation</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kazia Laboratories Pty Ltd</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Australia</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kazia Research Pty Ltd</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Australia</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kazia Therapeutics Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">United States (Delaware)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Glioblast Pty Ltd</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics (Hong Kong) Limited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australia</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hong Kong</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">D. Property, plant and equipment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During fiscal 2021, the Company continued to work out of a serviced office in Sydney that is subject to a renewable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> workspace license agreement. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_7" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;4A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unresolved Staff Comments </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_8" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and Financial Review and Prospects </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical accounting policies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We prepare our financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). As such, we are required to make certain estimates, judgments, and assumptions that management believes are reasonable based upon the information available. These estimates, judgments and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The critical accounting policies are summarized in Item 18. &#8220;Financial Statements&#8212;Note 3 &#8211; Critical Accounting Policies&#8221;. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion and analysis should be read in conjunction with Item 18. &#8220;Financial Statements&#8221; included below. Operating results are not necessarily indicative of results that may occur in future periods. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in the forward-looking statements as a result of many factors including, but not limited to, those set forth under &#8220;Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in Item 3 &#8220;Key Information&#8221; included above in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> All forward-looking statements included in this document are based on the information available to the Company on the date of this document and the Company assumes no obligation to update any forward-looking statements contained in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A. Operating results </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following discussion relates to our consolidated results of operations, financial condition and capital resources. You should read this discussion in conjunction with our consolidated financial statements and the notes thereto contained elsewhere in this report. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide a summary of revenues and income for the past three fiscal years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;fiscal&#160;year&#160;ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gain</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reimbursement of expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidies and grants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue and other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,565</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fiscal 2021 compared to fiscal 2020 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, finance income and other income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In fiscal 2021, the Company generated revenue from contracts with customers, being <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fees from the licensing of their two key assets to third parties. Revenue in fiscal 2021 amounted to A$15.2&#160;million compared with nil in fiscal 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company earns interest income derived from interest bearing bank account, which is directly linked with the amounts held on deposit. The amount of finance income earned decreased as a result of decreased cash balances as well as lower interest rates enjoyed during the year. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development rebate decreased from A$1.0&#160;million in fiscal 2020 to nil in fiscal 2021. In fiscal 2021, the amount of qualifying expenditure in Australia was not sufficiently large to warrant making a claim for the R&amp;D rebate, and we do not anticipate applying for the rebate in future fiscal years as this trend is set to continue. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses increased from A$9.5&#160;million in fiscal 2020 to A$14.5&#160;million in fiscal 2021 (53%). The increase was mainly as a result of the Company&#8217;s lead asset, paxalisib, entering into a registrational trial run by GCAR, which aims to recruit up to 200 patients. Funds were also spent on preparatory work for the Phase I trial for EVT801, which is anticipated to open later in 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative costs increased from A$3.7&#160;million in fiscal 2020 to A$7.0&#160;million in fiscal 2021 (89%). A total of A$1.5&#160;million represented VAT and withholding tax on revenue deducted at source, and the Company also incurred additional costs in legal fees to support the three license transactions concluded during the year. This is the first year that the Company has held significant balances in currencies other than A$, and a small FX loss was experienced on translation of year end balances. Corporate overheads were also increased as the Company somewhat expanded its operating base, however there is a continued focus on conserving funds. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s loss after income tax reduced from A$12.5&#160;million in fiscal 2020 to A$8.4&#160;million in fiscal 2021. The change was mainly as a result increased R&amp;D expenditure during the fiscal 2021 as described above, offset somewhat by the revenue from license transactions, also as described above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fiscal 2020 compared to fiscal 2019 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This analysis can be found in Item 5 of the Company&#8217;s annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> for fiscal 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">B. Liquidity and capital resources </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred cumulative losses and negative cash flows from operations since our inception and, as of June&#160;30, 2021, we had accumulated losses of A$44.2&#160;million. We anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development expenditure will continue to increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, other third-party funding, and other collaborations, strategic alliances and licensing arrangements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We had no borrowings in fiscal 2021 and do not currently have a credit facility.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we had cash and cash equivalents of A$27.6&#160;million, held in both A$ and US$. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts. Our short-term investments consist of term deposits with maturity within 90 days. At June&#160;30, 2021, term deposits amounting to A$6.5&#160;million had a weighted average interest rate of 0.04%. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to consume cash and incur operating losses for the foreseeable future as the Company continues developing its oncology drug candidates. The impact on cash resources and results from operations will vary with the extent and timing of the future clinical trial programs. The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the Company&#8217;s ability to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and are confident that the strategies in place are appropriate to generate sufficient funding to allow us to continue as a going concern. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash flows </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table set forth the sources and uses of cash for the past three fiscal years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in A$ thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(9,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(6,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,815</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating activities. </div></div>Net cash used in operating activities for the three fiscal years primarily represents net outflows for the cost of the R&amp;D programs and the general and administrative costs of running the business. This amount is heavily impacted by the cost of the clinical programs, as well as cost containment measures adopted to manage the general and administrative costs of the business. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing activities. </div></div>Net cash from investing activities in fiscal 2019 represents funds generated from the sale of shares in a listed entity, which were obtained via the settlement of an IP dispute. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing activities. </div></div>Net cash from financing activities in fiscal 2021, 2020 and 2019 arose as a result of private placements of ordinary shares to institutional investors in certain countries as well as Share Purchase Plans to shareholders in Australia. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021, the Company did not hold any derivative financial instruments for managing its foreign currency; however, the Company may from time to time enter into hedging arrangements where circumstances are deemed appropriate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that its future ability to fund its operations will depend on deriving sufficient cash from investors through successful capital raisings, from licensing and partnering activities and government grants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had no commitments for capital expenditure or material contractual obligations at the end of fiscal 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company continuously pursues opportunities for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-dilutive</div> funding, such as grant applications. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company cannot provide assurance that it or its subsidiaries will be able to raise the funds necessary to complete the planned clinical trial programs or find appropriate collaboration or licensing opportunities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company does not have any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity issues </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has historically financed its operations primarily from issuing equity capital. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2019 the Company issued 13,757,052 ordinary shares. The details of these share issues are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2018 the Company issued 8,900,001 shares to industry funds and other investors and raised A$3,382,000 before costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2018, the Company issued 2,820,824 shares in relation to a milestone associated with the acquisition of Glioblast Pty Limited. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2018 the Company issued 2,036,227 shares to qualifying existing shareholders under the Company&#8217;s Share Purchase Plan, raising funds of A$773,760 before costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2020 the Company issued 32,431,696 ordinary shares. The details of these share issues are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2019, the Company issued 10,000,000 shares to industry funds and other investors and raised A$4,000,000 before costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, the Company issued 18,041,667 shares to industry funds and other investors and raised A$7,216,667 before costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 the Company issued 4,390,010 shares to qualifying existing shareholders under the Company&#8217;s Share Purchase Plan, raising funds of A$1,756,004 before costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2021 the Company issued 37,413,840 ordinary shares. The details of those share issues are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2020 the Company issued 31,542,895 shares to industry funds and other investors and raised A$25,234,316 before costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2021 the Company issued 3,037,580 shares to a partner pharmaceutical company for the sum of US$4,000,000. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021 the Company issued 2,391,865 shares in satisfaction of a milestone payment relating to the acquisition of paxalisib. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020 and March 2021, the Company issued a total of 441,500 shares upon the exercise of options, raising a total of A$273,287. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency fluctuations were not material for the Company in fiscal 2020 however as the Company held balances in US$ during fiscal 2021, a conversion loss of A$0.4&#160;million was experienced in fiscal 2021. See Item 18. &#8220;Financial Statements &#8211; Note&#160;21 &#8211; Financial Instruments&#8221; for disclosures about financial risk management including interest rate risk, foreign currency risk and liquidity risk. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible note (Triaxial) carrying value of A$464,000 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended June&#160;30, 2013 the Company issued Convertible Notes with a face value of A$1,500,000 to Triaxial in consideration of the acquisition of patents and intellectual property assets. The terms of these Convertible Notes were amended on December&#160;4, 2014. The amended terms allow the conversion of debt into ordinary shares, provided that the Company achieves certain milestones. Accordingly, the Convertible Note has been reclassified as an equity instrument rather than debt instrument. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2017, Kazia reached two milestones that triggered the conversion of a portion of its Convertible Notes. On September&#160;14, 2016 the directors approved the issue of 20,000,000 ordinary shares as a consequence of a conversion of A$500,000 of the Convertible Notes, and on November&#160;1, 2016 a further 16,000,000 ordinary shares were issued as a result of the conversion of a further portion of the Convertible Notes. During fiscal 2018, one of the noteholders waived his rights to the remaining tranche of convertible notes, resulting in the reduction of the convertible note carrying value by a further A$136,000. As of June&#160;30, 2021, the Convertible Notes carrying value amounts to A$464,000. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">C. Research and development, Patents and Licenses, etc. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditure during the research phase of a project is recognized as an expense when incurred. Development costs are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist primarily of costs incurred for the development of our product candidates, which include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses incurred under agreements with academic research centres, clinical research organizations and investigative sites that conduct our clinical trials; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of acquiring, developing, and manufacturing clinical trial materials. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot determine with certainty the duration and completion costs of the current or future product development, preclinical studies or clinical trials of our product candidates. The duration, costs, and timing of clinical trials and development of our product candidates will depend on a variety of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope, rate of progress, and expense of our ongoing as well as any additional clinical trials and other research and development activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the countries in which trials are conducted; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">future clinical trial results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">uncertainties in clinical trial enrolment rates or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">drop-out</div> or discontinuation rates of patients; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential additional safety monitoring or other studies requested by regulatory agencies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant and changing government regulation; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing and receipt of any regulatory approvals. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2021, 2020 and 2019 we spent, respectively, a total of A$14.5&#160;million, A$9.5&#160;million and A$6.5&#160;million on company-sponsored research and development activities. We plan to increase our research and development expenses for the foreseeable future as we continue the development of product candidates and explore further potential applications of our technology. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D. Trend Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Further to the risk factors discussed in Item 3D, we note that the financial information disclosed in the SEC Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> may not be indicative of future results in the following areas: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we anticipate that funds will continue to be spent on research and development of our drug candidates, the amounts expended in recent years may not be indicative of the amounts to be expended in future years, because we may have more or fewer drug candidates, they may be at different stages of their lifecycle and the trials deemed suitable for their development may be more or less costly; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we generated revenue from licensing transactions in fiscal 2021, Kazia may not generate any revenue in future years, and if it does, the amounts generated in fiscal 2021 may not be representative of any such revenues in future years. This could be as a result of whether any further licensing transactions are entered into, as well as whether any milestones are met in relation to license agreements already in place; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The quantum of general and administrative expenditure in recent years may not be indicative of the expenditure required in future years; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">E. Critical Accounting Estimates &#8211; see Note 2. Significant accounting policies </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_9" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors, Senior Management and Employees </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A. Directors and Senior Management </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The names and details of the Company&#8217;s Directors and senior management at the date of this report are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 28%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 71%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Iain Ross</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Chairman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Bryce Carmine</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Steven Coffey</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">James Garner</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Managing Director and Chief Executive Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kate Hill</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Company Secretary</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Gabrielle Heaton</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Director of Finance and Administration</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors were in office for the entire period unless otherwise stated. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Names, titles, experience and expertise </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 24%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 75%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Iain Ross</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Chairman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Experience and expertise:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Iain, based in the UK, is an experienced Director and has served on a number of Australian company boards.&#160;He is Chairman of Silence Therapeutics plc (LSE&#160;&amp; NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited.&#160;He is also a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of Palla Pharma Limited (ASX:PAL).&#160;In his career he has held senior positions in Sandoz AG, Fisons Plc, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hoffmann-La</div> Roche AG and Celltech Group Plc and also undertaken a number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-ups</div> and turnarounds on behalf of banks and private equity groups. His track record includes multiple financing transactions having raised in excess of &#163;400&#160;million, both publicly and privately, as well as extensive experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Other current directorships:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Silence Therapeutics plc (LSE:SLN), ReNeuron Group plc (LSE:RENE), Palla Pharma Limited (ASX:PAL) and BiVictriX Therapeutics plc (LSE:BVX)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Special responsibilities:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Member of Remuneration and Nomination Committee, Member of the Audit, Risk and Governance Committee.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 24%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 75%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bryce Carmine</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Experience and expertise:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Bryce spent 36 years working for Eli Lilly&#160;&amp; Co. and retired as Executive Vice President for Eli Lilly&#160;&amp; Co, and President, Lilly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-Medicines.</div> Prior to this he led the Global Pharmaceutical Sales and Marketing and was a member of the Company&#8217;s Executive Committee. Bryce previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. During his career with Lilly, Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ&#160;&amp; General Manager of a JV for Lilly in Seoul, Korea. Bryce is currently Chairman and CEO of HaemaLogiX Pty Ltd, a Sydney based privately owned biotech.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Other current directorships:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">None</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Special responsibilities:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Chair of Remuneration and Nomination Committee, member of Audit, Risk and Governance Committee.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Steven Coffey</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Experience and expertise:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Steven is a Chartered Accountant and registered company auditor and has over 35 years experience in the accounting and finance industry. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993. Steven sits on the board of a number of large private family companies and audits a number of large private companies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-for-profit</div></div> entities.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Other current directorships:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">none</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Special responsibilities:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Chair of Audit, Risk and Governance Committee, member of Remuneration and Nomination Committee.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dr.&#160;James Garner</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Managing Director and Chief Executive Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Experience and expertise:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. <br/>Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain&#160;&amp; Company before entering the pharmaceutical industry. Prior to joining Kazia in 2016, he led R&amp;D strategy for Sanofi in Asia-Pacific and was based in Singapore.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Other current directorships:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">None</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Special responsibilities:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">None</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Kate Hill</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Company Secretary</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Experience and expertise:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Kate has over 20 years&#8217; experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately-owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment. She is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director of CountPlus Limited (ASX:CUP) and Elmo Software Limited (ASX:ELO) as well as Chair of the Audit and Risk Committee for both of these companies. She is also Chair of Seeing Machines Limited (LSE:SEE). Kate is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gabrielle Heaton</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Director of Finance and Administration</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Experience and expertise:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Gabrielle Heaton has over 30 years of commercial experience in media, property services and healthcare for multinational, ASX listed and overseas companies. She has held a number of senior Finance positions including CFO, Quality Auditor and been responsible for Human Resources and IT. Gabrielle has a Bachelor of Business from the University of Technology and is a member of CPA Australia.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">B. Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles used to determine the nature and amount of remuneration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Remuneration philosophy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remuneration for Directors and Senior Executives is based on the overall objective of attracting and retaining people of high quality who will make a worthwhile contribution to Kazia in the short, medium and long term, and thereby contribute to long term shareholder value. The Board and its Remuneration and Nomination Committee take a balanced position between the need to pay market rates to attract talent, and the financial resources of Kazia, in determining remuneration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors remuneration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Constitution of Kazia and the ASX listing rules specify that the aggregate remuneration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors shall be determined from time to time by General Meeting. The last determination for Kazia was at the Annual General Meeting held in&#160;November 2020 when the shareholders approved an aggregate remuneration of A$700,000. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors&#8217; fees are reviewed periodically by the Board and are regularly compared with those of companies of comparable market capitalisation and stage of development. The Chairman&#8217;s fees are determined independently to the fees of other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> Directors based on comparative roles in the external market. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Fees paid to director were relatively constant in recent years as a result of funding constraints, and in the current financial year, after conducting a benchmarking exercise, directors fees were increased to a market rate, and a bonus was paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors to reflect their service over recent years at a discounted remuneration level. Further, at the 2020 AGM the shareholders approved the award of 400,000 options to each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In relation to the cap on aggregate fees of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors, the value of the options has been excluded from the calculation of aggregate fees because the options were separately approved by the shareholders. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors fee structure is a fixed fee model and includes superannuation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive Directors and other Key Management Personnel (&#8220;KMP&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board and the Remuneration and Nomination Committee, in consultation with the Managing Director, have put in place a remuneration structure which provides incentive for employees to drive the activities of the company forward. These arrangements are reviewed annually at the end of the calendar year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board determines an appropriate level of fixed remuneration for the CEO and Group Executives, as well as the proportion of performance-based remuneration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The executive remuneration and reward framework has three components: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fixed remuneration </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">short-term performance incentives - cash bonus </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">share-based payments - award of options through the ESOP </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed remuneration is reviewed annually by the Remuneration and Nomination Committee based on individual performance, the overall performance of Kazia and comparable market remunerations. The Remuneration and Nomination Committee approved increases in fixed remuneration during fiscal 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The short-term incentives program is designed to align the targets of Kazia with the performance hurdles of executives. Short-term incentive payments are granted to executives based on specific annual performance objectives, metrics and performance appraisals. Annual performance reviews are conducted at the end of each calendar year and bonuses are paid shortly after the performance reviews are completed. Annual performance objectives cover matters such as progress in clinical trials, and management of the Company&#8217;s financial resources. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board or the Remuneration and Nomination Committee may, at its discretion, award bonuses for exceptional performance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Remuneration and Nomination Committee approved the payment of cash bonuses to the CEO and employees in respect of the financial year ended June&#160;30, 2020. The approval with respect to the financial year ended June&#160;30, 2021, is expected to occur subsequent to the filing of this annual report. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The long-term incentive comprises equity-based payments. Kazia aims to attract and retain high calibre executives, and align their interests with those of the shareholders, by granting equity-based payments based on tenure. The share-options issued to executives are governed by the ESOP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee share option plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Employee Share Option Plan (&#8216;ESOP&#8217;) was most recently approved by shareholders in&#160;November 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The ESOP provides for the issue of options to eligible individuals, being employees, Officers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-executive</div> directors of Kazia. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each option issued under the ESOP entitles its holder to acquire one fully paid ordinary share and is exercisable at a price based on a formula, which includes the weighted average price of such shares at the close of trading on the Australian Securities Exchange for the seven days prior to the date of issue. The number of options offered, the amount payable, the vesting period, the option period, the conditions of exercise or any other factors are at the discretion of the Board of Directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia issued 2,200,000 share options under the ESOP during fiscal 2021, of which 2,100,000 were issued to Key Management Personnel. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any change to the ESOP will require approval by shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of remuneration consultants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2021, the Company did not engage remuneration consultants to assist with the determination of remuneration levels. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Details of remuneration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts of remuneration </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of the remuneration of key management personnel of Kazia are set out in the following tables. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The KMP of Kazia consisted of the following directors of Kazia Therapeutics Limited: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Iain Ross - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director, Chairman </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bryce Carmine - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Steven Coffey - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Director </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr James Garner - Managing Director, CEO </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">And the following persons: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gabrielle Heaton - Director of Finance and Administration </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kate Hill - Company Secretary </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">employment</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Movements&#160;in</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">accrued leave</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Cash salary</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Cash</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Non-</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Super-</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity-</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">and fees</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Bonus</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">monetary</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">annuation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">settled&#160;options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">A$</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">A$</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">A$</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">A$</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">A$</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">A$</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Executive</div> Directors:</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I Ross*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">147,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">119,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">286,503</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">B Carmine</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">119,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">234,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S Coffey</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">119,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">234,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Directors:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J Garner</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">503,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">240,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">228,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,132,636</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Key Management Personnel:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G Heaton</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">204,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(241</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">265,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">K Hill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">108,525</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">155,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,127,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">356,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">112,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">616,598</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,303,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Salary paid in UK pounds, but disclosed in Australian dollars using an annual average rate of 0.5562 </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cash bonuses were granted by the Remuneration Committee at a meeting held in December 2020. The amounts were determined on a discretionary basis by the Remuneration Committee after assessing the corporate achievements for fiscal 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Remuneration and Nomination Committee policy, employment contracts are entered into with each of the executives who is considered to be KMP. Under the terms of the contracts, remuneration is reviewed at least annually. The employment contracts of KMPs include a termination clause whereby a party can terminate the agreement on notice. Such notice may vary between 4 weeks and 6 months. Under the terms of each contract, payment in lieu can be made by Kazia to substitute the notice period. Kazia may terminate the contracts at any time without cause if serious misconduct has occurred. In the event that employment is terminated for cause, no severance pay or other benefits are payable by Kazia. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 19%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Name:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Title:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreement commenced:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of agreement:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">James Garner</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer, Managing Director</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;1, 2016</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Full-time employment</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Base salary to be reviewed annually by the Remuneration and Nomination Committee. James&#8217;s appointment with Kazia may be terminated with Kazia giving 6 months&#8217; notice or by James giving 6 months&#8217; notice. Kazia may elect to pay James equal amount to that proportion of his salary equivalent 6 months&#8217; pay in lieu of notice, together with any outstanding entitlements due to him.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The current base salary, as from January&#160;1, 2021, is A$510,000 including an allowance for health benefits.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Name:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Title:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreement commenced:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of agreement:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gabrielle Heaton</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director of Finance and Administration</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;13, 2017</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Full time employment</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Base salary to be reviewed annually by the Remuneration and Nomination Committee. Gabrielle&#8217;s appointment with Kazia may be terminated with Kazia giving 4 weeks&#8217; notice or by Gabrielle giving 4 weeks&#8217; notice. Kazia may elect to pay Gabrielle equal amount to that proportion of her salary equivalent 4 weeks&#8217; pay in lieu of notice, together with any outstanding entitlements due to her.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The current base salary, from January&#160;1, 2021, is A$208,000.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Name:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Title:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreement commenced:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of agreement:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kate Hill</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company Secretary</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;9, 2016</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Part-time contractor</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">Base remuneration is based on time worked. Daily rate to be reviewed annually by the Remuneration and Nomination Committee, with monthly rate of A$11,900 for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-day</div> week, applied from January&#160;1, 2021. The contract is open ended. Kate&#8217;s appointment with Kazia may be terminated with Kazia giving 60 days&#8217; notice or by Kate giving 60 days&#8217; notice.</div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key management personnel have no entitlement to termination payments in the event of removal for misconduct. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based compensation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issue of shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The terms and conditions of each grant of options over ordinary shares granted as remuneration to Directors or other Key Management Personnel in this financial year or future financial years are set out below. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The options issued in November 2020 were to James Garner (800,000 options with a fair value at grant date of $402,000), Iain Ross (400,000 options with a fair value at grant date of $165,300), Bryce Carmine (400,000 options with a fair value at grant date of $165,300) and Steven Coffey (400,000 options with a fair value at grant date of $165,300) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The options issued in January 2021 were to Kate Hill (50,000 options, with a fair value at grant date of $29,929) and Gabrielle Heaton (50,000 options, with a fair value at grant date of $29,929).&#160;Service conditions are that any unvested options are forfeit on cessation of employment.&#160;There are no performance conditions, consistent with the Company&#8217;s Employee Share Option Plan rules, as reapproved by shareholders in November 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options issued during the financial year </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Grant date</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">No&#160;of<br/>options</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Vesting&#160;date</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Expiry&#160;date</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Exercise<br/>price&#160;$</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Fair&#160;value&#160;at<br/>grant&#160;date&#160;$</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.450</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.490</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">01/01/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.379</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">01/07/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">01/01/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">09/11/2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">01/07/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.446</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">04/01/2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">04/01/2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">04/01/2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.627</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">04/01/2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted carry no dividend or voting rights. Each option is convertible to one ordinary share upon exercise. During the year, 96,500 options were exercised by Gabrielle Heaton and 245,000 options were exercised by Kate Hill. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pension benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company paid A$112,290 during fiscal 2021 for employee superannuation benefits and pension benefits related to KMPs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">C. Board Practices </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The role of the Board is as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">representing and serving the interests of shareholders by overseeing and appraising the strategies, policies and performance of the Company. This includes overviewing the financial and human resources the Company has in place to meet its objectives and the review of management performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">protecting and optimising Company performance and building sustainable value for shareholders in accordance with any duties and obligations imposed on the Board by law and the Company&#8217;s Constitution and within a framework of prudent and effective controls that enable risk to be assessed and managed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">responsible for the overall Corporate Governance of Kazia Therapeutics Limited and its subsidiaries, including monitoring the strategic direction of the Company and those entities, formulating goals for management and monitoring the achievement of those goals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">setting, reviewing and ensuring compliance with the Company&#8217;s values (including the establishment and observance of high ethical standards); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ensuring shareholders are kept informed of the Company&#8217;s performance and major developments affecting its state of affairs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Responsibilities/functions of the Board include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">selecting, appointing and evaluating from time to time the performance of, determining the remuneration of, and planning for the successor of, the CEO; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing procedures in place for appointment of senior management and monitoring of its performance, and for succession planning. This includes ratifying the appointment and the removal of the Company Secretary; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">overseeing the Company, including its control and accountability systems; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">input into and final approval of management development of corporate strategy, including setting performance objectives and approving operating budgets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and guiding systems of risk management and internal control and ethical and legal compliance. This includes reviewing procedures in place to identify the main risks associated with the Company&#8217;s businesses and the implementation of appropriate systems to manage these risks; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">overseeing and monitoring compliance with the Code of Conduct and other corporate governance policies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring corporate performance and implementation of strategy and policy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approving major capital expenditure, acquisitions and divestitures, and monitoring capital management; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring and reviewing management processes in place aimed at ensuring the integrity of financial and other reporting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring and reviewing policies and processes in place relating to occupational health and safety, compliance with laws, and the maintenance of high ethical standards; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performing such other functions as are prescribed by law or are assigned to the Board. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In carrying out its responsibilities and functions, the Board may delegate any of its powers to a Board committee, a director, employee or other person subject to ultimate responsibility of the directors under the Australian Corporations Act 2001. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matters which are specifically reserved for the Board or its committees include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">appointment of a Chair; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">appointment and removal of the CEO; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">appointment of directors to fill a vacancy or as additional directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishment of Board committees, their membership and delegated authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval of dividends; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">development and review of corporate governance principles and policies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval of major capital expenditure, acquisitions and divestitures in excess of authority levels delegated to management; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calling of meetings of shareholders; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any other specific matters nominated by the Board from time to time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Structure of the Board </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Constitution governs the regulation of meetings and proceedings of the Board. The Board determines its size and composition, subject to the terms of the Constitution. The Board does not believe that it should establish a limit on tenure other than stipulated in the Company Constitution (refer to &#8216;Term of Directors&#8217; below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While tenure limits can help to ensure that there are fresh ideas and viewpoints available to the Board, they hold the disadvantage of losing the contribution of directors who have been able to develop, over a period of time, increasing insight in the Company and its operation and, therefore, an increasing contribution to the Board as a whole. It is intended that the Board should comprise a majority of independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors and comprise directors with a broad range of skills, expertise and experience from a diverse range of backgrounds. The Board regularly reviews the independence of each director in light of the interests disclosed to the Board. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board only considers directors to be independent where they are independent of management and free of any business or other relationship that could materially interfere with, or could reasonably be perceived to interfere with, the exercise of their unfettered and independent judgment. The Board has adopted a definition of independence based on that set out in Principle 2.3 of the ASX Corporate Governance Principles and Recommendations (4th edition). The Board will review the independence of each director in light of interests disclosed to the Board from time to time. In accordance with the definition of independence above, and the materiality thresholds set, the Board considers Bryce Carmine, Iain Ross and Steven Coffey to be independent directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">There are procedures in place, agreed by the Board, to enable directors in furtherance of their duties to seek independent professional advice at the Company&#8217;s expense. The appointment and expiration dates of each director in office at the date of this report is as follows:<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="width: 30%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Position</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;First&#160;Appointed</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Current&#160;term&#160;expires&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bryce Carmine</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-executive</div> Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2015</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Nov-23</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Iain Ross</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-executive</div> Director,</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chairman</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">2014</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Nov-21</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Steven Coffey</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-executive</div> Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2012</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Nov-22</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">James Garner</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Managing Director, CEO</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2016</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">N/A*</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The managing director is exempt from standing for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> under the Company&#8217;s constitution and Australian corporate law. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further details on each director can be found in &#8220;Names, titles, experience and expertise&#8221; above.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Term of Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s Constitution requires that at each Annual General Meeting of the Company, one third (or the number nearest to but not exceeding one third) of the directors, (excluding a director who is the Managing Director, and a director appointed to fill a casual vacancy) must retire from office provided that no director may retain office for more than three years without offering himself/herself for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> even though such submission results in more than one third of the directors retiring from office. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board of Directors has the power to appoint any person to be a director either to fill a casual vacancy or as an additional director (up to a maximum of 10). Any director so appointed may hold office only until the next Annual General Meeting when he or she shall be eligible for election by the Company shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Board of Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Board of Kazia Limited is elected by and accountable to shareholders. The Board monitors and directs the business and is responsible for the corporate governance of the Company. As at June&#160;30, 2021, the Board comprised of four directors, three of whom were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have a &#8216;diverse&#8217; board of directors as defined in Nasdaq Rule 5605(f). Kazia is a small company with four Directors. All of our Directors have been with the Company more than five years so there has not been an opportunity to consider &#8216;diverse&#8217; candidates. That being said, we believe in having a diverse workforce and will consider &#8216;diverse&#8217; director candidates when an opportunity arises. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Committees </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board has established an Audit, Risk and Governance Committee and a Remuneration and Nomination Committee. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit, Risk and Governance Committee </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Board has established an Audit, Risk and Governance Committee which operates under a Charter approved by the Board, which is available on the Company&#8217;s website. It is the Board&#8217;s responsibility to ensure that an effective internal control framework exists within the entity. This includes internal controls to deal with both the effectiveness and efficiency of significant business processes, the safeguarding of assets, the maintenance of proper accounting records, and the reliability of financial information as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> considerations such as the benchmarking of operational key performance indicators. The Board has delegated responsibility for establishing and maintaining a framework of internal control and ethical standards to the Audit, Risk and Governance Committee. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Committee also provides the Board with additional assurance regarding the reliability of financial information for inclusion in the financial reports. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members of the Audit, Risk and Governance Committee are Steven Coffey (Chairman), Bryce Carmine and Iain Ross, each of whom is an independent director. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remuneration and Nomination Committee </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the Remuneration and Nomination Committee is to assist and advise the Board to develop, implement and, from time to time, update policies in relation to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the selection, nomination and appointment processes for directors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the remuneration of key management personnel and directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This committee is accountable to the Board for its performance and is subject to an annual review by the Board. Members of the Remuneration and Nomination Committee are Bryce Carmine (Chairman), Steven Coffey and Iain Ross, each of whom is an independent director. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance of the Board and key executives is reviewed regularly using both measurable and qualitative indicators. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On at least a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-annual</div> basis, directors will provide written feedback in relation to the performance of the Board and its Committees against a set of agreed criteria: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each Committee of the Board will also be required to provide feedback in terms of a review of its own performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">feedback will be collected by the chair of the Board, or an external facilitator, and discussed by the Board, with consideration being given as to whether any steps should be taken to improve performance of the Board or its Committees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Chief Executive Officer will also provide feedback from senior management in connection with any issues that may be relevant in the context of Board performance review; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">where appropriate to facilitate the review process, assistance may be obtained from third party advisors.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remuneration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is the Company&#8217;s objective to provide maximum shareholder benefit from the retention of a high-quality Board and executive team by remunerating directors and key executives fairly and appropriately with reference to relevant employment market conditions. To assist in achieving this objective, the Board, in assuming the responsibilities of assessing remuneration to employees, links the nature and amount of executive directors&#8217; and officers&#8217; remuneration to the Company and Company&#8217;s financial and operational performance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected outcomes of the remuneration structure are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">retention and motivation of key executives; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">attraction of high-quality management to the Company and Company; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance incentives that allow executives to share in the success of Kazia Therapeutics Limited. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a more comprehensive explanation of the Company&#8217;s remuneration framework and the remuneration received by directors and key executives in the current period, please refer to the section &#8220;Compensation&#8221; above. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is no plan to provide retirement benefits to executive or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors, except for the Australian Government Superannuation Guarantee. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Remuneration and Nomination Committee is responsible for determining and reviewing compensation arrangements for the directors themselves and the Chief Executive Officer and executive team. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D. Employees </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the end of each of the last three fiscal years, the Company employed the following number of people - FTEs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Category of Activity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance and Administration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Geographic Location</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">E. Share Ownership </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Directors&#8217; and KMP interests in the shares and options of the Company for fiscal 2021: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shareholding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares in the Company held during fiscal 2021 by each Director and other members of Key Management Personnel of the Company, including their personally related parties, is set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at<br/>start&#160;of&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Received&#160;as<br/>part&#160;of&#160;rem</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disposals</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at<br/>end&#160;of&#160;year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">B Carmine*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">266,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">106,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">372,693</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S Coffey*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">326,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">107,791</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">434,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J Garner*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">275,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">155,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">430,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I Ross*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">800,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">K Hill*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">265,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">295,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G Heaton*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">103,168</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">113,168</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,707,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">937,359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,645,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Director and Key Management Personnel owns less than 1% of shareholding. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option holding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of options over ordinary shares in the company held during the financial year by each Director and other members of Key Management Personnel of Kazia, including their personally related parties, is set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at<br/>the start of<br/>the year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted as<br/>remuneration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at<br/>the end of<br/>the year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Options over ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J Garner*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">K Hill*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">320,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(245,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G Heaton*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">242,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(96,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">195,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Iain Ross*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bryce Carmine*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Steven Coffey*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,762,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(341,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,520,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options issued under the Employee Share Option Plan. Unvested options are forfeited upon cessation of employment with the Company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no shares issued to Directors or other KMP as part of compensation during fiscal 2021. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_10" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;7.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Major Shareholders and Related Party Transactions </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. Major shareholders </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table present certain information regarding the beneficial ownership of our ordinary shares based on 132,012,209 ordinary shares outstanding at September&#160;30, 2021, by each person known by us to be the beneficial owner of more than 5% of our ordinary shares, as well as their holdings on October&#160;14, 2020 and August&#160;31, 2019. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;shares</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;beneficially</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">5%&#160;or&#160;greater&#160;shareholders</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;14,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hishenk Pty Limited and associated entities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,715,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,570,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,108,792</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Platinum International Healthcare Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,084,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,356,760</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,578,948</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quest Asset Partners Pty Ltd</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,101,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,215,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2021, there were 3,130,299 of the Company&#8217;s ADSs outstanding, representing 31,302,996 ordinary shares (or 27.1% of the then outstanding ordinary shares). At September&#160;30, 2021, there were 52 registered holders of the Company&#8217;s ADSs. On that same date, 100 ordinary shares were held directly by U.S. holders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no other significant shareholders in the last three fiscal years. All shareholders have the same voting rights. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Related party transactions </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2021, and up to the date of this report, we did not enter into any transactions or loans with any: (i)&#160;enterprises that directly or indirectly, through one or more intermediaries, control, are controlled by or are under common control with us; (ii)&#160;associates; (iii)&#160;individuals owning, directly or indirectly, an interest in our voting power that gives them significant influence over us, and close members of any such individual&#8217;s family; (iv)&#160;executive officers and close members of such individuals&#8217; families; or (v)&#160;enterprises in which a substantial interest in our voting power is owned, directly or indirectly, by any person described in (iii)&#160;or (iv)&#160;or over which such person is able to exercise significant influence. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Transactions between related parties, when they occur, are on normal commercial terms and the conditions no more favorable than those available to other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div> parties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Interests of Experts and Counsel </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_11" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Information </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. Consolidated Statements and Other Financial Information </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Consolidated financial statements are included in Item 18. &#8220;Financial Statements&#8221; commencing on page <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal proceedings </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In prior periods, Kazia was prosecuting its Intellectual Property (&#8216;IP&#8217;) rights against an Austrian company, APOtrend, and had provided a guarantee to the value of &#8364;250,000 with the court to provide security for potential damage claimes raised by APOtrend. During fiscal 2021 the proceedings were settled and the deposit was released in full back to Kazia. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no dividends paid, recommended or declared during fiscal years 2021, 2020 or 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Significant Changes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">No significant change has occurred since the date of the annual financial statements included in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_12" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Offer and Listing </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. Offer and listing details </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See Item 9C for more information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Plan of Distribution </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Markets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia&#8217;s principal listing exchange and the exchange upon which its ordinary shares are quoted is the Australian Securities Exchange (&#8220;ASX&#8221;). The trading symbol on ASX is &#8216;KZA&#8217;. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia&#8217;s ordinary shares trade in the U.S. in the form of ADSs on the NASDAQ Capital Market. Each ADS represents 10 ordinary shares of Kazia. The trading symbol on the NASDAQ Capital Market is &#8216;KZIA&#8217;. Kazia has entered into a Deposit Agreement with The Bank of New York Mellon under which the Bank of New York, acting as depositary, issues the ADSs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">D. Selling Shareholders </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">E. Dilution </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">F. Expenses of the issue </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_13" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional Information </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. Share Capital </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Memorandum and Articles of Association </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Constitution is similar in nature to the bylaws of a U.S. corporation. It does not provide for or prescribe any specific objectives or purposes of Kazia. Our Constitution is subject to the terms of the ASX Listing Rules and the Corporations Act. It may be amended or repealed and replaced by special resolution of shareholders, passed by at least 75% of the votes cast by shareholders entitled to vote on the resolution.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Australian law, a company has the legal capacity and powers of an individual both within and outside Australia. The material provisions of our Constitution are summarized below. This summary is not intended to be complete nor to constitute a definitive statement of the rights and liabilities of our shareholders, and is qualified in its entirety by reference to the complete text of our Constitution, a copy of which is incorporated by reference as Exhibit 1.1 to this Annual Report. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interested Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the Corporations Act and the ASX Listing Rules, neither a director nor that director&#8217;s alternate may vote in respect of any contract or arrangement in which the director has, directly or indirectly, any material interest according to our Constitution. However, that director may execute or otherwise act in respect of that contract or arrangement notwithstanding any material personal interest. Unless a relevant exception applies, the Corporations Act requires our directors to provide disclosure of any material personal interest, and prohibits directors from voting on matters in which they have a material personal interest or being present while such matter is being considered at the board meeting. In addition, the Corporations Act and the ASX Listing Rules require shareholder approval of any provision of related party benefits to our directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our directors are paid remuneration for their services as directors (but excluding any remuneration payable to a director under any executive services contract with us or one of our related bodies corporate) which is determined in a general meeting of shareholders. The aggregate, fixed sum for directors&#8217; remuneration is to be divided among the directors in such proportion as the directors themselves agree and in accordance with our Constitution. The fixed sum remuneration for directors may not be increased except at a general meeting of shareholders and the particulars of the proposed increase are required to have been provided to shareholders in the notice convening the meeting. In addition, executive directors may be paid remuneration as determined by the directors from time to time and, subject to the ASX Listing Rules, including as a salary, commission or participation in profits and/or by the issue of shares, options to acquire shares or performance rights or other incentives (or a combination of any of these methods of remuneration). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Fees payable to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors must be by way of a fixed sum and not by way of a commission on or a percentage of profits or operating revenue. Remuneration paid to our executive directors must also not include a commission or percentage of operating revenue. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our Constitution, if, at our board&#8217;s request, any director performs extra services or makes special exertions, Kazia may remunerate that director by paying for those services and exertions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to other remuneration provided in our Constitution, all of our directors are entitled to be paid by us for all other travelling, accommodation and other expenses incurred by the directors in attending and returning from general meetings, board meetings, committee meetings or otherwise in connection with our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowing powers exercisable by Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our Constitution, the management and control of our business affairs are vested in our board of directors. Our board of directors has the power to raise or borrow money or obtain other financial accommodation for Company purposes, and may grant security for the repayment of that sum or sums or the payment, performance or fulfilment of any debts, liabilities, contracts or obligations incurred or undertaken by the Company in any manner and on any terms and conditions as our board thinks fit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retirement of Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to our Constitution and the ASX Listing Rules, at least one director, other than the Managing Director, must retire from office at every annual general meeting unless there has been an election of directors earlier that year. A director, other than the director who is the Managing Director, must retire from office at the conclusion of three years or following the third annual general meeting after which the director was elected, whichever is longer. If no director is required to retire at an annual general meeting, then the director to retire will be the director who has been longest in office since last being elected. Retired directors are eligible for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> to the board of directors unless disqualified from acting as a director under the Corporations Act or our Constitution. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rights and restrictions on classes of shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The rights attaching to our ordinary shares are detailed in our Constitution. Our Constitution provides that our directors may issue shares with any preferential, deferred or special rights, privileges or conditions or with any restriction (whether in relation to dividends, voting, return of share capital or otherwise) as our board of directors may determine. Subject to any approval which is required from our shareholders under the Corporations Act and the ASX Listing Rules, we may issue further shares on such terms and conditions as our board of directors resolves.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our board of directors may from time to time determine to pay and declare dividends to shareholders. All dividends unclaimed for one year after having been declared may be invested or otherwise made use of by our board of directors for our benefit until claimed or otherwise disposed of in accordance with our Constitution.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Voting rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under our Constitution, and subject to any voting exclusions imposed under the ASX Listing Rules (which typically exclude parties from voting on resolutions in which they have an interest), the rights and restrictions attaching to a class of shares, each shareholder has one vote on a show of hands at a meeting of the shareholders unless a poll is demanded under the Constitution or the Corporations Act. On a poll vote, each shareholder shall have one vote for each fully paid share and a fractional vote for each share held by that shareholder that is not fully paid, such fraction being equivalent to the proportion of the amount that has been paid to such date on that share. Shareholders may vote in person or by proxy, attorney or representative. Under Australian law, shareholders of a public company are generally not permitted to approve corporate matters by written consent. Our Constitution does not provide for cumulative voting. Note that ADS holders may not directly vote at a meeting of the shareholders but may instruct the depositary to vote the number of deposited ordinary shares their ADSs represent. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right to share in our profits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our Constitution, our shareholders are entitled to participate in our profits only by payment of dividends. Our board of directors may from time to time determine to pay dividends to the shareholders; however, no dividend is payable except in accordance with the thresholds set out in the Corporations Act. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rights to share in the surplus in the event of winding up </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Constitution provides for the right of shareholders to participate in a surplus in the event of our winding up, subject to the rights attaching to a class of shares, the Constitution, the Corporations Act and the ASX Listing Rules.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No redemption provision for ordinary shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There are no redemption provisions in our Constitution in relation to ordinary shares. Under our Constitution, any preference shares may be issued on the terms that they are, or may at the option of Kazia or the holder be, liable to be redeemed or converted into ordinary shares.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variation or cancellation of share rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the Corporations Act, the ASX Listing Rules and the terms of issue of shares of that class, the rights attached to shares in a class of shares may only be varied or cancelled by either: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a special resolution passed at a meeting of members holding shares in that class; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the written consent of members with at least 75% of the shares in that class. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors may make calls </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Constitution provides that our directors may make calls on a shareholder for all monies unpaid on shares held by that shareholder, other than monies payable at fixed times under the conditions of allotment.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General Meetings of Shareholders </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General meetings of shareholders may be called by our board of directors. Except as permitted under the Corporations Act, shareholders may not convene a meeting. The Corporations Act requires the directors to call and arrange to hold a general meeting on the request of shareholders with at least 5% of the votes that may be cast at a general meeting. Notice of the proposed meeting of our shareholders is required at least 28&#160;days prior to such meeting under the Corporations Act. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Ownership Regulation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Constitution does not impose specific limitations on the rights of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> to own securities. However, acquisitions and proposed acquisitions of securities in Australian companies may be subject to review and approval by the Australian Federal Treasurer under the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Acquisitions and Takeovers Act 1975</div></div> (Cth) (the &#8220;Foreign Takeovers Act&#8221;), which generally applies to acquisitions or proposed acquisitions: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by a foreign person (as defined in the Foreign Takeovers Act) or associated foreign persons that would result in such persons having an interest in 20% or more of the issued shares of, or control of 20% or more of the voting power in, an Australian company; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">by&#160;non-associated&#160;foreign</div> persons that would result in such foreign persons having an aggregate interest in 40% or more of the issued shares of, or control of 40% or more of the voting power in, an Australian company, where the Australian company is valued above the monetary threshold prescribed by Foreign Takeovers Act. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, in general terms, no such review or approval under the Foreign Takeovers Act is required if the foreign acquirer is a U.S. entity or an entity from certain other countries and the value of the target is less than A$1,154&#160;million, unless the company operates in certain sensitive industries. Exemptions do not apply to investments by foreign governments and their associated entities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Australian Federal Treasurer may prevent a proposed acquisition in the above categories or impose conditions on such acquisition if the Treasurer is satisfied that the acquisition would be contrary to the national interest. If a foreign person acquires shares or an interest in shares in an Australian company in contravention of the Foreign Takeovers Act, the Australian Federal Treasurer may make a range of orders including an order the divestiture of such person&#8217;s shares or interest in shares in that Australian company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ownership Threshold </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no specific provisions in our Constitution that require a shareholder to disclose ownership above a certain threshold. The Corporations Act, however, requires a shareholder to notify us and the ASX once it, together with its associates, acquires a 5% interest in our ordinary shares, at which point the shareholder will be considered to be a &#8220;substantial&#8221; shareholder. Further, once a shareholder owns (alone or together with associates) a 5% interest in us, such shareholder must notify us and the ASX of any increase or decrease of 1% or more in its holding of our ordinary shares, and must also notify us and the ASX on its ceasing to be a &#8220;substantial&#8221; shareholder. As we are also a U.S. public company, our shareholders are also subject to disclosure requirements under U.S. securities laws. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issues of Shares and Change in Capital </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, we may at any time issue shares and give any person a call or option over any shares on any terms, with preferential, deferred or special rights, privileges or conditions or with any restrictions and for the consideration and other terms that the directors determine. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subject to the requirements of our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, including relevant shareholder approvals, we may consolidate or divide our share capital into a larger or smaller number by resolution, reduce our share capital in any manner (provided that the reduction is fair and reasonable to our shareholders as a whole, does not materially prejudice our ability to pay creditors and obtains the necessary shareholder approval) or buy back our ordinary shares whether under an equal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">access&#160;buy-back&#160;or</div> on a selective basis. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change of Control </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Takeovers of listed Australian public companies, such as Kazia, are regulated by the Corporations Act, which prohibits the acquisition of a &#8220;relevant interest&#8221; in issued voting shares in a listed company if the acquisition will lead to that person&#8217;s or someone else&#8217;s &#8220;voting power&#8221; (being the person&#8217;s relevant interests plus those of its associates) in Kazia&#8217;s issued shares increasing from 20% or below to more than 20% or increasing from a starting point that is above 20% and below 90% (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeovers Prohibition</div></div>&#8221;), subject to a range of exceptions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, a person will have a relevant interest in securities if the person: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">is the holder of the securities or the holder of an ADS over the shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has power to exercise, or control the exercise of, a right to vote attached to the securities; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has the power to dispose of, or control the exercise of a power to dispose of, the securities, including any indirect or direct power or control. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If, at a particular time: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a person has a relevant interest in issued securities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the person has: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered or enters into an agreement with another person with respect to the securities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">given or gives another person an enforceable right, or has been or is given an enforceable right by another person, in relation to the securities (whether the right is enforceable presently or in the future and whether or not on the fulfillment of a condition); or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">granted or grants an option to, or has been or is granted an option by, another person with respect to the securities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the other person would have a relevant interest in the securities if the agreement were performed, the right enforced or the option exercised, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Then the other person is taken to already have a relevant interest in the securities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are a number of exceptions to the Takeovers Prohibition on acquiring a relevant interest in issued voting shares above 20%. In general terms, some of the more significant exceptions include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition results from the acceptance of an offer under a formal takeover bid; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition is conducted on market by or on behalf of the bidder during the bid period for a full takeover bid that is unconditional or only conditional on certain &#8216;prescribed&#8217; matters set out in the Corporations Act, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition has been previously approved by shareholders of Kazia by resolution passed at general meeting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an acquisition by a person if, throughout the six months before the acquisition, that person or any other person has had voting power in Kazia of at least 19% and, as a result of the acquisition, none of the relevant persons would have voting power in Kazia more than three percentage points higher than they had six months before the acquisition; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition results from the issue of securities under a pro rata rights issue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition results from the issue of securities under a dividend reinvestment scheme or bonus share plan; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition results from the issue of securities under certain underwriting arrangements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the acquisition results from the issue of securities through a will or through operation of law; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an acquisition that arises through the acquisition of a relevant interest in another listed company which is listed on a prescribed financial market or a foreign market approved by ASIC; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">an acquisition arising from an auction of forfeited shares <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">conducted&#160;on-market;</div> or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">an acquisition arising through a compromise, arrangement, liquidation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;buy-back.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Breaches of the takeovers provisions of the Corporations Act are criminal offenses. The Australian Securities and Investments Commission, or ASIC, and the Australian Takeover Panel have a wide range of powers relating to breaches of takeover provisions or other circumstances deemed to be unacceptable (whether or not they involve a breach of the takeover provisions), including the ability to make orders canceling contracts, freezing transfers of, and rights attached to, securities, and forcing a party to dispose of securities. There are certain defenses to breaches of the takeover provisions provided in the Corporations Act. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Access to and Inspection of Documents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Inspection of our records is governed by the Corporations Act. Any member of the public has the right to inspect or obtain copies of our registers on the payment of a prescribed fee. Shareholders are not required to pay a fee for inspection of our registers or minute books of the meetings of shareholders. Other corporate records, including minutes of directors&#8217; meetings, financial records and other documents, are not open for inspection by shareholders. Where a shareholder is acting in good faith and an inspection is deemed to be made for a proper purpose, a shareholder may apply to the court to make an order for inspection of our books.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Material contracts </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License Agreement with Genentech Inc. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2016, the Company entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">commercialise&#160;GDC-0084,&#160;a</div> small molecule inhibitor of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;phosphoinositide-3-kinase&#160;(PI3K)</div></div> pathway. Under the terms of the agreement, the Company paid Genentech an upfront payment of US$5&#160;million. In addition, the terms of the agreement call for performance-related consideration linked to regulatory and commercial outcomes and royalty <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">payments&#160;in-line&#160;with</div> industry benchmarks. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Glioblast Pty Ltd&#8212;Share Sale Agreement with Kilinwata Investments Pty. Ltd., Mi Ok Chong and Paul Hopper </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2016, the Company acquired 100% of the issued shares of Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. The transaction included an upfront payment of A$2.1&#160;million, comprising A$600,000 in cash and ordinary fully-paid shares valued at A$1.5&#160;million, with the actual number of shares determined on the basis of the volume-weighted average price of the Company&#8217;s shares on the ASX in the seven days prior to this announcement. The shareholders of Glioblast will be eligible for further payments in cash or equity on the achievement of performance related milestones. The first two of these milestones provide for the issue of ordinary fully-paid shares valued at A$1.25&#160;million respectively on commencement and successful completion of a phase&#160;II clinical trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;GDC-0084,&#160;with&#160;the</div> actual number of shares determined on the basis of the volume-weighted average price of the Company&#8217;s shares on the ASX in the seven days prior to satisfaction of the relevant milestone being announced. A further two milestones may trigger payments in cash or equity at the Company&#8217;s sole discretion. Any issue of equity in the Company will be subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">minimum&#160;six-month&#160;escrow</div> period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the date of this report, one milestone has lapsed and two have been settled in shares. The remaining milestone relates to the successful completion of a Phase&#160;II trial in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GDC-0084.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Note Deed Poll and Amendment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;4, 2014, we and Triaxial signed a Convertible Note Deed Poll (&#8216;Deed&#8217;) which superseded a Loan Agreement. The Deed extinguishes the liability created by the Loan Agreement, which previously allowed for a cash settlement and now allows Triaxial to convert their debt into ordinary shares, provided that the Company achieves defined milestones established in the schedule of the Deed. Accordingly, the convertible note has been reclassified as an equity instrument rather than debt instrument. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the fiscal 2017, the Company reached two milestones triggering the conversion of a portion of its convertible note as follows; </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;11, 2016 the Company announced the submission of an IND application. On September&#160;10, 2016, the Company received a letter from the FDA advising the study may proceed. This triggered the conversion of Convertible Notes with a face value of A$500,000 into 20,000,000 ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on October&#160;31, 2016, the Company announced it had licensed a Phase II ready molecule. This triggered the conversion of Convertible Notes with a face value of A$400,000 into 16,000,000 ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2018, A$136,000 of the Convertible Notes was extinguished. The remaining Convertible Notes with a face value of A$464,000 at year end may be converted into 1,856,000 ordinary shares of the Company (post share consolidation). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining portion of the convertible note will be exercised at the holders&#8217; discretion on completion of Phase II clinical trial or achieving &#8220;Breakthrough Designation&#8221;. Completion will be deemed to occur upon the receipt by the Company of a signed study report or notification of the designation. There is a possibility for an early conversion of the Convertible Notes if a third party acquires more than 50% of the issued capital of the Company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical Trial Collaboration and Supply Agreement with the Global Coalition for Adaptive Research </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2020, the Company entered into a Clinical Trial Collaboration and Supply Agreement with the Global Coalition for Adaptive Research (GCAR), a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> 501(C)(3) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> organisation. The agreement relates to the inclusion of Kazia&#8217;s investigational new drug, paxalisib <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(GDC-0084)</div> in a phase II/III adaptive clinical trial known as GBM AGILE (NCT03970447), which is expected to serve as the pivotal study for registration of paxalisib in glioblastoma by the US Food and Drug Administration (FDA). Under the terms of the agreement, the Company paid GCAR an upfront payment of US$5&#160;million on execution, and will make further payments to GCAR throughout the course of the study, as defined milestones are met, with the total cost of the study capped at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-defined</div> amount under the terms of the agreement. GCAR will serve as the sponsor of GBM AGILE and the company will supply investigational product for conduct of the study at its sole expense. It is expected that paxalisib&#8217;s participation in GBM AGILE will be approximately three to four years in duration. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License Agreement with Oasmia Pharmaceutical AB </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2021, the Company entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical A, an innovation-focused specialty pharmaceutical company, for Cantrixil <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TRX-E-002-1),</div></div></div> a clinical-stage, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> drug candidate under development for the treatment of ovarian cancer. Under the terms of the agreement, Oasmia assumed worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer. During fiscal 2021, Oasmia made an upfront payment of US$4&#160;million, with contingent milestones of up to US$42&#160;million and double-digit royalties on commercial sales. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License Agreement with Simcere Pharmaceutical Group Ltd </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2021, the Company entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (&#8220;Simcere&#8221;) to develop and commercialise the Company&#8217;s investigational new drug, paxalisib, in Greater China. Under the terms of the agreement, Simcere assumed responsibility for the development, registration and commercialization of paxalisib in Greater China (a territory which includes Mainland China, Hong Kong, Macau and Taiwan). The Company received an upfront payment of US$11&#160;million comprising US$7&#160;million in cash and a US$4&#160;million equity investment, priced at a 20% premium to recent trading. The Company will also receive contingent milestone payments of up to US$281&#160;million for glioblastoma, with further milestones payable for indications beyond glioblastoma. Simcere will additionally pay <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> percentage royalties on commercial sales. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License Agreement with Evotec SE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2021, the Company entered into a worldwide exclusive licensing agreement with Evotec SE, a leading European drug discovery and development company, for EVT801, a small-molecule, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> oncology drug candidate. Under the terms of the agreement, Evotec has granted Kazia an exclusive license to develop, manufacture, and commercialize EVT801 in all territories and indications. The Company paid an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> amount of &#8364;1&#160;million (approximately A$1.6 million). In addition, the terms of the agreement call for performance-related consideration linked to regulatory and commercial outcomes up to a maximum of &#8364;308&#160;million (approximately A$480 million) and tiered single-digit royalty payments. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">D. Exchange controls </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Australia has largely abolished exchange controls on investment transactions. The Australian dollar is freely convertible into U.S. dollars. In addition, (other than as specified under &#8220;taxation&#8221; below and certain restrictions imposed under Australian law in relation to dealings with the assets of and transactions with, designated countries, entities and persons specified by the Australian Government Department of Foreign Affairs and Trade from time to time, including, persons connected with terrorism) there are currently no specific rules or limitations regarding the export from Australia of profits, dividends, capital, or similar funds belonging to foreign investors, except that certain payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> must be reported to the Australian Transaction Reports and Analysis Centre, which monitors such transactions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under Australian law, foreign persons require the approval from the Australian Treasurer to acquire more than a limited percentage of the interests in an Australian company. These limitations are set forth in the A<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ustralian Foreign Acquisitions and Takeovers Act 1975</div></div> (Cth) (the &#8220;Foreign Takeovers Act&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Foreign Takeovers Act, in general terms, the approval of the Australian Treasurer is required for any foreign person (either alone or together with any one or more of its associates) to acquire an interest of 20% or more of the voting power (including potential voting power) or issued shares (including rights to issued shares) (&#8220;Substantial Interest&#8221;) in an Australian entity, whose total issued securities value or total asset value (whichever is higher) exceed A$275&#160;million. If the person is a U.S. investor, the A$275&#160;million threshold applies only for investments in prescribed sensitive sectors, otherwise a threshold of A$1,192&#160;million rather than A$275&#160;million applies. All direct investment by foreign governments and their related entities regardless of the value of the investment, including proposals to establish new businesses, must be notified to the Australian Treasurer. Where an acquisition is made in breach of these requirements, the Australian Treasurer may make a range of orders including an order requiring the acquirer to dispose of its Substantial Interest within a specified period of time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if a foreign person acquires a Substantial Interest in Kazia in circumstances where the above monetary thresholds would be exceeded and as a result the total holdings of all foreign persons and their associates exceeds 40% in aggregate without the approval of the Australian Treasurer, then the Australian Treasurer may make a range of orders including an order requiring the acquirer to dispose of its Substantial Interest within a specified period of time. The same rule applies if the total holdings of all foreign persons and their associates already exceeds 40% and a foreign person (or its associate) acquires any further interests, including in the course of trading in the secondary market of the ADSs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the current Australian foreign investment policy, the Australian Treasurer has the power to make such an order in relation to an acquisition that contravenes the Foreign Takeovers Act where the level of foreign ownership exceeds 40% in the ordinary course of trading, if the Australian Treasurer is satisfied that the acquisition is contrary to the national interest. The Foreign Takeovers Act allows foreign persons to seek prior approval of acquisitions of Kazia interests which could otherwise result in the Australian Treasurer making an order requiring the foreign person to dispose of any Substantial Interest. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If a foreign person holds more than 20% of the interests of Kazia or if the level of aggregate foreign ownership of Kazia exceeds 40% at any time, Kazia would be considered a foreign person under the Foreign Takeovers Act. In such event, Kazia would be required to obtain the approval of the Australian Treasurer for Kazia, together with its associates, to acquire: (i)&#160;more than 20% of an Australian company or business with a total issued securities value or total asset value (whichever is higher) totaling over A$275&#160;million; or (ii)&#160;any direct or indirect ownership interest in Australian land. However, as mentioned above, in general terms, proposals by U.S. investors for investment in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-sensitive</div> sectors do not require notification to the Australian Treasurer or the Australian Treasurer&#8217;s approval unless the value of the target Australian company or business exceeds A$1,192&#160;million. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The percentage of foreign ownership of Kazia would also be included in determining the foreign ownership of any Australian company or business in which it may choose to invest. Kazia has no current plans for any such acquisitions. The Company&#8217;s Constitution does not impose specific limitations on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident&#8217;s</div> right to hold or vote the Company&#8217;s securities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">E. Taxation </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Taxation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This section describes the material U.S. federal income tax consequences to a U.S. holder (as defined below) of owning ordinary shares or ADSs. It applies only to ordinary shares or ADSs that are held as capital assets for tax purposes. This section does not apply to a holder of ordinary shares or ADSs that is a member of a class of holders subject to special rules, including a financial institution, a dealer or trader in securities, a regulated investment company, a real estate investment trust, a grantor trust, a U.S. expatriate, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> organization, an insurance company, a person liable for alternative minimum tax, a person who actually or constructively owns 10% or more of the stock of the Company, a person that holds ordinary shares or ADSs as part of a straddle or a hedging or conversion transaction, a person that purchases or sells ordinary shares or ADSs as part of a wash sale for tax purposes, or a person whose functional currency is not the U.S. dollar. Further, this description does not address state, local, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S,</div> or other tax laws, nor does it address the 3.8% U.S. federal Medicare tax on net investment income, the alternative minimum tax or the U.S. federal gift and estate tax consequences of owning and disposing of ordinary shares or ADSs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of this description, a &#8220;U.S. holder&#8221; is a beneficial owner of ordinary shares or ADSs who holds such ordinary shares or ADSs as capital assets within the meaning of the Code and is, for U.S. federal income tax purposes: (i)&#160;an individual citizen or resident of the United States; (ii)&#160;a corporation created or organized in or under the laws of the United States or any state thereof, including the District of Columbia; (iii)&#160;an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (iv)&#160;a trust that either (a)&#160;is subject to the supervision of a court within the United States and has one or more U.S. persons with authority to control all substantial decisions or (b)&#160;has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a partnership holds the ordinary shares or ADSs, the U.S. federal income tax treatment of a partner generally will depend on the status of the partner and the tax treatment of the partnership. A partner in a partnership holding the ordinary shares or ADSs should consult its tax advisor with regard to the U.S. federal income tax treatment of an investment in the ordinary shares or ADSs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This section is in part based on the representations of the Depositary and the assumption that each obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. In general, for U.S. federal income tax purposes, a holder of ADSs will be treated as the owner of the ordinary shares represented by those ADSs. Exchanges of ordinary shares for ADSs, and ADSs for ordinary shares generally will not be subject to U.S. federal income tax. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the Passive Foreign Investment Company (&#8220;PFIC&#8221;) rules discussed below, U.S. holders generally will include as dividend income the U.S. dollar value of the gross amount of any distributions of cash or property (without deduction for any withholding tax), other than certain pro rata distributions of ordinary shares, with respect to ordinary shares or ADSs to the extent the distributions are made from our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. A U.S. holder will include the dividend income on the day actually or constructively received (i)&#160;by the holder, in the case of ordinary shares, or (ii)&#160;by the depositary, in the case of ADSs. We do not intend to maintain calculations of earnings and profits, as determined for U.S. federal income tax purposes. Consequently, any distributions generally will be treated as dividend income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Dividends paid to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. holder on shares or ADSs will generally be taxable at the preferential rates applicable to long-term capital gains provided (a)&#160;that certain holding period requirements are satisfied, (b)&#160;(i) the U.S.-Australia income tax treaty (&#8220;the Treaty&#8221;) is a qualified treaty and we are eligible for benefits under the Treaty or (ii)&#160;our ordinary shares or ADSs are readily tradable on a U.S. securities market, and (c)&#160;provided that we were not, in the taxable year prior to the year in which the dividend was paid, and are not, in the taxable year in which the dividend is paid, a PFIC. The Treaty has been approved for the purposes of the qualified dividend rules and the ADSs are listed on NASDAQ. If the Company is a PFIC, any dividends paid to a noncorporate U.S. holder will not qualify for the preferential tax rates ordinarily applicable to &#8220;qualified dividends.&#8221; In the case of a corporate U.S. holder, dividends on shares and ADSs are taxed as ordinary income and will not be eligible for the dividends received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of any cash distribution paid in any foreign currency will be equal to the U.S. dollar value of such currency, calculated by reference to the spot rate in effect on the date such distribution is received by the U.S. holder or, in the case of ADSs, by the Depositary, regardless of whether and when the foreign currency is in fact converted into U.S. dollars. If the foreign currency is converted into U.S. dollars on the date received, the U.S. holder generally should not recognize foreign currency gain or loss on such conversion. If the foreign currency is not converted into U.S. dollars on the date received, the U.S. holder will have a basis in the foreign currency equal to its U.S. dollar value on the date received, and generally will recognize foreign currency gain or loss on a subsequent conversion or other disposal of such currency. Such foreign currency gain or loss generally will be treated as U.S. source ordinary income or loss for foreign tax credit limitation purposes. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends will be income from sources outside the United States, and generally will be &#8220;passive category&#8221; income or, for certain taxpayers, &#8220;general category&#8221; income, which are treated separately from each other for the purpose of computing the foreign tax credit allowable to a U.S. holder. The availability of the foreign tax credit and the application of the limitations on its availability are fact specific and are subject to complex rules. In general, a taxpayer&#8217;s ability to use foreign tax credits may be limited and is dependent on the particular circumstances. U.S. holders should consult their own tax advisors with respect to these matters. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale, Exchange or other Disposition of Ordinary Shares or ADSs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the PFIC rules discussed below, a U.S. holder who sells or otherwise disposes of ordinary shares or ADSs will recognize a capital gain or loss for U.S. federal income tax purposes equal to the difference between the U.S. dollar value of the amount realized and the holder&#8217;s tax basis, determined in U.S. dollars, in those ordinary shares or ADSs. The gain or loss will generally be income or loss from sources within the United States for foreign tax credit limitation purposes. The capital gain of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. holder is generally taxed at preferential rates where the holder has a holding period greater than 12 months in the shares or ADSs sold. There are limitations on the deductibility of capital losses. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The U.S. dollar value of any foreign currency received upon a sale or other disposition of ordinary shares or ADSs will be calculated by reference to the spot rate in effect on the date of sale or other disposal (or, in the case of a cash basis or electing accrual basis taxpayer, at the spot rate of exchange on the settlement date). A U.S. holder will have a tax basis in the foreign currency received equal to that U.S. dollar amount, and generally will recognize foreign currency gain or loss on a subsequent conversion or other disposal of the foreign currency. This foreign currency gain or loss generally will be treated as U.S. source ordinary income or loss for foreign tax credit limitation purposes. If such foreign currency is converted into U.S. dollars on the date received by the U.S. holder, a cash basis or electing accrual basis U.S. holder should not recognize any gain or loss on such conversion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Passive Foreign Investment Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation will be a PFIC for U.S. federal income tax purposes for any taxable year if either: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75% or more of its gross income for such year is &#8220;passive income&#8221; which for this purpose generally includes dividends, interest, royalties, rents and gains from commodities and securities transactions and gains from assets that produce passive income; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50% or more of the value of its gross assets (based on an average of the quarterly values of the gross assets) during such year is attributable to assets that produce passive income or are held for the production of passive income. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Passive income does not include rents and royalties derived from the active conduct of a trade or business. If the stock of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation is publicly traded for the taxable year, the asset test is applied using the fair market value of the assets for purposes of measuring such corporation&#8217;s assets. If we own at least 25% (by value) of the stock of another corporation, we will be treated, for purposes of the PFIC tests, as owning our proportionate share of the other corporation&#8217;s assets and receiving our proportionate share of the other corporation&#8217;s income for purposes of the PFIC income and asset tests. If the stock of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation is publicly-traded for the taxable year, the asset test is applied using the fair market value of the assets for purposes of measuring such corporation&#8217;s assets. If we were a PFIC in any year during a U.S. holder&#8217;s holding period for our ordinary shares or ADSs, we would ordinarily continue to be treated as a PFIC for each subsequent year during which the U.S. holder owned the ordinary shares or ADSs. Based on the composition of our assets and income, we believe that we may be treated as a PFIC for U.S. federal income tax purposes with respect to our 2021 taxable year. However, the determination of PFIC status is a factual determination that must be made annually at the close of each taxable year and therefore, there can be no certainty as to our status in this regard until the close of the current or any future taxable year. Changes in the nature of our income or assets or a decrease in the trading price of our ordinary shares or ADSs may cause us to be considered a PFIC in the current or any subsequent year. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Information Reporting and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Back-up</div> Withholding </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dividend payments with respect to our ordinary shares or ADSs and proceeds from the sale or other disposition of our ordinary shares or ADSs may be subject to information reporting to the IRS and possible U.S. backup withholding. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Back-up</div> withholding will not apply, however, to a U.S. holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> withholding. U.S. holders who are required to establish their exempt status may be required to provide such certification on Internal Revenue Service (&#8220;IRS&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;W-9.</div> U.S. holders should consult their tax advisors regarding the application of the U.S. information reporting and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> withholding rules. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Back-up</div> withholding is not an additional tax. Amounts withheld as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> withholding may be credited against a U.S. holder&#8217;s U.S. federal income tax liability, and such holder may obtain a refund of any excess amounts withheld under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> withholding rules by timely filing the appropriate claim for refund with the IRS and furnishing any required information. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Information With Respect to Foreign Financial Assets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain U.S. holders that own &#8220;specified foreign financial assets&#8221; with an aggregate value in excess of $50,000 are generally required to file an information statement along with their U.S. federal tax returns, currently on IRS Form 8938, with respect to such assets. &#8220;Specified foreign financial assets&#8221; include any financial accounts held at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> financial institution, as well as securities issued by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> issuer that are not held in accounts maintained by financial institutions. If a U.S. holder does not include in such holder&#8217;s gross income an amount relating to one or more specified foreign financial assets, and the amount such U.S. holder omits is more than $5,000, any tax such U.S. holder owes for the tax year can be assessed at any time within 6 years after the filing of such U.S. holder&#8217;s federal tax return. U.S. holders who fail to report the required information could be subject to substantial penalties. U.S. holders are encouraged to consult with their own tax advisors regarding the possible application of the foregoing to our ordinary shares or ADSs in light of their particular circumstances. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australian Tax Considerations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In this section, we discuss the material Australian income tax, stamp duty and goods and services tax considerations related to the acquisition, ownership and disposal by the absolute beneficial owners of the ordinary shares or ADSs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">It is based upon existing Australian tax law as of the date of this registration statement, which is subject to change, possibly retrospectively. This discussion does not address all aspects of Australian tax law which may be important to particular investors in light of their individual investment circumstances, such as shares held by investors subject to special tax rules (for example, financial institutions, insurance companies or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> organizations). In addition, this summary does not discuss any foreign or state tax considerations, other than stamp duty. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prospective investors are urged to consult their tax advisors regarding the Australian and foreign income and other tax considerations of the acquisition, ownership and disposition of the shares. This summary is based upon the premise that the holder is not an Australian tax resident and is not carrying on business in Australia through a permanent establishment (referred to as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-Australian</div> Shareholder&#8221; in this summary). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australian Income Tax </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of ADSs for Australian Taxation Purposes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Ordinary shares represented by ADSs held by a U.S. holder will be treated for Australian taxation purposes as held under a &#8220;bare trust&#8221; for such holder. Consequently, the underlying ordinary shares will be regarded as owned by the ADS holder for Australian income tax and capital gains tax purposes. Dividends paid on the underlying ordinary shares will also be treated as dividends paid to the ADS holder, as the person beneficially entitled to those dividends. Therefore, in the following analysis we discuss the tax consequences to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders which, for Australian taxation purposes, will be the same as to U.S. holders of ADSs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxation of Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Australia operates a dividend imputation system under which dividends may be declared to be &#8220;franked&#8221; to the extent of tax paid on company profits. Fully franked dividends are not subject to dividend withholding tax. Dividends payable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders will be subject to dividend withholding tax, to the extent the dividends are not declared to be conduit foreign income, or CFI, and are unfranked. Dividend withholding tax will be imposed at 30%, unless a shareholder is a resident of a country with which Australia has a double taxation agreement and qualifies for the benefits of the treaty. In accordance with the provisions of the Double Taxation Convention between Australia and the United States, the maximum rate of Australian withholding tax on any unfranked portion of a dividend to which a resident of the United States is beneficially entitled is 15%, where the U.S. resident holds less than 10% of the voting rights in our company, or 5% where the U.S. resident holds 10% or more of the voting rights in our company. The Double Taxation Convention does not apply to impose withholding tax on dividends where the ADSs are effectively connected to a permanent establishment or a fixed base carried on by the owner of the ADSs in Australia through which the Non-Australian Shareholders carry on business or provide independent personal services, respectively. In such a case, the provisions of Article&#160;7 (Business profits) or Article&#160;14 (Independent personal services) of the Double Taxation Conventions, as the case may be, shall apply. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax on Sales or other Dispositions of Shares&#8212;Capital Gains Tax </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders will not be subject to Australian capital gains tax on the gain made on a sale or other disposal of ordinary shares, unless they, together with associates, hold 10% or more of our issued capital, at the time of disposal or for 12 months of the last two years prior to disposal. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders who own a 10% or more interest would be subject to Australian capital gains tax if more than 50% of our assets held directly or indirectly, determined by reference to market value, consists of Australian real property (which includes land and leasehold interests) or Australian mining, quarrying or prospecting rights. The Double Taxation Convention between the United States and Australia is unlikely to limit the amount of this taxable gain. Australian capital gains tax applies to net capital gains of foreign shareholders at the Australian tax rates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Australian</div> residents, which start at a marginal rate of 32.5% for individuals (or a flat rate of 26%-30% (2021) &amp; 25%-30% (2022) for companies, depending on the size of the company). Net capital gains are calculated after reduction for capital losses, which may only be offset against capital gains. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The 50% capital gains tax discount is not available to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders. Companies are not entitled to a capital gains tax discount. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Broadly, where there is a disposal of certain taxable Australian property, the purchaser will be required to withhold and remit to the Australian Taxation Office (&#8220;ATO&#8221;) 12.5% of the proceeds from the sale. A transaction is excluded from the withholding requirements in certain circumstances, including where the value of the taxable Australian property is less than A$750,000, the transaction is an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-market</div> transaction conducted on an approved stock exchange, a securities lending, or the transaction is conducted using a broker operated crossing system. There is also an exception to the requirement to withhold where the entity selling the shares provides the purchaser a declaration specifying either that they are an Australian resident or that the shares are not taxable Australian property (specifically, not &#8216;indirect Australian real property interests&#8217;). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholder may be entitled to receive a tax credit for the tax withheld by the purchaser which they may claim in their Australian income tax return. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax on Sales or other Dispositions of Shares&#8212;Shareholders Holding Shares on Revenue Account </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders may hold ordinary shares on revenue rather than on capital account for example, share traders. These shareholders may have the gains made on the sale or other disposal of the ordinary shares and/or warrants included in their assessable income under the ordinary income provisions of the income tax law, if the gains are sourced in Australia. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders assessable under these ordinary income provisions in respect of gains made on ordinary shares held on revenue account would be assessed for such gains at the Australian tax rates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Australian</div> residents, which start at a marginal rate of 32.5% for individuals (or a flat rate of 26%-30% (2021) &amp; 25%-30% (2022) for companies, depending on the size of the company). Some relief from Australian income tax may be available to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholders under the Double Taxation Convention between the United States and Australia. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent an amount would be included in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Australian</div> Shareholder&#8217;s assessable income under both the capital gains tax provisions and the ordinary income provisions, the capital gain amount would generally be reduced, so that the shareholder would not be subject to double tax on any part of the income gain or capital gain. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The comments above in &#8220;Tax on Sales or Other Dispositions of Shares&#8212;Capital Gains Tax&#8221; regarding a purchaser being required to withhold 12.5% tax on the acquisition of certain taxable Australian property equally applies where the disposal of the Australian real property asset by a foreign resident is likely to generate gains on revenue account, rather than a capital gain. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dual Residency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If a shareholder is a resident of both Australia and the United States under those countries&#8217; domestic taxation laws, that shareholder may be subject to tax as an Australian resident. If, however, the shareholder is determined to be a U.S. resident for the purposes of the Double Taxation Convention between the United States and Australia, the Australian tax would be subject to limitation by the Double Taxation Convention (albeit the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tie-breaker</div> rules only apply for individuals). Shareholders should obtain specialist taxation advice in these circumstances. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stamp Duty </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">No Australian stamp duty is payable by Australian residents or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Australian</div> residents on the issue, transfer and/or surrender of the ADSs or the ordinary shares in Kazia, provided that the shares issued, transferred and/or surrendered do not represent 90% or more of the issued shares in Kazia. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australian Death Duty </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australia does not have estate or death duties. As a general rule, no capital gains tax liability is realized upon the inheritance of a deceased person&#8217;s shares. The disposal of inherited shares by beneficiaries may, however, give rise to a capital gains tax liability if the gain falls within the scope of Australia&#8217;s jurisdiction to tax. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goods and Services Tax </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The supply of ADSs or ordinary shares in Kazia will not be subject to Australian goods and services tax. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">F. Dividends and paying agents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">G. Statement by experts </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">H. Documents on Display </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is subject to the reporting requirements of the Exchange Act that are applicable to a foreign private issuer. Under the Exchange Act, the Company is required to file periodic reports and other information with the SEC. These materials, including this Annual Report and the exhibits hereto, may be inspected without charge and copied at established rates at the public reference facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C., 20549. Please call the SEC at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-800-SEC-0330</div></div></div> to obtain information on the operation of the public reference room. Such materials can also be obtained at the SEC&#8217;s website at <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.sec.gov</div>. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">I. Subsidiary Information </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_14" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative and Qualitative Disclosures about Market Risk </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s exposure to market interest rates relate primarily to the investments of cash balances. The Company has cash reserves held primarily in Australian dollars and places funds on deposit with financial institutions for periods generally not exceeding three months. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company places its deposits with high credit quality financial institutions, and, by policy, limits the amount of credit exposure to any single counter-party. The Company is averse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk and reinvestment risk. The Company mitigates default risk by depositing funds with only the safest and highest credit quality financial institutions and by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has no interest rate exposure due to rate changes for long-term debt obligations. The Company primarily enters into debt obligations to support general corporate purposes, including capital expenditures and working capital needs. The Company does not consider the effects of interest rate movements to be a material risk to its financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For additional disclosure regarding interest rate risk see Item 18. &#8220;Financial Statements &#8211; Note&#160;21 &#8211; Financial Instruments&#8221;. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign currency risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the U.S. dollar. Foreign exchange risk arises from future transactions and recognised assets and liabilities denominated in a currency that is not the entity&#8217;s functional currency and net investments in foreign operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, the Company did not hold derivative financial instruments in managing its foreign currency, however, the Company may from time to time enter into hedging arrangements where circumstances are deemed appropriate. The Company used natural hedging to reduce the foreign currency risk, which involved processing USD payments from cash held in USD. Foreign subsidiaries with a functional currency of Australian Dollar (&#8220;AUD&#8221;) have exposure to the local currency of these subsidiaries and any other currency these subsidiaries trade in. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For additional disclosure regarding market risk see Item 18. &#8220;Financial Statements &#8211; Note 21 &#8211; Financial Instruments&#8221;. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_15" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;12.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Securities Other than Equity Securities </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. Debt Securities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. Warrants and Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Other Securities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">D. American Depositary Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The depositary collects its fees for delivery and surrender of American Depositary Shares (&#8220;ADSs&#8221;) directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deductions from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-attracting</div> services until its fees for those services are paid. The depositary may collect any of its fees by deduction from any cash distribution payable to you that are obligated to pay those fees. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the depositary may make payments to us to reimburse or share revenue from the fees collected from you, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties under the deposit agreement, the depositary may use brokers, dealers or other service providers that are affiliates of the depositary and that may earn or share fees or commissions. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons depositing or withdrawing shares must pay:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For:</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">US$.05 (or less) per ADS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Any cash distribution to ADS registered holders</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS registered holders</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">US$.05 (or less) per ADSs per calendar year</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Depositary services</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Registration or transfer fees</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Transfer and registration of shares on the Company&#8217;s share register to or from the name of the depositary or its agent when you deposit or withdraw shares</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Expenses of the depositary</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Converting foreign currency to U.S. dollars</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As necessary</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Any charges incurred by the depositary or its agents for servicing the deposited securities</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As necessary</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Depositary may collect any of the fees by deduction from any cash distribution payable, or by selling a portion of any securities to be distributed, to holders that are obligated to pay those fees. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc185056_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_17" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defaults, Dividend Arrearages and Delinquencies </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This item is not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_18" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Material Modifications to the Rights of Security Holders and the Use of Proceeds </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This item is not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_19" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;15.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Controls and Procedures </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(a) Disclosure controls and procedures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the end of the period covered by this Annual Report, the Company&#8217;s management, with the participation of the Chief Executive Officer and the Director of Finance and Administration, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Exchange Act). Based on that evaluation, the Company&#8217;s Chief Executive Officer and the Director of Finance and Administration have concluded that the Company&#8217;s disclosure controls and procedures are effective as of June&#160;30, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) Management&#8217;s annual report on internal controls over financial reporting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The management of Kazia Therapeutics Limited is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Director of Finance and Administration, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of June&#160;30, 2021 based on the criteria set forth in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control&#8212;Integrated Framework </div></div>issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013). Based on our evaluation under the criteria set forth in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control &#8212; Integrated Framework</div></div>, our management concluded that our internal control over financial reporting was effective as of June&#160;30, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited&#8217;s internal control was designed to provide reasonable assurance to the Company&#8217;s management and Board of Directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management maintains a comprehensive system of controls intended to ensure that transactions are executed in accordance with management&#8217;s authorization, assets are safeguarded, and financial records are reliable. Management also takes steps to ensure that information and communication flows are effective and monitor performance, including performance of internal control procedures. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of June&#160;30, 2021. Based on this assessment, management concluded that the Company&#8217;s internal control over financial reporting is effective as of June&#160;30, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(c) Attestation Report of the Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(d) Changes in Internal Control over Financial Reporting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There was no change in our internal control over financial reporting that occurred during the period covered by this annual report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_20" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">[Reserved] </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_21" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Committee Financial Expert </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Board of Directors has determined that Steven Coffey, qualifies as an &#8220;audit committee financial expert&#8221; as that term is defined in Item 16A of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> Steven Coffey meets the independence requirements of the NASDAQ Capital Market and SEC&#8217;s rules and regulations as he is a qualified Chartered Accountant and has spent over 30 years in public practice. He is also a registered company auditor. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_22" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Code of Ethics </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has adopted a Code of Ethics and Business Conduct (the &#8220;Code&#8221;). The Code establishes a clear set of values that emphasise a culture encompassing strong corporate governance, sound business practices and good ethical conduct. The Code confirms the Company&#8217;s belief in treating all individuals with respect and recognises that different skills and diversity are essential to enrich the Company&#8217;s perspective, improve corporate performance, increase shareholder value and maximise the achievement and goals of the Company. The Code applies to all Company employees, including management and Directors. The Code is available on the Company&#8217;s website <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">www.kaziatherapeutics.com</div>. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_23" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal Accounting Fees and Services </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant Thornton Audit Pty Ltd (&#8220;GT&#8221;) has audited the Company&#8217;s annual financial statements acting as the independent registered public accounting firm for the fiscal years ended June&#160;30, 2021 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below set forth the total fees for services performed by GT in fiscal years 2021 and 2020, and summarizes these amounts by the category of service. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/>A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit fees - Grant Thornton Audit Pty Ltd</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit fees </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The audit fees include the aggregate fees incurred in fiscal years 2021 and 2020 for professional services rendered in connection with the audit of the Company&#8217;s annual financial statements and for related services that are reasonably related to the performance of the audit or services that are normally provided by the auditor in connection with regulatory filings of engagements for those financial years (including review of the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F,</div> consents and other services related to SEC matters). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-approval</div> policies and procedures </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Audit Committee Charter sets forth the Company&#8217;s policy regarding the appointment of independent auditors. The Audit Committee Charter also requires the Audit Committee to review and approve in advance the appointment of the independent auditors for the performance of 100% of all audit services and, after taking into account the opinion of management, 100% of lawfully permitted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services. The Audit Committee may delegate authority to one or more members of the Audit Committee where appropriate, but no such delegation is permitted if the authority is required by law, regulation or listing standard to be exercised by the Audit Committee as a whole. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal year 2021, the amount paid to Grant Thornton for services other than Audit fees amounted to nil. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_24" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exemptions from the Listing Standards for Audit Committees </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This item is not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_25" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16E.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This item is not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_26" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16F.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in registrant&#8217;s Certifying Accountant </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This item is not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_27" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16G.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Governance </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Implications of Being a Foreign Private Issuer </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are also considered a &#8220;foreign private issuer.&#8221; In our capacity as a foreign private issuer, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&#160;14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section&#160;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our ordinary shares. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exemptions from Certain Corporate Governance Rules of the NASDAQ Stock Market, LLC </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exemptions from the corporate governance standards of the NASDAQ Stock Market, LLC (&#8220;NASDAQ&#8221;) are available to foreign private issuers such as Kazia when those standards are contrary to a law, rule or regulation of any public authority exercising jurisdiction over such issuer or contrary to generally accepted business practices in the issuer&#8217;s country of domicile. In connection with Kazia&#8217;s National Market Listing Application, NASDAQ granted Kazia exemptions from certain corporate governance standards that were contrary to the laws, rules, regulations or generally accepted business practices of Australia. These exemptions and the practices followed by Kazia are described below: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia is exempt from NASDAQ&#8217;s requirement that each NASDAQ issuer shall require shareholder approval of a plan or arrangement in connection with the acquisition of the stock or assets of another company if &#8220;any director, officer or substantial shareholder of the issuer has a 5&#160;percent or greater interest (or such persons collectively have a 10&#160;percent or greater interest), directly or indirectly, in the company or assets to be acquired or in the consideration to be paid in the transaction or series of related transactions and the present or potential issuance of common stock, or securities convertible into or exercisable for common stock, could result in an increase in outstanding common shares or voting power of 5&#160;percent or more&#8221;. Kazia is subject to Chapter 10 of the ASX listing rules, which requires shareholder approval for an acquisition from or disposal to a &#8220;related party&#8221; (including a director) or &#8220;substantial shareholder&#8221; (who is entitled to at least 10% of the voting securities) of &#8220;substantial assets&#8221;. The Australian Corporations Act to which Kazia is also subject generally requires shareholder approval for a transaction with a director or director-controlled entity unless on arm&#8217;s length terms. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq requirement under Rule 5620(c) that a quorum consist of holders of 33 1/3% of the outstanding ordinary shares &#8212; The ASX Listing Rules do not have an express requirement that each issuer listed on ASX have a quorum of any particular number of the outstanding ordinary shares, but instead allow a listed issuer to establish its own quorum requirements. Our quorum is currently three shareholders. We believe this quorum requirement is consistent with the requirements of the ASX and is appropriate and typical of generally accepted business practices in Australia. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq requirements under Rules 5605(b)(1) and (2)&#160;relating to director independence, including the requirements that a majority of the board of directors must be comprised of independent directors and that independent directors must have regularly scheduled meetings at which only independent directors are present &#8212; The Nasdaq and ASX definitions of what constitute an independent director are not identical and the requirements relating to the roles and obligations of independent directors are not identical. The ASX, unlike Nasdaq, permits an issuer to establish its own materiality threshold for determining whether a transaction between a director and an issuer affects the director&#8217;s status as independent and it does not require that a majority of the issuer&#8217;s board of directors be independent, as long as the issuer publicly discloses this fact. In addition, the ASX does not require that the independent directors have regularly scheduled meeting at which only independent directors are present. We believe that our Board composition is consistent with the requirements of the ASX and that it is appropriate and typical of generally accepted business practices in Australia. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The requirement that our independent directors meet regularly in executive sessions under Nasdaq Listing Rules. The ASX Listing Rules and the Corporations Act do not require the independent directors of an Australian company to have such executive sessions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Nasdaq requirements under Rules 5605(d) and 5605(e) that compensation of an issuer&#8217;s officers must be determined, or recommended to the Board for determination, either by a majority of the independent directors, or a compensation committee comprised solely of independent directors, and that director nominees must either be selected, or recommended for the Board&#8217;s selection, either by a majority of the independent directors, or a nominations committee comprised solely of independent directors. The Nasdaq compensation committee requirements are not identical to the ASX remuneration and nomination committee requirements. Issuers listed on the ASX are recommended under applicable listing standards to establish a remuneration committee consisting of a majority of independent directors and an independent chairperson, or publicly disclose that it has not done so. Kazia has, and expects to continue to have, a Remuneration and Nomination Committee consisting of three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> directors. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The requirement prescribed by Nasdaq Listing Rules that issuers obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions, private placements of securities, or the establishment or amendment of certain share option, purchase or other compensation plans. Applicable Australian law and the ASX Listing Rules differ from Nasdaq requirements, with the ASX Listing Rules providing generally for prior shareholder approval in numerous circumstances, including (i)&#160;issuance of equity securities exceeding 15% (or 25% under certain circumstances) of our issued share capital in any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period (but, in determining the 15% limit, securities issued under an exception to the rule or with shareholder approval are not counted), (ii) issuance of equity securities to related parties (as defined in the ASX Listing Rules) and (iii)&#160;issuances of securities to directors or their associates under an employee incentive plan. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_28" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16H.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mine Safety Disclosure </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This item is not applicable. </div></div> <div id="toc185056_29" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_30" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;17.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to &#8220;Item 18 &#8211; Financial Statements&#8221; below </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_31" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The financial statements filed as part of this Annual Report commencing on page <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1.</div> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc185056_32" style="width: 11%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;19.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td style="width: 90%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;1.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex11.htm">Constitution of Kazia Therapeutics Limited, as amended and restated on November&#160;16, 2016 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;2.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312516748662/d272985dex21.htm">Deposit Agreement, dated as of June&#160;6, 2016 among Novogen Limited, The Bank of New York, as Depositary, and owners and holders from time to time of ADSs issued thereunder (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;27, 2016 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312516748662/d272985dex41.htm">Lease Agreement, dated November&#160;1, 2015 between Coal Services Pty Limited and Novogen (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;27, 2016 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312516748662/d272985dex42.htm">Employment Agreement for Chief Executive Officer of Novogen Limited, dated December&#160;10, 2015 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;27, 2016 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex420.htm">Employment Agreement for Director of Finance and Administration of Novogen Limited, dated as of July&#160;3, 2017 (incorporated by reference to Exhibit 4.20 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312516748662/d272985dex46.htm">Convertible Note Deed Poll with Triaxial Pty Ltd Noteholders dated December&#160;6, 2012 (incorporated by reference to Exhibit 4.6 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;27, 2016 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312516748662/d272985dex47.htm">Amendment to Convertible Note Deed Poll with Triaxial Pty Ltd Noteholders dated December&#160;4, 2014 (incorporated by reference to Exhibit 4.7 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;27, 2016 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.6</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312516748662/d272985dex410.htm">Kazia Therapeutics Officers&#8217; and Employees&#8217; Share Option Plan (incorporated by reference to Exhibit 4.10 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;27, 2016 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex411.htm">Share Sale Agreement dated October&#160;31, 2016 between Kilinwata Investments Pty. Ltd., Mi Ok Chong, Paul Hopper and Novogen Limited (Incorporated by reference to Exhibit 4.11 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex412.htm">Exclusive License Agreement dated October&#160;25, 2016 between Genentech, Inc. and Novogen Limited (incorporated by reference to Exhibit 4.12 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 91%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.9</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex417.htm">Sabio Solutions Pty Limited Letter of Appointment &#8211; Company Secretary, dated as of September&#160;1, 2016 (incorporated by reference to Exhibit 4.17 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.10</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex418.htm">Sabio Solutions Pty Limited Contract Extension Letter, dated as of March&#160;1, 2017 (incorporated by reference to Exhibit 4.18 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.11</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312517318584/d464682dex419.htm">Sabio Solutions Pty Limited Contract Extension Letter, dated as of August&#160;23, 2017 (incorporated by reference to Exhibit 4.19 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;25, 2017 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.12</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312519270437/d759444dex412.htm">Investigator Initiated Clinical Trial Agreement between Kazia Therapeutics Limited and Dana-Farber/Partners Cancer Care Inc dated 17&#160;October 2018 (incorporated by reference to Exhibit&#160;4.12 to the Company&#8217;s Annual Report on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;20-F</span> filed with the SEC on October&#160;21, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.13</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312519270437/d759444dex413.htm">Research Funding and Supply Agreement between Alliance for Clinical Trials in Oncology Foundation and Kazia Therapeutics Limited, dated 11&#160;June 2019 (incorporated by reference to Exhibit&#160;4.13 to the Company&#8217;s Annual Report on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;20-F</span> filed with the SEC on October&#160;21, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.14</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312519270437/d759444dex414.htm">Master Clinical Trial Agreement between St Jude Children&#8217;s Hospital Inc. and Kazia Laboratories Pty Limited dated 17&#160;November 2017 and associated work order date 7&#160;June 2019 (incorporated by reference to Exhibit&#160;4.14 to the Company&#8217;s Annual Report on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;20-F</span> filed with the SEC on October&#160;21, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.15</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312520274018/d92594dex415.htm">Memorial Sloan Kettering Cancer Center Investigator-Initiated Clinical Trial Agreement with Kazia Therapeutics Limited dated as 22&#160;July 2019 (incorporated by reference to Exhibit&#160;4.15 to the Company&#8217;s Annual Report on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;20-F</span> filed with the SEC on October&#160;22, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.16</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312520274018/d92594dex416.htm">Investigator Initiated Clinical Trial Agreement with Kazia Therapeutics Limited Agreement dated as 18&#160;September 2020 (incorporated by reference to Exhibit 4.16 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;22, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.17</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312520274018/d92594dex417.htm">Global Coalition for Adaptive Research, (&#8220;GCAR&#8221;) Clinical trial collaboration and supply agreement dated as 15&#160;October 2020 (incorporated by reference to Exhibit&#160;4.17 to the Company&#8217;s Annual Report on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;20-F</span> filed with the SEC on October&#160;22, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.18*&#10003;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex418.htm">Development and Commercialisation Licence Agreement between Kazia Therapeutics Limited and Oasmia Pharmaceutical AB, dated March&#160;1, 2021. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.19*&#10003;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex419.htm">License Agreement between Kazia Therapeutics Limited and Simcere Pharmaceutical Co., Ltd., dated March&#160;29, 2021. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.20*&#10003;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex420.htm">License Agreement between Kazia Therapeutics Limited and Evotec (France) SAS, dated April&#160;19, 2021 </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">8.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1075880/000119312518305893/d600370dex81.htm">Company Subsidiaries (incorporated by reference to Exhibit 8.1 to the Company&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> filed with the SEC on October&#160;24, 2018 (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;0-29962)).</span> </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">12.1*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex121.htm">Certification of Chief Executive Officer pursuant to Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a)</span> of the Securities Exchange Act of 1934, as amended. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">12.2*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex122.htm">Certification of Director of Finance and Administration pursuant to Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a)</span> of the Securities Exchange Act of 1934, as amended. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">13.1*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex131.htm">Certification of Chief Executive Officer and the Director of Finance and Administration pursuant to 18 U.S.C. Section&#160;1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">15.1*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d185056dex151.htm">Consent of Independent Registered Public Accounting Firm. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">XBRL Instance Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Schema Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Calculation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Definition Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Label Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Presentation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#10003;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain confidential information in this exhibit was omitted by means of marking such information with brackets (&#8220;[***]&#8221;) because the identified confidential information is not material and is the type that the registrant treats as private or confidential. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">KAZIA THERAPEUTICS LIMITED</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ James Garner</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dr James Garner</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Managing Director and Chief Executive Officer</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: October&#160;7, 2021</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Index to Financial Statements </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 96%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements for June&#160;30, 2021, 2020 and 2019 and the years then ended:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin185056_1">Report of Independent Registered Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin185056_2">Consolidated Statement of Profit or Loss and Other Comprehensive Income</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin185056_3">Consolidated Statement of Financial Position</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin185056_4">Consolidated Statement of Changes in Equity</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin185056_5">Consolidated Statement of Cash Flows</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin185056_6">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; text-indent: 0px;"> <div id="fin185056_1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors and Shareholders </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated statements of financial position of Kazia Therapeutics Limited and subsidiaries (the &#8220;Company&#8221;) as of June&#160;30, 2021 and 2020, the related consolidated statements of profit or loss and other comprehensive income, changes in shareholders&#8217; equity, and cash flows for each of the three years in the period ended June&#160;30, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June&#160;30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June&#160;30, 2021, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis for opinion</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical audit matters </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible asset impairment</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Note 2, Note 3, Note 12)</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company carries in its statement of financial position intangible assets relating to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Licensing Agreement which grants the Company the right to develop the paxalisib molecule; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Licensing Agreement which grants the Company the right to develop the EVT801 molecule. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The paxalisib Licensing Agreement has a carrying value of $11.3m and the EVT801 Licensing Agreement has a carrying value of $10.7m. These assets are being amortised over the remaining life of the underlying patents at acquisition date, being 15&#160;years and 12.5&#160;years respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">IAS 36 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Assets</div></div> requires an entity to assess at the end of each reporting period whether there is any indication that an asset may be impaired. If any indication exists, the entity shall estimate the recoverable amount of the asset. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This is a critical audit matter due to the materiality of amounts in question and the high degree of management judgement required in assessing whether there are indicators of impairment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our procedures included, amongst others: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining an understanding of and evaluating management&#8217;s process and controls related to the assessment of the existence of impairment indicators; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing management&#8217;s assessment of the existence of any impairment indicators, including making enquiries of management&#8217;s experts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">considering each of the internal and external factors outlined by IAS 136 and assessing whether any indicators of impairment are present; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing management&#8217;s assessment of the potential impact of COVID-19 on the performance of the assets; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluating the adequacy of the relevant disclosures in the financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Asset acquisition accounting</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Note 2, Note 3, Note 12, and Note 15)</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On 19 April 2021 the Company entered into a worldwide exclusive licensing agreement with Evotec SE, for the oncology drug candidate EVT801. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction has been accounted for as an asset acquisition and as noted in note 15, the agreement contains contingent payments dependent on the achievement of contracted milestones. Management has exercised judgement in determining the probability of achieving such milestones and the timing of each. The estimated contingent consideration at 30 June 2021 is $11.08m. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This is a critical audit matter due to the materiality of amounts in question and the high degree of management judgement required. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our procedures included, amongst others: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining and testing the license agreement to understand the terms and conditions of the transaction; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing management&#8217;s assessment of the proposed accounting treatment of the transaction; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agreeing key terms of agreements utilised in management&#8217;s assessment; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing key assumptions made by management in its assessment of accounting treatment; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluating management&#8217;s method of amortisation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">making enquiries of management&#8217;s experts; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluating the adequacy of the relevant disclosures within the financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for license agreements under IFRS 15 Revenues from Contracts with Customers</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Note 2, Note 3, and Note 5)</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year, the Company entered into the following transactions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On 1 March 2021, the Company entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (Oasmia), granting Oasmia the worldwide rights to develop and commercialise Cantrixil; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On 29 March 2021 the Company entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere), granting Simcere the rights to develop and commercialise Paxalisib, in the Greater China territory. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transactions included the receipt of upfront cash payments of US$4 million and US$7 million from Oasmia and Simcere, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">This is a critical audit matter due to the materiality of the transactions and the judgement required by management in accounting for these transactions in accordance with IFRS 15 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our procedures included, amongst others: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining copies of the license agreements to understand the terms and conditions of the transactions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluating management&#8217;s accounting papers documenting the accounting treatments, including in relation to the applicability of IFRS 15; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agreeing key terms of agreements utilised in management&#8217;s assessment; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing key assumptions made by management in its assessment of accounting treatments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">making enquiries of management&#8217;s experts; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluating the adequacy of the relevant disclosures within the financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ GRANT THORNTON AUDIT PTY LTD </div><br/></div> <div style="padding: 0pt; text-indent: 0px;">
<table style="width: 100%; line-height: 0pt; border-spacing: 0px;">
<tr>
<td style="margin-left: 0in; font-size: 2pt; margin-bottom: 0px; padding: 0px; border-bottom: 1pt solid rgb(0, 0, 0); width: 25%;;text-align:left;">&#160;</td>
<td style="padding: 0px 0px 1pt; width: 37.5%;">&#160;</td>
<td style="padding: 0px 0px 1pt; width: 37.5%;">&#160;</td> </tr> </table> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>GRANT THORNTON AUDIT PTY LTD<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chartered Accountants</div><br/></div> <br/> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2012.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sydney, Australia </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 7, 2021 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;"></a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin185056_2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of profit or loss and other comprehensive income </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended 30&#160;June 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from continuing operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherRevenue" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherRevenue" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherRevenue" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance income &#8212; bank interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,785</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on disposal of fixed assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value losses on financial assets at fair value through profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on revaluation of contingent consideratio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:GainLossOnRevaluationOfContingentConsideration" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:GainLossOnRevaluationOfContingentConsideration" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:GainLossOnRevaluationOfContingentConsideration" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax expense from continuing operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">484</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense for the year</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Items that may be reclassified subsequently to profit or loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net exchange difference on translation of financial statements of foreign controlled entities, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income for the year, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income for the year</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,420</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,471</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,359</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss for the year is attributable to:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Owners of Kazia Therapeutics Limited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss for the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income for the year is attributable to:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Owners of Kazia Therapeutics Limited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income for the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,420</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,471</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,359</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The above consolidated statements of profit or loss or other comprehensive income should be read with the accompanying notes </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of profit or loss and other comprehensive income (continued) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended 30&#160;June 2021 </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per shar<div style="display:inline;">e</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin185056_3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of financial position </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at 30&#160;June 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade and other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,391</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,653</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade and other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentReceivables" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,697</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,088</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,063</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade and other payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">229</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,327</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,067</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div> liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,910</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,871</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,237</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,938</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,125</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other contributed equit<div style="display:inline;">y</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated losses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">44,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity attributable to the owners of Kazia Therapeutics Limited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,125</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,125</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The above consolidated statements of financial position should be read with the accompanying notes </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin185056_4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statements of changes in equity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended 30&#160;June 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 54%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">equity</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">equity</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">controlling</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total&#160;equity</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2018</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment for change in accounting policy</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2018 &#8211; restated</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,678</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2018" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense for the year</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income for the year, net of tax</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income for the year</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transactions with owners in their capacity as owners:</div></div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue costs</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">340</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">340</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfers</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share based payment</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issue of shares</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2019</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,948</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">equity</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">equity</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">controlling</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total&#160;equity</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,948</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense for the yea<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div></div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income for the year, net of tax</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income for the year</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transactions with owners in their capacity as owners:</div></div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue costs</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfers</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of convertible note</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee share-based payment options</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share based payment</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issue of shares</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired options</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statement<div style="display:inline;">s</div> of changes in equity (continued) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended 30 June 2021 </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 55%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">equity</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">equity</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">controlling</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total&#160;equity</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2020</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense for the year</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income for the year, net of tax</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income for the year</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transactions with owners in their capacity as owners:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributions of equity, net of transaction costs</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue costs</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfers</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of convertible note</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee share-based payment option<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share based payment</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issue of shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:IncreaseDecreaseThroughExpireOfOptions" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 55%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">44,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The above consolidated statements of changes in equity should be read with the accompanying notes </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin185056_5" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of cash flows </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended 30&#160;June 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 4.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax expense for the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments for:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net loss on disposal of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="kzia:NetLossOnDisposalOfNonCurrentAssets" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of property, plant and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange differences</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss/(gain) on contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value loss on financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,521</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,479</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,067</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in trade and other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in prepayments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForDecreaseIncreaseInPrepayments" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForDecreaseIncreaseInPrepayments" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:AdjustmentsForDecreaseIncreaseInPrepayments" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in trade and other payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in other provisions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in deferred tax liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">484</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in accrued revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activitie<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,111</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,810</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,714</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from disposal of shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInterestsInAssociates" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInterestsInAssociates" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfInterestsInAssociates" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,359</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issue of shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,816</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,109</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,139</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,816</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net decrease in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">539</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at the beginning of the financial year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2018" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effects of exchange rate changes on cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at the end of the financial year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,587</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,764</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,434</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The above consolidated statements of changes in equity should be read with the accompanying notes </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin185056_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30, 2021 </div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1. General information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements cover Kazia Therapeutics Limited as a consolidated entity consisting of Kazia Therapeutics Limited and its subsidiaries. The financial statements are presented in Australian dollars, which is Kazia Therapeutics Limited&#8217;s functional and presentation currency. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three International Towers </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;24, 300 Barangaroo Avenue </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sydney NSW 2000 </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">T</div>h<div style="display:inline;">e</div> financial statements were authorised for issue, in accordance with a resolution of Directors, on 7&#160;October 2021. The Directors have the power to amend and reissue the financial statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941739"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2. Significant accounting policies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </div></div> <ix:nonNumeric name="kzia:DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New or amended Accounting Standards and Interpretations adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (&#8216;IASB&#8217;) that are mandatory for the current reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. </div></div></ix:nonNumeric> <ix:nonNumeric name="kzia:DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Standards and Interpretations not yet mandatory or early adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30&#160;June 2021. The consolidated entity&#8217;s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfGoingConcernExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941712"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going concern </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity incurred a loss after income tax of $<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">8,421,960</ix:nonFraction> (2020: $<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">12,467,466</ix:nonFraction>), was in a net current asset position of $<ix:nonFraction name="ifrs-full:CurrentAssetsLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">21,064,264</ix:nonFraction>(2020: net current asset position of $<ix:nonFraction name="ifrs-full:CurrentAssetsLiabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">5,586,128</ix:nonFraction>) and had net cash outflows from operating activities of $<span style="-sec-ix-hidden:hidden26941709">9,110,516</span>(2020: $<span style="-sec-ix-hidden:hidden26941597">8,809,519</span>) for the year ended 30&#160;June 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at 30&#160;June 2021 the consolidated entity had cash in hand and at bank of $<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">27,586,760</ix:nonFraction>. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. In particular, the directors have considered the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the operations of the Company, and make the following observations: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Kazia&#8217;s key clinical trials have not been impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to date. The GBM Agile study, the pivotal study for paxalisib in glioblastoma, is on track with recruitment running to plan, and no disruption to this schedule is foreseen. The Phase II study of paxalisib in glioblastoma was fully recruited prior to the onset of restrictions and is in wrap up stage at the date of this report. Plans are on track for the commencement of a Phase I trial for EVT801 before the end of 2021; </div> </td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <ix:continuation id="TextSelection_26941739" continuedAt="TextSelectionAppend_26941739_1"><ix:continuation id="TextSelection_26941712">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr>
<td style="width: 3%; vertical-align: top;;text-align:left;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="width: 1%; vertical-align: top;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, clinical research in advanced cancer is relatively protected from pandemic disruption due to the ongoing and time-critical need for patient care in specialised facilities that cannot easily be repurposed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not reliant on ongoing revenue from customers, and so changes in customer behaviour over the next several years due to public health restrictions and reduced economic activity have little to no impact on its finances; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Company was able to secure funding of approximately $<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P04_01_2020To04_30_2020_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis" unitRef="Unit_AUD" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>&#160;million at the height of the initial wave of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> in April 2020, and additional funds of approximately $<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P07_01_2020To06_30_2021_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis" unitRef="Unit_AUD" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>&#160;million during the 2021 financial year; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on budgets and forecasts, the Company has sufficient cash to fund the operations for a period of at least 12 months from the date of this report; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">As a consequence the directors do not foresee any other impacts on the Company&#8217;s ability to raise additional funding as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. </div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of preparation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (&#8216;<div style="letter-spacing: 0px; top: 0px;;display:inline;">AASB</div>&#8217;) and the Corporations Act 2001, as appropriate for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-profit</div> oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8216;IASB&#8217;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for listed equity investments which are carried at fair value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical accounting estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity&#8217;s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. </div></div></ix:nonNumeric> <ix:nonNumeric name="kzia:DescriptionOfParentEntityInformationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent entity information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 28. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941548"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (&#8216;company&#8217; or &#8216;parent entity&#8217;) as at 30&#160;June 2021 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the &#8216;consolidated entity&#8217;. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-consolidated</div> from the date that control ceases. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_26941739_1" continuedAt="TextSelectionAppend_26941739_2"><ix:continuation id="TextSelection_26941548"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are presented using the &#8216;management approach&#8217;, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (&#8216;CODM&#8217;). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements are presented in Australian dollars, which is the consolidated entity&#8217;s functional and presentation currency. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign currency transactions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign operations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foreign currency reserve is recognised in profit or loss when the foreign operation is disposed of. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange differences arising on a monetary item that forms part of a reporting entity&#8217;s net investment in a foreign operation shall be recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941396"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recognition and derecognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below. Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and substantially all the risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and initial measurement of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with IFRS&#160;15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable). </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-11 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><ix:continuation id="TextSelection_26941396" continuedAt="TextSelectionAppend_26941396_1"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_26941739_2" continuedAt="TextSelectionAppend_26941739_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsequent measurement of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial assets at amortised cost </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial assets at fair value through profit or loss (FVPL) </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Classifications are determined by both: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The entity&#8217;s business model for managing the financial asset </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The contractual cash flow characteristics of the financial assets </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial assets at amortised cost </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group&#8217;s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial assets at fair value through profit or loss (FVPL) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets that are held within a business model other than &#8216;hold to collect&#8217; or &#8216;hold to collect and sell&#8217; are categorised at fair value through profit and loss. Further, irrespective of business model, financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.&#160;The Group&#8217;s investments in equity instruments and derivatives fall under this category. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IFRS 9&#8217;s new impairment model uses more forward looking information to recognize expected credit losses&#8212;the &#8216;expected credit losses (ECL) model&#8217;. The application of the new impairment model depends on whether there has been a significant increase in credit risk.&#160;The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In applying this forward-looking approach, a distinction is made between: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk (&#8216;Stage 1&#8217;) and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low (&#8216;Stage 2&#8217;). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8216;Stage 3&#8217; would cover financial assets that have objective evidence of impairment at the reporting date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;12-month</div> expected credit losses&#8217; are recognised for the first category while &#8216;lifetime expected credit losses&#8217; are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument. </div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-12 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <ix:continuation id="TextSelectionAppend_26941396_1" continuedAt="TextSelectionAppend_26941396_2"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941739_3" continuedAt="TextSelectionAppend_26941739_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and measurement of financial liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s financial liabilities comprise trade and other payables. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All interest-related charges and, if applicable, changes in an instrument&#8217;s fair value that are reported in profit or loss are included within finance costs or finance income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from contracts with customers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognised using a five step approach in accordance with IFRS&#160;15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognised when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognised as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognised as revenue within the 12 months following the balance sheet date are classified within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues, including milestone revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the consolidated entity&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the licence is transferred to the customer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Finance Income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941739_4" continuedAt="TextSelectionAppend_26941739_5"><ix:continuation id="TextSelectionAppend_26941396_2" continuedAt="TextSelectionAppend_26941396_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue is recognised when it is received or when the right to receive payment is established. </div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_26941396_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The R&amp;D Tax Incentive is a government program which helps to offset some of the incurred costs of R&amp;D. Eligible expenditure incurred under the scheme in a financial year attracts an additional <ix:nonFraction name="kzia:AdditionalTaxDeductionPercentage" contextRef="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">43.5</ix:nonFraction>% tax deduction, and for a group earning income of less than $<ix:nonFraction name="kzia:InterestIncomeLoss" contextRef="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_AUD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>&#160;million, the cash value of the additional deduction is remitted to the taxpayer. In accordance with IAS&#160;20, as the compensation relates to expenses already incurred, it is recognised in profit or loss of the period in which it becomes receivable. Accordingly the group accounts for the R&amp;D Tax Incentive in the same year as the expenses to which it relates. </div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax expense or benefit for the period is the tax payable on that period&#8217;s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amount of recognised and unrecognised deferred tax assets are reviewed each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited (the &#8216;parent entity&#8217;) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the &#8216;separate taxpayer in the group&#8217; allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interpretation 23 Uncertain tax positions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interpretation 23 clarified the application of the recognition and measurement criteria IAS&#160;12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Judgments are reassessed as and when new facts and circumstances are presented. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941739_5" continuedAt="TextSelectionAppend_26941739_6"> <ix:nonNumeric name="kzia:DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assets and liabilities are presented in the statement of financial position based on current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred tax assets and liabilities are always classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under IFRS&#160;16, leases are accounted for as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Depreciation on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and interest on lease liabilities are recognised in the consolidated statement of profit or loss; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total amount of cash paid under lease arrangements is separated into a principal portion (presented within financing activities) and interest (presented within operating activities) in the consolidated cash flow statement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lease incentives under IFRS 16 are recognised as part of the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;">Under IFRS&#160;16, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are tested for impairment in accordance with IAS 36 Impairment of assets. This replaces the previous requirement to recognise a provision for onerous lease contracts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For short-term leases (lease term of 12 months or less) and leases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets, the consolidated entity has opted to recognise a lease expense on a straight-line basis as permitted by IFRS&#160;16 Leases. This expense is presented within other expenses in the consolidated statement of profit or loss. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941700"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941739_6" continuedAt="TextSelectionAppend_26941739_7"><ix:continuation id="TextSelection_26941700"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing agreement for paxalisib </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Licensing Agreement asset was initially brought to account at fair value, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was <ix:nonNumeric name="kzia:IntangibleAssetsWithIndefiniteRemainingUsefulLife" contextRef="P07_01_2020To06_30_2021_LicenseAgreementForPaxalisibMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">15 years</ix:nonNumeric> from the date of acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing agreement for EVT801 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Licensing agreement asset was initially brought to account at cost and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was <ix:nonNumeric name="kzia:IntangibleAssetsWithIndefiniteRemainingUsefulLife" contextRef="P07_01_2020To06_30_2021_LicensingAgreementForEvtEightZeroOneMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">12.5 years</ix:nonNumeric> from the date of acquisition. </div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> assets with finite useful lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-in-use.</div></div> The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-in-use</div></div> is the present value of the estimated future cash flows relating to the asset using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compound financial instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortised cost using the effective interest rate method, whereas the equity component is not remeasured. Interest, gains and losses relating to the financial liability are recognised in profit or loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognised on conversion. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost. </div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941704"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Short-term employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Liabilities for wages and salaries, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other long-term employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined contribution superannuation expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_26941739_7" continuedAt="TextSelectionAppend_26941739_8"><ix:continuation id="TextSelection_26941704"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (&#8216;ESOP&#8217;) and consultants as compensation for services performed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vesting</div> conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cumulative charge to profit or loss until settlement of the liability is calculated as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vesting</div> condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. </div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941487"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">When an asset or liability, financial or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial,</div> is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. </div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-17 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2. Significant accounting policies </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_26941739_8"><ix:continuation id="TextSelection_26941487"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For recurring and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data. </div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued capital </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares are classified as equity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goods and Services Tax (&#8216;GST&#8217;) and other similar taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. </div></div></ix:nonNumeric> </ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941689"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3. Critical accounting judgements, estimates and assumptions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed as follows: </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-18 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3. Critical accounting judgements, estimates and assumptions (continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26941689" continuedAt="TextSelectionAppend_26941689_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Directors do not consider the development programs to be sufficiently advanced to reliably determine the economic benefits and technical feasibility to justify capitalisation of development costs. These costs have been recognised as an expense when incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development expenses relate primarily to the cost of conducting human clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being measured. The length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated entity applies judgement in determining whether contracts entered into fall within the scope of IFRS&#160;15 Revenue from Contracts with Customers. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contracts with each customer, management assessed that the contracts were within the scope of IFRS&#160;15 &#8216;Revenue from Contracts with Customers&#8217;. Management has also made the judgement in each case that the grant of the licence and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were also made in relation to the transfer of the licence and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> in each case, and whether this should be recognised over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical trial expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The timing of payment for work conducted under clinical trials often bears little relation to the timing of the work effort. Detailed estimates are made to determine the amount of work effort expended during a reporting period in order to determine the appropriate expense to be recognised, with the resulting prepayments or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">un-invoiced</div> amounts being recognised as a prepayment or an accrual respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payment transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes option pricing model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of intangible assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has applied judgement in determining the accounting treatment for the acquisition of the License agreement for EVT801. The License agreement has been determined to be a stand alone transaction, independent from any other agreements which have been or may be entered into with Evotec (France) SAS. Management has also made the decision to account for the cost of the asset conferred by the License agreement on the basis of the milestones that are probable of being payable, that is, those for which there is judged to be a probability of greater than <ix:nonFraction name="kzia:PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% that the milestone will be triggered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration relates to the intangible assets acquired, and the fair value of contingent consideration is dependent on the key assumptions used in accounting for the acquisition of those intangible assets. These assumptions include the probability of milestones occurring, and can also include the anticipated timing of settlement and discount rates used. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3. Critical accounting judgements, estimates and assumptions (continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941689_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the case where contingent consideration is recognised on the basis that the liability is probable of occurring, judgement is used in determining which milestones are considered probable of being triggered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible assets available for use </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has exercised judgement in determining that its intangible assets, being license agreements, have a finite life and are available for use once acquired. As the business model is to acquire such assets and then develop them to generate returns from future license transactions or other means, management have determined that the assets are available for use from the time that they are acquired. In each case the prima facie useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets other than goodwill and other indefinite life intangible assets </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">T</div>he consolidated entity assesses impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. Judgement is used to determine whether any indicators of impairment exist, and reference is made to the considerations included in IAS&#160;36 Impairment of Assets in this assessment. If an impairment trigger is found to exist, the recoverable amount of the asset is determined<div style="display:inline;">.</div></div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4. Operating segments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Identification of reportable operating segments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (&#8216;CODM&#8217;)) in assessing performance and in determining the allocation of resources. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity operates in the pharmaceutical research and development business. There are <ix:nonFraction name="kzia:NumberOfOperatingSegments1" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_Segments" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> operating segments for which discrete financial information exists. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major customers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year the consolidated entity transacted with <ix:nonFraction name="kzia:NumberOfMajorCustomers" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_Major_Customer" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> customers, and revenue from each customer amounted to in excess of <ix:nonFraction name="kzia:ConcentrationRiskMajorCustomerPercentage" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% of the total revenue from the period. Both companies entered into license agreements for the consolidated entity&#8217;s drug assets. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfRevenueExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5. Revenue </div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfProductsAndServicesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2020To06_30_2021_LicensingRevenueMemberifrsfullProductsAndServicesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2019To06_30_2020_LicensingRevenueMemberifrsfullProductsAndServicesAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2018To06_30_2019_LicensingRevenueMemberifrsfullProductsAndServicesAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregation of revenue </div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The disaggregation of revenue from contracts with customers is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Geographical regions</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">China</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2020To06_30_2021_CNifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2019To06_30_2020_CNifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2018To06_30_2019_CNifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sweden</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2020To06_30_2021_SwedanMemberifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2019To06_30_2020_SwedanMemberifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2018To06_30_2019_SwedanMemberifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Timing of revenue recognition</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing revenue at a point in time</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2020To06_30_2021_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2019To06_30_2020_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromContractsWithCustomers" contextRef="P07_01_2018To06_30_2019_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6. Other income </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gain</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeGain" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxRebatesOnPayroll" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxRebatesOnPayroll" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:TaxRebatesOnPayroll" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidies and grants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:SubsidiesAndGrants" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SubsidiesAndGrants" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SubsidiesAndGrants" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reimbursement of expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:ReimbursementOfExpenses" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:ReimbursementOfExpenses" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ReimbursementOfExpenses" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:RebateIncomeOnResearchAndDevelopment" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:RebateIncomeOnResearchAndDevelopment" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:RebateIncomeOnResearchAndDevelopment" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,431</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfExpensesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7. Expenses </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax includes the following specific</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amortisation</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib licensing agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2019To06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2018To06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evotech licensing agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021_EvotechLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net foreign exchange loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rental expense relating to operating leases</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimum lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:MinimumOperatingLeasePayment" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:MinimumOperatingLeasePayment" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:MinimumOperatingLeasePayment" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Superannuation expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined contribution superannuation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee benefits expense excluding superannuation</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits expense excluding superannuation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,526</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chinese With-Holding Tax incurred on license transaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ChineseWithholdingTaxIncurredOnLicenseTransaction" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chinese Value Added Tax incurred on license transaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ChineseValueAddedTaxIncurredOnLicenseTransaction" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExpenseByNature" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfIncomeTaxExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8. Income tax benefit </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerical reconciliation of income tax benefit and tax at the statutory rate</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax benefi<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at the statutory tax rate of <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>% (2020 &amp; 2019 <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">27.5</ix:nonFraction></ix:nonFraction>%)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax effect amounts which are not deductible/(taxable) in calculating taxable income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development claim</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfExpenseResearchAndDevelopmentClaim" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfExpenseResearchAndDevelopmentClaim" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation of intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfAmortisationOfIntangibles" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfAmortisationOfIntangibles" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee option plan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfExpenseEmployeeOptionPlan" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfExpenseEmployeeOptionPlan" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfExpenseEmployeeOptionPlan" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain/loss on revaluation of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to deferred tax balances as a result of change in statutory tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax losses and timing differences not recognised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">484</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax losses not recognised</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unused tax losses for which no deferred tax asset has been recognised-Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn06_30_2021_AUifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">70,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn06_30_2020_AUifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn06_30_2019_AUifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential tax benefit @ <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2020To06_30_2021_AUifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">26.0</ix:nonFraction>% (2020 <ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2018To06_30_2019_AUifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2019To06_30_2020_AUifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">27.5</ix:nonFraction></ix:nonFraction>%)- Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" contextRef="P07_01_2020To06_30_2021_AUifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" contextRef="P07_01_2019To06_30_2020_AUifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" contextRef="P07_01_2018To06_30_2019_AUifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Unused tax losses for which no deferred tax asset has been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">recognised-US</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn06_30_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,038</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn06_30_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn06_30_2019_USifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Potential tax benefit at statutory tax <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rates@<ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2018To06_30_2019_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2019To06_30_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P07_01_2020To06_30_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>%-US</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" contextRef="P07_01_2020To06_30_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" contextRef="P07_01_2019To06_30_2020_USifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" contextRef="P07_01_2018To06_30_2019_USifrsfullGeographicalAreasAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9. Current assets - cash and cash equivalents </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash at bank and on hand</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941386"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10. Trade and other receivables </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D tax rebate receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn06_30_2020_ResearchAndDevelopmentTaxRebateReceivableMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deposits held</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn06_30_2021_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn06_30_2020_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">567</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Provision for impairment of deposits held</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn06_30_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deposit paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:DepositPaidNonCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivables" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10. Trade and other receivables (continued) </div></div></div> <ix:continuation id="TextSelection_26941386"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the deposit paid, $<ix:nonFraction name="kzia:DepositPaidAsAdvance" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-4" scale="6" format="ixt:numdotdecimal">6.65</ix:nonFraction>m represents an advance to GCAR at the start of the GBM Agile trial, and is refundable if not utilised against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial, which is expected to be over 12 months from year end. </div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11. Other assets </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current assets </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12. Intangibles </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreement - at acquired fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,082</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreement - at cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,858</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reconciliations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="kzia:DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941412">Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26941412">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 63%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EVT801&#160;licensing</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib&#160;licensing</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2019To06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,858</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,858</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year the consolidated entity acquired exclusive rights to EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13. Trade and other payables </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AccrualsClassifiedAsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AccrualsClassifiedAsCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to note 21 for further information on financial instruments. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfProvisionsExplanatory" contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">N</div>ote 14. Employee benefits </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutProvisionsExplanatory" contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">229</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div> Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long service leave</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProvisionsForEmployeeBenefits" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory" contextRef="P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis" escape="true" continuedAt="TextSelection_26941692"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15. Contingent consideration </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" contextRef="P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationCurrent" contextRef="PAsOn06_30_2020_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration &#8211; EVT801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationCurrent" contextRef="PAsOn06_30_2021_ContingentConsiderationEvt801MemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2021_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2020_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration &#8211; EVT801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2021_ContingentConsiderationEvt801MemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,911</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsideration" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsideration" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the 2017 financial year, the consolidated entity acquired <ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="PAsOn06_30_2017_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of the issued shares in Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. On the same day, Kazia entered into a worldwide licensing agreement with Genentech to develop and commercialise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GDC-0084,</div> now known as paxalisib. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Glioblast acquisition contains <ix:nonFraction name="kzia:NumberOfContingentMilestonePayments" contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_Milestone" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> contingent milestone payments, the first two milestone payments are to be settled with Kazia shares, and the third and fourth milestone payments are to be settled with either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the value of $<ix:nonFraction name="kzia:PaymentsForContingentConsideration" contextRef="P07_01_2020To06_30_2021_MilestoneTwoMemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">1,250,000</ix:nonFraction>. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Genentech agreement comprises of <ix:nonFraction name="kzia:NumberOfContingentMilestonePayments" contextRef="P07_01_2020To06_30_2021_GenentechAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_Milestone" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> milestone payment payable on the first commercial licensed product sale, in the amount of $<ix:nonFraction name="kzia:MilestonePaymentPayable" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">1,394,000</ix:nonFraction>. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 15. Contingent consideration </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26941692"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each milestone payment is probability weighted for valuation purposes. The milestone payments are discounted to present value, using a discount rate of <ix:nonFraction name="kzia:MilestonePaymentDiscountRate" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% (previously <ix:nonFraction name="kzia:MilestonePaymentDiscountRate" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%) per annum. The discount rate was considered at 30&#160;June 2021 and it was determined that the risk of the asset, and therefore of the milestones being met, has been considerably decreased as a result of paxalisib entering the pivotal GBM Agile trial, which is progressing well, and the license transaction with Simcere Pharmaceutical Group, which provides an external validation of paxalisib. Accordingly, the discount rate applied to future expected cash flows has been revised downwards. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance, and are not considered as part of the consideration in relation to the Genentech agreement. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - EVT801 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As set out in note 2, the acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being booked as a current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liability at year end, according to the estimated payment date. Milestones where the payment is not considered probable at year end have not been accounted for as a liability. The total amount of milestone payments not booked at year end amounts to &#8364;<ix:nonFraction name="kzia:MilestonePaymentsNotBooked" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_EUR" decimals="0" scale="0" format="ixt:numdotdecimal">300,500,000</ix:nonFraction> ($<ix:nonFraction name="kzia:MilestonePaymentsNotBooked" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">475,474,684</ix:nonFraction>). </div></ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16. Deferred tax </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> Liabilities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability associated with Licensing Agreement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DisclosureOfIssuedCapitalExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941430"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17. Equity - contributed equity </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 47%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares - fully paid</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">132,012,209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">94,598,369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">80,290,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">48,781,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Movements in Ordinary share capital </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Details</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue&#160;price</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1&#160;July 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">62,166,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">36,641,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1&#160;November&#160;2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2019To06_30_2020_IssueDatedNovemberOneTwoThousandAndNineteenMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P11_01_2019To11_01_2019_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_IssueDatedNovemberOneTwoThousandAndNineteenMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">16&#160;April 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2019To06_30_2020_IssueDateSixteenthAprilTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">18,041,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P04_16_2020To04_16_2020_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_IssueDateSixteenthAprilTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">7,216,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued under the Share Purchase Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">11&#160;May 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,390,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P05_11_2020To05_11_2020_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">1,756,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2019To06_30_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P06_30_2021To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">4.000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P06_30_2021To06_30_2021_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">833,052</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">30&#160;June 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">94,598,369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">48,781,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">28 August 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDateTwentyEightAugustTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P08_28_2020To08_28_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDateTwentyEightAugustTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">12,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Institutional placement under ANREO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">12 October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">20,525,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P10_12_2020To10_12_2020_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">16,420,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retail placement under ANREO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">26 October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,017,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P10_26_2020To10_26_2020_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">8,813,660</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">2&#160;March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedSecondMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">391,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P03_02_2021To03_02_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedSecondMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">248,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">15&#160;March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedFifteenthMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P03_15_2021To03_15_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedFifteenthMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">12,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">28&#160;April 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,037,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P04_28_2021To04_28_2021_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">4,274,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on achievement of a milestone</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">21&#160;May 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,391,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P05_21_2021To05_21_2021_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">3,400,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: share issue transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:SharesIssuedPricePerShare1" contextRef="P06_30_2021To06_30_2021_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,673,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">30&#160;June 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">132,012,209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">80,290,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-25 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 17. Equity - contributed equity </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26941430"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary shares </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have <ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>par value and the company does not have a limited amount of authorised capital. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back</div> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There is no current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-market</div> share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back.</div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capital risk management </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The capital risk management policy remains unchanged from the prior year. </div></div></ix:continuation><ix:nonNumeric name="kzia:DisclosureOfOtherEquityExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941426"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 18. Equity - Other contributed equity </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutOtherEquityExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible note - Triaxial</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction>,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction>,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On 4&#160;December 2014, the consolidated entity and the convertible note holder (&#8216;Triaxial&#8217;) signed a Convertible Note Deed Poll (&#8216;Deed&#8217;) which superseded the precedent Loan Agreement between Triaxial shareholders and the consolidated entity. The Deed extinguishes the liability created by the Loan Agreement and provides that the Convertible Notes will convert into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-determined</div> number of ordinary shares on the achievement of defined milestones established in the schedule of the Deed. Accordingly the convertible note has been reclassified as an equity instrument rather than debt instrument. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the Financial year ended 30&#160;June 2017, the Company reached two milestones triggering the conversion of a portion of its convertible note as follows; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; On 11&#160;August 2016 the Company announced the submission of an IND application. On 10&#160;September 2016, the Company received a letter from the FDA advising the study may proceed triggering conversion of <ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn09_14_2016" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction> ordinary shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; On 31&#160;October 2016, the Company announced it had licensed a Phase II ready molecule triggering the conversion of <ix:nonFraction name="kzia:NumberOfOrdinarySharesAvailableForConversion" contextRef="PAsOn10_31_2016" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">16,000,000</ix:nonFraction> ordinary shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year ended 30&#160;June 2018, a portion of the convertible notes was extinguished. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-26 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 18. Equity - Other contributed equity (continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26941426"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining portion of the convertible note will be exercised at the holders&#8217; discretion on completion of Phase II clinical trial or achieving Breakthrough Designation, and would convert to <ix:nonFraction name="kzia:ConvertibleNoteRepresentsOrdinaryShares" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,856,000</ix:nonFraction> ordinary shares if converted. Completion will be deemed to occur upon the receipt by the consolidated entity of a signed study report or notification of the designation. There is a possibility for an early conversion of the convertible notes if a third party acquires more than <ix:nonFraction name="kzia:PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" contextRef="P07_01_2016To06_30_2017" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the issued capital of the consolidated entity.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 19. Equity - reserves </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign currency translation reserve </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reserve is used to recognise exchange differences arising from translation of the financial statements of foreign operations to Australian dollars. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments reserve </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reserve is used to recognise the value of equity benefits provided to employees and executive directors as part of their remuneration, and other parties as part of their compensation for services. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfDividendsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 20. Equity - dividends </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no dividends paid, recommended or declared during the current or previous financial year. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941421"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 21. Financial instruments </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial risk management objectives </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The consolidated entity uses different methods to measure and manage the different types of risks to which it is exposed. These methods include monitoring the levels of exposure to interest rates and foreign exchange, ageing analysis and monitoring of specific credit allowances to manage credit risk, and, rolling cash flow forecasts to manage liquidity risk. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency risk </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollars (&#8216;USD&#8217;). Foreign exchange risk arises from future transactions and recognised assets and liabilities denominated in a currency that is not the entity&#8217;s functional currency and net investments in foreign operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of 30&#160;June 2021, the consolidated entity did not hold derivative financial instruments in managing its foreign currency, however, the consolidated entity may from time to time enter into hedging arrangements where circumstances are deemed appropriate. The consolidated entity used natural hedging to reduce the foreign currency risk, which involved processing USD payments from cash held in USD. Foreign subsidiaries with a functional currency of Australian Dollars (&#8216;AUD&#8217;) have exposure to the local currency of these subsidiaries and any other currency these subsidiaries trade in. </div></div><ix:nonNumeric name="ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amount of the consolidated entity&#8217;s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euros</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 21. Financial instruments </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26941421" continuedAt="TextSelectionAppend_26941421_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity had net assets denominated in foreign currencies of A$<ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">17,608,845</ix:nonFraction> as at 30&#160;June 2021 (2020: net liabilities A$<ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">1,923,831</ix:nonFraction>). </div></div><ix:nonNumeric name="ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the AUD had strengthened against the USD by <ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% (2020: <ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%) then this would have had the following impact: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD strengthened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD weakened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect&#160;on<br/> profit&#160;before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect&#160;on<br/> profit&#160;before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euros</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD strengthened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD weakened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect on<br/> profit before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect on<br/> profit before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="INF" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Price risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity is not exposed to any significant price risk. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s exposure to market interest rates relate primarily to the investments of cash balances. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has cash reserves held primarily in Australian dollars and United States dollars and places funds on deposit with financial institutions for periods generally not exceeding three months. </div></div><ix:nonNumeric name="ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at the reporting date, the consolidated entity had the following variable interest rate balances: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">interest&#160;rate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">interest&#160;rate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash at bank and in hand</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:InterestRate" contextRef="P07_01_2020To06_30_2021_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:InterestRate" contextRef="P07_01_2019To06_30_2020_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short term deposits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:InterestRate" contextRef="P07_01_2020To06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:InterestRate" contextRef="P07_01_2019To06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net exposure to cash flow interest rate risk</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has cash and cash equivalents totalling $<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">27,586,760</ix:nonFraction> (2020: $<ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">8,764,044</ix:nonFraction>). An official increase/decrease in interest rates of <ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2021_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> basis points (2020: <ix:nonFraction name="kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" contextRef="PAsOn06_30_2020_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> basis points) would have a favourable/adverse effect on profit before tax and equity of $<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2021_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">275,867</ix:nonFraction> (2020 $<ix:nonFraction name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" contextRef="PAsOn06_30_2020_InterestRateRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">87,640</ix:nonFraction>) per annum. The percentage change is based on the expected volatility of interest rates using market data and analysts forecasts. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The entity is not exposed to significant credit risk on receivables. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-28 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 21. Financial instruments </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941421_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has adopted a lifetime expected loss allowance in estimating expected credit losses to trade receivables through the use of a provisions matrix using fixed rates of credit loss provisioning. These provisions are considered representative across all customers of the consolidated entity based on recent sales experience, historical collection rates and forward-looking information that is available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity places its cash deposits with high credit quality financial institutions and by policy, limits the amount of credit exposure to any single counter-party. The consolidated entity is averse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk, and reinvestment risk. The consolidated entity mitigates default risk by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no significant concentrations of credit risk within the consolidated entity. The credit risk on liquid funds is limited as the counter parties are banks with high credit ratings. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit risk is managed by limiting the amount of credit exposure to any single counter-party for cash deposits. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity risk </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated entity manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities. In particular, contingent consideration may be satisfied either by payment of cash or by issue of shares, at the discretion of the entity. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Remaining contractual maturities </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables detail the consolidated entity&#8217;s remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 53%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted&#160;average<br/> interest&#160;rate</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;year&#160;or&#160;less</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Between</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;and&#160;2&#160;years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Between</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;and&#160;5&#160;years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Over</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">5 years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">maturities</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-derivatives</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interest</div> bearing</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TradePayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TradePayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:AccruedPayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:AccruedPayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationUndiscountedCashFlows" contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationUndiscountedCashFlows" contextRef="PAsOn06_30_2021_LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationUndiscountedCashFlows" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn06_30_2021_LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted average<br/> interest&#160;rate<br/> %</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">1 year or less<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Between<br/> 1&#160;and&#160;2&#160;years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Between<br/> 2 and 5 years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Over<br/> 5&#160;years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Remaining<br/> contractual<br/> maturities<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-derivatives</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interest</div> bearing</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TradePayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:TradePayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:AccruedPayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:AccruedPayablesUndiscountedCashFlows" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationUndiscountedCashFlows" contextRef="PAsOn06_30_2020_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationUndiscountedCashFlows" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn06_30_2020_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,688</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 22. Fair value measurement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value hierarchy </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables detail the consolidated entity&#8217;s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs for the asset or liability </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;1<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;2<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;3<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:ContingentConsiderationNoncurrent" contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between levels during the financial year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the licence agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate. The estimated cashflows were adjusted based on the directors&#8217; assessment of achieving contracted milestones as disclosed in Note 15. The probabilities used fell in the range of <ix:nonFraction name="kzia:MilestonePaymentDiscountRate" contextRef="P07_01_2020To06_30_2021_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>% to <ix:nonFraction name="kzia:MilestonePaymentDiscountRate" contextRef="P07_01_2020To06_30_2021_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction>% and were informed by generally accepted industry probabilities of drugs achieving certain milestones in their progression towards registration. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 assets and liabilities </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Movements in level 3 assets and liabilities during the current and previous financial year are set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;3<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Available<br/> for sale<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidate<div style="display:inline;">d</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses recognised in profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" contextRef="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" contextRef="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" contextRef="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses recognised in profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payout of milestone</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:PayoutOfMilestone" contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:PayoutOfMilestone" contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:FairValueOfAssetsAndLiabilities" contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 23. Key management personnel disclosures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate compensation made to directors and other members of key management personnel (&#8216;KMP&#8217;) of the consolidated entity is set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please refer to Note 27 for other transactions with key management personnel and their related parties. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 24. Remuneration of auditors </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the consolidated entity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit services - Grant Thornton Audit Pty Ltd</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit or review of the financial statements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">151</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">124</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfContingentLiabilitiesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 25. Contingent liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than the contingent consideration set out in note 15, the consolidated entity does not have any other contingent liabilities. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfCommitmentsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 26. Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease commitments comprise contracted amounts for leases of premises. The agreement has a duration less than 12 months from financial year end. </div></div></ix:nonNumeric> <ix:nonNumeric name="ifrs-full:DisclosureOfRelatedPartyExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941398"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 27. Related party transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parent entity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited is the parent entity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsidiaries </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interests in subsidiaries are set out in note 29. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Key management personnel </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disclosures relating to key management personnel are set out in note 23 and the remuneration report included in the directors&#8217; report. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transactions with related parties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There was no other transaction with KMP and their related parties. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 27. Related party transactions (continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26941398"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receivable from and payable to related parties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <ix:nonFraction name="ifrs-full:AmountsReceivableRelatedPartyTransactions" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="ifrs-full:AmountsPayableRelatedPartyTransactions" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> trade receivables from or trade payables to related parties at the current and previous reporting date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Loans to/from related parties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <ix:nonFraction name="ifrs-full:OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="ifrs-full:OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction>loans to or from related parties at the current and previous reporting date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Terms and conditions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All transactions were made on normal commercial terms and conditions and at market rates. </div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DisclosureOfInterimFinancialReportingExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 28. Parent entity information </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfParentEntityFinancialInformationExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set out below is the supplementary information about the parent entity. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of profit or loss and other comprehensive income</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P07_01_2019To06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of financial position</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current asset<div style="display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated losses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">34,046</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,012</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves comprise Share Based Payments Reserve. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The parent entity contingent liabilities as at 30&#160;June 2021 and 30&#160;June 2020 are as set out in Note 15. The contingent consideration is specific to the parent entity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital commitments - Property, plant and equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The parent entity had no capital commitments for property, plant and equipment at as 30&#160;June 2021 and 30&#160;June 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 29. Interests in subsidiaries </div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements incorporate the assets, liabilities and results of the following sub<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>idiaries in ac<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ordance with the accounting policy described in note 2: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ownership&#160;interest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal&#160;place&#160;of&#160;business&#160;/</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country of incorporation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Laboratories Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2019To06_30_2020_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Research Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2019To06_30_2020_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">United States of America</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2019To06_30_2020_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Glioblast Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary" contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2019To06_30_2020_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics (Hong Kong) Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"><ix:nonNumeric name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Hong Kong</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 30. Reconciliation of loss after income tax to net cash used in operating activities </div></div></div> <ix:nonNumeric name="kzia:DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments for:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation&#160;&amp; amortisatio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of property, plant&#160;&amp; equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net fair value loss on financial assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share based payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange difference<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in operating assets&#160;&amp; liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in trade and other receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in accrued revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease/(increase) in prepayment<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForDecreaseIncreaseInPrepayments" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForDecreaseIncreaseInPrepayments" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:AdjustmentsForDecreaseIncreaseInPrepayments" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease/(increase) in trade and other payables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">484</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in other provisions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year the consolidated entity acquired a licensing agreement in relation to the asset EVT801. At year end no portion of the purchase price had been paid and accordingly the transaction does not appear in the cash flow statement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, the consolidated entity issued shares in satisfaction of an acquisition milestone. This transaction did not involve cash and accordingly the transaction does not appear in the cash flow statement. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-33 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941579"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 31. Earnings per share </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="ifrs-full:EarningsPerShareExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of ordinary shares used in calculating basic earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">117,674,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">73,053,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,503,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of ordinary shares used in calculating Diluted earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">117,674,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">73,053,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,503,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_AUD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:continuation id="TextSelection_26941579"> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kzia:NumberOfOrdinarySharesAvailableForConversion" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,865,000</ix:nonFraction> unlisted convertible notes with a face value of A$<ix:nonFraction name="ifrs-full:OtherEquityInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">464,000</ix:nonFraction> and <ix:nonFraction name="kzia:NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" contextRef="P07_01_2020To06_30_2021_UnlistedOptionsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,446,500</ix:nonFraction> unlisted options have been excluded from the above calculations as they were antidilutive. </div></div> </ix:continuation> <ix:nonNumeric name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941394"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 32. Share-based payments </div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true" continuedAt="TextSelection_26941353"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="0" scale="0" format="ixt:numdotdecimal">636,383</ix:nonFraction> was recognised. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">A$</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at&#160;the<br/> start&#160;of&#160;the</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">year</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired/<br/> lapsed on<br/> termination<br/> of<br/> employment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;the<br/> end&#160;of&#160;the&#160;year</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">16/11/2015</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941373">16/11/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">2.200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">236,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">236,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/09/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941591">05/09/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">12/10/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941375">17/10/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">62,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">62,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">31/10/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941376">01/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">12,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">12,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">21/11/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941377">23/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">07/08/2017</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941378">07/08/2022</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">224,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">121,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">15,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">87,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/02/2018</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941379">05/02/2023</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">440,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">120,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">320,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2019</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941380">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">12,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">37,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/11/2019</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941381">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/01/2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941382">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941383">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941384">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">800,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">800,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941385">04/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">2,775,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">2,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">441,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">314,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2021" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">4,219,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average exercise price</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD" decimals="3" scale="0" format="ixt:numdotdecimal">0.620</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn06_30_2021" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:continuation id="TextSelection_26941353" continuedAt="TextSelectionAppend_26941353_1"> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No options were forfeited during the year. </div></div> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-34 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 32. Share-based payments (continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26941394" continuedAt="TextSelectionAppend_26941394_1"><ix:continuation id="TextSelectionAppend_26941353_1" continuedAt="TextSelectionAppend_26941353_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of the period the following outstanding options were vested and exercisable: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 1 have expired during the year </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">- Options in tranches <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-</div> 8 were vested and exercisable except for tranche 6 which was vested as to <ix:nonFraction name="kzia:PercentageOfOptionsVested" contextRef="P07_01_2020To06_30_2021_TranchesTwoAndEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">53</ix:nonFraction>% </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 9 were vested as to <ix:nonFraction name="kzia:NumberOfOptionsVested" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>million of the <ix:nonFraction name="kzia:NumberOfOptionsIssued" contextRef="PAsOn06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction>million options on issue </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">- Options in tranches <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-12</div> were <ix:nonFraction name="kzia:PercentageOfOptionsVested" contextRef="P07_01_2020To06_30_2021_TranchesTenAndTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% vested </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 13 were unvested at year end </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining contractual life of options outstanding at the 30&#160;June 2021 is <ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P07_01_2020To06_30_2021" format="ixt-sec:duryear">2.6</ix:nonNumeric> years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">A$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at&#160;the<br/> start&#160;of&#160;the</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">year</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Modified</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;the<br/> end&#160;of&#160;the&#160;year</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/03/2015</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941600">16/12/2019</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">46,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">46,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/03/2015</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941602">18/12/2019</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">19,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">19,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">24/06/2015</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941603">30/06/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">4.000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">519,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">519,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">16/11/2015</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941605">16/11/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">2.200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">236,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">236,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">18/03/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941606">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">300,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">300,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">18/03/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941607">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">18/03/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941608">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">2.610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/09/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941609">05/09/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">12/10/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941610">17/10/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">62,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">62,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">31/10/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941611">01/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">12,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">12,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">21/11/2016</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941612">23/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">1.380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">07/08/2017</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941613">07/08/2022</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">224,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">224,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/02/2018</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941585">05/02/2023</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">440,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">440,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2019</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941586">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/11/2019</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941587">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/01/2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941588">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2019" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">2,660,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">450,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">585,599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn06_30_2020" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:numdotdecimal">2,775,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average exercise price</div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn06_30_2019" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="kzia:WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD" decimals="3" scale="0" format="ixt:numdotdecimal">2.348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">3.716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn06_30_2020" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation><ix:continuation id="TextSelectionAppend_26941353_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of the period the following outstanding options were vested and exercisable: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranches 4, 8, 10, 11 and 13 were vested and exercisable </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 16 were unvested </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in the other tranches were vested as follows: <ix:nonFraction name="kzia:NumberOfOptionsVested" contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction>: <ix:nonFraction name="kzia:PercentageOfOptionsVested" contextRef="P07_01_2019To06_30_2020_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%, <ix:nonFraction name="kzia:NumberOfOptionsVested" contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">12</ix:nonFraction>: <ix:nonFraction name="kzia:PercentageOfOptionsVested" contextRef="P07_01_2019To06_30_2020_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% <ix:nonFraction name="kzia:NumberOfOptionsVested" contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">14</ix:nonFraction>: <ix:nonFraction name="kzia:PercentageOfOptionsVested" contextRef="P07_01_2019To06_30_2020_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% and <ix:nonFraction name="kzia:NumberOfOptionsVested" contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15</ix:nonFraction>: <ix:nonFraction name="kzia:PercentageOfOptionsVested" contextRef="P07_01_2019To06_30_2020_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">67</ix:nonFraction>%. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All remaining options are expected to vest in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining contractual life of options outstanding at the 30&#160;June 2020 is <ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P07_01_2019To06_30_2020" format="ixt-sec:duryear">2.78</ix:nonNumeric> years. </div></div> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee share options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended 30&#160;June 2021, <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,200,000</ix:nonFraction> options have been issued to the employees by the consolidated entity pursuant to the Company&#8217;s Employee Share Option Plan. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Tranche 11 vests in four equal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-monthly</div> tranches from 1&#160;January 2021 </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tranche 12 vests in four equal annual amounts from 13&#160;January 2021 </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tranche 13 vests in four equal annual tranches from 4&#160;January 2022 </div></div> </td> </tr> </table> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 32. Share-based payments </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(continued)</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26941394_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options within all tranches will only vest if the option holder continues to be a full-time employee with the Company or an Associated Company during the vesting period relating to the option. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conditions for an option to be exercised: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The option must have vested. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option holder must have provided the Company with an Exercise Notice and have paid the Exercise Price for the option. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Exercise Notice must be for the exercise of at least the Minimum Number of Options; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Exercise Notice must have been provided to the Company and Exercise Price paid before the expiry of 5 years from the date the Option is issued. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Options Valuation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to obtain a fair valuation of these options, the following assumptions have been made: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Black Scholes option valuation methodology has been used with the expectation that the majority of these options would be exercised towards the end of the option term. Inputs into the Black Scholes model includes the share price at grant date, exercise price, volatility, and the risk free rate of a five year Australian Government Bond on grant date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free rate and grant date </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For all tranches, the risk-free rate of a five-year Australian Government bond on grant date was used. Please refer to the table below for details. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options in Tranches 1 to 13 have various vesting periods and exercising conditions. These options are unlisted as at 30&#160;June 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No dividends are expected to be declared or paid by the consolidated entity during the terms of the options. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underlying expected volatility was determined by reference to historical data of the Company&#8217;s shares over a period of time. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No special features inherent to the options granted were incorporated into measurement of fair value. </div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the above assumptions, the table below sets out the valuation for each tranche of options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 10%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 11%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share&#160;price<br/> at<br/> Grant&#160;Date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Volatility<br/> (%)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Life<br/> (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk&#160;free<br/> Rate&#160;(%)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value<br/> per&#160;option</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/09/2016</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941445">05/09/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.105</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.630</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">122.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.60</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.840</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">12/10/2016</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941446">17/10/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.098</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.560</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">122.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">1.29</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.89</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.780</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">31/10/2016</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941447">01/11/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.090</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.380</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">122.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">1.20</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.87</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.720</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">21/11/2016</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941448">23/11/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.092</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.380</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">122.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">1.20</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.730</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">07/08/2017</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941449">07/08/2022</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.430</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.670</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">74.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.08</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.95</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.206</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/02/2018</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941592">05/02/2023</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.500</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.780</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">74.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.58</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.95</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.200</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2019</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941451">04/01/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.340</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<span style="-sec-ix-hidden:hidden26941594">0.493</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">74.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">3.50</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.95</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.140</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/11/2019</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941452">04/01/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.410</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<span style="-sec-ix-hidden:hidden26941595">0.493</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">74.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.20</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.95</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.180</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/01/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941453">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.620</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">74.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.50</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.95</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.340</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941454">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.132</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.10</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.379</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941455">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.132</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.30</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.403</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941456">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.132</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.60</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.425</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941457">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.132</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.446</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941458">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.20</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.450</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941459">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.70</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.490</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941460">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">3.20</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.520</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941461">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.890</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.881</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">3.70</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.550</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941368">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.185</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.169</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">2.50</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.19</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.520</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941369">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.185</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.169</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.19</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.576</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941371">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.185</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.169</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">3.50</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.19</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.627</ix:nonFraction></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941372">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="kzia:SharePricePerShare" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.185</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_AUD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.169</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;<ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.00</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.19</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="3" scale="0" format="ixt:numdotdecimal">0.671</ix:nonFraction></td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" contextRef="P07_01_2020To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 33. Subsequent events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no significant events subsequent to the reporting date<div style="display:inline;">.</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-36 </div></div> </div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>2
<FILENAME>d185056dex418.htm
<DESCRIPTION>EX-4.18
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF MARKING SUCH INFORMATION WITH BRACKETS (&#147;[***]&#148;) BECAUSE THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kazia Therapeutics Limited </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Oasmia Pharmaceutical AB </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Development and Commercialisation Licence Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A licencing Agreement to develop and commercialise Cantrixil </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contents</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Definitions and Interpretation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commercialisation of Licensed Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Grant of Licence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Patents and Associated Intellectual Property Licence grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sub-licencing</FONT> and
<FONT STYLE="white-space:nowrap">sub-contracting</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights of Oasmia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transfer of <FONT STYLE="white-space:nowrap">Know-How</FONT> and assistance from
Kazia</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>11</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Cantrixil
Dossier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assistance in respect of Manufacturing and supply of Licensed Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commercialisation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>11</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and distribution in the Territory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Reports</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Payment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment requirements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Default in payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Alliance Manager</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oasmia&#146;s responsibilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia&#146;s responsibilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Governmental Matters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory approvals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prosecution, Proceedings and Protection of Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prosecution and maintenance of Kazia Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of Claims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Warranties and Indemnities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and warranties by the parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and warranties by Kazia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and warranties by Oasmia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warranties separate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No other representations or warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Period of warranties and indemnity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reliance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page (i)</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Indemnities and Liability</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exclusions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Insurance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The parties obligation to insure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Requirements for insurance policies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evidence of currency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Records and Audit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Reporting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Term and Termination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>22</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination by either party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination by Oasmia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination by Kazia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General consequences of termination and survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specific consequences of termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Assignment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment by Oasmia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment by Kazia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>18</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Confidentiality</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations of confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted Disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exceptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return or destruction of Confidential Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liability for breach by recipient</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Survival of Obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public announcements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>19</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Costs and Duty</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>20</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Notice</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Dispute Resolution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parties to attempt resolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meeting between Alliance Managers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Negotiations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arbitration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Continuation of rights and obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>22</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Force Majeure</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Event of Force Majeure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Force Majeure notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedy of Force Majeure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mitigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No requirement to settle labour dispute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No extension of Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page (ii)</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>23</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>General</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Schedule&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront fee, Milestone Payments and Royalty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Schedule 2</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Part 1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Schedule 3</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantrixil Manufacturers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Schedule 4</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assistance to be provided by Kazia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Schedule 5</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page (iii)</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Agreement </B>is made on </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Parties </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Kazia Therapeutics Limited </B>(ACN 063 259 754) of Three International Towers, Level&nbsp;24 300 Barangaroo
Avenue, Sydney NSW 2000<B> </B><B><I>(Kazia).</I></B><B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Oasmia Pharmaceutical AB </B>incorporated in Sweden of Vallongatan 1, 752 28 Uppsala, Sweden<B>
</B><I></I><B><I>(Oasmia)</I></B><I>.</I><B> </B></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recitals </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">A</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia is the registered owner of the Kazia Patents and is the owner of the Associated Intellectual Property in
relation to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia has agreed to grant Oasmia, and Oasmia accepts, a global exclusive licence to the Licensed Product and
the Associated Intellectual Property, on the terms and subject to the conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties have entered into this Agreement with the goal of transferring Kazia&#146;s world-wide rights to
Develop and Commercialise the Licensed Product to Oasmia and for Oasmia to use its Commercially Reasonable Efforts to maximise the earnings from the Licensed Product during the Term. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree to undertake their respective obligations under this Agreement in good faith in order to try
and achieve the above stated goal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>It is agreed </B>as follows. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and Interpretation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The following definitions apply unless the context requires otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate </I></B>means, with respect to a party, any entity that controls or is controlled by such party, or is under common control
with such party. For the purposes of this definition, an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of another entity (or other comparable
interest for an entity other than a corporation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement </I></B>means this Agreement including any schedules and annexures, and
any subsequent amendments to this Agreement made in accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Applicable Law </I></B>means the laws which apply to
the acts and omissions of either party in the course of carrying out this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Associated Intellectual Property </I></B>means
any intellectual property specifically and demonstrably referable to the Development of the Licensed Products that is owned or otherwise held by Kazia or one of its Affiliates including any copyright, trade mark, Kazia
<FONT STYLE="white-space:nowrap">Know-How,</FONT> confidential information or invention, that is reasonably required by Oasmia for the Development or Commercialisation of the Licensed Product, or is reasonably necessary to Oasmia to otherwise
exercise its rights or carry out its obligations under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Business Day </I></B>means a day which is not a Saturday,
Sunday or a public holiday in Sweden or Sydney, Australia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Cantrixil Dossier </I>means: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the original IND relating to the Licensed Product opened with the FDA in 2016 <I>(Original</I>
<B><I>IND</I></B><I>)</I>;<I></I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all subsequent submissions made to the FDA with respect to the Original IND; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all documents in the possession of Kazia and its Affiliates not yet submitted to the FDA but which would
reasonably be expected to be submitted under the IND in the normal course of drug development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any material correspondence relating to the Licensed Product between Kazia and its Affiliates with the FDA or
other regulatory agencies which would not be expected to form part of the IND, including any orphan drug applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all batch records, stability data, analytical results, and other customary documentation in the possession of
Kazia and its Affiliates pertaining to prior manufactured batches of Licensed Product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all known publications of Cantrixil data relating to Licensed Product, published and in draft;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any <FONT STYLE="white-space:nowrap">non-clinical</FONT> data in the possession of Kazia or its Affiliates,
such as through research collaborations, which may reasonably be considered necessary to Oasmia in the further development of Licensed Product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any clinical study protocols, study reports and safety information
<FONT STYLE="white-space:nowrap">(pre-clinical</FONT> and clinical) in the possession of Kazia or its Affiliates relating to Licensed Product, including clinical trial database, safety database, trial master file, audit reports and phase I trial
dashboard (eg. list of trial sites, trial screening and enrolment rate per site). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">With respect to each of the above
other than drafts contemplated expressly in paragraph (f), documents will be supplied in their final and definitive form. Documents which have not yet been finalised will be supplied in the form of the latest draft in Kazia&#146;s possession. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Cantrixil Manufacturers </I></B>means the manufacturers listed in Schedule 3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Claim </I></B>means, in relation to a party, a demand, claim, action or proceeding threatened, made or brought by or against the party,
however arising and whether present. unascertained, immediate, future or contingent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Commercialisation </I></B>means any and all
activities directed to marketing, promoting, detailing, distributing, supplying, importing, exporting, offering for sale, having sold and/or selling and other activities for the commercialisation of the Licensed Product in the Territory, including:
market research and educational activities; and activities necessary to obtain and maintain Marketing Approval, Pricing Approval, reimbursement and/or listing on health care providers&#146; and payers&#146; formularies in the Territory. For the
avoidance of doubt, use of the terms Commercialise, Commercialising and/or Commercialisation in this Agreement shall not be deemed to include sales where there is not a Marketing Approval. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Commercially Reasonable Efforts </I></B>means those efforts that would be made by a pharmaceutical company (of comparable size and
resources to the relevant party) acting in good faith and in the exercise of activities or in relation to products of a similar potential value, stage of research or development, life cycle and commercial potential of the Licensed Product, taking
into account all relevant factors that such party would normally take into account, including issues of safety and efficacy, product profile, the competitiveness of alternative products (including generic products), the patent or other proprietary
position of such product (including patent coverage and regulatory exclusivity), the regulatory requirements involved and the potential profitability of such product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 5</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Confidential Information </I></B>means the terms of this Agreement and all information
belonging or relating to a party to this Agreement, whether oral, graphic, electronic, written or in any other form, that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">or should reasonably be regarded as, confidential to the party to whom it belongs or relates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not generally available to the public other than by reason of a breach of this Agreement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is disclosed to the Receiving Party by a third party lawfully in possession of such information and who is
under no obligation to maintain such information in confidence. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Development </I></B>means activities directly and
specifically relating to research, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> nonclinical, or clinical drug development, including test method development and stability testing, assay development, toxicology, pharmacology, formulation,
quality assurance/quality control development, technology transfer, statistical analysis, process development and <FONT STYLE="white-space:nowrap">scale-up,</FONT> pharmacokinetic studies, data collection and management, clinical studies (including
research to design clinical studies), regulatory affairs, drug safety surveillance activities related to clinical studies, investigator sponsored studies, and the preparation, submission and maintenance of registration filings and approvals and any <FONT
STYLE="white-space:nowrap">non-approval</FONT> activity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosing Party </I></B>means the party to whom information belongs or
relates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Effective Date </I></B>means 1 March 2021. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>FDA </I></B>means the U.S. Food&nbsp;&amp; Drug Administration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Force Majeure </I></B>means an event or cause beyond the reasonable control of the party claiming force majeure. It includes each of the
following, to the extent it is beyond the reasonable control of that party: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">act of God, lightning, storm, flood, fire, earthquake or explosion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">strike, lockout or other labour difficulty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">act of public enemy, war (declared or undeclared), terrorism, sabotage, blockade, revolution, riot,
insurrection, civil commotion, epidemic, pandemic or public health emergency (excluding the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as in existence at the Effective Date), or any resulting governmental action including work
stoppages, mandatory business, service or workplace closures, full or partial lockdown of affected areas, quarantines, border closures and travel restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">embargo, inability to obtain any necessary materials, equipment, facilities or qualified employees, power or
water shortage, lack of transportation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">breakage or accident or other damage to machinery other than as a result of lack of appropriate maintenance,
care, process or security. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Good Distribution Practice </I></B>means the principles and rules in line with good
distribution practice guidelines in the country of the Marketing Approval which ensure that medicinal products are consistently stored, transported and handled under suitable conditions as required by the Marketing Approval of the Licensed Product.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>IND </I></B>means an investigational new drug application made to the FDA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Improvement </I></B>means any improvements, enhancements, modifications, adaptations, extensions, developments, mutations, applications
of and all other technical advances made by or on behalf of a person, whether or not protected by statute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Insolvency </I></B><B><I>Event </I></B>means the occurrence of any of the following
events in respect of either party: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any step is taken (including any resolution passed at a meeting, or an application made or proceedings
commenced, where that application or those proceedings are not withdrawn or set aside within 14 days of being made or commenced) for: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the winding up, dissolution, or administration of either party; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">either party entering into any arrangement, compromise or composition with or assignment for the benefit of its
creditors or any class of them, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">except for the purposes of a solvent reconstruction or amalgamation; or </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a receiver, receiver and manager, or other controller, administrator or similar officer is appointed with
respect to or takes control of either party or any of its assets or undertakings. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate </I></B>means a
rate of ten percent (10%) per month, or if lower, the maximum amount permitted under Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Kazia <FONT
STYLE="white-space:nowrap">Know-How</FONT> </I></B>means <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or controlled by Kazia or any of Kazia&#146;s Affiliates at the Effective Date or at any time thereafter during the Term which relates to
the Licensed Product and is reasonably required by Oasmia for the Development, Manufacturing and Commercialisation of the Licensed Product or as is reasonably necessary to otherwise exercise its rights or carry out its obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Kazia Patents </I></B>means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the patent registrations and pending patent registrations listed in Part 1 of Schedule 2; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all patents and all substitutions, divisions, continuations, continuations-in-part, reissues, renewals,
validations, reexaminations and extensions thereof and supplemental protection certificates relating thereto, and all counterparts thereof in any country in the world, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">but solely to the extent they relate to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a composition of matter comprising the chemical structure set out in Part 2 of Schedule 2;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a method of use involving said chemical structure; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a method of Manufacture of the Licensed Product comprising said chemical structure.. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Know-How</FONT> </I></B>means any and all information, data and materials whether proprietary or not,
and whether patentable or not, including without limitation, technical or scientific information, know-how, data, test results, knowledge, technology, methods, processes, techniques, discoveries, inventions, specifications, designs, trade secrets,
regulatory filings and other information (whether or not patentable or otherwise protected by trade secret law) in written, electronic or other form. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Liabilities </I></B>means any debts, obligations, liabilities, losses, expenses, costs and damages of any kind and however arising,
including penalties, fines, and interest and including those which are prospective or contingent and those the amount of which, for the time being, is not ascertained or ascertainable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Licence </I></B>has the meaning given to that term in clause 3.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Licensed Product </I></B>means any product containing the chemical structure set out in Part 2 of Schedule 2 for the indication of
ovarian cancer and any other future indications, when used as a monotherapy or in combination with other drugs and other therapeutic approaches. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing </I></B>means activities directed to the manufacture of the Licensed Product including, the planning, purchasing,
producing, manufacturing, processing, transportation, quality assurance testing, quality control, regulatory compliance, storage and maintenance of cell banks, manufacture and testing of future cell banks, waste disposal, sample retention,
formulation, stability testing, storage, filling, packaging, labelling, leafleting, release and dispatch and such other related matters in each case as applicable to the Licensed Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 7</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Approval </I></B>means any approval of the applicable regulatory authorities
necessary for the Commercialisation, marketing, labelling, and sale of the Licensed Product, but excluding any separate Pricing Approval. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Milestone Payment </I></B>means the payments set out in Schedule 1 Part C. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Named Patient Basis </I></B>means the supply of the Licensed Product directly to an individual patient upon unsolicited requests from
medical professionals, in a territory where the Licensed Product has not obtained Marketing Approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Net Sales </I></B>means the
gross invoiced price for all Licensed Products sold by Oasmia, its Affiliates or sub-licensees to third parties in the Territory, less the following deductions from such gross amounts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">normal and customary trade, cash and other quantity discounts, rebates and allowances actually allowed and
taken; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">credits or allowances actually granted to the customer for damaged goods, returns, recalls, rebates or
rejections of Licensed Products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sales taxes, excise taxes, value added taxes and custom duties actually paid to a governmental authority,
included in the invoiced price and not reimbursed directly or indirectly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reasonable chargebacks related to sales of Licensed Products, to the extent actually allowed and taken by a
third party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reasonable freight, insurance and other transportation and handling fees to the extent that such charges were
included on the invoice provided to the customer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">compulsory payments and rebates directly related to the sale of Licensed Products, accrued, paid or deducted
pursuant to governmental regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Pricing Approval </I></B>means such approval, agreement, determination or
governmental decision establishing pricing and reimbursement for the Licensed Product that can be charged to customers and will be reimbursed by governmental authorities or payers in any jurisdiction in the Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Receiving Party </I></B>means the party to whom information is disclosed or who possesses or otherwise acquires information belonging or
relating to a Disclosing Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Resolution Institute </I></B>means the Australian and New Zealand dispute resolution membership
organisation known as the Resolution Institute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Royalty </I></B>is the royalty to be paid by Oasmia to Kazia on Net Sales in the
Territory during the Term of this Agreement for the value given in Part B of Schedule 1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Term </I></B>has the meaning given in
clause 16.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Territory </I></B>means the world. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer </I></B>means providing information in a fully and properly documented form, and for soft copies, capable of being received,
opened, downloaded and saved through the use of commonly available and used commercial software. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 8</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Headings are for convenience only and do not affect interpretation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mentioning anything after includes, including, for example, or similar expressions, does not limit what else
might be included. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this Agreement is to be interpreted against a party solely on the ground that the party put forward
this Agreement or a relevant part of it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following rules apply unless the context requires otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The singular includes the plural, and the converse also applies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a word or phrase is defined, its other grammatical forms have a corresponding meaning.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A reference to a person includes a corporation, trust, partnership, unincorporated body or other entity,
whether or not it comprises a separate legal entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A reference to anything (including a right, obligation or concept) includes each part of it.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A reference to a clause is a reference to a clause of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A reference to writing includes any method of representing or reproducing words, figures, drawings or symbols
in a visible and tangible form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A reference to a party to this Agreement or another agreement or document includes the party&#146;s successors,
permitted substitutes and permitted assigns (and, where applicable, the party&#146;s legal personal representatives). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A reference to legislation or to a provision of legislation includes a modification or <FONT
STYLE="white-space:nowrap">re-enactment</FONT> of it, a legislative provision substituted for it and a regulation or statutory instrument issued under it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(ix)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A </B>reference to time is to time in Sydney, Australia. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commercialisation of Licensed Product </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties acknowledge that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as at the Effective Date, the Licensed Product has successfully completed phase I clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia will use its Commercially Reasonable Efforts to progress the Licensed Product through phase II and Ill
clinical trials, and to Commercialise the Licensed Product, within a reasonable time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties acknowledge that, while as at the Effective Date, the Licensed Product has successfully completed
phase I clinical trials and it is the parties&#146; hope that the results of such trials may be used to assist in obtaining Marketing Approvals in the Territory, no assurances, representations or warranties are given in this regard.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Grant of Licence </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Kazia Patents and Associated Intellectual Property Licence grant </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of this Agreement, on and from the Effective Date Kazia grants to Oasmia and Oasmia accepts an exclusive
licence under the Kazia Patents and Associated Intellectual Property to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Manufacture, supply and export the Licensed Product, or permit others to do so; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 9</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Develop the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make sales of or otherwise supply the Licensed Product on a Named Patient Basis to the extent permitted by
Applicable Law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commercialise the Licensed Product, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">for the duration of the Term (the <B><I>Licence).</I></B> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Sub-licencing</FONT> and
<FONT STYLE="white-space:nowrap">sub-contracting</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia may, without any requirement to consult with or seek approval from Kazia, sub-license the Licence or
subcontract any rights granted under this Agreement to any of its Affiliates or any other third parties. In such circumstances, Oasmia must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensure that any <FONT STYLE="white-space:nowrap">sub-licensee</FONT> or subcontractor agrees in writing to be
subject to, and bound by, to the extent applicable, terms and conditions substantially similar to the terms and conditions of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify Kazia of the identity of the sub-licensee or subcontractor within 7 days of their engagement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia will be responsible to Kazia for any Liability suffered by Kazia resulting from any act or omission of a
sub-licensee relating to a <FONT STYLE="white-space:nowrap">sub-</FONT> licence or subcontractor relating to a subcontract (a <B><I>Wrong), </I></B>but only to the extent that Oasmia would be liable to Kazia under this Agreement had Oasmia committed
the Wrong. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must enforce any sub-licensees&#146; or subcontractors&#146; obligations under any respective sublicense
or subcontract agreements granted to sub-licensees or subcontractors in accordance with this clause 3.2. Oasmia remains responsible for the performance of the obligations of its <FONT STYLE="white-space:nowrap">sub-licensees</FONT> and
subcontractors, as if such obligations were carried out by Oasmia itself, including the payment of Royalties or Milestone Payments as provided for under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights of Oasmia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Without limiting the Licence granted under clause 3.1, Kazia grants to Oasmia and its successors and assignees a royalty-free, irrevocable for
the Term, exclusive and sub-licensable licence to the Cantrixil Dossier, to the extent necessary for, and solely for the purpose of, the performance of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Improvements </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must notify Kazia of any Improvements which it or its personnel, sub-licensees or subcontractors
discovers or develops with respect to any of the Kazia Patents and Associated Intellectual Property within 30 days from the discovery or development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree that all rights, title and interest in Improvements to the Kazia Patents and Associated
Intellectual Property developed or discovered by or on behalf of Oasmia vest in (as between the parties) Oasmia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination or expiry of this Agreement, Oasmia agrees to grant Kazia a non-exclusive, royalty-free,
sub-licensable and perpetual licence to any Improvements to the Kazia Patents and Associated Intellectual Property in the Territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 10</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transfer of Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> and assistance from Kazia
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transfer of Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Cantrixil Dossier
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as reasonably practicable after the Effective Date Kazia must Transfer to Oasmia in its entirety, the
Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> and Cantrixil Dossier. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where Oasmia considers that any information provided to Oasmia in accordance with clause 4.1(a) is missing,
incomplete or unclear, Oasmia has the right to reasonably request through a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">question-and-answer</FONT></FONT> process additional information in relation to that information. Kazia
must act reasonably in considering any such request. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting clause 4.1(a), with regards to Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> related
to the Manufacturing of the Licensed Product, Kazia acknowledges that the Transfer to Oasmia may take some time to complete and that Kazia will provide reasonable assistance in connection with the Transfer when reasonably requested until the earlier
of the completion of the Transfer or 18 months after the Effective Date. Kazia must use Commercially Reasonable Efforts to maintain adequate available resources to effect the Transfer and provide reasonable assistance to Oasmia.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assistance in respect of Manufacturing and supply of Licensed Product </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Upon the reasonable request of Oasmia, Kazia agrees to use Commercially Reasonable Efforts to assist Oasmia: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by facilitating proper introductions to the Cantrixil Manufacturers to seek to facilitate those manufacturers
to enter into manufacturing agreements with Oasmia; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any of the circumstances set out in Schedule 4. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">For the purpose of this clause 4.2, Kazia acknowledges that its Commercially Reasonable Efforts must include, where available, the allocation
of Kazia resources and personnel that possess the appropriate experience, skills and qualifications required to provide the requested assistance to Oasmia. For the avoidance of doubt, the parties acknowledge that, in providing its best efforts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">while Kazia will seek to allocate sufficient resources to accommodate requested assistance in a timely manner,
such allocation will be dependent on Kazia&#146;s activities and resource capacity at the time of any request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia will not be obliged to obtain resources or engage personnel in addition to those personnel engaged by it
at the time a request for assistance is made by Oasmia. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commercialisation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sales and distribution in the Territory </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Oasmia shall invoice and book, and appropriately record, all sales of the Licensed Product in the Territory including for the avoidance of
doubt, any sale of Licensed Product in the Territory made by sub-licensees or subcontractors. Oasmia shall also be responsible for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the distribution of Licensed Product in the Territory and for paying all governmental discounts and/or rebates
which are due and owing with respect to the Licensed Product in the Territory using Good Distribution Practices, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">handling all returns of Licensed Product sold under this Agreement, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">handling all aspects of ordering, processing, invoicing, collection, distribution and receivables with respect
to Licensed Product in the Territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 11</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty Reports </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Starting from the first commercial sale or sale made on a Named Patient Basis, within 30 calendar days after
the end of each calendar quarter, Oasmia shall deliver to Kazia a written report setting forth, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in the Territory for such calendar quarter:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of units of each Licensed Product sold on a country by country basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gross sales of each Licensed Product for each country in which the Licensed Product is being sold via
commercial sale or on a Named Patient Basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Net Sales of each Licensed Product for each country in which the Licensed Product is being sold;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an accounting of the permitted deductions from gross sales on a country by country basis; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Royalties calculated on a per country basis, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(the, <B><I>Royalty Report).</I></B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Royalty Report referred to in this clause 5.2 shall be in electronic form. The financial data in the
Royalty Report will include calculations in the local currency for each relevant country, and US Dollars. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must provide with each Royalty Report evidence, to the reasonable satisfaction of Kazia, to support all
amounts set out in the Royalty Report. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 10 Business Days after the date on which the Royalty Report is given to Kazia <B><I>(Objection
Period)</I></B>, Kazia may dispute any amount set out in the Royalty Report by giving notice <B><I>(Objection Notice)</I></B> to Oasmia stating the amount or amounts in dispute and the reasons for that dispute <B><I>(Royalty Dispute)</I></B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If at the end of the Objection Period there is no Royalty Dispute, all amounts set out in the Royalty Report
are final and binding on the parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Objection Notice is given, then Kazia and Oasmia must use their reasonable endeavours to resolve the
Royalty Dispute between themselves. If Kazia and Oasmia are unable to resolve the Royalty Dispute within 5 Business Days after the Objection Notice is given, the parties must refer the Royalty Dispute to an Expert in accordance with, and for
determination in accordance with, Schedule 5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a Royalty Dispute but it is not resolved by the parties nor referred to an Expert in accordance
with clause 5.2(f), all amounts set out in the Royalty Report are final and binding on the parties, the Royalty Dispute is taken to be resolved and payments are to be made in accordance with the timing set out in clause 6.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a Royalty Dispute which is resolved by the parties or by an Expert in accordance with Schedule 5,
Oasmia must pay to Kazia the Royalty amounts due in accordance with Part B of Schedule 1 in respect of Net Sales made during the period of the relevant Royalty Report based on the Royalty Report amounts agreed between the parties or determined by
the Expert (as applicable) within 10 Business Days of such agreement or determination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Upfront fee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">In consideration of the grant of the Licence and other rights granted pursuant to this Agreement in relation to the Development of the Licensed
Product, Oasmia shall pay to Kazia the amount set out in Part A of Schedule 1 within 30 Business Days of receipt of a valid invoice from Kazia. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to the issue of a valid invoice by Kazia and clause 5.2(h) within 30 Business Days of issue of the Royalty Report in accordance with
clause 5.2(a) Oasmia must pay to Kazia an amount equal to the Royalty set out in Part B of Schedule 1 in respect of Net Sales made during the period of the relevant Royalty Report. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestone Payments </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In consideration of the rights granted pursuant to this Agreement, where a regulatory or commercial milestone
as set out in column 1 of the table in Part C of Schedule 1 is satisfied, Oasmia must pay to Kazia the corresponding Milestone Payment as set out in columns 2 and 3 (as applicable) of the table in Part C of Schedule 1 within 30 Business Days of
receipt of a valid invoice with respect to the same from Kazia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding clause 6.3(a), if for any reason the Milestone Payment relating to a phase Ill study (being the
Milestone Payment corresponding to the first regulatory milestone) has not been paid at the time a new drug application is submitted to the FDA, Oasmia agrees that that Milestone Payment as set out in Schedule 1 becomes due and payable within 30
Business Days of receipt of a valid invoice with respect to the same from Kazia. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment requirements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">All payments under this Agreement shall be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deposited by electronic funds transferred to Kazia&#146;s nominated bank account, as notified to Oasmia in
writing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">made in US dollars. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Default in payment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Agreement, if a party defaults in the payment of any money payable under this Agreement for a
period of more than 5 Business Days, then the non-defaulting party may charge interest on the amount outstanding at the Interest Rate, calculated from and including the date on which the payment became due until but excluding the date on which the
payment is made, which interest is payable on the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party making written demand to that effect. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No deductions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to clause 12.4, as between the parties, Oasmia is solely responsible for payment of any fee, royalty or other payment due to any third
party in connection with the research, development, manufacture, distribution, use, sale, import or export of a Licensed Product, and Oasmia shall not have the right to offset any amounts paid to such third party, including fee, royalty or other
payment, against any amount payable to Kazia under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Alliance Manager </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party shall appoint one alliance manager who possesses a general understanding of development,
manufacturing and marketing issues in relation to the Licensed Product (each an <B><I>Alliance Manager), </I></B>who will be dedicated to coordinating the activities of the parties under this Agreement and to act as a liaison with the other party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Alliance Managers are responsible for: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">facilitating the flow of information, and otherwise promoting communication and coordination, between the
parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">coordinating with the other party on practical issues; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing a point of communication for seeking consensus both within the respective party&#146;s organisation
and with the other party&#146;s organisation regarding material issues under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligations </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual obligations </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting clause 21, the parties shall exercise good faith to resolve business, financial and commercial
issues that are encountered during the performance of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Throughout the Term of this Agreement, the parties agree to cooperate, through their respective Alliance
Managers, in good faith to ensure the performance of each parties&#146; obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Oasmia&#146;s responsibilities </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia is responsible for: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Development strategies for the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the performance of Development activities with respect to the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensuring that the Development activities with respect to the Licensed Product are consistent with all
Applicable Laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obtaining and maintaining regulatory approvals pursuant to clause 9; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commercialisation strategies for the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the performance of marketing activities with respect to the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">market access and pricing with respect to the Licensed Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensuring that the Commercialisation activities with respect to the Licensed Product are consistent with any
Marketing Approvals and all Applicable Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On and from the Effective Date, Oasmia shall assume full responsibility for all activities related to the
Manufacturing, Development and Commercialisation of the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Kazia&#146;s responsibilities </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree Kazia will be solely responsible for all Liabilities directly incurred, suffered or sustained
by Oasmia and its Affiliates, directors, officers, employees, servants and agents as a result of or in connection with the Development, Commercialisation, sale or any other use of the Licensed Products by Oasmia, Kazia or any of their Affiliates, or
any third party prior to the Effective Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 14</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree Oasmia will be solely responsible for all Liabilities directly incurred, suffered or
sustained by Kazia and its Affiliates, directors, officers, employees, servants and agents as a result of or in connection with the Development, Commercialisation, sale or any other use of the Licensed Products by Oasmia, Kazia or any of their
Affiliates, or any third party after the Effective Date. [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On and from the Effective Date, the parties agree Kazia shall not be responsible (financially, operationally or
otherwise) for conducting, managing, controlling or participating in any activities related to the Licensed Product, except as specifically set out in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governmental Matters </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory approvals </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On and from the Effective Date, Oasmia is responsible for obtaining and maintaining all necessary approvals
from governmental authorities for Oasmia to Develop, Manufacture, Commercialise, market and sell the Licensed Products anywhere in the Territory, and for Oasmia to otherwise exploit the Licence granted pursuant to this Agreement. All such regulatory
filings made or filed, and all permits and clearances obtained, by Oasmia will be owned exclusively by Oasmia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia grants to Oasmia, their Affiliates and any sub-licensee a right of reference to any regulatory filings
relating to the Licensed Product as at the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Prosecution, Proceedings and Protection of Rights </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Prosecution and maintenance of Kazia Patents </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As between the parties, Kazia shall, in the first instance, be responsible for the preparation, filing,
prosecution and maintenance of the Kazia Patents within the Territory, such responsibility extending solely to filing, prosecution and maintenance of and relating to the patents set out in Schedule 2 within the applicable jurisdiction for each
respective patent as set out in column 1 of the table in Schedule 2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In fulfilling its responsibilities under clause 10.1(a), Kazia must use Commercially Reasonable Efforts to
prepare, file, prosecute and maintain at its cost the Kazia Patents within the Territory, such responsibility extending solely to using Commercially Reasonable Efforts to prepare, file, prosecute and maintain the patents set out in Schedule 2 within
the applicable jurisdiction for each respective patent as set out in column 1 of the table in Schedule 2. Kazia may elect not to prepare, file, prosecute or maintain any of the Kazia Patents, provided that it obtains Oasmia&#146;s prior written
consent, which must not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Kazia elects and Oasmia consents, in accordance with clause 10.1(b), not to prosecute and/or maintain any
Kazia Patents in any country in the Territory or Oasmia wishes to prosecute and/or maintain any Kazia Patents in a country in the Territory in addition to those set out in column 1 of the table in Schedule 2 with respect to the relevant patent,
Oasmia may undertake the prosecution and maintenance of such patents in the relevant jurisdiction in the Territory. Kazia must be given an opportunity to review and comment on correspondence with the patent offices, and Oasmia must incorporate
Kazia&#146;s reasonable comments. All costs (including outside counsel, annuities and other official fees) of preparing, filing, prosecuting and maintaining such patents in any jurisdiction in the Territory shall be borne solely by Oasmia.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 15</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, for the purposes of this Agreement, any patents prosecuted or maintained by Oasmia
in accordance with clause 10.1(c) will constitute Kazia Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where clause 10.1(c) applies, Kazia must provide to Oasmia reasonable assistance as Oasmia may reasonably
require from time to time in relation to maintaining and prosecuting registration of the applicable Kazia Patents in the relevant jurisdictions and not oppose or encourage or assist any person to oppose a grant or renewal of a registration in
respect of the Kazia Patents, nor encourage or assist any person to dispute or challenge the validity of the Kazia Patents. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notification of Claims </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Either party must notify the other party immediately if it receives any notice of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any actual or threatened infringements of the Kazia Patents or Associated Intellectual Property; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any allegation (written or otherwise) that the use of the Kazia Patents, Associated Intellectual Property or
Licensed Product infringes any third party rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 16</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.8</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Warranties and Indemnities </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and warranties by the parties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Each party represents and warrants to the other parties that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has full legal capacity and power to enter into this Agreement and to perform its obligations under this
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has taken all corporate action (if any) that is necessary or desirable to authorise its entry into this
Agreement and to perform its obligations under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Agreement constitutes its legal, valid and binding obligations, enforceable against it in accordance with
its terms (except to the extent limited by equitable principles and laws affecting creditors&#146; rights generally); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither its execution of this Agreement nor the carrying out by it of its obligations under this Agreement,
does or will contravene any law to which it is subject or any order of any government agency or other person that is binding on it, contravene any undertaking or instrument binding on it, or contravene its constitution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there are no actions, claims, proceedings or investigations pending or threatened against it or by, against or
before any person that may have a material effect on the subject matter of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is not the subject of an Insolvency Event. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and warranties by Kazia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Kazia represents and warrants to Oasmia that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia and its Affiliates are the legal and beneficial owner of the Kazia Patents and Associated Intellectual
Property and Kazia has the right to grant to Oasmia the Licence as set out in this Agreement in respect of the Kazia Patents and Associated Intellectual Property, <I>free </I>of all restrictions, liens, charges, encumbrances or other rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the best of its knowledge, any information provided in the Cantrixil Dossier and in relation to the Kazia <FONT
STYLE="white-space:nowrap">Know-How</FONT> is complete, adequate, true and accurate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the graphical representation in Part 2 of Schedule 2 accurately depicts the chemical structure of Cantrixil;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to clause 11.8 and to the best of its knowledge, the Kazia Patents and Associated Intellectual Property
are valid and enforceable and are not being, and have not been, infringed, and there is no matter, fact or circumstance which would, or would be likely to. render the Kazia Patents or Associated Intellectual Property void or voidable on any grounds;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to clause 11.8 and to the best of its knowledge, the Development, Manufacturing or Commercialisation of
the Licensed Product the subject of the Kazia Patents and Associated Intellectual Property by Oasmia in accordance with this Agreement will not infringe any right of any third party nor give rise to a right entitling any third party to make a claim
against Oasmia, any of its Affiliates, or any sub-licensee or subcontractor of Oasmia, whether for the payment of compensation, royalties or otherwise; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 17</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the best of its knowledge, none of Kazia or any of its Affiliates have transferred, assigned or granted to
any person any right, licence under or interest in the Kazia Patents or Associated Intellectual Property or which is inconsistent with the Licence as set out in this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and warranties by Oasmia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Oasmia represents and warrants that, as at the Effective Date and on each day during the Term, in conducting activities contemplated under this
Agreement, Oasmia will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with all Applicable Laws including those related to the manufacture, use, labelling, importation and
marketing of Licensed Products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not undertake any act or omission which will, or will have the likely effect to, bring Kazia, the Licensed
Product, the Kazia Patents or the Associated Intellectual Property into disrepute. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Warranties separate </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Each of the warranties is a separate and independent warranty and is not to be construed by reference to, or limited by, any other warranty.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No other representations or warranties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Except for the warranties expressly made in this Agreement, all conditions, warranties, undertakings or representations, express or implied,
arising by statute, general law or otherwise are expressly excluded to the extent permitted by law. In particular, with respect to warranties given by Kazia, subject to the express warranties granted in clause 11.2, nothing in this Agreement is or
will be construed as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a warranty or representation by Kazia as to the validity or scope of any claim or patent or patent application
within the Kazia Patents and Associated Intellectual Property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a warranty or representation by Kazia that anything made, used, sold, or otherwise disposed of under any
licence granted in this Agreement is or will be free from infringement of any patent rights or other intellectual property right of any third party; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a grant by Kazia, whether by implication, estoppel, or otherwise, of any licenses or rights other than that
expressly granted under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Period of warranties and indemnity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Each of the warranties and the indemnity contained in this clause 11 are continuing obligations. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reliance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Each party acknowledges that the other parties have executed this Agreement and agreed to take part in the transactions that this Agreement
contemplates in reliance on the representations and warranties that are expressly made in this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 18</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnities and Liability </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusions </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">TO THE EXTENT PERMISSIBLE BY LAW, OTHER THAN AS SET FORTH IN THIS AGREEMENT, NO WARRANTY IS GIVEN WITH RESPECT
TO MATERIALS, OR THE ASSOCIATED INTELLECTUAL PROPERTY, EXPRESS OR IMP LIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF THE ASSOCIATED INTELLECTUAL PROPERTY, OR <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL PROPERTY OR OTHER RIGHTS OF ANY THIRD PARTY. THE WARRANTIES SET FORTH IN CLAUSE 11 ARE IN LIEU OF
ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, NON-INFRINGEMENT AND ALL SUCH OTHER WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT, SAVE FOR ANY LIABILITY
STEMMING FROM DEATH OR PERSONAL INJURY, SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING LOSS OF PROFITS) WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT OR ANY OTHER
LEGAL THEORY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>TO THE EXTENT PERMISSIBLE BY LAW, AND SAVE FOR ANY LIABILITY STEMMING FROM DEATH OR PERSONAL INJURY, THE
MAXIMUM AMOUNT THAT OASMIA MAY RECOVER FROM KAZIA FOR ANY LIABILITY UNDER THIS AGREEMENT IS THE TOTAL AMOUNT PAID UNDER THE AGREEMENT AT THE POINT OF TIME THE LIABILITY ARISES. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation to insure </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must effect and maintain on an ongoing basis throughout the Term and the period of time required under
clause 13.2, at its own expense, the following insurance coverages: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commercial general liability insurance, including contractual liability and products liability insurance, in
the minimum amount of [***] in aggregate, combined single limit for bodily injury and property damage liability, increasing to [***] in aggregate, combined single limit for bodily injury and property damage liability upon the first commercial sale
of a Licensed Product. The deductible shall not be greater than [***] in the US and Canada combined and [***] in the rest of the world outside of the US and Canada; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 19</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">statutory workers&#146; compensation coverage, where limits and employers liability limits shall be at a
minimum amount of [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia as sponsor of clinical trials with the Licensed Product must effect and maintain, at its own expense for
the whole duration of the clinical trial, liability insurance with minimum limits and conditions as legally required in the jurisdiction of the trial in the Territory. For all countries in the Territory with
<FONT STYLE="white-space:nowrap">non-defined</FONT> minimum insurance limits, Oasmia shall acquire local insurance on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis at the statutory level,
as required by local Applicable Laws, save that where there is no level established by statute, the minimum insurance limit shall be based on the local standards and practices of the jurisdiction and will be presented by Oasmia to Kazia for
approval, which is not to be unreasonably withheld. This insurance shall be primary insurance. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Requirements for insurance policies </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All insurance coverage required pursuant to clause 13.1 must be primary insurance with respectto Oasmia&#146;s
own participation under this Agreement, and must be maintained with an insurance company or companies having an A.M. Best&#146;s rating of <FONT STYLE="white-space:nowrap">A-VII</FONT> or better. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must name Kazia as an additional insured by endorsement under its commercial general liability and
products liability insurance policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The insurance policies must be in aggregate and Oasmia must maintain the insurance coverage for at least 5
years following completing performance of its obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Evidence of currency </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No later than 30 days after the Effective Date, Oasmia must provide to Kazia a copy of the insurance policies
required to be held by Oasmia pursuant to clause 13.1 and certificates of currency with respect to such insurance policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must provide to Kazia at least 30 days prior written notice of any cancellation, nonrenewal or material
change in any of the insurance policies required to be held by Oasmia pursuant to clause 13.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must, upon receipt of written requestfrom Kazia, provide renewal certificates to Kazia in relation to
the insurance policies required to be held by Oasmia pursuant to clause 13.1 for as long as Oasmia is required to maintain insurance coverage under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Records and Audit </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Records </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia shall keep complete and accurate records of its compliance with its obligations under this Agreement,
and its and its sublicensees&#146; sales, transfers, and other dispositions of Licensed Product necessary for the calculation of payments to be made to Kazia hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia shall maintain such records for the longer of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the period of time required by any Applicable Law; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">3 years following expiration or termination of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 20</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audit </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia may at any time, but, subject to clause 14.2(b), not to exceed more than once in a 12 month period,
nominate an independent certified public accountant or other third party (as appropriate) <B><I>(Auditor) </I></B>whom Oasmia shall, no later than 10 Business Days of Kazia&#146;s notice of the same, permit to have access to Oasmia&#146;s records
during Oasmia&#146;s normal business hours for the purpose of verifying all payments made under this Agreement and <I>I </I>or compliance with Oasmia&#146;s obligations under this Agreement more generally. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where Kazia, acting reasonably, suspects that Oasmia may be in breach of any of its obligations under this
Agreement, Kazia may require Oasmia to submit to an audit in accordance with clause 14.2(a) notwithstanding there may have already been one or more audits during the relevant 12 month period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Auditor&#146;s audit report shows that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payments made by Oasmia are deficient, Oasmia shall pay Kazia the deficient amount within 30 days after
Kazia&#146;s notice to Oasmia of the same; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia is in breach of its obligations under this Agreement, the parties will promptly meet to agree a
remediation plan such that any breach by Oasmia may be remedied, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">provided, however, that Kazia provides to Oasmia
reasonable evidence of the relevant findings set out in the Auditor&#146;s audit report. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The costs of any audit under this clause 14.2 must be borne by Kazia unless the Auditor&#146;s audit report
shows that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payments made by Oasmia are deficient; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia is in breach of its obligations under this Agreement, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">in which case the costs of the relevant audit will be borne by Oasmia. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reporting </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 30 days after the end of each June and December during the Term, Oasmia will update Kazia in relation to
its progress on its activities under this Agreement. Such updates shall take the form of a written report detailing: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Development and Commercialization of the Licensed Product by Oasmia during the preceding 6 month period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the status of all progressing and planned clinical studies related to the Kazia Patents and Associated
Intellectual Property, including timelines for initiation and completion of such clinical studies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a summary of Oasmia&#146;s plans for the Development and Commercialisation of the Licensed Product in the next
6 months. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All reports provided by Oasmia to Kazia in accordance with clause 15(a) must be sufficiently detailed for Kazia
to ascertain whether Oasmia is using Commercially Reasonable Efforts to Develop and Commercialise the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the frequency of the reporting in accordance with clause 15(a), Oasmia must inform Kazia
immediately upon the achievement of a milestone listed in Schedule 1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 21</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term and Termination </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Licence and this Agreement commences on the Effective Date, as relates to each of the Kazia Patents,
[***]<B><I>(Term).</I></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the expiry of the Licence as it relates to any one of the Kazia Patents will not
affect the Licence as it relates to any of the other Kazia Patents and the Licence will survive any such expiry to that extent. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by either party </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to completion of the dispute resolution processes under clause 21, either party may immediately terminate this Agreement in writing, by
giving the other party written notice, where the other Party: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">undergoes an Insolvency Event (regardless of whether that Insolvency Event is continuing); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commits a material breach of this Agreement, unless the breach is capable of remedy, in which case the other
party may terminate this Agreement if the party who has committed that material breach has not remedied the material breach within 30 days after being required in writing to do so. Such written notice shall indicate the nature of the breach and any
remedial action required to be taken. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Oasmia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to completion of the dispute resolution processes under clause 21, Oasmia may immediately terminate this Agreement by notice in writing
if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Kazia Patents are revoked or abandoned, or otherwise cease to be in force for any reason other than the
expiry of its statutory term; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kazia breaches any of its representations and warranties under clause 11 above. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Kazia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to completion of the dispute resolution processes under clause 21, Kazia may immediately terminate this Agreement by notice in writing
if Oasmia: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">breaches any of its representations and warranties under clause 11 above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">through a failure to use Commercially Reasonable Efforts breaches any of its obligations under clause 8.2,
unless the breach is capable of remedy, in which case Kazia may terminate this Agreement if Oasmia has not remedied the breach within thirty days after being required in writing to do so. Such written notice shall indicate the nature of the breach
and any remedial action required to be taken; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">breaches any of its obligations under clauses 5 or 6, unless the breach is capable of remedy, in which case
Kazia may terminate this Agreement if Oasmia has not remedied the breach within thirty days after being required in writing to do so. Such written notice shall indicate the nature of the breach and any remedial action required to be taken.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 22</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General consequences of termination and survival </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Upon expiry or termination in accordance with this clause 16, this Agreement, and the Licence, is at an end as to its future operation, except
for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of any party which have accrued as at the date of expiry or termination; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights and obligations of the parties under clauses 10.2, 10.8, 12, 14, 17, 18, 19 and 23 (except 23(a)),
which survive termination. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specific consequences of termination </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On termination or expiry of this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must pay to Kazia in accordance with the terms of this Agreement any unpaid invoices submitted before
termination and any invoices properly submitted by Kazia after termination in accordance with clause 6; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rights and licenses granted to Oasmia under this Agreement will immediately terminate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must use its best endeavours to either transfer to Kazia, or assist Kazia to obtain, all necessary
approvals from governmental authorities for Kazia to Develop, Manufacture, Commercialise, market and sell the Licensed Products anywhere in the Territory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as reasonably practicable, Oasmia must Transfer to Kazia, in its entirety, the Kazia <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Cantrixil Dossier, as both have been amended and updated by Oasmia over the course of the Term, along with (for the avoidance of doubt) all <FONT STYLE="white-space:nowrap">Know-How</FONT> necessary for
Kazia to exploit the licence granted to it under clause 3.4(c), such that Kazia receives the most current and up to date Know-How and dossier relevant to the Licensed Product and is in a position to exploit the licence granted under clause 3.4(c);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must discontinue making any representation regarding its status as a licensee of Kazia for all Licensed
Products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Oasmia must cease conducting any activities with respect to the marketing, promotion, sale or distribution of
Licensed Products including ceasing all Manufacturing, Development and Commercialisation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rights granted under this Agreement will revert to Kazia. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the parties agree to provide reasonable run off and transitional assistance if a
clinical trial is ongoing as at the date of termination of this Agreement, to ensure trial participants affected by termination receive adequate medical care. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment by Oasmia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Kazia acknowledges that Oasmia is entitled to assign any or all of its rights or obligations under this Agreement to any of its Affiliates or
any other third party, including in relation to any restructure, sale of assets or change of control, without Kazia&#145;s consent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment by Kazia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Oasmia acknowledges that Kazia is entitled to assign any or all of its rights or obligations under this Agreement to any of its Affiliates or
any other third party, including in relation to any restructure or sale of assets, without Oasmia&#146;s consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 23</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligations of confidentiality </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Subject to clauses 18.2 and 18.3, the Receiving Party must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the Confidential Information confidential and not directly or indirectly disclose, divulge or communicate
any Confidential Information to, or otherwise place any Confidential Information at the disposal of, any other person without the prior written approval of the Disclosing Party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all reasonable steps to secure and keep secure all Confidential Information coming into its possession or
control as it would its own proprietary information, which in no event shall be less than a reasonable standard of care; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">only use the Confidential Information for the purposes of performing, and to the extent necessary to perform,
its obligations under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not deliberately memorise, modify, reverseengineer or make copies, notes or records of the Confidential
Information for any purpose other than in connection with the performance by the Receiving Party of its obligations under this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all reasonable steps to ensure that any person to whom the Receiving Party is permitted to disclose
Confidential Information under clause 18.2 complies at all times with the terms of this clause 18. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted disclosure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">A party may only disclose the other party&#146;s Confidential Information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under corresponding obligations of confidence as imposed by this clause 18: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to its professional advisers, auditors, bankers, insurers or insurance brokers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to persons which Control or are Controlled by or are under common control with the party within the meaning of
the <I>Corporations Act 2001 </I>(Cth), and the employees, professional advisers, auditors, bankers, insurers or insurance brokers of such persons; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which is at the time lawfully in the possession of the proposed recipient of the information through sources
other than another party, or an Affiliate of another party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in enforcing this Agreement or in a proceeding arising out of or in connection with this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with the prior written consent of the party which originally supplied that confidential information in
connection with this Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where such disclosure is necessary to comply with any court order, law, or the applicable rules of any stock
exchange or financial market to which the Receiving Party or an Affiliate of that party, is subject if, to the extent practicable and as soon as reasonably possible, the Receiving Party: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notifies the Disclosing Party of the proposed disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consults with the Disclosing Party as to its content; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provides the Disclosing Party a reasonable opportunity to seek a protective order or other appropriate remedy
and/or to waive compliance with the provisions of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">uses reasonable endeavours to comply with any reasonable request by the Disclosing Party concerning the
proposed disclosure. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 24</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exceptions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Clause 18.1 will cease to apply to any Confidential Information to the extent it enters the public domain, other than as a result of a breach
of this Agreement, or where such Confidential Information is lawfully received by the Receiving Party other than from the Disclosing Party without any obligation of confidence attaching to it. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, Oasmia acknowledges that the Kazia <FONT STYLE="white-space:nowrap">Know-How</FONT> is Confidential Information of
Kazia and is subject to the obligations set out under this clause 18. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return or destruction of Confidential Information </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clauses 16.6 and 18.5(b), immediately on the termination of this Agreement for any reason, a
Receiving Party must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cease the use of all Confidential Information of or relating to the Disclosing Party (or any Affiliate of the
Disclosing Party); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deliver to the Disclosing Party all documents and other materials in its possession or control containing,
recording or constituting that Confidential Information or, at the option of the Disclosing Party, destroy, and certify to the Disclosing Party that it has destroyed, those documents and materials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for Confidential Information stored electronically, permanently delete that Confidential Information from all
electronic media on which it is stored, so that it cannot be restored. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Receiving Party shall be permitted to retain a copy (or copies, as necessary) of Confidential Information of
or relating to the Disclosing Party which the Receiving Party has the right to retain under this Agreement, or otherwise for archival purposes or as required by any Applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Liability for breach by recipient </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The Receiving Party is liable for any breach of this clause 18 by a recipient of Confidential Information which is provided such information in
accordance with clause 18.2(a), as if that recipient was a Receiving Party in relation to the Confidential Information disclosed to the recipient. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival of obligation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The obligations under this clause 18 survive the termination or expiration of this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Public announcements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Except as required by law, a regulatory body or a stock exchange or financial market to which a party, or an Affiliate of a party, is subject,
all press releases and other public announcements in connection with this Agreement must use the form of press release set out in Schedule 6 or otherwise be in terms agreed by the parties. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Costs and duty </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Each party must bear its own costs arising out of the negotiation, preparation and execution of this Agreement. All duty (including stamp duty
and any fines, penalties and interest) payable on or in connection with this Agreement and any instrument executed under or any transaction evidenced by this Agreement must be borne equally by Kazia and Oasmia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 25</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>20</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Any notice, demand, consent or other communication (a <B><I>Notice</I></B>)<B><I> </I></B>given or made under this Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must be in writing and signed by the sender or a person duly authorised by the sender (or in the case of email,
set out the full name and position or title of the sender or person duly authorised by the sender); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must be delivered to the intended recipient by prepaid post (if posted to an address in another country, by
registered airmail) or by hand or email to the address or email address below or the address or email address last notified by the intended recipient to the sender: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(i)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">to Oasmia:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oasmia Pharmaceutical AB</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address: Vallongatan 1, 752 28 Uppsala,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sweden</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">with a copy to</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Allens</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address: Level&nbsp;4, 126 Phillip St Sydney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NSW2000</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: [***]Attention: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kazia Therapeutics Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(ii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">to Kazia:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address: Level&nbsp;24, 300 Barangaroo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Avenue, Sydney, New South</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wales, Australia 2000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">with a copy to</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">K&amp;L Gates</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address: Level&nbsp;25 South Tower, 525</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collins Street Melbourne,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Australia 3000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: [***]Attention: [***]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will be conclusively taken to be duly given or made and received: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of delivery in person, when delivered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of delivery by express post, to an address in the same country, two Business Days after the date of
posting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of delivery by any other method of post, six Business Days after the date of posting (if posted to
an address in the same country) or 10 Business Days after the date of posting (if posted to an address in another country); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 26</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of email, at the earliest of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the time that the sender receives an automated message from the intended recipient&#146;s information system
confirming delivery of the email; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the time that the intended recipient confirms receipt of the email by reply email; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">three hours after the time the email is sent (as recorded on the device from which the sender sent the email)
unless the sender receives, an automated message that the email has not been delivered, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">but if the result is that a
Notice would be taken to be given or made and received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of delivery by hand or post, at a time that is later than 5 pm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of delivery by email, at a time that is later than 7 pm; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(vii)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>on a day that is not a Business Day, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">in the place specified by the intended recipient as its postal address under clause 20(b), it will be conclusively taken to have been duly
given or made and received at the start of business on the next Business Day in that place. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Parties to attempt resolution </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">If a dispute arises relating to or arising out of this Agreement, the parties must first attempt to resolve that dispute in accordance with
this clause 21. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meeting between Alliance Managers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">As soon as reasonably practicable following the written notification by the Alliance Manager of one party to the Alliance Manager of the other
party of a dispute, the Alliance Managers must meet and use all reasonable endeavours acting in good faith to resolve the dispute by joint discussions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Negotiations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">If the Alliance Managers are unable to resolve the dispute within 20 Business Days after the delivery of the written notice, senior executives
of each party must meet as soon as is reasonably practicable, and no later than 10 Business Days following notice from the Alliance Managers of their failure to resolve the dispute, and use all reasonable endeavours acting in good faith to resolve
the dispute by negotiation. If the parties are unable to resolve the dispute within 20 Business Days of the negotiation, the dispute must promptly be submitted for arbitration in accordance with, and subject to, the Resolution Institute Arbitration
Rules, should either party wish to press for resolution of the dispute further. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Arbitration </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arbitrator will be an independent person agreed between the parties within 14 days of the names of one or
more independent persons being proposed by either party or, failing agreement, within 21 days of the proposal an arbitrator will be appointed by the Resolut ion Institute in accordance with article 8(3) of the Resolution Institute Arbitration Rules
2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arbitration will be conducted and held in accordance with the laws of New South Wales.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arbitration will be held in Sydney. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 27</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties will each bear their own costs with respect to any arbitration and the costs of the arbitrator will
be allocated equally between the parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree that an appeal may be made to the court on a question of law. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continuation of rights and obligations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Despite the existence of a dispute or difference, each party must continue to perform this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Event of Force Majeure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">If a party is prevented in whole or in part from carrying out its obligations under this Agreement (other than an obligation to pay money) as a
result of Force Majeure, it must promptly give a notice to the other party that complies with clause 22.2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Following this notice, and
while the Force Majeure continues, the obligations which cannot be performed (other than an obligation to pay money) because of the Force Majeure will be suspended if the party giving notice has taken all proper precautions, due care and reasonable
alternatives with the intention of avoiding the delay or failure and of carrying out its obligations under this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure notice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">A notice given under clause 22.1 must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specify the obligations a party cannot perform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fully describe the event of Force Majeure; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">estimate the time during which the Force Majeure will continue. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remedy of Force Majeure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The party that is prevented from carrying out its obligations under this Agreement as a result of Force Majeure must seek to mitigate the
effects of the Force Majeure to the extent reasonably practicable and resume performance of its obligations as soon as reasonably possible. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mitigation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The party that is prevented from carrying out its obligations under this Agreement as a result of Force Majeure must take all action reasonably
practicable to mitigate any loss suffered by a party or a third party as a result of its failure to carry out its obligations under this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No requirement to settle labour dispute </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">A party is not required, under clause 22.1, 22.2 or 22.3, to settle any labour dispute against its will. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>22.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No extension of Term </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The Term will not be extended by the period of Force Majeure. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>23</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party must do anything necessary or desirable (including executing agreements and documents) to give full
effect to this Agreement and the transactions contemplated by it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be amended only by another Agreement executed by all of the parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 28</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction is ineffective as to
that jurisdiction to the extent of the prohibition or unenforceability. That does not invalidate the remaining provisions of this Agreement nor affect the validity or enforceability of that provision in any other jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A failure to exercise or a delay in exercising any right, power or remedy under this Agreement does not operate
as a waiver. A single or partial exercise or waiver of the exercise of any right, power or remedy does not preclude any other or further exercise of that or any other right, power or remedy. A waiver is not valid or binding on the party granting
that waiver unless made in writing. For the avoidance of doubt, the doctrine of affirmation by election will not apply to any failure by a party to exercise, or delay by a party in exercising, any right, power or remedy under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement contains the entire agreement between the parties with respect to its subject matter. It sets
out the only conduct, representations, warranties, covenants, conditions, agreements or understandings (collectively Conduct) relied on by the parties and supersedes all earlier Conduct by or between the parties in connection with its subject
matter. No party has relied on or is relying on any other Conduct in entering into this Agreement and completing the transactions contemplated by it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this Agreement is to be construed as constituting an agency, partnership, joint venture, or any
other form of association between the parties in which one party may be liable for the acts or omissions of any other party. No party has the authority to incur any obligation or make any representation or warranty on behalf of, or to pledge the
credit of, any other party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be executed in any number of counterparts. All counterparts together will be taken to
constitute one instrument. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement is governed by the laws of New South Wales. In relation to this Agreement and related <FONT
STYLE="white-space:nowrap">non-contractual</FONT> matters, subject to clause 21, each party irrevocably submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of courts with jurisdiction there, and waives any right to
object to the venue on any ground. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 29</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upfront fee, Milestone Payments and Royalty </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Part A.
Upfront fee (cl 6.1) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Ovarian&nbsp;cancer&nbsp;indication</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Each&nbsp;successive&nbsp;indication</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">US$4&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Part B. Royalty (cl 6.2) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Ovarian&nbsp;cancer&nbsp;indication</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Each&nbsp;successive&nbsp;indication</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Part C. Milestone Payments (cl 6.3) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ovarian&nbsp;cancer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Each&nbsp;successive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>indication</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Regulatory milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***][***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commercial milestone fee(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 30</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 31</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 32</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 33</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 4 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assistance to be provided by Kazia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Within 3 months
from Effective Date</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Within Six Months
from Effective Date</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Activity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>First Eighteen Months from Effective Date</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Activity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 34</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; font-size:10pt; font-family:Times New Roman">All Activities outlined in this schedule will be pursued on the basis of Commercially Reasonable Efforts, but no warranty or
commitment can be provided as to outcome or timing. The parties recognise that drug development incurs inherent risk, and that the progression of any investigational new drug depends partly on emerging data, and partly on the actions of external
parties such as regulatory agencies, contractors, vendors, clinicians, and researchers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; padding-bottom:0pt; margin-left:1%; font-size:10pt; font-family:Times New Roman">The parties will regularly
communicate through their respective Alliance Managers to track progress on these objectives, and to jointly address any challenges or opportunities that emerge, and this plan may therefore evolve as the Licensed Product advances through its
development. </P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 35</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 5 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expert Determination </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delivering a dispute notice </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Oasmia and Kazia have been unable to resolve any dispute arising between them in relation to a Royalty
Dispute within the period stated in clause 5.2(f), then Oasmia and Kazia may refer the Royalty Dispute to an Expert for determination in accordance with this Schedule 5. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this Schedule 5, the <B>Expert </B>is a person: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">having appropriate qualifications and experience relevant to determining the Royalty Dispute;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">who is agreed by the parties or, failing agreement within 5 Business Days, is nominated at the request of any
party by the Resolution Institutein accordance with the Resolution Institute Expert Determination Rules <B>(Rules); </B>and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">who does not act, or whose firm does not act, generally for any party. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Determination by Expert </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The Expert: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must conduct its determination in accordance with the Rules, which Rules are taken to be incorporatedinto this
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will act as an expert and not as an arbitrator; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may determine the time, place and procedures (which will be as informal as is consistent with the proper
conduct of the matter) for the determination by the Expert, having regard to the nature of the Royalty Dispute and the provisions of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may communicate privately with the parties or with their lawyers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may or may not allow the appearance of lawyers on behalf of the parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may accept written submissions from a party in relation to the Royalty Dispute, provided a copy of the
submission is also given to all other parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may <FONT STYLE="white-space:nowrap">co-opt</FONT> other expert assistance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must have regard to the fairness and reasonableness of any matters pertaining to the Royalty Dispute; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must deal with any matter as expeditiously as possible and by no later than 20 Business Days after referral to
the Expert. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligations of parties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">If an Expert is required to resolve a Royalty Dispute: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Expert&#146;s determination will, except in the case of manifest error, be final and binding on the
parties; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 36</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the parties must attend the sessions with the Expert and make a determined and genuine effort to resolve the
Royalty Dispute as soon as reasonably possible; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without limiting item 3(b) of this Schedule 5, the parties must use their best endeavours to make available to
the Expert all information relevant to the Royalty Dispute and which the Expert reasonably requires in order to resolve the Royalty Dispute; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">everything that occurs before the Expert must be in confidence and in closed session; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all discussions must be without prejudice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each party must pay its own costs of complying with this Schedule 5 and the costs of the Expert and any other
costs of complying with this Schedule 5 must be shared half as to Oasmia and half as to Kazia; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the parties must continue performing their obligations under this Agreement while the Royalty Dispute is being
resolved. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other proceedings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">A party may not commence court proceedings in respect of a Royalty Dispute unless it has complied with the terms of the Agreement, and if
applicable until the procedures in this Schedule 5 have been followed in full, except where: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the party seeks injunctive relief in relation to a Royalty Dispute from an appropriate court where failure to
obtain such relief would cause irreparable damage to the party concerned; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following those procedures would mean that a limitation period for a cause of action relevant to the issues in
dispute will expire. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 37</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 38</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 39</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 40</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 41</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialisation Licence Agreement </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Executed as an Agreement</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Executed </B>as an Agreement by <B>Oasmia</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Francois Martelet</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Francois Martelet, CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Executed </B>in accordance with section 127 of the <I>Corporations Act 2001 </I>by <B>Kazia</B> <B>Therapeutics Limited:</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director/Secretary Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">/s/ James Garner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">/s/ kate Hill</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">James Garner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kate Hill</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Print Name</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">page 42</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>3
<FILENAME>d185056dex419.htm
<DESCRIPTION>EX-4.19
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.19</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.19 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (&#147;[***]&#148;) BECAUSE
THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
<B>L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL> </B>(the &#147;<B>Agreement</B>&#148;) is entered into on March 29, 2021 (the &#147;<B>Effective Date</B>&#148;) between: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>IMCERE</SMALL> P<SMALL>HARMACEUTICAL</SMALL> C<SMALL>O</SMALL>., L<SMALL>TD</SMALL>.,</B> a company organized under the laws of the People&#146;s
Republic of China and having a place of business at No.99, Huakang Road, Nanjing Jiangbei New Area, Nanjing, Jiangsu, China (&#147;<B>Simcere</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>K<SMALL>AZIA</SMALL> T<SMALL>HERAPEUTICS</SMALL>, L<SMALL>TD</SMALL></B><SMALL></SMALL>. <B>(ACN 063 259 754)</B>, a company organized under the laws of
New South Wales, Australia and having a place of business at Three International Towers, L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (&#147;<B>Kazia</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia and Simcere are sometimes referred to herein individually as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recitals </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Kazia is developing paxalisib (also known as <FONT STYLE="white-space:nowrap">GDC-0084),</FONT>
a proprietary PI3K/AKT/mTOR pathway inhibitor, for the treatment of glioblastoma and certain other cancers, and owns or controls certain patent, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property rights relating to such
product candidate; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Simcere wishes to obtain from Kazia, and Kazia is willing to grant
to Simcere licenses to research, develop, manufacture and commercialize such product in the greater China region, all on the terms and conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing premises and the mutual covenants
contained herein, the receipt and sufficiency of which are hereby acknowledged, Simcere and Kazia hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below,
or the meaning as designated in the indicated places throughout this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to a Party, any Person that controls, is controlled by, or
is under common control with that Party. For the purpose of this definition, &#147;control&#148; (including, with correlative meaning, the terms &#147;controlled by&#148; and &#147;under the common control&#148;) means the actual power, either
directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stock of such Person, by contract or
otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Claims</B>&#148; means all Third Party demands,
claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialize</B>&#148; or &#147;<B>Commercialization</B>&#148; means all activities directed to
marketing, distributing, detailing or selling the Product (as well as importing and exporting activities in connection therewith), including all activities directed to obtaining pricing and reimbursement approvals for the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the Development and
Commercialization of the Product under this Agreement, those efforts consistent with the exercise of prudent scientific and business judgment as applied by a Party to the development and commercialization of its own product that is at a similar
stage of development or commercialization and has similar market potential, taking into account efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market
conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors. Commercially Reasonable Efforts shall be determined on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">market-by-market</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indication-by-indication</FONT></FONT> basis, and it is anticipated that the level
of effort required may be different for different markets and indications and may change over time, reflecting changes in the status of the Product and markets involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Compound</B>&#148; means paxalisib (also known as <FONT STYLE="white-space:nowrap">GDC-0084)</FONT>
or any salt, polymorph, hydrate, solvate or metabolite, as set forth in <B>Exhibit A</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148; of a Party means all
<FONT STYLE="white-space:nowrap">Know-How,</FONT> unpublished patent applications and all other information and data, including information and data of a financial, commercial, business, operational or technical nature belonging or relating to a
Party or any of its Affiliates, whether made available orally, in writing, graphically, or in electronic or any other form. For the avoidance of doubt, the terms and conditions of this Agreement are the Confidential Information of both Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means, with respect to any <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Patents or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, access or other right (as
applicable) under such <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patents, or other intellectual property rights to the other Party on the terms and conditions set forth herein, in each case without breaching the terms of any agreement with a
Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Develop</B>&#148; or &#147;<B>Development</B>&#148; means all development
activities necessary or useful to obtain or maintain Regulatory Approval for the Product, including all <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials of the Product, manufacture process development, distribution of
the Product for use in clinical trials (including placebos and comparators), statistical analyses, and the preparation and submission of Regulatory Materials for, and all regulatory affairs related to, the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B>Dollar</B>&#148; means U.S. dollars, and &#147;$&#148; shall be interpreted accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B>Expert</B>&#148; has the meaning given to that term in <B>Exhibit H</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>E.U.</B>&#148; means the European Union and its
member states, territories and possessions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B>Field</B>&#148; means all therapeutic uses in
humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>First Commercial Sale</B>&#148; means, with respect to a Product in a region in the
Territory, the first sale of such Product by Simcere, its Affiliates or sublicensees to a Third Party for distribution, use or consumption in such region after Regulatory Approval of the Product has been granted in such region. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Genentech Agreement</B>&#148; means that certain Exclusive License Agreement between Kazia and
Genentech, Inc. (&#147;<B>Genentech</B>&#148;), dated October 25, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Global Clinical
Trial</B>&#148; means a clinical trial of the Product, other than GBM AGILE: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;that is conducted (in
whole or in part) by or on behalf of Kazia in collaboration with an academic or <FONT STYLE="white-space:nowrap">non-profit</FONT> collaborator (but not by Kazia itself or commercial partners of Kazia); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;that is conducted in sites in multiple jurisdictions, including in the Territory and at least one of the
U.S., United Kingdom, France, Germany, Italy or Spain; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;where the planned number of patients to be
enrolled in the Territory does not exceed twenty percent (20%) of the planned global enrollment in such clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, Kazia may not
conduct a clinical trial of the Product in the Territory by itself or through its Affiliate or any commercial partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Government Authority</B>&#148; means any federal, state, national, provincial or local government,
or political subdivision thereof, or any organization established under statute or any authority, agency or commission entitled to exercise any administrative, executive, legislative, regulatory or taxing authority or power (or any department,
bureau or division thereof, or any governmental body). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND</B>&#148; means any
investigational new drug application, clinical trial application, clinical trial exemption or similar or equivalent application filed with the applicable Regulatory Authority for approval to conduct clinical testing of a pharmaceutical product in
humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indication</B>&#148; means a separate and distinct disease, disorder or medical
condition for which a Product can be used to diagnose, treat or prevent, which use is the subject of a separate MA or separate approval within the same MA. For clarity, subpopulations or patients with a primary disease or condition, however
stratified, shall not be deemed to be separate &#147;Indications&#148; for the purposes of this Agreement, including stratification by stages or progression (including precursor condition), particular combinations of symptoms associated with the
primary disease or condition, prior treatment courses, response to prior treatment, different lines of treatment, family history, clinical history, phenotype, age (e.g. adult and pediatric) or other stratification. In addition, combination
treatments with the Product and another product shall not be deemed to be separate &#147;Indication&#148; for the purpose of this Agreement unless the Product&#146;s purpose is to diagnose, treat or prevent a separate and distinct disease, disorder
or medical condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Invention</B>&#148; means any data, results,
discovery, finding, process, improvement, enhancement, modification, development, method, composition of matter, article of manufacture, patentable or otherwise, that is invented, reduced to practice, or otherwise generated by either Party
exercising its rights or carrying out its obligations under this Agreement, whether directly or via its Affiliates, agents, contractors or sublicensees, including all rights, title and interest in and to the intellectual property rights therein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any technical, commercial,
scientific, regulatory or practical information, including discoveries, improvements, modifications, processes, methods, protocols, formulas, data, inventions, <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, patentable or
otherwise, but excluding any Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Law</B>&#148; means any federal, state, local, foreign
or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, the rules of the security exchange on which a Party&#146;s or its Affiliate&#146;s stock is publicly traded, or any order by any Government
Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22 </B>&#147;<B>Licensed IP</B>&#148; means the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Licensed Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all <FONT
STYLE="white-space:nowrap">Know-How</FONT> that (a)&nbsp;is Controlled by Kazia or its Affiliates as of the Effective Date or at any time during the Term, and (b)&nbsp;is necessary or reasonably useful, but not otherwise readily available, for the
Development, Manufacture or Commercialization of the Compound and Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed
Patents</B>&#148; means all Patents that are Controlled by Kazia or its Affiliates as of the Effective Date or at any time during the Term, and which claim or cover the Compound or Product (including composition of matter, methods of making and
using). Licensed Patents existing as of the Effective Date are set forth in <B>Exhibit B</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>MA</B>&#148; or &#147;<B>Marketing Authorization</B>&#148; means a Regulatory Approval issued by
an appropriate Regulatory Authority for the importation, promotion, marketing, sale and supply of a pharmaceutical product in a particular jurisdiction and all amendments and supplements thereto, including an approved New Drug Application
(&#147;<B>NDA</B>&#148;) and an approved Biologic License Application (&#147;<B>BLA</B>&#148;) following filing with the Food and Drug Administration in the U.S., and equivalent foreign approvals, but excluding pricing and reimbursement approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; means activities directed to the
manufacture of the Product, including the planning, purchasing, producing, manufacturing, processing, transportation, quality assurance testing, quality control, regulatory compliance, storage, waste disposal, sample retention, formulation,
stability testing, filling, packaging, labelling, leafleting, release and dispatch and such other related matters in each case as applicable to the Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacturing Cost</B>&#148; means, with respect
to the Compound and Product supplied by Kazia to Simcere hereunder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;if the Compound or Product is
Manufactured by Kazia&#146;s Third Party contract manufacturer, Kazia&#146;s actual Third Party cost of the Manufacture and supply of such Compound or Product; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;if the Compound or Product is Manufactured by Kazia itself or its Affiliate, the actual, fully-burdened cost
for the Manufacture and supply of such Compound or Product, including raw materials, direct labor and benefits, and the proportionate share of indirect Manufacturing costs. Such fully-burdened cost shall be calculated (i)&nbsp;if applicable, on a
theoretical full-capacity basis, with the percentage allocable to Manufacturing Cost representing the number of units or runs of the Compound or Product produced or performed as a percentage of the total number of units or runs, including those of
other products, that could be manufactured in such facility during a calendar year; and (ii)&nbsp;in accordance with applicable accounting standards consistently applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148; means the gross amount received by Simcere, its Affiliates or sublicensees for
sale of the Product to Third Parties (other than Simcere&#146;s sublicensees) less the following amounts incurred or paid by the selling party in connection with the sale of the Product: (a)&nbsp;normal and customary trade, cash and quantity
discounts or rebates; (b)&nbsp;credits or allowances actually granted to the customer for damaged goods, returns, recalls, rebates or rejections of the Product; (c)&nbsp;reasonable charges for insurance, freight, and other transportation costs
directly related to the delivery of the Product to the extent such charges were included on the invoice provided to the customer; (d)&nbsp;taxes (including sales tax and VAT, but not income taxes), tariff, duty or governmental charges levied on the
sales, transfer, transportation or delivery of the Product included on the invoice for the Product and not reimbursed directly or indirectly; (e)&nbsp;customary rebates and chargeback payments with respect to such Product granted to managed health
care organizations, pharmacy benefit managers (or equivalents thereof), national, state, provincial, local, and other governments, their agencies and purchasers and reimbursers, or to trade customers; and (f)&nbsp;any other similar and customary
deductions that are consistent with applicable accounting standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Product is sold in a region in the Territory as a combination
of the Compound with another active pharmaceutical ingredient or component that is not a Compound (&#147;<B>Combination</B>&#148;), then the gross amount invoiced, for the purposes of determining royalty payments on the Combination, shall be
calculated using one of the following alternative methods: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;by multiplying the gross amount invoiced for
the Combination by the fraction A/(A+B), where A is the gross amount invoiced, during the relevant reporting period, for the Product that contains the Compound as its only active ingredient (the &#147;<B>Mono Product</B>&#148;) when sold separately
in such region, and B is the gross amount invoiced, during the relevant reporting period, of the other active ingredients or components in the Combination (the &#147;<B>Other Products</B>&#148;) when sold separately in such region; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;if no such separate sales in such region are made of any
or all of the Other Products during the relevant reporting period, then the gross amount invoiced, for the purposes of determining royalty payments on the Combination, shall be calculated by multiplying the gross amount invoiced for the Combination
by the fraction A/C where A is the gross amount invoiced, during the relevant reporting period, for the Mono Product when sold separately in such region (provided that if there is no separate sale of the Mono Product in such region, then A shall be
estimated in good faith by Simcere), and C is the gross amount invoiced, during the relevant reporting period, for the Combination sold in such region. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where Simcere is considering or intends to supply or sell Product in a region in the Territory as a bundle with any other product or products
for the one (combined) price (&#147;<B>Bundle</B>&#148;), then Simcere must provide prior notice to Kazia, and Simcere and Kazia must agree how the price (including gross amount and Net Sales) of the Product in the Bundle should be allocated for the
purposes of this Agreement prior to the first such sale or supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NMPA</B>&#148; means
National Medical Products Administration of China (formerly known as the China Food and Drug Administration), or its successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patents</B>&#148; means all patents and patent applications (which for the purpose of this
Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> re- examinations, reissues, additions, renewals, revalidations, extensions, registrations, pediatric exclusivity periods and supplemental
protection certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means any individual, partnership, limited liability company, firm, corporation,
association, trust, unincorporated organization or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product</B>&#148; means any
pharmaceutical product that contains a Compound as an active pharmaceutical ingredient, in any formulation or dosage form and for any mode of administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Approval</B>&#148; means with respect to a Product, all registrations, approvals,
permits, authorizations or licenses issued by an applicable Regulatory Authority in a jurisdiction that are necessary for the Manufacture, importation, storage, promotion, marketing, sale, distribution or other Commercialization of that Product in
the relevant jurisdiction (including applicable approvals of labelling for that product in that jurisdiction and any customs and tax approvals, but excluding any price and reimbursement approval) and including any amendment or supplement thereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Authority</B>&#148; means any applicable Government Authority responsible for
granting Regulatory Approvals for the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Material</B>&#148; means any
regulatory application, submission, notification, communication, correspondence, registration and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise
Commercialize the Product in a particular country or jurisdiction. For clarity, Regulatory Materials include IND, MAs (including applications for the same) and Regulatory Approvals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; means China, including
mainland China, Hong Kong, Macao and Taiwan, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37&nbsp;&nbsp;&nbsp;&nbsp;</B>&#147;<B>Third Party</B>&#148; means any Person
other than a Party or an Affiliate of a Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148; means a claim of
(a)&nbsp;an issued and unexpired Patent that has not been revoked, held invalid or unenforceable by a patent office, court or other Government Authority of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT>
judgment (or judgment from which no appeal was taken within the allowable time period) and has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, <FONT STYLE="white-space:nowrap">re-examination</FONT> or
disclaimer, or (b)&nbsp;a pending patent application to the extent the claim continues to be prosecuted in good faith, has not been irretrievably cancelled, withdrawn or abandoned, and that has been pending for less than [***] years from its
earliest priority date; provided that if the claim ever issues, it shall become a Valid Claim again after issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and its
territories and possessions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40&nbsp;&nbsp;&nbsp;&nbsp;Interpretation. </B>In this Agreement, unless otherwise specified: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; shall be deemed to be followed
by the phrase &#147;without limitation&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;words denoting the singular shall include the plural and
vice versa and words denoting any gender shall include all genders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;the word &#147;or&#148; is used in
the inclusive sense typically associated with the phrase &#147;and/or&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;words such as
&#147;herein&#148;, &#147;hereof&#148;, and &#147;hereunder&#148; refer to this Agreement as a whole and not merely to the particular provision in which such words appear; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Exhibits and other attachments form part of the operative provision of this Agreement and references to
this Agreement shall include references to the Exhibits and attachments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Definitions.
</B>The following table identifies the location of definitions set forth in various Sections of the Agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.11(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Auditor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.11(b)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bankruptcy Code</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GCAR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GBM AGILE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IDL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.5(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnifying Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Steering Committee or JSC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Indemnitees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensed Trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior CDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product Marks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recipient</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedial Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Review Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Query</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Report</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities Regulators</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.6(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Subscription Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simcere Indemnitees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Territory Infringement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>License to Simcere</B>. As between the parties, Kazia hereby grants Simcere and its Affiliates an
exclusive (even as to Kazia and its Affiliates) and royalty bearing license for the Term (but subject to Section&nbsp;8.1(a)) under the Licensed IP solely to research, Develop, make, have made, use, sell, offer for sale, have sold, import and
Commercialize the Compound and Product in the Field in the Territory. Simcere acknowledges and agrees that Kazia obtained Control of certain Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> through a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license from Genentech under the Genentech Agreement, and therefore: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;the foregoing license granted by Kazia to Simcere under such Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> shall be exclusive with respect to Kazia and its Affiliates only; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>such
Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> may be otherwise used or licensed by Genentech. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;Subcontractors and Sublicenses</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to Sections 2.2(c) and 2.2(d), Simcere shall have the right to engage Third Party subcontractors in
connection with the Development, Manufacture and Commercialization of the Compound and Product in the Field in the Territory, and shall have the right to grant sublicenses to its subcontractors solely in order to enable the subcontractors to perform
such work for Simcere, provided that such sublicenses shall not include the right for the subcontractors to market, promote or sell the Product, unless the subcontractor serves as Simcere&#146;s distributor or contract sales force for the Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Sublicenses to any Third Party whom shall serve as Simcere&#146;s distributor or contract sales force
for the Product shall require Kazia&#146;s prior written consent, which shall not be unreasonably withheld, delayed or conditioned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere must ensure that any subcontractor or sublicensee agrees in writing to be subject to, and bound by,
to the extent applicable, terms and conditions substantially similar to the terms and conditions of this Agreement. Simcere will remain responsible to Kazia for all acts performed by, and omissions of, any subcontractor or sublicensee pursuant to
any subcontract or sublicense agreements as if such act or omission was undertaken by Simcere, and Simcere must ensure compliance by all subcontractors and sublicensees with the obligations of Simcere under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Irrespective of any subcontract or sublicense arrangement, Simcere will be responsible for the payment of
all amounts due under this Agreement, regardless of whether the terms of the subcontract or sublicense arrangement provide for such amount to be paid by the subcontractor or sublicensee directly to Kazia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>License Back</B>. Notwithstanding the exclusive (as between the parties) license granted to Simcere under
Section&nbsp;2.1, Simcere grants back to Kazia a royalty-free, sub- licensable, irrevocable for the Term, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under the Licensed IP to (a)&nbsp;conduct
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research, GBM AGILE and other Global Clinical Trials, in each case, of the Compound and the Product in the Field in the Territory, and (b)&nbsp;Manufacture the Compound and Product in the
Territory for export out of the Territory. For the avoidance of doubt, the Parties acknowledge that Kazia retains the exclusive right to practice, license and otherwise exploit the Licensed IP outside the scope of the license granted to Simcere
under Section&nbsp;2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Implied License. </B>Except as expressly set forth herein, neither Party
shall acquire any license, right or other interest, by implication or otherwise, under any intellectual property rights of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Genentech Agreement. </B>To the extent possible, upon the early termination of the
Genentech Agreement for any reason, this Agreement will continue in full force and effect, provided that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;all rights and licenses granted by Kazia under Section&nbsp;2.1 under any Licensed IP which Kazia obtained
Control of through a license from Genentech under the Genentech Agreement shall terminate; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;all necessary consequential amendments to this Agreement
will be taken to have been made (including with respect to applicable representations and warranties) with effect on and from the date upon which the Genentech Agreement terminates. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Steering Committee. </B>Subject to Section&nbsp;8.1(b), within thirty (30)&nbsp;days after
the Effective Date, the Parties shall establish a joint steering committee (the &#147;<B>Joint Steering Committee</B>&#148; or the &#147;<B>JSC</B>&#148;), composed of two (2)&nbsp;senior executives of each Party (or such number of representatives
as agreed by the Parties, provided that the Parties shall have equal number of representatives at the JSC), to oversee and coordinate the Parties&#146; activities under this Agreement. The JSC shall in particular: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;provide a forum for the discussion of the Parties&#146; activities under this Agreement and facilitate
communications between the Parties with respect thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;oversee the technology transfer and assistance
to be provided by Kazia to Simcere hereunder and related activities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;discuss and coordinate the
Development of the Compound and Product by each Party (including their respective Affiliates, licensees and sublicensees); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;review and discuss Simcere&#146;s reports of its Development and Commercialization of the Product in the
Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;establish joint subcommittees as it deems necessary or advisable for the Development,
Manufacture and Commercialization of the Compound and Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;discuss the status of GBM AGILE within
and outside the Territory and the status of any current or planned clinical trials of the Product in the Field in the Territory; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;perform such other functions as appropriate to further the purposes of this Agreement, as expressly set
forth in this Agreement or allocated to it by the Parties in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations of JSC
Authority</B>. The JSC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement and shall not have the authority to: (a)&nbsp;modify or amend the terms and conditions of this Agreement; (b)&nbsp;waive or
determine either Party&#146;s compliance with the terms and conditions of under this Agreement; or (c)&nbsp;decide any issue in a manner that would conflict with the express terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3&nbsp;&nbsp;&nbsp;&nbsp; JSC Membership and Meetings.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;8.1(b), within thirty (30)&nbsp;days following the Effective Date, each Party shall
designate its initial members to serve on the JSC. Each Party may replace its representatives on the JSC on written notice to the other Party. Each Party shall appoint one (1) of its representatives on the JSC to act as a <FONT
STYLE="white-space:nowrap">co-chairperson</FONT> of the JSC. The <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall jointly prepare and circulate agendas and reasonably detailed minutes for each JSC meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The JSC shall hold meetings at such times as it elects to
do so, but in no event shall such meetings be held less frequently than once every six (6)&nbsp;months.&nbsp;&nbsp;&nbsp;&nbsp;Meetings of the JSC must be conducted in English and may be held in person, by audio or video teleconference; provided
that the Parties shall endeavor to hold one JSC meeting in person each year.&nbsp;&nbsp;&nbsp;&nbsp;In person JSC meetings shall be held at locations selected alternatively by the Parties. Each Party shall be responsible for all of its own expenses
of participating in the JSC. No action taken at any meeting of the JSC shall be effective unless at least one (1)&nbsp;representative from each Party is participating. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Party may from time to time invite a reasonable number of participants, in addition to its
representatives, to attend the JSC meetings in a <FONT STYLE="white-space:nowrap">non-voting</FONT> capacity; provided that such participants shall be bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations
consistent with the terms of this Agreement and that each Party shall provide prior written notice to the other Party if it has invited any third party (including any consultant) to attend such a meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Decision-Making. </B>All decisions of the JSC shall be made by unanimous vote, with each Party&#146;s
representatives collectively having one (1)&nbsp;vote, which may be exercised by a Party&#146;s sole attendee at a meeting if both of its representatives do not attend. If after reasonable discussion and good faith consideration of each Party&#146;s
view on a matter before the JSC that is within its authority, the representatives of the Parties cannot reach unanimous agreement as to such matter within thirty (30)&nbsp;days after such matter was brought to the JSC for resolution, such
disagreement shall be referred to the Chief Executive Officer of Kazia and a Senior Vice President or Vice President level executive of Simcere (the &#147;<B>Executive Officers</B>&#148;) for resolution. If the Executive Officers do not resolve such
matter within ten (10)&nbsp;business days after such matter has been referred to them, then: Kazia shall have the final decision making authority with respect to the Development, Manufacture and Commercialization of the Compound and Product outside
the Territory, and Simcere shall have the final decision making authority with respect to the Development, Manufacture and Commercialization of the Compound and Product in the Territory; provided however that (a)&nbsp;Kazia may not make a decision
that is inconsistent with its obligations to use Commercially Reasonable Efforts to Develop the Product outside the Territory and to complete GBM AGILE (including sites in the Territory), (b) Simcere may not make a decision that is inconsistent with
its obligations to use Commercially Reasonable Efforts to Develop and Commercialize the Product in the Territory, (c)&nbsp;each Party shall use Commercially Reasonable Efforts not to make any decision that is reasonably expected to materially and
adversely affect the Compound and Product in the Territory; and (d)&nbsp;Simcere may not make any decision regarding a clinical trial of the Product in the Territory that will create material risk to the safety and wellbeing of the patients enrolled
in such clinical trial. For the avoidance of doubt, the Parties agree that Kazia will not breach any of its obligations under this Section&nbsp;3.4 if it ceases to pursue Commercialization of a Product in a jurisdiction outside the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;Alliance Manager. </B>In addition to the JSC, subject to Section&nbsp;8.1(b), within thirty (30) days after the
Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative who is fluent in English and has appropriate qualifications (including a general understanding of pharmaceutical development, manufacture and
commercialization issues) to act as its alliance manager under this Agreement (the &#147;<B>Alliance Manager</B>&#148;). The Alliance Managers shall serve as the primary contact points between the Parties regarding the activities contemplated by
this Agreement. The Alliance Managers shall facilitate the flow of information and otherwise promote communication, coordination and collaboration between the Parties, providing single point communication for seeking consensus both internally within
each Party&#146;s respective organization, including facilitating review of external corporate communications, and raising cross-Party and/or cross-functional issues in a timely manner. Each Party may replace its Alliance Manager by written notice
to the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>General. </B>Subject to the terms and conditions of this Agreement and except for GBM AGILE, Simcere
shall be solely responsible for the Development and Commercialization of the Product in the Field in the Territory, at Simcere&#146;s own cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Diligence. </B>Subject to Kazia complying with its obligations hereunder with respect to technology
transfer and supply of Compound and Product to Simcere, Simcere (either by itself or through its Affiliates and sublicensees) shall use Commercially Reasonable Efforts to Develop and Commercialize at least one Product in the Field in the Territory.
Kazia shall use Commercially Reasonable Efforts to Develop the Product outside the Territory and to complete GBM AGILE (including sites in the Territory). Notwithstanding the foregoing, Kazia acknowledges that certain Development activities planned
by Simcere overlap with activities otherwise being conducted as part of GBM AGILE, and agrees that, subject to Section&nbsp;4.4(c)(ii), Simcere shall not be required to conduct such Development activities to the extent such activities overlap with
any relevant activities conducted as part of GBM AGILE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Technology Transfer</B>. Within thirty
(30)&nbsp;days after receiving a notice from Simcere to initiate technology transfer, Kazia shall provide Simcere with all Licensed Know- How that exists on the Effective Date and not previously provided to Simcere, including those items, and on the
terms, set forth in <B>Exhibit C</B>. If any additional Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> comes into Kazia&#146;s Control during the Term of this Agreement (including any data resulting from GBM AGILE and other Development
work of the Compound and Product conducted by Kazia, its Affiliates, licensees and sublicensees), Kazia shall notify Simcere and provide copies thereof to Simcere at the next scheduled JSC meeting (except that data and reports from GBM AGILE shall
be provided to Simcere promptly (within five (5)&nbsp;days in any event)). Upon Simcere&#146;s request, Kazia shall also provide Simcere with reasonable technical assistance in connection with the practice of the Licensed IP in the Development of
the Compound and Product, including reasonable access to Kazia&#146;s available technical personnel involved in the research and Development of the Compound and Product, at no additional cost to Simcere (but subject to reimbursement of reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;Development</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, Kazia is conducting a global phase 2 / 3 clinical trial of the Product in
glioblastoma as part of the Glioblastoma Adaptive Global Innovative Learning Environment sponsored by the Global Coalition for Adaptive Research (&#147;<B>GCAR</B>&#148;) (such trial of the Product, the &#147;<B>GBM AGILE</B>&#148;). After the
Effective Date, Kazia (either by itself or through GCAR or Third Party contractors) shall use Commercially Reasonable Efforts to complete GBM AGILE (including sites in the Territory) at Kazia&#146;s own cost and expense. Kazia shall keep Simcere
informed on the progress and results of the GBM AGILE and shall consider in good faith suggestions and comments provided by Simcere regarding the conduct of GBM AGILE in the Territory, including the selection of sites and contractors in the
Territory for GBM AGILE. Without limiting the foregoing, where appropriate and when it is able, Kazia shall invite Simcere to participate in any meetings and discussions with GCAR regarding the conduct of GBM AGILE in the Territory. Kazia shall
provide Simcere with copies of all GBM AGILE data and reports within five (5)&nbsp;days after receipt from GCAR or clinical sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall notify Simcere if Kazia wishes to conduct a
Global Clinical Trial . Kazia shall keep Simcere informed on the planning, progress and results of any Global Clinical Trial and shall consider in good faith any suggestions and comments provided by Simcere regarding the conduct of any Global
Clinical Trial in the Territory, including with respect to Simcere&#146;s potential direct involvement, and the selection of sites and contractors, in the Territory for the Global Clinical Trial. Kazia shall also include in contractual arrangements
with collaborators with respect to Global Clinical Trials obligations consistent with those in Section&nbsp;7.5(b) with respect to the publication or disclosure of the results of a Global Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except for GBM AGILE and any Global Clinical Trial, Simcere (either by itself or through its Affiliates and
sublicensees), at its own cost and expense, shall be responsible for the Development of the Product in the Field in the Territory, including all <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and all clinical trials of the Product in
the Field in the Territory. As of the Effective Date, the Parties expect the efficacy data from GBM AGILE may be used to assist in obtaining the MA of the Product in glioblastoma in the Territory. However, the Parties acknowledge that neither Kazia,
nor GCAR, the respective Regulatory Authorities or any other party can provide binding assurances that GBM AGILE will be sufficient to obtain any such MA. If the data from GBM AGILE is not sufficient to support the granting of a MA, Simcere may
conduct additional clinical trials of the Product in glioblastoma in order to obtain a MA in the Territory and, subject to Simcere obtaining any necessary approvals or authorizations from all parties involved in a Global Clinical Trial, Simcere may
also participate in the Global Clinical Trial through clinical sites in the Territory. For clarity: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;where Simcere does not obtain any necessary approvals or authorizations from all parties involved in a
Global Clinical Trial, it will not participate in that Global Clinical Trial; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere shall be
responsible for any pharmacokinetic study that is required by a Regulatory Authority in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5&nbsp;&nbsp;&nbsp;&nbsp;Regulatory.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the remainder of this Section&nbsp;4.5, Simcere (either by itself or through its Affiliates and
sublicensees) shall apply for and maintain, at its own cost and expense, all Regulatory Approvals of the Product in the Field in the Territory. Subject to Section&nbsp;4.5(b), Simcere shall be responsible for the preparation of all Regulatory
Materials and all communications and interactions with Regulatory Authorities with respect to the Product in the Field in the Territory, both prior to and subsequent to Regulatory Approval. Simcere (or its Affiliate or sublicensee) shall file all
required regulatory dossiers to obtain (and maintain) Regulatory Approval of the Product in the Field in the Territory and shall be the holder of such Regulatory Approvals in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise agreed by the Parties in writing and
except in exigent circumstance, prior to responding to, or submitting, any material communication to any Regulatory Authority with respect to the Product in the Territory, Simcere shall submit such response or communication to Kazia for review and
shall consider in good faith any comments provided by Kazia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section&nbsp;4.5(a), Kazia
(and its collaborators and contractors, such as GCAR) shall have the right to submit Regulatory Materials, communicate with Regulatory Authorities, and hold Regulatory Approvals with respect to the Product in the Territory solely to the extent
required to continue and complete GBM AGILE or any other Global Clinical Trial, including the IND for GBM AGILE or such other Global Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;For Product that is first approved outside the Territory, Manufactured and supplied by Kazia to Simcere
pursuant to Section&nbsp;4.9(a), and approved in mainland China as an imported drug under an Imported Drug License (&#147;<B>IDL</B>&#148;), if applicable Laws do not allow Simcere to be the holder of the IDL or other Regulatory Materials related to
such imported Product, then Kazia shall initially be the holder of the IDL and such Regulatory Materials for the sole benefit of Simcere, until Simcere is permitted by applicable Law to be the holder of the IDL and such Regulatory Materials, at
which time Kazia shall use its best endeavors to promptly transfer the IDL and such Regulatory Materials to Simcere. While Kazia is the holder of the IDL and such Regulatory Materials, Kazia shall (i)&nbsp;subject to Section&nbsp;4.5(b), appoint
Simcere as its exclusive regulatory agent to communicate and handle regulatory activities relating to the IDL and such Regulatory Materials with the NMPA and other Regulatory Authorities in mainland China, (ii)&nbsp;appoint Simcere under the IDL as
the exclusive distributor of the Product in mainland China, and (iii)&nbsp;not take any action that adversely affects the IDL and such Regulatory Materials in mainland China (without limiting the foregoing, Kazia shall not transfer the ownership of
the corresponding Regulatory Approval of the Product outside the Territory to a Third Party, which transfer results in a change to the holder of the IDL in mainland China, unless the Third Party transferee expressly agrees to assume Kazia&#146;s
obligations to hold the IDL and such Regulatory Materials in mainland China for the benefit of Simcere as set forth above in this Section&nbsp;4.5(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Data Sharing. </B>At each JSC meeting, each Party shall keep the other Party reasonably informed on the
Development activities conducted by or on behalf of such Party (including its Affiliates, licensees and sublicensees) for the Compound and Product, and, subject to applicable Laws, shall provide the other Party with copies of all data and results,
including <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, clinical reports and reasonable supporting documentation (such as protocols and data analysis plans) directly relevant to the Development of the Compound or Product, or
Commercialization of the Product, in the Field, generated by or on behalf of such Party through the Development of the Compound and Product. Each Party shall have the right to use and reference such data and results provided by the other Party,
without additional consideration, for the purpose of obtaining and maintaining Regulatory Approval of the Product in the Field in its territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cross Reference</B>. Each Party shall also keep the
other Party reasonably informed on the regulatory activities conducted by or on behalf of such Party (including its Affiliates, licensees and sublicensees) for the Product, and shall promptly provide the other Party with copies of all Regulatory
Materials directly relevant to the Development of the Compound or Product, or Commercialization of the Product, in the Field submitted to or received from Regulatory Authorities in the Territory. Kazia will also promptly provide Simcere with copies
of any Regulatory Materials directly relevant to the Development of the Compound or Product, or Commercialization of the Product, in the Field in the Territory submitted by Kazia to or received from the US FDA, European Medicines Agency (EMA) and
Pharmaceuticals and Medical Devices Agency of Japan. Each Party hereby grants to the other Party a right of reference to all Regulatory Materials filed by or on behalf of such Party for the Product, which right of reference the other Party may use
for the purpose of seeking, obtaining and maintaining Regulatory Approvals of the Product in the Field in such other Party&#146;s territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Pharmacovigilance. </B>Each Party hereby agrees to comply with its respective obligations under the
<B>Exhibit E </B>with respect to the safety and pharmacovigilance procedures for the Parties with respect to the Product, such as safety data sharing and exchange, adverse events reporting and prescription events monitoring and to cause its
Affiliates, licensees and sublicensees to comply with such obligations. Promptly following the Effective Date, but in no event later than the date of the first IND approval for any clinical trial of the Product received by Simcere, Kazia and Simcere
shall enter into a written pharmacovigilance agreement which will be consistent with the above terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9&nbsp;&nbsp;&nbsp;&nbsp;Manufacture and Supply.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall (either by itself or through its Affiliate or Third Party contract manufacturer) Manufacture and
supply the Compound and Product requested by Simcere in accordance with <B>Exhibit F </B>for Development and Commercialization use at a price equal to: (i) Manufacturing Cost plus a [***] markup, for Compound and Product supplied for Development
use; and (ii)&nbsp;Manufacturing Cost plus a [***] markup, for Compound and Product supplied for Commercialization use. Kazia shall deliver the Compound and Product to Simcere CIF (Incoterms 2020) to Simcere designated port of import in the
Territory, provided that Simcere shall reimburse Kazia for the reasonable shipping cost incurred for the delivery of the Product. The Parties must comply with the obligations in <B>Exhibit F </B>with respect to the supply of Compound and Product.
The Parties may also negotiate in good faith and seek to agree to a detailed contract manufacturing agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to purchasing the Compound and Product from Kazia for Development and Commercialization use in
the Territory pursuant to Section&nbsp;4.9(a) above, Simcere shall have the right to Manufacture and have Manufactured the Compound and Product in the Territory, either by itself or through its own contract manufacturer, provided such contract
manufacturer is located in the Territory. Upon Simcere&#146;s reasonable request, Kazia shall make available to Simcere all Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> directly related to the Manufacture of the Compound and Product in
the Territory, and provide Simcere (or its designee) with any reasonable technical assistance to the extent necessary to enable Simcere (or its designee) to Manufacture the Compound and Product in the Territory, at no additional cost to Simcere (but
subject to reimbursement of reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost). In addition, upon Simcere&#146;s reasonable request, Kazia shall introduce Simcere to Kazia&#146;s contract
manufacturer for the Compound and Product and shall reasonably assist Simcere to negotiate a technology transfer agreement and, if such contract manufacturer Manufactures the Product in the Territory, a supply agreement directly with such contract
manufacturer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.10&nbsp;&nbsp;&nbsp;&nbsp;Commercialization.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;4.10(b), Simcere (either by itself or through its Affiliates and sublicensees) shall
be responsible for all aspects of the Commercialization of the Product in the Field in the Territory, at Simcere&#146;s own cost and expense, including: (a) developing and executing a commercial launch and
<FONT STYLE="white-space:nowrap">pre-launch</FONT> plan, (b)&nbsp;negotiating with applicable Government Authorities regarding the price and reimbursement status of the Product; (c) marketing and promotion; (d)&nbsp;booking sales and distribution
and performance of related services; (e)&nbsp;handling all aspects of order processing, invoicing and collection, inventory and receivables; (f)&nbsp;providing customer support, including handling medical queries, and performing other related
functions; and (g)&nbsp;conforming its practices and procedures to applicable Laws relating to the marketing, detailing and promotion of the Product in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere must only market, distribute and sell the Product in the Territory. Simcere (either by itself or
through its Affiliates or sublicensees) must not sell any Product to parties where it knows or should know, or where it reasonably suspects, that the party may seek to sell the Product outside of the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia must only market, distribute and sell the Product outside the Territory. Kazia (either by itself or
through its Affiliates, licensees or sublicensees, other than Simcere and Simcere&#146;s sublicensees) must not sell any Product to parties where it knows or should know, or where it reasonably suspects, that the party may seek to sell the Product
in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reporting. </B>Within sixty (60)&nbsp;days after the end of each calendar year,
Simcere shall provide to Kazia a report summarizing its Development and Commercialization of the Product in the Field in the Territory. Together with each report, Simcere shall also provide to Kazia a summary of its plans for the Development and
Commercialization of the Product in the next year. The Parties shall review and discuss such report and plan at the JSC meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Remedial Actions</B>. Each Party will notify the other Party immediately, and promptly confirm such
notice in writing, if it obtains information indicating that any Product may be subject to any recall, corrective action or other regulatory action with respect to such product taken by virtue of applicable Law (a &#147;<B>Remedial
Action</B>&#148;). The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. Simcere shall have sole discretion with respect to any matters relating to
any Remedial Action for the Product in the Field in the Territory. In the event that Simcere determines that any Remedial Action with respect to the Product should be commenced in the Field in the Territory, or if Remedial Action is required by any
Regulatory Authority having jurisdiction over the matter in the Territory, Simcere will control and coordinate all efforts necessary to conduct such Remedial Action in the Field in the Territory and shall be responsible for all cost and expense of
such Remedial Action (unless the Remedial Action is due to Manufacturing defect in the Compound or Product supplied by Kazia, in which case Kazia shall reimburse Simcere for the cost and expense of such Remedial Action). Notwithstanding the
foregoing, to the extent possible, Simcere will consult with Kazia regarding any such Remedial Action plan and provide to Kazia a copy of any communication from, or which Simcere proposes to provide to, a Regulatory Authority relating to a Remedial
Action. Kazia may review and provide comments on any proposed communications to a Regulatory Authority by Simcere, in which case Simcere must consider such comments in good faith and acting reasonably. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Regulatory/Quality Audit. </B>Upon reasonable advance
notice, Kazia shall have the right to audit the regulatory, safety, quality and compliance systems, procedures and practices of Simcere relating to the Development and Manufacture of the Compound and the Product in the Field in the Territory. Kazia
may not conduct such audit more than once each calendar year unless (a)&nbsp;a prior audit in that calendar year discovers material <FONT STYLE="white-space:nowrap">non-compliance</FONT> by Simcere with its obligations under this Agreement, or
(b)&nbsp;a Regulatory Authority conducts an audit of Kazia or its Affiliates for the purpose of verifying any matter related to the Compound or Product. Such audit shall take place during Simcere&#146;s normal business hours and shall not interfere
with Simcere&#146;s normal operations, and Simcere shall have the right to limit access to and/or redact information relating to other products. After the completion of the audit, Kazia shall promptly provide Simcere with a written audit report. If
the audit reveals any potential or actual non-compliance by Simcere or its Affiliates or areas of improvement, the Parties shall discuss such findings and Simcere shall take corrective or improvement actions as mutually agreed by the Parties. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Payments
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Upfront Payment. </B>Simcere shall pay to Kazia a
<FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of seven million Dollars ($7,000,000) within forty five (45)&nbsp;days after receipt of the invoice issued by Kazia after the
Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Equity Investment. </B>Prior to or concurrently with the execution of this
Agreement, the Parties (or their designated Affiliates) shall enter into a share subscription agreement, pursuant to which Kazia shall issue to Simcere, and Simcere shall subscribe from Kazia, four million Dollars ($4,000,000) of newly issued
American Depository Shares of Kazia, each representing 10 ordinary shares of Kazia (the &#147;<B>ADSs</B>&#148;), at a purchase price per ADS equal to one hundred twenty percent (120%) [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Development Milestone Payments. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Milestone Events. </B>Subject to the remainder of this Section&nbsp;5.3, Simcere shall pay to Kazia the
following <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> development milestone payments set forth in the table below upon the first achievement of the corresponding milestone event: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Development Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone&nbsp;Payment&nbsp;in<BR>Dollars</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Milestone Conditions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each development milestone payment set forth above shall be due and payable only once, regardless of how
many times such milestone event is achieved and/or the number of Products that achieve such milestone event. For milestone #3 (Obtainment of a MA for glioblastoma from NMPA), the milestone payments in either clause (a)&nbsp;or clause (b), but not
both, may be due and payable. For clarity, the aggregate milestone payments under this Section&nbsp;5.3 shall not exceed [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;Initiation&#148; of a human clinical trial means the first dosing of the first human subject enrolled
in such clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;Successful completion of GBM AGILE&#148; means
that the results of such clinical trial meet all study endpoints specified in <B>Exhibit D </B>attached hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;additional major Indication&#148; means (A)&nbsp;brain metastases from a primary tumour of the
breast, lung, skin, colon, or kidney, or combination thereof, or (B)&nbsp;newly-diagnosed unmethylated glioblastoma, newly-diagnosed methylated glioblastoma, or recurrent glioblastoma; provided that in both (A)&nbsp;and (B) that at least fifty per
cent (50%) of the patients covered by such new approval were not previously approved to receive treatment with the Product, and that the approval was the subject of a distinct MA filing to the applicable regulatory agency. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;additional <FONT STYLE="white-space:nowrap">non-major</FONT> Indication&#148; means primary brain
tumours other than glioblastoma, and brain metastases from primary tumours other than those listed in Section&nbsp;5.3(b)(iv). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;approvals in Indications which do not meet the definition of &#147;additional major Indication&#148; or
&#147;additional <FONT STYLE="white-space:nowrap">non-major</FONT> Indication&#148; will be discussed between the Parties in good faith to determine whether such approvals should be considered major or non-major Indications for the purposes of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, an additional major Indication or an additional <FONT STYLE="white-space:nowrap">non-major</FONT> Indication shall require a
separate MA to any other MA involving the Compound already in existence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice and Payment. </B>For
milestone #2 ([***]), Kazia shall notify Simcere in writing within thirty (30)&nbsp;days after the first achievement of such milestone and shall provide Simcere with reasonable supporting documents for the achievement of such milestone [***]. For
all other milestones set forth above, Simcere shall notify Kazia in writing within thirty (30)&nbsp;days after the first achievement of such milestone. Simcere shall pay to Kazia the corresponding milestone payment within forty five (45)&nbsp;days
after the receipt of the invoice issued by Kazia after the achievement of such milestone. For the avoidance of doubt, payment in accordance with these terms must be made even where notice of milestone satisfaction is not provided in accordance with
this clause 5.3(c). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sales Milestone Payments. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Milestone Events</B>. Subject to the remainder of this Section&nbsp;5.4, Simcere shall pay to Kazia the
following <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> sales milestone payments set forth in the table below when the aggregated annual Net Sales of the Product sold in the Territory in a
calendar year first reach the corresponding threshold value indicated below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>First time aggregate annual Net Sales (in Dollars) of the
Product<BR>in the Territory exceed:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone&nbsp;Payment&nbsp;in<BR>Dollars</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>First time aggregate annual Net Sales (in Dollars) of the
Product<BR>in the Territory exceed:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone&nbsp;Payment&nbsp;in<BR>Dollars</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Milestone Conditions.</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Each sales
milestone payment set forth above shall be due and payable only once, regardless of how many times such milestone event is achieved. The Net Sales of Product sold in a region in the Territory after the expiration of the Royalty Term in such region
shall not be included in the calculation of annual Net Sales to determine whether any Net Sales threshold has been achieved. The aggregate milestone payments under this Section&nbsp;5.4 shall not exceed [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice and Payment. </B>As part of the Royalty Report in Section&nbsp;5.5(e), Simcere shall provide
written notice to Kazia if the aggregated annual Net Sales of the Product in the Territory first reach any threshold value set forth in Section&nbsp;5.4(a) above during the time period to which such report pertains. Simcere shall pay to Kazia the
corresponding milestone payments within forty five (45)&nbsp;days after the receipt of the invoice issued by Kazia after the achievement of such milestone. For the avoidance of doubt, payment in accordance with these terms must be made even where
notice of milestone satisfaction is not provided in accordance with this clause 5.4(c). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty Payments. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty Rate. </B>Subject to the remainder of this Section&nbsp;5.5, Simcere shall make quarterly <FONT
STYLE="white-space:nowrap">non-refundable</FONT> royalty payments to Kazia on the Net Sales of the Product sold in the Territory, as calculated by multiplying the applicable royalty rate set forth in the table below by the corresponding amount of
incremental, aggregated annual Net Sales of the Product sold in the Territory during the applicable calendar year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>For that portion of annual Net Sales (in Dollars) of the Product in
the Territory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Royalty&nbsp;Rate</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:20.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty Term. </B>Simcere&#146;s obligation to pay royalties pursuant to
this Section&nbsp;5.5 shall expire, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis,
[***] after the First Commercial Sale of such Product in such region (the &#147;<B>Royalty Term</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty Conditions. </B>The royalties under this
Section&nbsp;5.5 shall be subject to the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;only one (1)&nbsp;royalty shall be due
with respect to each unit of Product, without regard to whether there is more than one Valid Claim or Licensed Patent claiming such Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;no royalties shall be due upon the sale or other transfer of the Product among Simcere, its Affiliates and
sublicensees, but in such cases the royalty shall be due and calculated upon Simcere&#146;s, its Affiliate&#146;s or sublicensee&#146;s Net Sales of Product to the first Third Party (other than sublicensee); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;no royalties shall accrue on the disposition of Product in reasonable quantities by Simcere, its
Affiliates or sublicensees for use in clinical trials and other development work, as part of an expanded access program, as free samples, or as donations to <FONT STYLE="white-space:nowrap">non-profit</FONT> institutions or government agencies for <FONT
STYLE="white-space:nowrap">non-commercial</FONT> purposes, provided that in each case no revenue is generated by Simcere, its Affiliates or sublicensees; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Net Sales of Product sold in a region after the expiration of the Royalty Term in such region shall
not be included in the calculation of annual Net Sales to determine the applicable royalty tiers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;Royalty
Reductions</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Product is sold in a region in the Territory during the applicable Royalty Term
at a time when there is no Valid Claim in the Licensed Patents that claims the composition of matter of the Compound contained in such Product in such region, then the royalty rate applicable to the Net Sales of such Product in such region during
such time shall be reduced by [***] of the royalty rate otherwise applicable to all Net Sales for such Product in the Territory under Section&nbsp;5.5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;If Simcere, its Affiliate or sublicensee, upon the advice of competent counsel properly qualified to
provide the advice, requires and obtains a license under a Third Party patent where such composition of matter patent covers the Compound included in a Product, then Simcere shall have the right to deduct, from the royalty payment that would
otherwise have been due pursuant to Section&nbsp;5.5(a), an amount equal to [***] of the amount paid by Simcere or its Affiliate or sublicensee to such Third Party pursuant to such license during the same period; provided, however, that in no event
shall the amount otherwise payable under Section&nbsp;5.5(a) to Kazia with respect to such Product be reduced more than [***] of what would otherwise be due on the sale of such Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Report. </B>Within forty five (45)&nbsp;days after the end of each calendar quarter, commencing with the
First Commercial Sale of the Product in the Territory, Simcere shall provide Kazia with a royalty report that contains the following information for the applicable calendar quarter and calendar year (to date if not yet a full calendar year), on a <FONT
STYLE="white-space:nowrap">Product-by-Product</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis: (i)&nbsp;the number of units of each Product sold; (ii)&nbsp;the amount of gross sales
of the Product, (iii)&nbsp;a calculation of Net Sales of the Product, (iv)&nbsp;a calculation of the royalty payment due on such Net Sales, including the application of any reduction made in accordance with Section&nbsp;5.5(d), (v) the exchange rate
for such region, and (vi)&nbsp;the aggregate annual Net Sales and whether any sales milestone has been achieved (&#147;<B>Royalty Report</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment. </B>Within ten (10)&nbsp;business days after
the date on which the Royalty Report is given to Kazia (&#147;<B>Review Period</B>&#148;), Kazia may, acting reasonably and in good faith, make an enquiry to Simcere about any aspect of the Royalty Report (&#147;<B>Royalty Query</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;If at the end of the Review Period, Kazia has not made any Royalty Query, all amounts set out in the
Royalty Report will be taken to be final and binding on the Parties and Simcere must, within forty five (45)&nbsp;days after the issue of a valid invoice by Kazia, pay to Kazia an amount equal to the royalty amount set out in Section&nbsp;5.5(a),
being the amount included in the Royalty Report in accordance with Section&nbsp;5.5(e)(iv), in respect of Net Sales made during the period of the relevant Royalty Report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Royalty Query is made within the Review Period, then Simcere must properly respond to such Royalty
Query, including (if applicable) providing evidence to support the amounts set out in the Royalty Report. If the Royalty Query has not been resolved within forty-five (45)&nbsp;business days after the Royalty Query is made, Kazia may exercise its
audit right in accordance with Section&nbsp;5.11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Where a Royalty Query is: (a)&nbsp;resolved or
otherwise agreed by the Parties; or (b)&nbsp;determined by an Auditor in accordance with Section&nbsp;5.11, Kazia must issue an invoice to Simcere for the agreed or determined royalty amount and Simcere must pay that amount within forty-five
(45)&nbsp;days after issue of the invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6&nbsp;&nbsp;&nbsp;&nbsp;Kazia&#146;s Third Parties Payment Obligations.</B> Kazia shall
be solely responsible for the payment of royalty, milestone and other payments due to Third Parties under any agreements between Kazia (or its Affiliates) and Third Parties (including the Genentech Agreement) on account of Simcere&#146;s, its
Affiliates&#146; and sublicensees&#146; Development, Manufacture and Commercialization of the Product in the Field in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Currency; Exchange Rate. </B>All payments due from Simcere to Kazia under this Agreement shall be made by
Simcere in Dollars by bank wire transfer in immediately available funds to a bank account designated by Kazia in writing. The rate of exchange to be used in computing the amount of currency equivalent in Dollars shall be made at the average of the
closing exchange rates reported by Bank of China for the first, middle and last business days of the applicable reporting period for the payment due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Blocked Currency. </B>If the conversion of a local currency in the Territory into Dollars or transfer of
funds out of a region in the Territory becomes materially restricted, forbidden or substantially delayed due to applicable Laws, then Simcere must immediately notify Kazia and amounts accrued in such region may be paid by Simcere in local currency
into an account in a local bank designated by Kazia, or such legal payment method as otherwise directed by Kazia. If the conversion of local currency into Dollars or transfer of funds out of a region in the Territory is materially restricted,
forbidden or substantially delayed due to applicable Laws for more than eight (8)&nbsp;months and while it continues, Kazia may, at its sole discretion, terminate this Agreement with immediate effect by giving written notice to Simcere. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9</B><B>&nbsp;&nbsp;&nbsp;&nbsp;Late Payments. </B>If Kazia does not receive payment of
any sum due to it on or before the due date, interest shall thereafter accrue on the sum due from the due date until the date of payment at a <FONT STYLE="white-space:nowrap">per-annum</FONT> rate of prime (as reported Bank of China) plus two
(2)&nbsp;percentage points or the maximum rate allowable by applicable Law, whichever is less. Notwithstanding the foregoing, the interest set forth in this Section&nbsp;5.9 shall not apply if the payment is delayed due to government restriction on
currency conversion or transfer of funds out of a region in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10&nbsp;&nbsp;&nbsp;&nbsp;Taxes. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Taxes on Income. </B>Each Party shall be solely responsible for the payment of all taxes imposed on its
share of income arising directly or indirectly from the activities of the Parties under this Agreement. For clarity, all payment amounts in this Article 5 are on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Cooperation. </B>The Parties agree to cooperate with one another and use reasonable efforts to avoid
or reduce tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made under this Agreement. To the extent Simcere is required to deduct and withhold taxes on any payment to Kazia, Simcere shall deduct
those taxes from the remittable payment, pay the taxes to the proper tax authority in a timely manner, and promptly send proof of payment to Kazia. Kazia shall provide Simcere any tax forms that may be reasonably necessary in order for Simcere to
not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Kazia shall use reasonable efforts to provide any such tax forms to Simcere in advance of the due date. At the request and expense of Kazia,
Simcere shall provide reasonable assistance to enable the recovery, to the extent permitted by Law, of withholding taxes or similar obligations resulting from payments made under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.11&nbsp;&nbsp;&nbsp;&nbsp;Records and Audit. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere shall maintain complete and accurate records of its, and its Affiliates&#146; and sublicensees&#146;
sales, transfers and other dispositions of the Product necessary for the calculation of payment due to Kazia under this Agreement. Simcere shall maintain such records for the longer of (i)&nbsp;the period of time required under any applicable Law,
and (ii)&nbsp;three (3) years following the end of the calendar year to which of such records pertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia may, at any time during the Term and for a period of three (3)&nbsp;years following the expiration or
termination of this Agreement, through an independent certified public accountant nominated by Kazia and acceptable to Simcere (the &#147;<B>Auditor</B>&#148;), undertake an audit of Simcere&#146;s records related to the sale and disposition of the
Product, for the three (3)&nbsp;year period before such notice for the purpose of verifying all payments made under this Agreement (&#147;<B>Audit</B>&#148;). Simcere shall, no later than thirty (30)&nbsp;days of Kazia&#146;s notice of an Audit,
permit the Auditor to have access to Simcere&#146;s records related to the sale and disposition of the Product, for the three (3)&nbsp;year period before such notice and during Simcere&#146;s normal business hours for the purpose of undertaking the
Audit. The Auditor shall be required to enter into a confidentiality agreement reasonably acceptable to Simcere to protect the confidentiality of Simcere&#146;s records before the Audit starts. Kazia may not conduct an Audit more than once each
calendar year unless: (i)&nbsp;a prior Audit in that calendar year determined an error by Simcere resulting in underpayment to Kazia of greater than five percent (5%) for the audited period; or (ii)&nbsp;Kazia is required to verify payments made
under this Agreement as a result of Genentech seeking to conduct an audit in accordance with the terms of the Genentech Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall bear the cost of an Audit under this
Section&nbsp;5.11, unless the Auditor&#146;s audit report reveals an uncontested underpayment by Simcere of more than five percent (5%) of the amount actually due for the time period being audited or a material breach by Simcere of its obligations
under this Agreement, in which case Simcere shall reimburse Kazia for the costs of the relevant Audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Upon completion of the Audit, the Auditor shall deliver its audit report to both Parties. Where the
Auditor&#146;s audit report shows that payments made by Simcere are deficient, Simcere shall pay to Kazia the uncontested underpayment within sixty (60)&nbsp;days after the date of the Auditor&#146;s audit report, plus interest (as set forth in
Section&nbsp;5.9) from the original due date. If the Auditor&#146;s audit report reveals an uncontested overpayment by Simcere, then Simcere may take a credit for such uncontested overpayment against any future payments due to Kazia (if there will
be no future payment due, then Kazia shall promptly refund such amount to Simcere). Contested amounts are subject to dispute resolution by an Expert under <B>Exhibit H</B>. The full amount of any underpayment by Simcere determined to be payable to
Kazia pursuant to this Section&nbsp;5.11(d) shall accrue interest in accordance with Section&nbsp;5.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;Where the Auditor&#146;s audit report shows that Simcere is in breach of its obligations under this
Agreement, the Parties will promptly meet to agree a remediation plan such that any breach by Simcere may be remedied. In such case, Kazia must provide to Simcere reasonable evidence of the relevant findings set out in the Auditor&#146;s audit
report. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;Inventions. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall solely own all Inventions invented or developed solely by or on behalf of such Party,
including its and its Affiliate&#146;s employees, contractors and/or agents. The Parties shall jointly own all Inventions invented or developed jointly by both Parties. Except to the extent restricted by the licenses and other rights granted to the
other Party under this Agreement or any other agreement between the Parties, with respect to jointly developed Inventions each Party, as joint owners, shall be entitled to practice, license, assign and otherwise exploit its interest in the jointly
owned Inventions without the duty of accounting or seeking consent from the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Party
shall promptly disclose to the other Party all Inventions invented or developed by or on behalf of such Party under this Agreement, including any invention disclosures, or other similar documents, submitted to it by its employees, agents or
independent contractors describing such Inventions, and shall promptly respond to reasonable request from the other Party for additional information relating to such Inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere hereby grants to Kazia a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> and royalty free license under any Inventions invented or developed solely by Simcere to (i)&nbsp;research, Develop, make, have made, use, sell, offer for sale, have sold, import and otherwise
Commercialize the Compound and Product in the Field outside the Territory, (ii)&nbsp;conduct <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, GBM AGILE and other Global Clinical Trials in each case for the Compound and the Product in
the Field in the Territory, and (iii)&nbsp;Manufacture the Compound and Product in the Territory for export out of the Territory, which license shall be sublicenseable by Kazia provided that the sublicensee grants to Kazia a sublicensable license
under any invention invented or developed by the sublicensee through the Development, Manufacture or Commercialization of the Product so that Kazia can include such invention in the Licensed IP and the license granted to Simcere hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;As between the Parties, Kazia shall have the first right to file, prosecute and maintain all Licensed
Patents throughout the world, at Kazia&#146;s own cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall consult with Simcere
and keep Simcere reasonably informed of the status of the Licensed Patents in the Territory and also in the US and EU, and shall promptly provide Simcere with all material correspondence received from any patent authority in the Territory in
connection therewith. In addition, Kazia shall promptly provide Simcere with drafts of all proposed material filings and correspondence to any patent authority in the Territory with respect to the Licensed Patents for Simcere&#146;s review and
comment prior to the submission of such proposed filings and correspondences. Kazia shall consider in good faith Simcere&#146;s comments prior to submitting such filing and correspondences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall notify Simcere of any decision to cease prosecution or maintenance of any Licensed Patents in
the Territory. Kazia shall provide such notice at least thirty (30)&nbsp;days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Patent. In such event, upon Simcere&#146;s request,
Kazia shall transfer the prosecution and maintenance of such Patents in the Territory to Simcere, and Simcere shall have the right to continue prosecution or maintenance of such Patents in the Territory at Simcere&#146;s own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall provide the other Party all reasonable assistance and cooperation in the patent prosecution
efforts under this Section&nbsp;6.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3&nbsp;&nbsp;&nbsp;&nbsp;Patent Enforcement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***][***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.4</B>&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.5</B>&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Bankruptcy Protection. </B>All licenses granted by a Party to the other Party under this Agreement are
and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of Title 11, United States Code or foreign equivalent Laws (the &#147;<B>Bankruptcy Code</B>&#148;), licenses of rights to &#147;intellectual property&#148; as defined in
Section&nbsp;101 of the Bankruptcy Code. To the extent permitted by Law, as the licensee, the <FONT STYLE="white-space:nowrap">non-bankruptcy</FONT> Party shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.
Upon the bankruptcy of a Party, the <FONT STYLE="white-space:nowrap">non-bankruptcy</FONT> Party, as the licensee, shall, to the extent permitted by Law, further be entitled to a complete duplicate of, or complete access to, any such intellectual
property, and such, if not already in its possession, shall be promptly delivered to the <FONT STYLE="white-space:nowrap">non-bankruptcy</FONT> Party, unless the bankruptcy Party elects to continue, and continues, to perform all of its obligations
under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7&nbsp;&nbsp;&nbsp;&nbsp;Trademarks. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia hereby grants to Simcere a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license (with the
right to sublicense) for the Term to the trademarks and trade names Controlled by Kazia and used by Kazia in connection with the Product (&#147;<B>Licensed Trademarks</B>&#148;) solely in order for Simcere to Commercialize the Product in the Field
in the Territory. During the Term, Kazia shall not grant any licence under the Licensed Trademarks to any Third Party in order for the Third Party to Commercialize the Product in the Territory. Kazia shall own all rights in the Licensed Trademarks,
and all goodwill in the Licensed Trademarks shall accrue to Kazia. Kazia shall register, maintain and enforce, at its own cost, expense and discretion, the Licensed Trademarks in the Territory as Kazia determines reasonably necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to (or in lieu of ) the Licensed Trademarks, Simcere shall have the right to brand the Product
for use in connection with its Commercialization in the Territory using Simcere related trademarks and any other trademarks and trade names (including Chinese character trademarks and trade names) Simcere determines appropriate for the Products,
which may vary by region or within a region in the Territory (&#147;<B>Product Marks</B>&#148;). Simcere shall own all rights in the Product Marks, and all goodwill in the Product Marks shall accrue to Simcere. Simcere shall register, maintain and
enforce, at its own cost and expense, the Product Marks in the Territory as Simcere determines reasonably necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>License Registration. </B>If required or permitted by applicable Laws, Simcere may register the license
granted by Kazia to Simcere hereunder with Government Authorities in the Territory, including the China National Intellectual Property Administration, by submitting this Agreement (or a simplified and/or Chinese language version of this Agreement)
and other required documents to the applicable Government Authorities. Upon Simcere&#146;s reasonable request, Kazia shall execute such documents and take such further action reasonably required by Simcere in connection with such registration. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality Obligations. </B>Except to the extent expressly authorized by this Agreement or otherwise
agreed in writing by the Parties, each Party agrees that, during the Term of this Agreement and ten (10)&nbsp;years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as
provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exceptions. </B>The obligations set forth in Section&nbsp;7.1 shall not apply to any information that the
receiving Party can demonstrate that such information: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;is known by the receiving Party at the time of its receipt
without an obligation of confidentiality, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#146;s business records; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;is in the public domain before its receipt from the disclosing Party, or thereafter enters the public domain
other than through the receiving Party&#146;s breach of the confidentiality obligations set forth herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an
obligation of confidentiality to the disclosing Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;is developed by the receiving Party
independently and without use of, or reference to, any Confidential Information of the disclosing Party, as documented by the Receiving Party&#146;s business records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or
available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp;Authorized Disclosures. </B>Notwithstanding the obligations set forth in Sections 7.1 and 7.6, a Party may
disclose the other Party&#146;s Confidential Information to any Affiliate, actual or bona fide potential sublicensee, subcontractor, agent, officer, investor, professional adviser, banker, auditor, clinician or other consultant (each a
&#147;<B>Recipient</B>&#148;) only if the disclosure is made strictly on a &#147;need to know basis&#148; and, prior to the disclosure, the Party (i)&nbsp;notifies the Recipient of the confidential nature of the Confidential Information to be
disclosed, and (ii)&nbsp;the Recipient enters into a written agreement of confidentiality with the Party, or the Recipient is bound by professional or ethics obligation regarding confidentiality, which in either case is at least as restrictive as
the obligations in this Article 7 (provided that the duration of such confidentiality obligation can be shorter (but no less than five (5)&nbsp;years) for a Recipient that is a banker, investor, or other financial partners). Without limiting the
foregoing, a Party may disclose Confidential Information to the extent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;such disclosure is necessary:
(i)&nbsp;for the filing, prosecution and enforcement of Patents as contemplated by this Agreement; (ii)&nbsp;in connection with regulatory filings for Product; (iii)&nbsp;for the prosecuting or defending litigation as contemplated by this Agreement;
or (iv)&nbsp;in connection with the exercise of a Party&#146;s rights or the performance of its obligations hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;such disclosure is required by applicable Laws, judicial or administrative process, provided that in such
event, to the extent possible, such Party shall promptly inform the other Party of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed
pursuant to this Section&nbsp;7.3(b) shall remain otherwise subject to the confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of this Article 7, and the Party disclosing Confidential Information pursuant to Law or court
order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Breach by Recipient. </B>A Party which discloses the
other Party&#146;s Confidential Information to a Recipient, is liable for breach of this Article 7 by a Recipient as if the Recipient was a Receiving Party in relation to the Confidential Information disclosed to the Recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5&nbsp;&nbsp;&nbsp;&nbsp;Scientific Publication. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except to the extent required by applicable Laws, Simcere shall not publish any peer-reviewed manuscripts,
or give other forms of public disclosure such as abstracts and presentations, relating to the Compound or Product other than in the Territory and with Kazia&#146;s approval. Simcere shall provide Kazia with a draft of any proposed publication
relating to the Compound or Product at least thirty (30)&nbsp;days prior to its intended submission for publication. Upon Kazia&#146;s request, Simcere shall remove any and all of Kazia&#146;s Confidential Information from the proposed publication,
and shall delay the submission for a period up to ninety (90)&nbsp;days to allow time for the preparation and filing of a patent application directed to any Inventions disclosed in such publication. Simcere shall also provide Kazia a copy of the
manuscript at the time of the submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall keep Simcere informed on any scientific
publication relating to the Compound and Product and shall provide Simcere with a draft of any such proposed publication for review at least thirty (30)&nbsp;days prior to its intended submission for publication. Kazia shall consider Simcere&#146;s
comments in good faith and shall not include any Confidential Information of Simcere in its publication, but Simcere shall not have the right to approve Kazia&#146;s publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6&nbsp;&nbsp;&nbsp;&nbsp;Publicity. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Parties have agreed on language of press release for each Party announcing this Agreement, which is
attached hereto as <B>Exhibit G</B>, to be issued by the Parties promptly after the Effective Date. Subject to the rest of this Section&nbsp;7.6 and Section&nbsp;7.3, no disclosure of the terms of this Agreement may be made by either Party, and
neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the
prior express written permission of the other Party, except as may be required by Law. Following the initial joint press release announcing this Agreement, either Party shall be free to disclose or publicize, without the other Party&#146;s prior
written consent, the existence of this Agreement, the identity of the other Party, and those terms of the Agreement which have already been publicly disclosed in accordance herewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;A Party may disclose this Agreement and its terms in securities filings with the Securities Exchange
Commission (or equivalent agency) or the stock exchange on which such Party&#146;s or its Affiliate&#146;s stock is publicly traded (the &#147;<B>Securities Regulators</B>&#148;) to the extent required by Law or the rules of the Securities Regulator
after complying with the procedure set forth in this Section&nbsp;7.6. In such event, the Party seeking such disclosure will, where possible, prepare a draft confidential treatment request and proposed redacted version of this Agreement to request
confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than seven (7)&nbsp;days after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner
in order to allow the Party seeking disclosure to file its request within the time lines proscribed by applicable Laws. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of this
Agreement as represented by the redacted version reviewed by the other Party or to the extent otherwise reasonably possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Party acknowledges that the other Party may be
legally required to make public disclosures (including in filings with Securities Regulators) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by
Law or the rules of the Securities Regulator, provided that the Party seeking such disclosure, where possible, first provides the other Party a copy of the proposed disclosure, and provided further that (except to the extent that the Party seeking
disclosure is required to disclose such information to comply with Law or the rules of the Securities Regulator and where possible) if the other Party demonstrates to the reasonable satisfaction of the Party seeking disclosure, within three
(3)&nbsp;business days of such Party&#146;s providing the copy, that the public disclosure of previously undisclosed information may adversely affect the Development and/or Commercialization of the Product, the Party seeking disclosure will remove
from the disclosure such specific previously undisclosed information as the other Party shall reasonably request to be removed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7&nbsp;&nbsp;&nbsp;&nbsp;Prior CDA.</B> This Agreement supersedes the Confidentiality Agreement between the Parties dated 21 April 2020
(the &#147;<B>Prior CDA</B>&#148;) with respect to information disclosed thereunder. All information exchanged between the Parties under the Prior CDA shall be deemed Confidential Information of the disclosing Party and shall be subject to the terms
of this Article 7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Equitable Relief. </B>Each Party acknowledges that a breach of this Article 7
cannot reasonably or adequately be compensated in damages in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition
to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND
TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;Term. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to clause 8.1(b), the term of this Agreement (&#147;<B>Term</B>&#148;) shall commence upon the
Effective Date and, unless terminated by either Party pursuant to Section&nbsp;8.2, shall continue in full force and effect, on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis, until the expiration of the Royalty Term for such Product in such region. After the expiration (but not early termination) of the Term for a particular
Product in a particular region, the licenses granted by Kazia to Simcere hereunder shall continue and shall become fully paid, royalty free, perpetual and irrevocable with respect to such Product in such region. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The formation of a binding contract by this Agreement,
other than this Section&nbsp;8.1 and Article 1 (Definitions), Section&nbsp;5.2 (Equity Investment), Article 7 (Confidentiality) and Article 11 (General Provisions) is subject to the fulfilment of the obligation in Section&nbsp;5.2 to enter into the
Share Subscription Agreement. Where that obligation is not fulfilled within forty five (45)&nbsp;days of the Effective Date, Kazia will be entitled to terminate this Agreement (to the limited extent it applies) upon written notice to Simcere with
immediate effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;Termination. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination where Development or Commercialization deemed unviable. </B>At any time during the Term, if
Simcere considers that the Development of the Compound or Product, or Commercialization of the Product, in the Field in the Territory is unviable, Simcere may request to terminate this Agreement (either in whole or on a <FONT
STYLE="white-space:nowrap">Product-by-Product</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis) by providing written notice to Kazia. The Parties must discuss any such notice in good
faith and following reasonable efforts to remediate, either Party may terminate this Agreement (either in whole or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis as requested by Simcere in its notice) on the basis of such notice by providing written notice of termination to the other Party, which notice includes
an effective date of termination at least thirty (30)&nbsp;days after the date of the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for Material Breach. </B>If either Party believes that the other is in breach of its material
obligations hereunder, then the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party may deliver notice of such breach to the other Party. The allegedly breaching Party shall have sixty (60)&nbsp;days from such notice to dispute or cure such
breach. If the Party receiving notice of breach fails to cure, or fails to dispute, that breach within the cure period set forth above, then the Party originally delivering the notice of breach may terminate this Agreement effective on written
notice of termination to the other Party. If the allegedly breaching Party disputes the existence, materiality or cure of the alleged breach, the other Party shall not have the right to terminate this Agreement until it has been determined pursuant
to Section&nbsp;11.6 that the alleged breaching Party is in material breach of this Agreement, and such breaching Party further fails to cure such breach within thirty (30)&nbsp;days after the conclusion of that dispute resolution procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination by Kazia. </B>Kazia may immediately terminate this Agreement by providing written notice of
termination to Simcere if Simcere (i)&nbsp;materially breaches any of its representations or warranties under Article 9, (ii) materially breaches any of its obligations under Article 5, or (iii)&nbsp;fails to use Commercially Reasonable Efforts to
satisfy each milestone event under Article 5 or to Develop and Commercialize the Licensed IP; and, in each case, fails to remedy the breach in (i), (ii) or (iii)&nbsp;within sixty (60)&nbsp;days of being given notice to do so by Kazia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Simcere&#146;s License. </B>Upon the early termination of this Agreement for any reason,
all rights and licenses granted by Kazia to Simcere under this Agreement shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Specific
Consequences. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;Reversion License.</B> Upon early termination of this Agreement for any reason, Simcere
shall grant to Kazia an exclusive license under the data, results and other Inventions generated by Simcere through the Development, Manufacture and Commercialization of the Compound and Product to research, Develop, make, have made, use, sell,
offer for sale, have sold, import and otherwise Commercialize the Compound and Product in the Field, which license shall not be subject to a royalty payment unless the Agreement is terminated by Simcere for Kazia&#146;s uncured material breach, in
which case any such royalty payment to Simcere will be negotiated and agreed by the Parties and shall become effective only upon such termination and the Parties&#146; agreement on such royalty payment. Upon expiration of this Agreement, Simcere
shall grant to Kazia a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under the data, results and other Inventions generated by Simcere through the Development, Manufacture and Commercialization of the Compound and Product to
research, Develop, make, have made, use, sell, offer for sale, have sold, import and otherwise Commercialize the Compound and Product in the Field, which license shall not be subject to a royalty payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment. </B>Upon expiration or early termination of this Agreement for any reason, Simcere must pay to
Kazia in accordance with the terms of this Agreement any unpaid invoices submitted before termination or any invoices submitted by Kazia after termination in relation to royalties or other payments accrued before termination and due in accordance
with Article 5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cessation of activities. </B>Upon early termination of this Agreement for any
reason, Simcere must cease conducting any activities with respect to Development or Manufacture of any Compound or Products and Commercialization of Products. Simcere must also discontinue making any representations regarding its status as a
licensee of Kazia for any Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reversion of prosecution and maintenance of Patents. </B>Upon
expiration or early termination of this Agreement for any reason, Simcere must transfer the prosecution and maintenance of such Licensed Patents in the Territory to Kazia it, at any time during the Term, became responsible for in accordance with
Section&nbsp;6.2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Regulatory Materials. </B>Upon early termination of this Agreement for any
reason, Simcere shall, to the extent permitted by applicable Laws, transfer and assign to Kazia all of Simcere&#146;s and its Affiliates&#146; right, title and interest in and to any and all Regulatory Approvals and other Regulatory Materials for
the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Data. </B>Upon expiration or early termination of this Agreement for any reason,
subject to applicable Laws, Simcere shall provide Kazia with copies of any data and results generated from clinical trials and other studies of the Product which were not previously provided to Kazia by Simcere. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)&nbsp;&nbsp;&nbsp;&nbsp;Product Inventory.</B> Upon early termination of this
Agreement for any reason, Kazia shall have the right to purchase from Simcere all or part of the inventory of the Product held by Simcere as of the effective date of termination at a price equal to the cost paid by Simcere for such inventory (or
Simcere&#146;s fully burdened manufacturing cost if such inventory is manufactured by Simcere itself). Kazia shall notify Simcere whether Kazia elects to exercise such right within thirty (30)&nbsp;days after the effective date of termination. If
Kazia does not exercise such right, then Simcere shall have the right to continue to sell any remaining inventory of the Product, for a period of no more than one (1)&nbsp;year after the date of termination, provided that Simcere continues to pay
Kazia royalties on the Net Sales of the Product sold after termination in accordance with Section&nbsp;5.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Product Marks. </B>Upon early termination of this Agreement for any reason, Simcere shall assign to
Kazia all Product Marks that relate exclusively to the Product (which, for clarity, exclude the corporate names and logos of Simcere, its Affiliates and sublicensees). Simcere must also provide to Kazia all records, information and documents related
to the registration and maintenance of any Product Marks which will be transferred to Kazia in accordance with this Section&nbsp;8.3(b)(viii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)&nbsp;&nbsp;&nbsp;&nbsp;Transition Assistance.</B> Upon early termination of this Agreement for any reason, at Kazia&#146;s reasonable
request and expense, Simcere shall provide assistance to Kazia as may be reasonably necessary or useful for Kazia to commence or continue the Development, Manufacture or Commercialization of the Product in the Field in the Territory, for a period of
no more than six (6)&nbsp;months after the effective date of such termination, and to the extent Simcere is then performing or having performed such activities, including transferring or amending as appropriate, upon Kazia&#146;s request, any
contracts with Third Parties for services related to the Development, Manufacture or Commercialization of the Product in the Field in the Territory. If any such contract is not assignable to Kazia, then Simcere shall reasonably cooperate with Kazia
in its efforts to obtain such services from such Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Return of Confidential Information.
</B>Upon early termination of this Agreement for any reason, each Party must (i)&nbsp;immediately cease using all Confidential Information of or relating to the other Party (or the other Party&#146;s Affiliate), (ii) deliver to the other Party all
documents and other materials in its possession or control containing, recording or constituting that Confidential Information or destroy, and certify to the other Party that it has destroyed, those documents and materials, and (iii)&nbsp;for
Confidential Information stored electronically, permanently delete that Confidential Information from all electronic media on which it is stored, so that it cannot be restored. Notwithstanding the foregoing, a Party shall be permitted to retain a
copy (or copies, as necessary) of Confidential Information of or relating to the other Party which it has the right to retain under this Agreement, or otherwise for archival purposes or as required by any applicable Law, and neither Party shall be
required to delete or destroy any electronic <FONT STYLE="white-space:nowrap">back-up</FONT> tapes or other electronic <FONT STYLE="white-space:nowrap">back-up</FONT> files that have been created by automatic or routine archiving and <FONT
STYLE="white-space:nowrap">back-up</FONT> procedures, to the extent created and retained in a manner consistent with standard archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures. For the avoidance of doubt, the confidentiality
obligations under Article 7 will continue to apply to any retained Confidential Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Clinical Trial Transition Assistance. </B>The Parties
agree to provide reasonable run off and transitional assistance if a clinical trial is ongoing as at the date of expiration or termination of this Agreement, to ensure trial participants affected by termination receive adequate medical care,
provided that if Kazia wishes to continue such clinical trial, then Kazia shall be bear the cost of such transition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Survival. </B>Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing prior to such expiration or termination. Without limiting the foregoing, the following provisions shall survive the expiration or termination of this Agreement: Sections 5.11, 6.1, 6.7(a), Article 7, Sections 8.3, 8.4, and 8.5, Article 10
and Article 11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination Not Sole Remedy. </B>Termination is not the sole remedy under this
Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1&nbsp;&nbsp;&nbsp;&nbsp;Mutual Representations and Warranties.</B> Each Party hereby represents, warrants, and covenants (as applicable)
to the other Party as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;it is a company or corporation duly organized, validly existing, and in
good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement, including, without limitation, the right to grant the licenses granted by it hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;as of the Effective Date, (i)&nbsp;it has the corporate power and authority and the legal right to enter
into this Agreement and perform its obligations hereunder; (ii)&nbsp;it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and
(iii)&nbsp;the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;it is not a party to any agreement that would materially prevent it from granting the rights granted to the
other Party under this Agreement or performing its obligations under the Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;it shall comply
in all material aspects with all applicable Laws in the course of performing its obligations and exercising its rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2&nbsp;&nbsp;&nbsp;&nbsp;Additional Representations and Warranties of Kazia.</B> Kazia represents, warrants, and covenants (as
applicable) to Simcere that, as of the Effective Date: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia is the sole owner of the Licensed IP (other than
Licensed IP that is <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Kazia from Genentech under the Genentech Agreement), free and clear of all liens, and Kazia has the right to grant to Simcere the rights and licenses under the Licensed IP as
purported to be granted hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia has obtained all necessary government approvals required for
the grant of the license and the transfer of the Licensed IP to Simcere, including such approvals required by applicable technology export control laws, and Kazia will do and execute or procure to be done and executed all such further acts, things,
agreements and other documents as may be necessary to give effect to the terms of this Agreement, including to comply with the applicable technology import and export laws and regulations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia and its Affiliates have not granted, and will not grant during the Term, any rights in the Licensed IP
that are inconsistent with the rights granted to Simcere under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;to the best of their
knowledge, Kazia and its Affiliates have not infringed or misappropriated any intellectual property of any Third Party during its development and manufacture of the Compound and Product, and have not received any notice from any Third Party
asserting or alleging any such infringement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;to the best of Kazia&#146;s knowledge, after undertaking
the inquiries set out in <B>Exhibit I</B>, the Development, Manufacture and Commercialization (as contemplated by the Parties as of the Effective Date) of the Compound and Product (as such Compound and Product exist as of the Effective Date) can be
carried out under this Agreement without infringing or misappropriating any intellectual property rights of any Third Party; there is no pending or, to the knowledge of Kazia and its Affiliates, alleged or threatened, adverse actions, suits,
proceedings, or claims against Kazia or its Affiliates involving the Licensed IP, Compound or Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;to the best of their knowledge, Kazia and its Affiliates are not aware of any infringement or
misappropriation of any Licensed IP by any Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit B </B>includes all Patents
Controlled by Kazia and its Affiliates as of the Effective Date that claim or cover the Compound and Product, all of which have been diligently prosecuted and maintained in accordance with applicable Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;there is no pending or, to the knowledge of Kazia and its Affiliates, alleged or threatened, <FONT
STYLE="white-space:nowrap">re-examination,</FONT> opposition, interference or litigation, or any written communication alleging that any Licensed Patent is invalid or unenforceable anywhere in the world; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia (including its Affiliates and, to the best of its knowledge, its contractors) has complied with all
applicable Laws in connection with the development of the Compound and Product, and has not used any employee, consultant or contractor who has been debarred by any Regulatory Authority, or to its knowledge, is the subject of a debarment proceeding
by any Regulatory Authority; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;except for the Genentech Agreement, there is no agreement
between Kazia or its Affiliates and any Third Party pursuant to which Kazia or its Affiliates obtained any right or license to the Compound or Product or any intellectual property rights related to the Compound or Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia has provided Simcere with a true and complete copy of the Genentech Agreement, and the Genentech
Agreement is in full force and effect; Kazia has the right to grant to Simcere the sublicense under the Genentech Agreement as purported to be granted hereunder; no written notice of default or termination has been received or given under the
Genentech Agreement; and there is no act or omission by Kazia that would provide a right to terminate the Genentech Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;during the Term of this Agreement, Kazia shall, at its own cost and expense, use best efforts to maintain
the Genentech Agreement in full force and effect and shall not terminate, amend, waive or otherwise modify (or consent to any of the foregoing) its rights under the Genentech Agreement in any manner that materially diminishes the rights or licenses
granted to Simcere hereunder, without first notifying Simcere and shall obtain Simcere&#146;s consent (not to be unreasonably withheld). If despite of Kazia&#146;s best efforts, the Genentech Agreement is terminated, Kazia shall use best efforts to
assist Simcere to obtain a direct license from Genentech. Where Simcere obtains a direct license from Genentech, the payment provisions of this Agreement will apply as though such license continued to be granted by Kazia, save that Simcere may
deduct from any payment due to Kazia under this Agreement any payment Simcere is obliged to make to Genentech under its license agreement with Genentech. In such circumstances, Kazia shall have the right (limited to Section&nbsp;5.11) to audit and
confirm any payments due to Genentech under Simcere&#146;s license agreement with Genentech; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>&nbsp;&nbsp;&nbsp;&nbsp;in the
event of any notice of breach of the Genentech Agreement by Kazia in a manner that will or is likely to affect Simcere&#146;s rights or obligations under this Agreement, Kazia shall immediately notify Simcere in writing, and if Kazia fails to cure
such breach in a timely manner, Simcere shall have the right, but not the obligation, to cure such breach and to seek reimbursement of or offset any reasonable amount incurred or paid by Simcere in connection with the cure against amount payable to
Kazia hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>&nbsp;&nbsp;&nbsp;&nbsp;in the event of any notice of breach of the Genentech Agreement by Genentech in a
manner that will or is likely to materially affect Simcere&#146;s rights or obligations under this Agreement, Kazia shall immediately notify Simcere in writing and, where it is reasonable for Kazia to do so, take reasonable actions requested by
Simcere to enforce the Genentech Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>&nbsp;&nbsp;&nbsp;&nbsp;to the best of Kazia&#146;s knowledge, all information
provided by Kazia to Simcere for due diligence purposes in relation to this Agreement is complete and accurate in all material respects. Without limiting the foregoing, to the best of its knowledge, Kazia has disclosed to Simcere and made available
to Simcere for review all material <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical data for the Compound and Product, and all other material information (including relevant correspondence with Regulatory Authorities) relating to
the Compound and Product, in each case that would be material for Simcere to assess the safety and efficacy of the Compound and Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3&nbsp;&nbsp;&nbsp;&nbsp;Additional Representations and Warranties of Simcere.</B>
Simcere represents, warrants, and covenants (as applicable) to Kazia that, as of the Effective Date and on each day during the Term, in conducting activities contemplated under this Agreement, Simcere will: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;hold the necessary Regulatory Approvals to perform its obligations under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;comply with all applicable Laws, including those related to Manufacture, use, labelling, importation and
marketing of Products;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer.</B> TO THE EXTENT PERMITTED BY LAW, EXCEPT AS EXPRESSLY STATED HEREIN,
NO OTHER REPRESENTATIONS OR WARRANTIES WHATSOEVER, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL SUCH OTHER REPRESENTATIONS AND WARRANTIES, WHETHER
ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. Both Parties understand that the Compound and Product are the subject of ongoing research and development and neither Party can assure that any Compound or Product can be
successfully Developed and Commercialized. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B>&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitation of Liability. </B>SUBJECT TO SECTION 10.6, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Personal Injury. </B>Nothing in this Agreement operates to exclude or restrict a Party&#146;s liability
for personal injury. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance. </B>Each Party shall procure and maintain
insurance, including product liability insurance, with respect to its activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being clinically
tested in human subjects or commercially distributed or sold by such Party. Each Party shall provide the other Party with evidence of such insurance upon request and shall provide the other Party with written notice at least sixty (60)&nbsp;days
prior to the cancellation, non-renewal or material changes in such insurance. Such insurance shall not be construed to create a limit of either Party&#146;s liability under this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Force Majeure. </B>Neither Party shall be held liable to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected
Party, potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, earthquakes, pandemic, or other acts
of God, or acts, omissions or delays in acting by any Government Authority (each a &#147;<B>Force Majeure Event</B>&#148;). The affected Party shall notify the other Party in writing of a Force Majeure Event, including the circumstances of that
Force Majeure Event, as soon as reasonably practical, and shall promptly undertake and continue diligently all reasonable efforts necessary to cure the Force Majeure Event or to perform its obligations in spite of the ongoing circumstances. If a
Force Majeure Event continues for more than eighteen (18)&nbsp;months and while it continues, the Party other than the affected Party may, at its sole discretion, terminate this Agreement by giving written notice to the affected Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment. </B>This Agreement may not be assigned or otherwise transferred, nor may any right or
obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and
obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its business or assets to which this Agreement relates. Any attempted
assignment not in accordance with the foregoing shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement shall be
binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability. </B>If any one or more of the provisions contained in this Agreement is held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices. </B>All notices which are required or
permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier, sent
by registered or certified mail, postage prepaid, return receipt requested or sent by email, addressed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">If&nbsp;to&nbsp;Kazia:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Kazia&nbsp;Therapeutics,&nbsp;Ltd.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">L24,&nbsp;300&nbsp;Barangaroo&nbsp;Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Sydney,&nbsp;NSW&nbsp;2000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Attn: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief&nbsp;Executive&nbsp;Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">with&nbsp;a&nbsp;copy&nbsp;to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">K&amp;L&nbsp;Gates</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">L25,&nbsp;525&nbsp;Collins&nbsp;Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Melbourne,&nbsp;VIC&nbsp;3000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Attn: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fax: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+61&nbsp;3 9205&nbsp;2055</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">If&nbsp;to&nbsp;Simcere:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Jiangsu&nbsp;Simcere&nbsp;Pharmaceutical&nbsp;Co,&nbsp;Ltd.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="white-space:nowrap">No.&nbsp;699-18&nbsp;Xuanwu&nbsp;Avenue,&nbsp;Xuanwu&nbsp;District</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Nanjing&nbsp;City,&nbsp;Jiangsu&nbsp;Province</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">China&nbsp;210042</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Attn: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate&nbsp;Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fax: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+86&nbsp;25&nbsp;8526&nbsp;2330</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">with&nbsp;a copy&nbsp;to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Simcere&nbsp;of&nbsp;America,&nbsp;Inc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">20&nbsp;Acorn&nbsp;Park&nbsp;Drive,&nbsp;Suite&nbsp;200,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Cambridge,&nbsp;MA&nbsp;02140</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Attn:&nbsp;[***],&nbsp;SVP,&nbsp;BD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="white-space:nowrap">Telephone:&nbsp;(857)242-4364&nbsp;x1005</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;[***]</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and&nbsp;a&nbsp;copy&nbsp;to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooley LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFC - Tower 2, Level&nbsp;35, Unit 3510</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8 Century Avenue</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pudong New Area</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shanghai, China 200120</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+86 21 6030
0700</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party
in writing in accordance herewith. Any such notice shall be deemed to have been given: (a)&nbsp;when delivered if personally delivered or sent by facsimile on a business day (or if delivered or sent on a
<FONT STYLE="white-space:nowrap">non-business</FONT> day, then on the next business day); (b) on the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) business day after dispatch if sent by nationally-recognized overnight courier;
(c)&nbsp;on the seventh (7<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) business day following the date of mailing, if sent by mail; or (d)&nbsp;if sent by email, two (2)&nbsp;hours after the time the email is sent to the recipient&#146;s
email address, as recorded on the sender&#146;s email system, unless the sender receives within that time period, an automatic notification (other than an out of office message) indicating that the email has not been delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law. </B>This Agreement shall be governed by and construed in accordance with the laws of
Singapore, without reference to any rules of conflict of laws that may require the application of the laws of a different jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp;Dispute Resolution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall negotiate in good faith and use good faith efforts to settle any dispute, controversy or
claim arising from or related to this Agreement or the breach thereof. Any such dispute, controversy or claim shall be referred to the Executive Officers of the Parties for attempted resolution. In the event the Executive Officers are unable to
resolve such dispute, controversy or claim within thirty (30)&nbsp;days after such matter is referred to them, then, upon the written request of either Party, such dispute, controversy or claim shall be (i)&nbsp;if arising from or related to
Section&nbsp;5.11(d), referred to an Expert and determined in accordance with <B>Exhibit H</B>, or (ii) if arising from or related to any section of this Agreement other than Section&nbsp;5.11(d) finally resolved by binding arbitration administered
by Singapore International Arbitration Centre (&#147;<B>SIAC</B>&#148;) pursuant to its arbitration rules. Judgment on the arbitration award may be entered in any court having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a dispute it to be resolved by arbitration under Section&nbsp;11.6(a)(ii), the arbitration shall be
conducted by a single arbitrator mutually agreed by the Parties within thirty (30) days after initiation of arbitration. If the Parties are unable or fail to agree upon the arbitrator, the arbitrator shall be appointed by SIAC. The arbitration shall
be held in Singapore, all arbitration proceedings and communications shall be in English and the following terms shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;Either Party may apply to the arbitrator for interim injunctive relief until the arbitration award is
rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of
that Party pending the arbitration award. The arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party&#146;s compensatory damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;The &#147;prevailing&#148; Party, as determined by the
arbitrator, shall be entitled to (A)&nbsp;its share of fees and expenses of the arbitrators, and (B)&nbsp;its reasonable attorneys&#146; fees and associated costs and expenses. If the arbitrator determines that, given the scope of the arbitration,
neither Party &#147;prevailed&#148;, the arbitrator shall order that the Parties (A)&nbsp;share equally the fees and expenses of the arbitrator&#146;s fees and any administrative fees of arbitration, and (B)&nbsp;bear their own attorney&#146;s fees
and associated costs and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except to the extent necessary to confirm an award or as may be
required by Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of
a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, in the event of a dispute with respect to the validity, scope, enforceability
or ownership of any Patent or other intellectual property rights, and such dispute is not resolved by the Executive Officers as set forth in Section&nbsp;11.6(a), such dispute shall not be submitted to an arbitration proceeding and instead, unless
otherwise agreed by the Parties in writing, either Party may initiate litigation in a court of competent jurisdiction in any country in which such rights apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement; Amendments. </B>This Agreement, together with the Exhibits hereto, contains the entire
understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof are
superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument
duly executed by authorized representative(s) of both Parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Headings; Language. </B>The
captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. This Agreement was prepared in the English
language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Contractors. </B>It is expressly agreed that Kazia and Simcere shall be independent
contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Kazia nor Simcere shall have the authority to make any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without the prior written consent of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiver. </B>The waiver by either Party hereto of any right hereunder, or of any failure of the other
Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cumulative Remedies. </B>No remedy referred to in
this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiver of Rule of Construction. </B>Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Business Day Requirements. </B>In the event that any notice or other action or omission is required to
be taken by a Party under this Agreement on a day that is not a business day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts. </B>This Agreement may be executed in two or more counterparts by original signature,
facsimile or PDF files, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(REMAINDER OF PAGE INTENTIONALLY LEFT BLANK) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to
be executed by their duly authorized representatives as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed by Simcere Pharmaceutical Co., Ltd.: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature of Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jinsheng Ren</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Jinsheng Ren</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Name (please print)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed by Kazia Therapeutics, Ltd. </B>AC 063 259 754 in accordance with section 127(1) of the <I>Corporations Act 2001
(Cth):</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature&nbsp;of&nbsp;director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signature&nbsp;of&nbsp;director&nbsp;or&nbsp;company&nbsp;secretary*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">*delete whichever does not apply</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Name </B>(please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Name </B>(please print)</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to
be executed by their duly authorized representatives as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed by Simcere Pharmaceutical Co., Ltd.: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; ">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature of Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jinsheng Ren</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Name (please print)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed </B>by <B>Kazia Therapeutics, Ltd. </B>ACN 063 259 754 in accordance with section 127(1) of the <I>Corporations
Act 2001 (Cth)</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signature of director or company secretary*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">*delete whichever does not apply</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">/s/ James Garner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">/s/ Kate Hill</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">James Garner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Kate Hill</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Company Secretary</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Name (please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Name (please print)</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit C:Technology Transfer Plan </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Project Scope: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon execution of the Agreement the Parties will effect transfer of the Key Items listed below from Kazia to Simcere. Technology transfer for manufacturing
will be elected by Simcere and a detailed plan will be discussed and agreed between the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governance and Support </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JSC will oversee the Technology Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For data and
information that is necessary for regulatory filing and Development of the Compound or Product in the Territory but not under Kazia&#146;s control, Kazia will reasonably assist Simcere to seek to acquire such data and information, at Simcere&#146;s
sole expense. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit D:Endpoints of GBM AGILE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of GBM AGILE will be Overall Survival (OS), defined as the time from randomization to death from any cause. Patients still alive at the
time of an analysis will be considered censored at their date of last contact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib will be deemed to have met its primary endpoint if the final
probability of HR [<I>Hazard Ratio</I>] &lt; 1.0 is at least 0.98, based on Kaplan-Meier analysis of the <FONT STYLE="white-space:nowrap">Intent-to-Treat</FONT> dataset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties acknowledge that, as of the Effective Date, Kazia and GCAR are in discussion with NMPA regarding the design and conduct of GBM AGILE in China. In
the event that NMPA recommends additional requirements or criteria for GBM AGILE, then &#147;successful completion of GBM AGILE&#148; shall also require that such additional requirements or criteria are met by GBM AGILE. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit E: Pharmacovigilance Terms </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Definitions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this <B>Exhibit
E</B>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Adverse Event</B>&#148; means an untoward medical occurrence in a patient or clinical investigation subject administered a Product and
which does not necessarily have to have a causal relationship with this treatment. An Adverse Event can therefore by any unfavourable and/or unintended sign (including an abnormal laboratory find, for example), symptom, or disease temporarily
associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events may also include pre- or post-treatment complications that occur as a result of protocol mandated procedures, lack of
efficacy, overdose or drug abuse/misuse reports. Pre- existing events that increase in severity or change in nature during or as a consequence of participation in a clinical study with all be considered Adverse Events; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the U.S. Food and Drug Administration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Investigator Brochure</B>&#148; means a comprehensive document summarizing the body of information about an investigational product (&#147;IP&#148;
or &#147;study drug&#148;) obtained during preclinical and clinical development, compiled in accordance with the principles described by the International Committee for Harmonisation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SUSAR</B>&#148; means a serious, unexpected or suspected Adverse Reaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Reporting to Regulatory Authorities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere shall be responsible for all necessary safety data reporting to Regulatory Authorities within the Territory, in accordance with applicable Laws. Kazia
shall be responsible for all necessary safety data reporting to Regulatory Authorities outside the Territory, in accordance with applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
Kazia&#146;s reasonable request, Simcere shall promptly provide a copy of any safety data reported to Regulatory Authorities within the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere shall promptly notify Kazia of any questions, directives, or other communications received from a Regulatory Authority in the Territory in relation to
the safety of the Licensed Product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Adverse Events During Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Adverse Event Collection. </U></B>All Adverse Events occurring during a clinical trial of the Licensed
Product sponsored by Simcere shall be collected in a customary manner, including without limitation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;verbatim
description; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;onset and duration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;treatment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;severity, according to NCI Common Terminology Criteria for Adverse Events; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;relatedness, per investigator assessment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;outcome, and action taken in response to study drug </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere must report this data to Kazia in aggregate, <FONT STYLE="white-space:nowrap">de-identified</FONT> form at the conclusion of the clinical trial, or at
any interim analysis of safety data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>SUSARs. </U></B>Any SUSAR to the Licensed Product must be
reported to Kazia within 72 hours of Simcere becoming aware, even if full information is not available, so that Kazia may satisfy its regulatory obligations to FDA and other Regulatory Authorities. Simcere will reasonably cooperate with Kazia to
investigate any SUSARs, and to resolve any queries from Regulatory Authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Pregnancies.
</U></B>Simcere shall notify Kazia within 24 hours of becoming aware of any patients who become pregnant while being treated with the Licensed Product, or within 28 days of the last dose of the Licensed Product. Simcere will reasonably cooperate
with Kazia to monitor the course and outcome of such pregnancies, and to resolve any queries from Regulatory Authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Clinical Hold. </U></B>In the event of a Regulatory Authority instituting a &#145;clinical hold&#146;
in respect of the Licensed Product, whereby a sponsor is directed to suspend administration of investigational product to trial patients, the Parties will promptly and reasonably collaborate to determine the appropriate course of action in the
Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Adverse Events following obtainment of MA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all post-market monitoring of the Licensed Product in the Territory, Simcere and Kazia shall reach an agreement before filing of a new drug application in
the Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;Simcere&#146;s responsibilities to Kazia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere shall provide to Kazia, in the form of line listings, such safety information as Kazia may reasonably
request for preparation of Development Safety Update Reports or similar reports to Regulatory Authorities. Kazia shall provide Simcere with at least thirty (30)&nbsp;calendar days&#146; notice prior to the data lock point, and Simcere shall provide
the requested information no later than fifteen (15)&nbsp;calendar days after the data lock point. Kazia may request such tabulations at no more than a quarterly frequency. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere shall perform customary surveillance for emerging
safety signals. Any material new safety signals shall be promptly shared with Kazia and the Parties shall cooperate to assess their impact and appropriate responses both in and outside the Territory. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Kazia&#146;s responsibilities to Simcere </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall maintain an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> Investigator Brochure for the Licensed Product, containing customary summaries of safety information and an updated risk-benefit analysis, and shall provide
that Investigator Brochure to Simcere no less than once per annum for their translation and appropriate distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall provide to Simcere a copy of the Development Safety Update Report (DSUR) that is prepared on an
annual basis for submission to the FDA for Simcere&#146;s information and reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall
establish and maintain a global safety database for the Licensed Product and shall perform customary surveillance for emerging safety signals. Any material new safety signals shall be promptly shared with Simcere and the Parties shall cooperate to
assess their impact and appropriate responses in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia shall promptly notify Simcere of
any SUSARs occurring in clinical trials of the Licensed Product outside of the Territory, and shall reasonably assist Simcere in reporting such events to IRBs, Regulatory Authorities, investigators, and other relevant parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;General obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall have in place customary and appropriate policies, standard operating procedures, processes,
and personnel to ensure that it is able to satisfy its obligations under this <B>Exhibit E </B>and under applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;All safety information exchanged under this <B>Exhibit E </B>shall be considered Confidential Information of
the Disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;English will be used as the common language for all safety information exchanged
between the Parties. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit F: Supply Terms </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp; Definitions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this
<B>Exhibit F</B>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Accepted Purchase Order</B>&#148; has the meaning given to it in item 3.2(a) of this <B>Exhibit F</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Defective Product</B>&#148; has the meaning given to it in item 5.3(b) of this <B>Exhibit F</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Defective Products Notice</B>&#148; has the meaning given to it in item 5.3(b) of this <B>Exhibit F</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Delivery Point</B>&#148; means a port in the Territory designated by Simcere; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Forecast&#148; </B>has the meaning given to it in item 4 of this <B>Exhibit F</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>GMP</B>&#148; means then-current applicable standards for the manufacture of pharmaceutical products, including, as applicable, the standards
detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, European Directive 2003/94/EC and Eudralex 4, ICH Q7 ICH guidance Q7 Good Manufacturing Practices, the PIC/S Guide to Good Manufacturing
Practice for Medicinal Products, <FONT STYLE="white-space:nowrap">PE009-8,</FONT> published by the Pharmaceutical Inspection Convention and Pharmaceutical Inspection <FONT STYLE="white-space:nowrap">Co-operation</FONT> Scheme dated 15&nbsp;January
2009 (as adopted by Therapeutics Goods (Manufacturing Principles) Determination No.&nbsp;1 of 2013), and corresponding regulations in the Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Minimum Lead Time</B>&#148; means the minimum period between the date of submitting a Purchase Order to Kazia and the delivery date for the Compound
or Product, as the case may be, being three (3)&nbsp;months; provided that the initial supply of the Compound and Product shall be provided as soon as possible to enable Simcere to start Development work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Price</B>&#148; means a price set out in Section&nbsp;4.9(a) of the Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Purchase Order</B>&#148; has the meaning given to it in item 3.1 of this <B>Exhibit F</B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp; Obligation to Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of any other provision of this Agreement, Kazia is not required to supply any Compound or Product to Simcere at any time when: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia is not able to obtain or have manufactured Compound or Product; provided that if the Compound or
Product is in short supply, Kazia shall allocate the available Compound and Product equitably between Kazia, Simcere and other third parties to whom Kazia&#146;s has supply obligations, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis
based on forecasted requirements; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere has not paid for Compound or Product previously
supplied by Kazia for which payment is then due, unless the amount unpaid is the subject of a dispute in good faith and only that portion in dispute is unpaid; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;there has been any other material breach of this Agreement by Simcere that has not been duly remedied. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Orders </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Purchase Orders. </B>Simcere must order Compound and Products by completing a purchase order in the form
approved (which approval not to be unreasonably withheld) by Kazia (&#147;<B>Purchase Order</B>&#148;) and submitting it to Kazia by email. All Purchase Orders submitted by Simcere to Kazia must (a)&nbsp;specify the quantity of Compound and/ or
Product required by Simcere, and (b)&nbsp;specify a delivery date that is no earlier than the Minimum Lead Time after the date of the Purchase Order. All Purchase Orders shall be governed exclusively by the terms of this Agreement, and any term or
condition in any purchase order, confirmation, invoice or other document furnished by Simcere or Kazia that is in any way inconsistent with the terms and conditions set forth in this Agreement is hereby expressly rejected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;Acceptance of Purchase Orders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless Simcere is in breach of any term of this Agreement (including that the Purchase Order fails to take
into account at least the Minimum Lead Time) and subject to item 2(a) of this <B>Exhibit F </B>in case of short supply and item 3.2(b) of this <B>Exhibit F </B>for Purchase Order that differs materially from Forecast, Kazia will use best endeavours
to accept Purchase Orders which are within the Forecasts. On acceptance by Kazia, the Purchase Order becomes an Accepted Purchase Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Kazia may reject a Purchase Order in whole or in part if the amount of Compound or Product ordered is
materially different (i.e. greater than twenty percent (20%) difference) to the quantity of the Compound or Product set out for that particular quarter in the applicable Forecast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Unfilled Purchase Order.</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>If Kazia is, or expects to be, unable to
satisfy a Purchase Order placed by Simcere under item 3.1 of this <B>Exhibit F</B>, whether before or after Kazia has accepted that Purchase Order under item 3.2 of this <B>Exhibit F </B>(a)&nbsp;Kazia must immediately notify Simcere of that fact,
and (b)&nbsp;Simcere may cancel all or part of the relevant Purchase Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cancellation or
suspension of Accepted Purchase Orders. </B>Subject to item 3.3 of this <B>Exhibit F</B>, an Accepted Purchase Order cannot be cancelled or suspended by either Party without the other Party&#146;s prior written agreement and, in the case of
cancelation or deferral by Simcere, then only on terms that Simcere will fully reimburse Kazia for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost (including manufacturing cost) incurred by
Kazia as a result of that cancellation or deferral. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Forecasts </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere must provide to Kazia each calendar quarter during the Term unless and until Simcere itself commences Manufacturing or having Manufactured Compound or
Product (as the case may be) in accordance with Section&nbsp;4.9(b) of the Agreement, a rolling yearly forecast (broken down to quarter level) of Simcere&#146;s anticipated volume requirements for the Compound and Product
(&#147;<B>Forecast</B>&#148;). The Forecast represents Simcere&#146;s estimate of requirements and is not binding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delivery of Finished Products </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Delivery. </B>Kazia will use reasonable endeavours to deliver the Compound and Products the subject of an
Accepted Purchase Order to the Delivery Point at the date specified therein. Kazia will not be liable for any loss of any kind whatsoever caused directly or indirectly by any failure to deliver or any delay in delivery that is outside Kazia&#146;s
control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Title and risk. </B>Title to the Compound and Product will pass to Simcere from Kazia on
payment in full by Simcere to Kazia in relation to the Compound or Product, as the case may be. Risk in the Compound and Product will pass to Simcere from Kazia on delivery of the Compound or Product, as the case may be, to the Delivery Point. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defective Products </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Simcere will use reasonable efforts to conduct a visual inspection of the Compound and Product on delivery.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If Simcere believes that any Compound or Products were, at the time of delivery, damaged or defective
(&#147;<B>Defective Products</B>&#148;), within thirty (30)&nbsp;business days of delivery of the Compound or Products (or ten (10)&nbsp;business days after the discovery of the defect for <FONT STYLE="white-space:nowrap">non-obvious</FONT> defects
not reasonably susceptible to discovery upon receipt), Simcere may issue a written notice to Kazia rejecting the Defective Products (&#147;<B>Defective Products Notice</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Following receipt by Kazia of a Defective Products Notice, Kazia may at its own cost (i)&nbsp;request access
to Simcere&#146;s premises and inspect the Defective Products, and/or (ii)&nbsp;instruct Simcere to either return the Defective Products to Kazia (or a designated third party) or to dispose of the Defective Products and Simcere must comply with such
request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the cause of the Compound or Products being Defective Products was not to any extent caused
by Simcere, Kazia must pay the cost of the return or disposal of the Defective Products undertaken in accordance with item 5.3(c)(ii) of this <B>Exhibit F </B>and, at Simcere&#146;s option, either refund to Simcere any payments made by Simcere in
respect of any Defective Products or replace the Defective Products. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;</B>If the cause of the Compound or Products being Defective
Products was partly or solely caused by Simcere, Simcere must pay a portion of (i)&nbsp;the cost of the return or disposal of the Defective Products undertaken in accordance with item 5.3(c)(ii) of this <B>Exhibit F</B>, and (ii)&nbsp;the invoice
relating to the Defective Products; which portion represents the extent to which Simcere&#146;s action or inaction caused the Compound or Products to be Defective Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the Parties do not agree whether a Product is Defective Product or the cause thereof, the Parties shall
engage a mutually agreed independent third party laboratory to examine the Product in question.&nbsp;&nbsp;&nbsp;&nbsp;The conclusion of such laboratory shall be final and binding upon the Parties, and the Party in error shall bear the cost of such
laboratory examination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Price, Invoicing and Payment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere must pay to Kazia the Price for all Compound and Product that is delivered to Simcere in accordance with an Accepted Purchase Order. On, or within
fifteen (15)&nbsp;days from the delivery of the Compound or Products to the Delivery Point, Kazia must provide an invoice to Simcere for the Price of the Compound or Products. Simcere must pay Kazia the amount invoiced within thirty (30)&nbsp;days
after the later of the date on which Simcere receives the invoice and the Compound and/or Products (including customs clearance documents). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<B>Manufacture Cost Audit. </B>Simcere shall have the right (similar to Section&nbsp;5.11) to audit and confirm the Manufacturing
Cost of the Product supplied by Kazia </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<B>Regulatory/Quality Audit</B>. Simcere shall have the right (similar to
Section&nbsp;4.13) to audit the regulatory, quality and compliance systems, procedures and practices of Kazia (and its contractor manufacturers, subject to Kazia&#146;s audits rights under any agreement with its contractor manufacturer) relating to
the Manufacture and supply of the Product. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Exhibit H:&nbsp;&nbsp;&nbsp;&nbsp;Expert Determination </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delivering a Dispute Notice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;If Simcere and Kazia have been unable to resolve any dispute arising between them in relation to any
underpayment or overpayment reported by an Auditor under Section&nbsp;5.11(d) (a &#147;<B>Financial Dispute</B>&#148;), then Simcere or Kazia may refer the Financial Dispute to an Expert for determination in accordance with this this <B>Exhibit
H</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;</B>For the purposes of this <B>Exhibit H</B>, the <B>Expert </B>is a person: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;having appropriate qualifications and experience relevant to determining the Financial Dispute; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;who is agreed by the Parties or, failing agreement within five (5)&nbsp;business days, is nominated at the
request of any Party by the Chinese Institute of Certified Public Accountants (&#147;<B>CICPA</B>&#148;) in accordance with CICPA&#146;s rules and procedures (<B>Rules</B>); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;</B>who does not act, or whose firm does not act, generally for any Party. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Determination by Expert </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Expert: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;must conduct its determination in accordance with the Rules, which Rules are taken to be incorporated into
this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;</B>will act as an expert and not as an arbitrator; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;may determine the time, place and procedures (which will be as informal as is consistent with the proper
conduct of the matter) for the determination by the Expert, having regard to the nature of the Financial Dispute and the provisions of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;</B>may communicate privately with the Parties or with their lawyers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;</B>may or may not allow the appearance of lawyers on behalf of the Parties; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;</B>may accept written submissions from a Party in relation to the Financial Dispute, provided a copy of the
submission is also given to all other Parties; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;</B>may <FONT STYLE="white-space:nowrap">co-opt</FONT> other
expert assistance; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;must have regard to the fairness and reasonableness of any
matters pertaining to the Royalty Dispute; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;must deal with any matter as expeditiously as possible
and by no later than twenty (20)&nbsp;Business Days after referral to the Expert. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligations of Parties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Expert is required to resolve a Financial Dispute: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Expert&#146;s determination will, except in the case of manifest error, be final and binding on the Parties;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Parties must attend the sessions with the Expert and make a determined and genuine effort to resolve
the Financial Dispute as soon as reasonably possible; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;without limiting item 3(b) of this <B>Exhibit
H</B>, the Parties must use their best endeavours to make available to the Expert all information relevant to the Financial Dispute and which the Expert reasonably requires in order to resolve the Financial Dispute; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;everything that occurs before the Expert must be in confidence and in closed session; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;</B>all discussions must be without prejudice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;each Party must pay its own costs of complying with this <B>Exhibit H </B>and the costs of the Expert and any
other costs of complying with this <B>Exhibit H </B>must be shared half as to Simcere and half as to Kazia; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Parties must continue performing their obligations under this Agreement while the Financial Dispute is
being resolved. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Proceedings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Party may not commence court proceedings in respect of a Financial Dispute unless it has complied with the terms of the Agreement, and if applicable until
the procedures in this <B>Exhibit H </B>have been followed in full, except where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Party seeks injunctive
relief in relation to a Financial Dispute from an appropriate court where failure to obtain such relief would cause irreparable damage to the Party concerned; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;following those procedures would mean that a limitation period for a cause of action relevant to the issues
in dispute will expire. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Exhibit I:&nbsp;&nbsp;&nbsp;&nbsp;Inquires made by Kazia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of Kazia&#146;s license agreement with Genentech (October 2016):- </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Review of prior art documents cited in International Search Report </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Review of prior art documents cited in US prosecution </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Review of prior art documents citied in European application </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Review of patent agency correspondence in key territories </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consultation with inventor (Dr Alan Olivero) </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.20
<SEQUENCE>4
<FILENAME>d185056dex420.htm
<DESCRIPTION>EX-4.20
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.20 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (&#147;[***]&#148;) BECAUSE
THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY
AND BETWEEN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EVOTEC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This LICENSE AGREEMENT (this &#147;<B>Agreement</B>&#148;) is entered into by and between Kazia Therapeutics Limited (ACN 063 259 754), a
company existing under the laws of Australia, having a place of business at Three International Towers, L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (&#147;<B>Kazia</B>&#148;), and Evotec (France) SAS, a company existing under the laws of
France, having a place of business at 195 Route d&#146;Espagne, 31036 Toulouse, France (&#147;<B>Evotec</B>&#148;). Each of Evotec and Kazia is sometimes referred to individually herein as a &#147;<B>Party</B>&#148; and collectively as the
&#147;<B>Parties</B>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Evotec and/or its Affiliates have developed and/or <FONT STYLE="white-space:nowrap">in-licensed</FONT> under a license agreement
between Evotec and Sanofi dated 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> July 2015 (&#147;<B>Sanofi License</B>&#148;) certain technology, patent rights and proprietary materials related to
<FONT STYLE="white-space:nowrap">EVT-801,</FONT> a <FONT STYLE="white-space:nowrap">pre-clinical-stage,</FONT> small molecule, orally available inhibitor of VEGFR3 for treating, preventing or delaying onset or progression of diseases in humans or as
biomarkers or stratification makers; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Kazia desires to obtain from Evotec, and Evotec is willing to grant to Kazia exclusive
rights to, and associated intellectual property in such molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants contained
herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>DEFINITIONS</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified herein
and therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Adverse Event</B>&#148; means any untoward medical occurrence in a Clinical Trial
subject or patient who is administered a Product, whether or not considered related to such Product, including any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or disease associated with the use of such
Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any Party, any other Person that, directly or
indirectly, controls, or is controlled by, or is under common control with, such Party. For purposes of this definition, &#147;control&#148; (including, with correlative meaning, the terms &#147;controlled by&#148; and &#147;under the common
control&#148;) means (a)&nbsp;ownership of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation, or more than fifty percent (50%) of the equity interests in the case of any
other type of legal entity, or, with respect to either of the foregoing, such lesser maximum percentage permitted in those jurisdictions where majority ownership by foreign entities is prohibited, (b)&nbsp;status as a general partner in any
partnership, or (c)&nbsp;any other arrangement whereby a Person controls or has the right to control the board of directors of a corporation or equivalent governing body of an entity other than a corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Annual Net Sales</B>&#148; means, with respect to any
Calendar Year, the aggregate amount of the Net Sales of Product sold in the Territory in such Calendar Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Applicable Laws</B>&#148; means any national, federal, state or local laws, treaties, statutes,
ordinances, rules and regulations, including any rules, regulations, guidance, guidelines or requirements of any Regulatory Authority having the binding effect of law, or of any national securities exchange or securities listing organization on
which a Party&#146;s or its Affiliates&#146; stock is publicly traded, or other government authority (other than a Regulatory Authority), legislative body or commission that are in effect from time to time during the Term and applicable to a
particular activity under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means any day other than a Saturday,
Sunday or public holiday in Germany and Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Quarter</B>&#148; means the period
beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls, and thereafter each successive period of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30,
September&nbsp;30 and December 31; provided that the final Calendar Quarter shall end on the last day of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Year</B>&#148; means the period beginning on the Effective Date and ending on December 31 of the
calendar year in which the Effective Date falls, and thereafter each successive period of twelve (12)&nbsp;months commencing on January&nbsp;1 and ending on December 31; provided that the final Calendar Year shall end on the last day of the Term.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Challenge</B>&#148; means any challenge to the validity or enforceability of any of the Licensed
Patent Rights, including without limitation by (a)&nbsp;filing a declaratory judgment action, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or for an enjoinment, injunction or any other equitable
remedy in which any of the Licensed Patent Rights is alleged to be invalid, not infringed or unenforceable, (b)&nbsp;citing prior art pursuant to 35 U.S.C. &#167;301 or third party submission pursuant to 35 U.S.C. &#167;122, filing third party
observations in any of the Licensed Patent Rights, or (c)&nbsp;filing any interference, derivation proceeding, reexamination, <I>inter partes </I>review, opposition, cancellation, nullity or similar proceedings against or based on any of the
Licensed Patent Rights in any country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clinical Trial</B>&#148; means, collectively, any Phase 1
Clinical Trial, Phase 2 Clinical Trial or Phase 3 Clinical Trial, as applicable, conducted by or on behalf of a Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Combination Product</B>&#148; means a single Product that includes, in combination with a Licensed
Product, one or more therapeutically-active ingredients other than the Licensed Product that are sold in a single package or as a unit at a single price either as a fixed dosage form or as separate dosage forms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means any and all activities directed to
the offering for sale and sale of a Product after Marketing Authorization has been received with respect to that Product, including (a)&nbsp;activities directed to marketing, promoting, detailing, distributing, importing, selling and offering to
sell that Product, (b)&nbsp;conducting approved investigator-initiated Clinical Trials and/or any other Clinical Trials with respect to that Product with respect to which Marketing Authorization has been received or for a use that is subject of an
investigator-initiated Clinical Trial, (c)&nbsp;interacting with Regulatory Authorities regarding the above, (d)&nbsp;seeking pricing approvals and reimbursement approvals (as applicable) for that Product in the Territory, and (e)&nbsp;undertaking
health economics studies and other activities designed in order to achieve favorable pricing approvals and reimbursement approvals for that Product in the Territory. When used as a verb, &#147;<B>to Commercialize</B>&#148; and
&#147;<B>Commercializing</B>&#148; means to engage in Commercialization and &#147;Commercialized&#148; has a corresponding meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the Research, Development, Manufacture
or Commercialization of any Licensed Product, as applicable, the efforts and resources that are consistent with those used by a Party in the research, development, manufacture or commercialization of compounds and products of comparable market
potential as such Licensed Product, taking into account all relevant factors including, as applicable, the stage of development, efficacy and safety relative to competitive products in the marketplace, actual or anticipated Regulatory Authority
approved labeling, the nature and extent of market exclusivity (including patent coverage and regulatory exclusivity), the cost and likelihood of obtaining Marketing Authorization, and actual or projected profitability. For purposes of clarity,
Commercially Reasonable Efforts is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">market-by-market</FONT></FONT> basis for each Licensed Product or particular Product, and it is anticipated that the level of effort
may be different for different markets and may change over time, reflecting changes in the status of each Licensed Product or Product and the market(s) involved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148; means (a)&nbsp;the
terms of this Agreement and its subject matter, (b) all Licensed Technology, and (c)&nbsp;all information, Technology and Proprietary Materials belong to or relating to a Party, whether oral, graphic, electronic, written or in any other form, that
is or should reasonably be regarded as confidential to the Party to whom it belongs or relates and that is disclosed or provided by or on behalf of a Disclosing Party to a Receiving Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means (a)&nbsp;with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license, sublicense, access or other right to such Technology or Patent Rights as provided herein, and (b)&nbsp;with respect to Proprietary Materials, the possession by a Party of the right
to supply, or grant access or another right to, such Proprietary Materials to the other Party as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cover</B>&#148; or &#147;<B>Covered</B>&#148; or &#147;<B>Covering</B>&#148; means, with respect to any
Patent Rights, Licensed Product or Product, that the use, import, manufacture or sale of such Licensed Product or Product in a particular country by an unlicensed Third Party would infringe a Valid Claim within such Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CTA</B>&#148; means (a)&nbsp;a Clinical Trial application or any successor application or procedure
required to initiate clinical testing of a Product in humans in the Territory in accordance with Applicable Laws, and (b)&nbsp;all supplements and amendments to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development</B>&#148; or &#147;<B>Develop</B>&#148; means, with respect to a Licensed Product or Product,
(a)&nbsp;all <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical drug development activities that are undertaken after the Initiation of the first GLP-toxicology study for such Licensed Product in order to file and maintain a
Regulatory Filing or obtain Marketing Authorization for such Licensed Product or Product in the Territory up to the date of receipt of Marketing Authorization with respect to that Licensed Product or Product, including toxicology and pharmacology
testing, the conduct of chemistry manufacturing and controls, test method development and stability testing, process development (including the manufacture of validation and engineering batches), formulation development, delivery system development,
quality assurance and quality control development, statistical analysis and report writing; the conduct of Clinical Trials; preparing and filing and all regulatory affairs related to the foregoing, and (b)&nbsp;the conduct of manufacturing
development activities. When used as a verb, &#147;<B>Developing</B>&#148; means to engage in Development and &#147;<B>Developed</B>&#148; has a corresponding meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Disclosing Party</B>&#148; means a Party to whom information belongs or relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Distributor</B>&#148; means any Person that purchases any Product from Kazia or any of Kazia&#146;s
Affiliates or Sublicensees for the purpose of reselling that Product to end users in the Territory (including any wholesalers, pharmacists or hospitals). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>DMF</B>&#148; means a Drug Master File maintained with a Regulatory Authority in any country within the
Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Effective Date</B>&#148; means the date of last signature under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency or authority thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FDA</B>&#148; means the United States Food and Drug
Administration, or any successor agency or authority thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FDCA</B>&#148; means the United States
Federal Food, Drug, and Cosmetic Act, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field</B>&#148; means all therapeutic,
prophylactic and diagnostic uses in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>First Commercial Sale</B>&#148; means, with respect to
any Product in any country in the Territory, the first sale, transfer or disposition for value of that Product in that country after Marketing Authorization for the Product has been received in that country; provided that the following shall not
constitute a First Commercial Sale: (a)&nbsp;any sale by Kazia to an Affiliate, Sublicensee or Distributor (unless the Affiliate, Sublicensee or Distributor is the last entity in the distribution chain of the Product), (b) any use of a Product in
Clinical Trials, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or other Research or Development activities, or (c)&nbsp;the disposal or transfer of Products for a bona fide charitable purpose, including compassionate use and/or
&#147;named patient sales&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Force Majeure</B>&#148; means any occurrence beyond the reasonable
control of a Party that (a)&nbsp;prevents or substantially interferes with the performance by such Party of any of its obligations hereunder, and (b) occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor
dispute, casualty or accident, or war, revolution, civil commotion, epidemic, pandemic, act of terrorism, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or of any
subdivision, authority or representative of any such government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GLP</B>&#148; means the
then-current Good Laboratory Practice Standards promulgated or endorsed by the FDA or in the case of any other country in the Territory, comparable regulatory standards promulgated or endorsed by that country, including those procedures expressed in
or contemplated by any Regulatory Filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GMP</B>&#148; means the then-current Good Manufacturing
Practices that apply to the Manufacture (including clinical or commercial supply ) of each Licensed Product, including where applicable the United States regulations set forth under Title 21 of the United States Code of Federal Regulations, parts
210 and 211, as may be amended from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> as well as all applicable guidance published from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> by the FDA and the ICH Guidelines ICHQ7A Good Manufacturing Practice Guidance for the principles and guidelines of Good Manufacturing Practices for
Medicinal Products as defined with EC Directive 2003/94/EC and associated EC Guide to Good Manufacturing Practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GCP</B>&#148; means the then-current good clinical practice applicable to the clinical Development of any
Licensed Product or Product under Applicable Laws, including as applicable the ICH guidelines and U.S. Good Clinical Practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.31&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hatch-Waxman Act</B>&#148; means the Drug Price Competition and Patent Term Restoration Act of 1984, as
amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.32&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ICH</B>&#148; means the International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.33&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Improvement</B>&#148; means any improvement, enhancement,
modification, adaptation, extension, development, mutation, application of and all other technical advances made by or on behalf of a Person, whether or not protected by statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.34&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND</B>&#148; means (a)&nbsp;an investigational new drug application as defined in the FDCA and
regulations promulgated thereunder or any successor application or procedure required to initiate clinical testing of a Licensed Product or Product in humans in the United States; (b)&nbsp;a foreign equivalent of an investigational new drug
application that is required in any other country or region in the Territory before beginning clinical testing of a Licensed Product or Product in humans in such country or region; and (c)&nbsp;all supplements and amendments to any of the foregoing.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.35&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indirect Taxes</B>&#148; means VAT, sales taxes,
consumption taxes and other similar taxes required by law to be disclosed on an invoice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.36&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initiation</B>&#148; means (a)&nbsp;with respect to a study, the commencement of such study, or
(b)&nbsp;with respect to a Clinical Trial, the date on which the first subject or patient is dosed in such Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.37&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Knowledge</B>&#148; means, with respect to a Party, the actual knowledge of the officers of such Party.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.38&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Patent Rights</B>&#148; means the Patent Rights listed on <U>Exhibit A</U> attached hereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.39&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Product</B>&#148; means <FONT STYLE="white-space:nowrap">EVT-801</FONT> a <FONT
STYLE="white-space:nowrap">pre-clinical-stage,</FONT> small molecule, orally available inhibitor of VEGFR3 as set out in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.40&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Technology</B>&#148; means (a)&nbsp;Technology Controlled or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> by Evotec or its Affiliates at the Effective Date which is reasonably required by Kazia for the Research, Development, Manufacture or Commercialization of the Licensed Product or Products as listed
on <U>Exhibit A</U>, and (b)&nbsp;pursuant to Section&nbsp;9.4, any Improvements thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.41&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>MAA</B>&#148; means any application for Regulatory Approval submitted to the EMA pursuant to the
centralized approval procedure to obtain European Commission approval for the marketing of a Product in the European Union, or any successor application or procedure required to sell a Product in the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.42&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; or &#147;<B>Manufactured</B>&#148; means all
activities related to the production of any clinical or commercial quantities of Licensed Product or Product, including, the manufacture, receipt, inspection, storage and handling of materials, and the manufacture, processing, purification,
packaging, labeling, warehousing, quality control testing (including <FONT STYLE="white-space:nowrap">in-process</FONT> release and stability testing), shipping and release of each such Licensed Product or Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.43&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Marketing Authorization</B>&#148; means, with respect to any Product, the Regulatory Approval required by
Applicable Laws to Commercialize such Product for use in a country or region in the Territory. For purposes of clarity (a) &#147;Marketing Authorization&#148; in the United States means final approval of an NDA or biological license application
permitting marketing of such Product in interstate commerce in the United States, and (b) &#147;Marketing Authorization&#148; in the European Union means marketing authorization for such Product granted either by a Regulatory Authority in any
European Country or by the EMA pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.44&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NDA</B>&#148; means a New Drug Application, as defined in the FDCA and regulations promulgated
thereunder, or any successor application or procedure required to sell a Licensed Product or Product in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.45&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148; means the gross invoiced amount on sales of the Products by or on behalf of Kazia and
its Affiliates and Sublicensees to Third Parties after deduction of the following amounts, to the extent taken (a) normal and customary trade, quantity or prompt settlement discounts (including chargebacks and allowances) actually allowed,
(b)&nbsp;amounts repaid or credited by reason of rejection, returns or recalls of goods, rebates or bona fide price reductions determined by Kazia or its Affiliates in good faith, (c)&nbsp;rebates and similar payments made with respect to sales paid
for by any Regulatory Authority such as, by way of illustration and not in limitation of the Parties&#146; rights hereunder, Federal or state Medicaid, Medicare or similar state program in the United States or equivalent governmental program in any
other country; (d)&nbsp;excise taxes, Indirect Taxes, customs duties, customs levies and import fees imposed on the sale, importation, use or distribution of the Products; for clarity, the portion of any annual fee on prescription drug manufacturers
imposed by the United States Patient Protection and Affordable Care Act, Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;111-148</FONT> (as amended) or other similar governmental fee based on revenues from pharmaceutical products that may be
allocated by Kazia, its Affiliates or its Sublicensees to sales of the Products shall not be considered for the purpose of this definition of Net Sales; (e)&nbsp;reasonable charges for insurance, freight, transportation costs directly related to the
delivery of the Product; (f)&nbsp;any other similar and customary deductions that are consistent with international financial reporting standards, or other applicable accounting standards. Net Sales shall be calculated using Kazia&#146;s internal
audited systems used to report such sales as adjusted for any of items (a)&nbsp;to (f) above not taken into account in such systems. Deductions pursuant to subsection (d)&nbsp;above are taken in the Calendar Quarter in which such sales are no longer
recorded as a receivable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net Sales for a Combination Product shall be calculated by multiplying the actual Net Sales of such
Combination Product in any country by the fraction A/(A+B), where A is the average gross invoice price in such country of a Product, containing the same amount of Licensed Product as the sole active ingredient as the Combination Product in question
(a &#147;<B>Comparable Product</B>&#148;), if sold separately, and B is the average gross invoice price in the given country of the ready for sale form of a product containing the same amount of the other therapeutically active ingredient(s) in the
Combination Product that are not Licensed Products (the &#147;<B>Other Ingredients</B>&#148;), if sold separately. If, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the Other
Ingredients are not sold separately in a country, Net Sales in such country for the purpose of determining royalties of the Combination Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the
fraction A/C where A is the average gross invoice price in such country of a Comparable Product, if sold separately, and C is the average gross invoice price of the Combination Product in such country. If, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a Comparable Product is not sold separately, Net Sales in such country for the purpose of determining royalties of the Combination Product shall be calculated by multiplying actual
Net Sales of such Combination Product by the fraction <FONT STYLE="white-space:nowrap">(C-B)/C,</FONT> where B is the average gross invoice price in such country of the Other Ingredients and C is the average gross invoice price in such country of
the Combination Product. For the purpose of the above, the average gross invoice price for a Comparable Product and for each Other Ingredient shall be for a quantity comparable to that used in the Combination Product in question and of the same
class, purity and potency. If, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, neither a Comparable Product nor the Other Ingredients are sold separately in a country, Net Sales in such
country for the purposes of determining royalties of such Combination Product shall be determined based on the ratio of the cost of the Licensed Product in the Combination Product to the sum of the cost of the Licensed Product in the Combination
Product and the cost of the Other Ingredients in the Combination Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.46&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Costs</B>&#148;
means the reasonable external costs and expenses incurred by Evotec(including reasonable attorneys&#146; fees) in preparing, filing, prosecuting or maintaining any Licensed Patents Rights in accordance with this Agreement. The Parties acknowledge
that such costs may include reasonable pass through costs incurred by Sanofi in it preparing, filing, prosecuting or maintaining any Licensed Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.47&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Rights</B>&#148; means the rights and interests in and to issued patents and pending patent
applications (which, for purposes of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional applications, substitutions, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals, all letters patent granted thereon, and all reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> utility models,
supplementary protection certificates, and extensions thereof, and all foreign counterparts of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.48&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or
agency of a government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.49&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 1 Clinical Trial</B>&#148; means a human clinical trial for a Product
in any country that would satisfy the requirements of 21 CFR 312.21(a), or its successor regulation, or the equivalent in any foreign country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.50&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 2 Clinical Trial</B>&#148; means a human clinical
trial conducted in any country that would satisfy the requirements of 21 CFR 312.21(b) or its successor regulation, or the equivalent in any foreign country and is intended to explore the safe and effective dose range for the proposed therapeutic
indication of Product and other characteristics of safety and efficacy, for any Product in a patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.51&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 3 Clinical Trial</B>&#148; means a clinical trial in any country in an extended human patient
population designed to obtain data determining efficacy and safety of any Product to support Regulatory Approvals in a therapeutic indication, as more fully defined in 21 CFR 312.21(c), or its successor regulation, or the equivalent in any foreign
country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.52&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product</B>&#148; means any pharmaceutical or medicinal item, substance, formulation or
dosage that comprises a Licensed Product as the active pharmaceutical ingredient. &#147;Product&#148; includes Combination Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.53&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Proprietary Materials</B>&#148; means any tangible chemical, biological or physical materials that are
Controlled by one Party and (a)&nbsp;are furnished by or on behalf of such Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary by the Party transferring that material, or (b)&nbsp;are
otherwise conceived or reduced to practice by or on behalf of such Party in connection with the Research, Development, Manufacture or Commercialization of Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.54&nbsp;&nbsp;&nbsp;&nbsp;&#148;<B>Receiving Party</B>&#148; means a Party to whom information is disclosed or who possesses or otherwise
acquires information belonging or relating to a Disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.55&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Approval</B>&#148;
means, with respect to any country or region in the Territory, any approval, product and establishment license, registration or authorization of any Regulatory Authority required for the Manufacture, use, storage, importation, exportation, transport
or distribution of a Licensed Product or Product for use in such country or region. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.56&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory
Authority</B>&#148; means any national, international, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity with authority over the distribution, importation, exportation, Manufacture,
production, use, storage, transport, clinical testing, pricing or sale of a Product in the Territory, including the FDA and the EMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.57&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Documentation</B>&#148; means any Regulatory Filings, submission, communications,
correspondence, registrations and other filings made to, received from or otherwise conducted with a Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.58&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Filing</B>&#148; means, collectively (a)&nbsp;any IND, CTA, MAA, establishment license
application, DMF, application for designation as an &#147;Orphan Product&#148; under the Orphan Drug Act, for &#147;Fast Track&#148; status under Section&nbsp;506 of the FDCA (21 U.S.C. &#167; 356) or for a Special Protocol Assessment under
Section&nbsp;505(b)(4)(B) and (C)&nbsp;of the FDCA (21 U.S.C. &#167; 355(b)(4)(B)) and all other similar filings (including counterparts of any of the foregoing in any country or region in the Territory), (b) all supplements and amendments to any of
the foregoing; and (c)&nbsp;all data and other information contained in, and correspondence relating to, any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.59&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Research</B>&#148; means, with respect to each Licensed Product, all research and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> drug development activities that are undertaken with respect to such Licensed Product prior to Initiation of the first <FONT STYLE="white-space:nowrap">GLP-toxicology</FONT> study conducted for such
Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.60&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Royalty Term</B>&#148; means, with respect to each Product in each country of the
Territory, the period beginning on the date of First Commercial Sale of such Product in such country [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.61&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Second Indication</B>&#148; means a claim the subject
of a Regulatory Approval received for a Product that is subsequent to the initial Regulatory Approval received for that Product, which claim is for a disease, disorder or medical condition which the Product can be used to diagnose, treat or prevent
that is separate and distinct from the disease, disorder or medical condition listed in the initial Regulatory Approval for the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.62&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensee</B>&#148; means a Person, other than an Affiliate of Kazia, who is granted a sublicense in
accordance with the provisions of this Agreement. For clarity, any Person to which a Sublicensee grants a further sublicense shall also be a Sublicensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.63&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tax</B>&#148; means any form of tax or taxation, levy, duty, charge, contribution, or withholding of
whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.64&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Technology</B>&#148; means, collectively, inventions, discoveries, improvements, trade secrets and
proprietary methods, whether or not patentable, including: (a)&nbsp;methods of Manufacture or use of, and structural and functional information pertaining to, chemical compounds; and (b)&nbsp;compositions of matter, data, formulations, processes,
techniques, <FONT STYLE="white-space:nowrap">know-how</FONT> and results (including any negative results). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.65&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; means any country or territory in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.66&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; means a Person other than Kazia and Evotec and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.67&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148; means any claim of a pending patent application to the extent such claim continues
to be prosecuted in good faith or an issued unexpired patent that (a)&nbsp;has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b)&nbsp;has not been permanently
revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c)&nbsp;has not been rendered unenforceable
through terminal disclaimer or otherwise, and (d)&nbsp;is not lost through an interference proceeding that is unappealable or unappealed within the time allowed for appeal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.68&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Definitions</B>. In addition, each of the following definitions have the respective meanings set
forth in the section of this Agreement indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Claims</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">13.1.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comparable Product</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.45</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diligence Failure Notice</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosing Party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.18</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evotec</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evotec Diligence Failure</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evotec Indemnitees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">13.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generic Entry</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generic Product</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">13.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnifying Party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">13.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2.1(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement Notice</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2.1(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement Response</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2.1(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Diligence Failure</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Indemnitees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">13.2</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Ingredients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.45</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Coordinator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Party/Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receiving Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.54</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2.1(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supply Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.69&nbsp;&nbsp;&nbsp;&nbsp;<B>List of Exhibits</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit A</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensed Patent Rights
and Licensed Technology (As of the Effective Date) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit
B</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;List of Countries for Patent Filing </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit C</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Structure of <FONT
STYLE="white-space:nowrap">EVT-801</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit
D</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quote from Third Party provider for delivery of Licensed Product </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>RESEARCH</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>AND DEVELOPMENT</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Objectives</U></B>. The objective of conducting the Research and Development activities with respect to the
Licensed Product under this Agreement is to progress Licensed Products and Commercialize Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Kazia
Responsibilities</B>.</U> During Term, Kazia shall use Commercially Reasonable Efforts to conduct Research and Development activities, at its own cost and expense, in order to Commercialize Products. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Evotec Responsibilities.</U> </B>Within sixty (60)&nbsp;days of the Effective Date, Evotec must provide to
Kazia all Licensed Technology that exists on the Effective Date as set out at <B><U>Exhibit A</U></B>, including by (a)&nbsp;providing to Kazia all tangible Licensed Technology and, to the extent possible, copies of documents describing the
intangible Licensed Technology, and (b)&nbsp;otherwise providing Kazia with access to intangible Licensed Technology. Upon Kazia&#146;s reasonable request, for a period of one hundred and twenty (120)&nbsp;days of the Effective Date, Evotec shall
also provide Kazia with reasonable technical assistance in connection with the Licensed Technology provided under this Section&nbsp;2.3, including reasonable access to Evotec&#146;s available technical personnel involved in the Research and
Development of the Licensed Product and Products at no additional cost to Kazia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compliance</U></B>.
Kazia shall perform Research and Development activities for which it is responsible under this Agreement in compliance with all Applicable Laws. In conducting Research and Development activities, Kazia shall comply, as applicable, with GLPs, GMPs or
GCPs (or, if and as appropriate under the circumstances, ICH guidance or other applicable comparable regulation or guidance of any Regulatory Authority in any country or region in the Territory). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Records; Reports</U>.</B> During the Term, Kazia shall maintain complete and accurate records of its Research
and Development activities conducted in relation to the Licensed Product and any Products. Such records shall be kept in sufficient detail and in a manner that reflects all work done and results achieved. Kazia shall inform Evotec in writing of the
progress of its Research and Development activities not less than once each Calendar Year by 31 October. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>MANUFACTURING</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>RIGHT</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Kazia Manufacturing Rights</U>.</B> Kazia shall have the sole right and responsibility, at its sole cost and
expense, to Manufacture and supply and/or obtain from Third Parties such quantities of each Licensed Product and Product as may be required by Kazia, including for all Clinical Trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Assignment of Licensed Product</U>.</B> Evotec herewith assigns to Kazia and Kazia herewith accepts such
assignment of Evotec&#146;s inventory of Licensed Products existing as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Supply
Arrangement.</U></B><B> </B>Kazia and Evotec will separately and in good faith discuss a potential supply agreement in which Evotec shall continue to manufacture Licensed Product on Kazia&#146;s behalf on commercial terms (&#147;<B>Supply
Agreement</B>&#148;). If the Parties enter into a Supply Agreement, Kazia shall consider Evotec as a preferred supplier for any Manufacturing of the Licensed Product and/or supply services of the Licensed Product that are outsourced by Kazia. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>REGULATORY</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>ACTIVITIES</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Responsibility for Regulatory Filings</U>.</B> Kazia shall have the exclusive right and responsibility for
(a)&nbsp;preparing, filing and maintaining all Regulatory Filings for each Product in its own name, (b) to the extent required by Applicable Laws, reporting to Regulatory Authorities any Adverse Events related to a Product that it is reasonably
aware of, and (c)&nbsp;otherwise communicating and interacting with Regulatory Authorities with respect to Products prior and subsequent to Regulatory Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Reports</U></B>. Kazia shall, at its own cost and expense: (a)&nbsp;maintain records of its Regulatory
Filings for each Product; and (b)&nbsp;inform Evotec on the progress of its Regulatory Filings not less than once each Calendar Year by 31 October. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Existing Documentation</U></B>. Within sixty (60)&nbsp;days of the Effective Date, Evotec shall, at its own
cost and expense, assign and provide to Kazia all of the Regulatory Documentation and any available Regulatory Approvals with respect to the Licensed Product Controlled by Evotec, if any, as of the Effective Date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>COMMERCIALIZATION</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>OF PRODUCTS</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Responsibility</U></B>. Kazia shall have the exclusive right and responsibility for Commercialization of
Products in the Territory, at its sole cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Reports</U>.</B> Kazia shall inform Evotec on
the progress of its Commercialization plans not less than once each Calendar Year by 31 October. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Commercialization Diligence</U>.</B> Kazia shall use Commercially Reasonable Efforts during the Term to
(a)&nbsp;Commercialize Products in the Territory and (b)&nbsp;commit such resources (including employees, consultants, contractors, facilities, equipment and materials) as it deems reasonably necessary to Commercialize such Products in the
Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Failure by Kazia to Satisfy Diligence Obligations</U>.</B> Evotec shall have the right, in
its sole discretion, to provide Kazia with written notice if it reasonably believes Kazia has failed to satisfy its diligence obligations under Section&nbsp;5.3 of this Agreement with respect to any Product in any country or countries in the
Territory (a &#147;<B>Kazia Diligence Failure</B>&#148;). Such written notice (a &#147;<B>Diligence Failure Notice</B>&#148;) shall set forth in reasonable detail the nature of the alleged failure and shall request written justification, in the form
of detailed reasons that would support the proposition that Kazia has satisfied such diligence obligations. The Parties shall meet within thirty (30)&nbsp;days after such notice to discuss in good faith Evotec&#146;s concerns and Kazia&#146;s plans
for Development and Commercialization with respect to the applicable Product in the applicable country(ies). If, after such good faith discussions (a)&nbsp;Kazia remains reasonably found by Evotec in material breach of its obligations under
Section&nbsp;5.3 of this Agreement with respect to such Product in such country, and (b)&nbsp;Kazia does not take all reasonable steps designated to rectify such breach within ninety (90)&nbsp;days after meeting with Evotec pursuant to this
Section&nbsp;5.4 (or if such failure cannot be rectified within such ninety <FONT STYLE="white-space:nowrap">(90)-day</FONT> period, if Kazia does not commence actions to rectify such breach within such period and thereafter diligently pursue such
actions), then Evotec shall have the right, in its discretion, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis as to the Product with respect to which such Kazia Diligence Failure
occurred to (i)&nbsp;terminate any or all of the licenses and rights granted under Section&nbsp;8.1.1 hereof with respect to the Product that is the subject of the Diligence Failure Notice, or (ii)&nbsp;convert the licenses and rights granted under
any or all of Section&nbsp;8.1.1 from exclusive licenses to non- exclusive licenses only as such licenses and rights apply to such Product, which termination or conversion, as the case may be, shall be at the discretion of Evotec and be effective
immediately upon issuance by Evotec of written notice to Kazia specifying the remedy that Evotec is electing to exercise under this Section&nbsp;5.4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Failure by Evotec to Satisfy Diligence Obligations.</U>
Evotec must notify Kazia immediately in writing upon receiving a written notice from Sanofi regarding any alleged failure by Evotec to satisfy its diligence obligations under the Sanofi License (&#147;Evotec Diligence Failure&#148;). If such Evotec
Diligence Failure can reasonably be attributed to any action or inaction of Kazia resulting in a Kazia Diligence Failure, the terms of Section&nbsp;5.4 shall apply provided, however, that in such case the time periods set out in Section&nbsp;5.4
shall be adjusted to reflect the time periods applicable to the rectification or otherwise of the Evotec Diligence Failure under the Sanofi License. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>PAYMENTS</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Upfront Payment</U>.</B> In consideration of the rights granted by Evotec to Kazia under this Agreement, Kazia
shall pay Evotec a <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee of 1,000,000.00 (One million) Euros after execution of this Agreement and within thirty (30)&nbsp;Business Days after receipt of a valid tax invoice from Evotec. Such fee
will be unconditional and as such shall not be subject to any offset, credit, reduction or repayment for any reason whatsoever, whether provided for in this Agreement or not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, Kazia will reimburse Evotec (at cost up to [***]) for the purchase of certain Licensed Product that are being purchased by Evotec
from a third party provider similar in all material aspects as per the quotes set out in Exhibit D hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Milestone Payments</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Development and Regulatory Milestones</U>.</B> Subject to Section&nbsp;6.3.4, Kazia shall make the
following <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payments to Evotec within thirty (30)&nbsp;Business Days after receipt of a
valid tax invoice from Evotec issued following the first achievement of the corresponding milestone event by Kazia or its Affiliates or Sublicensees: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><U>Milestone Event</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>Milestone Payment</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>Milestone
Event</U></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Milestone Payment</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">For the avoidance of doubt, the Parties agree that all payments under this Section&nbsp;6.2.1 are payable only once, unless expressly noted.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Sales Milestones</U></B>. In addition to the milestone payments contemplated by Section&nbsp;6.2.1, Kazia shall make the following one-time, non-refundable, non-creditable payments to Evotec within
thirty (30) Business Days after receipt of a valid tax invoice from Evotec issued following the first achievement of the corresponding milestone event by Kazia or its Affiliates or Sublicensees:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Milestone Event</U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">[***]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Parties agree that all payments under this Section&nbsp;6.2.2 are payable only once. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notice of Milestones</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Milestone Events</U>. Kazia shall provide Evotec with prompt written notice upon the occurrence of
each milestone event set forth in this Section&nbsp;6.2. If Evotec believes any such milestone event has occurred and has not received a written notice of same from Kazia, it shall so notify Kazia in writing and shall provide to Kazia documentation
or other information that supports its belief. Any dispute under this Section&nbsp;6.2.3(a) that relates to whether or not a milestone event has occurred shall be resolved in accordance with Section&nbsp;14.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment of Royalties; Royalty Rates; Accounting and Records</U>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment of Royalties</U></B>. Kazia shall pay Evotec a royalty amount on Annual Net Sales in each Calendar
Year of the Term, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, commencing with the First Commercial Sale of such Product in any country in the Territory and ending upon the last day
of the last Royalty Term for such Product, at the following rates: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Annual Net Sales within first 24 months from First</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><U>Royalty&nbsp;Rate&nbsp;(%)</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.71em; font-size:10.5pt; font-family:Times New Roman"><B><U>Commercial Sale</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All amounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Annual Net Sales Increment following 24 months</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><U>Royalty&nbsp;Rate&nbsp;(%)</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.71em; font-size:10.5pt; font-family:Times New Roman"><B><U>from First Commercial Sale</U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Royalty Adjustment for Third Party Intellectual Property</U></B>. If Kazia
or its Affiliates or their Sublicensees, as applicable, determines, in its reasonable judgment, that it is necessary to obtain a license from any Third Party (a &#147;<B>Third Party License</B>&#148;) under any Valid Claim in order to avoid
potential infringement or misappropriation of such Valid Claim by the importation, sale, manufacture or use of a Licensed Product, then the royalty payment that would otherwise be due in any Calendar Quarter pursuant to Section&nbsp;6.3.1 shall be
reduced, on a Calendar <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Quarter-by-Calendar</FONT></FONT> Quarter basis, by fifty percent (50%) of any royalty amount payable by Kazia or its Affiliates or their Sublicensees in such
Calendar Quarter to such Third Party in consideration for such Third Party License, in the event such Third Party License is obtained by Kazia or its Affiliate or their Sublicensees. Notwithstanding the foregoing, the royalty payment that would
otherwise be due to Evotec pursuant to Section&nbsp;6.3.1 with respect to any particular Calendar Quarter shall not be reduced by more than fifty percent (50%) by operation of this Section&nbsp;6.3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Royalty Adjustment in Certain Circumstances</U></B>. On a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, if in any Calendar Quarter during the Royalty Term following introduction of a
Generic Product in a country (&#147;<B>Generic Entry</B>&#148;) there is no Valid Claim within the Licensed Rights in such country then the applicable royalty payable to Evotec under Section&nbsp;6.3.1 shall be reduced by fifty percent (50%). For
the purposes of this Section&nbsp;6.3.3, &#147;<B>Generic Product</B>&#148; means, with respect to a Product being sold by Kazia and its Affiliates or their Sublicensees or subcontractors, as applicable, any pharmaceutical product containing the
same Licensed Product as that contained in such Product (and the same other active ingredient(s), as applicable, in the case of a Combination Product) which is marketed by an entity other than Kazia and its Affiliates or their Sublicensees or
subcontractors, to the extent such Sublicensees or subcontractors are acting in their capacity as sublicensees or subcontractors of Kazia or its Affiliates, in the Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Sublicensing Revenues</B>. If Kazia sublicenses Commercialization rights to any Sublicensee, Kazia shall pay
to Evotec the greater of, at Evotec&#146;s sole discretion, (i)&nbsp;the milestone and royalty payments pursuant to Sections 6.2 and 6.3, or (ii)&nbsp;in lieu of the then outstanding milestone and royalty payments under Sections 6.2 and 6.3, a
percentage of any and all payments received by Kazia or its Affiliates from each such Sublicensee in consideration for such sublicense, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;[***] of any upfront payment received by Kazia from each Sublicensee for a Sublicense granted prior to
Initiation of Phase 2 Clinical Trial; and (b) [***] of any upfront payment received by Kazia from each Sublicensee for a Sublicense granted after Initiation of Phase 2 Clinical Trial; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)&nbsp;&nbsp;&nbsp;&nbsp;[***]&nbsp;of</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Development and Regulatory Milestones received by Kazia from each Sublicensee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)&nbsp;&nbsp;&nbsp;&nbsp;[***]&nbsp;of</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sales Milestones received by Kazia from each Sublicensee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]&nbsp;of any Royalties received by Kazia from each Sublicensee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment Dates and Reports</U></B>. Royalty payments shall be made by Kazia with respect to each Product
within thirty (30)&nbsp;Business Days after the receipt of a valid tax invoice from Evotec issued following the end of each Calendar Quarter in which a sale of such Product occurs, commencing with the Calendar Quarter in which the First Commercial
Sale of such Product occurs. Within 20 Business Days after the end of each Calendar Quarter, Kazia shall provide a report showing (a)&nbsp;the Net Sales of each Product by type of Product and country in the Territory, (b)&nbsp;the total amount of
deductions from gross sales to determine Net Sales, (c)&nbsp;the applicable royalty rates for Product in each country in the Territory after applying any deductions set forth above; and (d)&nbsp;a calculation of the amount of royalty due to Evotec,
taking into account any royalty adjustments under Sections 6.3.2, 6.3.3 and 6.3.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.6&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Records; Audit
Rights</U></B>. Kazia shall, and shall procure that its Affiliates and Sublicensees will, keep and maintain for three (3)&nbsp;years from the date of each payment of royalties hereunder complete and accurate records of gross amounts invoiced and Net
Sales by Kazia and its Affiliates and Sublicensees of each Product, in sufficient detail to allow royalties to be determined accurately. Evotec shall have the right for a period of three (3)&nbsp;years after receiving any royalty payment under this
Section&nbsp;6.3 to appoint at its expense an independent certified public accountant reasonably acceptable to Kazia to audit the relevant records of Kazia and its Affiliates and Sublicensees to verify that the amount of such payment was correctly
determined. Kazia shall make, and shall procure that its Affiliates and Sublicensees make, its records available for audit by such independent certified public accountant during regular business hours at such place or places where such records are
customarily kept, upon thirty (30)&nbsp;days written notice from Evotec. Such audit right shall not be exercised by Evotec more than once in any Calendar Year or more than once with respect to sales of a particular Product in a particular period.
All records made available for audit shall be deemed to be Confidential Information of Kazia. In the event that an underpayment by Kazia hereunder is identified as a result of the audit, Kazia shall promptly (but in any event no later than thirty
(30)&nbsp;days after Kazia&#146;s receipt of any undisputed audit report so concluding) make payment to Evotec of any shortfall.&nbsp;&nbsp;&nbsp;&nbsp;In the event that an overpayment by Kazia hereunder is identified as a result of the audit, then
Kazia may take credit for such overpayment against any future payments due to Evotec (if no future payment is due, then Evotec shall promptly refund such amount to Kazia). Evotec shall bear the full cost of any audit unless such audit discloses an
underreporting by Kazia of five percent (5%) or greater of the aggregate amount of royalties payable in any Calendar Year, in which case Kazia shall reimburse Evotec for all reasonable costs incurred by Evotec in connection with such audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.7&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Overdue Payments</U></B>. All payments not made by Kazia to Evotec when due under this Agreement, shall
bear interest at a rate equal to 5&nbsp;percent (5%) per year from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Laws. Any such overdue payment shall, when made, be accompanied by, and credited first
to, all interest so accrued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.8&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Tax</U></B>. The royalties, milestones and other amounts payable by one
Party to the other Party pursuant to this Agreement (&#147;<B>Payments</B>&#148;) shall not be reduced on account of any Taxes unless required by Applicable Law. Each Party alone shall be responsible for paying any and all Taxes (other than
withholding taxes required by Applicable Law to be paid by Kazia) levied on account of, or measured in whole or in part by reference to, the income of such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.9&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payments; Indirect Taxes</U></B>. All Payments are exclusive of Indirect Taxes. If any Indirect Taxes are
chargeable in respect of any Payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of such Payments following receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by the
receiving Party in respect of those Payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement
purposes.&nbsp;&nbsp;&nbsp;&nbsp;If such amounts of Indirect Taxes are refunded by the applicable Regulatory Authority or other fiscal authority subsequent to payment, the Party receiving such refund shall transfer such amount to the paying Party
within thirty (30)&nbsp;days of receipt. The Parties agree to reasonably cooperate to provide any information required by the Party pursuing a refund of Indirect Taxes paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.10&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Withholding Tax</U></B>. If Applicable Laws require
withholding of income or other taxes imposed upon any payments made by Kazia to Evotec under this Agreement, Kazia shall (i)&nbsp;make such withholding payments as may be required, (ii)&nbsp;subtract such withholding payments from such payments,
(iii)&nbsp;submit appropriate proof of payment of the withholding taxes to Evotec within a reasonable period of time, and (iv)&nbsp;promptly provide Evotec with all official receipts with respect thereto. Kazia shall render Evotec reasonable
assistance in order to allow Evotec to obtain the benefit of any present or future treaty against double taxation which may apply to such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3.11&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Foreign Currency Exchange</U></B>.&nbsp;&nbsp;&nbsp;&nbsp;All payments to be made by Kazia to Evotec under
this Agreement shall be made in Euros and shall be paid by bank wire transfer in immediately available funds to such bank account as may be designated in writing by Evotec from time to time. If, in any Calendar Quarter, Net Sales are made in any
currency other than Euros, such Net Sales shall be converted into Euros as follows: (A/B), where A = foreign Net Sales in such Calendar Quarter expressed in such foreign currency; and B = the applicable foreign exchange conversion rate, expressed in
local currency of the foreign country per Euro (in accordance with the rates of exchange for the relevant month for converting such other currency into Euros used by Kazia&#146;s internal accounting systems, which are independently audited on an
annual basis). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>TREATMENT</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>OF CONFIDENTIAL INFORMATION; PUBLICITY</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Confidentiality</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Confidentiality Obligations</U></B>. Evotec and Kazia each recognize that the other Party&#146;s
Confidential Information and Proprietary Materials constitute highly valuable assets of such other Party. Evotec and Kazia each agrees that subject to Sections 7.1.2 and 7.1.3, during the Term and for an additional five (5)&nbsp;years after
termination or expiration of this Agreement it shall (a)&nbsp;not disclose, and shall cause its Affiliates and Sublicensees not to disclose, any Confidential Information of the other Party, (b)&nbsp;not use, and shall cause its Affiliates and
Sublicensees not to use, any Confidential Information of the other Party, except as expressly permitted in this Agreement, and (c)&nbsp;take all reasonable steps to ensure that any person to whom it discloses Confidential Information under
Section&nbsp;7.1.3 complies at all times with the terms of this Section&nbsp;7 as if that Person were a Receiving Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exceptions</U>. </B>The obligations of confidentiality under Section&nbsp;7.1.1 do not apply to any
Confidential Information that (a)&nbsp;as of the date of disclosure, is known to the Receiving Party or its Affiliates as demonstrated by contemporaneous credible written documentation, other than by virtue of a prior confidential disclosure to such
Receiving Party, (b)&nbsp;as of the date of disclosure is in the public domain, or it subsequently enters the public domain through no fault of the Receiving Party, (c)&nbsp;it is obtained by the Receiving Party from a Third Party having a lawful
right to make such disclosure free from any obligation of confidentiality to the Disclosing Party, (d)&nbsp;it is independently developed by or for the Receiving Party without reference to or use of any Confidential Information of the Disclosing
Party as demonstrated by contemporaneous credible written documentation, or (e)&nbsp;is required to be disclosed as a result of Applicable Law, in which case only that information which must be disclosed in order to comply with Applicable Law should
be disclosed and, where possible, the confidential nature of the disclosed information must be highlighted to the recipient of the disclosed information. Notwithstanding the foregoing, the obligations of confidentially under Section&nbsp;7.1.1 shall
apply to any scientific, technical, manufacturing or financial information of a Party that is disclosed at any meeting of the Parties or disclosed through an audit report. For the avoidance of doubt, any combination of Confidential Information shall
not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and
its principles are in the public domain or in the possession of the Receiving Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Limited Disclosure</U></B>. Evotec and Kazia each agrees
that disclosure of its Confidential Information may be made by a Receiving Party to any employee or consultant of such other Party or its Affiliates or any Third Party subcontractor engaged by a Party to enable such other Party to exercise its
rights or to carry out its responsibilities under this Agreement; provided, that, any such disclosure shall only be made to Persons who are bound by written obligations of confidentiality consistent with those in this Article 7. In addition, Evotec
and Kazia each agrees that a Receiving Party may disclose a Disclosing Party&#146;s Confidential Information (a)&nbsp;on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">need-to-know</FONT></FONT> basis to the Receiving
Party&#146;s legal and financial advisors, (b)&nbsp;as reasonably necessary in connection with an actual or potential (i)&nbsp;permitted sublicense of such Receiving Party&#146;s rights hereunder, (ii)&nbsp;debt or equity financing of such Receiving
Party or (iii)&nbsp;merger, acquisition, consolidation, share exchange or other similar transaction involving such Receiving Party and any Third Party, (c)&nbsp;to any Third Party that is engaged by the Receiving Party to perform services in
connection with the Research or Development of Products or the Commercialization of Products as necessary to enable such Third Party to perform such services, and (d)&nbsp;for any other purpose with the other Party&#146;s consent, which consent
shall not be unreasonably withheld. Furthermore, Evotec and Kazia each agrees that a copy of this agreement is provided to Sanofi within ten (10)&nbsp;days from the Effective Date. Each Party further agrees that a Receiving Party may disclose the
Disclosing Party&#146;s Confidential Information or provide the Disclosing Party&#146;s Proprietary Materials (A)&nbsp;as reasonably necessary or useful to file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related
to Patent Rights, in accordance with this Agreement; (B)&nbsp;as reasonably necessary or useful to obtain government regulatory approval to Develop, Manufacture, transport, or Commercialize a Product; or (C)&nbsp;as required by Applicable Laws;
provided that in the case of any disclosure under (C), the Receiving Party shall (1)&nbsp;if practicable, provide the Disclosing Party with reasonable advance notice of and an opportunity to comment on any such required disclosure and (2) if
requested by the Disclosing Party, cooperate in all reasonable respects with the Disclosing Party&#146;s efforts to obtain confidential treatment or a protective order with respect to any such disclosure, at the Receiving Party&#146;s expense. The
Receiving Party is liable for any breach of this Article 7 by any Person to whom it has disclosed the Disclosing Party&#146;s Confidential Information to as if that Person were the Receiving Party in relation to the Confidential Information
disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Employees and Consultants</U></B>. Evotec and Kazia each hereby represents that all of its
employees and consultants, and all of the employees and consultants of its Affiliates, who have access to Confidential Information or Proprietary Materials of the other Party are or shall, prior to having such access, be bound by written obligations
to maintain such Confidential Information or Proprietary Materials in confidence. Each Party agrees to use, and to cause its Affiliates to use, reasonable efforts to enforce such obligations and to prohibit its employees and consultants from using
such information except as expressly permitted hereunder. Each Party shall be liable to the other for any disclosure or misuse by its employees of Confidential Information or Proprietary Materials of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Publicity</U></B>. Each Party shall be permitted to publicly announce material developments with respect to
any Licensed Product or Product, including the occurrence of any milestone event and the amount of any milestone payment under Section&nbsp;6.2 and any other event with respect to a Licensed Product or Product that such Party reasonably believes is
material; provided that, subject to compliance with the requirements of Applicable Laws: (i)&nbsp;the disclosing Party shall provide the other Party with a draft of any proposed publication at least thirty (30)&nbsp;days prior to the intended
publication; and (ii)&nbsp;if any such disclosure is reasonably likely to affect the ability of the Parties to publish or present data with respect to a Licensed Product or Product or otherwise names the other Party, the disclosing Party shall
obtain the other Party&#146;s prior written consent to the content to such release, which consent shall not be unreasonably withheld, delayed or conditioned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Publications and Presentations</U></B>. Except to the extent required by Applicable Laws, the Parties shall
not publish any scientific or medical publications or give other forms of similar public disclosure, such as abstracts or presentations, relating to the Licensed Product or a Product other than with the other Party&#146;s approval (not to be
unreasonably withheld). If either Party, its employees or consultants wish to make such a publication or presentation, that Party shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at
least thirty (30)&nbsp;days prior to submission for publication or presentation. Without derogating from its general approval right, the reviewing Party shall have the right to require a delay of up to ninety (90)&nbsp;days in publication or
presentation in order to enable patent applications protecting each Party&#146;s rights in such information to be filed and each Party shall have the right to prohibit disclosure of any of its Confidential Information in any such proposed
publication or presentation. In any permitted publication or presentation by a Party, the other Party&#146;s contribution shall be duly recognized, and <FONT STYLE="white-space:nowrap">co-authorship</FONT> shall be determined in accordance with
customary standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Use of Names</U></B>. Except as expressly stated in this
Agreement, Kazia shall not, and shall ensure that its Affiliates and Sublicensees shall not use or register the name of Evotec and/or Sanofi (alone or as part of another name) for any purpose except with the prior written approval of, and in
accordance with restrictions required by, Evotec and/or Sanofi. This restriction shall not apply to any information required by Applicable Laws to be disclosed to any Regulatory Authority. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>LICENSE GRANTS; EXCLUSIVITY</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Licenses</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exclusive License Grants</U></B>. Subject to the terms and conditions of this Agreement, during the Term of
this Agreement, Evotec hereby grants to Kazia an exclusive license or sub-license under the Licensed Technology and the Licensed Patent Rights, including the right to grant sublicenses as provided in Section&nbsp;8.2, to Research, Develop,
Manufacture and Commercialize Licensed Products and Products in the Field in the Territory. Kazia hereby agrees and covenants that Kazia shall not, and will procure that its Affiliates and Sublicensees shall not, use the Licensed Technology and the
Licensed Patents rights outside the scope of the license granted to Kazia under this Section&nbsp;8.1.1. For purposes of clarity, the licenses granted to Kazia under this Section&nbsp;8.1.1 shall be subject to the retained rights of Evotec and
Sanofi solely to conduct Research (but not Development or Commercialization) with respect to Licensed Products and Products in the Field in the Territory. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Right to Sublicense</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Development and Manufacturing Activities</U></B>. Kazia shall have the right to grant sublicenses under the
licenses granted to it under Section&nbsp;8.1.1 to any of its Affiliates and to any Third Party engaged by it to conduct Research, Development and Manufacturing activities subject to the same restrictions, limitations and obligations imposed upon
Kazia in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Commercialization of Products</U></B>. Kazia shall have the right to grant
sublicenses under the licenses granted to it under Section&nbsp;8.1.1 to any of its Affiliates and to any Third Party; provided that (a)&nbsp;it shall be a condition of any such sublicense that Kazia shall remain responsible to Evotec for the
compliance of all terms of this Agreement applicable to the Commercialization of Products in the Territory by such Third Party, (b)&nbsp;Kazia shall provide written notice to Evotec of any such proposed sublicense agreement at least thirty
(30)&nbsp;days prior to such execution and provide copies to Evotec of each such sublicense agreement within ten (10)&nbsp;days of its execution, and (c)&nbsp;Kazia shall not be relieved of its obligations pursuant to this Agreement as a result of
such sublicense agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Other Rights</U></B>. Kazia shall have no rights to use or otherwise
exploit Licensed Technology or Licensed Patent Rights, except as expressly set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exclusivity</U>. </B>As from the Effective Date, and subject to the exclusive licenses granted under
Section&nbsp;8.1.1, Evotec shall not, independently of this Agreement, either itself or through an Affiliate or Sublicensee, initiate any Development or Commercialization activities, whether for its own account or for the benefit of any Third Party,
during the Term with respect to any Licensed Product or Product or, for a period of two (2)&nbsp;years following the Effective Date, with respect to any product for which the primary mechanism of action relies on small molecule inhibition of
vascular endothelial growth factor receptor 3 (&#147;<B>VEGFR3</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, Evotec shall be free to </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conduct screens on VEGFR3(s) hereunder if, (a)&nbsp;requested by a Third Party or Evotec Affiliate and
(b)&nbsp;solely in connection with screening to determine whether a certain compound has <FONT STYLE="white-space:nowrap">off-target</FONT> activity. By way of example, if target A is VEGFR3, and target B is a separate target, then Evotec would have
the right to screen compounds that a Third Party is evaluating for use in connection with Target B in a counter-screen containing VEGFR3 solely in order to attempt to determine whether such compounds have
<FONT STYLE="white-space:nowrap">off-target</FONT> activity against VEGFR3; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conduct screens and profiling of compounds on VEGFR3 hereunder if, (a)&nbsp;requested by a Third Party and
(b)&nbsp;such certain compounds are provided by the Third Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine biophysical properties (Kd, Ki, kon, koff, DH, DS) as part of compound screening and profiling
campaigns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine target protein-ligand complex structures by <FONT STYLE="white-space:nowrap">X-Ray</FONT>
crystallography and related methods if such ligands/compounds are provided by the Third Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conduct fee for service protein, cells, probes and other reagent production, without using any gene constructs
that are Kazia&#146;s property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conduct biomarker discovery, development and testing services on VEGFR3 and/or related biological pathway for a
Third Party client of Evotec to characterize drug mechanism of action and efficacy, diagnose disease state, and stratify patients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conduct any development activities including IND enabling studies, CMC, formulation and API manufacture on
candidate molecules as identified by a Third Party where the target might be known but is not required to perform the scope of work. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>INTELLECTUAL</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>PROPERTY RIGHTS</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Evotec Intellectual Property Rights</U></B>. As between the Parties, Evotec shall have exclusive ownership of
all right, title and interest, on a worldwide basis in and to any and all Licensed Patent Rights and Licensed Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Kazia Intellectual Property Rights</U></B>. As between the Parties, Kazia shall have sole and exclusive
ownership of all right, title and interest on a worldwide basis in and to any and all Patent Rights and Technology owned by Kazia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Patent Coordinators</U></B>.&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall appoint a patent coordinator reasonably
acceptable to the other Party (each, a &#147;<B>Patent Coordinator</B>&#148;) to serve as such Party&#146;s primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance and enforcement of Patent Rights under
this Agreement. Each Party may replace its Patent Coordinator at any time by notice in writing to the other Party. Such notice becomes effective upon written acknowledgment of receipt by the other Party. The initial Patent Coordinators shall be:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Kazia:&nbsp;&nbsp;&nbsp;&nbsp; Dr James Garner [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Evotec: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Improvements.</U></B><B> </B>Each Party must notify the other Party of any Improvements which it or its
personnel, Affiliates, Sublicensees or subcontractors discovers or develops with respect to any of the Licensed Patent Rights or Licensed Technology within sixty (60)&nbsp;days of discovery or development. The Parties agree that (a)&nbsp;all rights,
title and interest in Improvements to the Licensed Patent Rights or Licensed Technology developed or discovered by or on behalf of a Party, vest in (as between the Parties) Evotec, and (b)&nbsp;upon discovery or development of any Improvement to the
(i)&nbsp;Licensed Patent Rights, the Improvement will become part of the Licensed Patent Rights, and (ii)&nbsp;Licensed Technology, the Improvement will become part of the Licensed Technology. For the avoidance of doubt, any Improvements in and to
any Patent Rights and Technology owned by Kazia will vest in Kazia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>MANAGEMENT OF PATENT RIGHTS</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Patent Filing, Prosecution and Maintenance</U>.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Evotec Prosecution Rights</U></B>. As between the Parties, Evotec, acting through patent counsel or agents
of its choice, shall be responsible for the prosecution and maintenance of the Licensed Patent Rights. At Evotec&#146;s reasonable request, Kazia shall cooperate with and assist Evotec in all reasonable respects, in connection with the preparation,
filing, prosecution (including, at Kazia&#146;s option, reviewing and commenting on draft responses to office actions from patent offices in the Territory) and maintenance of the Licensed Patent Rights. From the Effective Date, Evotec (via Sanofi,
as the case may be) shall use Commercially Reasonable Efforts to prosecute and maintain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> claims within the Licensed Patent Rights set forth on
Exhibit A in the countries set forth on Exhibit B attached hereto. Evotec shall be free, at is sole discretion and at any time upon ninety (90)&nbsp;days prior written notice to Kazia, to abandon any Licensed Patent Rights, provided that Evotec
shall not abandon any of the Licensed Patent Rights set forth on Exhibit A in the countries set forth on Exhibit B that Cover a Licensed Product being Researched, Developed or Commercialized by Kazia hereunder after the Effective Date. Any Licensed
Patent Rights set forth on Exhibit A in other countries than those countries set forth on Exhibit B that Cover a Licensed Product being Researched, Developed or Commercialized by Kazia hereunder may only be abandoned by Evotec with Kazia&#146;s
prior written consent, which consent shall not be unreasonably withheld, in which case Kazia shall have the right (but no obligation) to continue to prosecute and maintain such Licensed Patent Rights, in Evotec&#146;s and/or Sanofi&#146;s name and
at Kazia&#146;s cost and expense, acting through patent counsel or agents of its choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Kazia
Prosecution Option</U></B><U>. </U>Evotec must promptly notify Kazia in writing of any decision it makes to abandon any Licensed Patent Rights. In such event, upon Kazia&#146;s request, Evotec shall use best endeavours to transfer the right to file,
prosecute and maintain such Licensed Patent Rights to Kazia and Kazia shall have the right to continue filing, prosecution and / or maintenance of such Licensed Patents Rights at Kazia&#146;s own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Patent Costs.</U> </B>Prior to incurring any Patent Costs, Evotec must obtain Kazia&#146;s prior written
consent, which consent shall not be unreasonably withheld or delayed. If Kazia consents to any Patent Costs being incurred, such Patent Costs shall be borne by Kazia. If Kazia does not consent to Patent Costs being incurred, Kazia will not be
responsible for such Patent Costs, in which case (i)&nbsp;Evotec may continue to prosecute and maintain the applicable Licensed Patent Rights solely at its cost and expense or (ii)&nbsp;Evotec may elect to cease such prosecution and maintenance, in
which case Kazia shall have the right (but no obligation) to continue to prosecute and maintain such Licensed Patent Rights, in Evotec&#146;s and/or Sanofi&#146;s name and at Kazia&#146;s sole cost and expense, acting through patent counsel or
agents of its choice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Kazia Prosecution Rights</U></B>. Kazia, at its sole expense and acting through
patent counsel or agents of its choice, shall be responsible for the preparation, filing, prosecution and maintenance of all Patent Rights owned by Kazia. At Kazia&#146;s request and cost, Evotec shall cooperate with and assist Kazia in all
reasonable respects, in connection with Kazia&#146;s preparation, filing, prosecution and maintenance of such Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>National Registration of Exclusive License</U></B>. Kazia shall at is sole discretion be responsible for,
and shall support all costs relating to, the filing of the exclusive licenses granted hereunder with any national patent register in the Territory as is required by Applicable Law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Enforcement and Defense</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Patent Term Extension</U></B>. The Parties shall cooperate
with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country in the Territory where applicable to Licensed Patent Rights. Such cooperation shall include diligently and timely
conferring and coordinating with respect to such matters to ensure compliance with applicable filing deadlines, and agreeing on procedures to be followed by the Parties to ensure such compliance. In the event that elections with respect to obtaining
such patent term extension are to be made with respect to a Product, Kazia shall have the right to make the election with respect to Licensed Patent Rights. All costs and expenses reasonably incurred by either Party in connection with obtaining and
maintaining such patent term extension shall be paid by Kazia. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>TERM AND TERMINATION</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term</U></B>. This Agreement shall commence on the Effective Date and shall continue in full force and
effect, unless otherwise terminated pursuant to Section&nbsp;11.2, until the expiration of all payment obligations under this Agreement with respect to Products in all countries in the Territory (the &#147;<B>Term</B>&#148;). Upon the expiration of
this Agreement as set forth in this Section&nbsp;11.1, the license rights granted under Section&nbsp;8.1.1 and 8.2 shall be converted to perpetual and fully <FONT STYLE="white-space:nowrap">paid-up</FONT>
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U></B>. This Agreement may
be terminated by either Party as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Unilateral Right to Terminate Agreement</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Kazia Right to Terminate Agreement</U>. Kazia may terminate this Agreement effective immediately at any time
after the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) anniversary of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Evotec Rights to Terminate</U>. Except to the extent the following is unenforceable under the law of a
particular jurisdiction where a patent application within the Licensed Patent Rights is pending or a patent within the Licensed Patent Rights is issued, Evotec may terminate this Agreement immediately upon written notice to Kazia in the event that
(i)&nbsp;Kazia or any of its Affiliates, Sublicensees or Distributors Challenges any Licensed Patent Rights or assists a Third Party in initiating a Challenge of any Licensed Patent Rights; or (ii)&nbsp;the Sanofi License terminates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination for Breach</U></B>. If a Party materially
breaches any of its obligations under the Agreement, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party may provide the breaching Party with a written notice specifying the nature of the breach, and stating its intention to terminate
this Agreement if such breach is not cured. If the material breach is not cured within ninety (90)&nbsp;days after the receipt of such notice, the non- breaching Party shall be entitled, without prejudice to any of its other rights under this
Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement by providing written notice to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination for Insolvency</U></B>. To the extent permitted by Applicable Law, if either Party makes an
assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which
is not discharged within sixty (60)&nbsp;days of the filing thereof, the other Party may terminate this Agreement effective immediately upon written notice to such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Consequences of Termination of Agreement</U></B>. If this Agreement is terminated pursuant to
Section&nbsp;11.2, the following provisions shall apply, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination by Evotec under
11.2.1(b), 11.2.2 or 11.2.3 or by Kazia under Section&nbsp;11.2.1(a)</U></B>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated
by Kazia pursuant to Section&nbsp;11.2.1(a) or by Evotec pursuant to Section&nbsp;11.2.1(b), 11.2.2 or 11.2.3, all licenses and rights granted pursuant to this Agreement shall immediately terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Kazia pursuant to Section&nbsp;11.2.1(a) or by Evotec pursuant to
Section&nbsp;11.2.1(b)(i), 11.2.2 or 11.2.3, Kazia shall and hereby does grant to Evotec an option to obtain (i)&nbsp;an exclusive license to all Patent Rights and (ii)&nbsp;an <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to all
Technology; in each case (i)&nbsp;and (ii) owned or Controlled by Kazia and required to research, develop, have developed, make, have made, use, distribute for sale, sell, offer for sale, import and have imported Licensed Products and Products for
use in the Field (&#147;<B>Termination License</B>&#148;). If Evotec - at its sole discretion - exercises the option to obtain the Termination License, the Termination License will be royalty bearing, with the royalty payment for the Termination
License calculated at the following rates: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;If Evotec - at its sole discretion - exercises the option to
obtain the Termination License and Kazia has not completed the Phase 1 Clinical Trial for the relevant Licensed Products or Products that is subject to the Termination License, the Termination License shall be royalty- free. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Evotec - at its sole discretion - exercises the option to obtain the Termination License and Kazia has
completed the Phase 1 Clinical Trial but not the Phase 2 Clinical Trial for the relevant Licensed Products or Products that is subject to the Termination License, the Termination License shall be subject to royalty payment for the Termination
License calculated at the following rates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Net Sales of Licensed Products or Products</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***][***][***][***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***][***][***][***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If Evotec - at its sole discretion - exercises the option to
obtain the Termination License and Kazia has completed the Phase 2 Clinical Trial for the relevant Licensed Products or Products that is subject to the Termination License, the Termination License shall be subject to royalty payment for the
Termination License calculated at the following rates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Net Sales of Licensed Products or Products</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The royalty term for such reverse royalties per these Sections 12.3.1 (b)&nbsp;(ii) and (iii) shall be, with respect to each
Product in each country of the Territory, the period beginning on the date of First Commercial Sale of such Product in such country [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Kazia pursuant to Section&nbsp;11.2.1(a) or by Evotec pursuant to
Section&nbsp;11.2.1(b)(i), 11.2.2 or 11.2.3, upon Evotec&#146;s request Kazia shall, where permitted under Applicable Laws, use Commercially Reasonable Efforts to transfer to Evotec all Regulatory Approvals held by Kazia with respect to such
Products within thirty (30)&nbsp;Business Days after the effective date of the termination. All transfers described in this Section&nbsp;11.3.1(c) shall be at Kazia&#146;s expense in cases of termination by Evotec pursuant to
Section&nbsp;11.2.1(b)(i), 11.2.2 or 11.2.3; and at Evotec&#146;s expense in cases of termination by Kazia pursuant to Section&nbsp;11.2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Kazia pursuant to Section&nbsp;11.2.1(a) or by Evotec pursuant to
Section&nbsp;11.2.1(b), 11.2.2 or 11.2.3, each Party shall promptly cease use of and return all Confidential Information and Proprietary Materials of the other Party that are not subject to a continuing license hereunder; provided that each Party
may retain one copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If the notice of the termination by Kazia under 11.2.1(a) is given at a time when any Clinical Trials have been
initiated but not yet completed, then the Parties shall work together in good faith during the termination notice period to ensure that Kazia&#146;s involvement in and responsibilities for such activities shall be discontinued and ceased as
efficiently and promptly as possible (by way of transitioning such involvement and responsibilities to Evotec or by other means agreed to by the Parties), subject to Applicable Laws, including GCP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Kazia pursuant to Section&nbsp;11.2.1(a) or by Evotec pursuant to
Section&nbsp;11.2.1(b), 11.2.2 or 11.2.3, all sublicense agreements between Kazia and its Affiliates or Sublicensees, shall terminate as of the effective date of the termination, unless Evotec provides written consent, which it shall not
unreasonably withhold, delay or condition, to the assignment of any such sublicense agreement, or license agreement, as the case may be, to Evotec (to the extent assignable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Kazia pursuant to Section&nbsp;11.2.1(a) or by Evotec pursuant to
Section&nbsp;11.2.1(b), 11.2.2 or 11.2.3, any continuing reporting obligations of Kazia shall be verified exclusively through a Third Party to be mutually agreed, and Evotec shall not have direct access anymore to Kazia&#146;s Confidential
Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination by Kazia</U></B>. If this Agreement is
terminated by Kazia pursuant to Section&nbsp;11.2.2 or 11.2.3: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the Sanofi License remaining in
force, all licenses and rights granted by Evotec to Kazia pursuant to this Agreement, including, all licenses granted to Kazia under Section&nbsp;8.1.1, survive the termination in each case subject to Kazia&#146;s continued payment of all milestone,
royalty and other payments under and in accordance with this Agreement with respect thereto; provided that, in case this Agreement is terminated by Kazia pursuant to Section&nbsp;11.2.2, Kazia shall have the right to reduce any such payment by half;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All licenses and rights granted by Kazia to Evotec pursuant to this Agreement terminate; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall promptly cease use of and return all Confidential Information and Proprietary Materials of the
other Party that are not subject to a continuing license hereunder; provided that each Party may retain one copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and
ensuring compliance with its obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Surviving Provisions</U></B>. Termination or
expiration of this Agreement for any reason shall be without prejudice to: (a)&nbsp;the survival of rights specifically stated in this Agreement to survive, including as set forth in Section&nbsp;11.3; (b) the rights and obligations of the Parties
provided in the following Sections: Section&nbsp;6.3.6 (for a period of three (3)&nbsp;years, as provided therein); Article 7 (for a period of five (5)&nbsp;years, as provided in Section&nbsp;7.1.1); this Section&nbsp;11.4; and Article 1, Article
13, and Article 14 (including all other Sections or Articles referenced in any such Section or Article), all of which shall survive such termination except as provided in this Article 11; and (c)&nbsp;any other rights or remedies provided at law or
equity which either Party may otherwise have. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>REPRESENTATIONS, WARRANTIES AND COVENANTS</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Mutual Representations and Warranties</U></B>. Evotec and Kazia each represents and warrants to the other,
as of the Effective Date, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.1.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Organization</U></B>. It is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.1.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Authorization</U></B>. The execution and delivery of this Agreement and the performance by it of the
transactions contemplated hereby have been duly authorized by all necessary corporate action and shall not violate (a)&nbsp;such Party&#146;s certificate of incorporation or bylaws, (b)&nbsp;any agreement, instrument or contractual obligation to
which such Party is bound in any material respect, (c)&nbsp;any requirement of any Applicable Laws, or (d)&nbsp;any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable
to such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.1.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Binding Agreement</U></B>. This Agreement is a legal, valid and binding obligation of
such Party, enforceable against it in accordance with its terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.1.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Inconsistent
Obligation</U></B>. It is not under any contractual obligation to any Person that conflicts with or is inconsistent in any respect with the terms of this Agreement or that would materially impede the diligent and complete fulfillment of its
obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Additional Representations of Evotec</U></B>. Evotec further represents and
warrants to Kazia as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Licensed Patent Rights</U></B>. Except as expressly
disclosed in Exhibit A, as at the Effective Date, the Licensed Patent Rights set forth on Exhibit A (i)&nbsp;are Controlled by Evotec, (ii)&nbsp;represent the complete and accurate (in all material respects) list of all Licensed Patent Rights
Controlled by Evotec that relate to the Licensed Product; and (iii)&nbsp;to Evotec&acute;s Knowledge have been filed in accordance with the requirements of the applicable patent office, prosecuted with Commercially Reasonable Efforts and are not
lapsed or abandoned. To Evotec&#146;s Knowledge, it has the ability to grant to Kazia the rights and licenses granted to Kazia under the Licensed Patents. Kazia hereby acknowledges that the certain Licensed Patent Rights is either owned by Sanofi or
jointly owned by Evotec and Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Claims</U></B>. As at the Effective Date, there are no claims,
judgment or settlements against Evotec pending, or to Evotec&#146;s Knowledge, threatened in writing (including email), that invalidate or seek to invalidate the Licensed Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Infringement or Misappropriation.</U> </B>To Evotec&#146;s Knowledge, as at the Effective Date, Evotec
and its Affiliates have not infringed or misappropriated any intellectual property of any Third Party during its Research, Development, Manufacture or Commercialization of the Licensed Product or any Products. Evotec and its Affiliates have not
received any notice from any Third Party asserting or alleging any such infringement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compliance with
Applicable Laws.</U></B><B> </B>To Evotec&#146;s Knowledge, as at the Effective Date, Evotec and its Affiliates have complied with all Applicable Laws in connection with the Research, Development, and Manufacture of the Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Information</U></B>. The information provided to Kazia by or on behalf of Evotec in relation to the
Licensed Product, Licensed Patent Rights or the Licensed Technology is complete, true and accurate and all the information that Kazia could reasonably require in order to understand and appreciate the composition and status of these items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.6&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Conflicting Rights</U></B>. Except for the Sanofi License, as at the Effective Date and on each day
during the Term, there is no agreement between Evotec or its Affiliates and any Third Party pursuant to which Evotec or its Affiliates obtained any right or license to the Licensed Product or Product or any intellectual property rights related to
the Licensed Product or Product. Evotec has not granted any right, license or interest under the Licensed Patent Rights or the Licensed Technology that is inconsistent with the licenses granted to Kazia under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.7&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Licensed Technology</U></B>. The Licensed Technology set forth in Exhibit A represents the complete and
accurate (in all material respects) list of all Technology Controlled or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Evotec or its Affiliates at the Effective Date which is reasonably required by Kazia for Research, Development,
Manufacture or Commercialization of the Licensed Product or Products. Evotec has the ability to grant to Kazia the rights and <FONT STYLE="white-space:nowrap">sub-licenses</FONT> granted to Kazia under the Licensed Technology. Kazia hereby
acknowledges that the certain Licensed Technology is either owned by Sanofi or jointly owned by Evotec and Sanofi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.8&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Sanofi License</U></B>. As at the Effective Date, no written notice of default or termination has been
received or given under the Sanofi License and there is no act or omission by Evotec that would give rise to a right to terminate the Sanofi License. During the Term, Evotec will, at its own cost and expense, use best efforts to maintain the Sanofi
License in full force and effect.&nbsp;&nbsp;&nbsp;&nbsp;In the event of any breach of the Sanofi License by Evotec, Evotec shall immediately notify Kazia in writing. If Evotec fails to cure such breach in a timely manner, Kazia shall have the right
(but not the obligation) to support Evotec to cure such breach and to offset any reasonable amount incurred or paid by Kazia in connection with the cure against the amount payable to Evotec under this Agreement. Evotec shall not terminate the Sanofi
License without first obtaining Kazia&#146;s prior written consent, which consent shall not be unreasonably withheld. If, despite Evotec&#146;s best efforts, the Sanofi License is terminated, Evotec shall use best efforts to assist Kazia to obtain a
direct license from Sanofi. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2.9&nbsp;&nbsp;&nbsp;&nbsp;<B>[***]</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Additional Representations of Kazia</U></B>.&nbsp;&nbsp;&nbsp;&nbsp;Kazia further represents and warrants to
Evotec as of the Effective Date, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Debarment</U></B>. Neither Kazia nor any of its
Affiliates has been debarred or is subject to debarment pursuant to Section&nbsp;306 (or comparable law or regulation) of the USFDA. During the Term, Kazia and its Affiliates shall use Commercially Reasonable Efforts to avoid using in any capacity,
in connection with the Research or Development of any Licensed Product or Product, or the Manufacture or Commercialization of any Product, any Person who to Kazia&#146;s Knowledge has been debarred pursuant to Section&nbsp;306 (or comparable law or
regulation) of the USFDA, or who, to Kazia&#146;s Knowledge, is the subject of a conviction described in such section. Kazia agrees to inform Evotec in writing if it or any Person who is performing services hereunder is debarred or is the subject of
a conviction described in Section&nbsp;306 (or comparable law or regulation), or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Kazia&#146;s knowledge, is threatened, relating to the debarment or
conviction of Kazia or any Person used in any capacity by Kazia or any of its Affiliates in connection with the Research or Development of any Licensed Product or Product, or the Manufacture or Commercialization of any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Warranty Disclaimer</U></B>. TO THE EXTENT PERMITTED BY LAW, EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. WITHOUT LIMITING THE FOREGOING AND EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, EVOTEC MAKES NO REPRESENTATIONS OR
WARRANTIES OF ANY KIND WITH RESPECT TO (A)&nbsp;OWNERSHIP OF INTELLECTUAL PROPERTY RELATED TO COMPOUNDS, OR PRODUCTS, OR (B)&nbsp;NONINFRINGEMENT OR MISAPPROPRIATION OF ANY THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>INDEMNIFICATION; INSURANCE</U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1&nbsp;&nbsp;&nbsp;&nbsp;<B>[***]</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2&nbsp;&nbsp;&nbsp;&nbsp;<B>[***]</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Insurance</U></B>. Not later than thirty (30)&nbsp;days before the date on which Kazia or any Affiliate,
Sublicensee or Distributor of Kazia shall, on a commercial basis, Commercialize or Manufacture any Products, and at all times thereafter until the expiration of (a)&nbsp;all applicable statutes of limitation pertaining to any such Commercialization
or Manufacture of any Products or (b)&nbsp;where the applicable statute of limitation is unknown, five (5)&nbsp;years following the expiration or termination of this Agreement, Kazia shall, at its expense, with respect to Products, obtain and
maintain in full force and effect, comprehensive general liability insurance, with a minimum coverage of [***] per occurrence and [***] annual aggregate. Such commercial general liability insurance shall provide: (a)&nbsp;product liability coverage
and (b)&nbsp;broad form contractual liability coverage for Kazia&#146;s indemnification obligations under this Agreement. Kazia shall provide Evotec with written notice at least fifteen (15)&nbsp;days prior to the cancellation, <FONT
STYLE="white-space:nowrap">non-renewal</FONT> or material change in such insurance and shall obtain replacement insurance providing comparable coverage within such fifteen (15)&nbsp;day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.6&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Personal Injury</U></B>. Nothing in this Agreement
operates to exclude or restrict a Party&#146;s liability for (a)&nbsp;its gross negligence, intentional misconduct or fraud, or (b)&nbsp;for personal injury or death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>MISCELLANEOUS</U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U></B>. All notices and communications shall be in writing and delivered by email to the email
address below or personally or by internationally-recognized express courier providing evidence of delivery or mailed via certified mail, return receipt requested, addressed as follows, or to such other address as may be designated from time to
time: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Evotec:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Evotec (France) SAS</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">195 route d&#146;Espagne</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">31036 Toulouse Cedex</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">France</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attention: General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Kazia:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kazia Therapeutics Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">L24, 300 Barangaroo Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sydney, NSW 2000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">K&amp;L Gates</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">L25, 525 Collins Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Melbourne, VIC 3000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided in this Agreement or mutually agreed by the Parties in writing,
any notice, communication or document (excluding payment) required to be given or made shall be deemed given or made and effective upon actual receipt or, if earlier, (a)&nbsp;three (3) Business Days after deposit with an internationally-recognized
express courier with charges prepaid, (b)&nbsp;seven (7) Business Days after mailed by certified, registered or regular mail, postage prepaid, or (c)&nbsp;if sent by email, two (2)&nbsp;hours after the time the email is sent to the recipient&#146;s
email address, as recorded on the sender&#146;s email system, unless the sender receives within that time period, an automatic notification (other than an out of office message) indicating that the email has not been delivered, in each case
addressed to a Party at its address stated above or to such other address as such Party may designate by written notice given in accordance with this Section&nbsp;14.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing Law</U></B>.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be governed by and construed in
accordance with the laws of New York State, United States of America, without regard to the application of principles of conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Dispute Resolution</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.1&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Referral of Disputes</U></B>. In the event of any dispute between the Parties arising out of or in
connection with this Agreement (&#147;<B>Dispute&#148;</B>), either Party may, provide a written notice (&#147;<B>Dispute Notice</B>&#148;) to the other which sets out the nature of the Dispute and the relief or remedy that the Party seeks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.2&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Negotiation by Parties&#146; Senior
Executives</U></B><U>.</U> During the period thirty (30)&nbsp;days after delivery of the Dispute Notice, or any longer period agreed in writing by the Parties (&#147;<B>Initial Period</B>&#148;), the senior executives of each Party must use their
reasonable endeavours and act in good faith to resolve the Dispute by discussion and negotiation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.3&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Referral to Arbitration</U></B><U>.</U> If the Dispute is not resolved within the Initial Period, then the
Dispute must be resolved by arbitration administered by the American Arbitration Association in accordance with the Commercial Arbitration Rules which are operating at the time the Dispute is referred to arbitration. Judgment on the award rendered
by the arbitrator(s) may be entered in any court having jurisdiction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Conduct of
Arbitration</U></B>. The arbitration shall be conducted by a single arbitrator mutually agreed by the Parties within thirty (30)&nbsp;days after initiation of arbitration. If the Parties are unable or fail to agree upon the arbitrator, the
arbitrator shall be appointed by the American Arbitration Association. The seat of arbitration must be New York State and the language of arbitration must be English. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Other Proceedings</U></B>. Subject to Section&nbsp;14.3.7, no Party may commence any judicial proceedings
in relation to the Dispute unless those proceedings are commenced for the purpose of enforcing this Section&nbsp;14.3 or to seek interlocutory relief during the Initial Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.6&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Costs</U></B>. The &#147;prevailing&#148; Party, as determined by the arbitrator, shall be entitled to its
share of reasonable attorney fees associated with the arbitration.&nbsp;&nbsp;&nbsp;&nbsp;If the arbitrator determines that, given the scope of the arbitration, neither Party &#147;prevailed&#148;, the arbitrator shall order that the Parties
(a)&nbsp;share equally the arbitrators&#146; fees and any administrative fees of arbitration, and (b)&nbsp;bear their own attorneys&#146; fees and associated costs and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.7&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Intellectual Property Disputes</U></B>. Notwithstanding anything to the contrary, any and all issues
regarding the scope, inventorship, construction, validity, enforceability or ownership of any Patent Rights hereunder shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent
Rights in question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3.8&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Jurisdiction</U></B>. Subject to this Section&nbsp;14.3, the Parties submit to
the exclusive jurisdiction of the courts of New York State, United States of America, in respect of any dispute, controversy or claim arising out of or relating to this Agreement, including the existence, negotiation, validity, formation,
interpretation, breach, performance or application of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Binding Effect</U></B>. This
Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.5&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Headings</U></B>. Section and subsection headings are inserted for convenience of reference only and do not
form a part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.6&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Counterparts</U></B>. This Agreement may be executed simultaneously in
two or more counterparts, each of which shall be deemed an original and both of which, together, shall constitute a single agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.7&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Amendment; Waiver</U></B>. This Agreement may be amended, modified, superseded or canceled, and any of the
terms of this Agreement may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of either Party at any time or times to require performance of any
provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances,
shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.8&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Partnership</U></B>. Nothing in this Agreement shall be
construed (a)&nbsp;to create or imply a general partnership between the Parties, (b)&nbsp;to make either Party the agent of the other for any purpose, (c)&nbsp;to alter, amend, supersede or vitiate any other arrangements between the Parties with
respect to any subject matters not covered hereunder, (d)&nbsp;to give either Party the right to bind the other, (e)&nbsp;to create any duties or obligations between the Parties except as expressly set forth herein, or (f)&nbsp;to grant any direct
or implied licenses or any other right other than as expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.9&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Assignment and
Successors</U></B>. Neither this Agreement nor any obligation of a Party hereunder may be assigned by either Party without the consent of the other which shall not be unreasonably withheld, except that each Party may assign this Agreement and the
rights, obligations and interests of such Party, (a)&nbsp;in whole or in part, to any of its Affiliates, or (b)&nbsp;in whole, but not in part, to any purchaser of all of its assets or all of its assets to which this Agreement relates or shares
representing a majority of its common stock voting rights or to any successor corporation resulting from any merger, consolidation, share exchange or other similar transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.10&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Force Majeure</U></B>. Neither Kazia nor Evotec shall be liable for failure of or delay in performing
obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force Majeure, the Party affected shall use reasonable efforts to cure or
overcome the same and resume performance of its obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.11&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Interpretation</U></B>. The
Parties hereto acknowledge and agree that: (a)&nbsp;each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule of construction to the effect that any
ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)&nbsp;the terms and provisions of this Agreement shall be construed fairly as to each Party and not in a favor of or against
either Party, regardless of which Party was generally responsible for the preparation of this Agreement. In addition, unless a context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any
gender shall be applicable to all genders, the word &#147;or&#148; is used in the inclusive sense (and/or) and the word &#147;including&#148; is used without limitation and means &#147;including without limitation&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.12&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Integration; Severability</U></B>. This Agreement (including the Exhibits attached hereto) sets forth the
entire agreement with respect to the subject matter hereof and thereof and supersedes all other agreements and understandings between the Parties with respect to such subject matter. If any provision of this Agreement is or becomes invalid or is
ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. In the event of any conflict or inconsistency between the text of this
Agreement and the attached Exhibits, the text of this Agreement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.13&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Further
Assurances</U></B>. Each of Evotec and Kazia agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such additional
assignments, agreements, documents and instruments, as the other Party may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure
and confirm unto such other Party its rights and remedies under, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature page follows] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed </B>by <B>Evotec (France) SAS</B>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Craig Johnstone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Christian Dargel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature of director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature of director or company secretary*</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*delete whichever does not apply</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Craig Johnstone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Christian Dargel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Name (please print)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Name (please print)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed </B>by <B>Kazia Therapeutics, Ltd. </B>ACN 063 259 754 in accordance with section 127(1) of the <I>Corporations
Act 2001 (Cth)</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ James Garner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kate Hill</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature of director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature of director or company secretary*</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*delete whichever does not apply</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">James Garner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kate Hill&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
Secretary</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Name (please print)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Name (please print)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[***]</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>d185056dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 12.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of the Chief Executive Officer as required by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(a)&nbsp;of</FONT> the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Garner, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;for</FONT> the
fiscal year ended June&nbsp;30, 2021 (&#145;Report&#146;) of Kazia Therapeutics Limited (the &#145;Company&#146;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this Report,
fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)&nbsp;and&nbsp;15d-15(e)&nbsp;)</FONT></FONT> and internal control over financial reporting (as
defined in the Exchange Act <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(f)&nbsp;and&nbsp;15d-15(f)&nbsp;for</FONT></FONT> the Company and have: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the Company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the Company&#146;s internal control over financial reporting that
occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect the Company&#146;s internal control over financial reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the Company&#146;s auditors and the audit committee of the Company&#146;s Board of Directors (or persons performing the equivalent functions). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the Company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Garner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James Garner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October 7, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>d185056dex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 12.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of the Director of Finance and Administration as required by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(a)&nbsp;of</FONT> the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Gabrielle Heaton, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;for</FONT> the
fiscal year ended June&nbsp;30, 2021 (&#145;Report&#146;) of Kazia Therapeutics Limited (the &#145;Company&#146;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this Report,
fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)&nbsp;and&nbsp;15d-15(e)&nbsp;)</FONT></FONT> and internal control over financial reporting (as
defined in the Exchange Act <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(f)&nbsp;and&nbsp;15d-15(f))&nbsp;for</FONT></FONT> the Company and have: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the Company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the Company&#146;s internal control over financial reporting that
occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect the Company&#146;s internal control over financial reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the Company&#146;s auditors and the audit committee of the Company&#146;s Board of Directors (or persons performing the equivalent functions). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the Company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gabrielle Heaton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gabrielle Heaton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director of Finance and Administration</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October 7, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>d185056dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 13.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of the Chief Executive Officer and the Director of Finance and Administration as required by
<FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(b)&nbsp;of</FONT> the Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement set forth in <FONT
STYLE="white-space:nowrap">Rule&nbsp;13a-14(b)&nbsp;of</FONT> the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), James
Garner, Chief Executive Officer, and Gabrielle Heaton, Director of Finance and Administration, of Kazia Therapeutics Limited, an Australian corporation (the &#145;Company&#146;), hereby certifies that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s periodic report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;for</FONT> the
period ended June&nbsp;30, 2021 (the <FONT STYLE="white-space:nowrap">&#145;Form&nbsp;20-F&#146;)&nbsp;fully</FONT> complies with the requirements of section 13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934 as amended; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the <FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;fairly</FONT> presents,
in all material respects, the financial condition and results of operations of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director of Finance and Administration</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Garner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gabrielle Heaton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James Garner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Gabrielle Heaton</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 7, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date: October 7, 2021</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification accompanies the <FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;to</FONT> which it relates, is not
deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Kazia Therapeutics Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended
(whether made before or after the date of the <FONT STYLE="white-space:nowrap">Form&nbsp;20-F),&nbsp;irrespective</FONT> of any general incorporation language contained in such filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to
the Securities and Exchange Commission or its staff upon request. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>d185056dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 15.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have issued our report dated October 7, 2021 with respect to the consolidated financial statements included in the Annual Report of Kazia Therapeutics
Limited on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended June&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference of the
said report in the Registration Statement of Kazia Therapeutics Limited on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Grant Thornton Audit Pty Ltd</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">GRANT THORNTON AUDIT PTY LTD</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;7, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>kzia-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-October-2021 [03:11:17] {PM}-->
<schema targetNamespace="http://www.kaziatherapeutics.com/20210630" elementFormDefault="qualified" xmlns:kzia="http://www.kaziatherapeutics.com/20210630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/Cover" id="Cover">
<link:definition>1001 - Document - Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" id="ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome">
<link:definition>1002 - Statement - Consolidated statements of profit or loss and other comprehensive income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
<link:definition>1003 - Statement - Consolidated statements of financial position</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
<link:definition>1004 - Statement - Statements of changes in equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1005 - Statement - Consolidated statements of cash flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/GeneralInformation" id="GeneralInformation">
<link:definition>1006 - Disclosure - General information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>1007 - Disclosure - Significant accounting policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions" id="CriticalAccountingJudgementsEstimatesAndAssumptions">
<link:definition>1008 - Disclosure - Critical accounting judgements, estimates and assumptions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OperatingSegments" id="OperatingSegments">
<link:definition>1009 - Disclosure - Operating segments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/Revenue" id="Revenue">
<link:definition>1010 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OtherIncome" id="OtherIncome">
<link:definition>1011 - Disclosure - Other income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/Expenses" id="Expenses">
<link:definition>1012 - Disclosure - Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefit" id="IncomeTaxBenefit">
<link:definition>1013 - Disclosure - Income tax benefit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents" id="CurrentAssetsCashAndCashEquivalents">
<link:definition>1014 - Disclosure - Current assets - cash and cash equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables" id="TradeAndOtherReceivables">
<link:definition>1015 - Disclosure - Trade and other receivables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OtherAssets" id="OtherAssets">
<link:definition>1016 - Disclosure - Other assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/Intangibles" id="Intangibles">
<link:definition>1017 - Disclosure - Intangibles</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1018 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefits" id="EmployeeBenefits">
<link:definition>1019 - Disclosure - Employee benefits</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ContingentConsideration" id="ContingentConsideration">
<link:definition>1020 - Disclosure - Contingent consideration</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/DeferredTax" id="DeferredTax">
<link:definition>1021 - Disclosure - Deferred tax</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquity" id="EquityContributedEquity">
<link:definition>1022 - Disclosure - Equity - contributed equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity" id="EquityOtherContributedEquity">
<link:definition>1023 - Disclosure - Equity - Other contributed equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityReserves" id="EquityReserves">
<link:definition>1024 - Disclosure - Equity - reserves</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityDividends" id="EquityDividends">
<link:definition>1025 - Disclosure - Equity - dividends</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstruments" id="FinancialInstruments">
<link:definition>1026 - Disclosure - Financial instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1027 - Disclosure - Fair value measurement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures" id="KeyManagementPersonnelDisclosures">
<link:definition>1028 - Disclosure - Key management personnel disclosures</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditors" id="RemunerationOfAuditors">
<link:definition>1029 - Disclosure - Remuneration of auditors</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ContingentLiabilities" id="ContingentLiabilities">
<link:definition>1030 - Disclosure - Contingent liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/Commitments" id="Commitments">
<link:definition>1031 - Disclosure - Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1032 - Disclosure - Related party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformation" id="ParentEntityInformation">
<link:definition>1033 - Disclosure - Parent entity information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries" id="InterestsInSubsidiaries">
<link:definition>1034 - Disclosure - Interests in subsidiaries</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities" id="ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities">
<link:definition>1035 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShare" id="EarningsPerShare">
<link:definition>1036 - Disclosure - Earnings per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPayments" id="ShareBasedPayments">
<link:definition>1037 - Disclosure - Share-based payments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1038 - Disclosure - Subsequent events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1039 - Disclosure - Significant accounting policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RevenueTables" id="RevenueTables">
<link:definition>1040 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeTables" id="OtherIncomeTables">
<link:definition>1041 - Disclosure - Other income (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ExpensesTables" id="ExpensesTables">
<link:definition>1042 - Disclosure - Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables" id="IncomeTaxBenefitTables">
<link:definition>1043 - Disclosure - Income tax benefit (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables" id="CurrentAssetsCashAndCashEquivalentsTables">
<link:definition>1044 - Disclosure - Current assets - cash and cash equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables" id="TradeAndOtherReceivablesTables">
<link:definition>1045 - Disclosure - Trade and other receivables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OtherAssetsTables" id="OtherAssetsTables">
<link:definition>1046 - Disclosure - Other Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IntangiblesTables" id="IntangiblesTables">
<link:definition>1047 - Disclosure - Intangibles (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1048 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables" id="EmployeeBenefitsTables">
<link:definition>1049 - Disclosure - Employee benefits (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationTables" id="ContingentConsiderationTables">
<link:definition>1050 - Disclosure - Contingent consideration (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/DeferredTaxTables" id="DeferredTaxTables">
<link:definition>1051 - Disclosure - Deferred tax (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquityTables" id="EquityContributedEquityTables">
<link:definition>1052 - Disclosure - Equity - contributed equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables" id="EquityOtherContributedEquityTables">
<link:definition>1053 - Disclosure - Equity - Other contributed equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
<link:definition>1054 - Disclosure - Financial instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1055 - Disclosure - Fair value measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables" id="KeyManagementPersonnelDisclosuresTables">
<link:definition>1056 - Disclosure - Key management personnel disclosures (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables" id="RemunerationOfAuditorsTables">
<link:definition>1057 - Disclosure - Remuneration of auditors (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationTables" id="ParentEntityInformationTables">
<link:definition>1058 - Disclosure - Parent entity information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables" id="InterestsInSubsidiariesTables">
<link:definition>1059 - Disclosure - Interests in subsidiaries (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables" id="ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables">
<link:definition>1060 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
<link:definition>1061 - Disclosure - Earnings per share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables" id="ShareBasedPaymentsTables">
<link:definition>1062 - Disclosure - Share-based payments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" id="SignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1063 - Disclosure - Significant accounting policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail" id="CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail">
<link:definition>1064 - Disclosure - Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail" id="OperatingSegmentsAdditionalInformationDetail">
<link:definition>1065 - Disclosure - Operating segments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail" id="RevenueSummaryOfLicensingRevenueDetail">
<link:definition>1066 - Disclosure - Revenue - Summary of licensing revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail" id="RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail">
<link:definition>1067 - Disclosure - Revenue - Summary of disaggregation of revenue from contracts with customers  (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail" id="OtherIncomeSummaryOfOtherIncomeDetail">
<link:definition>1068 - Disclosure - Other income - Summary of other income (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail" id="ExpensesSummaryOfExpensesDetail">
<link:definition>1069 - Disclosure - Expenses - Summary of expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" id="IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail">
<link:definition>1070 - Disclosure - Income tax benefit - Summary of Income tax benefit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail" id="IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail">
<link:definition>1071 - Disclosure - Income tax benefit - Summary of Income tax benefit (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" id="CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail">
<link:definition>1072 - Disclosure - Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" id="TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail">
<link:definition>1073 - Disclosure - Trade and other receivables - Summary of current assets - trade and other receivables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail" id="TradeAndOtherReceivablesAdditionalInformationDetail">
<link:definition>1074 - Disclosure - Trade and other receivables - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail" id="OtherAssetsSummaryOfCurrentAssetsOtherDetail">
<link:definition>1075 - Disclosure - Other assets - Summary of current assets - other (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail" id="IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail">
<link:definition>1076 - Disclosure - Intangibles - Summary of non-current assets - intangibles (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail" id="IntangiblesSummaryOfReconciliationsOfIntangiblesDetail">
<link:definition>1077 - Disclosure - Intangibles - Summary of reconciliations of intangibles (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail">
<link:definition>1078 - Disclosure - Trade and other payables - Summary of current liabilities - trade and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail" id="EmployeeBenefitsSummaryOfProvisionDetail">
<link:definition>1079 - Disclosure - Employee benefits - Summary of provision (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail" id="ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail">
<link:definition>1080 - Disclosure - Contingent consideration - Summary of liabilities - contingent consideration (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail" id="ContingentConsiderationAdditionalInformationDetail">
<link:definition>1081 - Disclosure - Contingent consideration - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail" id="DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail">
<link:definition>1082 - Disclosure - Deferred tax - Summary of non-current liabilities - deferred tax (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail" id="EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail">
<link:definition>1083 - Disclosure - Equity - contributed equity - Summary of movements in ordinary share capital (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail" id="EquityContributedEquitySummaryOfEquityContributedEquityDetail">
<link:definition>1084 - Disclosure - Equity - contributed equity - Summary of equity - contributed equity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail" id="EquityContributedEquityAdditionalInformationDetail">
<link:definition>1085 - Disclosure - Equity - contributed equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail" id="EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail">
<link:definition>1086 - Disclosure - Equity - Other contributed equity - Summary of equity -Other contributed equity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail" id="EquityOtherContributedEquityAdditionalInformationDetail">
<link:definition>1087 - Disclosure - Equity - Other contributed equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail" id="FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail">
<link:definition>1088 - Disclosure - Financial instruments - Summary of foreign currency risk (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail" id="FinancialInstrumentsAdditionalInformationDetail">
<link:definition>1089 - Disclosure - Financial instruments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail" id="FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail">
<link:definition>1090 - Disclosure - Financial instruments - Summary of foreign currency risk sensitivity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail" id="FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail">
<link:definition>1091 - Disclosure - Financial instruments - Summary of variable interest rate balances (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail" id="FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail">
<link:definition>1092 - Disclosure - Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail" id="FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail">
<link:definition>1093 - Disclosure - Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail" id="FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail">
<link:definition>1094 - Disclosure - Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail" id="FairValueMeasurementAdditionalInformationDetail">
<link:definition>1095 - Disclosure - Fair value measurement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" id="KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail">
<link:definition>1096 - Disclosure - Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" id="RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail">
<link:definition>1097 - Disclosure - Remuneration of auditors - Summary of remuneration of auditors (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1098 - Disclosure - Related party transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail" id="ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail">
<link:definition>1099 - Disclosure - Parent entity information - Statement of profit or loss and other comprehensive income (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail" id="ParentEntityInformationStatementOfFinancialPositionDetail">
<link:definition>1100 - Disclosure - Parent entity information - Statement of financial position (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail" id="InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail">
<link:definition>1101 - Disclosure - Interests in subsidiaries - Summary of interest in subsidiaries (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail" id="ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail">
<link:definition>1102 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail" id="EarningsPerShareSummaryOfEarningsPerShareDetail">
<link:definition>1103 - Disclosure - Earnings per share - Summary of earnings per share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail" id="EarningsPerShareAdditionalInformationDetail">
<link:definition>1104 - Disclosure - Earnings per share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail" id="ShareBasedPaymentsAdditionalInformationDetail">
<link:definition>1105 - Disclosure - Share-based payments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail" id="ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail">
<link:definition>1106 - Disclosure - Share-based payments - Summary of share-based payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail" id="ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail">
<link:definition>1107 - Disclosure - Share-based payments - Summary of valuation for each tranche of options (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1" id="ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1">
<link:definition>1108 - Statement - Consolidated statements of profit or loss and other comprehensive income Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="kzia-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<element name="BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" substitutionGroup="xbrli:item" />
<element name="GainLossOnRevaluationOfContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_GainLossOnRevaluationOfContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentConsiderationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_ContingentConsiderationCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentConsiderationNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_ContingentConsiderationNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughExpireOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_IncreaseDecreaseThroughExpireOfOptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="AdjustmentsForDecreaseIncreaseInPrepayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_AdjustmentsForDecreaseIncreaseInPrepayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetLossOnDisposalOfNonCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NetLossOnDisposalOfNonCurrentAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TextBlockAbstract" substitutionGroup="xbrli:item" />
<element name="StatementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_StatementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="StatementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_StatementLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfContingentConsiderationLiabilitiesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfOtherEquityExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfOtherEquityExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfParentEntityInformationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DescriptionOfParentEntityInformationExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutProvisionsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherEquityExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfParentEntityFinancialInformationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfParentEntityFinancialInformationExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="InterestIncomeLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_InterestIncomeLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IntangibleAssetsWithIndefiniteRemainingUsefulLife" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" substitutionGroup="xbrli:item" />
<element name="AdditionalTaxDeductionPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_AdditionalTaxDeductionPercentage" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentTaxIncentiveProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" substitutionGroup="xbrli:item" />
<element name="FundingPurposeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_FundingPurposeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="FundingPurposeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_FundingPurposeMember" substitutionGroup="xbrli:item" />
<element name="ClinicalTrialsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ClinicalTrialsMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementForPaxalisibMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_LicenseAgreementForPaxalisibMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementForEvtEightZeroOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_LicensingAgreementForEvtEightZeroOneMember" substitutionGroup="xbrli:item" />
<element name="UncertainityAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_UncertainityAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="UncertainityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_UncertainityMember" substitutionGroup="xbrli:item" />
<element name="CovidNinteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_CovidNinteenMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" substitutionGroup="xbrli:item" />
<element name="PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" substitutionGroup="xbrli:item" />
<element name="NumberOfMajorCustomers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NumberOfMajorCustomers" substitutionGroup="xbrli:item" />
<element name="NumberOfOperatingSegments1" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NumberOfOperatingSegments1" substitutionGroup="xbrli:item" />
<element name="ConcentrationRiskMajorCustomerPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_ConcentrationRiskMajorCustomerPercentage" substitutionGroup="xbrli:item" />
<element name="LicensingRevenueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_LicensingRevenueMember" substitutionGroup="xbrli:item" />
<element name="SwedanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_SwedanMember" substitutionGroup="xbrli:item" />
<element name="ReimbursementOfExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_ReimbursementOfExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SubsidiesAndGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_SubsidiesAndGrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxRebatesOnPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxRebatesOnPayroll" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RebateIncomeOnResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_RebateIncomeOnResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfExpensesByNatureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfExpensesByNatureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PaxalisibLicensingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_PaxalisibLicensingAgreementMember" substitutionGroup="xbrli:item" />
<element name="EvotechLicensingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EvotechLicensingAgreementMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfExpensesByNatureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfExpensesByNatureLineItems" substitutionGroup="xbrli:item" />
<element name="ChineseWithholdingTaxIncurredOnLicenseTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MinimumOperatingLeasePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_MinimumOperatingLeasePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChineseValueAddedTaxIncurredOnLicenseTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfIncomeTaxBenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfIncomeTaxBenefitsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfIncomeTaxBenefitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfIncomeTaxBenefitLineItems" substitutionGroup="xbrli:item" />
<element name="TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" substitutionGroup="xbrli:item" />
<element name="TaxEffectOfExpenseResearchAndDevelopmentClaim" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfAmortisationOfIntangibles" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfAmortisationOfIntangibles" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfExpenseEmployeeOptionPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfExpenseEmployeeOptionPlan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxLossesNotRecognisedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TaxLossesNotRecognisedAbstract" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentTaxRebateReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ResearchAndDevelopmentTaxRebateReceivableMember" substitutionGroup="xbrli:item" />
<element name="DepositsHeldMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DepositsHeldMember" substitutionGroup="xbrli:item" />
<element name="DepositPaidNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_DepositPaidNonCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DepositPaidAsAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_DepositPaidAsAdvance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicensingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_LicensingAgreementMember" substitutionGroup="xbrli:item" />
<element name="EVT801LicensingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EVT801LicensingAgreementMember" substitutionGroup="xbrli:item" />
<element name="ContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_ContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContingentConsiderationPaxalisibMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ContingentConsiderationPaxalisibMember" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationEvt801Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ContingentConsiderationEvt801Member" substitutionGroup="xbrli:item" />
<element name="PaymentsForContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_PaymentsForContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_MilestonePaymentPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentDiscountRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_MilestonePaymentDiscountRate" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsNotBooked" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_MilestonePaymentsNotBooked" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfContingentMilestonePayments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NumberOfContingentMilestonePayments" substitutionGroup="xbrli:item" />
<element name="MilestoneTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_MilestoneTwoMember" substitutionGroup="xbrli:item" />
<element name="GlioblastPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_GlioblastPtyLtdMember" substitutionGroup="xbrli:item" />
<element name="GenentechAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_GenentechAgreementMember" substitutionGroup="xbrli:item" />
<element name="SharesIssuedPricePerShare1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_SharesIssuedPricePerShare1" substitutionGroup="xbrli:item" />
<element name="EquityTransactionsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EquityTransactionsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EquityTransactionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EquityTransactionsMember" substitutionGroup="xbrli:item" />
<element name="SharePurchasePlanIssueDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_SharePurchasePlanIssueDateAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SharePurchasePlanIssueDateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_SharePurchasePlanIssueDateDomain" substitutionGroup="xbrli:item" />
<element name="IssueDatedNovemberOneTwoThousandAndNineteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" substitutionGroup="xbrli:item" />
<element name="IssueDatedSecondMarchTwoThousandTwentyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="IssueDatedFifteenthMarchTwoThousandTwentyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="IssueDateTwentyEightAugustTwoThousandAndTwentyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" substitutionGroup="xbrli:item" />
<element name="IssueDateSixteenthAprilTwoThousandAndTwentyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" substitutionGroup="xbrli:item" />
<element name="ConversionOfOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ConversionOfOptionsMember" substitutionGroup="xbrli:item" />
<element name="ShareIssueTransactionCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ShareIssueTransactionCostsMember" substitutionGroup="xbrli:item" />
<element name="SharePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_SharePlacementMember" substitutionGroup="xbrli:item" />
<element name="SharePurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_SharePurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="InstitutionalPlacementUnderAnreoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_InstitutionalPlacementUnderAnreoMember" substitutionGroup="xbrli:item" />
<element name="RetailPlacementUnderAnreoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_RetailPlacementUnderAnreoMember" substitutionGroup="xbrli:item" />
<element name="IssuedOnAchievementOfAMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IssuedOnAchievementOfAMilestoneMember" substitutionGroup="xbrli:item" />
<element name="NumberOfOrdinarySharesAvailableForConversion" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_NumberOfOrdinarySharesAvailableForConversion" substitutionGroup="xbrli:item" />
<element name="ConvertibleNoteRepresentsOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_ConvertibleNoteRepresentsOrdinaryShares" substitutionGroup="xbrli:item" />
<element name="PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" substitutionGroup="xbrli:item" />
<element name="RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" substitutionGroup="xbrli:item" />
<element name="EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" substitutionGroup="xbrli:item" />
<element name="EffectOfIncreaseInMarketRiskOnEquityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EffectOfIncreaseInMarketRiskOnEquityMember" substitutionGroup="xbrli:item" />
<element name="EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" substitutionGroup="xbrli:item" />
<element name="EffectOfDecreaseInMarketRiskOnEquityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_EffectOfDecreaseInMarketRiskOnEquityMember" substitutionGroup="xbrli:item" />
<element name="IncreaseInMarketRiskMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_IncreaseInMarketRiskMember" substitutionGroup="xbrli:item" />
<element name="DecreaseInMarketRiskMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DecreaseInMarketRiskMember" substitutionGroup="xbrli:item" />
<element name="InterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_InterestRate" substitutionGroup="xbrli:item" />
<element name="CashAtBankAndInHandMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_CashAtBankAndInHandMember" substitutionGroup="xbrli:item" />
<element name="ShortTermDepositsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ShortTermDepositsMember" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_ContingentConsiderationUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TradePayablesUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_TradePayablesUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedPayablesUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_AccruedPayablesUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="FairValueOfAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_FairValueOfAssetsAndLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PayoutOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_PayoutOfMilestone" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfParentEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfParentEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfParentEntityInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfParentEntityInformationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfParentEntityInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfParentEntityInformationLineItems" substitutionGroup="xbrli:item" />
<element name="KaziaTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_KaziaTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="KaziaLaboratoriesPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_KaziaLaboratoriesPtyLtdMember" substitutionGroup="xbrli:item" />
<element name="KaziaResearchPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_KaziaResearchPtyLtdMember" substitutionGroup="xbrli:item" />
<element name="KaziaTherapeuticsHongKongLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_KaziaTherapeuticsHongKongLimitedMember" substitutionGroup="xbrli:item" />
<element name="ReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_ReconciliationAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" substitutionGroup="xbrli:item" />
<element name="AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnlistedOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_UnlistedOptionsMember" substitutionGroup="xbrli:item" />
<element name="NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" substitutionGroup="xbrli:item" />
<element name="NumberOfOptionsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kzia_NumberOfOptionsIssued" substitutionGroup="xbrli:item" />
<element name="PercentageOfOptionsVested" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_PercentageOfOptionsVested" substitutionGroup="xbrli:item" />
<element name="NumberOfOptionsVested" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NumberOfOptionsVested" substitutionGroup="xbrli:item" />
<element name="OtherTrancheOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_OtherTrancheOneMember" substitutionGroup="xbrli:item" />
<element name="OtherTrancheTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_OtherTrancheTwoMember" substitutionGroup="xbrli:item" />
<element name="TranchesTwoAndEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TranchesTwoAndEightMember" substitutionGroup="xbrli:item" />
<element name="TrancheNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheNineMember" substitutionGroup="xbrli:item" />
<element name="OtherTrancheThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_OtherTrancheThreeMember" substitutionGroup="xbrli:item" />
<element name="TranchesTenAndTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TranchesTenAndTwelveMember" substitutionGroup="xbrli:item" />
<element name="OtherTrancheFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_OtherTrancheFourMember" substitutionGroup="xbrli:item" />
<element name="AwardTypesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_AwardTypesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AwardTypesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_AwardTypesMember" substitutionGroup="xbrli:item" />
<element name="TrancheFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheFifteenMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwoMember" substitutionGroup="xbrli:item" />
<element name="TrancheOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheOneMember" substitutionGroup="xbrli:item" />
<element name="TrancheSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheSevenMember" substitutionGroup="xbrli:item" />
<element name="TrancheSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheSixMember" substitutionGroup="xbrli:item" />
<element name="TrancheTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTenMember" substitutionGroup="xbrli:item" />
<element name="TrancheThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheThirteenMember" substitutionGroup="xbrli:item" />
<element name="TrancheThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheThreeMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwelveMember" substitutionGroup="xbrli:item" />
<element name="TrancheSixteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheSixteenMember" substitutionGroup="xbrli:item" />
<element name="TrancheFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheFiveMember" substitutionGroup="xbrli:item" />
<element name="TrancheFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheFourMember" substitutionGroup="xbrli:item" />
<element name="TrancheEighteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheEighteenMember" substitutionGroup="xbrli:item" />
<element name="TrancheNineteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheNineteenMember" substitutionGroup="xbrli:item" />
<element name="TrancheFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheFourteenMember" substitutionGroup="xbrli:item" />
<element name="TrancheEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheEightMember" substitutionGroup="xbrli:item" />
<element name="TrancheElevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheElevenMember" substitutionGroup="xbrli:item" />
<element name="TrancheSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheSeventeenMember" substitutionGroup="xbrli:item" />
<element name="NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="ShareBasedPaymentArrangementOptionsExpiryDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_ShareBasedPaymentArrangementOptionsExpiryDate" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyFourMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentySixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentySixMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyEightMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwentyNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheTwentyNineMember" substitutionGroup="xbrli:item" />
<element name="TrancheThirtyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheThirtyMember" substitutionGroup="xbrli:item" />
<element name="TrancheThirtyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kzia_TrancheThirtyOneMember" substitutionGroup="xbrli:item" />
<element name="SharePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kzia_SharePricePerShare" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>kzia-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-October-2021 [03:11:17] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncomeSummaryOfOtherIncomeDetail" roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ExpensesSummaryOfExpensesDetail" roleURI="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefitsSummaryOfProvisionDetail" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_ProfitLossBeforeTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GainLossOnRevaluationOfContingentConsideration" xlink:label="loc_KZIA_GainLossOnRevaluationOfContingentConsideration" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_KZIA_GainLossOnRevaluationOfContingentConsideration" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_RevenueFromInterest" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_OtherRevenue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_FinanceIncome" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_OtherComprehensiveIncome" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_IssuedCapital" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_OtherEquityInterest" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_OtherReserves" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-full_RetainedEarnings" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="loc_ifrs-full_Liabilities" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities" xlink:to="loc_ifrs-full_CurrentLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationCurrent" xlink:label="loc_KZIA_ContingentConsiderationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_KZIA_ContingentConsiderationCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities" xlink:to="loc_ifrs-full_NoncurrentLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_DeferredTaxLiabilities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_KZIA_ContingentConsiderationNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_KZIA_ContingentConsiderationNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="loc_ifrs-full_Assets" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_CurrentAssets" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CashAndCashEquivalents" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_OtherCurrentAssets" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_NoncurrentAssets" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="loc_ifrs-full_NoncurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_NoncurrentReceivables" use="optional" order="22" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xlink:label="loc_KZIA_AdjustmentsForDecreaseIncreaseInPrepayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_KZIA_AdjustmentsForDecreaseIncreaseInPrepayments" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForProvisions" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xlink:label="loc_KZIA_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_KZIA_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_ConsiderationPaidReceived" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NetLossOnDisposalOfNonCurrentAssets" xlink:label="loc_KZIA_NetLossOnDisposalOfNonCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_KZIA_NetLossOnDisposalOfNonCurrentAssets" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-full_OtherIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="loc_ifrs-full_NetForeignExchangeGain" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxRebatesOnPayroll" xlink:label="loc_KZIA_TaxRebatesOnPayroll" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="loc_KZIA_TaxRebatesOnPayroll" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SubsidiesAndGrants" xlink:label="loc_KZIA_SubsidiesAndGrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="loc_KZIA_SubsidiesAndGrants" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ReimbursementOfExpenses" xlink:label="loc_KZIA_ReimbursementOfExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="loc_KZIA_ReimbursementOfExpenses" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RebateIncomeOnResearchAndDevelopment" xlink:label="loc_KZIA_RebateIncomeOnResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="loc_KZIA_RebateIncomeOnResearchAndDevelopment" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNature" xlink:label="loc_ifrs-full_ExpenseByNature" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xlink:label="loc_KZIA_ChineseWithholdingTaxIncurredOnLicenseTransaction" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseByNature" xlink:to="loc_KZIA_ChineseWithholdingTaxIncurredOnLicenseTransaction" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xlink:label="loc_KZIA_ChineseValueAddedTaxIncurredOnLicenseTransaction" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseByNature" xlink:to="loc_KZIA_ChineseValueAddedTaxIncurredOnLicenseTransaction" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="loc_ifrs-full_Cash" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositPaidNonCurrent" xlink:label="loc_KZIA_DepositPaidNonCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="loc_KZIA_DepositPaidNonCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_ProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProvisionsForEmployeeBenefits" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProvisionsForEmployeeBenefits" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-full_AuditorsRemuneration" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xlink:label="loc_KZIA_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_KZIA_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xlink:label="loc_KZIA_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_KZIA_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xlink:label="loc_KZIA_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_KZIA_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" use="optional" order="3" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>kzia-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-October-2021 [03:11:17] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Cover" roleURI="http://www.kaziatherapeutics.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#StatementsOfChangesInEquity" roleURI="http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefits" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefits" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsideration" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsideration" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayablesTables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefitsTables" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsiderationTables" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsTables" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RevenueSummaryOfLicensingRevenueDetail" roleURI="http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail" roleURI="http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ExpensesSummaryOfExpensesDetail" roleURI="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail" roleURI="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IntangiblesSummaryOfReconciliationsOfIntangiblesDetail" roleURI="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsiderationAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformationStatementOfFinancialPositionDetail" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail" roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail" roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShareAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncomeSummaryOfOtherIncomeDetail" roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OperatingSegmentsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherAssetsSummaryOfCurrentAssetsOtherDetail" roleURI="http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail" roleURI="http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquityAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquityAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquitySummaryOfEquityContributedEquityDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShareSummaryOfEarningsPerShareDetail" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#GeneralInformation" roleURI="http://www.kaziatherapeutics.com/role/GeneralInformation" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SignificantAccountingPolicies" roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CriticalAccountingJudgementsEstimatesAndAssumptions" roleURI="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OperatingSegments" roleURI="http://www.kaziatherapeutics.com/role/OperatingSegments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Revenue" roleURI="http://www.kaziatherapeutics.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncome" roleURI="http://www.kaziatherapeutics.com/role/OtherIncome" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncomeTables" roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Expenses" roleURI="http://www.kaziatherapeutics.com/role/Expenses" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ExpensesTables" roleURI="http://www.kaziatherapeutics.com/role/ExpensesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefit" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefit" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitTables" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalents" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalentsTables" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherAssets" roleURI="http://www.kaziatherapeutics.com/role/OtherAssets" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherAssetsTables" roleURI="http://www.kaziatherapeutics.com/role/OtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Intangibles" roleURI="http://www.kaziatherapeutics.com/role/Intangibles" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IntangiblesTables" roleURI="http://www.kaziatherapeutics.com/role/IntangiblesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SubsequentEvents" roleURI="http://www.kaziatherapeutics.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurement" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementTables" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosures" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosuresTables" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditors" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditors" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditorsTables" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentLiabilities" roleURI="http://www.kaziatherapeutics.com/role/ContingentLiabilities" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Commitments" roleURI="http://www.kaziatherapeutics.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RelatedPartyTransactions" roleURI="http://www.kaziatherapeutics.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformation" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformation" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformationTables" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#InterestsInSubsidiaries" roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#InterestsInSubsidiariesTables" roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShare" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShare" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShareTables" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPayments" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPayments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsTables" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquity" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquityTables" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityReserves" roleURI="http://www.kaziatherapeutics.com/role/EquityReserves" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityDividends" roleURI="http://www.kaziatherapeutics.com/role/EquityDividends" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstruments" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#DeferredTax" roleURI="http://www.kaziatherapeutics.com/role/DeferredTax" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#DeferredTaxTables" roleURI="http://www.kaziatherapeutics.com/role/DeferredTaxTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquity" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquity" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquityTables" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquityTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities" roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables" roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RevenueTables" roleURI="http://www.kaziatherapeutics.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefitsSummaryOfProvisionDetail" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_10" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_5" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_5" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_6" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_3" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_3_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_3_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_3" xlink:to="loc_dei_BusinessContactMember_7" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_26" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_13" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_12" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_34" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_18" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_11" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_16" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1095728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_Security12bTitle_1095728" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_20" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_27" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_36" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_32" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CityAreaCode_35" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_38" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelName_9" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CountryRegion_33" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_15" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_19" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_25" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_14" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityShellCompany_23" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_22" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_8" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_28" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_29" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressCountry_31" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_30" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1095730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_1095730" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1095731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_SecurityExchangeName_1095731" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_24" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_17" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_37" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1095717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1095717" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1095721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFileNumber_1095721" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1095722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1095722" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_Equity_119" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_121" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_ComprehensiveIncome_122" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_ProfitLoss_120" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_111" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_111" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_106" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_106" xlink:to="loc_ifrs-full_EquityMember_107" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_106" xlink:to="loc_ifrs-full_EquityMember_107_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_RetainedEarningsMember_116" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_IssuedCapitalMember_113" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterestMember" xlink:label="loc_ifrs-full_OtherEquityInterestMember_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_OtherEquityInterestMember_114" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_OtherReservesMember_115" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_743777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_743777" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_111" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" xlink:to="loc_ifrs-full_RestatedMember_108" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" xlink:to="loc_ifrs-full_RestatedMember_108_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="loc_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_108" xlink:to="loc_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_118" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_108" xlink:to="loc_ifrs-full_PreviouslyStatedMember_117" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:label="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_127" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xlink:label="loc_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions_128" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_129" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_125" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IssueOfEquity_130" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_1095519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_1095519" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_124" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseDecreaseThroughExpireOfOptions" xlink:label="loc_kzia_IncreaseDecreaseThroughExpireOfOptions_757032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_kzia_IncreaseDecreaseThroughExpireOfOptions_757032" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_930" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_930" xlink:to="loc_kzia_StatementTable_931" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_931" xlink:to="loc_ifrs-full_MaturityAxis_929" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_929" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_928" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_928_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_929" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_928_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_928" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_932" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_930" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_933" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EmployeeBenefits">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_946" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_946" xlink:to="loc_kzia_StatementTable_947" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_947" xlink:to="loc_ifrs-full_MaturityAxis_945" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_945" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_944" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_944_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_945" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_944_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_944" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_948" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_946" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_949" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsideration">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_962" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_962" xlink:to="loc_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory_966" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_962" xlink:to="loc_kzia_StatementTable_963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_963" xlink:to="loc_ifrs-full_MaturityAxis_961" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_961" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_960" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_960_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_961" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_960_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_960" xlink:to="loc_ifrs-full_LaterThanOneYearMember_965" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_895" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_895" xlink:to="loc_kzia_StatementTable_896" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_896" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" xlink:to="loc_ifrs-full_FinancialAssetsMember_894" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_894_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" xlink:to="loc_ifrs-full_FinancialAssetsMember_894_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_895" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory_898" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_938" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_938" xlink:to="loc_kzia_StatementTable_939" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_939" xlink:to="loc_ifrs-full_MaturityAxis_937" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_937" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_936" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_936_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_937" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_936_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_936" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_940" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_938" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_941" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_954" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_954" xlink:to="loc_kzia_StatementTable_955" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_955" xlink:to="loc_ifrs-full_MaturityAxis_953" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_953" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_952" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_953" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_952_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_952" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_956" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_954" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory_957" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsiderationTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_971" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_971" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory_975" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_971" xlink:to="loc_kzia_StatementTable_972" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_972" xlink:to="loc_ifrs-full_MaturityAxis_970" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_970" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_969" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_969_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_970" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_969_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_969" xlink:to="loc_ifrs-full_LaterThanOneYearMember_974" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_1007" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_1011" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1012" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_1014" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_1013" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_kzia_StatementTable_1008" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_StatementTable_1008" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1009" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1009" xlink:to="loc_ifrs-full_TypesOfRisksMember_1010" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1010_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1009" xlink:to="loc_ifrs-full_TypesOfRisksMember_1010_default" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_CurrentAssetsLiabilities_187" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xlink:label="loc_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183" xlink:to="loc_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember_201" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_RangeAxis_180" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_180" xlink:to="loc_ifrs-full_RangesMember_181" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_180" xlink:to="loc_ifrs-full_RangesMember_181_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_181" xlink:to="loc_ifrs-full_TopOfRangeMember_200" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeAxis" xlink:label="loc_kzia_FundingPurposeAxis_743822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_kzia_FundingPurposeAxis_743822" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeMember" xlink:label="loc_kzia_FundingPurposeMember_743824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kzia_FundingPurposeAxis_743822" xlink:to="loc_kzia_FundingPurposeMember_743824" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeMember" xlink:label="loc_kzia_FundingPurposeMember_743824_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kzia_FundingPurposeAxis_743822" xlink:to="loc_kzia_FundingPurposeMember_743824_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ClinicalTrialsMember" xlink:label="loc_kzia_ClinicalTrialsMember_743827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_FundingPurposeMember_743824" xlink:to="loc_kzia_ClinicalTrialsMember_743827" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_179" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_179_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_757030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" xlink:to="loc_ifrs-full_NonadjustingEventsMember_757030" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_757030_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" xlink:to="loc_ifrs-full_NonadjustingEventsMember_757030_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicenseAgreementForPaxalisibMember" xlink:label="loc_kzia_LicenseAgreementForPaxalisibMember_1096114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" xlink:to="loc_kzia_LicenseAgreementForPaxalisibMember_1096114" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingAgreementForEvtEightZeroOneMember" xlink:label="loc_kzia_LicensingAgreementForEvtEightZeroOneMember_1096116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" xlink:to="loc_kzia_LicensingAgreementForEvtEightZeroOneMember_1096116" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityAxis" xlink:label="loc_kzia_UncertainityAxis_743829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_kzia_UncertainityAxis_743829" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityMember" xlink:label="loc_kzia_UncertainityMember_743830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kzia_UncertainityAxis_743829" xlink:to="loc_kzia_UncertainityMember_743830" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityMember" xlink:label="loc_kzia_UncertainityMember_743830_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kzia_UncertainityAxis_743829" xlink:to="loc_kzia_UncertainityMember_743830_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_CovidNinteenMember" xlink:label="loc_kzia_CovidNinteenMember_743831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_UncertainityMember_743830" xlink:to="loc_kzia_CovidNinteenMember_743831" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InterestIncomeLoss" xlink:label="loc_kzia_InterestIncomeLoss_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_InterestIncomeLoss_192" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xlink:label="loc_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife_195" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_743819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_743819" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_CashAndCashEquivalents_189" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_188" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdditionalTaxDeductionPercentage" xlink:label="loc_kzia_AdditionalTaxDeductionPercentage_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_AdditionalTaxDeductionPercentage_191" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_ProfitLoss_186" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_1095528" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_1095532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_1095528" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_1095532" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesTable" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_1095528" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_1095529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_1095529" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1095530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1095529" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1095530" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1095530_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1095529" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1095530_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingRevenueMember" xlink:label="loc_kzia_LicensingRevenueMember_1095531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1095530" xlink:to="loc_kzia_LicensingRevenueMember_1095531" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_1095535" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_1095535" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1095542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1095542" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1095536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1095536" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1095537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1095536" xlink:to="loc_ifrs-full_GeographicalAreasMember_1095537" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1095537_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1095536" xlink:to="loc_ifrs-full_GeographicalAreasMember_1095537_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="loc_country_CN_1095538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1095537" xlink:to="loc_country_CN_1095538" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SwedanMember" xlink:label="loc_kzia_SwedanMember_1095539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1095537" xlink:to="loc_kzia_SwedanMember_1095539" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_1095543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_1095543" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1095544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1095543" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1095544" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1095544_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1095543" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1095544_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingRevenueMember" xlink:label="loc_kzia_LicensingRevenueMember_1095545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1095544" xlink:to="loc_kzia_LicensingRevenueMember_1095545" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_1095546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_1095535" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_1095546" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfExpensesByNatureLineItems" xlink:label="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xlink:label="loc_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction_1095551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction_1095551" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MinimumOperatingLeasePayment" xlink:label="loc_kzia_MinimumOperatingLeasePayment_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_MinimumOperatingLeasePayment_237" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xlink:label="loc_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction_1095553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction_1095553" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNature" xlink:label="loc_ifrs-full_ExpenseByNature_1095554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_ExpenseByNature_1095554" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_239" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_238" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-full_ProfitLossAbstract_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_ProfitLossAbstract_231" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAbstract_231" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_245" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfExpensesByNatureTable" xlink:label="loc_kzia_DisclosureOfExpensesByNatureTable_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_DisclosureOfExpensesByNatureTable_229" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfExpensesByNatureTable_229" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaxalisibLicensingAgreementMember" xlink:label="loc_kzia_PaxalisibLicensingAgreementMember_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" xlink:to="loc_kzia_PaxalisibLicensingAgreementMember_243" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EvotechLicensingAgreementMember" xlink:label="loc_kzia_EvotechLicensingAgreementMember_1101993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" xlink:to="loc_kzia_EvotechLicensingAgreementMember_1101993" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfExpensesByNatureTable_229" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_232" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_232_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_232_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_1095550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_1095550" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitLineItems" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitsTable" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" xlink:to="loc_ifrs-full_GeographicalAreasAxis_253" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_253" xlink:to="loc_ifrs-full_GeographicalAreasMember_254" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_254_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_253" xlink:to="loc_ifrs-full_GeographicalAreasMember_254_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_254" xlink:to="loc_country_AU_258" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_254" xlink:to="loc_country_US_259" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_260" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_261" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:label="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xlink:label="loc_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim_263" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xlink:label="loc_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable_266" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAmortisationOfIntangibles" xlink:label="loc_kzia_TaxEffectOfAmortisationOfIntangibles_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfAmortisationOfIntangibles_264" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfExpenseEmployeeOptionPlan" xlink:label="loc_kzia_TaxEffectOfExpenseEmployeeOptionPlan_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfExpenseEmployeeOptionPlan_265" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xlink:label="loc_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate_1095555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate_1095555" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xlink:label="loc_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped_269" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xlink:label="loc_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised_270" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxLossesNotRecognisedAbstract" xlink:label="loc_kzia_TaxLossesNotRecognisedAbstract_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_kzia_TaxLossesNotRecognisedAbstract_257" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxLossesNotRecognisedAbstract_257" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes_273" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_TaxLossesNotRecognisedAbstract_257" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_272" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitLineItems" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_276" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_276" xlink:to="loc_ifrs-full_ApplicableTaxRate_280" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitsTable" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_276" xlink:to="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" xlink:to="loc_ifrs-full_GeographicalAreasAxis_278" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_278" xlink:to="loc_ifrs-full_GeographicalAreasMember_279" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_279_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_278" xlink:to="loc_ifrs-full_GeographicalAreasMember_279_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_279" xlink:to="loc_country_AU_281" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_279" xlink:to="loc_country_US_282" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_300" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_CurrentTradeReceivables_298" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" xlink:to="loc_ifrs-full_CarryingAmountMember_291" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_291_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" xlink:to="loc_ifrs-full_CarryingAmountMember_291_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xlink:label="loc_kzia_ResearchAndDevelopmentTaxRebateReceivableMember_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_kzia_ResearchAndDevelopmentTaxRebateReceivableMember_296" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_295" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositsHeldMember" xlink:label="loc_kzia_DepositsHeldMember_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_kzia_DepositsHeldMember_297" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_294" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_OtherCurrentReceivables_299" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositPaidNonCurrent" xlink:label="loc_kzia_DepositPaidNonCurrent_1095562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_kzia_DepositPaidNonCurrent_1095562" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_1095563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_1095563" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_363" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_363" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" xlink:to="loc_ifrs-full_CarryingAmountMember_361" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_361_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" xlink:to="loc_ifrs-full_CarryingAmountMember_361_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_361" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_367" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_361" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_366" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LicencesMember" xlink:label="loc_ifrs-full_LicencesMember_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" xlink:to="loc_ifrs-full_LicencesMember_370" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingAgreementMember" xlink:label="loc_kzia_LicensingAgreementMember_1095567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" xlink:to="loc_kzia_LicensingAgreementMember_1095567" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_363" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_368" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaxalisibLicensingAgreementMember" xlink:label="loc_kzia_PaxalisibLicensingAgreementMember_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" xlink:to="loc_kzia_PaxalisibLicensingAgreementMember_384" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EVT801LicensingAgreementMember" xlink:label="loc_kzia_EVT801LicensingAgreementMember_1096249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" xlink:to="loc_kzia_EVT801LicensingAgreementMember_1096249" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_377" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_378" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_380" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1095581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1095581" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1095581_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1095581_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationPaxalisibMember" xlink:label="loc_kzia_ContingentConsiderationPaxalisibMember_1095582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1095581" xlink:to="loc_kzia_ContingentConsiderationPaxalisibMember_1095582" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationEvt801Member" xlink:label="loc_kzia_ContingentConsiderationEvt801Member_1095583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1095581" xlink:to="loc_kzia_ContingentConsiderationEvt801Member_1095583" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationCurrent" xlink:label="loc_kzia_ContingentConsiderationCurrent_1095577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_kzia_ContingentConsiderationCurrent_1095577" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_kzia_ContingentConsiderationNoncurrent_1095578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_kzia_ContingentConsiderationNoncurrent_1095578" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsideration" xlink:label="loc_kzia_ContingentConsideration_1095579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_kzia_ContingentConsideration_1095579" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1095592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1095592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1095592_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1095592_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestoneTwoMember" xlink:label="loc_kzia_MilestoneTwoMember_1095593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1095592" xlink:to="loc_kzia_MilestoneTwoMember_1095593" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1096415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1096415" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1096415" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1096415" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GlioblastPtyLtdMember" xlink:label="loc_kzia_GlioblastPtyLtdMember_1096421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" xlink:to="loc_kzia_GlioblastPtyLtdMember_1096421" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GenentechAgreementMember" xlink:label="loc_kzia_GenentechAgreementMember_1096425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" xlink:to="loc_kzia_GenentechAgreementMember_1096425" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaymentsForContingentConsideration" xlink:label="loc_kzia_PaymentsForContingentConsideration_1095588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_PaymentsForContingentConsideration_1095588" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentPayable" xlink:label="loc_kzia_MilestonePaymentPayable_1095589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_MilestonePaymentPayable_1095589" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentDiscountRate" xlink:label="loc_kzia_MilestonePaymentDiscountRate_1096347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_MilestonePaymentDiscountRate_1096347" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_1096410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_1096410" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentsNotBooked" xlink:label="loc_kzia_MilestonePaymentsNotBooked_1095590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_MilestonePaymentsNotBooked_1095590" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfContingentMilestonePayments" xlink:label="loc_kzia_NumberOfContingentMilestonePayments_1096429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_NumberOfContingentMilestonePayments_1096429" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_461" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsAxis" xlink:label="loc_kzia_EquityTransactionsAxis_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_kzia_EquityTransactionsAxis_455" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsMember" xlink:label="loc_kzia_EquityTransactionsMember_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kzia_EquityTransactionsAxis_455" xlink:to="loc_kzia_EquityTransactionsMember_456" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsMember" xlink:label="loc_kzia_EquityTransactionsMember_456_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kzia_EquityTransactionsAxis_455" xlink:to="loc_kzia_EquityTransactionsMember_456_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_450" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_450" xlink:to="loc_ifrs-full_EquityMember_454" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_454_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_450" xlink:to="loc_ifrs-full_EquityMember_454_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_454" xlink:to="loc_ifrs-full_IssuedCapitalMember_470" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_449" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_449" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_453" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_453_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_449" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_453_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateAxis" xlink:label="loc_kzia_SharePurchasePlanIssueDateAxis_744896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_kzia_SharePurchasePlanIssueDateAxis_744896" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateDomain" xlink:label="loc_kzia_SharePurchasePlanIssueDateDomain_744897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kzia_SharePurchasePlanIssueDateAxis_744896" xlink:to="loc_kzia_SharePurchasePlanIssueDateDomain_744897" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateDomain" xlink:label="loc_kzia_SharePurchasePlanIssueDateDomain_744897_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kzia_SharePurchasePlanIssueDateAxis_744896" xlink:to="loc_kzia_SharePurchasePlanIssueDateDomain_744897_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xlink:label="loc_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember_744901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember_744901" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" xlink:label="loc_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember_1095602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember_1095602" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" xlink:label="loc_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember_1095603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember_1095603" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xlink:label="loc_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember_1096679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember_1096679" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xlink:label="loc_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember_1096681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember_1096681" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xlink:label="loc_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember_744902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember_744902" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_457_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_457_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConversionOfOptionsMember" xlink:label="loc_kzia_ConversionOfOptionsMember_744739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_ConversionOfOptionsMember_744739" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareIssueTransactionCostsMember" xlink:label="loc_kzia_ShareIssueTransactionCostsMember_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_ShareIssueTransactionCostsMember_474" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePlacementMember" xlink:label="loc_kzia_SharePlacementMember_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_SharePlacementMember_472" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanMember" xlink:label="loc_kzia_SharePurchasePlanMember_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_SharePurchasePlanMember_473" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InstitutionalPlacementUnderAnreoMember" xlink:label="loc_kzia_InstitutionalPlacementUnderAnreoMember_1095599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_InstitutionalPlacementUnderAnreoMember_1095599" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RetailPlacementUnderAnreoMember" xlink:label="loc_kzia_RetailPlacementUnderAnreoMember_1095600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_RetailPlacementUnderAnreoMember_1095600" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssuedOnAchievementOfAMilestoneMember" xlink:label="loc_kzia_IssuedOnAchievementOfAMilestoneMember_1095601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_IssuedOnAchievementOfAMilestoneMember_1095601" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_459" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_Equity_464" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_IssueOfEquity_466" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharesIssuedPricePerShare1" xlink:label="loc_kzia_SharesIssuedPricePerShare1_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_kzia_SharesIssuedPricePerShare1_463" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" xlink:to="loc_ifrs-full_TypesOfRisksAxis_510" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_510" xlink:to="loc_ifrs-full_TypesOfRisksMember_511" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_511_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_510" xlink:to="loc_ifrs-full_TypesOfRisksMember_511_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_511" xlink:to="loc_ifrs-full_CurrencyRiskMember_516" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" xlink:to="loc_srt_CurrencyAxis_507" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_507" xlink:to="loc_currency_AllCurrenciesDomain_506" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_506_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_507" xlink:to="loc_currency_AllCurrenciesDomain_506_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_506" xlink:to="loc_currency_USD_512" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_506" xlink:to="loc_currency_EUR_513" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" xlink:to="loc_ifrs-full_FinancialAssets_514" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" xlink:to="loc_ifrs-full_FinancialLiabilities_515" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_CashAndCashEquivalents_528" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_srt_CurrencyAxis_520" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_520" xlink:to="loc_currency_AllCurrenciesDomain_519" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_519_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_520" xlink:to="loc_currency_AllCurrenciesDomain_519_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_519" xlink:to="loc_currency_USD_525" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_ifrs-full_TypesOfRisksAxis_523" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_523" xlink:to="loc_ifrs-full_TypesOfRisksMember_524" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_523" xlink:to="loc_ifrs-full_TypesOfRisksMember_524_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_524" xlink:to="loc_ifrs-full_CurrencyRiskMember_530" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_524" xlink:to="loc_ifrs-full_InterestRateRiskMember_531" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_743961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_743961" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_743962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_743961" xlink:to="loc_ifrs-full_InterestRateTypesMember_743962" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_743962_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_743961" xlink:to="loc_ifrs-full_InterestRateTypesMember_743962_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_Assets_526" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_529" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xlink:label="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_527" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_745002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_Liabilities_745002" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_ifrs-full_RangeAxis_538" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_538" xlink:to="loc_ifrs-full_RangesMember_539" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_539_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_538" xlink:to="loc_ifrs-full_RangesMember_539_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:label="loc_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember_550" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xlink:label="loc_kzia_EffectOfIncreaseInMarketRiskOnEquityMember_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfIncreaseInMarketRiskOnEquityMember_547" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:label="loc_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember_546" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xlink:label="loc_kzia_EffectOfDecreaseInMarketRiskOnEquityMember_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfDecreaseInMarketRiskOnEquityMember_549" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseInMarketRiskMember" xlink:label="loc_kzia_IncreaseInMarketRiskMember_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_IncreaseInMarketRiskMember_545" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DecreaseInMarketRiskMember" xlink:label="loc_kzia_DecreaseInMarketRiskMember_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_DecreaseInMarketRiskMember_548" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_srt_CurrencyAxis_535" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_535" xlink:to="loc_currency_AllCurrenciesDomain_534" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_535" xlink:to="loc_currency_AllCurrenciesDomain_534_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_534" xlink:to="loc_currency_USD_542" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_1091500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_534" xlink:to="loc_currency_EUR_1091500" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_ifrs-full_TypesOfRisksAxis_540" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_540" xlink:to="loc_ifrs-full_TypesOfRisksMember_541" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_540" xlink:to="loc_ifrs-full_TypesOfRisksMember_541_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_541" xlink:to="loc_ifrs-full_CurrencyRiskMember_551" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" xlink:to="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_544" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xlink:label="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" xlink:to="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_543" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_568" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_RangeAxis_559" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_559" xlink:to="loc_ifrs-full_RangesMember_560" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_560_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_559" xlink:to="loc_ifrs-full_RangesMember_560_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageMember" xlink:label="loc_ifrs-full_WeightedAverageMember_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_560" xlink:to="loc_ifrs-full_WeightedAverageMember_571" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_561" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_561" xlink:to="loc_ifrs-full_InterestRateTypesMember_558" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_561" xlink:to="loc_ifrs-full_InterestRateTypesMember_558_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_558" xlink:to="loc_ifrs-full_FloatingInterestRateMember_570" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_TypesOfRisksAxis_562" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_562" xlink:to="loc_ifrs-full_TypesOfRisksMember_563" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_562" xlink:to="loc_ifrs-full_TypesOfRisksMember_563_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_563" xlink:to="loc_ifrs-full_InterestRateRiskMember_572" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_CashAtBankAndInHandMember" xlink:label="loc_kzia_CashAtBankAndInHandMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" xlink:to="loc_kzia_CashAtBankAndInHandMember_564" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShortTermDepositsMember" xlink:label="loc_kzia_ShortTermDepositsMember_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" xlink:to="loc_kzia_ShortTermDepositsMember_565" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_FinancialAssets_569" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InterestRate" xlink:label="loc_kzia_InterestRate_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_kzia_InterestRate_566" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_Cash_567" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" xlink:to="loc_ifrs-full_MaturityAxis_580" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_580" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_575" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_580" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_575_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_575" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_582" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1096348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_575" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1096348" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_575" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_581" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_579" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_579_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_588" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationUndiscountedCashFlows" xlink:label="loc_kzia_ContingentConsiderationUndiscountedCashFlows_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_kzia_ContingentConsiderationUndiscountedCashFlows_587" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TradePayablesUndiscountedCashFlows" xlink:label="loc_kzia_TradePayablesUndiscountedCashFlows_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_kzia_TradePayablesUndiscountedCashFlows_585" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AccruedPayablesUndiscountedCashFlows" xlink:label="loc_kzia_AccruedPayablesUndiscountedCashFlows_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_kzia_AccruedPayablesUndiscountedCashFlows_586" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_kzia_ContingentConsiderationNoncurrent_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" xlink:to="loc_kzia_ContingentConsiderationNoncurrent_608" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_599" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_599_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_604" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_MeasurementAxis_601" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_601" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_594" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_601" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_594_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_594" xlink:to="loc_ifrs-full_AtFairValueMember_602" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" xlink:to="loc_ifrs-full_Liabilities_609" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1095630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_1095630" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1095632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1095632" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1095632_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1095632_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember_1095634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1095632" xlink:to="loc_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember_1095634" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_1102008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_ifrs-full_MeasurementAxis_1102008" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1102009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_1102008" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1102009" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1102009_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_1102008" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1102009_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_1102010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1102009" xlink:to="loc_ifrs-full_AtFairValueMember_1102010" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FairValueOfAssetsAndLiabilities" xlink:label="loc_kzia_FairValueOfAssetsAndLiabilities_1095635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_kzia_FairValueOfAssetsAndLiabilities_1095635" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets_1095636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets_1095636" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PayoutOfMilestone" xlink:label="loc_kzia_PayoutOfMilestone_1095638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_kzia_PayoutOfMilestone_1095638" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_614" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentDiscountRate" xlink:label="loc_kzia_MilestonePaymentDiscountRate_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_614" xlink:to="loc_kzia_MilestonePaymentDiscountRate_622" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_614" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" xlink:to="loc_ifrs-full_RangeAxis_616" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_616" xlink:to="loc_ifrs-full_RangesMember_617" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_617_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_616" xlink:to="loc_ifrs-full_RangesMember_617_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_617" xlink:to="loc_ifrs-full_BottomOfRangeMember_623" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_617" xlink:to="loc_ifrs-full_TopOfRangeMember_624" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_657" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_658" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_656" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_656_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions_660" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions_659" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationLineItems" xlink:label="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" xlink:to="loc_ifrs-full_ComprehensiveIncome_671" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationTable" xlink:label="loc_kzia_DisclosureOfParentEntityInformationTable_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" xlink:to="loc_kzia_DisclosureOfParentEntityInformationTable_668" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable_668" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669" xlink:to="loc_ifrs-full_ParentMember_672" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" xlink:to="loc_ifrs-full_ProfitLoss_670" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationLineItems" xlink:label="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationTable" xlink:label="loc_kzia_DisclosureOfParentEntityInformationTable_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_kzia_DisclosureOfParentEntityInformationTable_677" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable_677" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678" xlink:to="loc_ifrs-full_ParentMember_684" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_CurrentAssets_680" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_CurrentLiabilities_682" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_Assets_681" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_EquityAbstract_679" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_RetainedEarnings_688" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_Equity_689" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_IssuedCapital_685" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_OtherEquityInterest_686" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_OtherReserves_687" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_Liabilities_683" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaTherapeuticsIncMember" xlink:label="loc_kzia_KaziaTherapeuticsIncMember_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaTherapeuticsIncMember_701" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GlioblastPtyLtdMember" xlink:label="loc_kzia_GlioblastPtyLtdMember_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_GlioblastPtyLtdMember_702" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaLaboratoriesPtyLtdMember" xlink:label="loc_kzia_KaziaLaboratoriesPtyLtdMember_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaLaboratoriesPtyLtdMember_699" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaResearchPtyLtdMember" xlink:label="loc_kzia_KaziaResearchPtyLtdMember_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaResearchPtyLtdMember_700" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaTherapeuticsHongKongLimitedMember" xlink:label="loc_kzia_KaziaTherapeuticsHongKongLimitedMember_1095508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaTherapeuticsHongKongLimitedMember_1095508" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_697" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="loc_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_696" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_698" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable_744087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" xlink:to="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable_744087" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_744093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" xlink:to="loc_ifrs-full_ProfitLoss_744093" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_744096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_744096" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_744099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_744099" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_744101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_744101" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_744104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_744104" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_744110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_744110" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_744144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_744144" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_757111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_757111" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xlink:label="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments_744151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments_744151" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_744115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_744115" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables_744155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables_744155" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xlink:label="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities_744159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities_744159" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_744160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_744160" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_744162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_744162" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_757104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_757104" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_714" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_ifrs-full_EarningsPerShareTable_715" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_EarningsPerShareTable_715" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" xlink:to="loc_ifrs-full_FinancialAssetsMember_716" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_716_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" xlink:to="loc_ifrs-full_FinancialAssetsMember_716_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UnlistedOptionsMember" xlink:label="loc_kzia_UnlistedOptionsMember_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_716" xlink:to="loc_kzia_UnlistedOptionsMember_720" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xlink:label="loc_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare_719" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOrdinarySharesAvailableForConversion" xlink:label="loc_kzia_NumberOfOrdinarySharesAvailableForConversion_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_kzia_NumberOfOrdinarySharesAvailableForConversion_717" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_ifrs-full_OtherEquityInterest_718" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_728" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOptionsIssued" xlink:label="loc_kzia_NumberOfOptionsIssued_1095506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_kzia_NumberOfOptionsIssued_1095506" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_733" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageOfOptionsVested" xlink:label="loc_kzia_PercentageOfOptionsVested_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_kzia_PercentageOfOptionsVested_730" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_744540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_ifrs-full_RangeAxis_744540" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_744541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_744540" xlink:to="loc_ifrs-full_RangesMember_744541" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_744541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_744540" xlink:to="loc_ifrs-full_RangesMember_744541_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_744542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_744541" xlink:to="loc_ifrs-full_BottomOfRangeMember_744542" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_744543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_744541" xlink:to="loc_ifrs-full_TopOfRangeMember_744543" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_726_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheOneMember" xlink:label="loc_kzia_OtherTrancheOneMember_744544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheOneMember_744544" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheTwoMember" xlink:label="loc_kzia_OtherTrancheTwoMember_744545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheTwoMember_744545" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TranchesTwoAndEightMember" xlink:label="loc_kzia_TranchesTwoAndEightMember_1095505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_TranchesTwoAndEightMember_1095505" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_TrancheNineMember_736" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheThreeMember" xlink:label="loc_kzia_OtherTrancheThreeMember_744546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheThreeMember_744546" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TranchesTenAndTwelveMember" xlink:label="loc_kzia_TranchesTenAndTwelveMember_1095507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_TranchesTenAndTwelveMember_1095507" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheFourMember" xlink:label="loc_kzia_OtherTrancheFourMember_744547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheFourMember_744547" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesAxis" xlink:label="loc_kzia_AwardTypesAxis_750953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_kzia_AwardTypesAxis_750953" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesMember" xlink:label="loc_kzia_AwardTypesMember_750954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kzia_AwardTypesAxis_750953" xlink:to="loc_kzia_AwardTypesMember_750954" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesMember" xlink:label="loc_kzia_AwardTypesMember_750954_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kzia_AwardTypesAxis_750953" xlink:to="loc_kzia_AwardTypesMember_750954_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_745070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_745070" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOptionsVested" xlink:label="loc_kzia_NumberOfOptionsVested_750952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_kzia_NumberOfOptionsVested_750952" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_749" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_746" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_745073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_745073" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_744_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_744_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFifteenMember" xlink:label="loc_kzia_TrancheFifteenMember_744211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFifteenMember_744211" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheNineMember_767" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwoMember" xlink:label="loc_kzia_TrancheTwoMember_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheTwoMember_760" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheOneMember" xlink:label="loc_kzia_TrancheOneMember_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheOneMember_759" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSevenMember" xlink:label="loc_kzia_TrancheSevenMember_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSevenMember_765" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixMember" xlink:label="loc_kzia_TrancheSixMember_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSixMember_764" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTenMember" xlink:label="loc_kzia_TrancheTenMember_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheTenMember_768" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirteenMember" xlink:label="loc_kzia_TrancheThirteenMember_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheThirteenMember_771" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThreeMember" xlink:label="loc_kzia_TrancheThreeMember_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheThreeMember_761" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwelveMember" xlink:label="loc_kzia_TrancheTwelveMember_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheTwelveMember_770" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixteenMember" xlink:label="loc_kzia_TrancheSixteenMember_744212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSixteenMember_744212" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFiveMember" xlink:label="loc_kzia_TrancheFiveMember_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFiveMember_763" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourMember" xlink:label="loc_kzia_TrancheFourMember_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFourMember_762" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEighteenMember" xlink:label="loc_kzia_TrancheEighteenMember_1096737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheEighteenMember_1096737" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineteenMember" xlink:label="loc_kzia_TrancheNineteenMember_1096738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheNineteenMember_1096738" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourteenMember" xlink:label="loc_kzia_TrancheFourteenMember_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFourteenMember_772" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEightMember" xlink:label="loc_kzia_TrancheEightMember_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheEightMember_766" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheElevenMember" xlink:label="loc_kzia_TrancheElevenMember_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheElevenMember_769" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSeventeenMember" xlink:label="loc_kzia_TrancheSeventeenMember_1096736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSeventeenMember_1096736" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_744664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_744664" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745066" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xlink:label="loc_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement_744648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement_744648" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xlink:label="loc_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement_744655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement_744655" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_744662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_744662" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_745072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_745072" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_750" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xlink:label="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_747" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745069" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_786" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_785" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_777_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_777_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTenMember" xlink:label="loc_kzia_TrancheTenMember_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTenMember_796" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirteenMember" xlink:label="loc_kzia_TrancheThirteenMember_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheThirteenMember_799" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheNineMember_795" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixteenMember" xlink:label="loc_kzia_TrancheSixteenMember_744707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheSixteenMember_744707" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwelveMember" xlink:label="loc_kzia_TrancheTwelveMember_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwelveMember_798" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyOneMember" xlink:label="loc_kzia_TrancheTwentyOneMember_1095869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyOneMember_1095869" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyTwoMember" xlink:label="loc_kzia_TrancheTwentyTwoMember_1096853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyTwoMember_1096853" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyThreeMember" xlink:label="loc_kzia_TrancheTwentyThreeMember_1096854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyThreeMember_1096854" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyFourMember" xlink:label="loc_kzia_TrancheTwentyFourMember_1096859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyFourMember_1096859" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyFiveMember" xlink:label="loc_kzia_TrancheTwentyFiveMember_1096862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyFiveMember_1096862" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentySixMember" xlink:label="loc_kzia_TrancheTwentySixMember_1096863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentySixMember_1096863" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourteenMember" xlink:label="loc_kzia_TrancheFourteenMember_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheFourteenMember_800" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEightMember" xlink:label="loc_kzia_TrancheEightMember_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheEightMember_794" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheElevenMember" xlink:label="loc_kzia_TrancheElevenMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheElevenMember_797" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyMember" xlink:label="loc_kzia_TrancheTwentyMember_1095868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyMember_1095868" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentySevenMember" xlink:label="loc_kzia_TrancheTwentySevenMember_1096865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentySevenMember_1096865" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyEightMember" xlink:label="loc_kzia_TrancheTwentyEightMember_1096867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyEightMember_1096867" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyNineMember" xlink:label="loc_kzia_TrancheTwentyNineMember_1096868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyNineMember_1096868" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirtyMember" xlink:label="loc_kzia_TrancheThirtyMember_1096869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheThirtyMember_1096869" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirtyOneMember" xlink:label="loc_kzia_TrancheThirtyOneMember_1096870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheThirtyOneMember_1096870" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFifteenMember" xlink:label="loc_kzia_TrancheFifteenMember_744706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheFifteenMember_744706" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_779" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_783" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_784" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xlink:label="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_780" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePricePerShare" xlink:label="loc_kzia_SharePricePerShare_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_kzia_SharePricePerShare_781" use="optional" order="33" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>kzia-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-October-2021 [03:11:17] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress" xml:lang="en-US">Contact Personnel Email Address</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_ContactPersonnelEmailAddress" xml:lang="en-US">Contact Personnel Email Address</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CountryRegion" xml:lang="en-US">Country Region</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CountryRegion" xml:lang="en-US">Country Region</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Contact Personnel, Contact Person Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Contact Person Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xml:lang="en-US">Profit or loss [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromInterest" xml:lang="en-US">Interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RevenueFromInterest" xml:lang="en-US">Revenue from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest" xlink:to="lab_ifrs-full_RevenueFromInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xml:lang="en-US">Comprehensive income attributable to [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xml:lang="en-US">Total comprehensive income for the year is attributable to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xml:lang="en-US">Comprehensive income, attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xml:lang="en-US">Owners of Kazia Therapeutics Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" xlink:label="loc_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" xml:lang="en-US">Basic and Diluted Earnings Per Share Continuing Operations [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" xml:lang="en-US">Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" xlink:to="lab_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" xml:lang="en-US">Basic and Diluted Earnings Per Share Continuing Operations [abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Basic earnings (loss) per share from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xml:lang="en-US">Diluted earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xml:lang="en-US">Expenses by nature [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" xml:lang="en-US">Gains (losses) on disposals of non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" xml:lang="en-US">Loss on disposal of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" xlink:to="lab_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GainLossOnRevaluationOfContingentConsideration" xlink:label="loc_kzia_GainLossOnRevaluationOfContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_GainLossOnRevaluationOfContingentConsideration" xml:lang="en-US">Gain loss on revaluation of contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_GainLossOnRevaluationOfContingentConsideration" xml:lang="en-US">Loss on revaluation of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_GainLossOnRevaluationOfContingentConsideration" xlink:to="lab_kzia_GainLossOnRevaluationOfContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_GainLossOnRevaluationOfContingentConsideration" xml:lang="en-US">Gain (loss) on revaluation of contingent consideration.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xml:lang="en-US">Fair value losses on financial assets at fair value through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit (loss) before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Loss before income tax expense from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Loss before income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that may be reclassified subsequently to profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Net exchange difference on translation of financial statements of foreign controlled entities, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income for the year, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xml:lang="en-US">Other comprehensive income for the year, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherRevenue" xml:lang="en-US">Other revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherRevenue" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income - bank interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Profit (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Loss after income tax expense for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Loss after income tax expense for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Loss before income tax expense for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Consolidated loss after income tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Loss after income tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Loss after income tax expense from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xml:lang="en-US">Loss for the year is attributable to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract" xlink:to="lab_ifrs-full_ProfitLossAttributableToAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Owners of Kazia Therapeutics Limited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xml:lang="en-US">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Income tax benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of financial position [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Net assets denominated in foreign currencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other current receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents at the end of the financial year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents at the beginning of the financial year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Consolidated cash in hand and at bank</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentAssets" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherCurrentAssets" xml:lang="en-US">Prepayments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Total non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="loc_ifrs-full_NoncurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentReceivables" xml:lang="en-US">Trade and other non-current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentReceivables" xlink:to="lab_ifrs-full_NoncurrentReceivables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xml:lang="en-US">Assets (liabilities)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xml:lang="en-US">Net assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="lab_ifrs-full_NetAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xml:lang="en-US">Liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract" xlink:to="lab_ifrs-full_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Net Liabilities denominated in foreign currencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationCurrent" xlink:label="loc_kzia_ContingentConsiderationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ContingentConsiderationCurrent" xml:lang="en-US">Contingent Consideration Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ContingentConsiderationCurrent" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ContingentConsiderationCurrent" xlink:to="lab_kzia_ContingentConsiderationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ContingentConsiderationCurrent" xml:lang="en-US">Contingent consideration current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Trade and other current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Total trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Current provisions for employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_kzia_ContingentConsiderationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ContingentConsiderationNoncurrent" xml:lang="en-US">Contingent Consideration Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ContingentConsiderationNoncurrent" xml:lang="en-US">Contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_ContingentConsiderationNoncurrent" xml:lang="en-US">Contingent Consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ContingentConsiderationNoncurrent" xlink:to="lab_kzia_ContingentConsiderationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ContingentConsiderationNoncurrent" xml:lang="en-US">Contingent consideration noncurrent.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liability associated with Licensing Agreement - Non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Total non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Non-current provisions for employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xml:lang="en-US">Long service leave</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xml:lang="en-US">Equity attributable to owners of parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xml:lang="en-US">Equity attributable to the owners of Kazia Therapeutics Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Issued capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Contributed equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Ordinary shares - fully paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Retained earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Accumulated losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherEquityInterest" xml:lang="en-US">Other equity interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_OtherEquityInterest" xml:lang="en-US">Other contributed equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherEquityInterest" xml:lang="en-US">Convertible note - Triaxial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherEquityInterest" xml:lang="en-US">Face value of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEquityInterest" xlink:to="lab_ifrs-full_OtherEquityInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Other reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherReserves" xml:lang="en-US">Reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xml:lang="en-US">Statement of changes in equity [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xml:lang="en-US">Statement of changes in equity [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xml:lang="en-US">Statement of changes in equity [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xml:lang="en-US">Components of equity [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xml:lang="en-US">Components of equity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityMember" xml:lang="en-US">Equity [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityMember" xml:lang="en-US">Equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Retained earnings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Accumulated Losses [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Issued capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Contributed equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterestMember" xlink:label="loc_ifrs-full_OtherEquityInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherEquityInterestMember" xml:lang="en-US">Other equity interest [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherEquityInterestMember" xml:lang="en-US">Other Contributed equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEquityInterestMember" xlink:to="lab_ifrs-full_OtherEquityInterestMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReservesMember" xml:lang="en-US">Other reserves [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherReservesMember" xml:lang="en-US">Reserves [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xml:lang="en-US">Non-controlling interests [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xml:lang="en-US">Non-controlling interests [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RestatedMember" xml:lang="en-US">Currently stated [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RestatedMember" xml:lang="en-US">Currently stated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember" xlink:to="lab_ifrs-full_RestatedMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="loc_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xml:lang="en-US">Increase (decrease) due to changes in accounting policy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xml:lang="en-US">Increase (decrease) due to changes in accounting policy [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lab_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PreviouslyStatedMember" xml:lang="en-US">Previously stated [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PreviouslyStatedMember" xml:lang="en-US">Previously stated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PreviouslyStatedMember" xlink:to="lab_ifrs-full_PreviouslyStatedMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xml:lang="en-US">Statement of changes in equity [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xml:lang="en-US">Statement of changes in equity [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:label="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xml:lang="en-US">Transactions with Owners in Their Capacity as Owners [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xml:lang="en-US">Transactions with owners in their capacity as owners:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="lab_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xml:lang="en-US">Transactions with owners in their capacity as owners.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xml:lang="en-US">Increase (decrease) through conversion of convertible instruments, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xml:lang="en-US">Conversion of convertible note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xlink:label="loc_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xml:lang="en-US">Increase (decrease) through employee share-based payment options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xml:lang="en-US">Employee share-based payment options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xlink:to="lab_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xml:lang="en-US">Increase (decrease) through employee share-based payment options.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Share based payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xml:lang="en-US">Increase (decrease) through other changes, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xml:lang="en-US">Transfers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Issue of equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssueOfEquity" xml:lang="en-US">Issue of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xml:lang="en-US">Increase through other contributions by owners, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xml:lang="en-US">Contributions of equity, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xml:lang="en-US">Share issue related cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xml:lang="en-US">Share issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseDecreaseThroughExpireOfOptions" xlink:label="loc_kzia_IncreaseDecreaseThroughExpireOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IncreaseDecreaseThroughExpireOfOptions" xml:lang="en-US">Increase Decrease Through Expire Of Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_IncreaseDecreaseThroughExpireOfOptions" xml:lang="en-US">Expired options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IncreaseDecreaseThroughExpireOfOptions" xlink:to="lab_kzia_IncreaseDecreaseThroughExpireOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IncreaseDecreaseThroughExpireOfOptions" xml:lang="en-US">Increase (decrease) through expire of Options</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of cash flows [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xml:lang="en-US">Proceeds from sales of interests in associates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xml:lang="en-US">Proceeds from disposal of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:to="lab_ifrs-full_ProceedsFromSalesOfInterestsInAssociates" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Cash flows from (used in) investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Adjustments for net changes in operating assets and liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Change in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="lab_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Adjustments for net changes in operating assets &amp; liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xml:lang="en-US">Increase in trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xml:lang="en-US">Decrease in trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xlink:label="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xml:lang="en-US">Adjustments For Decrease Increase In Prepayments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xml:lang="en-US">Increase/(decrease) in prepayments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xml:lang="en-US">Decrease/(increase) in prepayments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xlink:to="lab_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xml:lang="en-US">Adjustments for decrease increase in prepayments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xml:lang="en-US">Adjustments for increase (decrease) in deferred income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xml:lang="en-US">Increase/(decrease) in accrued revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Increase/(decrease) in trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xml:lang="en-US">Adjustments for provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xml:lang="en-US">Increase/(decrease) in other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xml:lang="en-US">Increase/(decrease) in other provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xlink:label="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xml:lang="en-US">Adjustments for increase (decrease) in deferred tax liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xml:lang="en-US">Decrease in deferred tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xlink:to="lab_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xml:lang="en-US">Adjustments for increase (decrease) in deferred tax liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments for:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xml:lang="en-US">Depreciation and amortisation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xml:lang="en-US">Depreciation &amp; amortisation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Adjustments for share-based payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Share-based payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Share based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xml:lang="en-US">Foreign exchange differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xml:lang="en-US">Cash flows from used in operations before changes in working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xml:lang="en-US">Change in operating assets &amp; liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ConsiderationPaidReceived" xml:lang="en-US">Consideration paid (received)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ConsiderationPaidReceived" xml:lang="en-US">Loss/(gain) on contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_ConsiderationPaidReceived" xml:lang="en-US">Loss on contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConsiderationPaidReceived" xlink:to="lab_ifrs-full_ConsiderationPaidReceived" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xml:lang="en-US">Fair value loss on financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xml:lang="en-US">Net fair value loss on financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:to="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NetLossOnDisposalOfNonCurrentAssets" xlink:label="loc_kzia_NetLossOnDisposalOfNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NetLossOnDisposalOfNonCurrentAssets" xml:lang="en-US">Net Loss On Disposal Of Non Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_kzia_NetLossOnDisposalOfNonCurrentAssets" xml:lang="en-US">Net loss on disposal of non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NetLossOnDisposalOfNonCurrentAssets" xlink:to="lab_kzia_NetLossOnDisposalOfNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NetLossOnDisposalOfNonCurrentAssets" xml:lang="en-US">Net loss on disposal of non current assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xml:lang="en-US">Impairment of property, plant &amp; equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Cash flows from (used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Net cash outflows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Cash flows from (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Net cash from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issuing shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issue of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xml:lang="en-US">Effects of exchange rate changes on cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TextBlockAbstract" xml:lang="en-US">Text block [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TextBlockAbstract" xlink:to="lab_kzia_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TextBlockAbstract" xml:lang="en-US">Text block [abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xml:lang="en-US">General information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xml:lang="en-US">Disclosure of significant accounting policies [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xml:lang="en-US">Significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xml:lang="en-US">Critical accounting judgements, estimates and assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xml:lang="en-US">Disclosure of operating segments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xml:lang="en-US">Operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xml:lang="en-US">Disclosure of revenue [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xml:lang="en-US">Disclosure of other operating income [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExpensesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfExpensesExplanatory" xml:lang="en-US">Disclosure of expenses [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfExpensesExplanatory" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Disclosure of income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xml:lang="en-US">Current assets - cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xml:lang="en-US">Disclosure of other current assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xml:lang="en-US">Current assets - other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_StatementTable" xml:lang="en-US">Statement [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_StatementTable" xml:lang="en-US">Statement [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_StatementTable" xlink:to="lab_kzia_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_StatementTable" xml:lang="en-US">Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders Equity and Other Comprehensive Income, or other statement as needed.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAxis" xml:lang="en-US">Maturity [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaturityAxis" xml:lang="en-US">Maturity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xml:lang="en-US">Aggregated time bands [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xml:lang="en-US">Aggregated time bands [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Not later than one year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">1 year or less [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_StatementLineItems" xml:lang="en-US">Statement [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_StatementLineItems" xml:lang="en-US">Statement [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_StatementLineItems" xlink:to="lab_kzia_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_StatementLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xml:lang="en-US">Disclosure of provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xml:lang="en-US">Employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProvisionsExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Disclosure Of Contingent Consideration Liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:to="lab_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">The disclosure of contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xml:lang="en-US">Later than one year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xml:lang="en-US">Later than one year [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xml:lang="en-US">Disclosure of deferred taxes [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xml:lang="en-US">Deferred tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xml:lang="en-US">Disclosure of issued capital [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xml:lang="en-US">Equity - contributed equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfOtherEquityExplanatory" xlink:label="loc_kzia_DisclosureOfOtherEquityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfOtherEquityExplanatory" xml:lang="en-US">Disclosure Of Other Equity Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfOtherEquityExplanatory" xml:lang="en-US">Equity - Other contributed equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfOtherEquityExplanatory" xlink:to="lab_kzia_DisclosureOfOtherEquityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfOtherEquityExplanatory" xml:lang="en-US">Disclosure of other equity.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Disclosure of reserves within equity [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Equity - reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDividendsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDividendsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDividendsExplanatory" xml:lang="en-US">Disclosure of dividends [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDividendsExplanatory" xml:lang="en-US">Equity - dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDividendsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDividendsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xml:lang="en-US">Disclosure of fair value measurement [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xml:lang="en-US">Fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xml:lang="en-US">Key management personnel disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xml:lang="en-US">Disclosure of auditors' remuneration [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xml:lang="en-US">Remuneration of auditors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xml:lang="en-US">Disclosure of contingent liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xml:lang="en-US">Contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xml:lang="en-US">Disclosure of commitments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xml:lang="en-US">Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Disclosure of related party [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xml:lang="en-US">Disclosure of interim financial reporting [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xml:lang="en-US">Parent entity information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="loc_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xml:lang="en-US">Investments accounted for using equity method [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="lab_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xml:lang="en-US">Disclosure of interests in subsidiaries [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xml:lang="en-US">Interests in subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" xlink:label="loc_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Adjustments For Reconcile Profit Loss Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" xml:lang="en-US">Reconciliation of loss after income tax to net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" xlink:to="lab_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Adjustments For Reconcile Profit Loss Explanatory.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" xlink:label="loc_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" xml:lang="en-US">Description Of Accounting Policy For Current And Noncurrent Classification Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" xml:lang="en-US">Current and non-current classification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" xlink:to="lab_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" xml:lang="en-US">Description of accounting policy for current and noncurrent classification.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xml:lang="en-US">Employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xml:lang="en-US">Fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xml:lang="en-US">Description of accounting policy for finance costs [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xml:lang="en-US">Finance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xml:lang="en-US">Operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xml:lang="en-US">Goods and Services Tax ('GST') and other similar taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Foreign currency translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xml:lang="en-US">Financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xml:lang="en-US">Compound financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xml:lang="en-US">Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGoingConcernExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGoingConcernExplanatory" xml:lang="en-US">Disclosure of going concern [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGoingConcernExplanatory" xml:lang="en-US">Going concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGoingConcernExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xml:lang="en-US">Impairment of non-financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xml:lang="en-US">Income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" xlink:label="loc_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" xml:lang="en-US">Description of accounting policy for new Accounting Standards and Interpretations not yet mandatory or early adopted [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" xml:lang="en-US">New Accounting Standards and Interpretations not yet mandatory or early adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" xlink:to="lab_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" xml:lang="en-US">Description of accounting policy for new accounting standards and interpretations not yet mandatory or early adopted.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfParentEntityInformationExplanatory" xlink:label="loc_kzia_DescriptionOfParentEntityInformationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DescriptionOfParentEntityInformationExplanatory" xml:lang="en-US">Description Of Parent Entity Information [policy text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DescriptionOfParentEntityInformationExplanatory" xml:lang="en-US">Parent entity information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DescriptionOfParentEntityInformationExplanatory" xlink:to="lab_kzia_DescriptionOfParentEntityInformationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DescriptionOfParentEntityInformationExplanatory" xml:lang="en-US">Description Of Parent Entity Information</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xml:lang="en-US">Disclosure of basis of consolidation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xml:lang="en-US">Principles of consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Basis of preparation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" xlink:label="loc_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" xml:lang="en-US">Description of accounting policy for new, revised or amending Accounting Standards and Interpretations adopted [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" xml:lang="en-US">New or amended Accounting Standards and Interpretations adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" xlink:to="lab_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" xml:lang="en-US">Description of accounting policy for new, revised or amending accounting standards and interpretations adopted.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xml:lang="en-US">Description of accounting policy for issued capital [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xml:lang="en-US">Issued capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesExplanatory" xml:lang="en-US">Disclosure of products and services [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesExplanatory" xml:lang="en-US">Summary of licensing revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xml:lang="en-US">Summary of disaggregation of revenue from contracts with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Other Income [Text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xml:lang="en-US">Summary of other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xml:lang="en-US">Disclosure of detailed information about other income.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xml:lang="en-US">Summary of expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" xml:lang="en-US">Disclosure of detailed information about income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" xml:lang="en-US">Summary of income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" xml:lang="en-US">Disclosure of detailed information about income tax.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xml:lang="en-US">Disclosure of detailed information about cash and cash equivalents [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xml:lang="en-US">Summary of cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xml:lang="en-US">The disclosure for detailed information about cash and cash equivalent.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Disclosure of detailed information about trade and other receivables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Summary of current assets - trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xml:lang="en-US">The disclosure of detailed information about trade and other receivables.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" xml:lang="en-US">Disclosure of Detailed Information About Other Current Assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" xml:lang="en-US">Summary of current assets - other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" xml:lang="en-US">Disclosure of detailed information about other current assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xml:lang="en-US">Summary of non-current assets - intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets other than goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Summary of reconciliations of intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets other than goodwill.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xml:lang="en-US">Disclosure of detailed information about trade and other payables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xml:lang="en-US">Summary of trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xml:lang="en-US">The disclosure of detailed information about trade and other payables.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xml:lang="en-US">Summary of provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xml:lang="en-US">Disclosure of detailed information about provisions.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Disclosure of detailed information about contingent consideration liabilities explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Summary of liabilities - contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xml:lang="en-US">Disclosure of detailed information about contingent consideration liabilities.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Deferred Taxes Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" xml:lang="en-US">Summary of non-current liabilities - deferred tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" xml:lang="en-US">Disclosure of detailed information about deferred taxes.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" xml:lang="en-US">Disclosure of Detailed Information About Issued Capital Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" xml:lang="en-US">Summary of equity - contributed equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" xml:lang="en-US">Disclosure of detailed information about issued capital.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" xml:lang="en-US">Disclosure of detailed information about movement in ordinary share capital explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" xml:lang="en-US">Summary of movements in ordinary share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" xml:lang="en-US">Disclosure of detailed information about movement in ordinary share capital.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" xml:lang="en-US">Disclosure of detailed information about other equity explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" xml:lang="en-US">Summary of equity - other contributed equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" xml:lang="en-US">Disclosure of detailed information about other equity.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xml:lang="en-US">Summary of foreign currency risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xml:lang="en-US">Sensitivity analysis for types of market risk [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xml:lang="en-US">Summary of foreign currency risk sensitivity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:to="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xml:lang="en-US">Summary of remaining contractual maturities of financial instrument liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xml:lang="en-US">Summary of variable interest rate balances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xml:lang="en-US">Types of risks [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xml:lang="en-US">Types of risks [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksMember" xml:lang="en-US">Risks [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfRisksMember" xml:lang="en-US">Risks [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" xml:lang="en-US">Disclosure Of Detailed Information About Fair Value Measurement Explanatory [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" xml:lang="en-US">Summary of assets and liabilities, measured or disclosed at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" xml:lang="en-US">Disclosure of detailed information about fair value measurement.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of Detailed Information about Movements in level 3 Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of movements in level 3 assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of detailed information about movements in level 3 assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" xml:lang="en-US">Disclosure of detailed information about key management personnel [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" xml:lang="en-US">Summary of compensation made to directors and other members of key management personnel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" xml:lang="en-US">Disclosure of detailed information about key management personnel.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" xml:lang="en-US">Disclosure of detailed information about auditors remuneration [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" xml:lang="en-US">Summary of remuneration of auditors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" xml:lang="en-US">The disclosure of detailed information about auditors remuneration.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityFinancialInformationExplanatory" xlink:label="loc_kzia_DisclosureOfParentEntityFinancialInformationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfParentEntityFinancialInformationExplanatory" xml:lang="en-US">Disclosure of Parent Entity Financial Information [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfParentEntityFinancialInformationExplanatory" xml:lang="en-US">Parent entity financial information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfParentEntityFinancialInformationExplanatory" xlink:to="lab_kzia_DisclosureOfParentEntityFinancialInformationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfParentEntityFinancialInformationExplanatory" xml:lang="en-US">The entire disclosure of parent entity financial information.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xml:lang="en-US">Disclosure of subsidiaries [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xml:lang="en-US">Summary of interest in subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" xml:lang="en-US">Disclosure Of Reconciliation Of Profit Or Loss To Operating Cash Flows [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" xml:lang="en-US">Disclosure of reconciliation of profit or loss to operating cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" xlink:to="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" xml:lang="en-US">Disclosure Of Reconciliation Of Profit Or Loss To Operating Cash Flows</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xml:lang="en-US">Earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xml:lang="en-US">Summary of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xml:lang="en-US">Summary of valuation for each tranche of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xml:lang="en-US">Summary of share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xml:lang="en-US">Disclosure of summary of significant accounting policies [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xml:lang="en-US">Disclosure of summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Disclosure of summary of significant accounting policies [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Disclosure of summary of significant accounting policies [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Disclosure of summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Disclosure Of Summary Of Significant Accounting Policies [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Disclosure of summary of significant accounting policies [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Line items representing the disclosure of summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsLiabilities" xml:lang="en-US">Current assets (liabilities)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAssetsLiabilities" xml:lang="en-US">Net current asset position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="lab_ifrs-full_CurrentAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InterestIncomeLoss" xlink:label="loc_kzia_InterestIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_InterestIncomeLoss" xml:lang="en-US">Interest Income loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_InterestIncomeLoss" xml:lang="en-US">Earning income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_InterestIncomeLoss" xlink:to="lab_kzia_InterestIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_InterestIncomeLoss" xml:lang="en-US">Interest income loss.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xlink:label="loc_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xml:lang="en-US">Intangible assets with indefinite remaining useful life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xml:lang="en-US">Remaining useful life,licensing agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xlink:to="lab_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xml:lang="en-US">Intangible assets with indefinite remaining useful life.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from non-current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from funding for project purpose</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdditionalTaxDeductionPercentage" xlink:label="loc_kzia_AdditionalTaxDeductionPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AdditionalTaxDeductionPercentage" xml:lang="en-US">Additional Tax Deduction Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_AdditionalTaxDeductionPercentage" xml:lang="en-US">Additional tax deduction percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AdditionalTaxDeductionPercentage" xlink:to="lab_kzia_AdditionalTaxDeductionPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AdditionalTaxDeductionPercentage" xml:lang="en-US">Additional tax deduction percentage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xlink:label="loc_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xml:lang="en-US">Research and development tax incentive program [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xml:lang="en-US">Research and development tax incentive program [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xlink:to="lab_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xml:lang="en-US">Research and development tax incentive program.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeAxis" xml:lang="en-US">Range [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RangeAxis" xml:lang="en-US">Range [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesMember" xml:lang="en-US">Ranges [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RangesMember" xml:lang="en-US">Ranges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeAxis" xlink:label="loc_kzia_FundingPurposeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_FundingPurposeAxis" xml:lang="en-US">Funding Purpose [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_FundingPurposeAxis" xlink:to="lab_kzia_FundingPurposeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_FundingPurposeAxis" xml:lang="en-US">Funding purpose</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeMember" xlink:label="loc_kzia_FundingPurposeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_FundingPurposeMember" xml:lang="en-US">Funding Purpose [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_FundingPurposeMember" xlink:to="lab_kzia_FundingPurposeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_FundingPurposeMember" xml:lang="en-US">Funding purpose</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ClinicalTrialsMember" xlink:label="loc_kzia_ClinicalTrialsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ClinicalTrialsMember" xml:lang="en-US">Clinical Trials [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ClinicalTrialsMember" xlink:to="lab_kzia_ClinicalTrialsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ClinicalTrialsMember" xml:lang="en-US">Clinical trials</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xml:lang="en-US">Intangible assets other than goodwill [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xml:lang="en-US">Intangible assets other than goodwill [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicenseAgreementForPaxalisibMember" xlink:label="loc_kzia_LicenseAgreementForPaxalisibMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_LicenseAgreementForPaxalisibMember" xml:lang="en-US">License Agreement For Paxalisib [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_LicenseAgreementForPaxalisibMember" xml:lang="en-US">Licensing agreement for paxalisib [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_LicenseAgreementForPaxalisibMember" xlink:to="lab_kzia_LicenseAgreementForPaxalisibMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_LicenseAgreementForPaxalisibMember" xml:lang="en-US">Licensing agreement for paxalisib.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingAgreementForEvtEightZeroOneMember" xlink:label="loc_kzia_LicensingAgreementForEvtEightZeroOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_LicensingAgreementForEvtEightZeroOneMember" xml:lang="en-US">Licensing Agreement For EVT Eight Zero One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_LicensingAgreementForEvtEightZeroOneMember" xml:lang="en-US">Licensing agreement for EVT801 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_LicensingAgreementForEvtEightZeroOneMember" xlink:to="lab_kzia_LicensingAgreementForEvtEightZeroOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_LicensingAgreementForEvtEightZeroOneMember" xml:lang="en-US">Licensing agreement for EVT801.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityAxis" xlink:label="loc_kzia_UncertainityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_UncertainityAxis" xml:lang="en-US">Uncertainity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_UncertainityAxis" xlink:to="lab_kzia_UncertainityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_UncertainityAxis" xml:lang="en-US">Uncertainity</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityMember" xlink:label="loc_kzia_UncertainityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_UncertainityMember" xml:lang="en-US">Uncertainity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_UncertainityMember" xlink:to="lab_kzia_UncertainityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_UncertainityMember" xml:lang="en-US">Uncertainity</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_CovidNinteenMember" xlink:label="loc_kzia_CovidNinteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_CovidNinteenMember" xml:lang="en-US">Covid Ninteen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_CovidNinteenMember" xlink:to="lab_kzia_CovidNinteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_CovidNinteenMember" xml:lang="en-US">Covid ninteen</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" xlink:label="loc_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" xml:lang="en-US">Disclosure of significant accounting judgments assumptions and estimates [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" xlink:to="lab_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" xml:lang="en-US">Abstract represents significant accounting judgments, assumptions and estimates.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" xlink:label="loc_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" xml:lang="en-US">Percentage Milestone Trigger to Account Cost of Asset Conferred Under License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" xml:lang="en-US">Percentage milestone trigger to account cost of asset conferred under license agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" xlink:to="lab_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" xml:lang="en-US">Percentage milestone trigger to account cost of asset conferred under license agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xml:lang="en-US">Disclosure of operating segments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfMajorCustomers" xlink:label="loc_kzia_NumberOfMajorCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfMajorCustomers" xml:lang="en-US">Number of Major Customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfMajorCustomers" xml:lang="en-US">Number of major customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfMajorCustomers" xlink:to="lab_kzia_NumberOfMajorCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfMajorCustomers" xml:lang="en-US">Number of major customers.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOperatingSegments1" xlink:label="loc_kzia_NumberOfOperatingSegments1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfOperatingSegments1" xml:lang="en-US">Number Of Operating Segments1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfOperatingSegments1" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfOperatingSegments1" xlink:to="lab_kzia_NumberOfOperatingSegments1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfOperatingSegments1" xml:lang="en-US">Number of operating segments.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConcentrationRiskMajorCustomerPercentage" xlink:label="loc_kzia_ConcentrationRiskMajorCustomerPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ConcentrationRiskMajorCustomerPercentage" xml:lang="en-US">Concentration Risk Major Customer Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ConcentrationRiskMajorCustomerPercentage" xml:lang="en-US">Concentration risk major customer percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ConcentrationRiskMajorCustomerPercentage" xlink:to="lab_kzia_ConcentrationRiskMajorCustomerPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ConcentrationRiskMajorCustomerPercentage" xml:lang="en-US">Concentration risk major customer percentage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesAbstract" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesAbstract" xml:lang="en-US">Disclosure of products and services [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesTable" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesTable" xml:lang="en-US">Disclosure of products and services [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProductsAndServicesLineItems" xml:lang="en-US">Disclosure of products and services [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:to="lab_ifrs-full_DisclosureOfProductsAndServicesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xml:lang="en-US">Revenue from contracts with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xml:lang="en-US">Products and services [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xml:lang="en-US">Products and services [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingRevenueMember" xlink:label="loc_kzia_LicensingRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_LicensingRevenueMember" xml:lang="en-US">Licensing Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_LicensingRevenueMember" xml:lang="en-US">Licensing revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_LicensingRevenueMember" xlink:to="lab_kzia_LicensingRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_LicensingRevenueMember" xml:lang="en-US">Licensing revenue.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xml:lang="en-US">Timing of transfer of goods or services [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xml:lang="en-US">Timing of transfer of goods or services [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xml:lang="en-US">Goods or services transferred at point in time [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xml:lang="en-US">Timing of revenue recognition [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="loc_country_CN" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CN" xml:lang="en-US">CHINA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CN" xml:lang="en-US">China [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SwedanMember" xlink:label="loc_kzia_SwedanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SwedanMember" xml:lang="en-US">Swedan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_SwedanMember" xml:lang="en-US">Swedan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SwedanMember" xlink:to="lab_kzia_SwedanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SwedanMember" xml:lang="en-US">Swedan.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaterialIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_MaterialIncomeAndExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaterialIncomeAndExpenseAbstract" xml:lang="en-US">Material income and expense [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_MaterialIncomeAndExpenseAbstract" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ReimbursementOfExpenses" xlink:label="loc_kzia_ReimbursementOfExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ReimbursementOfExpenses" xml:lang="en-US">Reimbursement Of Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ReimbursementOfExpenses" xml:lang="en-US">Reimbursement of expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ReimbursementOfExpenses" xlink:to="lab_kzia_ReimbursementOfExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ReimbursementOfExpenses" xml:lang="en-US">Reimbursement of expenses.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SubsidiesAndGrants" xlink:label="loc_kzia_SubsidiesAndGrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SubsidiesAndGrants" xml:lang="en-US">Subsidies and grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_SubsidiesAndGrants" xml:lang="en-US">Subsidies and grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SubsidiesAndGrants" xlink:to="lab_kzia_SubsidiesAndGrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SubsidiesAndGrants" xml:lang="en-US">Subsidies and grants.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxRebatesOnPayroll" xlink:label="loc_kzia_TaxRebatesOnPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxRebatesOnPayroll" xml:lang="en-US">Tax rebates on payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxRebatesOnPayroll" xml:lang="en-US">Payroll tax rebate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxRebatesOnPayroll" xlink:to="lab_kzia_TaxRebatesOnPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxRebatesOnPayroll" xml:lang="en-US">Tax rebates on payroll.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-full_OtherIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherIncome" xml:lang="en-US">Other income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RebateIncomeOnResearchAndDevelopment" xlink:label="loc_kzia_RebateIncomeOnResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_RebateIncomeOnResearchAndDevelopment" xml:lang="en-US">Rebate income on research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_RebateIncomeOnResearchAndDevelopment" xml:lang="en-US">Research and development rebate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_RebateIncomeOnResearchAndDevelopment" xlink:to="lab_kzia_RebateIncomeOnResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_RebateIncomeOnResearchAndDevelopment" xml:lang="en-US">Rebate income on research and development.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xml:lang="en-US">Net foreign exchange gain</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xml:lang="en-US">Net foreign exchange gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfExpensesByNatureTable" xlink:label="loc_kzia_DisclosureOfExpensesByNatureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfExpensesByNatureTable" xml:lang="en-US">Disclosure Of Expenses By Nature [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfExpensesByNatureTable" xml:lang="en-US">Disclosure of expenses by nature [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfExpensesByNatureTable" xlink:to="lab_kzia_DisclosureOfExpensesByNatureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfExpensesByNatureTable" xml:lang="en-US">Schedule disclosing information related to expenses by nature.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaxalisibLicensingAgreementMember" xlink:label="loc_kzia_PaxalisibLicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_PaxalisibLicensingAgreementMember" xml:lang="en-US">Paxalisib Licensing Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_kzia_PaxalisibLicensingAgreementMember" xml:lang="en-US">Paxalisib licensing agreement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_PaxalisibLicensingAgreementMember" xlink:to="lab_kzia_PaxalisibLicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_PaxalisibLicensingAgreementMember" xml:lang="en-US">Paxalisib Licensing Agreement.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EvotechLicensingAgreementMember" xlink:label="loc_kzia_EvotechLicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EvotechLicensingAgreementMember" xml:lang="en-US">Evotech Licensing Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EvotechLicensingAgreementMember" xml:lang="en-US">Evotech Licensing Agreement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EvotechLicensingAgreementMember" xlink:to="lab_kzia_EvotechLicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EvotechLicensingAgreementMember" xml:lang="en-US">Evotech licensing agreement.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfExpensesByNatureLineItems" xlink:label="loc_kzia_DisclosureOfExpensesByNatureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfExpensesByNatureLineItems" xml:lang="en-US">Disclosure Of Expenses By Nature [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfExpensesByNatureLineItems" xml:lang="en-US">Disclosure of expenses by nature [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems" xlink:to="lab_kzia_DisclosureOfExpensesByNatureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfExpensesByNatureLineItems" xml:lang="en-US">Disclosure of expenses by nature.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xlink:label="loc_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xml:lang="en-US">Chinese Withholding Tax Incurred on License Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xml:lang="en-US">Chinese With-Holding Tax incurred on license transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xlink:to="lab_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xml:lang="en-US">Chinese withholding tax incurred on license transaction.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MinimumOperatingLeasePayment" xlink:label="loc_kzia_MinimumOperatingLeasePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_MinimumOperatingLeasePayment" xml:lang="en-US">Minimum Operating Lease Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_MinimumOperatingLeasePayment" xml:lang="en-US">Minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_MinimumOperatingLeasePayment" xlink:to="lab_kzia_MinimumOperatingLeasePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_MinimumOperatingLeasePayment" xml:lang="en-US">Minimum Operating Lease Payment.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xlink:label="loc_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xml:lang="en-US">Chinese Value Added Tax Incurred on License Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xml:lang="en-US">Chinese Value Added Tax incurred on license transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xlink:to="lab_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xml:lang="en-US">Chinese value added tax incurred on license transaction.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNature" xlink:label="loc_ifrs-full_ExpenseByNature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseByNature" xml:lang="en-US">Expenses, by nature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ExpenseByNature" xml:lang="en-US">Total Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNature" xlink:to="lab_ifrs-full_ExpenseByNature" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xml:lang="en-US">Post-employment benefit expense, defined benefit plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xml:lang="en-US">Employee benefits expense excluding superannuation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xml:lang="en-US">Defined contribution superannuation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-full_ProfitLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAbstract" xml:lang="en-US">Profit (loss) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAbstract" xml:lang="en-US">Loss before income tax includes the following specific</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xml:lang="en-US">Net foreign exchange loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitsTable" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfIncomeTaxBenefitsTable" xml:lang="en-US">Disclosure of income tax benefits [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfIncomeTaxBenefitsTable" xml:lang="en-US">Disclosure of income tax benefits [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable" xlink:to="lab_kzia_DisclosureOfIncomeTaxBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfIncomeTaxBenefitsTable" xml:lang="en-US">Schedule disclosing information about income tax benefits.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitLineItems" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfIncomeTaxBenefitLineItems" xml:lang="en-US">Disclosure Of Income Tax Benefit [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfIncomeTaxBenefitLineItems" xml:lang="en-US">Disclosure Of Income Tax Benefit [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems" xlink:to="lab_kzia_DisclosureOfIncomeTaxBenefitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfIncomeTaxBenefitLineItems" xml:lang="en-US">Disclosure of income tax benefit [line items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xml:lang="en-US">Reconciliation of accounting profit multiplied by applicable tax rates [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xml:lang="en-US">Numerical reconciliation of income tax benefit and tax at the statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">Tax expense (income) at applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">Tax at the statutory tax rate of 26% (2020 &amp; 2019 27.5%)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:label="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xml:lang="en-US">Tax effect amounts which are not deductible/(taxable) in calculating taxable income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xml:lang="en-US">Tax effect amounts which are not deductible/(taxable) in calculating taxable income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:to="lab_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xml:lang="en-US">Tax effect amounts which are not deductible/(taxable) in calculating taxable income.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xlink:label="loc_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xml:lang="en-US">Tax effect of expense research and development claim</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xml:lang="en-US">Research and Development claim</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xlink:to="lab_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xml:lang="en-US">Tax effect of expense research and development claim.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xlink:label="loc_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xml:lang="en-US">Tax Effect of Gain loss on revaluation of contingent consideration payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xml:lang="en-US">Gain/loss on revaluation of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xlink:to="lab_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xml:lang="en-US">Tax Effect of Gain loss on revaluation of contingent consideration payable</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAmortisationOfIntangibles" xlink:label="loc_kzia_TaxEffectOfAmortisationOfIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfAmortisationOfIntangibles" xml:lang="en-US">Tax Effect Of Amortisation Of Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfAmortisationOfIntangibles" xml:lang="en-US">Amortisation of intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfAmortisationOfIntangibles" xlink:to="lab_kzia_TaxEffectOfAmortisationOfIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfAmortisationOfIntangibles" xml:lang="en-US">Tax effect of amortisation of intangibles.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfExpenseEmployeeOptionPlan" xlink:label="loc_kzia_TaxEffectOfExpenseEmployeeOptionPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfExpenseEmployeeOptionPlan" xml:lang="en-US">Tax effect of expense employee option plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfExpenseEmployeeOptionPlan" xml:lang="en-US">Employee option plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfExpenseEmployeeOptionPlan" xlink:to="lab_kzia_TaxEffectOfExpenseEmployeeOptionPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfExpenseEmployeeOptionPlan" xml:lang="en-US">Tax effect of expense employee option plan.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xlink:label="loc_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xml:lang="en-US">Tax Effect of Adjustment to Deferred Tax Balances as a Result of Change in Statutory Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xml:lang="en-US">Adjustment to deferred tax balances as a result of change in statutory tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xlink:to="lab_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xml:lang="en-US">Tax effect of adjustment to deferred tax balances as a result of change in statutory tax rate.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xlink:label="loc_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xml:lang="en-US">Tax effect of prior year tax losses not recognised now recouped</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xml:lang="en-US">Prior year tax losses not recognised now recouped</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xlink:to="lab_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xml:lang="en-US">Tax effect of prior year tax losses not recognised now recouped.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xlink:label="loc_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xml:lang="en-US">Tax effect of Tax losses and timing differences not recognised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xml:lang="en-US">Tax losses and timing differences not recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xlink:to="lab_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xml:lang="en-US">Tax effect of tax losses and timing differences not recognised.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxLossesNotRecognisedAbstract" xlink:label="loc_kzia_TaxLossesNotRecognisedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TaxLossesNotRecognisedAbstract" xml:lang="en-US">Tax losses not recognised [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TaxLossesNotRecognisedAbstract" xml:lang="en-US">Tax losses not recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TaxLossesNotRecognisedAbstract" xlink:to="lab_kzia_TaxLossesNotRecognisedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TaxLossesNotRecognisedAbstract" xml:lang="en-US">Tax losses not recognised.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" xml:lang="en-US">Deferred tax expense (income) relating to tax rate changes or imposition of new taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" xml:lang="en-US">Potential tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Unused tax losses for which no deferred tax asset has been recognised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_AU" xml:lang="en-US">AUSTRALIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_AU" xml:lang="en-US">Australia [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">US [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Statutory tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and cash equivalents [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash at bank and on hand</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash at bank and in hand</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xml:lang="en-US">Short-term deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xml:lang="en-US">Short term deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xml:lang="en-US">Trade and other receivables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xml:lang="en-US">Disclosure of financial assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xlink:label="loc_kzia_ResearchAndDevelopmentTaxRebateReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xml:lang="en-US">Research and development tax rebate receivable [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xml:lang="en-US">R&amp;D tax rebate receivable [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xlink:to="lab_kzia_ResearchAndDevelopmentTaxRebateReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xml:lang="en-US">Research and development tax rebate receivable.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xml:lang="en-US">Accumulated impairment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xml:lang="en-US">Provision for impairment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedImpairmentMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositsHeldMember" xlink:label="loc_kzia_DepositsHeldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DepositsHeldMember" xml:lang="en-US">Deposits held [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DepositsHeldMember" xml:lang="en-US">Deposits held [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DepositsHeldMember" xlink:to="lab_kzia_DepositsHeldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DepositsHeldMember" xml:lang="en-US">Deposits held.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Gross carrying amount [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Gross carrying amount [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xml:lang="en-US">Disclosure of financial assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xml:lang="en-US">Disclosure of financial assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Current trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">R&amp;D tax rebate receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xml:lang="en-US">Other current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositPaidNonCurrent" xlink:label="loc_kzia_DepositPaidNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DepositPaidNonCurrent" xml:lang="en-US">Deposit Paid Non Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DepositPaidNonCurrent" xml:lang="en-US">Deposit paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DepositPaidNonCurrent" xlink:to="lab_kzia_DepositPaidNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DepositPaidNonCurrent" xml:lang="en-US">Deposit paid non current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="lab_ifrs-full_TradeAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositPaidAsAdvance" xlink:label="loc_kzia_DepositPaidAsAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DepositPaidAsAdvance" xml:lang="en-US">Deposit Paid as Advance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_kzia_DepositPaidAsAdvance" xml:lang="en-US">Deposit paid as advance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DepositPaidAsAdvance" xlink:to="lab_kzia_DepositPaidAsAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DepositPaidAsAdvance" xml:lang="en-US">Deposit paid as advance.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LicencesMember" xlink:label="loc_ifrs-full_LicencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LicencesMember" xml:lang="en-US">Licences [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LicencesMember" xml:lang="en-US">GDC licensing agreement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingAgreementMember" xlink:label="loc_kzia_LicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_LicensingAgreementMember" xml:lang="en-US">Licensing Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_LicensingAgreementMember" xlink:to="lab_kzia_LicensingAgreementMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EVT801LicensingAgreementMember" xlink:label="loc_kzia_EVT801LicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EVT801LicensingAgreementMember" xml:lang="en-US">EVT801 Licensing Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_EVT801LicensingAgreementMember" xml:lang="en-US">EVT801 licensing agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EVT801LicensingAgreementMember" xlink:to="lab_kzia_EVT801LicensingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EVT801LicensingAgreementMember" xml:lang="en-US">EVT801 licensing agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesAbstract" xml:lang="en-US">Trade and other payables [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherPayablesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xml:lang="en-US">Accruals classified as current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xml:lang="en-US">Accrued payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Current trade payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Trade payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_ProvisionsForEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProvisionsForEmployeeBenefits" xml:lang="en-US">Provisions for employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProvisionsForEmployeeBenefits" xml:lang="en-US">Provisions for employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_ProvisionsForEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xml:lang="en-US">Disclosure of contingent liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xml:lang="en-US">Disclosure of contingent liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xml:lang="en-US">Disclosure of contingent liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsideration" xlink:label="loc_kzia_ContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ContingentConsideration" xml:lang="en-US">Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_kzia_ContingentConsideration" xml:lang="en-US">Contingent Consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ContingentConsideration" xlink:to="lab_kzia_ContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ContingentConsideration" xml:lang="en-US">Contingent consideration.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xml:lang="en-US">Classes of contingent liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xml:lang="en-US">Contingent liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember" xlink:to="lab_ifrs-full_ContingentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationPaxalisibMember" xlink:label="loc_kzia_ContingentConsiderationPaxalisibMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ContingentConsiderationPaxalisibMember" xml:lang="en-US">Contingent consideration paxalisib [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ContingentConsiderationPaxalisibMember" xml:lang="en-US">Contingent consideration - paxalisib</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ContingentConsiderationPaxalisibMember" xlink:to="lab_kzia_ContingentConsiderationPaxalisibMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationEvt801Member" xlink:label="loc_kzia_ContingentConsiderationEvt801Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ContingentConsiderationEvt801Member" xml:lang="en-US">Contingent consideration EVT801 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ContingentConsiderationEvt801Member" xml:lang="en-US">Contingent consideration &#8211; EVT801</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ContingentConsiderationEvt801Member" xlink:to="lab_kzia_ContingentConsiderationEvt801Member" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaymentsForContingentConsideration" xlink:label="loc_kzia_PaymentsForContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_PaymentsForContingentConsideration" xml:lang="en-US">Payments For Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_PaymentsForContingentConsideration" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_PaymentsForContingentConsideration" xlink:to="lab_kzia_PaymentsForContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_PaymentsForContingentConsideration" xml:lang="en-US">Payments for contingent consideration.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentPayable" xlink:label="loc_kzia_MilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_MilestonePaymentPayable" xml:lang="en-US">Milestone Payment Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_MilestonePaymentPayable" xml:lang="en-US">Milestone payment payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_MilestonePaymentPayable" xlink:to="lab_kzia_MilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_MilestonePaymentPayable" xml:lang="en-US">Milestone payment payable.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentDiscountRate" xlink:label="loc_kzia_MilestonePaymentDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_MilestonePaymentDiscountRate" xml:lang="en-US">Milestone Payment Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_MilestonePaymentDiscountRate" xml:lang="en-US">Milestone payment discount rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_MilestonePaymentDiscountRate" xml:lang="en-US">Milestone payment discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_MilestonePaymentDiscountRate" xlink:to="lab_kzia_MilestonePaymentDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_MilestonePaymentDiscountRate" xml:lang="en-US">Milestone payment discount rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xml:lang="en-US">Percentage of voting equity interests acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xml:lang="en-US">Percentage of equity interests acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentsNotBooked" xlink:label="loc_kzia_MilestonePaymentsNotBooked" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_MilestonePaymentsNotBooked" xml:lang="en-US">Milestone Payments not Booked</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_MilestonePaymentsNotBooked" xml:lang="en-US">Milestone payments not booked</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_MilestonePaymentsNotBooked" xlink:to="lab_kzia_MilestonePaymentsNotBooked" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_MilestonePaymentsNotBooked" xml:lang="en-US">Milestone payments not booked.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfContingentMilestonePayments" xlink:label="loc_kzia_NumberOfContingentMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfContingentMilestonePayments" xml:lang="en-US">Number of contingent milestone payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_NumberOfContingentMilestonePayments" xml:lang="en-US">Number of contingent milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfContingentMilestonePayments" xlink:to="lab_kzia_NumberOfContingentMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfContingentMilestonePayments" xml:lang="en-US">Number of contingent milestone payments.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestoneTwoMember" xlink:label="loc_kzia_MilestoneTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_MilestoneTwoMember" xml:lang="en-US">Milestone Two [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_MilestoneTwoMember" xlink:to="lab_kzia_MilestoneTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_MilestoneTwoMember" xml:lang="en-US">Milestone Two.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GlioblastPtyLtdMember" xlink:label="loc_kzia_GlioblastPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_GlioblastPtyLtdMember" xml:lang="en-US">Glioblast Pty Ltd [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_GlioblastPtyLtdMember" xml:lang="en-US">Glioblast Pty Ltd [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_GlioblastPtyLtdMember" xlink:to="lab_kzia_GlioblastPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_GlioblastPtyLtdMember" xml:lang="en-US">Glioblast Pty Ltd.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GenentechAgreementMember" xlink:label="loc_kzia_GenentechAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_GenentechAgreementMember" xml:lang="en-US">Genentech agreement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_GenentechAgreementMember" xlink:to="lab_kzia_GenentechAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_GenentechAgreementMember" xml:lang="en-US">Genentech agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Deferred tax assets and liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xml:lang="en-US">Disclosure of classes of share capital [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xml:lang="en-US">Disclosure of classes of share capital [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xml:lang="en-US">Disclosure of classes of share capital [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xml:lang="en-US">Increase (decrease) in number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xml:lang="en-US">Increase (decrease) in shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharesIssuedPricePerShare1" xlink:label="loc_kzia_SharesIssuedPricePerShare1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SharesIssuedPricePerShare1" xml:lang="en-US">Shares Issued Price Per Share 1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_SharesIssuedPricePerShare1" xml:lang="en-US">Issue price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SharesIssuedPricePerShare1" xlink:to="lab_kzia_SharesIssuedPricePerShare1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SharesIssuedPricePerShare1" xml:lang="en-US">Shares issued price per share.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsAxis" xlink:label="loc_kzia_EquityTransactionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EquityTransactionsAxis" xml:lang="en-US">Equity Transactions [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EquityTransactionsAxis" xml:lang="en-US">Equity Transactions [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EquityTransactionsAxis" xlink:to="lab_kzia_EquityTransactionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EquityTransactionsAxis" xml:lang="en-US">Equity Transactions [axis]</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsMember" xlink:label="loc_kzia_EquityTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EquityTransactionsMember" xml:lang="en-US">Equity Transactions [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EquityTransactionsMember" xml:lang="en-US">Equity Transactions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EquityTransactionsMember" xlink:to="lab_kzia_EquityTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EquityTransactionsMember" xml:lang="en-US">Equity Transactions [member]</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateAxis" xlink:label="loc_kzia_SharePurchasePlanIssueDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SharePurchasePlanIssueDateAxis" xml:lang="en-US">Share Purchase Plan Issue Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SharePurchasePlanIssueDateAxis" xlink:to="lab_kzia_SharePurchasePlanIssueDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SharePurchasePlanIssueDateAxis" xml:lang="en-US">Share Purchase Plan Issue Date</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateDomain" xlink:label="loc_kzia_SharePurchasePlanIssueDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SharePurchasePlanIssueDateDomain" xml:lang="en-US">Share Purchase Plan Issue Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain" xlink:to="lab_kzia_SharePurchasePlanIssueDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SharePurchasePlanIssueDateDomain" xml:lang="en-US">Share Purchase Plan Issue Date</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xlink:label="loc_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xml:lang="en-US">Issue Dated November One Two Thousand And Nineteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xml:lang="en-US">1 November 2019 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xlink:to="lab_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xml:lang="en-US">Issue dated november One two thousand and nineteen.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" xlink:label="loc_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" xml:lang="en-US">Issue Dated Second March Two Thousand Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" xml:lang="en-US">2&#160;March 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" xlink:to="lab_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" xlink:label="loc_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" xml:lang="en-US">Issue Dated Fifteenth March Two Thousand Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" xml:lang="en-US">15&#160;March 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" xlink:to="lab_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xlink:label="loc_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xml:lang="en-US">Issue Date Twenty Eight April Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xml:lang="en-US">28 April 2021 {Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xlink:to="lab_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xml:lang="en-US">Issue Date Twenty Eight April Two Thousand And Twenty One.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xlink:label="loc_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xml:lang="en-US">Issue Date Twenty Eight August Two Thousand And Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xml:lang="en-US">28 August 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xlink:to="lab_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xml:lang="en-US">Issue Date Twenty Eight August Two Thousand And Twenty.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xlink:label="loc_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xml:lang="en-US">Issue Date Sixteenth April Two Thousand And Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xml:lang="en-US">16 April 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xlink:to="lab_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xml:lang="en-US">Issue date sixteenth april two thousand and twenty.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConversionOfOptionsMember" xlink:label="loc_kzia_ConversionOfOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ConversionOfOptionsMember" xml:lang="en-US">Conversion Of Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ConversionOfOptionsMember" xml:lang="en-US">Conversion of options [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ConversionOfOptionsMember" xlink:to="lab_kzia_ConversionOfOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ConversionOfOptionsMember" xml:lang="en-US">Conversion of options.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareIssueTransactionCostsMember" xlink:label="loc_kzia_ShareIssueTransactionCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ShareIssueTransactionCostsMember" xml:lang="en-US">Share issue transaction costs [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ShareIssueTransactionCostsMember" xml:lang="en-US">Share issue transaction costs [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ShareIssueTransactionCostsMember" xlink:to="lab_kzia_ShareIssueTransactionCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ShareIssueTransactionCostsMember" xml:lang="en-US">Share issue transaction costs.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePlacementMember" xlink:label="loc_kzia_SharePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SharePlacementMember" xml:lang="en-US">Share Placement [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_SharePlacementMember" xml:lang="en-US">Share Placement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SharePlacementMember" xlink:to="lab_kzia_SharePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SharePlacementMember" xml:lang="en-US">Share placement.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanMember" xlink:label="loc_kzia_SharePurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SharePurchasePlanMember" xml:lang="en-US">Share purchase plan [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_SharePurchasePlanMember" xml:lang="en-US">Share purchase plan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SharePurchasePlanMember" xlink:to="lab_kzia_SharePurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SharePurchasePlanMember" xml:lang="en-US">Share purchase plan.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InstitutionalPlacementUnderAnreoMember" xlink:label="loc_kzia_InstitutionalPlacementUnderAnreoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_InstitutionalPlacementUnderAnreoMember" xml:lang="en-US">Institutional placement under ANREO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_InstitutionalPlacementUnderAnreoMember" xlink:to="lab_kzia_InstitutionalPlacementUnderAnreoMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RetailPlacementUnderAnreoMember" xlink:label="loc_kzia_RetailPlacementUnderAnreoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_RetailPlacementUnderAnreoMember" xml:lang="en-US">Retail placement under ANREO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_RetailPlacementUnderAnreoMember" xlink:to="lab_kzia_RetailPlacementUnderAnreoMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssuedOnAchievementOfAMilestoneMember" xlink:label="loc_kzia_IssuedOnAchievementOfAMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IssuedOnAchievementOfAMilestoneMember" xml:lang="en-US">Issued on achievement of a milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IssuedOnAchievementOfAMilestoneMember" xlink:to="lab_kzia_IssuedOnAchievementOfAMilestoneMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Number of shares issued and fully paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Ordinary shares - fully paid, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Number of ordinary shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Fully paid ordinary shares par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOrdinarySharesAvailableForConversion" xlink:label="loc_kzia_NumberOfOrdinarySharesAvailableForConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfOrdinarySharesAvailableForConversion" xml:lang="en-US">Number of ordinary shares available for conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfOrdinarySharesAvailableForConversion" xml:lang="en-US">Number of ordinary shares available for conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_NumberOfOrdinarySharesAvailableForConversion" xml:lang="en-US">Number of unlisted convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfOrdinarySharesAvailableForConversion" xlink:to="lab_kzia_NumberOfOrdinarySharesAvailableForConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfOrdinarySharesAvailableForConversion" xml:lang="en-US">Number of ordinary shares available for conversion.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConvertibleNoteRepresentsOrdinaryShares" xlink:label="loc_kzia_ConvertibleNoteRepresentsOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ConvertibleNoteRepresentsOrdinaryShares" xml:lang="en-US">convertible note represents ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ConvertibleNoteRepresentsOrdinaryShares" xml:lang="en-US">Number of convertible note may be converted into ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ConvertibleNoteRepresentsOrdinaryShares" xlink:to="lab_kzia_ConvertibleNoteRepresentsOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ConvertibleNoteRepresentsOrdinaryShares" xml:lang="en-US">convertible note represents ordinary shares.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" xlink:label="loc_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" xml:lang="en-US">Percentage of capital acquired by third party for early conversion of Convertibles notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" xml:lang="en-US">Percentage of capital acquired by third party for early conversion of convertibles notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" xlink:to="lab_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" xml:lang="en-US">Percentage of capital acquired by third party for early conversion of convertibles notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Foreign currency risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD" xml:lang="en-US">United States of America, Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_USD" xml:lang="en-US">US dollars [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro Member Countries, Euro</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_EUR" xml:lang="en-US">Euros [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinancialAssets" xml:lang="en-US">Net exposure to cash flow interest rate risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Financial liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilities" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xml:lang="en-US">Risk exposure associated with instruments sharing characteristic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xml:lang="en-US">Favourable/adverse effect on profit before tax and equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xml:lang="en-US">Effect on profit before tax/equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:to="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xlink:label="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xml:lang="en-US">Risk exposure associated with instruments sharing characteristic, percentage change in risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xml:lang="en-US">Hypothetical percentage change in risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xml:lang="en-US">% change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xlink:to="lab_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xml:lang="en-US">Risk exposure associated with instruments sharing characteristic, percentage change in risk.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateRiskMember" xml:lang="en-US">Interest rate risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestRateRiskMember" xml:lang="en-US">Interest rate risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateRiskMember" xlink:to="lab_ifrs-full_InterestRateRiskMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xml:lang="en-US">Types of interest rates [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xml:lang="en-US">Types of interest rates [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateTypesMember" xml:lang="en-US">Interest rate types [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestRateTypesMember" xml:lang="en-US">Interest rate types [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:label="loc_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xml:lang="en-US">Effect of decrease in market risk on profit (loss) before tax [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xml:lang="en-US">Effect of decrease in market risk on profit (loss) before tax [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:to="lab_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xml:lang="en-US">Effect of decrease in market risk on profit (loss) before tax.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xlink:label="loc_kzia_EffectOfIncreaseInMarketRiskOnEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xml:lang="en-US">Effect of increase in market risk on equity [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xml:lang="en-US">Effect of increase in market risk on equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xlink:to="lab_kzia_EffectOfIncreaseInMarketRiskOnEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xml:lang="en-US">Effect of increase in market risk on equity.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:label="loc_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xml:lang="en-US">Effect of increase in market risk on profit (loss) before tax [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xml:lang="en-US">Effect of increase in market risk on profit (loss) before tax [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:to="lab_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xml:lang="en-US">Effect of increase in market risk on profit (loss) before tax.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xlink:label="loc_kzia_EffectOfDecreaseInMarketRiskOnEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xml:lang="en-US">Effect of decrease in market risk on equity [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xml:lang="en-US">Effect of decrease in market risk on equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xlink:to="lab_kzia_EffectOfDecreaseInMarketRiskOnEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xml:lang="en-US">Effect of decrease in market risk on equity.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseInMarketRiskMember" xlink:label="loc_kzia_IncreaseInMarketRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_IncreaseInMarketRiskMember" xml:lang="en-US">Increase in market risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_IncreaseInMarketRiskMember" xml:lang="en-US">Increase in market risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_IncreaseInMarketRiskMember" xlink:to="lab_kzia_IncreaseInMarketRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_IncreaseInMarketRiskMember" xml:lang="en-US">Increase in market risk.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DecreaseInMarketRiskMember" xlink:label="loc_kzia_DecreaseInMarketRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DecreaseInMarketRiskMember" xml:lang="en-US">Decrease in market risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DecreaseInMarketRiskMember" xml:lang="en-US">Decrease in market risk [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DecreaseInMarketRiskMember" xlink:to="lab_kzia_DecreaseInMarketRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DecreaseInMarketRiskMember" xml:lang="en-US">Decrease in market risk.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InterestRate" xlink:label="loc_kzia_InterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_InterestRate" xml:lang="en-US">Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_InterestRate" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_InterestRate" xlink:to="lab_kzia_InterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_InterestRate" xml:lang="en-US">Interest rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageMember" xlink:label="loc_ifrs-full_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageMember" xml:lang="en-US">Weighted average [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageMember" xlink:to="lab_ifrs-full_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xml:lang="en-US">Floating interest rate [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xml:lang="en-US">Variable interest rate [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FloatingInterestRateMember" xlink:to="lab_ifrs-full_FloatingInterestRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xml:lang="en-US">Classes of financial instruments [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xml:lang="en-US">Classes of financial instruments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xml:lang="en-US">Financial instruments, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xml:lang="en-US">Financial instruments, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_CashAtBankAndInHandMember" xlink:label="loc_kzia_CashAtBankAndInHandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_CashAtBankAndInHandMember" xml:lang="en-US">Cash at bank and in hand [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_CashAtBankAndInHandMember" xml:lang="en-US">Cash at bank and in hand [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_CashAtBankAndInHandMember" xlink:to="lab_kzia_CashAtBankAndInHandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_CashAtBankAndInHandMember" xml:lang="en-US">Cash at bank and in hand.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShortTermDepositsMember" xlink:label="loc_kzia_ShortTermDepositsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ShortTermDepositsMember" xml:lang="en-US">Short term deposits [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ShortTermDepositsMember" xml:lang="en-US">Short term deposits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ShortTermDepositsMember" xlink:to="lab_kzia_ShortTermDepositsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ShortTermDepositsMember" xml:lang="en-US">Short term deposits.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Later than two years and not later than five years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xml:lang="en-US">Between 2 and 5 years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xml:lang="en-US">Later than one year and not later than two years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xml:lang="en-US">Between 1 and 2 years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Non-derivative financial liabilities, undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Total non-derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationUndiscountedCashFlows" xlink:label="loc_kzia_ContingentConsiderationUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ContingentConsiderationUndiscountedCashFlows" xml:lang="en-US">Contingent consideration undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ContingentConsiderationUndiscountedCashFlows" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ContingentConsiderationUndiscountedCashFlows" xlink:to="lab_kzia_ContingentConsiderationUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ContingentConsiderationUndiscountedCashFlows" xml:lang="en-US">Contingent consideration undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TradePayablesUndiscountedCashFlows" xlink:label="loc_kzia_TradePayablesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TradePayablesUndiscountedCashFlows" xml:lang="en-US">Trade payables undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TradePayablesUndiscountedCashFlows" xml:lang="en-US">Trade payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TradePayablesUndiscountedCashFlows" xlink:to="lab_kzia_TradePayablesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TradePayablesUndiscountedCashFlows" xml:lang="en-US">Trade payables undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AccruedPayablesUndiscountedCashFlows" xlink:label="loc_kzia_AccruedPayablesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AccruedPayablesUndiscountedCashFlows" xml:lang="en-US">Accrued payables undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_AccruedPayablesUndiscountedCashFlows" xml:lang="en-US">Accrued payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AccruedPayablesUndiscountedCashFlows" xlink:to="lab_kzia_AccruedPayablesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AccruedPayablesUndiscountedCashFlows" xml:lang="en-US">Accrued payables undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xml:lang="en-US">Classes of financial liabilities [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xml:lang="en-US">Classes of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xml:lang="en-US">Financial liabilities, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xml:lang="en-US">Financial liabilities, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" xml:lang="en-US">Disclosure of fair value measurement of assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xml:lang="en-US">Categories of financial assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xml:lang="en-US">Categories of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xml:lang="en-US">Financial assets, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xml:lang="en-US">Financial assets, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xml:lang="en-US">All levels of fair value hierarchy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xml:lang="en-US">All levels of fair value hierarchy [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xml:lang="en-US">Level 3 [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xml:lang="en-US">Level 3 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MeasurementAxis" xml:lang="en-US">Measurement [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MeasurementAxis" xml:lang="en-US">Measurement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xml:lang="en-US">Aggregated measurement [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xml:lang="en-US">Aggregated measurement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At fair value [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At fair value [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" xml:lang="en-US">Disclosure of detailed information about movements in level 3 assets and liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" xml:lang="en-US">Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" xlink:to="lab_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FairValueOfAssetsAndLiabilities" xlink:label="loc_kzia_FairValueOfAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_FairValueOfAssetsAndLiabilities" xml:lang="en-US">Fair Value Of Assets and Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_kzia_FairValueOfAssetsAndLiabilities" xml:lang="en-US">Balance Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_kzia_FairValueOfAssetsAndLiabilities" xml:lang="en-US">Balance Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_FairValueOfAssetsAndLiabilities" xlink:to="lab_kzia_FairValueOfAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_FairValueOfAssetsAndLiabilities" xml:lang="en-US">Fair value of assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" xml:lang="en-US">Losses recognised in profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PayoutOfMilestone" xlink:label="loc_kzia_PayoutOfMilestone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_PayoutOfMilestone" xml:lang="en-US">Payout of Milestone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_PayoutOfMilestone" xml:lang="en-US">Payout of milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_PayoutOfMilestone" xlink:to="lab_kzia_PayoutOfMilestone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_PayoutOfMilestone" xml:lang="en-US">Payout of milestone.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" xml:lang="en-US">Financial assets available-for-sale, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" xml:lang="en-US">Available for sale [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related party transactions [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xml:lang="en-US">Post-employment benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Short-term employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="loc_ifrs-full_AuditorsRemunerationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemunerationAbstract" xml:lang="en-US">Auditor's remuneration [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract" xlink:to="lab_ifrs-full_AuditorsRemunerationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-full_AuditorsRemuneration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemuneration" xml:lang="en-US">Auditor's remuneration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AuditorsRemuneration" xml:lang="en-US">Auditors remuneration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemuneration" xlink:to="lab_ifrs-full_AuditorsRemuneration" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xml:lang="en-US">Auditor's remuneration for audit services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xml:lang="en-US">Audit or review of the financial statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForAuditServices" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xml:lang="en-US">Disclosure of transactions between related parties [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xml:lang="en-US">Disclosure of transactions between related parties [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xml:lang="en-US">Disclosure of transactions between related parties [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xml:lang="en-US">Disclosure of transactions between related parties [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xml:lang="en-US">Amounts receivable, related party transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xml:lang="en-US">Trade receivables from related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xml:lang="en-US">Amounts payable, related party transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xml:lang="en-US">Trade payables to related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" xml:lang="en-US">Outstanding commitments made by entity, related party transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" xml:lang="en-US">Loan from related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="lab_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" xml:lang="en-US">Outstanding commitments made on behalf of entity, related party transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" xml:lang="en-US">Loan to related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" xlink:to="lab_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xml:lang="en-US">Categories of related parties [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xml:lang="en-US">Categories of related parties [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Entity's total for related parties [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Entity's total for related parties [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationAbstract" xlink:label="loc_kzia_DisclosureOfParentEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfParentEntityInformationAbstract" xml:lang="en-US">Disclosure Of Parent Entity Information [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfParentEntityInformationAbstract" xlink:to="lab_kzia_DisclosureOfParentEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfParentEntityInformationAbstract" xml:lang="en-US">Information about parent entity information.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationTable" xlink:label="loc_kzia_DisclosureOfParentEntityInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfParentEntityInformationTable" xml:lang="en-US">Disclosure Of Parent Entity Information [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfParentEntityInformationTable" xml:lang="en-US">Disclosure Of Parent Entity Information [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable" xlink:to="lab_kzia_DisclosureOfParentEntityInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfParentEntityInformationTable" xml:lang="en-US">Disclosure of parent entity information.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ParentMember" xml:lang="en-US">Parent [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ParentMember" xml:lang="en-US">Parent [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParentMember" xlink:to="lab_ifrs-full_ParentMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationLineItems" xlink:label="loc_kzia_DisclosureOfParentEntityInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfParentEntityInformationLineItems" xml:lang="en-US">Disclosure Of Parent Entity Information [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_DisclosureOfParentEntityInformationLineItems" xml:lang="en-US">Disclosure of parent entity information [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems" xlink:to="lab_kzia_DisclosureOfParentEntityInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfParentEntityInformationLineItems" xml:lang="en-US">Line item related to disclosure of parent entity information.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xml:lang="en-US">Disclosure of subsidiaries [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xml:lang="en-US">Disclosure of subsidiaries [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xml:lang="en-US">Disclosure of subsidiaries [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xml:lang="en-US">Disclosure of subsidiaries [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xml:lang="en-US">Disclosure of subsidiaries [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xml:lang="en-US">Country of incorporation of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xml:lang="en-US">Country of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="lab_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="loc_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xml:lang="en-US">Principal place of business of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xml:lang="en-US">Principal place of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:to="lab_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xml:lang="en-US">Ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaTherapeuticsIncMember" xlink:label="loc_kzia_KaziaTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_KaziaTherapeuticsIncMember" xml:lang="en-US">Kazia Therapeutics Inc [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_KaziaTherapeuticsIncMember" xml:lang="en-US">Kazia Therapeutics Inc [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_KaziaTherapeuticsIncMember" xlink:to="lab_kzia_KaziaTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_KaziaTherapeuticsIncMember" xml:lang="en-US">Kazia Therapeutics Inc.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaLaboratoriesPtyLtdMember" xlink:label="loc_kzia_KaziaLaboratoriesPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_KaziaLaboratoriesPtyLtdMember" xml:lang="en-US">Kazia Laboratories Pty Ltd [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_KaziaLaboratoriesPtyLtdMember" xml:lang="en-US">Kazia Laboratories Pty Ltd [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_KaziaLaboratoriesPtyLtdMember" xlink:to="lab_kzia_KaziaLaboratoriesPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_KaziaLaboratoriesPtyLtdMember" xml:lang="en-US">Kazia Laboratories Pty Ltd.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaResearchPtyLtdMember" xlink:label="loc_kzia_KaziaResearchPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_KaziaResearchPtyLtdMember" xml:lang="en-US">Kazia Research Pty Ltd [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_KaziaResearchPtyLtdMember" xml:lang="en-US">Kazia Research Pty Ltd [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_KaziaResearchPtyLtdMember" xlink:to="lab_kzia_KaziaResearchPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_KaziaResearchPtyLtdMember" xml:lang="en-US">Kazia Research Pty Ltd.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaTherapeuticsHongKongLimitedMember" xlink:label="loc_kzia_KaziaTherapeuticsHongKongLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_KaziaTherapeuticsHongKongLimitedMember" xml:lang="en-US">Kazia Therapeutics (Hong Kong) Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_KaziaTherapeuticsHongKongLimitedMember" xml:lang="en-US">Kazia Therapeutics (Hong Kong) Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_KaziaTherapeuticsHongKongLimitedMember" xlink:to="lab_kzia_KaziaTherapeuticsHongKongLimitedMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ReconciliationAbstract" xlink:label="loc_kzia_ReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ReconciliationAbstract" xml:lang="en-US">Reconciliation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ReconciliationAbstract" xlink:to="lab_kzia_ReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ReconciliationAbstract" xml:lang="en-US">Reconciliation</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" xml:lang="en-US">Disclosure of reconciliation of profit or loss to operating cash flows [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" xlink:to="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" xml:lang="en-US">Disclosure of reconciliation of profit or loss to operating cash flows</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" xml:lang="en-US">Disclosure of reconciliation of profit or loss to operating cash flows [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" xlink:to="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" xml:lang="en-US">Disclosure of reconciliation of profit or loss to operating cash flows</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Adjustment For Increase Decrease In Trade And Other Payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Decrease/(increase) in trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Adjustment for increase decrease in trade and other payables.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareTable" xml:lang="en-US">Earnings per share [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareTable" xml:lang="en-US">Earnings per share [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareTable" xlink:to="lab_ifrs-full_EarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UnlistedOptionsMember" xlink:label="loc_kzia_UnlistedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_UnlistedOptionsMember" xml:lang="en-US">Unlisted Options [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_UnlistedOptionsMember" xml:lang="en-US">Unlisted options [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_UnlistedOptionsMember" xlink:to="lab_kzia_UnlistedOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_UnlistedOptionsMember" xml:lang="en-US">Unlisted options.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xml:lang="en-US">Earnings per share [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xml:lang="en-US">Earnings per share [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareLineItems" xlink:to="lab_ifrs-full_EarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xlink:label="loc_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xml:lang="en-US">Number Of Antidilutive Share Options Excluded From Calculation Of Earnings Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xml:lang="en-US">Number of options that have been excluded from the calculations as they were antidilutive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xlink:to="lab_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xml:lang="en-US">Number of antidilutive share options excluded from calculation of earnings per share.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Employee remuneration expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOptionsIssued" xlink:label="loc_kzia_NumberOfOptionsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfOptionsIssued" xml:lang="en-US">Number of Options Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfOptionsIssued" xml:lang="en-US">Number of options issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfOptionsIssued" xlink:to="lab_kzia_NumberOfOptionsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfOptionsIssued" xml:lang="en-US">Number of options issued.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of options issued to employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Granted, share options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageOfOptionsVested" xlink:label="loc_kzia_PercentageOfOptionsVested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_PercentageOfOptionsVested" xml:lang="en-US">Percentage of options vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_PercentageOfOptionsVested" xml:lang="en-US">Percentage of Options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_PercentageOfOptionsVested" xlink:to="lab_kzia_PercentageOfOptionsVested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_PercentageOfOptionsVested" xml:lang="en-US">Percentage of options vested.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOptionsVested" xlink:label="loc_kzia_NumberOfOptionsVested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfOptionsVested" xml:lang="en-US">Number of Options vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfOptionsVested" xml:lang="en-US">Number of Options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfOptionsVested" xlink:to="lab_kzia_NumberOfOptionsVested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfOptionsVested" xml:lang="en-US">Number of options vested.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheOneMember" xlink:label="loc_kzia_OtherTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_OtherTrancheOneMember" xml:lang="en-US">Other Tranche One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_OtherTrancheOneMember" xlink:to="lab_kzia_OtherTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_OtherTrancheOneMember" xml:lang="en-US">Other tranche one.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheTwoMember" xlink:label="loc_kzia_OtherTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_OtherTrancheTwoMember" xml:lang="en-US">Other Tranche Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_OtherTrancheTwoMember" xlink:to="lab_kzia_OtherTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_OtherTrancheTwoMember" xml:lang="en-US">Other tranche two.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TranchesTwoAndEightMember" xlink:label="loc_kzia_TranchesTwoAndEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TranchesTwoAndEightMember" xml:lang="en-US">Tranches Two and Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TranchesTwoAndEightMember" xml:lang="en-US">Tranches 2 and 8 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TranchesTwoAndEightMember" xlink:to="lab_kzia_TranchesTwoAndEightMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheNineMember" xml:lang="en-US">Tranche nine [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheNineMember" xml:lang="en-US">Tranche 9 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheNineMember" xlink:to="lab_kzia_TrancheNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheNineMember" xml:lang="en-US">Tranche nine.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheThreeMember" xlink:label="loc_kzia_OtherTrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_OtherTrancheThreeMember" xml:lang="en-US">Other Tranche Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_OtherTrancheThreeMember" xlink:to="lab_kzia_OtherTrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_OtherTrancheThreeMember" xml:lang="en-US">Other tranche three.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TranchesTenAndTwelveMember" xlink:label="loc_kzia_TranchesTenAndTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TranchesTenAndTwelveMember" xml:lang="en-US">Tranches Ten and Twelve [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TranchesTenAndTwelveMember" xml:lang="en-US">Tranches 10 and 12 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TranchesTenAndTwelveMember" xlink:to="lab_kzia_TranchesTenAndTwelveMember" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheFourMember" xlink:label="loc_kzia_OtherTrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_OtherTrancheFourMember" xml:lang="en-US">Other Tranche Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_OtherTrancheFourMember" xlink:to="lab_kzia_OtherTrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_OtherTrancheFourMember" xml:lang="en-US">Other tranche four.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesAxis" xlink:label="loc_kzia_AwardTypesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AwardTypesAxis" xml:lang="en-US">Award Types [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AwardTypesAxis" xlink:to="lab_kzia_AwardTypesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AwardTypesAxis" xml:lang="en-US">Award Types [axis]</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesMember" xlink:label="loc_kzia_AwardTypesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_AwardTypesMember" xml:lang="en-US">Award types [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_AwardTypesMember" xlink:to="lab_kzia_AwardTypesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_AwardTypesMember" xml:lang="en-US">Award Types [member]</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFifteenMember" xlink:label="loc_kzia_TrancheFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheFifteenMember" xml:lang="en-US">Tranche Fifteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_TrancheFifteenMember" xml:lang="en-US">Tranche 15 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheFifteenMember" xlink:to="lab_kzia_TrancheFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheFifteenMember" xml:lang="en-US">Tranche Fifteen</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwoMember" xlink:label="loc_kzia_TrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwoMember" xml:lang="en-US">Tranche Two [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwoMember" xml:lang="en-US">Tranche 2 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwoMember" xlink:to="lab_kzia_TrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwoMember" xml:lang="en-US">Tranche two.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheOneMember" xlink:label="loc_kzia_TrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheOneMember" xml:lang="en-US">Tranche One [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheOneMember" xml:lang="en-US">Tranche 1 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheOneMember" xlink:to="lab_kzia_TrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheOneMember" xml:lang="en-US">Tranche one.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSevenMember" xlink:label="loc_kzia_TrancheSevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheSevenMember" xml:lang="en-US">Tranche Seven [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheSevenMember" xml:lang="en-US">Tranche 7 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheSevenMember" xlink:to="lab_kzia_TrancheSevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheSevenMember" xml:lang="en-US">Tranche seven.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixMember" xlink:label="loc_kzia_TrancheSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheSixMember" xml:lang="en-US">Tranche Six [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheSixMember" xml:lang="en-US">Tranche 6 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheSixMember" xlink:to="lab_kzia_TrancheSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheSixMember" xml:lang="en-US">Tranche six.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTenMember" xlink:label="loc_kzia_TrancheTenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTenMember" xml:lang="en-US">Tranche ten [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTenMember" xml:lang="en-US">Tranche 10 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTenMember" xlink:to="lab_kzia_TrancheTenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTenMember" xml:lang="en-US">Tranche ten.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirteenMember" xlink:label="loc_kzia_TrancheThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheThirteenMember" xml:lang="en-US">Tranche Thirteen [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheThirteenMember" xml:lang="en-US">Tranche 13 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheThirteenMember" xlink:to="lab_kzia_TrancheThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheThirteenMember" xml:lang="en-US">Tranche thirteen.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThreeMember" xlink:label="loc_kzia_TrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheThreeMember" xml:lang="en-US">Tranche Three [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheThreeMember" xml:lang="en-US">Tranche 3 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheThreeMember" xlink:to="lab_kzia_TrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheThreeMember" xml:lang="en-US">Tranche three.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwelveMember" xlink:label="loc_kzia_TrancheTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwelveMember" xml:lang="en-US">Tranche Twelve [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwelveMember" xml:lang="en-US">Tranche 12 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwelveMember" xlink:to="lab_kzia_TrancheTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwelveMember" xml:lang="en-US">Tranche twelve.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixteenMember" xlink:label="loc_kzia_TrancheSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheSixteenMember" xml:lang="en-US">Tranche Sixteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kzia_TrancheSixteenMember" xml:lang="en-US">Tranche 16 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheSixteenMember" xlink:to="lab_kzia_TrancheSixteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheSixteenMember" xml:lang="en-US">Tranche Sixteen</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFiveMember" xlink:label="loc_kzia_TrancheFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheFiveMember" xml:lang="en-US">Tranche Five [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheFiveMember" xml:lang="en-US">Tranche 5 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheFiveMember" xlink:to="lab_kzia_TrancheFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheFiveMember" xml:lang="en-US">Tranche five.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourMember" xlink:label="loc_kzia_TrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheFourMember" xml:lang="en-US">Tranche Four [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheFourMember" xml:lang="en-US">Tranche 4 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheFourMember" xlink:to="lab_kzia_TrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheFourMember" xml:lang="en-US">Tranche four.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEighteenMember" xlink:label="loc_kzia_TrancheEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheEighteenMember" xml:lang="en-US">Tranche Eighteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheEighteenMember" xml:lang="en-US">Tranche 18 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheEighteenMember" xlink:to="lab_kzia_TrancheEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheEighteenMember" xml:lang="en-US">Tranche eighteen.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineteenMember" xlink:label="loc_kzia_TrancheNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheNineteenMember" xml:lang="en-US">Tranche Nineteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheNineteenMember" xml:lang="en-US">Tranche 19 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheNineteenMember" xlink:to="lab_kzia_TrancheNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheNineteenMember" xml:lang="en-US">Tranche nineteen.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourteenMember" xlink:label="loc_kzia_TrancheFourteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheFourteenMember" xml:lang="en-US">Tranche Fourteen [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheFourteenMember" xml:lang="en-US">Tranche 14 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheFourteenMember" xlink:to="lab_kzia_TrancheFourteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheFourteenMember" xml:lang="en-US">Tranche Fourteen.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEightMember" xlink:label="loc_kzia_TrancheEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheEightMember" xml:lang="en-US">Tranche Eight [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheEightMember" xml:lang="en-US">Tranche 8 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheEightMember" xlink:to="lab_kzia_TrancheEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheEightMember" xml:lang="en-US">Tranche eight.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheElevenMember" xlink:label="loc_kzia_TrancheElevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheElevenMember" xml:lang="en-US">Tranche eleven [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheElevenMember" xml:lang="en-US">Tranche 11 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheElevenMember" xlink:to="lab_kzia_TrancheElevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheElevenMember" xml:lang="en-US">Tranche eleven.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSeventeenMember" xlink:label="loc_kzia_TrancheSeventeenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheSeventeenMember" xml:lang="en-US">Tranche Seventeen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheSeventeenMember" xml:lang="en-US">Tranche 17 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheSeventeenMember" xlink:to="lab_kzia_TrancheSeventeenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheSeventeenMember" xml:lang="en-US">Tranche seventeen.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Balance at the start of the year, share options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Balance at the end of the year, share options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xml:lang="en-US">Date of grant of share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xml:lang="en-US">Grant date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Balance at the start of the year, Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Balance at the end of the year, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xml:lang="en-US">Expired, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Exercise price, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xlink:label="loc_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xml:lang="en-US">Number Of Share Options Modified In Sharebased Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xml:lang="en-US">Exercised and modified</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xlink:to="lab_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options modified in sharebased payment arrangement.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xlink:label="loc_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xml:lang="en-US">Weighted Average Exercise Price Modified In Sharebased Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xml:lang="en-US">Modified, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xlink:to="lab_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xml:lang="en-US">Weighted average exercise price modified in sharebased payment arrangement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options expired in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xml:lang="en-US">Expired /lapsed on termination of employment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">Granted, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xlink:label="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xml:lang="en-US">Share Based Payment Arrangement Options expiry Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xml:lang="en-US">Expiry date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xlink:to="lab_kzia_ShareBasedPaymentArrangementOptionsExpiryDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xml:lang="en-US">The date on which share-based payment arrangement options expire.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyOneMember" xlink:label="loc_kzia_TrancheTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyOneMember" xml:lang="en-US">Tranche Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyOneMember" xml:lang="en-US">Tranche 21 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyOneMember" xlink:to="lab_kzia_TrancheTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyOneMember" xml:lang="en-US">Tranche twenty one.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyTwoMember" xlink:label="loc_kzia_TrancheTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyTwoMember" xml:lang="en-US">Tranche Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyTwoMember" xml:lang="en-US">Tranche 22 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyTwoMember" xlink:to="lab_kzia_TrancheTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyTwoMember" xml:lang="en-US">Tranche twenty two.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyThreeMember" xlink:label="loc_kzia_TrancheTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyThreeMember" xml:lang="en-US">Tranche Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyThreeMember" xml:lang="en-US">Tranche 23 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyThreeMember" xlink:to="lab_kzia_TrancheTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyThreeMember" xml:lang="en-US">Tranche twenty three.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyFourMember" xlink:label="loc_kzia_TrancheTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyFourMember" xml:lang="en-US">Tranche Twenty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyFourMember" xml:lang="en-US">Tranche 24 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyFourMember" xlink:to="lab_kzia_TrancheTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyFourMember" xml:lang="en-US">Tranche twenty four.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyFiveMember" xlink:label="loc_kzia_TrancheTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyFiveMember" xml:lang="en-US">Tranche Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyFiveMember" xml:lang="en-US">Tranche 25 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyFiveMember" xlink:to="lab_kzia_TrancheTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyFiveMember" xml:lang="en-US">Tranche twenty five.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentySixMember" xlink:label="loc_kzia_TrancheTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentySixMember" xml:lang="en-US">Tranche Twenty Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentySixMember" xml:lang="en-US">Tranche 26 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentySixMember" xlink:to="lab_kzia_TrancheTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentySixMember" xml:lang="en-US">Tranche twenty six.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyMember" xlink:label="loc_kzia_TrancheTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyMember" xml:lang="en-US">Tranche Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyMember" xml:lang="en-US">Tranche 20 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyMember" xlink:to="lab_kzia_TrancheTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyMember" xml:lang="en-US">Tranche twenty.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentySevenMember" xlink:label="loc_kzia_TrancheTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentySevenMember" xml:lang="en-US">Tranche Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentySevenMember" xml:lang="en-US">Tranche 27 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentySevenMember" xlink:to="lab_kzia_TrancheTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentySevenMember" xml:lang="en-US">Tranche twenty seven.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyEightMember" xlink:label="loc_kzia_TrancheTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyEightMember" xml:lang="en-US">Tranche Twenty Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyEightMember" xml:lang="en-US">Tranche 28 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyEightMember" xlink:to="lab_kzia_TrancheTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyEightMember" xml:lang="en-US">Tranche twenty eight.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyNineMember" xlink:label="loc_kzia_TrancheTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheTwentyNineMember" xml:lang="en-US">Tranche Twenty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheTwentyNineMember" xml:lang="en-US">Tranche 29 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheTwentyNineMember" xlink:to="lab_kzia_TrancheTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheTwentyNineMember" xml:lang="en-US">Tranche twenty nine.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirtyMember" xlink:label="loc_kzia_TrancheThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheThirtyMember" xml:lang="en-US">Tranche Thirty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheThirtyMember" xml:lang="en-US">Tranche 30 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheThirtyMember" xlink:to="lab_kzia_TrancheThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheThirtyMember" xml:lang="en-US">Tranche thirty.</label>
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirtyOneMember" xlink:label="loc_kzia_TrancheThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_TrancheThirtyOneMember" xml:lang="en-US">Tranche Thirty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_TrancheThirtyOneMember" xml:lang="en-US">Tranche 31 [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_TrancheThirtyOneMember" xlink:to="lab_kzia_TrancheThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_TrancheThirtyOneMember" xml:lang="en-US">Tranche thirty one.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xml:lang="en-US">Fair value per option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk free interest rate, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk free Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Expected volatility, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Volatility (%)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Option life, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Remaining Option Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePricePerShare" xlink:label="loc_kzia_SharePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kzia_SharePricePerShare" xml:lang="en-US">Share price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kzia_SharePricePerShare" xml:lang="en-US">Share price at Grant Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kzia_SharePricePerShare" xlink:to="lab_kzia_SharePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kzia_SharePricePerShare" xml:lang="en-US">Share price per share.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>kzia-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-October-2021 [03:11:17] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Cover" roleURI="http://www.kaziatherapeutics.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#StatementsOfChangesInEquity" roleURI="http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#GeneralInformation" roleURI="http://www.kaziatherapeutics.com/role/GeneralInformation" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SignificantAccountingPolicies" roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CriticalAccountingJudgementsEstimatesAndAssumptions" roleURI="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OperatingSegments" roleURI="http://www.kaziatherapeutics.com/role/OperatingSegments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Revenue" roleURI="http://www.kaziatherapeutics.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncome" roleURI="http://www.kaziatherapeutics.com/role/OtherIncome" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Expenses" roleURI="http://www.kaziatherapeutics.com/role/Expenses" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefit" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefit" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalents" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherAssets" roleURI="http://www.kaziatherapeutics.com/role/OtherAssets" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Intangibles" roleURI="http://www.kaziatherapeutics.com/role/Intangibles" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefits" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefits" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsideration" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsideration" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#DeferredTax" roleURI="http://www.kaziatherapeutics.com/role/DeferredTax" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquity" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquity" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquity" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityReserves" roleURI="http://www.kaziatherapeutics.com/role/EquityReserves" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityDividends" roleURI="http://www.kaziatherapeutics.com/role/EquityDividends" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstruments" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurement" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosures" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditors" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditors" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentLiabilities" roleURI="http://www.kaziatherapeutics.com/role/ContingentLiabilities" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#Commitments" roleURI="http://www.kaziatherapeutics.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RelatedPartyTransactions" roleURI="http://www.kaziatherapeutics.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformation" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformation" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#InterestsInSubsidiaries" roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities" roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShare" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShare" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPayments" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPayments" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SubsequentEvents" roleURI="http://www.kaziatherapeutics.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RevenueTables" roleURI="http://www.kaziatherapeutics.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncomeTables" roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ExpensesTables" roleURI="http://www.kaziatherapeutics.com/role/ExpensesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitTables" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalentsTables" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherAssetsTables" roleURI="http://www.kaziatherapeutics.com/role/OtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IntangiblesTables" roleURI="http://www.kaziatherapeutics.com/role/IntangiblesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayablesTables" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefitsTables" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsiderationTables" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#DeferredTaxTables" roleURI="http://www.kaziatherapeutics.com/role/DeferredTaxTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquityTables" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquityTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquityTables" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsTables" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementTables" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosuresTables" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditorsTables" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformationTables" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#InterestsInSubsidiariesTables" roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables" roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShareTables" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsTables" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OperatingSegmentsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RevenueSummaryOfLicensingRevenueDetail" roleURI="http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail" roleURI="http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherIncomeSummaryOfOtherIncomeDetail" roleURI="http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ExpensesSummaryOfExpensesDetail" roleURI="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail" roleURI="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" roleURI="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherReceivablesAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#OtherAssetsSummaryOfCurrentAssetsOtherDetail" roleURI="http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail" roleURI="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#IntangiblesSummaryOfReconciliationsOfIntangiblesDetail" roleURI="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" roleURI="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EmployeeBenefitsSummaryOfProvisionDetail" roleURI="http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ContingentConsiderationAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail" roleURI="http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquitySummaryOfEquityContributedEquityDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityContributedEquityAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EquityOtherContributedEquityAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail" roleURI="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" roleURI="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" roleURI="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ParentEntityInformationStatementOfFinancialPositionDetail" roleURI="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail" roleURI="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail" roleURI="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShareSummaryOfEarningsPerShareDetail" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#EarningsPerShareAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsAdditionalInformationDetail" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="kzia-20210630.xsd#ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail" roleURI="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_DocumentInformationTable_5" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_6" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_3" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_3" xlink:to="loc_dei_BusinessContactMember_7" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_8" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_10" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_11" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_12" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_13" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_14" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_15" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_16" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_17" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_18" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_19" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_20" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_22" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityShellCompany_23" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_24" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_25" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_26" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_27" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelName_9" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_38" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_28" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_29" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_30" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressCountry_31" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_32" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_34" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CountryRegion_33" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CityAreaCode_35" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_37" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_36" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1095722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1095722" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1095721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFileNumber_1095721" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1095728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_Security12bTitle_1095728" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1095730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_1095730" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1095731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_SecurityExchangeName_1095731" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1095717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1095717" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_40" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_RevenueFromInterest_64" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_OtherRevenue_65" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_FinanceIncome_66" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_45" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_45" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_57" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_45" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_58" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_45" xlink:to="loc_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets_59" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_45" xlink:to="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_60" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GainLossOnRevaluationOfContingentConsideration" xlink:label="loc_kzia_GainLossOnRevaluationOfContingentConsideration_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_45" xlink:to="loc_kzia_GainLossOnRevaluationOfContingentConsideration_61" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_45" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_63" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_67" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_ProfitLoss_68" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_46" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_46" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_42" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_42" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_51" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_42" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_52" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_743774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_42" xlink:to="loc_ifrs-full_ComprehensiveIncome_743774" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_ProfitLossAttributableToAbstract_47" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_47" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_69" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_743775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_47" xlink:to="loc_ifrs-full_ProfitLoss_743775" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_43" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_43" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_53" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_43" xlink:to="loc_ifrs-full_ComprehensiveIncome_54" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract" xlink:label="loc_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract_41" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract_41" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_48" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract_41" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_49" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_40" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_44" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_44" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_55" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_44" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_56" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_71" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_71" xlink:to="loc_ifrs-full_AssetsAbstract_72" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_72" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_73" xlink:to="loc_ifrs-full_CashAndCashEquivalents_80" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_73" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_81" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_73" xlink:to="loc_ifrs-full_OtherCurrentAssets_82" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_73" xlink:to="loc_ifrs-full_CurrentAssets_83" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_72" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_77" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="loc_ifrs-full_NoncurrentReceivables_1095514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_77" xlink:to="loc_ifrs-full_NoncurrentReceivables_1095514" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_77" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_98" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_77" xlink:to="loc_ifrs-full_NoncurrentAssets_99" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_72" xlink:to="loc_ifrs-full_Assets_79" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_71" xlink:to="loc_ifrs-full_LiabilitiesAbstract_76" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_76" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_74" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_74" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_84" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_1095515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_74" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_1095515" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationCurrent" xlink:label="loc_kzia_ContingentConsiderationCurrent_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_74" xlink:to="loc_kzia_ContingentConsiderationCurrent_87" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_74" xlink:to="loc_ifrs-full_CurrentLiabilities_88" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_76" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_78" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_78" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_100" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1095516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_78" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1095516" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_kzia_ContingentConsiderationNoncurrent_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_78" xlink:to="loc_kzia_ContingentConsiderationNoncurrent_101" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_78" xlink:to="loc_ifrs-full_NoncurrentLiabilities_102" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_76" xlink:to="loc_ifrs-full_Liabilities_95" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-full_NetAssetsLiabilities_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_71" xlink:to="loc_ifrs-full_NetAssetsLiabilities_103" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_71" xlink:to="loc_ifrs-full_EquityAbstract_75" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_75" xlink:to="loc_ifrs-full_IssuedCapital_89" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_75" xlink:to="loc_ifrs-full_OtherEquityInterest_90" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_75" xlink:to="loc_ifrs-full_OtherReserves_91" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_75" xlink:to="loc_ifrs-full_RetainedEarnings_92" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_75" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_93" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_75" xlink:to="loc_ifrs-full_Equity_94" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_105" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_105" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_111" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_111" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_106" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_106" xlink:to="loc_ifrs-full_EquityMember_107" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_IssuedCapitalMember_113" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterestMember" xlink:label="loc_ifrs-full_OtherEquityInterestMember_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_OtherEquityInterestMember_114" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-full_OtherReservesMember_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_OtherReservesMember_115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_RetainedEarningsMember_116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_743777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_107" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_743777" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_111" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_109" xlink:to="loc_ifrs-full_RestatedMember_108" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_108" xlink:to="loc_ifrs-full_PreviouslyStatedMember_117" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="loc_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_108" xlink:to="loc_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_118" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_111" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_Equity_119" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_ProfitLoss_120" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_121" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_ComprehensiveIncome_122" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:label="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_1095519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_1095519" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_124" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_125" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_127" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions" xlink:label="loc_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions_128" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_129" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_ifrs-full_IssueOfEquity_130" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseDecreaseThroughExpireOfOptions" xlink:label="loc_kzia_IncreaseDecreaseThroughExpireOfOptions_757032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_112" xlink:to="loc_kzia_IncreaseDecreaseThroughExpireOfOptions_757032" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_110" xlink:to="loc_ifrs-full_Equity_123" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_132" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_137" xlink:to="loc_ifrs-full_ProfitLoss_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_137" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_146" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NetLossOnDisposalOfNonCurrentAssets" xlink:label="loc_kzia_NetLossOnDisposalOfNonCurrentAssets_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_kzia_NetLossOnDisposalOfNonCurrentAssets_147" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_148" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_149" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_150" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_154" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_134" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_156" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_137" xlink:to="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_138" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xlink:label="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" xlink:to="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments_140" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_141" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_142" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xlink:label="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" xlink:to="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities_144" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract_133" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_145" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_137" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_167" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_136" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInterestsInAssociates_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_136" xlink:to="loc_ifrs-full_ProceedsFromSalesOfInterestsInAssociates_164" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_136" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_165" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_135" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_135" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_157" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_135" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_159" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_168" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_CashAndCashEquivalents_169" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_170" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_132" xlink:to="loc_ifrs-full_CashAndCashEquivalents_171" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/GeneralInformation">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_817" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_817" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_818" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_820" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_820" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_821" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_853" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_853" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_854" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OperatingSegments">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_856" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_856" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_857" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/Revenue">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_859" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_859" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_860" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherIncome">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_865" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_865" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_866" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/Expenses">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_871" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExpensesExplanatory_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_871" xlink:to="loc_ifrs-full_DisclosureOfExpensesExplanatory_872" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefit">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_877" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_877" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_878" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_883" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_883" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_884" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_889" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_889" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_890" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherAssets">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_901" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_901" xlink:to="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_902" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/Intangibles">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_920" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_920" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_921" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_927" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_927" xlink:to="loc_kzia_StatementTable_931" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_931" xlink:to="loc_ifrs-full_MaturityAxis_929" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_929" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_928" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_928" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_932" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_931" xlink:to="loc_kzia_StatementLineItems_930" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_930" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_933" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EmployeeBenefits">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_943" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_943" xlink:to="loc_kzia_StatementTable_947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_947" xlink:to="loc_ifrs-full_MaturityAxis_945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_945" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_944" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_944" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_948" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_947" xlink:to="loc_kzia_StatementLineItems_946" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_946" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_949" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsideration">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_959" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_959" xlink:to="loc_kzia_StatementTable_963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_963" xlink:to="loc_ifrs-full_MaturityAxis_961" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_961" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_960" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_960" xlink:to="loc_ifrs-full_LaterThanOneYearMember_965" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_963" xlink:to="loc_kzia_StatementLineItems_962" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_962" xlink:to="loc_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory_966" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/DeferredTax">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_978" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_978" xlink:to="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_979" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityContributedEquity">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_984" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_984" xlink:to="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_985" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_991" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfOtherEquityExplanatory" xlink:label="loc_kzia_DisclosureOfOtherEquityExplanatory_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_991" xlink:to="loc_kzia_DisclosureOfOtherEquityExplanatory_992" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityReserves">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_997" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_997" xlink:to="loc_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_998" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityDividends">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1000" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDividendsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDividendsExplanatory_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1000" xlink:to="loc_ifrs-full_DisclosureOfDividendsExplanatory_1001" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstruments">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1003" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1003" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1004" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1017" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1017" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_1018" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1023" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1023" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_1024" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RemunerationOfAuditors">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1029" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1029" xlink:to="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_1030" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentLiabilities">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1035" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1035" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_1036" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/Commitments">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1038" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1038" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_1039" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1041" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1041" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1042" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ParentEntityInformation">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1047" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1047" xlink:to="loc_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory_1048" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="loc_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_1053" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_1054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_1053" xlink:to="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_1054" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_744040" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock" xlink:label="loc_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock_744041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_744040" xlink:to="loc_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock_744041" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EarningsPerShare">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1059" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1059" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1060" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPayments">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1065" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_1066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1065" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_1066" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1075" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1075" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1076" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_823" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory" xlink:label="loc_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory_824" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory" xlink:label="loc_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory_851" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGoingConcernExplanatory_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DisclosureOfGoingConcernExplanatory_825" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfParentEntityInformationExplanatory" xlink:label="loc_kzia_DescriptionOfParentEntityInformationExplanatory_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_kzia_DescriptionOfParentEntityInformationExplanatory_827" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_828" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_829" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_830" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_831" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_835" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory" xlink:label="loc_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory_836" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_837" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_839" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_840" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_841" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_842" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_843" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_844" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_845" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_846" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_847" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_848" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_849" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_823" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_850" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_862" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory_1095522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_862" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesExplanatory_1095522" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_1095523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_862" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_1095523" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherIncomeTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_868" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_868" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_869" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ExpensesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_874" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_874" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_875" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_880" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_880" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory_881" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_886" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_886" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_887" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_892" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_892" xlink:to="loc_kzia_StatementTable_896" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_896" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_893" xlink:to="loc_ifrs-full_FinancialAssetsMember_894" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_896" xlink:to="loc_kzia_StatementLineItems_895" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_895" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory_898" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherAssetsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_904" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_904" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory_905" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IntangiblesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_923" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_923" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_924" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_923" xlink:to="loc_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory_925" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_935" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_935" xlink:to="loc_kzia_StatementTable_939" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_939" xlink:to="loc_ifrs-full_MaturityAxis_937" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_937" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_936" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_936" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_940" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_939" xlink:to="loc_kzia_StatementLineItems_938" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_938" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_941" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_951" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_951" xlink:to="loc_kzia_StatementTable_955" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_955" xlink:to="loc_ifrs-full_MaturityAxis_953" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_953" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_952" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_952" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_956" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_955" xlink:to="loc_kzia_StatementLineItems_954" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_954" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory_957" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsiderationTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_968" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_968" xlink:to="loc_kzia_StatementTable_972" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_972" xlink:to="loc_ifrs-full_MaturityAxis_970" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_970" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_969" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-full_LaterThanOneYearMember_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_969" xlink:to="loc_ifrs-full_LaterThanOneYearMember_974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_972" xlink:to="loc_kzia_StatementLineItems_971" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_971" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory_975" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/DeferredTaxTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_981" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_981" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory_982" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityContributedEquityTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_987" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_987" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory_988" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_987" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory_989" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_994" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_994" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory_995" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1006" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementTable" xlink:label="loc_kzia_StatementTable_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1006" xlink:to="loc_kzia_StatementTable_1008" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_1008" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1009" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1009" xlink:to="loc_ifrs-full_TypesOfRisksMember_1010" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_StatementLineItems" xlink:label="loc_kzia_StatementLineItems_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementTable_1008" xlink:to="loc_kzia_StatementLineItems_1007" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_1011" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1012" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_1013" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_StatementLineItems_1007" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_1014" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1020" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1020" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory_1021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock_1095509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1020" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock_1095509" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1026" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1026" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory_1027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1032" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1032" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory_1033" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ParentEntityInformationTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1050" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityFinancialInformationExplanatory" xlink:label="loc_kzia_DisclosureOfParentEntityFinancialInformationExplanatory_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1050" xlink:to="loc_kzia_DisclosureOfParentEntityFinancialInformationExplanatory_1051" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:label="loc_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_1056" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_1056" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_1057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_744043" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock_751383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_744043" xlink:to="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock_751383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EarningsPerShareTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1062" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1062" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_1063" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1068" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1068" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1069" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1068" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_1070" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_173" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_173" xlink:to="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_175" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_174" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicenseAgreementForPaxalisibMember" xlink:label="loc_kzia_LicenseAgreementForPaxalisibMember_1096114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" xlink:to="loc_kzia_LicenseAgreementForPaxalisibMember_1096114" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingAgreementForEvtEightZeroOneMember" xlink:label="loc_kzia_LicensingAgreementForEvtEightZeroOneMember_1096116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_178" xlink:to="loc_kzia_LicensingAgreementForEvtEightZeroOneMember_1096116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_RangeAxis_180" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_180" xlink:to="loc_ifrs-full_RangesMember_181" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_181" xlink:to="loc_ifrs-full_TopOfRangeMember_200" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_182" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ResearchAndDevelopmentTaxIncentiveProgramMember" xlink:label="loc_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_183" xlink:to="loc_kzia_ResearchAndDevelopmentTaxIncentiveProgramMember_201" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeAxis" xlink:label="loc_kzia_FundingPurposeAxis_743822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_kzia_FundingPurposeAxis_743822" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FundingPurposeMember" xlink:label="loc_kzia_FundingPurposeMember_743824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_FundingPurposeAxis_743822" xlink:to="loc_kzia_FundingPurposeMember_743824" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ClinicalTrialsMember" xlink:label="loc_kzia_ClinicalTrialsMember_743827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_FundingPurposeMember_743824" xlink:to="loc_kzia_ClinicalTrialsMember_743827" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityAxis" xlink:label="loc_kzia_UncertainityAxis_743829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_kzia_UncertainityAxis_743829" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UncertainityMember" xlink:label="loc_kzia_UncertainityMember_743830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_UncertainityAxis_743829" xlink:to="loc_kzia_UncertainityMember_743830" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_CovidNinteenMember" xlink:label="loc_kzia_CovidNinteenMember_743831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_UncertainityMember_743830" xlink:to="loc_kzia_CovidNinteenMember_743831" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_757030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_757029" xlink:to="loc_ifrs-full_NonadjustingEventsMember_757030" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_177" xlink:to="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_ProfitLoss_186" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_CurrentAssetsLiabilities_187" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_188" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_CashAndCashEquivalents_189" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdditionalTaxDeductionPercentage" xlink:label="loc_kzia_AdditionalTaxDeductionPercentage_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_AdditionalTaxDeductionPercentage_191" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InterestIncomeLoss" xlink:label="loc_kzia_InterestIncomeLoss_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_InterestIncomeLoss_192" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife" xlink:label="loc_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife_195" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_743819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_176" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_743819" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract" xlink:label="loc_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract_203" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement" xlink:label="loc_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement_1095520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract_203" xlink:to="loc_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement_1095520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_206" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOperatingSegments1" xlink:label="loc_kzia_NumberOfOperatingSegments1_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_206" xlink:to="loc_kzia_NumberOfOperatingSegments1_207" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfMajorCustomers" xlink:label="loc_kzia_NumberOfMajorCustomers_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_206" xlink:to="loc_kzia_NumberOfMajorCustomers_208" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConcentrationRiskMajorCustomerPercentage" xlink:label="loc_kzia_ConcentrationRiskMajorCustomerPercentage_1095521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_206" xlink:to="loc_kzia_ConcentrationRiskMajorCustomerPercentage_1095521" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesAbstract" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract_1095526" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesTable" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesAbstract_1095526" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_1095529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_1095529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1095530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1095529" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1095530" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingRevenueMember" xlink:label="loc_kzia_LicensingRevenueMember_1095531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1095530" xlink:to="loc_kzia_LicensingRevenueMember_1095531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfProductsAndServicesLineItems" xlink:label="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_1095528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesTable_1095527" xlink:to="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_1095528" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_1095532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfProductsAndServicesLineItems_1095528" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_1095532" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_1095533" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_1095533" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1095536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1095536" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_1095537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1095536" xlink:to="loc_ifrs-full_GeographicalAreasMember_1095537" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="loc_country_CN_1095538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1095537" xlink:to="loc_country_CN_1095538" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SwedanMember" xlink:label="loc_kzia_SwedanMember_1095539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1095537" xlink:to="loc_kzia_SwedanMember_1095539" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_1095543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_1095543" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_1095544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_1095543" xlink:to="loc_ifrs-full_ProductsAndServicesMember_1095544" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingRevenueMember" xlink:label="loc_kzia_LicensingRevenueMember_1095545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_1095544" xlink:to="loc_kzia_LicensingRevenueMember_1095545" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_1095540" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1095542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_1095541" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1095542" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_1095535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_1095534" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_1095535" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_1095546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_1095535" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_1095546" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaterialIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" xlink:to="loc_ifrs-full_NetForeignExchangeGain_216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxRebatesOnPayroll" xlink:label="loc_kzia_TaxRebatesOnPayroll_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" xlink:to="loc_kzia_TaxRebatesOnPayroll_217" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SubsidiesAndGrants" xlink:label="loc_kzia_SubsidiesAndGrants_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" xlink:to="loc_kzia_SubsidiesAndGrants_218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ReimbursementOfExpenses" xlink:label="loc_kzia_ReimbursementOfExpenses_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" xlink:to="loc_kzia_ReimbursementOfExpenses_220" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RebateIncomeOnResearchAndDevelopment" xlink:label="loc_kzia_RebateIncomeOnResearchAndDevelopment_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" xlink:to="loc_kzia_RebateIncomeOnResearchAndDevelopment_221" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-full_OtherIncome_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaterialIncomeAndExpenseAbstract_215" xlink:to="loc_ifrs-full_OtherIncome_223" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_225" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfExpensesByNatureTable" xlink:label="loc_kzia_DisclosureOfExpensesByNatureTable_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_225" xlink:to="loc_kzia_DisclosureOfExpensesByNatureTable_229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureTable_229" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_227" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_232" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureTable_229" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_226" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaxalisibLicensingAgreementMember" xlink:label="loc_kzia_PaxalisibLicensingAgreementMember_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" xlink:to="loc_kzia_PaxalisibLicensingAgreementMember_243" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EvotechLicensingAgreementMember" xlink:label="loc_kzia_EvotechLicensingAgreementMember_1101993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_230" xlink:to="loc_kzia_EvotechLicensingAgreementMember_1101993" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfExpensesByNatureLineItems" xlink:label="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureTable_229" xlink:to="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-full_ProfitLossAbstract_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_ProfitLossAbstract_231" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_231" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_245" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_1095550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_1095550" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MinimumOperatingLeasePayment" xlink:label="loc_kzia_MinimumOperatingLeasePayment_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_MinimumOperatingLeasePayment_237" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_238" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_239" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction" xlink:label="loc_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction_1095551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction_1095551" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction" xlink:label="loc_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction_1095553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction_1095553" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNature" xlink:label="loc_ifrs-full_ExpenseByNature_1095554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfExpensesByNatureLineItems_228" xlink:to="loc_ifrs-full_ExpenseByNature_1095554" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_250" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitsTable" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_250" xlink:to="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" xlink:to="loc_ifrs-full_GeographicalAreasAxis_253" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_253" xlink:to="loc_ifrs-full_GeographicalAreasMember_254" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_254" xlink:to="loc_country_AU_258" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_254" xlink:to="loc_country_US_259" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitLineItems" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_252" xlink:to="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_260" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_255" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_261" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:label="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim" xlink:label="loc_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim_263" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAmortisationOfIntangibles" xlink:label="loc_kzia_TaxEffectOfAmortisationOfIntangibles_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfAmortisationOfIntangibles_264" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfExpenseEmployeeOptionPlan" xlink:label="loc_kzia_TaxEffectOfExpenseEmployeeOptionPlan_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfExpenseEmployeeOptionPlan_265" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable" xlink:label="loc_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable_266" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped" xlink:label="loc_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped_269" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate" xlink:label="loc_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate_1095555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate_1095555" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised" xlink:label="loc_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised_270" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_256" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_271" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TaxLossesNotRecognisedAbstract" xlink:label="loc_kzia_TaxLossesNotRecognisedAbstract_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_251" xlink:to="loc_kzia_TaxLossesNotRecognisedAbstract_257" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxLossesNotRecognisedAbstract_257" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_272" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TaxLossesNotRecognisedAbstract_257" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes_273" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_275" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitsTable" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_275" xlink:to="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" xlink:to="loc_ifrs-full_GeographicalAreasAxis_278" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_278" xlink:to="loc_ifrs-full_GeographicalAreasMember_279" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_279" xlink:to="loc_country_AU_281" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_279" xlink:to="loc_country_US_282" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfIncomeTaxBenefitLineItems" xlink:label="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitsTable_277" xlink:to="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_276" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfIncomeTaxBenefitLineItems_276" xlink:to="loc_ifrs-full_ApplicableTaxRate_280" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_284" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_284" xlink:to="loc_ifrs-full_Cash_285" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_284" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_286" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_284" xlink:to="loc_ifrs-full_CashAndCashEquivalents_287" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_289" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_289" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_290" xlink:to="loc_ifrs-full_CarryingAmountMember_291" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_294" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_295" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ResearchAndDevelopmentTaxRebateReceivableMember" xlink:label="loc_kzia_ResearchAndDevelopmentTaxRebateReceivableMember_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_kzia_ResearchAndDevelopmentTaxRebateReceivableMember_296" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositsHeldMember" xlink:label="loc_kzia_DepositsHeldMember_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_291" xlink:to="loc_kzia_DepositsHeldMember_297" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_293" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_CurrentTradeReceivables_298" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_OtherCurrentReceivables_299" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_300" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositPaidNonCurrent" xlink:label="loc_kzia_DepositPaidNonCurrent_1095562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_kzia_DepositPaidNonCurrent_1095562" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_1095563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_292" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_1095563" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1095565" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DepositPaidAsAdvance" xlink:label="loc_kzia_DepositPaidAsAdvance_1095566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1095565" xlink:to="loc_kzia_DepositPaidAsAdvance_1095566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_317" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:label="loc_ifrs-full_OtherCurrentAssets_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_317" xlink:to="loc_ifrs-full_OtherCurrentAssets_318" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_359" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_359" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_362" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LicencesMember" xlink:label="loc_ifrs-full_LicencesMember_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" xlink:to="loc_ifrs-full_LicencesMember_370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_LicensingAgreementMember" xlink:label="loc_kzia_LicensingAgreementMember_1095567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_365" xlink:to="loc_kzia_LicensingAgreementMember_1095567" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_360" xlink:to="loc_ifrs-full_CarryingAmountMember_361" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_361" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_366" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_361" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_367" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_364" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_363" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_363" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_368" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_372" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_372" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_373" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaxalisibLicensingAgreementMember" xlink:label="loc_kzia_PaxalisibLicensingAgreementMember_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" xlink:to="loc_kzia_PaxalisibLicensingAgreementMember_384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EVT801LicensingAgreementMember" xlink:label="loc_kzia_EVT801LicensingAgreementMember_1096249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_376" xlink:to="loc_kzia_EVT801LicensingAgreementMember_1096249" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_375" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_377" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_378" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_380" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_374" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_381" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_386" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_386" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_387" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_386" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_388" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_386" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_390" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1095569" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_1095570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1095569" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_1095570" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1095571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1095569" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_1095571" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_ProvisionsForEmployeeBenefits_1095572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_1095569" xlink:to="loc_ifrs-full_ProvisionsForEmployeeBenefits_1095572" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1095574" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1095574" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1095581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095580" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1095581" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationPaxalisibMember" xlink:label="loc_kzia_ContingentConsiderationPaxalisibMember_1095582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1095581" xlink:to="loc_kzia_ContingentConsiderationPaxalisibMember_1095582" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationEvt801Member" xlink:label="loc_kzia_ContingentConsiderationEvt801Member_1095583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1095581" xlink:to="loc_kzia_ContingentConsiderationEvt801Member_1095583" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095575" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationCurrent" xlink:label="loc_kzia_ContingentConsiderationCurrent_1095577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_kzia_ContingentConsiderationCurrent_1095577" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_kzia_ContingentConsiderationNoncurrent_1095578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_kzia_ContingentConsiderationNoncurrent_1095578" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsideration" xlink:label="loc_kzia_ContingentConsideration_1095579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095576" xlink:to="loc_kzia_ContingentConsideration_1095579" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1095585" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_1095585" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1095592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1095591" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1095592" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestoneTwoMember" xlink:label="loc_kzia_MilestoneTwoMember_1095593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1095592" xlink:to="loc_kzia_MilestoneTwoMember_1095593" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1096415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1096415" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1096415" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GlioblastPtyLtdMember" xlink:label="loc_kzia_GlioblastPtyLtdMember_1096421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" xlink:to="loc_kzia_GlioblastPtyLtdMember_1096421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GenentechAgreementMember" xlink:label="loc_kzia_GenentechAgreementMember_1096425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_1096420" xlink:to="loc_kzia_GenentechAgreementMember_1096425" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_1095586" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PaymentsForContingentConsideration" xlink:label="loc_kzia_PaymentsForContingentConsideration_1095588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_PaymentsForContingentConsideration_1095588" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentPayable" xlink:label="loc_kzia_MilestonePaymentPayable_1095589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_MilestonePaymentPayable_1095589" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentsNotBooked" xlink:label="loc_kzia_MilestonePaymentsNotBooked_1095590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_MilestonePaymentsNotBooked_1095590" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentDiscountRate" xlink:label="loc_kzia_MilestonePaymentDiscountRate_1096347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_MilestonePaymentDiscountRate_1096347" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_1096410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_1096410" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfContingentMilestonePayments" xlink:label="loc_kzia_NumberOfContingentMilestonePayments_1096429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_1095587" xlink:to="loc_kzia_NumberOfContingentMilestonePayments_1096429" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract_414" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract_414" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_448" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_448" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_458" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePlacementMember" xlink:label="loc_kzia_SharePlacementMember_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_SharePlacementMember_472" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanMember" xlink:label="loc_kzia_SharePurchasePlanMember_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_SharePurchasePlanMember_473" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareIssueTransactionCostsMember" xlink:label="loc_kzia_ShareIssueTransactionCostsMember_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_ShareIssueTransactionCostsMember_474" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConversionOfOptionsMember" xlink:label="loc_kzia_ConversionOfOptionsMember_744739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_ConversionOfOptionsMember_744739" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InstitutionalPlacementUnderAnreoMember" xlink:label="loc_kzia_InstitutionalPlacementUnderAnreoMember_1095599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_InstitutionalPlacementUnderAnreoMember_1095599" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RetailPlacementUnderAnreoMember" xlink:label="loc_kzia_RetailPlacementUnderAnreoMember_1095600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_RetailPlacementUnderAnreoMember_1095600" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssuedOnAchievementOfAMilestoneMember" xlink:label="loc_kzia_IssuedOnAchievementOfAMilestoneMember_1095601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_457" xlink:to="loc_kzia_IssuedOnAchievementOfAMilestoneMember_1095601" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_450" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_450" xlink:to="loc_ifrs-full_EquityMember_454" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_454" xlink:to="loc_ifrs-full_IssuedCapitalMember_470" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_449" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_449" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_453" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsAxis" xlink:label="loc_kzia_EquityTransactionsAxis_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_kzia_EquityTransactionsAxis_455" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EquityTransactionsMember" xlink:label="loc_kzia_EquityTransactionsMember_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_EquityTransactionsAxis_455" xlink:to="loc_kzia_EquityTransactionsMember_456" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateAxis" xlink:label="loc_kzia_SharePurchasePlanIssueDateAxis_744896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_kzia_SharePurchasePlanIssueDateAxis_744896" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePurchasePlanIssueDateDomain" xlink:label="loc_kzia_SharePurchasePlanIssueDateDomain_744897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateAxis_744896" xlink:to="loc_kzia_SharePurchasePlanIssueDateDomain_744897" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember" xlink:label="loc_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember_744901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember_744901" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember" xlink:label="loc_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember_744902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember_744902" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember" xlink:label="loc_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember_1095602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember_1095602" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember" xlink:label="loc_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember_1095603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember_1095603" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember" xlink:label="loc_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember_1096679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember_1096679" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember" xlink:label="loc_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember_1096681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_SharePurchasePlanIssueDateDomain_744897" xlink:to="loc_kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember_1096681" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_452" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_459" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_461" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_462" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharesIssuedPricePerShare1" xlink:label="loc_kzia_SharesIssuedPricePerShare1_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_kzia_SharesIssuedPricePerShare1_463" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_Equity_464" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_IssueOfEquity_466" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_451" xlink:to="loc_ifrs-full_Equity_468" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_477" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_477" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_478" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_477" xlink:to="loc_ifrs-full_IssuedCapital_479" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_485" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_485" xlink:to="loc_ifrs-full_ParValuePerShare_486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_488" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_488" xlink:to="loc_ifrs-full_OtherEquityInterest_489" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_491" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_491" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_492" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOrdinarySharesAvailableForConversion" xlink:label="loc_kzia_NumberOfOrdinarySharesAvailableForConversion_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_491" xlink:to="loc_kzia_NumberOfOrdinarySharesAvailableForConversion_493" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes" xlink:label="loc_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_491" xlink:to="loc_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ConvertibleNoteRepresentsOrdinaryShares" xlink:label="loc_kzia_ConvertibleNoteRepresentsOrdinaryShares_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_491" xlink:to="loc_kzia_ConvertibleNoteRepresentsOrdinaryShares_495" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_505" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_505" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" xlink:to="loc_ifrs-full_TypesOfRisksAxis_510" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_510" xlink:to="loc_ifrs-full_TypesOfRisksMember_511" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_511" xlink:to="loc_ifrs-full_CurrencyRiskMember_516" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" xlink:to="loc_srt_CurrencyAxis_507" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_507" xlink:to="loc_currency_AllCurrenciesDomain_506" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_506" xlink:to="loc_currency_USD_512" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_506" xlink:to="loc_currency_EUR_513" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_509" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" xlink:to="loc_ifrs-full_FinancialAssets_514" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-full_FinancialLiabilities_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_508" xlink:to="loc_ifrs-full_FinancialLiabilities_515" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_518" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_518" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_ifrs-full_TypesOfRisksAxis_523" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_523" xlink:to="loc_ifrs-full_TypesOfRisksMember_524" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_524" xlink:to="loc_ifrs-full_CurrencyRiskMember_530" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_524" xlink:to="loc_ifrs-full_InterestRateRiskMember_531" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_srt_CurrencyAxis_520" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_520" xlink:to="loc_currency_AllCurrenciesDomain_519" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_519" xlink:to="loc_currency_USD_525" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_743961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_743961" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_743962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_743961" xlink:to="loc_ifrs-full_InterestRateTypesMember_743962" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_522" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_Assets_526" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_745002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_Liabilities_745002" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xlink:label="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_527" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_CashAndCashEquivalents_528" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_521" xlink:to="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_529" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_533" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_533" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_ifrs-full_RangeAxis_538" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_538" xlink:to="loc_ifrs-full_RangesMember_539" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_IncreaseInMarketRiskMember" xlink:label="loc_kzia_IncreaseInMarketRiskMember_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_IncreaseInMarketRiskMember_545" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:label="loc_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember_546" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfIncreaseInMarketRiskOnEquityMember" xlink:label="loc_kzia_EffectOfIncreaseInMarketRiskOnEquityMember_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfIncreaseInMarketRiskOnEquityMember_547" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DecreaseInMarketRiskMember" xlink:label="loc_kzia_DecreaseInMarketRiskMember_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_DecreaseInMarketRiskMember_548" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember" xlink:label="loc_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember_550" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_EffectOfDecreaseInMarketRiskOnEquityMember" xlink:label="loc_kzia_EffectOfDecreaseInMarketRiskOnEquityMember_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_539" xlink:to="loc_kzia_EffectOfDecreaseInMarketRiskOnEquityMember_549" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_ifrs-full_TypesOfRisksAxis_540" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_540" xlink:to="loc_ifrs-full_TypesOfRisksMember_541" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_541" xlink:to="loc_ifrs-full_CurrencyRiskMember_551" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_srt_CurrencyAxis_535" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_535" xlink:to="loc_currency_AllCurrenciesDomain_534" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_534" xlink:to="loc_currency_USD_542" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_1091500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_534" xlink:to="loc_currency_EUR_1091500" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_537" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk" xlink:label="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" xlink:to="loc_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk_543" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_536" xlink:to="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_544" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract_553" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract_553" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_TypesOfRisksAxis_562" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_562" xlink:to="loc_ifrs-full_TypesOfRisksMember_563" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="loc_ifrs-full_InterestRateRiskMember_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_563" xlink:to="loc_ifrs-full_InterestRateRiskMember_572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_561" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_561" xlink:to="loc_ifrs-full_InterestRateTypesMember_558" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="loc_ifrs-full_FloatingInterestRateMember_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_558" xlink:to="loc_ifrs-full_FloatingInterestRateMember_570" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_RangeAxis_559" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_559" xlink:to="loc_ifrs-full_RangesMember_560" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageMember" xlink:label="loc_ifrs-full_WeightedAverageMember_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_560" xlink:to="loc_ifrs-full_WeightedAverageMember_571" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_554" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_CashAtBankAndInHandMember" xlink:label="loc_kzia_CashAtBankAndInHandMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" xlink:to="loc_kzia_CashAtBankAndInHandMember_564" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShortTermDepositsMember" xlink:label="loc_kzia_ShortTermDepositsMember_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_555" xlink:to="loc_kzia_ShortTermDepositsMember_565" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_557" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_InterestRate" xlink:label="loc_kzia_InterestRate_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_kzia_InterestRate_566" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_Cash_567" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_568" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_556" xlink:to="loc_ifrs-full_FinancialAssets_569" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_574" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_574" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" xlink:to="loc_ifrs-full_MaturityAxis_580" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_580" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_575" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_575" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_581" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1096348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_575" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1096348" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_575" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_582" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_576" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_579" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_578" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TradePayablesUndiscountedCashFlows" xlink:label="loc_kzia_TradePayablesUndiscountedCashFlows_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_kzia_TradePayablesUndiscountedCashFlows_585" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AccruedPayablesUndiscountedCashFlows" xlink:label="loc_kzia_AccruedPayablesUndiscountedCashFlows_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_kzia_AccruedPayablesUndiscountedCashFlows_586" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationUndiscountedCashFlows" xlink:label="loc_kzia_ContingentConsiderationUndiscountedCashFlows_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_kzia_ContingentConsiderationUndiscountedCashFlows_587" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_577" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_588" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract_593" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract_593" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_MeasurementAxis_601" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_601" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_594" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_594" xlink:to="loc_ifrs-full_AtFairValueMember_602" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_600" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_595" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_604" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_596" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_599" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_598" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ContingentConsiderationNoncurrent" xlink:label="loc_kzia_ContingentConsiderationNoncurrent_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" xlink:to="loc_kzia_ContingentConsiderationNoncurrent_608" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_597" xlink:to="loc_ifrs-full_Liabilities_609" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TextBlockAbstract" xlink:label="loc_kzia_TextBlockAbstract_1095511" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_TextBlockAbstract_1095511" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_1102008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_ifrs-full_MeasurementAxis_1102008" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1102009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_1102008" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1102009" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_1102010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1102009" xlink:to="loc_ifrs-full_AtFairValueMember_1102010" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1095627" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1095630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1095629" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_1095630" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1095632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_1095631" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1095632" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAvailableforsaleCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember_1095634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1095632" xlink:to="loc_ifrs-full_FinancialAssetsAvailableforsaleCategoryMember_1095634" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems" xlink:label="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable_1095512" xlink:to="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FairValueOfAssetsAndLiabilities" xlink:label="loc_kzia_FairValueOfAssetsAndLiabilities_1095635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_kzia_FairValueOfAssetsAndLiabilities_1095635" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets_1095636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets_1095636" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PayoutOfMilestone" xlink:label="loc_kzia_PayoutOfMilestone_1095638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_kzia_PayoutOfMilestone_1095638" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_FairValueOfAssetsAndLiabilities" xlink:label="loc_kzia_FairValueOfAssetsAndLiabilities_1095639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems_1095513" xlink:to="loc_kzia_FairValueOfAssetsAndLiabilities_1095639" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract_613" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract_613" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" xlink:to="loc_ifrs-full_RangeAxis_616" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_616" xlink:to="loc_ifrs-full_RangesMember_617" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_617" xlink:to="loc_ifrs-full_BottomOfRangeMember_623" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_617" xlink:to="loc_ifrs-full_TopOfRangeMember_624" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_615" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_614" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_MilestonePaymentDiscountRate" xlink:label="loc_kzia_MilestonePaymentDiscountRate_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_614" xlink:to="loc_kzia_MilestonePaymentDiscountRate_622" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_626" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_626" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_627" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_626" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_628" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_626" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_631" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_626" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_632" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemunerationAbstract" xlink:label="loc_ifrs-full_AuditorsRemunerationAbstract_634" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_634" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_635" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-full_AuditorsRemuneration_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AuditorsRemunerationAbstract_634" xlink:to="loc_ifrs-full_AuditorsRemuneration_638" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_652" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_652" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_653" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_656" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_655" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_657" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_658" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions_659" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_654" xlink:to="loc_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions_660" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationAbstract" xlink:label="loc_kzia_DisclosureOfParentEntityInformationAbstract_665" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationTable" xlink:label="loc_kzia_DisclosureOfParentEntityInformationTable_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationAbstract_665" xlink:to="loc_kzia_DisclosureOfParentEntityInformationTable_668" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable_668" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_666" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_669" xlink:to="loc_ifrs-full_ParentMember_672" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationLineItems" xlink:label="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable_668" xlink:to="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" xlink:to="loc_ifrs-full_ProfitLoss_670" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_667" xlink:to="loc_ifrs-full_ComprehensiveIncome_671" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationAbstract" xlink:label="loc_kzia_DisclosureOfParentEntityInformationAbstract_674" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationTable" xlink:label="loc_kzia_DisclosureOfParentEntityInformationTable_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationAbstract_674" xlink:to="loc_kzia_DisclosureOfParentEntityInformationTable_677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable_677" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_675" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParentMember" xlink:label="loc_ifrs-full_ParentMember_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_678" xlink:to="loc_ifrs-full_ParentMember_684" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfParentEntityInformationLineItems" xlink:label="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationTable_677" xlink:to="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_CurrentAssets_680" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_Assets_681" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_CurrentLiabilities_682" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_Liabilities_683" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfParentEntityInformationLineItems_676" xlink:to="loc_ifrs-full_EquityAbstract_679" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_IssuedCapital_685" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_OtherEquityInterest_686" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-full_OtherReserves_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_OtherReserves_687" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_RetainedEarnings_688" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_679" xlink:to="loc_ifrs-full_Equity_689" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_691" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_691" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_695" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaLaboratoriesPtyLtdMember" xlink:label="loc_kzia_KaziaLaboratoriesPtyLtdMember_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaLaboratoriesPtyLtdMember_699" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaResearchPtyLtdMember" xlink:label="loc_kzia_KaziaResearchPtyLtdMember_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaResearchPtyLtdMember_700" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaTherapeuticsIncMember" xlink:label="loc_kzia_KaziaTherapeuticsIncMember_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaTherapeuticsIncMember_701" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_GlioblastPtyLtdMember" xlink:label="loc_kzia_GlioblastPtyLtdMember_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_GlioblastPtyLtdMember_702" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_KaziaTherapeuticsHongKongLimitedMember" xlink:label="loc_kzia_KaziaTherapeuticsHongKongLimitedMember_1095508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_694" xlink:to="loc_kzia_KaziaTherapeuticsHongKongLimitedMember_1095508" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_693" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="loc_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_696" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_697" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_692" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_698" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail">
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ReconciliationAbstract" xlink:label="loc_kzia_ReconciliationAbstract_744081" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable_744087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_ReconciliationAbstract_744081" xlink:to="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable_744087" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems" xlink:label="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable_744087" xlink:to="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_744093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" xlink:to="loc_ifrs-full_ProfitLoss_744093" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems_744088" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_744096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_744096" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_744099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_744099" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_744101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_744101" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_744104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_744104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_757104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_757104" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_744110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_744110" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_757111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_757111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_744115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_744115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_744144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_744144" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForDecreaseIncreaseInPrepayments" xlink:label="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments_744151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_kzia_AdjustmentsForDecreaseIncreaseInPrepayments_744151" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables_744155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables_744155" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities" xlink:label="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities_744159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities_744159" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_744160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_744160" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_744162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_744095" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_744162" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_704" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_704" xlink:to="loc_ifrs-full_ProfitLoss_705" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_704" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_706" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_704" xlink:to="loc_ifrs-full_WeightedAverageShares_707" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_704" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_708" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_704" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_709" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_704" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_710" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_712" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_712" xlink:to="loc_ifrs-full_EarningsPerShareTable_715" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_715" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_713" xlink:to="loc_ifrs-full_FinancialAssetsMember_716" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_UnlistedOptionsMember" xlink:label="loc_kzia_UnlistedOptionsMember_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_716" xlink:to="loc_kzia_UnlistedOptionsMember_720" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_715" xlink:to="loc_ifrs-full_EarningsPerShareLineItems_714" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOrdinarySharesAvailableForConversion" xlink:label="loc_kzia_NumberOfOrdinarySharesAvailableForConversion_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_kzia_NumberOfOrdinarySharesAvailableForConversion_717" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_ifrs-full_OtherEquityInterest_718" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare" xlink:label="loc_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_714" xlink:to="loc_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare_719" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_723" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_723" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_727" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_TrancheNineMember_736" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheOneMember" xlink:label="loc_kzia_OtherTrancheOneMember_744544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheOneMember_744544" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheTwoMember" xlink:label="loc_kzia_OtherTrancheTwoMember_744545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheTwoMember_744545" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheThreeMember" xlink:label="loc_kzia_OtherTrancheThreeMember_744546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheThreeMember_744546" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_OtherTrancheFourMember" xlink:label="loc_kzia_OtherTrancheFourMember_744547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_OtherTrancheFourMember_744547" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TranchesTwoAndEightMember" xlink:label="loc_kzia_TranchesTwoAndEightMember_1095505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_TranchesTwoAndEightMember_1095505" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TranchesTenAndTwelveMember" xlink:label="loc_kzia_TranchesTenAndTwelveMember_1095507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_726" xlink:to="loc_kzia_TranchesTenAndTwelveMember_1095507" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_744540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_ifrs-full_RangeAxis_744540" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_744541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_744540" xlink:to="loc_ifrs-full_RangesMember_744541" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_744542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_744541" xlink:to="loc_ifrs-full_BottomOfRangeMember_744542" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_744543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_744541" xlink:to="loc_ifrs-full_TopOfRangeMember_744543" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesAxis" xlink:label="loc_kzia_AwardTypesAxis_750953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_kzia_AwardTypesAxis_750953" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_AwardTypesMember" xlink:label="loc_kzia_AwardTypesMember_750954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kzia_AwardTypesAxis_750953" xlink:to="loc_kzia_AwardTypesMember_750954" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_725" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_728" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_PercentageOfOptionsVested" xlink:label="loc_kzia_PercentageOfOptionsVested_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_kzia_PercentageOfOptionsVested_730" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOptionsVested" xlink:label="loc_kzia_NumberOfOptionsVested_750952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_kzia_NumberOfOptionsVested_750952" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_745070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_745070" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_733" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfOptionsIssued" xlink:label="loc_kzia_NumberOfOptionsIssued_1095506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_724" xlink:to="loc_kzia_NumberOfOptionsIssued_1095506" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_741" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_741" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_745" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheOneMember" xlink:label="loc_kzia_TrancheOneMember_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheOneMember_759" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwoMember" xlink:label="loc_kzia_TrancheTwoMember_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheTwoMember_760" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThreeMember" xlink:label="loc_kzia_TrancheThreeMember_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheThreeMember_761" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourMember" xlink:label="loc_kzia_TrancheFourMember_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFourMember_762" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFiveMember" xlink:label="loc_kzia_TrancheFiveMember_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFiveMember_763" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixMember" xlink:label="loc_kzia_TrancheSixMember_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSixMember_764" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSevenMember" xlink:label="loc_kzia_TrancheSevenMember_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSevenMember_765" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEightMember" xlink:label="loc_kzia_TrancheEightMember_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheEightMember_766" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheNineMember_767" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTenMember" xlink:label="loc_kzia_TrancheTenMember_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheTenMember_768" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheElevenMember" xlink:label="loc_kzia_TrancheElevenMember_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheElevenMember_769" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwelveMember" xlink:label="loc_kzia_TrancheTwelveMember_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheTwelveMember_770" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirteenMember" xlink:label="loc_kzia_TrancheThirteenMember_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheThirteenMember_771" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourteenMember" xlink:label="loc_kzia_TrancheFourteenMember_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFourteenMember_772" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFifteenMember" xlink:label="loc_kzia_TrancheFifteenMember_744211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheFifteenMember_744211" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixteenMember" xlink:label="loc_kzia_TrancheSixteenMember_744212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSixteenMember_744212" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSeventeenMember" xlink:label="loc_kzia_TrancheSeventeenMember_1096736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheSeventeenMember_1096736" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEighteenMember" xlink:label="loc_kzia_TrancheEighteenMember_1096737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheEighteenMember_1096737" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineteenMember" xlink:label="loc_kzia_TrancheNineteenMember_1096738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_744" xlink:to="loc_kzia_TrancheNineteenMember_1096738" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_743" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_746" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xlink:label="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_747" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745066" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_749" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_750" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement" xlink:label="loc_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement_744648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement_744648" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_744662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_744662" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_753" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_745073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_745073" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_745072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_745072" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement" xlink:label="loc_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement_744655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement_744655" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_744664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_744664" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_745074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_742" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_745074" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_774" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_774" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_778" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheEightMember" xlink:label="loc_kzia_TrancheEightMember_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheEightMember_794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheNineMember" xlink:label="loc_kzia_TrancheNineMember_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheNineMember_795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTenMember" xlink:label="loc_kzia_TrancheTenMember_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTenMember_796" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheElevenMember" xlink:label="loc_kzia_TrancheElevenMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheElevenMember_797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwelveMember" xlink:label="loc_kzia_TrancheTwelveMember_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwelveMember_798" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirteenMember" xlink:label="loc_kzia_TrancheThirteenMember_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheThirteenMember_799" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFourteenMember" xlink:label="loc_kzia_TrancheFourteenMember_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheFourteenMember_800" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheFifteenMember" xlink:label="loc_kzia_TrancheFifteenMember_744706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheFifteenMember_744706" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheSixteenMember" xlink:label="loc_kzia_TrancheSixteenMember_744707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheSixteenMember_744707" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyMember" xlink:label="loc_kzia_TrancheTwentyMember_1095868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyMember_1095868" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyOneMember" xlink:label="loc_kzia_TrancheTwentyOneMember_1095869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyOneMember_1095869" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyTwoMember" xlink:label="loc_kzia_TrancheTwentyTwoMember_1096853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyTwoMember_1096853" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyThreeMember" xlink:label="loc_kzia_TrancheTwentyThreeMember_1096854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyThreeMember_1096854" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyFourMember" xlink:label="loc_kzia_TrancheTwentyFourMember_1096859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyFourMember_1096859" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyFiveMember" xlink:label="loc_kzia_TrancheTwentyFiveMember_1096862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyFiveMember_1096862" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentySixMember" xlink:label="loc_kzia_TrancheTwentySixMember_1096863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentySixMember_1096863" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentySevenMember" xlink:label="loc_kzia_TrancheTwentySevenMember_1096865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentySevenMember_1096865" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyEightMember" xlink:label="loc_kzia_TrancheTwentyEightMember_1096867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyEightMember_1096867" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheTwentyNineMember" xlink:label="loc_kzia_TrancheTwentyNineMember_1096868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheTwentyNineMember_1096868" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirtyMember" xlink:label="loc_kzia_TrancheThirtyMember_1096869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheThirtyMember_1096869" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_TrancheThirtyOneMember" xlink:label="loc_kzia_TrancheThirtyOneMember_1096870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_777" xlink:to="loc_kzia_TrancheThirtyOneMember_1096870" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_776" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_779" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_ShareBasedPaymentArrangementOptionsExpiryDate" xlink:label="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_kzia_ShareBasedPaymentArrangementOptionsExpiryDate_780" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kzia-20210630.xsd#kzia_SharePricePerShare" xlink:label="loc_kzia_SharePricePerShare_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_kzia_SharePricePerShare_781" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_745069" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_783" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_784" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_785" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_775" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_786" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g185056g185056g48n95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g185056g185056g48n95.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'24&AO=&]S:&]P(#,N,  X0DE-! 0
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M    &0!< %P 4P!. $< 1@!" %4 +0!- %< 4P M $8 4  Q #  7 !3 $X
M1P Y #  ,0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!8
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"
M24T$)@      #@             _@   .$))300-       $    6CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #/0    8              ?(   +0    ! !S '0 <  T     0
M                   !              +0   !\@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !\@    !29VAT;&]N9P
M M     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   ?(     4F=H=&QO;F<   +0     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !O * # 2(  A$! Q$!_]T !  *_\0!/P
M 04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !
M  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H # ,!  (1 Q$ /P#U!0%U)L-8L:;&D-<P.&X$C?M+/I?0]ZFN0ZMTSZON
MZCFLNRK,'-OL99;D6AIJ>TMK+\:IGT+&>DS=[F_SMOZ?U:OT*("GK396VQM;
MG 6/U:PD;C'[K?I.4OP7(#I'U8K@Y'5,ASLA[W!MSSZCQN]&^BSU*_7_ )VJ
MRBUGZ.W\RQ6NEY'1.C?:/1S,G,^TEMCC:'/(+&U5>CJUFU[?5;ZG_<;^:RO2
M]!*E/2I+/LZ[TNMX:;MS"'1:QKG5G9L]398QI;;L;;^D]'U&4[+?6]/TE(=:
MZ8ZNRUMTLJ:USR&/XL+JZH;LW/=8YGL8SWH4IO)+//7^CANXY30T\$M> ?=Z
M/M]GN]^[_MNVS^;JL2'7NEF@Y'JN%8+&NW,>UP=8WUJV^G8QK]SJO?[$J*G0
M26?;UWIE36/-I<RP,=N:T[0+&NNK]1[@UC/T+/5]-SO6]/\ P:9O7^E.:YS;
MB6L$N(K>8G0!S6L+V/=[ME=C&66;+/3_ )NQ*BIT4EFGZP]+#=QL<):Y[?8Z
M"UKKF;A8!Z?O^RWVMWO_ )EGJV>FB4=;Z;?D_9J[2;""02UP:8#W/]SFC;M9
M7ZGO]GIV4^GO]1&BIO)+-J^L/2+,<Y'KAC6,%EC'M<VQ@)8QK;*MN]MCGVUU
MLK_PK_YK>G_YP=)+FM9>'[G.:7-:[:T,8^]]EEC@UC*?2IMV6_X7T[/1]3T[
M$J*G1266?K#A-:[?5D,>QC;75.J(>*GN].J[:3_A'?0J_I'YGH^HE_SCZ<&.
MLB[TV-ML<X5.,-I97D.?L;NLVVX]]-U/L_PGI^R[]$E14ZB222"E))))*?_0
M]066_/\ JO:_U++\"QY,[W.J<Z88WZ3OY-57_;5:U6_2"\NQG8'H5&QN*7-:
M"[<ZT.)UTL97-=C]W]119<AA5=;;W(\G'F!D,C,<'#7M@'Y^/][^X]S]H^J1
MK;6;< LK8:V NJ.UA#FEC'?F_P Y9_VXG^U?52:CZV!-!#J2'5>P@ES2S]WW
MNWKB&OP!#MF&8 &POM@GZ6YSG,_-^@DU^ '.FO#<)]I+K8C;^9 W>US?SO\
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>0B(XQ#2$A!1%ZK]:=V)JQ0.5T_&!+(*L68BZ=I(($.H6R3!FQ6^4D1EMH.
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M'7%K!/RAIBSN(. 0@4HZ.*X,X2I-SM\6))CVR+(0Y+1N.//J2"E)&,#NG"<
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M 8 &@TTK=N[#+:K1R;:4%NZ14)*!NJ"5$%0)&"=[BK.=XZG76J>WYER$G?\
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M3OH.<I.\"1G>4#C!P<5FM"'-WE$[^XI*T9) "T$*22!@*W5)2H!0("DI5C>
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MT\W17?=TW= _=-W!$0 W0>Z(A[X ;WA$/PAUZAC(Z148/'&G36H452E[XI*
M3H ]X2& O0?>'O"'3H/4.@]?/UR,CI'6*G!Z#U&MO)J*U^#.!@()#@<>G0G=
M'O#U#J'0O3J/4/.'0/.'GR,CI'73!SC!ST<]? *8>]T*8>X'4_0!'NA_.;H'
MW(?Z1Z8R.D:\-:8.NATX][PUJ*DJ<O>(DH8OG^Z*0QB^;W_. "'F_#C(Z1UU
M.#T'JK0!3&Z]THFZ )AZ (]"A[YAZ>\ ?A$?,'X<FHJMG,GDG!<->*^]^4MJ
MKSRT0VD==3-Y&JM'P0[FV2#,6[.#K*$PHRD"1(S\V^C8H948^0+'$=B\%BZ!
M+P![8[)DOLQT* 4ZL(WL;VX-2I>[D9W4@G&1G&,UBM7)MK<(!W4E0"B4)4>"
M4E>ZK=!) *MU6!K@U*6GKC+[-U)JO8\Q6AJ4YL+6M&ODS3TI 9LM2DKA68RP
MO*R$P5JR"8"!6D318RH,619 S4796;4%003P< ;<<1O;P0XM"5' WPA12%8R
M<9QG'-G&O&LDY4E!*<*4A*E)!*MTJ )2#@9 SC.!GC@<*K3*\P54NT*JO FN
MZV]L3A;C!/\ )[9VTR6]!HEK.'1NQ:%2JDXIP0SA65D[G+^%=%=J3T:K&QZ9
M%RQKU)45DKA&/:2IJG-T&2F,TWN@\H=W?<5O;V0$# T2<DZD: U<LGMCM8 %
M88,A9._E*2O<0  @M]T4KSO.)4"!N(<&^INZV:]6UN%25,7O%34,7S_=%(82
M^;W_ #@ AYOP^?S9&1TCKJ<'H/55)>2_,%?0._\ A#QV@-8.-F7'F?M6Z4I%
M=O9R0!=:4'6E.]N>P=H.V(0LPK96\ P59-RP8+P*:YW1ECS*7@ 07VF(Q>9F
M/ESDT0VD+/<;W*+<6$(;R5)"-[4[PWCG "=24TK="'8[7<%<A:T@*6I*@AML
MJ6MM*6UAQ23N@I6II 25*Y0K"&G+M DH8HF(FH8@=?N@(82AT\X]1 ! .@><
M?/YLU<CG(!\-78)X GQ5I[A^\!.X;OF !*7NCWA ?. @7IU$!#S@(!Y_P8R.
MD==,'A@YZ,5].FHGT\(0Y.OO=\IB]>GO].H!UR<@\"#4$$<01X:^BBJ4O?%)
M0"=.O>$A@+T'WA[PATZ#_/UZ9&1TCK%3@]!ZJV\FHK<!)4Q>^5-0Q//]T!#"
M7S>_]T =/-^'S^;(R.D==3@]!ZJ^>#4$_@P3/WP]\G<-WP\W7_-Z=?>\_O>]
MY\9''(QTYJ,'.,'/1SU\.0Z8@!R&((AU #E$HB'O=0 0 1#K^')R#P(-"".(
M(\-:C)*D+WCI*%+YONC$,4OG][SB !Y_P9&1TCKJ<'H/57PB:BG7P:9S]/,/
M<(8W01]X![H#TZ_Z<9 XD#QTP3P!/BJ(]\[NUOQHTULO?FXYM6LZQU)5G]PN
M\TA'/99VPAH\R::OB<3'I+/Y)^NNLBV91[1([EVZ53;HE,H<I1L:;6^ZVRT
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MLSD.F/0Y#$$0Z@!RB41#SAUZ" #TZ@(=?] XR#P.:C!'$8KX "(@  (B(@
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MR,]'/5V#QQITT[INZ)NZ/= 0 3=![H"/O (^\ C^ .O4<9'2*8/'&G30 $1
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MTA:G"D-.[ERN8O/;1G"0^LX#9,9M/8FU]VRTS":6T%H77DOM/=&TG]<38JV
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MM<BVEEEAMK>W@A#2=T ')TZ!S</#,2.8C')%SE7%.O/.O!M+1=<?<4XI90C
MWNZP5<58WB22:M-R"TW5.2>BMP<?=A*2 TK<^N+=K:QKL%A))1\?;(9U$GEH
MHZ@BB65B%'"<E'"N11N+MJB5PFH@90AM9EQ3#S3[82'&7$.HR 4E2%!0"ASI
M.,$=%7.H2^TZRX5%MYM;2]U2DJ"7$E*BE22%)4 =%)((.H(.M>6W'7ASVJ-
M2XUZ9VGSLTFQXR<5Y&J(Q<OH?3=@A>17(^B:[*C&4O6N\92^RT_KFK55:N-V
ML1:O:!!+2LRV:)>$?JR@C.EWWI-N7R[K4)XR) 7D2'@6&%N$E3C*6TH6I6>&
M^2,X(W1W!H:9EHW4+E-<BWR8;#+*@ZM"$D+;>4^X_E*U;I04[JT(24J4ZM7*
MIL7I_@>XK&XNTOVAMC8"%Y2[0B;KD$D2 BUX:RZXTM5M3/\ 5D-1@FI9:6;N
MI2/:S$J_9NF3$D2FJ9L95FL8AB!KN2U+9@-(1N""%J 404+=6Z'%+(3@]U@
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M0V8YC-,I>5RK:>9[E#G?=&N$'#8[D#4%1@-.H0H-R2'%/\L5J:24%!426-T
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MK-<6$LPC(I0T7&T&(BU)5%LHQ<.EI-PHFF8$%.^G6B64,ST%O+TY2,NY&ZA
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M,AA:G.V8JFFI:65,)6^AQQI395OA+B$.-E20H;Q"5)<*@D)=0G?2YQ+%P#Y
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M8PTVA 3R0!).2IPZ)"P-X*UW8TR0IDNSFT--2$.+89CD<NT@E00ZZM947,A
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M:\2;<)!NQB%GKF#:MFC!5M*%.X4-IQ);49R4%1RY$E-K:4R'"'6VR26RE?\
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MS8+%S4U<("FE6NW3!.-MG7HQY$H1(UY3;)Z[,[$-Q1-:8#RU1VGF5K[A'0)
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M!L#5]$OYJ"@EFT<H46C"/AX^)9%3CDC(*8J6259WDJ4OE%;FXV>4"DJWL!L
M'>2%*!!!5@@#=2!M,;%;-P6T1X<*; [7]:TLKC76>Q+ANV.W3+3;'XTCE2['
MF1X-PN"'9*</294Z3-?*I*TK3&Q" F0B91.8"%*0#*',HH8"@  )U#B)CG$
MZF.81,8>HCYQS G))P!DYP!@#P#F%=H4HJ4I1"05**B$)"$@J))"4IP$IR=$
M@8 T&E>]_8.?]ZN57^R=0?\ OWO/5^Q?_P!(N?\ V5G_ +PNOSA_Y1K_ *E[
M#?\ VW;C_P#,V=K]&F>P5^6E,4IBE,4IBE,4IBE,4K\^G;U_]E\1_P#Q3N#_
M .S=4SRCLI>XLG_W5U_^?:*_3'_DX?\ IG9J_P!T;#_^*7JO"QGN^YU34D[I
M".LB-9I%OV+';1EW,=)2M?M4A88FINJ2G%#-QLS'IN:>O"OE3R,"ZCW?AY4K
M5[XZD"";?/+$S'^T7(*0.17(9DKPG52V&I#2 H\5)W9*]YL]PK RDZY_1)_8
M&Q7?;*W[>RK4NZWZR[,R=DX3<J+$N5GC6V9>6;^J8($J#(4U>VI["4QKBS)9
MY.&76"POE%KJ58GECM"&TVWT@A ZY=P#+5]VTG'W)_!SRFP8[46PYU&S62CQ
MKIK9FE49%5FD$G9+/[57%F>H)M6,N_?MF2(#>F[/(A"&E#:0([T/?PYOB(_)
M[<<82"[R20J2IUSE4LIE!+SK DACDVF^HS.P[LE-VW<V^7<-IV;B_M98=O)-
MBCW"WIV:D[9[-6]RUVN_RFG;6_=WRB"ZME5I]=F[5'6MY^%'C.R%XS%'G=O%
MO:];7!" TZV?Z<F99SJR-B:(\K\12*3/T%?6E@TO!C#V)M*--42]87,],P&0
M5MD=<N]<(RV-I!9PBKL(OTI#[#X2T%15NIC)#24ICPWV P] :+?)N"*XC>R2
MZ9*7''I#4EN6^](7P:_4][ N6C:FRKN.VSL;;>%#:VME3-H6+E,OU]MVT:-J
MK;MS<!-MCL1[;&%=6PPF0(R+-)L9%EE6AV,AM:>F=\TMS+>%;QM=UE5X,M2T
M?18NNUZE61I7*W3^.^V5]U:KC(A22M$B\[AKNY71FY:8E9)U;X7PS=JX;S N
M9<8-\E;JTI2RVVJ*S"0VE*<-L,3!.;0@+4MU2T/)Y1Q;JW7E*6M<AQ97D[S/
M8*V&0$NRKGM5=IZKSM]?YESN5^M3MSNMZ[)FQR-A=KY4U$6T16=Y-@:;7 AP
M8D5JRSRAQYMR%R,*NN;\N-ELJCN.JQM1U/$R.^Y*\/MF[$BJ]96MWFX_8MN"
MZVBN+M%+>O1Y)B$KX2/J\[.5.3MU-KBSB)A)TBRWL@2H7989GI2PR'[@5B1*
M"70\XRX\T^65!+Z8I0'&DJ2HQ%/H)6&WT(5N#:<[#.RK]ZV*O$J\[8S(_8[C
M6%C9/9F7<K4]8($C9FR^L5HN;;R;*U?XLCM0(DW:W0+Q&LU[N;;<R= *$=K*
MSZ/[0+>+&Q6*WKTS0T[:IK8]UW# S]@U]-2,CK':E\K$)3Y>ZZW5/<0+'.&$
M)78D8>*GB3\<E*H$EWH/'C5F*-R;\^'G9"V(KSRIL^Y1W76$J<@W"X);#DN(
M4J0$NMEIM;*7Q(9;<::>+*G6T+3UV3ZG#8"1;;99F[YV0[?:(&S%CV*N%MMV
MT<"-%VKV1V>NT^]PK%M0A-D)DM29]SF=NS+>JWR51'##8+++KP<@75%]J]<H
M6\M.[(;VIUK;=]:@WBDQ ,&TI9ZSN+74F\G]8[#28RZ[!A9H"0>RD]5-BMD5
MTW#V!GEG\:N:3A4$B:\6:E#,F+*07&7T-N-!M;:5,2X@=5"4,E/<#E'XKK:W
M4A$:6^\VA;[;*%^B;8[.W:Z;1; ;;;,.V=K:C8*ZW!E,&XR7(EINNQ&TT1BW
M;5;,KD06I,BU7&*Q$M]XV9<<;4U'N%O1'E-=JSUJ5)"7,[<!M;O:*^JFF7EI
ME])O>.LQO5S2GSK=SW2DI%DA'M!=6+V=1K,B*<,FE#L;<^J2MC;QS=N3PQG!
M/&AO3?'FVE!J/$1*,15O%P$<=M^MY0&DQ2I2S'4E#"1'0\N,J8W'"66Y2$(2
M!U9?8.V*3M0QM#&N^W#%IA;>1^R9!['S5^CM; L;=1)BI\?:%JV^M[EUBA4Y
M2YTBS1[PBV.27'#N!I7)5KV1S.W-LNH/*>I!:IH:\Y%4" N5\U1KYY";>V)
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MR4=VWLQ"EP+@FZT*"L?'K6=GG-/S+,*-P?UK<:QR4)-6UM FV!7]HV..J^E
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M*8I3%*8I3%*8I3%*8I7Y].WK_P"R^(__ (IW!_\ 9NJ9Y1V4O<63_P"ZNO\
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MMA,II*@VVI.ZE0Z$IUR-56";M\E&KO22:T4B_>HQ"DJFB#=.7/$I+DC33"2
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MW[UN,E''436.PE#(+IFDV1W"23DS1^9PW,Z33="F+@A5 !1'1Q!QNI(!!!&
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M0.A'9Q,=R54QS",%1/1QSHE(U\0'#'<^]&B<"LRK/^BWP4-&FQG>S@G"1E2
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MB1@G9WT6V@W<\8$TBKK2"L*S:Q)3+KJHMV*/@FJ*(K.#JR5J*0@J)2"2 22
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M\-M?-3WWO3\X[,_<K:/IQ=/N6OI>P2C3=0+RVM9A !,(%T]7!Z%#WQ'I:QZ
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MCLS]REH^G%T^Y>^.NOOD$([SA_*TMG4# 00]QVN^8X^\0?\ I5YC#^ OOC^
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M2\T&1N3.2<5:NU^P1*9#WA*8<-7[B<>NF%CMK%2Q+(K3CV/6 '+2J!/PAQ%
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MG^N,_P"])9"N!\!^JE4\[8;5%RWAK/2.M]>!$N;BYVE:+:PBI=Q,,TI2-HM
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M&?T:+_[[!_AC'L;W_HB?ST/^^I[?'U._3V3OH-&_]14_DR<C/Z-%_P#?8/\
M#&/8WO\ T1/YZ'_?4]OCZG?I[)WT&C?^HJZQ[Q^WQ'2E=A7NOG"$I;EYQM7&
MO@+6J$DXK<0,]-IBY0J"K1CXC#E.\ TFX8D>"7Q:/.[>_P#-ACV.+_II$US_
M /7H?-__ !M/'T:=Y[?+U._3V3M,9_\ 8:-G!T&!^462<]&=*[/^3)R,_HT7
M_P!]@_PQD^QO?^B)_/0_[ZGM\?4[]/9.^@T;_P!14_DR<C/Z-%_]]@_PQCV-
M[_T1/YZ'_?4]OCZG?I[)WT&C?^HJ?R9.1G]&B_\ OL'^&,>QO?\ HB?ST/\
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M+X=OZ0AZS&#T'J--]'OD_&'GK>;'3%P@ +("(K)= !=$1$>^7H  !Q$1'W@
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M0[QBB "("4! 0 >@^;&\G!.\, X)R, ]!/32ML"F$HF HB4H@!C  B4HB(@
M"/O (B @ "/G$!Z8R,XR,]'/U4IT$/.(" ><.O3\(>^'_EU#K_-DY'32OF*4
MQ2L<N%QJ.O*I/WR_V>"I5)JK()&R6RS2",7!0K,ZR;9%5Z]7$"@HZ=+(M&31
M$JSQ\[62:LVZZYRICBM;;33C[SB&6&4A3KSAW4-I)"1D@$DJ40E*$A2UJ.$I
M)TK<MUNN%XN$2TVB#*NETGN%F%;X+*GY<IQ*%.+#;:?]%II*G7G5E#++:2XZ
MXA(S6+ZGW/J'?-<<6[2>RZ?M.MLI,860E:;*!(DBY@$RK%C)9FJDVDHMXN@8
MKAHD_9-_'6Y@7:&72 3!7'D1Y;?+1'VY+6]N%;86"E>N$K;<0VZ@JW5;I4@)
M7NJW22DXW[_LSM%LI,;M^T]CN5AFO,"3'8N3')&3'WMPO1G4*<CR&T. MNEE
MY9:<!0X$' ,G FH84P*0QO"@(I=T!,"H%$2F%,0Z@<"F*8HB41 ! 0'S@(9=
MT=_AW_!TUPF0,Y.,<>]X:^ 4Q@$0 1  [PC_ # (@ #_ /01$ #^<1Q2@$,)
MDB]![R_A/ E'S&6\#T\-X$H]!5\%U#PO< W@^H=_IU#'1W\X[^...G'/T4Z3
MS#&3T9X9Z,\W30I#'_S $WG,'W/GZ&(7OF*/3_-,4G0QBCT$"B B'00QQX:Z
MX\8XCPBA../XR<?77P"F$0 "B(C[P  B(]1  Z 'O]1$ _\ J(8I00$!$! 0
M$/,("'00'^80'WL4J5]4_P#7V#_5X_\ ]Y;,T<?&/J56"^'B/UIJ8,MJJF*4
MQ2F*4Q2F*4Q2F*5#>U?OZ _V:]_OP92OW1\7U"KD>Y'C^LU%>8UE3%*8I3%*
M8I3%*8I3%*8I3%*\YNT@T-R(W5$\*;AQCIE V+L/B9STU)RTDZ!L?:3;34)=
M*EKBD;*@7M;87YW7;6VB)F2E+=$I(JK0,@1!EXZ]%H\%KXDX>?\ 'X\G3'.?
M .;P^+GZ<\]>>D[V??/J U_K6UQU$X^;4Y#73MK(?MA>1-/K&^3ZQU+KAO2&
M<5'5GC_K>TW>D.7]\F['&I. L.Q B6S.'F69A\1M3%RSDP<.CKSK_4<>]XC3
M.<Z$>+B!X,$'Q9USKBI?T?V0 NMI<E]K<G]N;>61M_/OF9RJXYZ%H.TX"1XS
MTTV_(*3J>K>1-HH*5&96YUR,JT%:[2Z>1#C8P5^%DDF9F;%(LC*EDG$D\,G.
MG0>D=/1X._1/<@#CNC' ZZ<WAUX:Y/36'\*^&W:=Z@WMP1K>T+1 ZSXL\$]#
M6WCULE#4W,&V6O1O.>K1]:N41H6YQW"P*/!(:CVQ5).QQ,YM"]WZ;>/K6\@&
MCEB#9=BS8O)'?X#FZ<^/Q$\V/ *'!X Y.F<'3 QDYX8P<8XDZ:$D>^N14TQ2
MF*4Q2F*4Q2F*4Q2F*4Q2N0S^_F'^T&']\0R%<#X#]5*\^^W;=O&G'_3@LG\B
MP55WNFF*L;(/8U8Z1JS+$53478G15,F*9S&!,SE(OA2)JE(LJDD*/0^R1NFR
M10H _P"7MJP0",IAS5)."-2%!/3ID$;I57W#_P GZRR]V:[XB1&B2FAV.=J%
M%N7$CRVPM$NRJ0I+<EMU"5;P"2H)!*%+0HE"UI5^9CQR6[XJ>V.V]\0[HG]N
M%H[XEZ]>Z)O9?J(=?/TZ].N>';W\+?R37H5^O7:MOQCUGL)&<X.S]E(STX,#
M&<:9XXTK3XS)]T2>V&U]P1[PD]MUG[HFZ]>\)?9;H(]?/UZ=>OGQOGWK?1_F
MFO0_!UXU/:\#.]ZT6'> P%>L%ESCAC/:&<8TQPQIC%:A=RPF XV.VB<H" '&
MWVCO  ^^ &]E^H /X0 >@XWOX6_DFO0J.U;?@I]9K!NDY*?R?LF"1P)':&"1
MS$C(YJ^>,RG=,3VPVSN'$1.7VW6?NF$??$Q?9;H81Z!U$0$1Z>?&\<YW6\__
M '37E[C6I[6M^0?6>PY&B5>L%ERD#@ >T,C'-@C'-074J;N]ZQ6P>X @3K;[
M./= 0Z"!>LM]R AYA .G4/-[V-[^%OY)KT*@1K>,XL]@&][K&S]DUUSK_D&N
MNNO/6XH_F5CJ**V:X*J+ 4%5%+E:3G5 A 3*"AS2XF.!4RE3*!A'H0H%#H4
M#&]_"WI_JFO0J!$MR0E(LU@ 1[@#9^R83DY.Z.T.YR=3C&3DG4YK;\:E/N ]
ML5LZ)^=/_I?9_N!Z=.I/_FWW/F\WW/3S8WS[UOY)KT*R[6M_='UGL/=>Z_Y@
MLO=<_=?Y!KKKKG7!YA7WQN5ZF-[8[;WC@ ''VWVCJ< #H &'V7ZF  \P /4
M#S8WOX6_DFO0J.U;?@#UGL&$G*1^3]EP#G.0.T-,GCCC6PN"KM(4'[R2E4!3
M,D"4Q*24N1-(_G431"3=.O%R*#T%0J'@P.8I#&ZF(02MXYR E)SGN4I3K_\
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MQ)!'*85]9>H[:BN;?[4O/17G94?9:*F)*$;E(T5#]T DMN2MT]K2Y);CJCM
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MZ*X6'U-$Y+:9",/LI) *N0<:4O@M2D]S7>LUU8ULFRC#!%LD0Z(LHLA(UDB
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M@RVJJ8I3%*8I3%*8I3%*8I6!W.I/K,YC5F;QDU*Q:.&ZA797(F.99P"Q3$\
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M?_L^-Q71Y1YZ;XZ#Y//3W+9KY6A_H/\ ]GQN*Z/*//3?'0?)YZ>Y;-?*T/\
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M!\)_I6;ONM>.ZG/55JK!4&MI.R5<N7[<6*2R! 9HHJ%."ZA53"H*I3"!BB4
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MCX":]"1_:,;YZ!Y?/3</2/+YJ>Z;6/@)KT)']HQOGH'E\]-P](\OFI[IM8^
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MDP(/G9E:+B*^5K]TGQ?6>^/QUU:C_-K_ ,?^'C/@YZN-EE54Q2F*4Q2MYO\
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MZB'@7#=\EU23ZAMZ^_'L+;D=YUAPSHZ2XRXMI91VG<%EO>0I*BE2D(4H \4
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M_-K\.NG-^,:9Z:NWEM4TQ2F*4Q2MYO\ ?"']<E_QER%<#X#]52GB/"/KJGW
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ME2]ZOL=27Y"6X*C<'-7FM:20/;C.ET5#MA9QT<->;\8Z"=<]6E98'$:8U)/
MX ).2--.YTQQXY.:ZZ&[3WG)*\7.3DJEROT@TEN/_,SCM0T=]S6Q^!:=SO6@
M]K<;KAN6YZWU!N9.G1_9^[!WI$V&NHO*XK)0,3&SE>B[5KJ#O$C<'%;7>N.<
M][HQXN'#'1S\W"HP.&3C7*LZ\W'FX::GAC3G$A#VH?-&]\C^/M8UYMBG:\U[
M8=2]G'>=:5#E%7^,?&6S<]6?)J2<Q.^['*Z_N!;;L=.U+3<7+4#7M.X6W"1J
MVL+>E$RT])S\!--YE=_Q\/-IWCKP/7C--.<XQGAP P=",G! QC.,YSP.ES.
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M (\VE6NRRJZ8I3%*8I50MT"L'+/@Z!!6\$+OD[X8"!("B(!IUF*?C MUB,
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ME*SC;+7X^NR<B[K+PR4LHU5C%D&YDI5D8_:"W:"IX=IL)[6*4.@,C(4XO<0
M,DJWE$)2K.Z!J3W)KAT&<KD1VTX0^@N-KRWN%*4[ZB<-:$)UW G.A(TR1KMV
MW.T\HRU&;6KD]N:,4V7L&,U73 )NQ@X+)WB9J]#N4?&*G1/UCF:E=V92W:LL
MZ C-LXDG+%0WC,:^*EDEBTK0ZM$1E0:8,A8Y#!#86MO()&%$N-N)P-3NYX%)
M)9FMEM*I:TEUQ++9); +JT[R$ZM\XQ@C.I.FFMU>-G.3;]7N-/MF\ME7&S5F
MBVPW%7FA V22-8(&@6126?PVE>3M=.T0.DQ;SDM%2-&VO-ME$(Z2GX5>0>%?
M/KE!)-.L7E"8$J-.9SZR7 -L.A0PS;WU)'(RXR2I!0A]>ZA]L(>*T!Q6\SD$
M_0'8WLMF[).P6UNQ4>UV]GLJ[((<VNV0N4=IMB[;9V1MQ:=H=EY[I=;%REPD
M*0_:&PR764JC!@M,1YRW_7?D39^45+LNO$="TG7MSK<@+MCL./MTW#P]H>29
M;/6CQ['5IYB8BFTW.&I06V2=Q"A#MWD=X&38OF\HP9-WFLXE]"BA#;)P>37R
MKJ&W ]OJ&XT%* 4D-I4I:@'5$X2VV5X4GK&Q4'L?W6WWY6U]WOEJN+ 9?L#]
MKA/SK8F.(,Y,AS:$1F)#T6.NZJMD:/*:(++W*-OM.1W7%M13$6CGZXC8Z:E:
MUI]E,L&:Q+!4BNJ.ZU_++J6F;=-)Z.OK.UFLL=#,M9&B7\HB+<HFLE:L9T5A
MAW*QVU03/[D%MK1LAT$L[A>'=E:5MDE#:6B$E*GCJDO+W"HH3V&5"[#B7WHD
M29M,['>D(,.X[MR3=H[2;9%;=A/VMR ;?(D/;0)E)COMJ"A;9L)M2#*:(<QY
MKM+G:16'-'T[35QKS]!1DW),V?5E,W"L[E&5H/2)R=JD%L":U\D6;ES5IG.P
M]6L+LC6#9-)JL*V!Q-3K%C&_)6@$(8WUG",J80M047>2<<:#P2CE &MQII*R
MONBE92'%5R#VSW8AY.4EV[;4VZX,.(>5VI;;]=-F%,,/V]%WBPKA+L\*]I=A
M1Q<'F9-Q@(0)"U19Z(*6(CS]BM#V?D3+^V.&Y&:X9U"P1$33%HJR508)?7=D
MDBP;>,OK> ?,K#)3BZSBXMI"R0[>5AXYNQJDDQ8INU7#0R 6IY7+G*H;;P4\
MFEMP.Y&#RA6M(" HJW5)0@J2D%2=[ 05]&VN@;$QE0Y.Q%]?ND*1*NS;\"Y(
MEM7J!&$Q;]F7,0Y"8AE(MCC4&2[&DO+>N$9]Y33;;B5&2]HVE[1-5[3OD8W:
M.Y2AZRV!>(MG(%5/'/).HU*7L,>TD2-U4'!X]R[CD4'I&Z[=P=L=4J*Z*@E4
M+7(<4S%F/H"2N-"ER6TK!*%.1X[CR$K ()0I2 %X(.Z3@@XK@;'!:NM_V?M#
MZW&V+Q?[+:)#K)2'FF+G<HT)YQDK2M"7D-OJ4TI:%H"PDK0M(*3XP\8NT2Y[
M[[J,%MI?4'"<NL%YB192T5,[D/IR^3,?7S$+9)*K)6R[SWL:W:&!VDSD):&D
M&*CAFX(9%PBD*X]1B;17B1ATQ+(J.%#E&W9S<"04I"5NAGMB4%92VH;KQ96U
MDDEM824U].[?]A;L2;(7&5L\SM%V43?41F'F9$?9]O:2T0WIHWH4>X&#9X)D
MK<2II2VHLEATI<1A;:E% ],;CS U/6JMI^[0$;>]FUG>=$VSLS7[G7D-%2CY
MY3-'TIKL'9#APREIR",>;CZVX6+ 0#0ZC^T3+!U$L2-W1FQ%^WL/L2F&9499
M7&D(Y1E9&"4[Q0H*&=%(6E:%#3*DY  (-?+UUM5RL=UN-DN\;M.Z6F6Y!N$9
M2L\E(; 5W*AD*;<0IMU"@5#<< RH@FL<E>>?'"*6<+*6"Q+5F(N7'&HW&^C6
MG$=1M=L.6-%+?M([*O\ .33B,]K6I)5DLTKEPO#IL9*@7%\WAK$P11([?M<R
M0,Z\,=9X ]'AK0UX8P=< G4@'!QC.<<< \.)'"I<U+OJF[CMC'7T%%6ZL[!=
MZLK>XG5-O$0UA9.#J%MO,]KR$0FW#.2E8]K85)^ %=["H.72C&$FZU*JK&3F
M$DB3X-3ID#FR0!X]=1T8//6))!(QID@')P2!O::8QC SGCD=!,(:]Y^Z-V/5
M-=W.*B]C1L+MA_MN,H0R4'7WCB0D=*T^TW.YQ<\G7+5.%ILRZ;TZ:K]6@[0:
M-E[%:E(>,:LR-IAH_%^!W_P,GG_K61!!QIIQXZ=8&==.COYTK'*SVDO'RU..
M/S5A!;<07Y*[2E]-ZZ!Q3HQ9$EXB&^JG9PDG+&RNDI"M.&VZ**K[9*>-H;,!
M3N2,HW9+T><33>'//S<^FG'OC)&0*CNM=$G=P3A7$9QIIQT. 3KI@]'7QG::
M<?)&L:<N7M9VZE7=[6:UU77[AI7JG8I5S*TF:J%>LK1[6ZM=IJP>S$9*WB$*
MXJ49'R=R3C$Y:=- !#QJCM1]7@P?Q^.;62#WM..O-TC3ASY.!CPBO1-=$[=9
M9NH*8J(*J(J"DH19(3I'$AQ353$2*IB8H]Q0@B0Y>ABB(" XIQJC>]MP;5=7
M?;%!U9;CZCHW'75U2O\ OG<->U(CR#W)+WG:I7+S4''S0&E7R;B#E;78ZRR4
MM%BN,W%6@[=Y/TNIP4%'+.)VPM73X!GASXQQY]0=-0#G2HXXR#@D@:D:C.<8
M\?$XR.!.*KCQPY;;;?T/1>\;#<]H;<X^;?W!"Z!V;7>1/'BB<=^4?%>\W]V2
M)U/LF1=:I\0U'M?1=BLSJ&A+Q,QZ4A[!QUK@)NF6R5D8FV51I.G#37Q$'PZ
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ML_2;\S.S^8F)U5D7W*\$3>!(?N>*:19+'_RQJ[)'0[Q1 /\ )V&L>$_S3&F
M#Q$M2_=#P#ZSX?J-6HQR:^GFZA^.JKL9;55,4IBE,4K>;_?"']<E_P 9<A7
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M19=]*.FC5)(@=XZBQ2AYQS5FG%ON(PI15;IS:4H25*4MR*ZVA*4@$E2EJ2D
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M3TF2\U&"Q&:>D//-1@XHK<$=MQ:D,!Q9*W RE 6L[RP5:UV0")1 Q1$#%$!
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MZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\
MWE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\
MMI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R
M+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICK
MUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[
MIOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI
M'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\B
MUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]
M=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z
M;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\
MR_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4
MRO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,C
MWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG
M7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R_
M_>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]XU\BUZ%,
MK_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9UZ8Z]=C(]
MXU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\ WE.Z;X9U
MZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\ MI'\R_\
MWE.Z;X9UZ8Z]=C(]XU\BUZ%,K_MI'\R__>4[IOAG7ICKUV,CWC7R+7H4RO\
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ME/VB7_??4_\ X/MO_P"78;/H7L*_]4;2?[SMG_=)-?'GJG/_ '@V)_W)?_\
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ML(45*;WTX5R94HMD[A4K=WCZB=G-_P!VMQ_^,*Q_]FL\#[-O_3]E_P#=<_\
M\057UOZE[_JG;K_?]K_\&8KT<SQ.OJ&F*4Q2F*4Q2F*4Q2F*5Y3]HE_WWU/_
M .#[;_\ EV&SZ%["O_5&TG^\[9_W237QYZIS_P!X-B?]R7__ ,0M-?GIYC<7
MMG[\LBLE1:MHUI.-->M('5&_W5QVKJGD5Q^V($S)/G-M96C7*#PNS=?1::D9
M.5W6CQY7V8VQL]1GR2D),.EFO:MJMGKE>92'H46T%QJ&AJ!=W)=QMMYM$T.+
M7RX?A\H)T1@8=B1LM%N2LE:%-E97Y]L%MA9=FX#D>YS=H R_<'7KML^U;[5>
MMF]H+:IEIL1#%N);-JN,D@L3I^'PY"0E+2VW0VEON&G#R5)M>J[(E7FNIE6&
MYJS7**=D'=>_Z1V."<<;PTS"-5E"Q96B5W86\H6U,GA1KL+&F\!!+HND&Z26
M+.R,A%P8G//0'EM[4NWYYU32^V'HQM283"=&4H3+1+2J46D%##.\%,K"DI0F
M7^R#$<M$JUQV;I&0]L*QLG'8#R#$CRTW]=SE+.9"EN6YRWJ3!Y5:5RY"DJ3(
M9+:UN*KG*\">1;BHZTU@GLBCNZ%2Z)QQA&S-E<KU2J_6K1I_>QMK7Z:E:?7J
MJJZW@I;(E")9:M;WVS1%4U;(MYHJ5155E1FW'"*V'V@[3A6X3X:XK$*UQ^XG
MS8L>.]!NRKE(<=B-QE*O'*I4.T#*=9CP'%R (P<*)"NT-]D_9(W"Y7A5IN+<
M^3<K]+27;7;9TN7%NNSZ;/#:8N#TY"-G3'<!%V[09DS+LPW$*IQ92Y"1<74W
M'6V:^VFSODM8JS(1C6=YIRIV,:G*D?F0Y,\@J_M^FHD\:;D;>&K,!$.(BU&,
MJ":DTJ@>'\98"HJ3MULL,J#=O7!Q^,MKEMJW-QLN\INW^[,3X@PIM*<LLM*1
M)[H!+I2&N53E5>>WG:N#<MGO6=F+,;D&-L$R77@QR 5LG8)-HGG*'5.;LJ0\
MAV"=S*F HR PYANN@0XDBILR2V%+-M:RB\ASFA^5AG+JO \G3U*N:''5E;KS
MEZ\C%#+7"OV0Z\W"+'<GB(F-<**1[QO(G.F;45LLM4QR6LP5..;9-[2%TH47
MNT&;8J)'BE?)[W;<>4I3S*0HLMA2G$.I<)2=]&W;:+?'M[?KJVRSV.'-C.0#
MK8C"ZRKXBXS)R4!TI[0DP4"+(46A(?4E#;K"V4A0JHRX [OK6E5]+Q"W'FT)
MWWCK7./MTMMH3LZ8ZS)5][;'VFVM.O8L*V[<6*)?5_80')5E'=378[3J-2LH
MR*D2R$6_64;#7MBU&TM^L,CMRSLVB7+?,C>M_(7F==4R(0,;>>:=9F)2J. R
MH7&/&?*N3:U[L[V4=F)=]1?G?RKA&W[12-H(%OB)A[EV,K9VUV142YJ3,#<9
MYE^W*4F4HR$*M,R=$2CEG\)R+;? C9=QO<U=6,S!V>,LUBYBQ<O1$-L7W32+
MK7W*:9UA+-%Y.VU2J6&3</V;:@R%8VE7635).T5F7C1KDXTE81$RUMRV'NTB
M2](;>COHDS]HG%Q$7*7;6DP[ZY"4V5+;ANJ*PF,XS<XZ,]L12PAAP.-!546?
MLH6&)#CPWF)L1<.U[',M3W++;[V^JX[+-71MT(;?GL(#2USF9-FE.A/:DQ,E
MR4TIJ04B7(OBIL*O/N1FNX:/U,^U+R(>S$RAL.Q2,_*;3U&E(\4XWC;'4RN0
MCFO."VAM4SP4::HV)[<(95#6TQ;JW+-E9R0*[>\PWLU<&?7FVM-6M5KN_*J1
M<9#S[URMB5[/FQM0V&EQ]]]N*=Q,5Y;[93;5RV'5%Z1O#KCVVEGD_DW>7WKX
MF^;.%AMRSQ6(L>RWM2-L$;4R+E+?1*#<5Z> XN=';C.A=Z1;YC($:(4&/:!P
MXW]UUV_V'*:3@7>M8?L\*=$1](E;I80DJMPMV%.W*[2,K)R]9@"IS&P"RYCT
M>(9,_8^N%.2-GY!ZLW6EG6E#V2O9,!<URTLFW)V.C-)C/R7RY$V:DOOS''5K
MBLCEY:G=^(TA(;;24LOKWFU/N<G<>R#LP$W9JULW^2F\J[(\Q]R=%A1 S/VV
M@QHEO:9:;G25]J0 P47%Y:E.O+"I$1D-N(B-9]Q'XA6OC_=BR-P]B[,WIU8V
MM4J/L(NVK[8)*0B=G[9-L5VUC]0RM>C:CK=K(,R1Q[J1&R6M=Y<8A!_7E$(Y
M\_6-N;*;*2K#-+DHM/MQHD^+#FIN,MUQU$V>9>&[6II$>WH6W_TQ"WY)5+0A
MR.=U;BCQVWNWMOVKM:6( >B/3)UIG7*VJLT&.TRY;+5VCEV^-R'95W<;D#-N
M6B+"2B"ZXW+2'&VFQJK?#&PQVWC[$GI+74W$)\B>8^[F$:XBGK^08M>2.M*;
M0JBF@$A&G9H6>NG@)D;0^0.5(\1*$:Q+MT9=XAE#.QDQ-V7/>?MSC"KUM1=$
MME#RW W?8;$6&DI6SN%YE;2U2D[VXELI#:W"5)&U([)-O78&[3'CW=B4C9O8
MBQ+?"XZ&5.[+W*7.N#@4A\N]K26WVD024AQ3J"74,!"'#A]5X'W""K.PXU[/
MZT<V&TT3L]J97IY".EO&(-'AXZJK^\-SOU8P))K$VA_7UGU(:1ZG=2=G:NIQ
M%BN4QB5L[$S6XUR:7(MRI$N#L7#BO#E_T'Y-"$;AO++(6AN4Y%*HH;!*SR:G
MDLD$BR3V3K<],LSR(MW3#@77LE7&=&68O^5C;4W,6G<;$A3:W8+<\(GETI#:
M>51%5)20%:K9Q!W,T->5J8TT1<%MB4?G/KAR2^/;+"ITYCR[W]);4@[7'BSI
M]D]FRUNKRAXK8U5)["+6V58LVT1/HL ,Y+;-V5NY=FNQ/6J29\3:R 4RI+\;
MM-&TEW?GLRT$0I =+$5\LS(R0VIU22VR\M!WJKMNWFSX8M;$]5^A>M-PV!NJ
M50H<67ZX.[';/1;5(@N W&,8XE38PD6V8HNHCH6'I,=#B2BLJC^)&P:'L&M;
M$K#RB["4IW(76>RXZ(MCY_ S-@I57X:5GBA.+S-B/ 6!!G>V\O!^Z/&)(-7D
M9)LT&T.O)Q\J"+Y&U.RUPA3(LZ,J%<%0KG;9+#4EU;#ST6+LS'V>>==?5'=2
MS+0\R)[*$[Z% 8+B70G&J=NK3<+?.MDU-RM2;E9+S"D2(3#<J-'G3MMY>U\=
MIF*B6PY(MSD>2JU27%<DXDJ6KD%1U+S#<?P VR>JU'6$I8-9A5]-:KYR:[I5
M\._GY"T[G7YBR,BJQ5V=7CUM!.HPE192SB2O;%*?O*UWNS"+EXTL<T34[G&-
M[%7<1XMO6_!#%HMNUD"%-5(><<NJMI@^AM<R,F,%06H:'U.R$\K,+TEM!:&X
MLN)YQ_LFV RYUV;BW-4J_P![V NMRMB(<=EBQ(V)[6<>1;9IFE%U?N#L1MB$
MOD+<F)"=<2^2M"6UW<Y)\?R[BXR7#0-#/5:&,A&T<*HT/"@SHC1QK^[5.],*
MU*PD BAXK3;&M50K<ZA%LE3(0\LZ53CWO@Q9K]PO]C%TV;EV&#VK!Y5J((R>
M1W8;;D25'EAI33*1R<=];!:<*&U%"'"ODU;I0?.ME-IS9-LH&U-T[?N09D7!
M4U29._<76KA F6]3Z'Y*E<M+C(E)?:#KJ XZRE/+-Y"Q$M"XT[$4W,;>U]9:
MLK$I/\E;3O*<U[4'4E8HVOPSKC$EQ_@&L;8'E;@4)W84Q--&=TOUD]B8:.>H
MMHQLR*Y?Q";EQQ-NV=G^N[5ZGMVV.M5[E75^WQW%R6V&G+%ZTQ^0<5&:0Y.=
MD!,NX/80ATMM+3^D;"3V&[[96G\GWMF[2]>9C3>S$&Q1;M-9;AO27FMJOR@E
MF4PF8\XS;&8A5;[3&RZZQRKZ%X9>4H<[E)Q-F-[[/T_>*U+52%BD$4=9<D&=
MA)*J2.Q>.;;8-.W&A2JN5@U=- L9-C4*-;%7EE(UHE5K7;R%?G45"-?V;2[*
MN7VX6R6R[&::2E$"^(?+A<G69N?%N:8T<I2X$OB5&*0?T.6WG IU2<H53L5M
MVQLO9[U;Y3,U]]:W+KLNY%Y$,VS:1RU3K*J;,2M;17&5"G!>X!)(D1&5)92K
M==1B<'Q"LD;R9W=M^9IVF[1"[HV+-S@[ /?]HU_;U+U]:]/5W5D_68NF-*V_
MUK+S:)8B57C))_*HD.SF^\LLBZ8(!FBC8^2F^W6YN1[3(8N4N4L2S.N3%SBP
M)L!,!]AJ(B,N X\A!=+2G'% \IDJ24HW>4<[(<)S92QV1J9M!$EV:#"0J BU
MV:58YUUMUV<NL:6_/=FLW9J,XYR >;:90H%D!*"E2]^-*UPZY.(+:KB)>\4:
MOQVHN/.U..LG9*GM7<KNN;UJ3_5ECUIH1U8^/TFQ3UW0)^A*2,1:]A65J[LT
MQ.SK!=* <*18QS6,TD;);1*3 8<DP(Z+?9+A8W9+%SN:V;PP[;WX%H4]:%-]
MKP3!"VW9BPIY3SV\XUOI"$-\DYV0=CT*N\EJ%=)CEXVFM&T[,&78[(T_L[+9
MN\6Z;0B+M"V[V[<TW3DWH]N:4B.B-'#;3X;67779 5[/>ALM#:1TM5XN#K*=
M:V1QKO.\WL+;-E0RM^3TI #%6,].L<;.)6JISLN[_P O6WL(_K -T!,1\LV,
M<Z9MM6P45%GM-MBICL.LW"R3;V\F1/3VZ+<PXU*,1Q#@>9>6MQ2HQ:,3(RI2
MVU8K0;[*\U>T>T%ZG+E2F)-IVEMVS4=<.UK];3>I33\,7!EQI4:3':;:2B:E
MX3^[T::>1PQ&:X7[.:\3WO$=*H\?]RTJ0G-Q&<V'9%OV12;3+.+#-FGM+[@O
M$C5JW,+7+:-;?RDD[W&#E5,]YE(6!EH280.]D&C2E[9*Z)V<5LVB-9;C&5+N
M;IE2I<R'+47E!=INDEQF.M,F=&6X^+DR4J[80U&2P[JHIV8W9!L*MLD;:NS-
MI;1,1!L;*8,&WV^XP&TQVU,W^R0V9$QHP[9+0U%-D?0I A+>FF7'W0A*_1ZA
MPDY6:'1:S:+,O=;/6J54Z[9;FY:)Q[BWV""@(^*FK2LP1,=)BI8))HYECLTS
M&(V%V*0#]QGH$)EZ-!A1I#YE2(T.+'?E$%)DO,,-M.R"DDE)>6E3A!)(WM=:
M\BN<B/,NESF1(J8,29<I\N+"2H+3#C293K[$4+"4A88:6EK>"0#NY&1J<JS9
MK2IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KZ4
MZB9TU45EVSA!5%PV=-E3(.FCINJ1=L[:KD$#H.FJZ::[=8@@9)9,AR^<N" 0
MI*DI6A:5(<;<2%MN-K24K;<0=%MN()0M)T4DD<] 5)4A;;CC+K:VW6GF5J:>
M9>96EUE]EQ.%-O,NH0XTXDY0M*5#ABO3O5':()1D&QA=Q56;E)9@D1L:XU!)
M@X3F$4B%(DZE()X^8KLI53NB+TT>L[8+J"*Z)&8'\53\,V@[#:GY3LK9J?%8
MCO**Q;+DMUM49:B2IN/+;:=0['3_ /H^62V\A.$*+I'**^J]C_5)-QH#$';>
MTSY$V.A+:KW9&X[S4Y"$A*7I5N=?CO1IB\$OIBF1&6K+C?()5R*);IW+"&Y&
M[&8:>JL'.56M3$'8)&PV"<?-XVP34;'MT$U*]6&L,^<.(MT^*\%=_,*OT'K*
M-:NB1K<KM8C]CUVY=CZ5L797=H[A*B3YT>5#9APXC:WXD5]Y:U"9.<D-(0^A
MHM;C,9+2FG7G$*>66TEEWN5B[,$#LE[3L;%VBW7&U6N7;;E,N-SN$AJ'<)L>
M,EELVVTL09#ST9U\22[*FN2&'XT9EQ,5HONB3$C#F9QJT[K_ %2C?:!7(J@S
M%?EX&(\1AQ5:QEECY1TE&#'.8T5#H+2K4#E?LI)(A'PE;.B/%7*"H^"Y[L:;
M;[27C:!5HO$V1=XTV/+D<K*(<?@O,-J?#[;^ M+#A!9=842UW;:FTH6D;W4^
MS;V+MB=G-CD[0[.6J!LW-M<NW0Q'MZ>UHETBS)#4,Q'8B2&7);06)$:2A(D#
MD7$.K<:6H)\^ZKM2X4R*1AX<E5?-(^3>SM97M51A[5(T.PR;864I8*$\EDU/
M:Y*R;0PD?'\"^9K+ 5WXD5T K&]?N%AMMS?7(DFX-./1VHDY%ON,FWL7>$PX
M'8\.\-1RGMV/'<&\R-YIQ _1\H6\)'SE:-K;U9(K,.$BRR6H<R1<K.[>;'!O
M$O9NZ3&%Q9ETV9DS 3:9TN.XXW(7R<EAPK6YVN'''%+Z,UUM!J&36(RAPHZ5
MN-?$XLI *[3M9D!1]DBR93 Y*D13_P"9(M"@5)"9ZRB(D<9M"V0!=S?1''KH
MJVBT*?)RT;>%;W(%@C<)*/\ )U.$E2XO^3J!1K6@;W=%;.(V25*)L#=[_*-$
M0)W7TWGW0E)EI(<2A,C_ "]ME*0&[E_EK:TN@8R&S;<O%OC5(V75KC47TU!V
M2R3%<JT57;'>[)6!3-6YZ_S+ @*V:2@U44G3$3HLVGCQ1?N&KAV(+%TX.SMJ
MMSR7XR9SG(Q9<&%&G7"1.A6F#/WNWH=GBNG=@,2TJ4V]A3CA:/(I<2WD'DKM
MMC?KW&<BS?6ACMFXVR\76=:K+$M=UVCN]EY$V>Y[2SV,JN\NV+CLO1<M1V$O
MMH><8<6A!3VIMY7A6?LEB=16M)%:WR$+8+'!RFNH>1J#ZZ5XARQ6Q4JXZ640
M9[!(8XJO+&V<$]DE *#QDJBFDBG0-EK4F)!A-R+ZPBVLRH<*7'O4EBY-6R;C
MMBRJFMH"G;,K&ZW"6@\BDJY-T*4I2MI6WE]7<;K<WK?LC*7>YEMNMTMTS9:'
M*LDF_P!I.8&U2;8\\H,[4ME+:G;PA_+ZV6"Y'*6&4M\* W-?ZZ$H*#FMSJ\I
M9'UU3>7"I0ME=UR[R;86<A<:8+E%%K5YYVV$$U3L6AH\3)HK!' JEWS63-FK
M/-Y +;FQ$,0FK6INVW&3!;FVIAP.LVVZ;BEN7"(VL;R0ZX'M2GEMT@"JW;<;
M26PRU-NVFXNR[N_M F1?K+#N[]KV@E,&-)OE@Y7DF+-<GV24+5&85%R L1 H
MN%R+A$PB8QSG4.<YU%%%#=Y1550PJ*JJ&\W>454,910W0 $YC"   ] YX]X
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M]'9/WO3R==G_ *7:[^ADK^_\>S7!_9B9\[,?8J>UBN?[<V_Z.R?O>GDZ[/\
MTNUW]#)7]_X]FN#^S$SYV8^Q4]K%<_VYM_T=D_>]8/.<,VM;O5 UK,;NC&]S
MVBTNCZD1R&K+I(,)-KKQA%R=N4D+#'O'-?KAHYE-1JK-&QR<6M.*+J-H,D@X
M:.TD8]FR!G'Y,S,_[U8[V->TN?-2/4P74@D;<6[ X_\ L])SU>N_XTZ<C./)
MUV?^EVN_H9*_O_)]FN#^S$SYV8^Q5'M8KG^W-O\ H[)^]Z>3KL_]+M=_0R5_
M?^/9K@_LQ,^=F/L5/:Q7/]N;?]'9/WO3R==G_I=KOZ&2O[_Q[-<']F)GSLQ]
MBI[6*Y_MS;_H[)^]Z>3KL_\ 2[7?T,E?W_CV:X/[,3/G9C[%3VL5S_;FW_1V
M3][UJ)V=%I4,4A-NUT3&'H4/:;*!U'^;J-@  _\ ,<'LUP1J=F)GSLQ]BI[6
M&Z<VW%OSS?\ L[)^]ZP;6_#%MMRBUK95 W=%RU,M[ \G7I*2U;<ZL^>,DW;E
MB=5S7[0]B+!%G!TS<)@WE(UHN8A"K%3%%5)0\#LV0",C9B;X[LP-?Y+_ (U)
M]3!=$G!VXMV>]L])(Z_7>LW\G79_Z7:[^ADK^_\ )]FN#^S$SYV8^Q5'M8KG
M^W-O^CLG[WIY.NS_ -+M=_0R5_?^/9K@_LQ,^=F/L5/:Q7/]N;?]'9/WO3R=
M=G_I=KOZ&2O[_P >S7!_9B9\[,?8J>UBN?[<V_Z.R?O>GDZ[/_2[7?T,E?W_
M (]FN#^S$SYV8^Q4]K%<_P!N;?\ 1V3][T\G79_Z7:[^ADK^_P#'LUP?V8F?
M.S'V*GM8KG^W-O\ H[)^]Z>3KL_]+M=_0R5_?^/9K@_LQ,^=F/L5/:Q7/]N;
M?]'9/WO3R==G_I=KOZ&2O[_Q[-<']F)GSLQ]BI[6*Y_MS;_H[)^]Z>3KL_\
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MJ>UBN?[<V_Z.R?O>GDZ[/_2[7?T,E?W_ (]FN#^S$SYV8^Q4]K%<_P!N;?\
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ML?>-R:EC;W"0MIG+<DQEVQ&D7)Z<#Q?UR<<WA/?H$C4;QUZ2?#H<!6N@T/.
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MFO+0.FW+1NR:-%=2!.5M^76?BK:-C46I*26#2;$CH\4")F8M#(NKQ@'G!Y_
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M73CF3B*+(1WM&V/.L9-2ZVC6U);3:LM=DSQ49&,Z^#(UXZ@XP.;37P]$D*!
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M;J<T(X>/^@K-WW7B'XXGZ^JI5VC_ -O1_P#L=/\ O*^5J]T?!_YUU*.!\/\
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M7_M!A_\ I!\<0_TYB>!\!J:Q_?AXU7F9P;BWZC<QI1GR^028+KIE\?0+JJL
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M'SUJW]5.^/X88]9;O^H._&;].GKW9OA*-\8T\O?V0'SUJW]5.^/X88]9;O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d185056d20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:kzia="http://www.kaziatherapeutics.com/20210630"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kzia-20210630.xsd" xlink:type="simple"/>
    <context id="P07_01_2020To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_14_2016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <instant>2016-09-14</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="P07_01_2016To06_30_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_AUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_LicensingRevenueMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">kzia:LicensingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">kzia:LicensingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_SwedanMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">kzia:SwedanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2018To06_30_2019_CNifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_AUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaResearchPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:GlioblastPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:OtherTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">kzia:ShortTermDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">kzia:CashAtBankAndInHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_IssueDateSixteenthAprilTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis">kzia:IssueDateSixteenthAprilTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_IssueDatedNovemberOneTwoThousandAndNineteenMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis">kzia:IssueDatedNovemberOneTwoThousandAndNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ShareIssueTransactionCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_LicensingRevenueMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">kzia:LicensingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">kzia:LicensingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_SwedanMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">kzia:SwedanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_CNifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAvailableforsaleCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaResearchPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:GlioblastPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">kzia:KaziaTherapeuticsHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:EVT801LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_EvotechLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:EvotechLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_AUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_UnlistedOptionsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">kzia:UnlistedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TranchesTwoAndEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TranchesTwoAndEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TranchesTenAndTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TranchesTenAndTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">kzia:ShortTermDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">kzia:CashAtBankAndInHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:IssuedOnAchievementOfAMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis">kzia:IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedFifteenthMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis">kzia:IssueDatedFifteenthMarchTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedSecondMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis">kzia:IssueDatedSecondMarchTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:RetailPlacementUnderAnreoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:InstitutionalPlacementUnderAnreoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDateTwentyEightAugustTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:SharePurchasePlanIssueDateAxis">kzia:IssueDateTwentyEightAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">kzia:ResearchAndDevelopmentTaxIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">kzia:ResearchAndDevelopmentTaxIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_LicenseAgreementForPaxalisibMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:LicenseAgreementForPaxalisibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_LicensingAgreementForEvtEightZeroOneMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:LicensingAgreementForEvtEightZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ShareIssueTransactionCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:FundingPurposeAxis">kzia:ClinicalTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kzia:UncertainityAxis">kzia:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_LicensingRevenueMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">kzia:LicensingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">kzia:LicensingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_SwedanMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">kzia:SwedanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_CNifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_MilestoneTwoMemberifrsfullClassesOfContingentLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">kzia:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">kzia:GlioblastPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_GenentechAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">kzia:GenentechAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020_ResearchAndDevelopmentTaxRebateReceivableMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">kzia:ResearchAndDevelopmentTaxRebateReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">kzia:DepositsHeldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_InterestRateRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:DecreaseInMarketRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:IncreaseInMarketRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">kzia:ContingentConsiderationPaxalisibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">kzia:DepositsHeldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_InterestRateRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:DecreaseInMarketRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:DecreaseInMarketRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:IncreaseInMarketRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:IncreaseInMarketRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">kzia:EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ContingentConsiderationEvt801MemberifrsfullClassesOfContingentLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">kzia:ContingentConsiderationEvt801Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">kzia:ContingentConsiderationPaxalisibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_AUifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2017_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">kzia:GlioblastPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="P11_01_2019To11_01_2019_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="P04_16_2020To04_16_2020_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-16</startDate>
            <endDate>2020-04-16</endDate>
        </period>
    </context>
    <context id="P05_11_2020To05_11_2020_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-11</endDate>
        </period>
    </context>
    <context id="P08_28_2020To08_28_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="P10_12_2020To10_12_2020_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:InstitutionalPlacementUnderAnreoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-12</startDate>
            <endDate>2020-10-12</endDate>
        </period>
    </context>
    <context id="P10_26_2020To10_26_2020_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:RetailPlacementUnderAnreoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-26</startDate>
            <endDate>2020-10-26</endDate>
        </period>
    </context>
    <context id="P03_02_2021To03_02_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-02</startDate>
            <endDate>2021-03-02</endDate>
        </period>
    </context>
    <context id="P03_15_2021To03_15_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-15</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="P04_28_2021To04_28_2021_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:SharePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-28</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="P05_21_2021To05_21_2021_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:IssuedOnAchievementOfAMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-21</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="P06_30_2021To06_30_2021_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ShareIssueTransactionCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P06_30_2021To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:ConversionOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kzia:FundingPurposeAxis">kzia:ClinicalTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kzia:UncertainityAxis">kzia:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:EVT801LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">kzia:PaxalisibLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">kzia:TrancheNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001075880</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAvailableforsaleCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <unit id="Unit_AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Segments">
        <measure>kzia:Segments</measure>
    </unit>
    <unit id="Unit_AUD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:AUD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Major_Customer">
        <measure>kzia:Major_Customer</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Milestone">
        <measure>kzia:Milestone</measure>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P07_01_2020To06_30_2021">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P07_01_2020To06_30_2021">FY</dei:DocumentFiscalPeriodFocus>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      id="hidden26941597"
      unitRef="Unit_AUD">-8810000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      id="hidden26941709"
      unitRef="Unit_AUD">-9111000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <dei:EntityCentralIndexKey contextRef="P07_01_2020To06_30_2021">0001075880</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P07_01_2020To06_30_2021">--06-30</dei:CurrentFiscalYearEndDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941445">2021-09-05</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941446">2021-10-17</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941447">2021-11-01</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941448">2021-11-23</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941449">2022-08-07</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941451">2024-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941452">2024-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941453">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941454">2024-11-09</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941455">2024-11-09</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941456">2024-11-09</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941457">2024-11-09</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941458">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941459">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941460">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941461">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941368">2025-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941369">2025-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941371">2025-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941372">2025-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941592">2023-02-05</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941373">2020-11-16</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941375">2021-10-17</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941376">2021-11-01</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941377">2021-11-23</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941378">2022-08-07</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941379">2023-02-05</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941380">2024-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941381">2024-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941382">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941383">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941384">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941385">2025-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941591">2021-09-05</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941585">2023-02-05</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941586">2024-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941587">2024-01-04</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941588">2025-01-13</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941600">2019-12-16</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941602">2019-12-18</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941603">2020-06-30</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941605">2020-11-16</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941606">2021-02-01</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941607">2021-02-01</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941608">2021-02-01</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941609">2021-09-05</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941610">2021-10-17</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941611">2021-11-01</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941612">2021-11-23</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <kzia:ShareBasedPaymentArrangementOptionsExpiryDate
      contextRef="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      id="hidden26941613">2022-08-07</kzia:ShareBasedPaymentArrangementOptionsExpiryDate>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      id="hidden26941594"
      unitRef="Unit_AUD_per_Share">0.492</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      id="hidden26941595"
      unitRef="Unit_AUD_per_Share">0.492</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <dei:DocumentType contextRef="P07_01_2020To06_30_2021">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P07_01_2020To06_30_2021">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P07_01_2020To06_30_2021">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P07_01_2020To06_30_2021">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P07_01_2020To06_30_2021">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P07_01_2020To06_30_2021">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="P07_01_2020To06_30_2021">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="P07_01_2020To06_30_2021">0-29962</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P07_01_2020To06_30_2021">Kazia Therapeutics Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2020To06_30_2021">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P07_01_2020To06_30_2021">Three International Towers Level 24, 300 Barangaroo Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P07_01_2020To06_30_2021">Sydney</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P07_01_2020To06_30_2021">2000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P07_01_2020To06_30_2021">AU</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Gabrielle Heaton</dei:ContactPersonnelName>
    <dei:ContactPersonnelEmailAddress contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Gabrielle.Heaton@kaziatherapeutics.com</dei:ContactPersonnelEmailAddress>
    <dei:CountryRegion contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">61</dei:CountryRegion>
    <dei:CityAreaCode contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">2</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">9472-4101</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Three International Towers Level 24, 300 Barangaroo Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Sydney</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">2000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P07_01_2020To06_30_2021_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">AU</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="P07_01_2020To06_30_2021">American Depositary Shares, each representing ten Ordinary Shares*</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P07_01_2020To06_30_2021">KZIA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P07_01_2020To06_30_2021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">132012209</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P07_01_2020To06_30_2021">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P07_01_2020To06_30_2021">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P07_01_2020To06_30_2021">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P07_01_2020To06_30_2021">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P07_01_2020To06_30_2021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="P07_01_2020To06_30_2021">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P07_01_2020To06_30_2021">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="P07_01_2020To06_30_2021">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="P07_01_2020To06_30_2021">false</dei:EntityShellCompany>
    <ifrs-full:RevenueFromInterest
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">15183000</ifrs-full:RevenueFromInterest>
    <ifrs-full:OtherRevenue
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">995000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1465000</ifrs-full:OtherRevenue>
    <ifrs-full:FinanceIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">42000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">66000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">100000</ifrs-full:FinanceIncome>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">14541000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">9494000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">6475000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">7022000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3690000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">3785000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-1000</ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">0</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-168000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-1809000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <kzia:GainLossOnRevaluationOfContingentConsideration
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-2570000</kzia:GainLossOnRevaluationOfContingentConsideration>
    <kzia:GainLossOnRevaluationOfContingentConsideration
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-474000</kzia:GainLossOnRevaluationOfContingentConsideration>
    <kzia:GainLossOnRevaluationOfContingentConsideration
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-63000</kzia:GainLossOnRevaluationOfContingentConsideration>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8906000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12765000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10568000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-484000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-298000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-298000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-4000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-89000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-4000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-89000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8420000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12471000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10359000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8420000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12471000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10359000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8420000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12471000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10359000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-7.16</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.07</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="P07_01_2018To06_30_2019"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.86</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-7.16</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.07</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="P07_01_2018To06_30_2019"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.86</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-7.16</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.07</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P07_01_2018To06_30_2019"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.86</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-7.16</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.07</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P07_01_2018To06_30_2019"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.86</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">27587000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">8764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">84000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1352000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1720000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">537000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">29391000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">10653000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentReceivables
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">6694000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">22003000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">28697000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">58088000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">23063000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">4933000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3489000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">229000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">191000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <kzia:ContingentConsiderationCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">3165000</kzia:ContingentConsiderationCurrent>
    <kzia:ContingentConsiderationCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1387000</kzia:ContingentConsiderationCurrent>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">8327000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">5067000</ifrs-full:CurrentLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2928000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3413000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">55000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">8927000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">458000</kzia:ContingentConsiderationNoncurrent>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">11910000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3871000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">20237000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">8938000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">37851000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">14125000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">80290000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">48781000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherReserves
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1301000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1066000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-44204000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-36186000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">37851000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">14125000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">37851000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">14125000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis"
      decimals="-3"
      unitRef="Unit_AUD">31576000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1843000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-14641000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis"
      decimals="-3"
      unitRef="Unit_AUD">19242000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">37000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-37000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_FinancialEffectOfChangesInAccountingPolicyMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">31576000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1880000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-14678000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2018"
      decimals="-3"
      unitRef="Unit_AUD">19242000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-89000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-89000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-89000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10359000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">340000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">340000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2018To06_30_2019"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2018To06_30_2019"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">246000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">246000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2018To06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">5406000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2018To06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2018To06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2018To06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">5406000</ifrs-full:IssueOfEquity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">36642000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">2037000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-24948000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">14195000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">36642000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">2037000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-24948000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">14195000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-4000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-4000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-4000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12471000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">833000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">833000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">262000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">262000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">12972000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12972000</ifrs-full:IssueOfEquity>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2019To06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2019To06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1230000</kzia:IncreaseDecreaseThroughExpireOfOptions>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1230000</kzia:IncreaseDecreaseThroughExpireOfOptions>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2019To06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">48781000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1066000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-36186000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">14125000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">48781000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1066000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-36186000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">14125000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8420000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">32909000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">32909000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1673000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1673000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">637000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">637000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">273000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-80000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">80000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">273000</ifrs-full:IssueOfEquity>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2020To06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2020To06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-323000</kzia:IncreaseDecreaseThroughExpireOfOptions>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2020To06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">323000</kzia:IncreaseDecreaseThroughExpireOfOptions>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2020To06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:IncreaseDecreaseThroughExpireOfOptions
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">80290000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_OtherEquityInterestMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_OtherReservesMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1301000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      unitRef="Unit_AUD">-44204000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_NoncontrollingInterestsMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">37851000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1265000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <kzia:NetLossOnDisposalOfNonCurrentAssets
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">637000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">262000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">246000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">430000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P07_01_2018To06_30_2019"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-2570000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-474000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-63000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-168000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-1809000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-3521000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-10479000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-7067000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-5027000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">358000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">825000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <kzia:AdjustmentsForDecreaseIncreaseInPrepayments
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-1182000</kzia:AdjustmentsForDecreaseIncreaseInPrepayments>
    <kzia:AdjustmentsForDecreaseIncreaseInPrepayments
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-168000</kzia:AdjustmentsForDecreaseIncreaseInPrepayments>
    <kzia:AdjustmentsForDecreaseIncreaseInPrepayments
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">398000</kzia:AdjustmentsForDecreaseIncreaseInPrepayments>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1010000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1722000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-409000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">93000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">55000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-25000</ifrs-full:AdjustmentsForProvisions>
    <kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-484000</kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities>
    <kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-298000</kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities>
    <kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-298000</kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-138000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-9111000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-8810000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-6714000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:ProceedsFromSalesOfInterestsInAssociates
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromSalesOfInterestsInAssociates
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromSalesOfInterestsInAssociates
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">2359000</ifrs-full:ProceedsFromSalesOfInterestsInAssociates>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">2359000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">28109000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12139000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">3816000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">28109000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12139000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">3816000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">18998000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3329000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-539000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">8764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">5434000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2018"
      decimals="-3"
      unitRef="Unit_AUD">5956000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-175000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">17000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">27587000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">8764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">5434000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1. General information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements cover Kazia Therapeutics Limited as a consolidated entity consisting of Kazia Therapeutics Limited and its subsidiaries. The financial statements are presented in Australian dollars, which is Kazia Therapeutics Limited&#x2019;s functional and presentation currency. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three International Towers &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;24, 300 Barangaroo Avenue &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sydney NSW 2000 &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;T&lt;/div&gt;h&lt;div style="display:inline;"&gt;e&lt;/div&gt; financial statements were authorised for issue, in accordance with a resolution of Directors, on 7&#160;October 2021. The Directors have the power to amend and reissue the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 2. Significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New or amended Accounting Standards and Interpretations adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (&#x2018;IASB&#x2019;) that are mandatory for the current reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Standards and Interpretations not yet mandatory or early adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30&#160;June 2021. The consolidated entity&#x2019;s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity incurred a loss after income tax of $8,421,960 (2020: $12,467,466), was in a net current asset position of $21,064,264(2020: net current asset position of $5,586,128) and had net cash outflows from operating activities of $&lt;span style="-sec-ix-hidden:hidden26941709"&gt;9,110,516&lt;/span&gt;(2020: $&lt;span style="-sec-ix-hidden:hidden26941597"&gt;8,809,519&lt;/span&gt;) for the year ended 30&#160;June 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at 30&#160;June 2021 the consolidated entity had cash in hand and at bank of $27,586,760. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. In particular, the directors have considered the impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on the operations of the Company, and make the following observations: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Kazia&#x2019;s key clinical trials have not been impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; to date. The GBM Agile study, the pivotal study for paxalisib in glioblastoma, is on track with recruitment running to plan, and no disruption to this schedule is foreseen. The Phase II study of paxalisib in glioblastoma was fully recruited prior to the onset of restrictions and is in wrap up stage at the date of this report. Plans are on track for the commencement of a Phase I trial for EVT801 before the end of 2021; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In general, clinical research in advanced cancer is relatively protected from pandemic disruption due to the ongoing and time-critical need for patient care in specialised facilities that cannot easily be repurposed; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not reliant on ongoing revenue from customers, and so changes in customer behaviour over the next several years due to public health restrictions and reduced economic activity have little to no impact on its finances; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Company was able to secure funding of approximately $9&#160;million at the height of the initial wave of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; in April 2020, and additional funds of approximately $25&#160;million during the 2021 financial year; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on budgets and forecasts, the Company has sufficient cash to fund the operations for a period of at least 12 months from the date of this report; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;As a consequence the directors do not foresee any other impacts on the Company&#x2019;s ability to raise additional funding as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of preparation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (&#x2018;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;AASB&lt;/div&gt;&#x2019;) and the Corporations Act 2001, as appropriate for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for-profit&lt;/div&gt; oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#x2018;IASB&#x2019;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for listed equity investments which are carried at fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Critical accounting estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity&#x2019;s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent entity information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 28. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (&#x2018;company&#x2019; or &#x2018;parent entity&#x2019;) as at 30&#160;June 2021 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the &#x2018;consolidated entity&#x2019;. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;de-consolidated&lt;/div&gt; from the date that control ceases. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are presented using the &#x2018;management approach&#x2019;, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (&#x2018;CODM&#x2019;). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements are presented in Australian dollars, which is the consolidated entity&#x2019;s functional and presentation currency. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign currency transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The foreign currency reserve is recognised in profit or loss when the foreign operation is disposed of. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exchange differences arising on a monetary item that forms part of a reporting entity&#x2019;s net investment in a foreign operation shall be recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recognition and derecognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below. Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and substantially all the risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Classification and initial measurement of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with IFRS&#160;15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent measurement of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial assets at amortised cost &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial assets at fair value through profit or loss (FVPL) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Classifications are determined by both: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The entity&#x2019;s business model for managing the financial asset &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The contractual cash flow characteristics of the financial assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial assets at amortised cost &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group&#x2019;s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial assets at fair value through profit or loss (FVPL) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets that are held within a business model other than &#x2018;hold to collect&#x2019; or &#x2018;hold to collect and sell&#x2019; are categorised at fair value through profit and loss. Further, irrespective of business model, financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.&#160;The Group&#x2019;s investments in equity instruments and derivatives fall under this category. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IFRS 9&#x2019;s new impairment model uses more forward looking information to recognize expected credit losses&#x2014;the &#x2018;expected credit losses (ECL) model&#x2019;. The application of the new impairment model depends on whether there has been a significant increase in credit risk.&#160;The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In applying this forward-looking approach, a distinction is made between: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk (&#x2018;Stage 1&#x2019;) and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low (&#x2018;Stage 2&#x2019;). &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&#x2018;Stage 3&#x2019; would cover financial assets that have objective evidence of impairment at the reporting date. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2018;12-month&lt;/div&gt; expected credit losses&#x2019; are recognised for the first category while &#x2018;lifetime expected credit losses&#x2019; are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Classification and measurement of financial liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s financial liabilities comprise trade and other payables. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All interest-related charges and, if applicable, changes in an instrument&#x2019;s fair value that are reported in profit or loss are included within finance costs or finance income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from contracts with customers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognised using a five step approach in accordance with IFRS&#160;15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognised when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognised as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognised as revenue within the 12 months following the balance sheet date are classified within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing revenues, including milestone revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the consolidated entity&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the licence is transferred to the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Finance Income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue is recognised when it is received or when the right to receive payment is established. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Grant income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The R&amp;amp;D Tax Incentive is a government program which helps to offset some of the incurred costs of R&amp;amp;D. Eligible expenditure incurred under the scheme in a financial year attracts an additional 43.5% tax deduction, and for a group earning income of less than $20&#160;million, the cash value of the additional deduction is remitted to the taxpayer. In accordance with IAS&#160;20, as the compensation relates to expenses already incurred, it is recognised in profit or loss of the period in which it becomes receivable. Accordingly the group accounts for the R&amp;amp;D Tax Incentive in the same year as the expenses to which it relates. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The income tax expense or benefit for the period is the tax payable on that period&#x2019;s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amount of recognised and unrecognised deferred tax assets are reviewed each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics Limited (the &#x2018;parent entity&#x2019;) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the &#x2018;separate taxpayer in the group&#x2019; allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interpretation 23 Uncertain tax positions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interpretation 23 clarified the application of the recognition and measurement criteria IAS&#160;12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Judgments are reassessed as and when new facts and circumstances are presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; classification &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Assets and liabilities are presented in the statement of financial position based on current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; classification. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Deferred tax assets and liabilities are always classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under IFRS&#160;16, leases are accounted for as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Depreciation on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and interest on lease liabilities are recognised in the consolidated statement of profit or loss; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total amount of cash paid under lease arrangements is separated into a principal portion (presented within financing activities) and interest (presented within operating activities) in the consolidated cash flow statement. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Lease incentives under IFRS 16 are recognised as part of the measurement of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;Under IFRS&#160;16, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are tested for impairment in accordance with IAS 36 Impairment of assets. This replaces the previous requirement to recognise a provision for onerous lease contracts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For short-term leases (lease term of 12 months or less) and leases of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; assets, the consolidated entity has opted to recognise a lease expense on a straight-line basis as permitted by IFRS&#160;16 Leases. This expense is presented within other expenses in the consolidated statement of profit or loss. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing agreement for paxalisib &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Licensing Agreement asset was initially brought to account at fair value, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 15 years from the date of acquisition. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing agreement for EVT801 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Licensing agreement asset was initially brought to account at cost and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 12.5 years from the date of acquisition. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-financial&lt;/div&gt; assets with finite useful lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value-in-use.&lt;/div&gt;&lt;/div&gt; The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value-in-use&lt;/div&gt;&lt;/div&gt; is the present value of the estimated future cash flows relating to the asset using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compound financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortised cost using the effective interest rate method, whereas the equity component is not remeasured. Interest, gains and losses relating to the financial liability are recognised in profit or loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognised on conversion. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Short-term employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Liabilities for wages and salaries, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-monetary&lt;/div&gt; benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other long-term employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined contribution superannuation expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (&#x2018;ESOP&#x2019;) and consultants as compensation for services performed. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vesting&lt;/div&gt; conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cumulative charge to profit or loss until settlement of the liability is calculated as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vesting&lt;/div&gt; condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;When an asset or liability, financial or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial,&lt;/div&gt; is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For recurring and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued capital &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares are classified as equity. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goods and Services Tax (&#x2018;GST&#x2019;) and other similar taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <kzia:DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New or amended Accounting Standards and Interpretations adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (&#x2018;IASB&#x2019;) that are mandatory for the current reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. &lt;/div&gt;&lt;/div&gt;</kzia:DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory>
    <kzia:DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Standards and Interpretations not yet mandatory or early adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30&#160;June 2021. The consolidated entity&#x2019;s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity. &lt;/div&gt;&lt;/div&gt;</kzia:DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory>
    <ifrs-full:DisclosureOfGoingConcernExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity incurred a loss after income tax of $8,421,960 (2020: $12,467,466), was in a net current asset position of $21,064,264(2020: net current asset position of $5,586,128) and had net cash outflows from operating activities of $&lt;span style="-sec-ix-hidden:hidden26941709"&gt;9,110,516&lt;/span&gt;(2020: $&lt;span style="-sec-ix-hidden:hidden26941597"&gt;8,809,519&lt;/span&gt;) for the year ended 30&#160;June 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at 30&#160;June 2021 the consolidated entity had cash in hand and at bank of $27,586,760. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. In particular, the directors have considered the impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on the operations of the Company, and make the following observations: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Kazia&#x2019;s key clinical trials have not been impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; to date. The GBM Agile study, the pivotal study for paxalisib in glioblastoma, is on track with recruitment running to plan, and no disruption to this schedule is foreseen. The Phase II study of paxalisib in glioblastoma was fully recruited prior to the onset of restrictions and is in wrap up stage at the date of this report. Plans are on track for the commencement of a Phase I trial for EVT801 before the end of 2021; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In general, clinical research in advanced cancer is relatively protected from pandemic disruption due to the ongoing and time-critical need for patient care in specialised facilities that cannot easily be repurposed; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not reliant on ongoing revenue from customers, and so changes in customer behaviour over the next several years due to public health restrictions and reduced economic activity have little to no impact on its finances; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Company was able to secure funding of approximately $9&#160;million at the height of the initial wave of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; in April 2020, and additional funds of approximately $25&#160;million during the 2021 financial year; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on budgets and forecasts, the Company has sufficient cash to fund the operations for a period of at least 12 months from the date of this report; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;As a consequence the directors do not foresee any other impacts on the Company&#x2019;s ability to raise additional funding as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfGoingConcernExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">-8421960</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="0"
      unitRef="Unit_AUD">-12467466</ifrs-full:ProfitLoss>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">21064264</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="PAsOn06_30_2020"
      decimals="0"
      unitRef="Unit_AUD">5586128</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">27586760</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P04_01_2020To04_30_2020_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis"
      decimals="-6"
      unitRef="Unit_AUD">9000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P07_01_2020To06_30_2021_ClinicalTrialsMemberKZIAFundingPurposeAxis_CovidNinteenMemberKZIAUncertainityAxis"
      decimals="-6"
      unitRef="Unit_AUD">25000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of preparation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (&#x2018;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;AASB&lt;/div&gt;&#x2019;) and the Corporations Act 2001, as appropriate for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for-profit&lt;/div&gt; oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#x2018;IASB&#x2019;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for listed equity investments which are carried at fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Critical accounting estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity&#x2019;s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <kzia:DescriptionOfParentEntityInformationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent entity information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 28. &lt;/div&gt;&lt;/div&gt;</kzia:DescriptionOfParentEntityInformationExplanatory>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (&#x2018;company&#x2019; or &#x2018;parent entity&#x2019;) as at 30&#160;June 2021 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the &#x2018;consolidated entity&#x2019;. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;de-consolidated&lt;/div&gt; from the date that control ceases. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. &lt;/div&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are presented using the &#x2018;management approach&#x2019;, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (&#x2018;CODM&#x2019;). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements are presented in Australian dollars, which is the consolidated entity&#x2019;s functional and presentation currency. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign currency transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The foreign currency reserve is recognised in profit or loss when the foreign operation is disposed of. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exchange differences arising on a monetary item that forms part of a reporting entity&#x2019;s net investment in a foreign operation shall be recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recognition and derecognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below. Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and substantially all the risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Classification and initial measurement of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with IFRS&#160;15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent measurement of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial assets at amortised cost &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial assets at fair value through profit or loss (FVPL) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Classifications are determined by both: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The entity&#x2019;s business model for managing the financial asset &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The contractual cash flow characteristics of the financial assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial assets at amortised cost &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group&#x2019;s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial assets at fair value through profit or loss (FVPL) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets that are held within a business model other than &#x2018;hold to collect&#x2019; or &#x2018;hold to collect and sell&#x2019; are categorised at fair value through profit and loss. Further, irrespective of business model, financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.&#160;The Group&#x2019;s investments in equity instruments and derivatives fall under this category. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IFRS 9&#x2019;s new impairment model uses more forward looking information to recognize expected credit losses&#x2014;the &#x2018;expected credit losses (ECL) model&#x2019;. The application of the new impairment model depends on whether there has been a significant increase in credit risk.&#160;The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In applying this forward-looking approach, a distinction is made between: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk (&#x2018;Stage 1&#x2019;) and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low (&#x2018;Stage 2&#x2019;). &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&#x2018;Stage 3&#x2019; would cover financial assets that have objective evidence of impairment at the reporting date. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2018;12-month&lt;/div&gt; expected credit losses&#x2019; are recognised for the first category while &#x2018;lifetime expected credit losses&#x2019; are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Classification and measurement of financial liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s financial liabilities comprise trade and other payables. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All interest-related charges and, if applicable, changes in an instrument&#x2019;s fair value that are reported in profit or loss are included within finance costs or finance income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from contracts with customers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognised using a five step approach in accordance with IFRS&#160;15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognised when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognised as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognised as revenue within the 12 months following the balance sheet date are classified within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing revenues, including milestone revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the consolidated entity&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the licence is transferred to the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Finance Income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue is recognised when it is received or when the right to receive payment is established. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Grant income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The R&amp;amp;D Tax Incentive is a government program which helps to offset some of the incurred costs of R&amp;amp;D. Eligible expenditure incurred under the scheme in a financial year attracts an additional 43.5% tax deduction, and for a group earning income of less than $20&#160;million, the cash value of the additional deduction is remitted to the taxpayer. In accordance with IAS&#160;20, as the compensation relates to expenses already incurred, it is recognised in profit or loss of the period in which it becomes receivable. Accordingly the group accounts for the R&amp;amp;D Tax Incentive in the same year as the expenses to which it relates. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <kzia:AdditionalTaxDeductionPercentage
      contextRef="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="INF"
      unitRef="Unit_pure">0.435</kzia:AdditionalTaxDeductionPercentage>
    <kzia:InterestIncomeLoss
      contextRef="P07_01_2020To06_30_2021_ResearchAndDevelopmentTaxIncentiveProgramMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_AUD">20000000</kzia:InterestIncomeLoss>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The income tax expense or benefit for the period is the tax payable on that period&#x2019;s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amount of recognised and unrecognised deferred tax assets are reviewed each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics Limited (the &#x2018;parent entity&#x2019;) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the &#x2018;separate taxpayer in the group&#x2019; allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interpretation 23 Uncertain tax positions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interpretation 23 clarified the application of the recognition and measurement criteria IAS&#160;12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Judgments are reassessed as and when new facts and circumstances are presented. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <kzia:DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; classification &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Assets and liabilities are presented in the statement of financial position based on current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; classification. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Deferred tax assets and liabilities are always classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt;</kzia:DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under IFRS&#160;16, leases are accounted for as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Depreciation on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and interest on lease liabilities are recognised in the consolidated statement of profit or loss; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total amount of cash paid under lease arrangements is separated into a principal portion (presented within financing activities) and interest (presented within operating activities) in the consolidated cash flow statement. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Lease incentives under IFRS 16 are recognised as part of the measurement of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;Under IFRS&#160;16, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are tested for impairment in accordance with IAS 36 Impairment of assets. This replaces the previous requirement to recognise a provision for onerous lease contracts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For short-term leases (lease term of 12 months or less) and leases of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-value&lt;/div&gt; assets, the consolidated entity has opted to recognise a lease expense on a straight-line basis as permitted by IFRS&#160;16 Leases. This expense is presented within other expenses in the consolidated statement of profit or loss. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing agreement for paxalisib &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Licensing Agreement asset was initially brought to account at fair value, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 15 years from the date of acquisition. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing agreement for EVT801 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Licensing agreement asset was initially brought to account at cost and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 12.5 years from the date of acquisition. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <kzia:IntangibleAssetsWithIndefiniteRemainingUsefulLife contextRef="P07_01_2020To06_30_2021_LicenseAgreementForPaxalisibMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">15 years</kzia:IntangibleAssetsWithIndefiniteRemainingUsefulLife>
    <kzia:IntangibleAssetsWithIndefiniteRemainingUsefulLife contextRef="P07_01_2020To06_30_2021_LicensingAgreementForEvtEightZeroOneMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">12.5 years</kzia:IntangibleAssetsWithIndefiniteRemainingUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-financial&lt;/div&gt; assets with finite useful lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value-in-use.&lt;/div&gt;&lt;/div&gt; The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value-in-use&lt;/div&gt;&lt;/div&gt; is the present value of the estimated future cash flows relating to the asset using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compound financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortised cost using the effective interest rate method, whereas the equity component is not remeasured. Interest, gains and losses relating to the financial liability are recognised in profit or loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognised on conversion. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Short-term employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Liabilities for wages and salaries, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-monetary&lt;/div&gt; benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other long-term employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined contribution superannuation expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (&#x2018;ESOP&#x2019;) and consultants as compensation for services performed. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vesting&lt;/div&gt; conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cumulative charge to profit or loss until settlement of the liability is calculated as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vesting&lt;/div&gt; condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;When an asset or liability, financial or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial,&lt;/div&gt; is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For recurring and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued capital &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares are classified as equity. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goods and Services Tax (&#x2018;GST&#x2019;) and other similar taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3. Critical accounting judgements, estimates and assumptions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and development expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Directors do not consider the development programs to be sufficiently advanced to reliably determine the economic benefits and technical feasibility to justify capitalisation of development costs. These costs have been recognised as an expense when incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Research and development expenses relate primarily to the cost of conducting human clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being measured. The length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The consolidated entity applies judgement in determining whether contracts entered into fall within the scope of IFRS&#160;15 Revenue from Contracts with Customers. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contracts with each customer, management assessed that the contracts were within the scope of IFRS&#160;15 &#x2018;Revenue from Contracts with Customers&#x2019;. Management has also made the judgement in each case that the grant of the licence and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were also made in relation to the transfer of the licence and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; in each case, and whether this should be recognised over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Clinical trial expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The timing of payment for work conducted under clinical trials often bears little relation to the timing of the work effort. Detailed estimates are made to determine the amount of work effort expended during a reporting period in order to determine the appropriate expense to be recognised, with the resulting prepayments or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;un-invoiced&lt;/div&gt; amounts being recognised as a prepayment or an accrual respectively. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payment transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes option pricing model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisition of intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has applied judgement in determining the accounting treatment for the acquisition of the License agreement for EVT801. The License agreement has been determined to be a stand alone transaction, independent from any other agreements which have been or may be entered into with Evotec (France) SAS. Management has also made the decision to account for the cost of the asset conferred by the License agreement on the basis of the milestones that are probable of being payable, that is, those for which there is judged to be a probability of greater than 50% that the milestone will be triggered. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration relates to the intangible assets acquired, and the fair value of contingent consideration is dependent on the key assumptions used in accounting for the acquisition of those intangible assets. These assumptions include the probability of milestones occurring, and can also include the anticipated timing of settlement and discount rates used. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the case where contingent consideration is recognised on the basis that the liability is probable of occurring, judgement is used in determining which milestones are considered probable of being triggered. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangible assets available for use &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has exercised judgement in determining that its intangible assets, being license agreements, have a finite life and are available for use once acquired. As the business model is to acquire such assets and then develop them to generate returns from future license transactions or other means, management have determined that the assets are available for use from the time that they are acquired. In each case the prima facie useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets other than goodwill and other indefinite life intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;T&lt;/div&gt;he consolidated entity assesses impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. Judgement is used to determine whether any indicators of impairment exist, and reference is made to the considerations included in IAS&#160;36 Impairment of Assets in this assessment. If an impairment trigger is found to exist, the recoverable amount of the asset is determined&lt;div style="display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <kzia:PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_pure">0.50</kzia:PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4. Operating segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Identification of reportable operating segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity&#x2019;s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (&#x2018;CODM&#x2019;)) in assessing performance and in determining the allocation of resources. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity operates in the pharmaceutical research and development business. There are no operating segments for which discrete financial information exists. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Major customers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year the consolidated entity transacted with two customers, and revenue from each customer amounted to in excess of 10% of the total revenue from the period. Both companies entered into license agreements for the consolidated entity&#x2019;s drug assets. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <kzia:NumberOfOperatingSegments1
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_Segments">0</kzia:NumberOfOperatingSegments1>
    <kzia:NumberOfMajorCustomers
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_Major_Customer">2</kzia:NumberOfMajorCustomers>
    <kzia:ConcentrationRiskMajorCustomerPercentage
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_pure">0.10</kzia:ConcentrationRiskMajorCustomerPercentage>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5. Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregation of revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The disaggregation of revenue from contracts with customers is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Geographical regions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sweden&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Timing of revenue recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing revenue at a point in time&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfProductsAndServicesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfProductsAndServicesExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2020To06_30_2021_LicensingRevenueMemberifrsfullProductsAndServicesAxis"
      decimals="-3"
      unitRef="Unit_AUD">15183000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2019To06_30_2020_LicensingRevenueMemberifrsfullProductsAndServicesAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2018To06_30_2019_LicensingRevenueMemberifrsfullProductsAndServicesAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The disaggregation of revenue from contracts with customers is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Geographical regions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sweden&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Timing of revenue recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing revenue at a point in time&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2020To06_30_2021_CNifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">10006000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2019To06_30_2020_CNifrsfullGeographicalAreasAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2018To06_30_2019_CNifrsfullGeographicalAreasAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2020To06_30_2021_SwedanMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">5177000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2019To06_30_2020_SwedanMemberifrsfullGeographicalAreasAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2018To06_30_2019_SwedanMemberifrsfullGeographicalAreasAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">15183000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2018To06_30_2019"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2020To06_30_2021_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis"
      decimals="-3"
      unitRef="Unit_AUD">15183000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2019To06_30_2020_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="P07_01_2018To06_30_2019_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 6. Other income &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange gain&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll tax rebate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsidies and grants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reimbursement of expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development rebate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;995&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,465&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange gain&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll tax rebate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsidies and grants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reimbursement of expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development rebate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;995&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,465&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">5000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P07_01_2018To06_30_2019"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:TaxRebatesOnPayroll
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2000</kzia:TaxRebatesOnPayroll>
    <kzia:TaxRebatesOnPayroll
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">2000</kzia:TaxRebatesOnPayroll>
    <kzia:TaxRebatesOnPayroll
      contextRef="P07_01_2018To06_30_2019"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:SubsidiesAndGrants
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:SubsidiesAndGrants
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">20000</kzia:SubsidiesAndGrants>
    <kzia:SubsidiesAndGrants
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">9000</kzia:SubsidiesAndGrants>
    <kzia:ReimbursementOfExpenses
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:ReimbursementOfExpenses
      contextRef="P07_01_2019To06_30_2020"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:ReimbursementOfExpenses
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">25000</kzia:ReimbursementOfExpenses>
    <kzia:RebateIncomeOnResearchAndDevelopment
      contextRef="P07_01_2020To06_30_2021"
      unitRef="Unit_AUD"
      xsi:nil="true"/>
    <kzia:RebateIncomeOnResearchAndDevelopment
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">968000</kzia:RebateIncomeOnResearchAndDevelopment>
    <kzia:RebateIncomeOnResearchAndDevelopment
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1431000</kzia:RebateIncomeOnResearchAndDevelopment>
    <ifrs-full:OtherIncome
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">995000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1465000</ifrs-full:OtherIncome>
    <ifrs-full:DisclosureOfExpensesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 7. Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax includes the following specific&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amortisation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paxalisib licensing agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Evotech licensing agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total amortisation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net foreign exchange loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rental expense relating to operating leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Minimum lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Superannuation expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined contribution superannuation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee benefits expense excluding superannuation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits expense excluding superannuation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chinese With-Holding Tax incurred on license transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chinese Value Added Tax incurred on license transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfExpensesExplanatory>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax includes the following specific&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amortisation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paxalisib licensing agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Evotech licensing agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total amortisation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net foreign exchange loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rental expense relating to operating leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Minimum lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Superannuation expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined contribution superannuation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee benefits expense excluding superannuation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits expense excluding superannuation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chinese With-Holding Tax incurred on license transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chinese Value Added Tax incurred on license transaction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2019To06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2018To06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021_EvotechLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">181000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1265000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">430000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">18000</ifrs-full:NetForeignExchangeLoss>
    <kzia:MinimumOperatingLeasePayment
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">93000</kzia:MinimumOperatingLeasePayment>
    <kzia:MinimumOperatingLeasePayment
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">108000</kzia:MinimumOperatingLeasePayment>
    <kzia:MinimumOperatingLeasePayment
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">79000</kzia:MinimumOperatingLeasePayment>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">138000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">140000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">128000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1563000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1526000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1396000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <kzia:ChineseWithholdingTaxIncurredOnLicenseTransaction
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">931000</kzia:ChineseWithholdingTaxIncurredOnLicenseTransaction>
    <kzia:ChineseValueAddedTaxIncurredOnLicenseTransaction
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">538000</kzia:ChineseValueAddedTaxIncurredOnLicenseTransaction>
    <ifrs-full:ExpenseByNature
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1469000</ifrs-full:ExpenseByNature>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8. Income tax benefit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Numerical reconciliation of income tax benefit and tax at the statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax benefi&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax at the statutory tax rate of 26% (2020 &amp;amp; 2019 27.5%)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax effect amounts which are not deductible/(taxable) in calculating taxable income:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development claim&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortisation of intangibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee option plan&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain/loss on revaluation of contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(2,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(2,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustment to deferred tax balances as a result of change in statutory tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax losses and timing differences not recognised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(484&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tax losses not recognised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unused tax losses for which no deferred tax asset has been recognised-Australia&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;70,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;67,430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Potential tax benefit @ 26.0% (2020 27.5%)- Australia&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Unused tax losses for which no deferred tax asset has been &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognised-US&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Potential tax benefit at statutory tax &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;rates@21%-US&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Numerical reconciliation of income tax benefit and tax at the statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income tax benefi&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax at the statutory tax rate of 26% (2020 &amp;amp; 2019 27.5%)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax effect amounts which are not deductible/(taxable) in calculating taxable income:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development claim&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortisation of intangibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee option plan&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain/loss on revaluation of contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(2,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(2,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustment to deferred tax balances as a result of change in statutory tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax losses and timing differences not recognised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(484&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tax losses not recognised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unused tax losses for which no deferred tax asset has been recognised-Australia&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;70,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;67,430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,050&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Potential tax benefit @ 26.0% (2020 27.5%)- Australia&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Unused tax losses for which no deferred tax asset has been &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognised-US&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Potential tax benefit at statutory tax &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;rates@21%-US&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8906000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12765000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10568000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_pure">0.26</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2019To06_30_2020"
      decimals="3"
      unitRef="Unit_pure">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2018To06_30_2019"
      decimals="3"
      unitRef="Unit_pure">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-2316000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-3511000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-2906000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <kzia:TaxEffectOfExpenseResearchAndDevelopmentClaim
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">280000</kzia:TaxEffectOfExpenseResearchAndDevelopmentClaim>
    <kzia:TaxEffectOfExpenseResearchAndDevelopmentClaim
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">394000</kzia:TaxEffectOfExpenseResearchAndDevelopmentClaim>
    <kzia:TaxEffectOfAmortisationOfIntangibles
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">348000</kzia:TaxEffectOfAmortisationOfIntangibles>
    <kzia:TaxEffectOfAmortisationOfIntangibles
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">298000</kzia:TaxEffectOfAmortisationOfIntangibles>
    <kzia:TaxEffectOfExpenseEmployeeOptionPlan
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">175000</kzia:TaxEffectOfExpenseEmployeeOptionPlan>
    <kzia:TaxEffectOfExpenseEmployeeOptionPlan
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">72000</kzia:TaxEffectOfExpenseEmployeeOptionPlan>
    <kzia:TaxEffectOfExpenseEmployeeOptionPlan
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">67000</kzia:TaxEffectOfExpenseEmployeeOptionPlan>
    <kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">707000</kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable>
    <kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">131000</kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable>
    <kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">17000</kzia:TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable>
    <kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-1086000</kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped>
    <kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-2730000</kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped>
    <kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-2428000</kzia:TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped>
    <kzia:TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-186000</kzia:TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate>
    <kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">788000</kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised>
    <kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">2432000</kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised>
    <kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">2130000</kzia:TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-484000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-298000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-298000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn06_30_2021_AUifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">70896000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn06_30_2020_AUifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">67430000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn06_30_2019_AUifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">57050000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2020To06_30_2021_AUifrsfullGeographicalAreasAxis"
      decimals="3"
      unitRef="Unit_pure">0.260</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2018To06_30_2019_AUifrsfullGeographicalAreasAxis"
      decimals="3"
      unitRef="Unit_pure">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2019To06_30_2020_AUifrsfullGeographicalAreasAxis"
      decimals="3"
      unitRef="Unit_pure">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes
      contextRef="P07_01_2020To06_30_2021_AUifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">18433000</ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes
      contextRef="P07_01_2019To06_30_2020_AUifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">17531000</ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes
      contextRef="P07_01_2018To06_30_2019_AUifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">15689000</ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn06_30_2021_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">2038000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn06_30_2020_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">1570000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn06_30_2019_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">2366000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2018To06_30_2019_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.21</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2019To06_30_2020_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.21</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P07_01_2020To06_30_2021_USifrsfullGeographicalAreasAxis"
      decimals="2"
      unitRef="Unit_pure">0.21</ifrs-full:ApplicableTaxRate>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes
      contextRef="P07_01_2020To06_30_2021_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">428000</ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes
      contextRef="P07_01_2019To06_30_2020_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">330000</ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes
      contextRef="P07_01_2018To06_30_2019_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      unitRef="Unit_AUD">497000</ifrs-full:DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 9. Current assets - cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash at bank and on hand&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;27,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash at bank and on hand&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term deposits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;27,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory>
    <ifrs-full:Cash
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">21087000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1264000</ifrs-full:Cash>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">6500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">7500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">27587000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">8764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 10. Trade and other receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D tax rebate receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deposits held&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Provision for impairment of deposits held&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deposit paid&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Of the deposit paid, $6.65m represents an advance to GCAR at the start of the GBM Agile trial, and is refundable if not utilised against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial, which is expected to be over 12 months from year end. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D tax rebate receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deposits held&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Provision for impairment of deposits held&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deposit paid&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn06_30_2020_ResearchAndDevelopmentTaxRebateReceivableMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_AUD">1017000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1017000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_AUD">76000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_AUD">177000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn06_30_2021_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_AUD">8000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn06_30_2020_DepositsHeldMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_AUD">567000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn06_30_2020_AccumulatedImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      unitRef="Unit_AUD">-409000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">84000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1352000</ifrs-full:TradeAndOtherCurrentReceivables>
    <kzia:DepositPaidNonCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">6694000</kzia:DepositPaidNonCurrent>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">6778000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1352000</ifrs-full:TradeAndOtherReceivables>
    <kzia:DepositPaidAsAdvance
      contextRef="PAsOn06_30_2021"
      decimals="-4"
      unitRef="Unit_AUD">6650000</kzia:DepositPaidAsAdvance>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 11. Other assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepayments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepayments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1720000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">537000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 12. Intangibles &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing agreement - at acquired fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortisation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing agreement - at cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortisation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reconciliations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EVT801&#160;licensing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paxalisib&#160;licensing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 1&#160;July 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortisation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortisation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the financial year the consolidated entity acquired exclusive rights to EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing agreement - at acquired fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortisation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing agreement - at cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated amortisation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">16408000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">16408000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">-5082000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">-3998000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">11326000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">10858000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">-181000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">10677000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020_LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">22003000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <kzia:DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory contextRef="P07_01_2020To06_30_2021">Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EVT801&#160;licensing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paxalisib&#160;licensing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 1&#160;July 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortisation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortisation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2019_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">13494000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">13494000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2019To06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">12410000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">10858000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">10858000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">181000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1265000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_EVT801LicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">10677000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021_PaxalisibLicensingAgreementMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      unitRef="Unit_AUD">11326000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">22003000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 13. Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to note 21 for further information on financial instruments. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1893000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1694000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">3040000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1795000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">4933000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3489000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;N&lt;/div&gt;ote 14. Employee benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;229&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Current&lt;/div&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long service leave&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfProvisionsExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutProvisionsExplanatory contextRef="P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;229&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Current&lt;/div&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long service leave&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutProvisionsExplanatory>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">229000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">191000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">55000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">284000</ifrs-full:ProvisionsForEmployeeBenefits>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">191000</ifrs-full:ProvisionsForEmployeeBenefits>
    <kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory contextRef="P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 15. Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration - paxalisib&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration &#x2013; EVT801&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration - paxalisib&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration &#x2013; EVT801&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,927&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration - paxalisib &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During the 2017 financial year, the consolidated entity acquired 100% of the issued shares in Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. On the same day, Kazia entered into a worldwide licensing agreement with Genentech to develop and commercialise &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GDC-0084,&lt;/div&gt; now known as paxalisib. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Glioblast acquisition contains four contingent milestone payments, the first two milestone payments are to be settled with Kazia shares, and the third and fourth milestone payments are to be settled with either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the value of $1,250,000. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Genentech agreement comprises of one milestone payment payable on the first commercial licensed product sale, in the amount of $1,394,000. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each milestone payment is probability weighted for valuation purposes. The milestone payments are discounted to present value, using a discount rate of 15% (previously 35%) per annum. The discount rate was considered at 30&#160;June 2021 and it was determined that the risk of the asset, and therefore of the milestones being met, has been considerably decreased as a result of paxalisib entering the pivotal GBM Agile trial, which is progressing well, and the license transaction with Simcere Pharmaceutical Group, which provides an external validation of paxalisib. Accordingly, the discount rate applied to future expected cash flows has been revised downwards. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance, and are not considered as part of the consideration in relation to the Genentech agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration - EVT801 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As set out in note 2, the acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being booked as a current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liability at year end, according to the estimated payment date. Milestones where the payment is not considered probable at year end have not been accounted for as a liability. The total amount of milestone payments not booked at year end amounts to &#x20ac;300,500,000 ($475,474,684). &lt;/div&gt;</kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory contextRef="P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Current Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration - paxalisib&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration &#x2013; EVT801&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration - paxalisib&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration &#x2013; EVT801&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,927&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory>
    <kzia:ContingentConsiderationCurrent
      contextRef="PAsOn06_30_2020_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">1387000</kzia:ContingentConsiderationCurrent>
    <kzia:ContingentConsiderationCurrent
      contextRef="PAsOn06_30_2021_ContingentConsiderationEvt801MemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">3165000</kzia:ContingentConsiderationCurrent>
    <kzia:ContingentConsiderationCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">3165000</kzia:ContingentConsiderationCurrent>
    <kzia:ContingentConsiderationCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1387000</kzia:ContingentConsiderationCurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2021_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2020_ContingentConsiderationPaxalisibMemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">458000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2021_ContingentConsiderationEvt801MemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">7911000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">8927000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">458000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsideration
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">12091000</kzia:ContingentConsideration>
    <kzia:ContingentConsideration
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1845000</kzia:ContingentConsideration>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="PAsOn06_30_2017_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <kzia:NumberOfContingentMilestonePayments
      contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullBusinessCombinationsAxis"
      decimals="INF"
      unitRef="Unit_Milestone">4</kzia:NumberOfContingentMilestonePayments>
    <kzia:PaymentsForContingentConsideration
      contextRef="P07_01_2020To06_30_2021_MilestoneTwoMemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="0"
      unitRef="Unit_AUD">1250000</kzia:PaymentsForContingentConsideration>
    <kzia:NumberOfContingentMilestonePayments
      contextRef="P07_01_2020To06_30_2021_GenentechAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="INF"
      unitRef="Unit_Milestone">1</kzia:NumberOfContingentMilestonePayments>
    <kzia:MilestonePaymentPayable
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">1394000</kzia:MilestonePaymentPayable>
    <kzia:MilestonePaymentDiscountRate
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_pure">0.15</kzia:MilestonePaymentDiscountRate>
    <kzia:MilestonePaymentDiscountRate
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_pure">0.35</kzia:MilestonePaymentDiscountRate>
    <kzia:MilestonePaymentsNotBooked
      contextRef="P07_01_2020To06_30_2021"
      decimals="0"
      unitRef="Unit_EUR">300500000</kzia:MilestonePaymentsNotBooked>
    <kzia:MilestonePaymentsNotBooked
      contextRef="P07_01_2020To06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">475474684</kzia:MilestonePaymentsNotBooked>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 16. Deferred tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liability associated with Licensing Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liability associated with Licensing Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,928&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</kzia:DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2928000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">3413000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 17. Equity - contributed equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 47%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares - fully paid&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132,012,209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;94,598,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;80,290,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,781,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Movements in Ordinary share capital &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Details&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issue&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1&#160;July 2019&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,166,673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;36,641,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1&#160;November&#160;2019&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;16&#160;April 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,041,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,216,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued under the Share Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;11&#160;May 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,390,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,756,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share issue transaction costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(833,052&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;30&#160;June 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;94,598,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,781,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;28 August 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.493&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Institutional placement under ANREO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;12 October 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,525,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,420,656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Retail placement under ANREO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;26 October 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,017,075&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,813,660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;2&#160;March 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;391,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;248,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;15&#160;March 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.493&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;28&#160;April 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,037,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,274,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on achievement of a milestone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;21&#160;May 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,391,865&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,400,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: share issue transaction costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,673,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;30&#160;June 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132,012,209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;80,290,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;buy-back&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;There is no current &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-market&lt;/div&gt; share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;buy-back.&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capital risk management &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity&#x2019;s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The capital risk management policy remains unchanged from the prior year. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 47%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares - fully paid&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132,012,209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;94,598,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;80,290,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,781,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">132012209</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">94598369</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">80290062</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn06_30_2020"
      decimals="0"
      unitRef="Unit_AUD">48781214</ifrs-full:IssuedCapital>
    <kzia:DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Movements in Ordinary share capital &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Details&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issue&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1&#160;July 2019&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,166,673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;36,641,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1&#160;November&#160;2019&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;16&#160;April 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,041,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,216,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued under the Share Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;11&#160;May 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,390,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,756,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share issue transaction costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(833,052&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;30&#160;June 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;94,598,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,781,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;28 August 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.493&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Institutional placement under ANREO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;12 October 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,525,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,420,656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Retail placement under ANREO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;26 October 2020&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,017,075&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,813,660&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;2&#160;March 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;391,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;248,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on conversion of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;15&#160;March 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.493&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;28&#160;April 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,037,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,274,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued on achievement of a milestone&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;21&#160;May 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,391,865&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,400,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: share issue transaction costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,673,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;30&#160;June 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132,012,209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;80,290,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</kzia:DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">62166673</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">36641519</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2019To06_30_2020_IssueDatedNovemberOneTwoThousandAndNineteenMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P11_01_2019To11_01_2019_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.400</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_IssueDatedNovemberOneTwoThousandAndNineteenMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">4000000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2019To06_30_2020_IssueDateSixteenthAprilTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_shares">18041667</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P04_16_2020To04_16_2020_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.400</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_IssueDateSixteenthAprilTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">7216667</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_shares">4390010</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P05_11_2020To05_11_2020_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.400</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePurchasePlanMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">1756004</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2019To06_30_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">19</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P06_30_2021To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">4.000</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">76</ifrs-full:IssueOfEquity>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P06_30_2021To06_30_2021_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.000</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2019To06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">-833052</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">94598369</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">48781214</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDateTwentyEightAugustTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P08_28_2020To08_28_2020_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.493</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDateTwentyEightAugustTwoThousandAndTwentyMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">12313</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">20525820</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P10_12_2020To10_12_2020_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.800</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_InstitutionalPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">16420656</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_shares">11017075</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P10_26_2020To10_26_2020_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.800</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_RetailPlacementUnderAnreoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">8813660</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedSecondMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">391500</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P03_02_2021To03_02_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.635</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedSecondMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">248661</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedFifteenthMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P03_15_2021To03_15_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.493</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_ConversionOfOptionsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_IssueDatedFifteenthMarchTwoThousandTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">12313</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_shares">3037580</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P04_28_2021To04_28_2021_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.407</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMemberKZIASharePurchasePlanIssueDateAxis_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">4274633</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_shares">2391865</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P05_21_2021To05_21_2021_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.421</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_IssuedOnAchievementOfAMilestoneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">3400000</ifrs-full:IssueOfEquity>
    <kzia:SharesIssuedPricePerShare1
      contextRef="P06_30_2021To06_30_2021_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.000</kzia:SharesIssuedPricePerShare1>
    <ifrs-full:IssueOfEquity
      contextRef="P07_01_2020To06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis_ShareIssueTransactionCostsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_AUD">-1673388</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      unitRef="Unit_shares">132012209</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_AUD">80290062</ifrs-full:Equity>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD_per_Share">0</ifrs-full:ParValuePerShare>
    <kzia:DisclosureOfOtherEquityExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 18. Equity - Other contributed equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible note - Triaxial&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;464,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;464,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On 4&#160;December 2014, the consolidated entity and the convertible note holder (&#x2018;Triaxial&#x2019;) signed a Convertible Note Deed Poll (&#x2018;Deed&#x2019;) which superseded the precedent Loan Agreement between Triaxial shareholders and the consolidated entity. The Deed extinguishes the liability created by the Loan Agreement and provides that the Convertible Notes will convert into a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-determined&lt;/div&gt; number of ordinary shares on the achievement of defined milestones established in the schedule of the Deed. Accordingly the convertible note has been reclassified as an equity instrument rather than debt instrument. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the Financial year ended 30&#160;June 2017, the Company reached two milestones triggering the conversion of a portion of its convertible note as follows; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022; On 11&#160;August 2016 the Company announced the submission of an IND application. On 10&#160;September 2016, the Company received a letter from the FDA advising the study may proceed triggering conversion of 20,000,000 ordinary shares. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022; On 31&#160;October 2016, the Company announced it had licensed a Phase II ready molecule triggering the conversion of 16,000,000 ordinary shares. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the financial year ended 30&#160;June 2018, a portion of the convertible notes was extinguished. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The remaining portion of the convertible note will be exercised at the holders&#x2019; discretion on completion of Phase II clinical trial or achieving Breakthrough Designation, and would convert to 1,856,000 ordinary shares if converted. Completion will be deemed to occur upon the receipt by the consolidated entity of a signed study report or notification of the designation. There is a possibility for an early conversion of the convertible notes if a third party acquires more than 50% of the issued capital of the consolidated entity.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;</kzia:DisclosureOfOtherEquityExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutOtherEquityExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible note - Triaxial&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;464,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;464,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</kzia:DisclosureOfDetailedInformationAboutOtherEquityExplanatory>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn09_14_2016"
      decimals="INF"
      unitRef="Unit_shares">20000000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <kzia:NumberOfOrdinarySharesAvailableForConversion
      contextRef="PAsOn10_31_2016"
      decimals="INF"
      unitRef="Unit_shares">16000000</kzia:NumberOfOrdinarySharesAvailableForConversion>
    <kzia:ConvertibleNoteRepresentsOrdinaryShares
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">1856000</kzia:ConvertibleNoteRepresentsOrdinaryShares>
    <kzia:PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes
      contextRef="P07_01_2016To06_30_2017"
      decimals="INF"
      unitRef="Unit_pure">0.50</kzia:PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes>
    <ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 19. Equity - reserves &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign currency translation reserve &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reserve is used to recognise exchange differences arising from translation of the financial statements of foreign operations to Australian dollars. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payments reserve &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reserve is used to recognise the value of equity benefits provided to employees and executive directors as part of their remuneration, and other parties as part of their compensation for services. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfDividendsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 20. Equity - dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no dividends paid, recommended or declared during the current or previous financial year. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDividendsExplanatory>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 21. Financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial risk management objectives &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity&#x2019;s activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The consolidated entity uses different methods to measure and manage the different types of risks to which it is exposed. These methods include monitoring the levels of exposure to interest rates and foreign exchange, ageing analysis and monitoring of specific credit allowances to manage credit risk, and, rolling cash flow forecasts to manage liquidity risk. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Market risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency risk &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollars (&#x2018;USD&#x2019;). Foreign exchange risk arises from future transactions and recognised assets and liabilities denominated in a currency that is not the entity&#x2019;s functional currency and net investments in foreign operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of 30&#160;June 2021, the consolidated entity did not hold derivative financial instruments in managing its foreign currency, however, the consolidated entity may from time to time enter into hedging arrangements where circumstances are deemed appropriate. The consolidated entity used natural hedging to reduce the foreign currency risk, which involved processing USD payments from cash held in USD. Foreign subsidiaries with a functional currency of Australian Dollars (&#x2018;AUD&#x2019;) have exposure to the local currency of these subsidiaries and any other currency these subsidiaries trade in. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amount of the consolidated entity&#x2019;s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US dollars&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euros&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity had net assets denominated in foreign currencies of A$17,608,845 as at 30&#160;June 2021 (2020: net liabilities A$1,923,831). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the AUD had strengthened against the USD by 10% (2020: 10%) then this would have had the following impact: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD strengthened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD weakened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect&#160;on&lt;br/&gt; profit&#160;before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect&#160;on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect&#160;on&lt;br/&gt; profit&#160;before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect&#160;on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US dollars&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euros&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD strengthened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD weakened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;% change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect on&lt;br/&gt; profit before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;% change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect on&lt;br/&gt; profit before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US dollars&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Price risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity is not exposed to any significant price risk. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest rate risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity&#x2019;s exposure to market interest rates relate primarily to the investments of cash balances. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has cash reserves held primarily in Australian dollars and United States dollars and places funds on deposit with financial institutions for periods generally not exceeding three months. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at the reporting date, the consolidated entity had the following variable interest rate balances: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash at bank and in hand&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short term deposits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net exposure to cash flow interest rate risk&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;27,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has cash and cash equivalents totalling $27,586,760 (2020: $8,764,044). An official increase/decrease in interest rates of 100 basis points (2020: 100 basis points) would have a favourable/adverse effect on profit before tax and equity of $275,867 (2020 $87,640) per annum. The percentage change is based on the expected volatility of interest rates using market data and analysts forecasts. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Credit risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The entity is not exposed to significant credit risk on receivables. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity has adopted a lifetime expected loss allowance in estimating expected credit losses to trade receivables through the use of a provisions matrix using fixed rates of credit loss provisioning. These provisions are considered representative across all customers of the consolidated entity based on recent sales experience, historical collection rates and forward-looking information that is available. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated entity places its cash deposits with high credit quality financial institutions and by policy, limits the amount of credit exposure to any single counter-party. The consolidated entity is averse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk, and reinvestment risk. The consolidated entity mitigates default risk by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no significant concentrations of credit risk within the consolidated entity. The credit risk on liquid funds is limited as the counter parties are banks with high credit ratings. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit risk is managed by limiting the amount of credit exposure to any single counter-party for cash deposits. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The consolidated entity manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities. In particular, contingent consideration may be satisfied either by payment of cash or by issue of shares, at the discretion of the entity. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Remaining contractual maturities &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables detail the consolidated entity&#x2019;s remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; interest&#160;rate&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#160;year&#160;or&#160;less&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Between&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#160;and&#160;2&#160;years&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Between&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&#160;and&#160;5&#160;years&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Over&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 years&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maturities&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-derivatives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-interest&lt;/div&gt; bearing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Weighted average&lt;br/&gt; interest&#160;rate&lt;br/&gt; %&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;1 year or less&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Between&lt;br/&gt; 1&#160;and&#160;2&#160;years&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Between&lt;br/&gt; 2 and 5 years&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Over&lt;br/&gt; 5&#160;years&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; maturities&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-derivatives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-interest&lt;/div&gt; bearing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,688&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amount of the consolidated entity&#x2019;s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US dollars&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euros&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;272&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">21073000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">272000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">3448000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">2196000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">16000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">21073000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">272000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">3464000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">2196000</ifrs-full:FinancialLiabilities>
    <ifrs-full:Assets
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="0"
      unitRef="Unit_AUD">17608845</ifrs-full:Assets>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="0"
      unitRef="Unit_AUD">1923831</ifrs-full:Liabilities>
    <ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the AUD had strengthened against the USD by 10% (2020: 10%) then this would have had the following impact: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD strengthened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD weakened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect&#160;on&lt;br/&gt; profit&#160;before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect&#160;on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect&#160;on&lt;br/&gt; profit&#160;before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect&#160;on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US dollars&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Euros&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="12" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD strengthened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AUD weakened&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;% change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect on&lt;br/&gt; profit before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;% change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect on&lt;br/&gt; profit before&lt;br/&gt; tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect on&lt;br/&gt; equity&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US dollars&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1762000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1762000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">-0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1762000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1762000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EURsrtCurrencyAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_EURsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">-0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_EURsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_EURsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1761000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis"
      decimals="-3"
      unitRef="Unit_AUD">-1761000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis"
      decimals="-3"
      unitRef="Unit_AUD">1761000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis"
      decimals="-3"
      unitRef="Unit_AUD">1761000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">192000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfIncreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">192000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_DecreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="INF"
      unitRef="Unit_pure">-0.10</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-192000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2020_CurrencyRiskMemberifrsfullTypesOfRisksAxis_EffectOfDecreaseInMarketRiskOnEquityMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-192000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at the reporting date, the consolidated entity had the following variable interest rate balances: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash at bank and in hand&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short term deposits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net exposure to cash flow interest rate risk&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;27,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory>
    <kzia:InterestRate
      contextRef="P07_01_2020To06_30_2021_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0000</kzia:InterestRate>
    <ifrs-full:Cash
      contextRef="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">21087000</ifrs-full:Cash>
    <kzia:InterestRate
      contextRef="P07_01_2019To06_30_2020_CashAtBankAndInHandMemberifrsfullClassesOfFinancialInstrumentsAxis_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_WeightedAverageMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0004</kzia:InterestRate>
    <ifrs-full:Cash
      contextRef="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">1264000</ifrs-full:Cash>
    <kzia:InterestRate
      contextRef="P07_01_2020To06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0004</kzia:InterestRate>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">6500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <kzia:InterestRate
      contextRef="P07_01_2019To06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis_ShortTermDepositsMemberifrsfullClassesOfFinancialInstrumentsAxis_WeightedAverageMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0095</kzia:InterestRate>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">7500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">27587000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn06_30_2020_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      unitRef="Unit_AUD">8764000</ifrs-full:FinancialAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">27586760</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="0"
      unitRef="Unit_AUD">8764044</ifrs-full:CashAndCashEquivalents>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2021_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="INF"
      unitRef="Unit_pure">1</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk
      contextRef="PAsOn06_30_2020_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="INF"
      unitRef="Unit_pure">1</kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2021_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="0"
      unitRef="Unit_AUD">275867</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="PAsOn06_30_2020_InterestRateRiskMemberifrsfullTypesOfRisksAxis"
      decimals="0"
      unitRef="Unit_AUD">87640</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; interest&#160;rate&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#160;year&#160;or&#160;less&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Between&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#160;and&#160;2&#160;years&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Between&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&#160;and&#160;5&#160;years&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Over&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 years&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maturities&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-derivatives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-interest&lt;/div&gt; bearing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Weighted average&lt;br/&gt; interest&#160;rate&lt;br/&gt; %&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;1 year or less&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Between&lt;br/&gt; 1&#160;and&#160;2&#160;years&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Between&lt;br/&gt; 2 and 5 years&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Over&lt;br/&gt; 5&#160;years&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; maturities&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-derivatives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-interest&lt;/div&gt; bearing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-derivatives&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,688&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <kzia:TradePayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1893000</kzia:TradePayablesUndiscountedCashFlows>
    <kzia:TradePayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1893000</kzia:TradePayablesUndiscountedCashFlows>
    <kzia:AccruedPayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">3039000</kzia:AccruedPayablesUndiscountedCashFlows>
    <kzia:AccruedPayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">3039000</kzia:AccruedPayablesUndiscountedCashFlows>
    <kzia:ContingentConsiderationUndiscountedCashFlows
      contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">3165000</kzia:ContingentConsiderationUndiscountedCashFlows>
    <kzia:ContingentConsiderationUndiscountedCashFlows
      contextRef="PAsOn06_30_2021_LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">9306000</kzia:ContingentConsiderationUndiscountedCashFlows>
    <kzia:ContingentConsiderationUndiscountedCashFlows
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">12471000</kzia:ContingentConsiderationUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">8097000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021_LaterThanTwoYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">9306000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">17403000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <kzia:TradePayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1694000</kzia:TradePayablesUndiscountedCashFlows>
    <kzia:TradePayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1694000</kzia:TradePayablesUndiscountedCashFlows>
    <kzia:AccruedPayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">1795000</kzia:AccruedPayablesUndiscountedCashFlows>
    <kzia:AccruedPayablesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1795000</kzia:AccruedPayablesUndiscountedCashFlows>
    <kzia:ContingentConsiderationUndiscountedCashFlows
      contextRef="PAsOn06_30_2020_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">4199000</kzia:ContingentConsiderationUndiscountedCashFlows>
    <kzia:ContingentConsiderationUndiscountedCashFlows
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">4199000</kzia:ContingentConsiderationUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">3489000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      unitRef="Unit_AUD">4199000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">7688000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 22. Fair value measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair value hierarchy &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables detail the consolidated entity&#x2019;s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Unobservable inputs for the asset or liability &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;1&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;2&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;3&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Total&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers between levels during the financial year. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the licence agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate. The estimated cashflows were adjusted based on the directors&#x2019; assessment of achieving contracted milestones as disclosed in Note 15. The probabilities used fell in the range of 35% to 55% and were informed by generally accepted industry probabilities of drugs achieving certain milestones in their progression towards registration. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Movements in level 3 assets and liabilities during the current and previous financial year are set out below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;3&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Available&lt;br/&gt; for sale&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Total&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidate&lt;div style="display:inline;"&gt;d&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 1&#160;July 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses recognised in profit or loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;475&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;475&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses recognised in profit or loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payout of milestone&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables detail the consolidated entity&#x2019;s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Unobservable inputs for the asset or liability &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;1&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;2&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;3&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Total&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated - 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</kzia:ContingentConsiderationNoncurrent>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</ifrs-full:Liabilities>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1845000</kzia:ContingentConsiderationNoncurrent>
    <kzia:ContingentConsiderationNoncurrent
      contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1845000</kzia:ContingentConsiderationNoncurrent>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1845000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1845000</ifrs-full:Liabilities>
    <kzia:MilestonePaymentDiscountRate
      contextRef="P07_01_2020To06_30_2021_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.35</kzia:MilestonePaymentDiscountRate>
    <kzia:MilestonePaymentDiscountRate
      contextRef="P07_01_2020To06_30_2021_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.55</kzia:MilestonePaymentDiscountRate>
    <kzia:DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Movements in level 3 assets and liabilities during the current and previous financial year are set out below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Level&#160;3&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Available&lt;br/&gt; for sale&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Total&lt;br/&gt; A$&#x2019;000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidate&lt;div style="display:inline;"&gt;d&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 1&#160;July 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses recognised in profit or loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;475&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;475&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses recognised in profit or loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payout of milestone&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at 30&#160;June 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1370000</kzia:FairValueOfAssetsAndLiabilities>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1370000</kzia:FairValueOfAssetsAndLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">475000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_AUD">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="P07_01_2019To06_30_2020_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">475000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1845000</kzia:FairValueOfAssetsAndLiabilities>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1845000</kzia:FairValueOfAssetsAndLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">2570000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">2570000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <kzia:PayoutOfMilestone
      contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">-3400000</kzia:PayoutOfMilestone>
    <kzia:PayoutOfMilestone
      contextRef="P07_01_2020To06_30_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">-3400000</kzia:PayoutOfMilestone>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</kzia:FairValueOfAssetsAndLiabilities>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis_FinancialAssetsAvailableforsaleCategoryMemberifrsfullCategoriesOfFinancialAssetsAxis"
      decimals="-3"
      unitRef="Unit_AUD">0</kzia:FairValueOfAssetsAndLiabilities>
    <kzia:FairValueOfAssetsAndLiabilities
      contextRef="PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis"
      decimals="-3"
      unitRef="Unit_AUD">1015000</kzia:FairValueOfAssetsAndLiabilities>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 23. Key management personnel disclosures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate compensation made to directors and other members of key management personnel (&#x2018;KMP&#x2019;) of the consolidated entity is set out below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term employee benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Please refer to Note 27 for other transactions with key management personnel and their related parties. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate compensation made to directors and other members of key management personnel (&#x2018;KMP&#x2019;) of the consolidated entity is set out below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term employee benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1574000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1324000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1176000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">112000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">97000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">84000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">617000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">230000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">125000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">2303000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1651000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1385000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 24. Remuneration of auditors &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the consolidated entity: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Audit services - Grant Thornton Audit Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Audit or review of the financial statements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;151&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;124&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the consolidated entity: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Audit services - Grant Thornton Audit Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Audit or review of the financial statements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;151&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;124&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;120&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">151000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">124000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">120000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemuneration
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">151000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">124000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">120000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 25. Contingent liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other than the contingent consideration set out in note 15, the consolidated entity does not have any other contingent liabilities. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 26. Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease commitments comprise contracted amounts for leases of premises. The agreement has a duration less than 12 months from financial year end. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 27. Related party transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parent entity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics Limited is the parent entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsidiaries &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interests in subsidiaries are set out in note 29. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Key management personnel &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disclosures relating to key management personnel are set out in note 23 and the remuneration report included in the directors&#x2019; report. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Transactions with related parties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There was no other transaction with KMP and their related parties. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Receivable from and payable to related parties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no trade receivables from or trade payables to related parties at the current and previous reporting date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Loans to/from related parties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no loans to or from related parties at the current and previous reporting date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Terms and conditions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All transactions were made on normal commercial terms and conditions and at market rates. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_AUD">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_AUD">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_AUD">0</ifrs-full:OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions>
    <ifrs-full:OutstandingCommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_AUD">0</ifrs-full:OutstandingCommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:DisclosureOfInterimFinancialReportingExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 28. Parent entity information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Set out below is the supplementary information about the parent entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Parent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of profit or loss and other comprehensive income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total comprehensive income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of financial position&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current asset&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,042&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,522&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contributed equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other contributed equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserves&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated losses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(50,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(34,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,012&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserves comprise Share Based Payments Reserve. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The parent entity contingent liabilities as at 30&#160;June 2021 and 30&#160;June 2020 are as set out in Note 15. The contingent consideration is specific to the parent entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital commitments - Property, plant and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The parent entity had no capital commitments for property, plant and equipment at as 30&#160;June 2021 and 30&#160;June 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInterimFinancialReportingExplanatory>
    <kzia:DisclosureOfParentEntityFinancialInformationExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Set out below is the supplementary information about the parent entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Parent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of profit or loss and other comprehensive income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total comprehensive income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;br/&gt; A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Statement of financial position&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current asset&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,042&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,522&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contributed equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other contributed equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserves&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated losses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(50,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(34,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,012&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </kzia:DisclosureOfParentEntityFinancialInformationExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">-16854000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">-11064000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">-16854000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P07_01_2019To06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">-11064000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">25042000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">9703000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">47044000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">22113000</ifrs-full:Assets>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">3177000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">1522000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">15032000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">5393000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">80290000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">48781000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherReserves
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">1754000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">1521000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">-50496000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">-34046000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">32012000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn06_30_2020_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      unitRef="Unit_AUD">16720000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 29. Interests in subsidiaries &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements incorporate the assets, liabilities and results of the following sub&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;idiaries in ac&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ordance with the accounting policy described in note 2: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ownership&#160;interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&#160;place&#160;of&#160;business&#160;/&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Country of incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Laboratories Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Australia&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Research Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Australia&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;United States of America&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Glioblast Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Australia&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics (Hong Kong) Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Hong Kong&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements incorporate the assets, liabilities and results of the following sub&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;idiaries in ac&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ordance with the accounting policy described in note 2: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ownership&#160;interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&#160;place&#160;of&#160;business&#160;/&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Country of incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Laboratories Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Australia&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Research Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Australia&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;United States of America&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Glioblast Pty Ltd&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Australia&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazia Therapeutics (Hong Kong) Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Hong Kong&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2019To06_30_2020_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2020To06_30_2021_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2019To06_30_2020_KaziaResearchPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">United States of America</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">United States of America</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2019To06_30_2020_KaziaTherapeuticsIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Australia</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2020To06_30_2021_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2019To06_30_2020_GlioblastPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Hong Kong</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Hong Kong</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P07_01_2020To06_30_2021_KaziaTherapeuticsHongKongLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="INF"
      unitRef="Unit_pure">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 30. Reconciliation of loss after income tax to net cash used in operating activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax expense from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments for:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&#160;&amp;amp; amortisatio&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of property, plant&#160;&amp;amp; equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net fair value loss on financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share based payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign exchange difference&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in operating assets&#160;&amp;amp; liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,067&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease in trade and other receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;825&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase in accrued revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease/(increase) in prepayment&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease/(increase) in trade and other payables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease in deferred tax liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(484&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase/(decrease) in other provisions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(8,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(6,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; transactions &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year the consolidated entity acquired a licensing agreement in relation to the asset EVT801. At year end no portion of the purchase price had been paid and accordingly the transaction does not appear in the cash flow statement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furthermore, the consolidated entity issued shares in satisfaction of an acquisition milestone. This transaction did not involve cash and accordingly the transaction does not appear in the cash flow statement. &lt;/div&gt;&lt;/div&gt;</kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock>
    <kzia:DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock contextRef="P07_01_2020To06_30_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax expense from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments for:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&#160;&amp;amp; amortisatio&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of property, plant&#160;&amp;amp; equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net fair value loss on financial assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share based payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign exchange difference&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in operating assets&#160;&amp;amp; liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,067&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease in trade and other receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;825&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase in accrued revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease/(increase) in prepayment&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease/(increase) in trade and other payables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease in deferred tax liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(484&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase/(decrease) in other provisions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(8,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(6,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </kzia:DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1265000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1084000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">1000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-168000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-1809000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">637000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">262000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">246000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">430000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-2570000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-474000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-63000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-3521000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-10479000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-7067000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-5027000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">358000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">825000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-138000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
    <kzia:AdjustmentsForDecreaseIncreaseInPrepayments
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-1182000</kzia:AdjustmentsForDecreaseIncreaseInPrepayments>
    <kzia:AdjustmentsForDecreaseIncreaseInPrepayments
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-168000</kzia:AdjustmentsForDecreaseIncreaseInPrepayments>
    <kzia:AdjustmentsForDecreaseIncreaseInPrepayments
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">398000</kzia:AdjustmentsForDecreaseIncreaseInPrepayments>
    <kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">1010000</kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables>
    <kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">1722000</kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables>
    <kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-409000</kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables>
    <kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-484000</kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities>
    <kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-298000</kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities>
    <kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-298000</kzia:AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">93000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">55000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-25000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-9111000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-8810000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-6714000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 31. Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax attributable to the owners of Kazia Therapeutics Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(8,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax attributable to the owners of Kazia Therapeutics Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(8,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of ordinary shares used in calculating basic earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,674,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,053,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,503,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of ordinary shares used in calculating Diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,674,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,053,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,503,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,865,000 unlisted convertible notes with a face value of A$464,000 and 4,446,500 unlisted options have been excluded from the above calculations as they were antidilutive. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="P07_01_2020To06_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax attributable to the owners of Kazia Therapeutics Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(8,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss after income tax attributable to the owners of Kazia Therapeutics Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(8,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(10,270&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of ordinary shares used in calculating basic earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,674,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,053,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,503,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of ordinary shares used in calculating Diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,674,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,053,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,503,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_AUD">-8422000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_AUD">-12467000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="P07_01_2018To06_30_2019"
      decimals="-3"
      unitRef="Unit_AUD">-10270000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">117674543</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P07_01_2019To06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">73053514</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P07_01_2018To06_30_2019"
      decimals="INF"
      unitRef="Unit_shares">57503555</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">117674543</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P07_01_2019To06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">73053514</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P07_01_2018To06_30_2019"
      decimals="INF"
      unitRef="Unit_shares">57503555</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-7.16</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.07</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P07_01_2018To06_30_2019"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.86</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P07_01_2020To06_30_2021"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-7.16</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P07_01_2019To06_30_2020"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.07</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P07_01_2018To06_30_2019"
      decimals="2"
      unitRef="Unit_AUD_per_Share">-17.86</ifrs-full:DilutedEarningsLossPerShare>
    <kzia:NumberOfOrdinarySharesAvailableForConversion
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">1865000</kzia:NumberOfOrdinarySharesAvailableForConversion>
    <ifrs-full:OtherEquityInterest
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">464000</ifrs-full:OtherEquityInterest>
    <kzia:NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare
      contextRef="P07_01_2020To06_30_2021_UnlistedOptionsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="INF"
      unitRef="Unit_shares">4446500</kzia:NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 32. Share-based payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $636,383 was recognised. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tranche&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; start&#160;of&#160;the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expired/&lt;br/&gt; lapsed on&lt;br/&gt; termination&lt;br/&gt; of&lt;br/&gt; employment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; end&#160;of&#160;the&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16/11/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941373"&gt;16/11/2020&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/09/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941591"&gt;05/09/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941375"&gt;17/10/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941376"&gt;01/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21/11/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941377"&gt;23/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;07/08/2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941378"&gt;07/08/2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;224,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(121,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(15,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;87,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/02/2018&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941379"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;440,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(120,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;320,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/01/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941380"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;37,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/11/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941381"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/01/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941382"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;09/11/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941383"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;09/11/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941384"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;800,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;800,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/01/2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941385"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,775,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(441,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(314,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,219,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="8" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.620&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.826&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No options were forfeited during the year. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of the period the following outstanding options were vested and exercisable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 1 have expired during the year &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;- Options in tranches &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-&lt;/div&gt; 8 were vested and exercisable except for tranche 6 which was vested as to 53% &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 9 were vested as to 1million of the 1.2million options on issue &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;- Options in tranches &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-12&lt;/div&gt; were 25% vested &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 13 were unvested at year end &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average remaining contractual life of options outstanding at the 30&#160;June 2021 is 2.6 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tranche&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; start&#160;of&#160;the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Modified&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; end&#160;of&#160;the&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/03/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941600"&gt;16/12/2019&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(46,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/03/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941602"&gt;18/12/2019&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,952&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(19,952&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24/06/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941603"&gt;30/06/2020&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;519,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(519,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16/11/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941605"&gt;16/11/2020&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18/03/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941606"&gt;01/02/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;300,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(300,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18/03/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941607"&gt;01/02/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18/03/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941608"&gt;01/02/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/09/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941609"&gt;05/09/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941610"&gt;17/10/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941611"&gt;01/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21/11/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941612"&gt;23/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;07/08/2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941613"&gt;07/08/2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;224,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;224,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/02/2018&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941585"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;440,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;440,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/01/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941586"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/11/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941587"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/01/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941588"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,660,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;450,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(585,599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,775,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td colspan="8" style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average exercise price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of the period the following outstanding options were vested and exercisable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranches 4, 8, 10, 11 and 13 were vested and exercisable &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 16 were unvested &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in the other tranches were vested as follows: 9: 75%, 12: 50% 14: 50% and 15: 67%. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All remaining options are expected to vest in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average remaining contractual life of options outstanding at the 30&#160;June 2020 is 2.78 years. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee share options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended 30&#160;June 2021, 2,200,000 options have been issued to the employees by the consolidated entity pursuant to the Company&#x2019;s Employee Share Option Plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Tranche 11 vests in four equal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6-monthly&lt;/div&gt; tranches from 1&#160;January 2021 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tranche 12 vests in four equal annual amounts from 13&#160;January 2021 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tranche 13 vests in four equal annual tranches from 4&#160;January 2022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options within all tranches will only vest if the option holder continues to be a full-time employee with the Company or an Associated Company during the vesting period relating to the option. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conditions for an option to be exercised: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The option must have vested. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option holder must have provided the Company with an Exercise Notice and have paid the Exercise Price for the option. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Exercise Notice must be for the exercise of at least the Minimum Number of Options; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Exercise Notice must have been provided to the Company and Exercise Price paid before the expiry of 5 years from the date the Option is issued. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Options Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to obtain a fair valuation of these options, the following assumptions have been made: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Black Scholes option valuation methodology has been used with the expectation that the majority of these options would be exercised towards the end of the option term. Inputs into the Black Scholes model includes the share price at grant date, exercise price, volatility, and the risk free rate of a five year Australian Government Bond on grant date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-free rate and grant date &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For all tranches, the risk-free rate of a five-year Australian Government bond on grant date was used. Please refer to the table below for details. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options in Tranches 1 to 13 have various vesting periods and exercising conditions. These options are unlisted as at 30&#160;June 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No dividends are expected to be declared or paid by the consolidated entity during the terms of the options. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underlying expected volatility was determined by reference to historical data of the Company&#x2019;s shares over a period of time. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No special features inherent to the options granted were incorporated into measurement of fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the above assumptions, the table below sets out the valuation for each tranche of options: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 10%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 11%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share&#160;price&lt;br/&gt; at&lt;br/&gt; Grant&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Volatility&lt;br/&gt; (%)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Life&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Risk&#160;free&lt;br/&gt; Rate&#160;(%)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;br/&gt; per&#160;option&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;05/09/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941445"&gt;05/09/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.105&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.630&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.60%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.840&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12/10/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941446"&gt;17/10/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.098&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.560&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.89%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.780&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31/10/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941447"&gt;01/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.090&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.87%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.720&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21/11/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941448"&gt;23/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.092&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.730&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;07/08/2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941449"&gt;07/08/2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.430&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.670&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.08&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.206&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;05/02/2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941592"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.500&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.780&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.200&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941451"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.340&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$&lt;span style="-sec-ix-hidden:hidden26941594"&gt;0.493&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.140&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13/11/2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941452"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.410&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$&lt;span style="-sec-ix-hidden:hidden26941595"&gt;0.493&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.180&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13/01/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941453"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.620&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.340&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941454"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.379&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941455"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.403&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941456"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.60&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.425&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941457"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.446&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941458"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.450&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941459"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.70&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.490&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941460"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.520&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941461"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.70&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.550&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941368"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.520&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941369"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.00&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.576&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941371"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.627&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941372"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.00&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.671&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $636,383 was recognised. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tranche&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; start&#160;of&#160;the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expired/&lt;br/&gt; lapsed on&lt;br/&gt; termination&lt;br/&gt; of&lt;br/&gt; employment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; end&#160;of&#160;the&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16/11/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941373"&gt;16/11/2020&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/09/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941591"&gt;05/09/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941375"&gt;17/10/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941376"&gt;01/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21/11/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941377"&gt;23/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;07/08/2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941378"&gt;07/08/2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;224,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(121,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(15,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;87,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/02/2018&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941379"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;440,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(120,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;320,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/01/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941380"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;37,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/11/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941381"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/01/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941382"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;09/11/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941383"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;09/11/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941384"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;800,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;800,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/01/2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941385"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,775,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(441,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(314,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,219,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="8" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.620&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.826&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No options were forfeited during the year. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of the period the following outstanding options were vested and exercisable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 1 have expired during the year &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;- Options in tranches &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-&lt;/div&gt; 8 were vested and exercisable except for tranche 6 which was vested as to 53% &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 9 were vested as to 1million of the 1.2million options on issue &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;- Options in tranches &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-12&lt;/div&gt; were 25% vested &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 13 were unvested at year end &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average remaining contractual life of options outstanding at the 30&#160;June 2021 is 2.6 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tranche&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; start&#160;of&#160;the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Modified&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;the&lt;br/&gt; end&#160;of&#160;the&#160;year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/03/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941600"&gt;16/12/2019&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(46,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/03/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941602"&gt;18/12/2019&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,952&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(19,952&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24/06/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941603"&gt;30/06/2020&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;519,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(519,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16/11/2015&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941605"&gt;16/11/2020&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;236,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18/03/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941606"&gt;01/02/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;300,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(300,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18/03/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941607"&gt;01/02/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18/03/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941608"&gt;01/02/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/09/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941609"&gt;05/09/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941610"&gt;17/10/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;62,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31/10/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941611"&gt;01/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21/11/2016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941612"&gt;23/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;07/08/2017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941613"&gt;07/08/2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;224,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;224,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;05/02/2018&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941585"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;440,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;440,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;04/01/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941586"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/11/2019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941587"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13/01/2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941588"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,660,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;450,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(585,599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,775,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td colspan="8" style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average exercise price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of the period the following outstanding options were vested and exercisable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranches 4, 8, 10, 11 and 13 were vested and exercisable &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in tranche 16 were unvested &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Options in the other tranches were vested as follows: 9: 75%, 12: 50% 14: 50% and 15: 67%. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All remaining options are expected to vest in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average remaining contractual life of options outstanding at the 30&#160;June 2020 is 2.78 years. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P07_01_2020To06_30_2021"
      decimals="0"
      unitRef="Unit_AUD">636383</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">16/11/2015</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">2.200</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">236667</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">236667</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/09/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.630</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">12/10/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.560</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">62000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">62000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">31/10/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.380</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">12500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">12500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">21/11/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.380</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">07/08/2017</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.670</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">224000</ifrs-full:NumberOfOutstandingShareOptions>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">-121500</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">15500</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">87000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/02/2018</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.780</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">440000</ifrs-full:NumberOfOutstandingShareOptions>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">-120000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">320000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2019</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.492</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">-200000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">12500</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">37500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/11/2019</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.492</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">1200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">1200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/01/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.132</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">1200000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheSeventeenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">1200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">800000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheEighteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">800000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.690</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">200000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021_TrancheNineteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_pure">2775167</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_pure">2200000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_pure">-441500</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_pure">314667</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_pure">4219000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn06_30_2020"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.797</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P07_01_2020To06_30_2021"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.090</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <kzia:WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021"
      decimals="3"
      unitRef="Unit_AUD">0.620</kzia:WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P07_01_2020To06_30_2021"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.850</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn06_30_2021"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.826</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <kzia:PercentageOfOptionsVested
      contextRef="P07_01_2020To06_30_2021_TranchesTwoAndEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.53</kzia:PercentageOfOptionsVested>
    <kzia:NumberOfOptionsVested
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_shares">1000000</kzia:NumberOfOptionsVested>
    <kzia:NumberOfOptionsIssued
      contextRef="PAsOn06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-5"
      unitRef="Unit_shares">1200000</kzia:NumberOfOptionsIssued>
    <kzia:PercentageOfOptionsVested
      contextRef="P07_01_2020To06_30_2021_TranchesTenAndTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</kzia:PercentageOfOptionsVested>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P07_01_2020To06_30_2021">P2Y7M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/03/2015</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.500</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">46647</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">46647</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/03/2015</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.500</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">19952</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">19952</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">24/06/2015</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">4.000</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">519000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">519000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">16/11/2015</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">2.200</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">236667</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">236667</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">18/03/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.990</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">300000</ifrs-full:NumberOfOutstandingShareOptions>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">-300000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">18/03/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.990</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">200000</ifrs-full:NumberOfOutstandingShareOptions>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheSixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">-200000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">18/03/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">2.610</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheSevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">-250000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/09/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.630</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">12/10/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.560</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">62000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">62000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">31/10/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.380</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">12500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">12500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">21/11/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">1.380</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">50000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">07/08/2017</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.670</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">224000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">224000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/02/2018</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.780</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">440000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">440000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2019</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.492</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/11/2019</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.492</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">1200000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">1200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/01/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2019"
      decimals="INF"
      unitRef="Unit_pure">2660766</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020"
      decimals="INF"
      unitRef="Unit_pure">250000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020"
      decimals="INF"
      unitRef="Unit_pure">450000</kzia:NumberOfShareOptionsModifiedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020"
      decimals="INF"
      unitRef="Unit_pure">585599</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_pure">2775167</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn06_30_2019"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.960</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P07_01_2019To06_30_2020"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.880</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <kzia:WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement
      contextRef="P07_01_2019To06_30_2020"
      decimals="3"
      unitRef="Unit_AUD">2.348</kzia:WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P07_01_2019To06_30_2020"
      decimals="3"
      unitRef="Unit_AUD_per_Share">3.716</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn06_30_2020"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.797</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <kzia:NumberOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">9</kzia:NumberOfOptionsVested>
    <kzia:PercentageOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_OtherTrancheOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</kzia:PercentageOfOptionsVested>
    <kzia:NumberOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">12</kzia:NumberOfOptionsVested>
    <kzia:PercentageOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_OtherTrancheTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</kzia:PercentageOfOptionsVested>
    <kzia:NumberOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">14</kzia:NumberOfOptionsVested>
    <kzia:PercentageOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_OtherTrancheThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</kzia:PercentageOfOptionsVested>
    <kzia:NumberOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_BottomOfRangeMemberifrsfullRangeAxis_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">15</kzia:NumberOfOptionsVested>
    <kzia:PercentageOfOptionsVested
      contextRef="P07_01_2019To06_30_2020_OtherTrancheFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.67</kzia:PercentageOfOptionsVested>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="P07_01_2019To06_30_2020">P2Y9M10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P07_01_2020To06_30_2021"
      decimals="0"
      unitRef="Unit_shares">2200000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the above assumptions, the table below sets out the valuation for each tranche of options: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 10%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 12%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 11%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share&#160;price&lt;br/&gt; at&lt;br/&gt; Grant&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Volatility&lt;br/&gt; (%)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Life&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Risk&#160;free&lt;br/&gt; Rate&#160;(%)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;br/&gt; per&#160;option&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;05/09/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941445"&gt;05/09/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.105&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.630&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.60%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.840&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12/10/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941446"&gt;17/10/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.098&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.560&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.89%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.780&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31/10/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941447"&gt;01/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.090&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.87%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.720&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21/11/2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941448"&gt;23/11/2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.092&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.380&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.730&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;07/08/2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941449"&gt;07/08/2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.430&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.670&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.08&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.206&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;05/02/2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941592"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.500&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.780&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.58&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.200&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941451"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.340&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$&lt;span style="-sec-ix-hidden:hidden26941594"&gt;0.493&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.140&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13/11/2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941452"&gt;04/01/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.410&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$&lt;span style="-sec-ix-hidden:hidden26941595"&gt;0.493&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.180&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13/01/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941453"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.620&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;74.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.340&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941454"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.379&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941455"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.403&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941456"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.60&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.425&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941457"&gt;09/11/2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.132&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.446&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941458"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.450&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941459"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.70&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.490&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941460"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.20&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.520&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;09/11/2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941461"&gt;13/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.890&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.881&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.70&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.550&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941368"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.520&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941369"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.00&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.576&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941371"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.50&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.627&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;04/01/2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden26941372"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.185&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$1.169&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#160;&#160;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.00&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.19%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;$0.671&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/09/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.105</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.630</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">1.2200</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">1.16</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0160</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.840</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">12/10/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.098</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.560</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">1.2200</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">1.29</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0189</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.780</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">31/10/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.090</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.380</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">1.2200</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">1.20</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0187</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.720</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">21/11/2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.092</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.380</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">1.2200</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">1.20</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0210</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheElevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.730</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">07/08/2017</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.430</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.670</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7450</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.08</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwelveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.206</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">05/02/2018</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.500</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.780</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7450</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.58</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheThirteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.200</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2019</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.340</kzia:SharePricePerShare>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7450</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">3.50</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheFourteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.140</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/11/2019</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.410</kzia:SharePricePerShare>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7450</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">4.20</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheFifteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.180</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">13/01/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.620</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.7450</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">4.50</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0195</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheSixteenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.340</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.132</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.379</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.132</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.30</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.403</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.132</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.60</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyTwoMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.425</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.132</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.80</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyThreeMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.446</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.20</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyFourMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.450</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.70</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyFiveMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.490</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">3.20</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentySixMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.520</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">09/11/2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.890</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">0.881</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">3.70</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentySevenMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.550</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.185</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.169</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">2.50</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.520</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.185</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.169</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">3.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheTwentyNineMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.576</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.185</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.169</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">3.50</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheThirtyMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.627</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">04/01/2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <kzia:SharePricePerShare
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.185</kzia:SharePricePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_AUD_per_Share">1.169</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="2"
      unitRef="Unit_Y">4.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P07_01_2020To06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="4"
      unitRef="Unit_pure">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn06_30_2021_TrancheThirtyOneMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="3"
      unitRef="Unit_USD">0.671</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="P07_01_2020To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 33. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no significant events subsequent to the reporting date&lt;div style="display:inline;"&gt;.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306276792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Kazia Therapeutics Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001075880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Three International Towers Level 24, 300 Barangaroo Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sydney<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">132,012,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-29962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing ten Ordinary Shares*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KZIA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Gabrielle Heaton<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">Gabrielle.Heaton@kaziatherapeutics.com<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Three International Towers Level 24, 300 Barangaroo Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sydney<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">9472-4101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306141336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of profit or loss and other comprehensive income - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Revenue from continuing operations</a></td>
<td class="nump">$ 15,183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other income</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 995,000<span></span>
</td>
<td class="nump">$ 1,465,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income - bank interest</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(14,541,000)<span></span>
</td>
<td class="num">(9,494,000)<span></span>
</td>
<td class="num">(6,475,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="num">(7,022,000)<span></span>
</td>
<td class="num">(3,690,000)<span></span>
</td>
<td class="num">(3,785,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Fair value losses on financial assets at fair value through profit or loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(168,000)<span></span>
</td>
<td class="num">(1,809,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_GainLossOnRevaluationOfContingentConsideration', window );">Loss on revaluation of contingent consideration</a></td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(474,000)<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax expense from continuing operations</a></td>
<td class="num">(8,906,000)<span></span>
</td>
<td class="num">(12,765,000)<span></span>
</td>
<td class="num">(10,568,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">484,000<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="num">(8,421,960)<span></span>
</td>
<td class="num">(12,467,466)<span></span>
</td>
<td class="num">(10,270,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified subsequently to profit or loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Net exchange difference on translation of financial statements of foreign controlled entities, net of tax</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(89,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the year, net of tax</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(89,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="num">(8,420,000)<span></span>
</td>
<td class="num">(12,471,000)<span></span>
</td>
<td class="num">(10,359,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Loss for the year is attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of Kazia Therapeutics Limited</a></td>
<td class="num">(8,422,000)<span></span>
</td>
<td class="num">(12,467,000)<span></span>
</td>
<td class="num">(10,270,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="num">(8,421,960)<span></span>
</td>
<td class="num">(12,467,466)<span></span>
</td>
<td class="num">(10,270,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Total comprehensive income for the year is attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of Kazia Therapeutics Limited</a></td>
<td class="num">(8,420,000)<span></span>
</td>
<td class="num">(12,471,000)<span></span>
</td>
<td class="num">(10,359,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="num">$ (8,420,000)<span></span>
</td>
<td class="num">$ (12,471,000)<span></span>
</td>
<td class="num">$ (10,359,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract', window );"><strong>Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share</a></td>
<td class="num">$ (7.16)<span></span>
</td>
<td class="num">$ (17.07)<span></span>
</td>
<td class="num">$ (17.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share</a></td>
<td class="num">(7.16)<span></span>
</td>
<td class="num">(17.07)<span></span>
</td>
<td class="num">(17.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share</a></td>
<td class="num">(7.16)<span></span>
</td>
<td class="num">(17.07)<span></span>
</td>
<td class="num">(17.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share</a></td>
<td class="num">$ (7.16)<span></span>
</td>
<td class="num">$ (17.07)<span></span>
</td>
<td class="num">$ (17.86)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on disposals of non-current assets. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and Diluted Earnings Per Share Continuing Operations [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_GainLossOnRevaluationOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on revaluation of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_GainLossOnRevaluationOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305650648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of financial position - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,586,760<span></span>
</td>
<td class="nump">$ 8,764,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">1,352,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other</a></td>
<td class="nump">1,720,000<span></span>
</td>
<td class="nump">537,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">29,391,000<span></span>
</td>
<td class="nump">10,653,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">6,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">22,003,000<span></span>
</td>
<td class="nump">12,410,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">28,697,000<span></span>
</td>
<td class="nump">12,410,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">58,088,000<span></span>
</td>
<td class="nump">23,063,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">4,933,000<span></span>
</td>
<td class="nump">3,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">229,000<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationCurrent', window );">Contingent consideration</a></td>
<td class="nump">3,165,000<span></span>
</td>
<td class="nump">1,387,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">8,327,000<span></span>
</td>
<td class="nump">5,067,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax</a></td>
<td class="nump">2,928,000<span></span>
</td>
<td class="nump">3,413,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">8,927,000<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">11,910,000<span></span>
</td>
<td class="nump">3,871,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,237,000<span></span>
</td>
<td class="nump">8,938,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="nump">37,851,000<span></span>
</td>
<td class="nump">14,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Contributed equity</a></td>
<td class="nump">80,290,062<span></span>
</td>
<td class="nump">48,781,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Other contributed equity</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,301,000<span></span>
</td>
<td class="nump">1,066,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(44,204,000)<span></span>
</td>
<td class="num">(36,186,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to the owners of Kazia Therapeutics Limited</a></td>
<td class="nump">37,851,000<span></span>
</td>
<td class="nump">14,125,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">$ 37,851,000<span></span>
</td>
<td class="nump">$ 14,125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG63<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304643464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of changes in equity - AUD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Contributed equity [member]</div></th>
<th class="th"><div>Other Contributed equity [member]</div></th>
<th class="th"><div>Reserves [member]</div></th>
<th class="th"><div>Accumulated Losses [member]</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance (Previously stated [member]) at Jun. 30, 2018</a></td>
<td class="nump">$ 19,242,000<span></span>
</td>
<td class="nump">$ 31,576,000<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="nump">$ 1,843,000<span></span>
</td>
<td class="num">$ (14,641,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance (Increase (decrease) due to changes in accounting policy [member]) at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="nump">19,242,000<span></span>
</td>
<td class="nump">31,576,000<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
<td class="num">(14,678,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="num">(10,270,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,270,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the year, net of tax</a></td>
<td class="num">(89,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(89,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="num">(10,359,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(89,000)<span></span>
</td>
<td class="num">(10,270,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(340,000)<span></span>
</td>
<td class="num">(340,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Transfers</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">246,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="nump">5,406,000<span></span>
</td>
<td class="nump">5,406,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">14,195,000<span></span>
</td>
<td class="nump">36,641,519<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">2,037,000<span></span>
</td>
<td class="num">(24,948,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="num">(12,467,466)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,467,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the year, net of tax</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="num">(12,471,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(12,467,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(833,000)<span></span>
</td>
<td class="num">(833,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Transfers</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of convertible note</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions', window );">Employee share-based payment options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">262,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="nump">12,972,000<span></span>
</td>
<td class="nump">12,972,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_IncreaseDecreaseThroughExpireOfOptions', window );">Expired options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,230,000)<span></span>
</td>
<td class="nump">1,230,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">14,125,000<span></span>
</td>
<td class="nump">48,781,214<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">1,066,000<span></span>
</td>
<td class="num">(36,186,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="num">(8,421,960)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,422,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the year, net of tax</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income for the year</a></td>
<td class="num">(8,420,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="num">(8,422,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Contributions of equity, net of transaction costs</a></td>
<td class="nump">32,909,000<span></span>
</td>
<td class="nump">32,909,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(1,673,000)<span></span>
</td>
<td class="num">(1,673,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Transfers</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of convertible note</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions', window );">Employee share-based payment options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">637,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">637,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="nump">273,000<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_IncreaseDecreaseThroughExpireOfOptions', window );">Expired options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(323,000)<span></span>
</td>
<td class="nump">323,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 37,851,000<span></span>
</td>
<td class="nump">$ 80,290,062<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="nump">$ 1,301,000<span></span>
</td>
<td class="num">$ (44,204,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through employee share-based payment options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_IncreaseDecreaseThroughExpireOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through expire of Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_IncreaseDecreaseThroughExpireOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307147256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of cash flows - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss before income tax expense for the year</a></td>
<td class="num">$ (8,421,960)<span></span>
</td>
<td class="num">$ (12,467,466)<span></span>
</td>
<td class="num">$ (10,270,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortisation</a></td>
<td class="nump">1,265,000<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NetLossOnDisposalOfNonCurrentAssets', window );">Net loss on disposal of non-current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payments</a></td>
<td class="nump">637,000<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange differences</a></td>
<td class="nump">430,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Loss/(gain) on contingent consideration</a></td>
<td class="nump">2,570,000<span></span>
</td>
<td class="nump">474,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets', window );">Fair value loss on financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">1,809,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows from used in operations before changes in working capital</a></td>
<td class="num">(3,521,000)<span></span>
</td>
<td class="num">(10,479,000)<span></span>
</td>
<td class="num">(7,067,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Increase in trade and other receivables</a></td>
<td class="num">(5,027,000)<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdjustmentsForDecreaseIncreaseInPrepayments', window );">Increase/(decrease) in prepayments</a></td>
<td class="num">(1,182,000)<span></span>
</td>
<td class="num">(168,000)<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase/(decrease) in trade and other payables</a></td>
<td class="nump">1,010,000<span></span>
</td>
<td class="nump">1,722,000<span></span>
</td>
<td class="num">(409,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Increase/(decrease) in other provisions</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities', window );">Decrease in deferred tax liability</a></td>
<td class="num">(484,000)<span></span>
</td>
<td class="num">(298,000)<span></span>
</td>
<td class="num">(298,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Increase/(decrease) in accrued revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,111,000)<span></span>
</td>
<td class="num">(8,810,000)<span></span>
</td>
<td class="num">(6,714,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInterestsInAssociates', window );">Proceeds from disposal of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,359,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,359,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issue of shares</a></td>
<td class="nump">28,109,000<span></span>
</td>
<td class="nump">12,139,000<span></span>
</td>
<td class="nump">3,816,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="nump">28,109,000<span></span>
</td>
<td class="nump">12,139,000<span></span>
</td>
<td class="nump">3,816,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">18,998,000<span></span>
</td>
<td class="nump">3,329,000<span></span>
</td>
<td class="num">(539,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the financial year</a></td>
<td class="nump">8,764,044<span></span>
</td>
<td class="nump">5,434,000<span></span>
</td>
<td class="nump">5,956,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the financial year</a></td>
<td class="nump">$ 27,586,760<span></span>
</td>
<td class="nump">$ 8,764,044<span></span>
</td>
<td class="nump">$ 5,434,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_a_ii&amp;doctype=Standard&amp;book=b<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInterestsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of interests in associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInterestsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdjustmentsForDecreaseIncreaseInPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdjustmentsForDecreaseIncreaseInPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net changes in operating assets &amp; liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NetLossOnDisposalOfNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss on disposal of non current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NetLossOnDisposalOfNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305535576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1. General information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements cover Kazia Therapeutics Limited as a consolidated entity consisting of Kazia Therapeutics Limited and its subsidiaries. The financial statements are presented in Australian dollars, which is Kazia Therapeutics Limited&#8217;s functional and presentation currency. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three International Towers </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;24, 300 Barangaroo Avenue </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sydney NSW 2000 </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">T</div>h<div style="display:inline;">e</div> financial statements were authorised for issue, in accordance with a resolution of Directors, on 7&#160;October 2021. The Directors have the power to amend and reissue the financial statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304746536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant accounting policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2. Significant accounting policies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New or amended Accounting Standards and Interpretations adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (&#8216;IASB&#8217;) that are mandatory for the current reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Standards and Interpretations not yet mandatory or early adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30&#160;June 2021. The consolidated entity&#8217;s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going concern </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity incurred a loss after income tax of $8,421,960 (2020: $12,467,466), was in a net current asset position of $21,064,264(2020: net current asset position of $5,586,128) and had net cash outflows from operating activities of $<span style="-sec-ix-hidden:hidden26941709">9,110,516</span>(2020: $<span style="-sec-ix-hidden:hidden26941597">8,809,519</span>) for the year ended 30&#160;June 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at 30&#160;June 2021 the consolidated entity had cash in hand and at bank of $27,586,760. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. In particular, the directors have considered the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the operations of the Company, and make the following observations: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Kazia&#8217;s key clinical trials have not been impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to date. The GBM Agile study, the pivotal study for paxalisib in glioblastoma, is on track with recruitment running to plan, and no disruption to this schedule is foreseen. The Phase II study of paxalisib in glioblastoma was fully recruited prior to the onset of restrictions and is in wrap up stage at the date of this report. Plans are on track for the commencement of a Phase I trial for EVT801 before the end of 2021; </div> </td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr>
<td style="width: 3%; vertical-align: top;;text-align:left;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="width: 1%; vertical-align: top;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, clinical research in advanced cancer is relatively protected from pandemic disruption due to the ongoing and time-critical need for patient care in specialised facilities that cannot easily be repurposed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not reliant on ongoing revenue from customers, and so changes in customer behaviour over the next several years due to public health restrictions and reduced economic activity have little to no impact on its finances; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Company was able to secure funding of approximately $9&#160;million at the height of the initial wave of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> in April 2020, and additional funds of approximately $25&#160;million during the 2021 financial year; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on budgets and forecasts, the Company has sufficient cash to fund the operations for a period of at least 12 months from the date of this report; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">As a consequence the directors do not foresee any other impacts on the Company&#8217;s ability to raise additional funding as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of preparation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (&#8216;<div style="letter-spacing: 0px; top: 0px;;display:inline;">AASB</div>&#8217;) and the Corporations Act 2001, as appropriate for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-profit</div> oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8216;IASB&#8217;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for listed equity investments which are carried at fair value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical accounting estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity&#8217;s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent entity information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 28. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (&#8216;company&#8217; or &#8216;parent entity&#8217;) as at 30&#160;June 2021 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the &#8216;consolidated entity&#8217;. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-consolidated</div> from the date that control ceases. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are presented using the &#8216;management approach&#8217;, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (&#8216;CODM&#8217;). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements are presented in Australian dollars, which is the consolidated entity&#8217;s functional and presentation currency. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign currency transactions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign operations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foreign currency reserve is recognised in profit or loss when the foreign operation is disposed of. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange differences arising on a monetary item that forms part of a reporting entity&#8217;s net investment in a foreign operation shall be recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recognition and derecognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below. Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and substantially all the risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and initial measurement of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with IFRS&#160;15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsequent measurement of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial assets at amortised cost </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial assets at fair value through profit or loss (FVPL) </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Classifications are determined by both: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The entity&#8217;s business model for managing the financial asset </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The contractual cash flow characteristics of the financial assets </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial assets at amortised cost </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group&#8217;s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial assets at fair value through profit or loss (FVPL) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets that are held within a business model other than &#8216;hold to collect&#8217; or &#8216;hold to collect and sell&#8217; are categorised at fair value through profit and loss. Further, irrespective of business model, financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.&#160;The Group&#8217;s investments in equity instruments and derivatives fall under this category. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IFRS 9&#8217;s new impairment model uses more forward looking information to recognize expected credit losses&#8212;the &#8216;expected credit losses (ECL) model&#8217;. The application of the new impairment model depends on whether there has been a significant increase in credit risk.&#160;The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In applying this forward-looking approach, a distinction is made between: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk (&#8216;Stage 1&#8217;) and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low (&#8216;Stage 2&#8217;). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8216;Stage 3&#8217; would cover financial assets that have objective evidence of impairment at the reporting date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;12-month</div> expected credit losses&#8217; are recognised for the first category while &#8216;lifetime expected credit losses&#8217; are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and measurement of financial liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s financial liabilities comprise trade and other payables. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All interest-related charges and, if applicable, changes in an instrument&#8217;s fair value that are reported in profit or loss are included within finance costs or finance income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from contracts with customers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognised using a five step approach in accordance with IFRS&#160;15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognised when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognised as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognised as revenue within the 12 months following the balance sheet date are classified within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues, including milestone revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the consolidated entity&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the licence is transferred to the customer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Finance Income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue is recognised when it is received or when the right to receive payment is established. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The R&amp;D Tax Incentive is a government program which helps to offset some of the incurred costs of R&amp;D. Eligible expenditure incurred under the scheme in a financial year attracts an additional 43.5% tax deduction, and for a group earning income of less than $20&#160;million, the cash value of the additional deduction is remitted to the taxpayer. In accordance with IAS&#160;20, as the compensation relates to expenses already incurred, it is recognised in profit or loss of the period in which it becomes receivable. Accordingly the group accounts for the R&amp;D Tax Incentive in the same year as the expenses to which it relates. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax expense or benefit for the period is the tax payable on that period&#8217;s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amount of recognised and unrecognised deferred tax assets are reviewed each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited (the &#8216;parent entity&#8217;) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the &#8216;separate taxpayer in the group&#8217; allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interpretation 23 Uncertain tax positions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interpretation 23 clarified the application of the recognition and measurement criteria IAS&#160;12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Judgments are reassessed as and when new facts and circumstances are presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assets and liabilities are presented in the statement of financial position based on current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred tax assets and liabilities are always classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under IFRS&#160;16, leases are accounted for as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Depreciation on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and interest on lease liabilities are recognised in the consolidated statement of profit or loss; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total amount of cash paid under lease arrangements is separated into a principal portion (presented within financing activities) and interest (presented within operating activities) in the consolidated cash flow statement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lease incentives under IFRS 16 are recognised as part of the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;">Under IFRS&#160;16, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are tested for impairment in accordance with IAS 36 Impairment of assets. This replaces the previous requirement to recognise a provision for onerous lease contracts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For short-term leases (lease term of 12 months or less) and leases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets, the consolidated entity has opted to recognise a lease expense on a straight-line basis as permitted by IFRS&#160;16 Leases. This expense is presented within other expenses in the consolidated statement of profit or loss. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing agreement for paxalisib </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Licensing Agreement asset was initially brought to account at fair value, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 15 years from the date of acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing agreement for EVT801 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Licensing agreement asset was initially brought to account at cost and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 12.5 years from the date of acquisition. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> assets with finite useful lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-in-use.</div></div> The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-in-use</div></div> is the present value of the estimated future cash flows relating to the asset using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compound financial instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortised cost using the effective interest rate method, whereas the equity component is not remeasured. Interest, gains and losses relating to the financial liability are recognised in profit or loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognised on conversion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Short-term employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Liabilities for wages and salaries, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other long-term employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined contribution superannuation expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (&#8216;ESOP&#8217;) and consultants as compensation for services performed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vesting</div> conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cumulative charge to profit or loss until settlement of the liability is calculated as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vesting</div> condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">When an asset or liability, financial or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial,</div> is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For recurring and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued capital </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares are classified as equity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goods and Services Tax (&#8216;GST&#8217;) and other similar taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303467288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical accounting judgements, estimates and assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Critical accounting judgements, estimates and assumptions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3. Critical accounting judgements, estimates and assumptions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Directors do not consider the development programs to be sufficiently advanced to reliably determine the economic benefits and technical feasibility to justify capitalisation of development costs. These costs have been recognised as an expense when incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development expenses relate primarily to the cost of conducting human clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being measured. The length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated entity applies judgement in determining whether contracts entered into fall within the scope of IFRS&#160;15 Revenue from Contracts with Customers. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contracts with each customer, management assessed that the contracts were within the scope of IFRS&#160;15 &#8216;Revenue from Contracts with Customers&#8217;. Management has also made the judgement in each case that the grant of the licence and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were also made in relation to the transfer of the licence and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> in each case, and whether this should be recognised over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical trial expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The timing of payment for work conducted under clinical trials often bears little relation to the timing of the work effort. Detailed estimates are made to determine the amount of work effort expended during a reporting period in order to determine the appropriate expense to be recognised, with the resulting prepayments or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">un-invoiced</div> amounts being recognised as a prepayment or an accrual respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payment transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes option pricing model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of intangible assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has applied judgement in determining the accounting treatment for the acquisition of the License agreement for EVT801. The License agreement has been determined to be a stand alone transaction, independent from any other agreements which have been or may be entered into with Evotec (France) SAS. Management has also made the decision to account for the cost of the asset conferred by the License agreement on the basis of the milestones that are probable of being payable, that is, those for which there is judged to be a probability of greater than 50% that the milestone will be triggered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration relates to the intangible assets acquired, and the fair value of contingent consideration is dependent on the key assumptions used in accounting for the acquisition of those intangible assets. These assumptions include the probability of milestones occurring, and can also include the anticipated timing of settlement and discount rates used. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the case where contingent consideration is recognised on the basis that the liability is probable of occurring, judgement is used in determining which milestones are considered probable of being triggered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible assets available for use </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has exercised judgement in determining that its intangible assets, being license agreements, have a finite life and are available for use once acquired. As the business model is to acquire such assets and then develop them to generate returns from future license transactions or other means, management have determined that the assets are available for use from the time that they are acquired. In each case the prima facie useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets other than goodwill and other indefinite life intangible assets </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">T</div>he consolidated entity assesses impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. Judgement is used to determine whether any indicators of impairment exist, and reference is made to the considerations included in IAS&#160;36 Impairment of Assets in this assessment. If an impairment trigger is found to exist, the recoverable amount of the asset is determined<div style="display:inline;">.</div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303474552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Operating segments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4. Operating segments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Identification of reportable operating segments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (&#8216;CODM&#8217;)) in assessing performance and in determining the allocation of resources. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity operates in the pharmaceutical research and development business. There are no operating segments for which discrete financial information exists. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major customers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year the consolidated entity transacted with two customers, and revenue from each customer amounted to in excess of 10% of the total revenue from the period. Both companies entered into license agreements for the consolidated entity&#8217;s drug assets. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305646264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5. Revenue </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregation of revenue </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The disaggregation of revenue from contracts with customers is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Geographical regions</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">China</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sweden</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Timing of revenue recognition</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing revenue at a point in time</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303487112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other income</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6. Other income </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gain</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidies and grants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reimbursement of expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303477592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesExplanatory', window );">Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7. Expenses </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax includes the following specific</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amortisation</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib licensing agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evotech licensing agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">181</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net foreign exchange loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rental expense relating to operating leases</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimum lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Superannuation expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined contribution superannuation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee benefits expense excluding superannuation</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits expense excluding superannuation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chinese With-Holding Tax incurred on license transaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chinese Value Added Tax incurred on license transaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304168184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax benefit</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8. Income tax benefit </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerical reconciliation of income tax benefit and tax at the statutory rate</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax benefi<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,765</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at the statutory tax rate of 26% (2020 &amp; 2019 27.5%)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,511</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax effect amounts which are not deductible/(taxable) in calculating taxable income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development claim</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation of intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee option plan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain/loss on revaluation of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to deferred tax balances as a result of change in statutory tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(186</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax losses and timing differences not recognised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,432</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(484</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax losses not recognised</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unused tax losses for which no deferred tax asset has been recognised-Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67,430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential tax benefit @ 26.0% (2020 27.5%)- Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Unused tax losses for which no deferred tax asset has been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">recognised-US</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,366</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Potential tax benefit at statutory tax <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rates@21%-US</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">497</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303714760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current assets - cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Current assets - cash and cash equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9. Current assets - cash and cash equivalents </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash at bank and on hand</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305551384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and other receivables</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10. Trade and other receivables </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D tax rebate receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deposits held</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">567</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Provision for impairment of deposits held</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deposit paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the deposit paid, $6.65m represents an advance to GCAR at the start of the GBM Agile trial, and is refundable if not utilised against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial, which is expected to be over 12 months from year end. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073309910664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Current assets - other</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11. Other assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current assets </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073302530248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangibles</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12. Intangibles </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreement - at acquired fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,082</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreement - at cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reconciliations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 63%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EVT801&#160;licensing</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib&#160;licensing</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year the consolidated entity acquired exclusive rights to EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304483480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">1 year or less [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13. Trade and other payables </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to note 21 for further information on financial instruments. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305773592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">1 year or less [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Employee benefits</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">N</div>ote 14. Employee benefits </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">229</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div> Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long service leave</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304992872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory', window );">Contingent consideration</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15. Contingent consideration </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration &#8211; EVT801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">458</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration &#8211; EVT801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,927</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">458</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the 2017 financial year, the consolidated entity acquired 100% of the issued shares in Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. On the same day, Kazia entered into a worldwide licensing agreement with Genentech to develop and commercialise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GDC-0084,</div> now known as paxalisib. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Glioblast acquisition contains four contingent milestone payments, the first two milestone payments are to be settled with Kazia shares, and the third and fourth milestone payments are to be settled with either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the value of $1,250,000. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Genentech agreement comprises of one milestone payment payable on the first commercial licensed product sale, in the amount of $1,394,000. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each milestone payment is probability weighted for valuation purposes. The milestone payments are discounted to present value, using a discount rate of 15% (previously 35%) per annum. The discount rate was considered at 30&#160;June 2021 and it was determined that the risk of the asset, and therefore of the milestones being met, has been considerably decreased as a result of paxalisib entering the pivotal GBM Agile trial, which is progressing well, and the license transaction with Simcere Pharmaceutical Group, which provides an external validation of paxalisib. Accordingly, the discount rate applied to future expected cash flows has been revised downwards. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance, and are not considered as part of the consideration in relation to the Genentech agreement. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - EVT801 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As set out in note 2, the acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being booked as a current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liability at year end, according to the estimated payment date. Milestones where the payment is not considered probable at year end have not been accounted for as a liability. The total amount of milestone payments not booked at year end amounts to &#8364;300,500,000 ($475,474,684). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304568136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Deferred tax</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16. Deferred tax </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> Liabilities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability associated with Licensing Agreement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073309865256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - contributed equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">Equity - contributed equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17. Equity - contributed equity </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 47%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares - fully paid</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,012,209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,598,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,290,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48,781,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Movements in Ordinary share capital </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Details</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue&#160;price</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1&#160;July 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,166,673</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36,641,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1&#160;November&#160;2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">16&#160;April 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,041,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,216,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued under the Share Purchase Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">11&#160;May 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,390,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,756,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(833,052</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">30&#160;June 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,598,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48,781,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">28 August 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Institutional placement under ANREO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">12 October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,525,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,420,656</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retail placement under ANREO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">26 October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,017,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,813,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">2&#160;March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">391,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.635</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">248,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">15&#160;March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">28&#160;April 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,037,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,274,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on achievement of a milestone</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">21&#160;May 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,391,865</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: share issue transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,673,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">30&#160;June 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,012,209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,290,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary shares </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back</div> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There is no current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-market</div> share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">buy-back.</div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capital risk management </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The capital risk management policy remains unchanged from the prior year. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305737608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Other contributed equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfOtherEquityExplanatory', window );">Equity - Other contributed equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 18. Equity - Other contributed equity </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible note - Triaxial</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On 4&#160;December 2014, the consolidated entity and the convertible note holder (&#8216;Triaxial&#8217;) signed a Convertible Note Deed Poll (&#8216;Deed&#8217;) which superseded the precedent Loan Agreement between Triaxial shareholders and the consolidated entity. The Deed extinguishes the liability created by the Loan Agreement and provides that the Convertible Notes will convert into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-determined</div> number of ordinary shares on the achievement of defined milestones established in the schedule of the Deed. Accordingly the convertible note has been reclassified as an equity instrument rather than debt instrument. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the Financial year ended 30&#160;June 2017, the Company reached two milestones triggering the conversion of a portion of its convertible note as follows; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; On 11&#160;August 2016 the Company announced the submission of an IND application. On 10&#160;September 2016, the Company received a letter from the FDA advising the study may proceed triggering conversion of 20,000,000 ordinary shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; On 31&#160;October 2016, the Company announced it had licensed a Phase II ready molecule triggering the conversion of 16,000,000 ordinary shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year ended 30&#160;June 2018, a portion of the convertible notes was extinguished. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining portion of the convertible note will be exercised at the holders&#8217; discretion on completion of Phase II clinical trial or achieving Breakthrough Designation, and would convert to 1,856,000 ordinary shares if converted. Completion will be deemed to occur upon the receipt by the consolidated entity of a signed study report or notification of the designation. There is a possibility for an early conversion of the convertible notes if a third party acquires more than 50% of the issued capital of the consolidated entity.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfOtherEquityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfOtherEquityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073309865256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory', window );">Equity - reserves</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 19. Equity - reserves </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign currency translation reserve </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reserve is used to recognise exchange differences arising from translation of the financial statements of foreign operations to Australian dollars. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments reserve </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reserve is used to recognise the value of equity benefits provided to employees and executive directors as part of their remuneration, and other parties as part of their compensation for services. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reserves within equity. [Refer: Other reserves [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305550264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - dividends<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDividendsExplanatory', window );">Equity - dividends</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 20. Equity - dividends </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no dividends paid, recommended or declared during the current or previous financial year. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDividendsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDividendsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305114616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 21. Financial instruments </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial risk management objectives </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The consolidated entity uses different methods to measure and manage the different types of risks to which it is exposed. These methods include monitoring the levels of exposure to interest rates and foreign exchange, ageing analysis and monitoring of specific credit allowances to manage credit risk, and, rolling cash flow forecasts to manage liquidity risk. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency risk </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollars (&#8216;USD&#8217;). Foreign exchange risk arises from future transactions and recognised assets and liabilities denominated in a currency that is not the entity&#8217;s functional currency and net investments in foreign operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of 30&#160;June 2021, the consolidated entity did not hold derivative financial instruments in managing its foreign currency, however, the consolidated entity may from time to time enter into hedging arrangements where circumstances are deemed appropriate. The consolidated entity used natural hedging to reduce the foreign currency risk, which involved processing USD payments from cash held in USD. Foreign subsidiaries with a functional currency of Australian Dollars (&#8216;AUD&#8217;) have exposure to the local currency of these subsidiaries and any other currency these subsidiaries trade in. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amount of the consolidated entity&#8217;s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euros</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity had net assets denominated in foreign currencies of A$17,608,845 as at 30&#160;June 2021 (2020: net liabilities A$1,923,831). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the AUD had strengthened against the USD by 10% (2020: 10%) then this would have had the following impact: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD strengthened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD weakened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect&#160;on<br/> profit&#160;before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect&#160;on<br/> profit&#160;before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euros</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD strengthened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD weakened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect on<br/> profit before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect on<br/> profit before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(192</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(192</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Price risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity is not exposed to any significant price risk. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity&#8217;s exposure to market interest rates relate primarily to the investments of cash balances. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has cash reserves held primarily in Australian dollars and United States dollars and places funds on deposit with financial institutions for periods generally not exceeding three months. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at the reporting date, the consolidated entity had the following variable interest rate balances: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">interest&#160;rate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">interest&#160;rate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash at bank and in hand</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short term deposits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net exposure to cash flow interest rate risk</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has cash and cash equivalents totalling $27,586,760 (2020: $8,764,044). An official increase/decrease in interest rates of 100 basis points (2020: 100 basis points) would have a favourable/adverse effect on profit before tax and equity of $275,867 (2020 $87,640) per annum. The percentage change is based on the expected volatility of interest rates using market data and analysts forecasts. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The entity is not exposed to significant credit risk on receivables. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has adopted a lifetime expected loss allowance in estimating expected credit losses to trade receivables through the use of a provisions matrix using fixed rates of credit loss provisioning. These provisions are considered representative across all customers of the consolidated entity based on recent sales experience, historical collection rates and forward-looking information that is available. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity places its cash deposits with high credit quality financial institutions and by policy, limits the amount of credit exposure to any single counter-party. The consolidated entity is averse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk, and reinvestment risk. The consolidated entity mitigates default risk by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no significant concentrations of credit risk within the consolidated entity. The credit risk on liquid funds is limited as the counter parties are banks with high credit ratings. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit risk is managed by limiting the amount of credit exposure to any single counter-party for cash deposits. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity risk </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated entity manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities. In particular, contingent consideration may be satisfied either by payment of cash or by issue of shares, at the discretion of the entity. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Remaining contractual maturities </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables detail the consolidated entity&#8217;s remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 53%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted&#160;average<br/> interest&#160;rate</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;year&#160;or&#160;less</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Between</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;and&#160;2&#160;years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Between</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;and&#160;5&#160;years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Over</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">5 years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">maturities</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-derivatives</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interest</div> bearing</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,097</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted average<br/> interest&#160;rate<br/> %</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">1 year or less<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Between<br/> 1&#160;and&#160;2&#160;years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Between<br/> 2 and 5 years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Over<br/> 5&#160;years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Remaining<br/> contractual<br/> maturities<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-derivatives</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interest</div> bearing</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304922696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 22. Fair value measurement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value hierarchy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables detail the consolidated entity&#8217;s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs for the asset or liability </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;1<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;2<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;3<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between levels during the financial year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the licence agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate. The estimated cashflows were adjusted based on the directors&#8217; assessment of achieving contracted milestones as disclosed in Note 15. The probabilities used fell in the range of 35% to 55% and were informed by generally accepted industry probabilities of drugs achieving certain milestones in their progression towards registration. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 assets and liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Movements in level 3 assets and liabilities during the current and previous financial year are set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;3<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Available<br/> for sale<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidate<div style="display:inline;">d</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses recognised in profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">475</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">475</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses recognised in profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payout of milestone</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305813416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key management personnel disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Key management personnel disclosures</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 23. Key management personnel disclosures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate compensation made to directors and other members of key management personnel (&#8216;KMP&#8217;) of the consolidated entity is set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please refer to Note 27 for other transactions with key management personnel and their related parties. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304047864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of auditors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Remuneration of auditors</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 24. Remuneration of auditors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the consolidated entity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit services - Grant Thornton Audit Pty Ltd</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit or review of the financial statements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">151</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">124</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">120</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305626344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Contingent liabilities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 25. Contingent liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than the contingent consideration set out in note 15, the consolidated entity does not have any other contingent liabilities. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2020-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305792344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 26. Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease commitments comprise contracted amounts for leases of premises. The agreement has a duration less than 12 months from financial year end. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305539832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 27. Related party transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parent entity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited is the parent entity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsidiaries </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interests in subsidiaries are set out in note 29. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Key management personnel </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disclosures relating to key management personnel are set out in note 23 and the remuneration report included in the directors&#8217; report. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transactions with related parties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There was no other transaction with KMP and their related parties. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receivable from and payable to related parties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no trade receivables from or trade payables to related parties at the current and previous reporting date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Loans to/from related parties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no loans to or from related parties at the current and previous reporting date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Terms and conditions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All transactions were made on normal commercial terms and conditions and at market rates. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305873832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent entity information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory', window );">Parent entity information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 28. Parent entity information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set out below is the supplementary information about the parent entity. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of profit or loss and other comprehensive income</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of financial position</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current asset<div style="display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,522</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated losses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,012</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves comprise Share Based Payments Reserve. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The parent entity contingent liabilities as at 30&#160;June 2021 and 30&#160;June 2020 are as set out in Note 15. The contingent consideration is specific to the parent entity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital commitments - Property, plant and equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The parent entity had no capital commitments for property, plant and equipment at as 30&#160;June 2021 and 30&#160;June 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interim financial reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2020-01-01<br> -Section Content of an interim financial report<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS34_g5-25_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterimFinancialReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073302497096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests in subsidiaries<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract', window );"><strong>Investments accounted for using equity method [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory', window );">Interests in subsidiaries</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 29. Interests in subsidiaries </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements incorporate the assets, liabilities and results of the following sub<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>idiaries in ac<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ordance with the accounting policy described in note 2: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ownership&#160;interest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal&#160;place&#160;of&#160;business&#160;/</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country of incorporation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Laboratories Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Australia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Research Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Australia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">United States of America</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Glioblast Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Australia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics (Hong Kong) Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Hong Kong</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 2<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_2_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304377480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of loss after income tax to net cash used in operating activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock', window );">Reconciliation of loss after income tax to net cash used in operating activities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 30. Reconciliation of loss after income tax to net cash used in operating activities </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments for:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation&#160;&amp; amortisatio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of property, plant&#160;&amp; equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net fair value loss on financial assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share based payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange difference<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in operating assets&#160;&amp; liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in trade and other receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">825</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in accrued revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease/(increase) in prepayment<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease/(increase) in trade and other payables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(484</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in other provisions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(6,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year the consolidated entity acquired a licensing agreement in relation to the asset EVT801. At year end no portion of the purchase price had been paid and accordingly the transaction does not appear in the cash flow statement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, the consolidated entity issued shares in satisfaction of an acquisition milestone. This transaction did not involve cash and accordingly the transaction does not appear in the cash flow statement. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Adjustments For Reconcile Profit Loss Explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303487112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 31. Earnings per share </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of ordinary shares used in calculating basic earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,674,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73,053,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,503,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of ordinary shares used in calculating Diluted earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,674,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73,053,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,503,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table>   <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,865,000 unlisted convertible notes with a face value of A$464,000 and 4,446,500 unlisted options have been excluded from the above calculations as they were antidilutive. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304590984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 32. Share-based payments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $636,383 was recognised. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">A$</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at&#160;the<br/> start&#160;of&#160;the</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">year</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired/<br/> lapsed on<br/> termination<br/> of<br/> employment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;the<br/> end&#160;of&#160;the&#160;year</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16/11/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941373">16/11/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/09/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941591">05/09/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941375">17/10/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941376">01/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21/11/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941377">23/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">07/08/2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941378">07/08/2022</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">224,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(121,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(15,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">87,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/02/2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941379">05/02/2023</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">440,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(120,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">320,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941380">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/11/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941381">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941382">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">200,000</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941383">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941384">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941385">04/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,775,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(441,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(314,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,219,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average exercise price</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.620</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">$0.826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No options were forfeited during the year. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of the period the following outstanding options were vested and exercisable: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 1 have expired during the year </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">- Options in tranches <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-</div> 8 were vested and exercisable except for tranche 6 which was vested as to 53% </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 9 were vested as to 1million of the 1.2million options on issue </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">- Options in tranches <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-12</div> were 25% vested </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 13 were unvested at year end </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining contractual life of options outstanding at the 30&#160;June 2021 is 2.6 years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">A$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at&#160;the<br/> start&#160;of&#160;the</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">year</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Modified</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;the<br/> end&#160;of&#160;the&#160;year</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/03/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941600">16/12/2019</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(46,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/03/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941602">18/12/2019</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,952</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,952</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24/06/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941603">30/06/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">519,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(519,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16/11/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941605">16/11/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18/03/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941606">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18/03/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941607">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18/03/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941608">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/09/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941609">05/09/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941610">17/10/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941611">01/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21/11/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941612">23/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">07/08/2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941613">07/08/2022</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">224,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">224,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/02/2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941585">05/02/2023</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">440,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">440,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941586">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/11/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941587">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941588">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,660,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">450,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(585,599</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,775,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average exercise price</div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3.716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of the period the following outstanding options were vested and exercisable: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranches 4, 8, 10, 11 and 13 were vested and exercisable </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 16 were unvested </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in the other tranches were vested as follows: 9: 75%, 12: 50% 14: 50% and 15: 67%. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All remaining options are expected to vest in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining contractual life of options outstanding at the 30&#160;June 2020 is 2.78 years. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee share options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended 30&#160;June 2021, 2,200,000 options have been issued to the employees by the consolidated entity pursuant to the Company&#8217;s Employee Share Option Plan. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Tranche 11 vests in four equal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-monthly</div> tranches from 1&#160;January 2021 </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tranche 12 vests in four equal annual amounts from 13&#160;January 2021 </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tranche 13 vests in four equal annual tranches from 4&#160;January 2022 </div></div> </td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options within all tranches will only vest if the option holder continues to be a full-time employee with the Company or an Associated Company during the vesting period relating to the option. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conditions for an option to be exercised: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The option must have vested. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option holder must have provided the Company with an Exercise Notice and have paid the Exercise Price for the option. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Exercise Notice must be for the exercise of at least the Minimum Number of Options; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Exercise Notice must have been provided to the Company and Exercise Price paid before the expiry of 5 years from the date the Option is issued. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Options Valuation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to obtain a fair valuation of these options, the following assumptions have been made: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Black Scholes option valuation methodology has been used with the expectation that the majority of these options would be exercised towards the end of the option term. Inputs into the Black Scholes model includes the share price at grant date, exercise price, volatility, and the risk free rate of a five year Australian Government Bond on grant date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free rate and grant date </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For all tranches, the risk-free rate of a five-year Australian Government bond on grant date was used. Please refer to the table below for details. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options in Tranches 1 to 13 have various vesting periods and exercising conditions. These options are unlisted as at 30&#160;June 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No dividends are expected to be declared or paid by the consolidated entity during the terms of the options. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underlying expected volatility was determined by reference to historical data of the Company&#8217;s shares over a period of time. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No special features inherent to the options granted were incorporated into measurement of fair value. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the above assumptions, the table below sets out the valuation for each tranche of options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 10%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 11%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share&#160;price<br/> at<br/> Grant&#160;Date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Volatility<br/> (%)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Life<br/> (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk&#160;free<br/> Rate&#160;(%)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value<br/> per&#160;option</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">05/09/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941445">05/09/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.105</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.630</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.60%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.840</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12/10/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941446">17/10/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.098</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.560</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.29</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.89%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.780</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31/10/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941447">01/11/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.090</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.380</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.87%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.720</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21/11/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941448">23/11/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.092</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.380</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.730</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">07/08/2017</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941449">07/08/2022</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.430</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.670</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.08</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.206</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">05/02/2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941592">05/02/2023</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.500</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.780</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.58</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.200</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941451">04/01/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.340</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<span style="-sec-ix-hidden:hidden26941594">0.493</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.140</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13/11/2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941452">04/01/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.410</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<span style="-sec-ix-hidden:hidden26941595">0.493</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.180</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13/01/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941453">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.620</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.340</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941454">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.379</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941455">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.30</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.403</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941456">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.60</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.425</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941457">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.446</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941458">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.450</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941459">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.70</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.490</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941460">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.520</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941461">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.70</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.550</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941368">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.520</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941369">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.576</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941371">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.627</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941372">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.671</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073302516328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 33. Subsequent events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no significant events subsequent to the reporting date<div style="display:inline;">.</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306124552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory', window );">New or amended Accounting Standards and Interpretations adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New or amended Accounting Standards and Interpretations adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (&#8216;IASB&#8217;) that are mandatory for the current reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory', window );">New Accounting Standards and Interpretations not yet mandatory or early adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Standards and Interpretations not yet mandatory or early adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30&#160;June 2021. The consolidated entity&#8217;s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoingConcernExplanatory', window );">Going concern</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going concern </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity incurred a loss after income tax of $8,421,960 (2020: $12,467,466), was in a net current asset position of $21,064,264(2020: net current asset position of $5,586,128) and had net cash outflows from operating activities of $<span style="-sec-ix-hidden:hidden26941709">9,110,516</span>(2020: $<span style="-sec-ix-hidden:hidden26941597">8,809,519</span>) for the year ended 30&#160;June 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at 30&#160;June 2021 the consolidated entity had cash in hand and at bank of $27,586,760. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. In particular, the directors have considered the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the operations of the Company, and make the following observations: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Kazia&#8217;s key clinical trials have not been impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to date. The GBM Agile study, the pivotal study for paxalisib in glioblastoma, is on track with recruitment running to plan, and no disruption to this schedule is foreseen. The Phase II study of paxalisib in glioblastoma was fully recruited prior to the onset of restrictions and is in wrap up stage at the date of this report. Plans are on track for the commencement of a Phase I trial for EVT801 before the end of 2021; </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr>
<td style="width: 3%; vertical-align: top;;text-align:left;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="width: 1%; vertical-align: top;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, clinical research in advanced cancer is relatively protected from pandemic disruption due to the ongoing and time-critical need for patient care in specialised facilities that cannot easily be repurposed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not reliant on ongoing revenue from customers, and so changes in customer behaviour over the next several years due to public health restrictions and reduced economic activity have little to no impact on its finances; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Company was able to secure funding of approximately $9&#160;million at the height of the initial wave of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> in April 2020, and additional funds of approximately $25&#160;million during the 2021 financial year; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on budgets and forecasts, the Company has sufficient cash to fund the operations for a period of at least 12 months from the date of this report; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">As a consequence the directors do not foresee any other impacts on the Company&#8217;s ability to raise additional funding as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of preparation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (&#8216;<div style="letter-spacing: 0px; top: 0px;;display:inline;">AASB</div>&#8217;) and the Corporations Act 2001, as appropriate for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-profit</div> oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8216;IASB&#8217;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for listed equity investments which are carried at fair value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical accounting estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity&#8217;s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DescriptionOfParentEntityInformationExplanatory', window );">Parent entity information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent entity information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 28. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Principles of consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (&#8216;company&#8217; or &#8216;parent entity&#8217;) as at 30&#160;June 2021 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the &#8216;consolidated entity&#8217;. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-consolidated</div> from the date that control ceases. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Operating segments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are presented using the &#8216;management approach&#8217;, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (&#8216;CODM&#8217;). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements are presented in Australian dollars, which is the consolidated entity&#8217;s functional and presentation currency. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign currency transactions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign operations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foreign currency reserve is recognised in profit or loss when the foreign operation is disposed of. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange differences arising on a monetary item that forms part of a reporting entity&#8217;s net investment in a foreign operation shall be recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recognition and derecognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below. Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and substantially all the risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and initial measurement of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with IFRS&#160;15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable). </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subsequent measurement of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial assets at amortised cost </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial assets at fair value through profit or loss (FVPL) </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Classifications are determined by both: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The entity&#8217;s business model for managing the financial asset </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The contractual cash flow characteristics of the financial assets </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial assets at amortised cost </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group&#8217;s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial assets at fair value through profit or loss (FVPL) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets that are held within a business model other than &#8216;hold to collect&#8217; or &#8216;hold to collect and sell&#8217; are categorised at fair value through profit and loss. Further, irrespective of business model, financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.&#160;The Group&#8217;s investments in equity instruments and derivatives fall under this category. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of financial assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IFRS 9&#8217;s new impairment model uses more forward looking information to recognize expected credit losses&#8212;the &#8216;expected credit losses (ECL) model&#8217;. The application of the new impairment model depends on whether there has been a significant increase in credit risk.&#160;The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In applying this forward-looking approach, a distinction is made between: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk (&#8216;Stage 1&#8217;) and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low (&#8216;Stage 2&#8217;). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8216;Stage 3&#8217; would cover financial assets that have objective evidence of impairment at the reporting date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8216;12-month</div> expected credit losses&#8217; are recognised for the first category while &#8216;lifetime expected credit losses&#8217; are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification and measurement of financial liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s financial liabilities comprise trade and other payables. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All interest-related charges and, if applicable, changes in an instrument&#8217;s fair value that are reported in profit or loss are included within finance costs or finance income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from contracts with customers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognised using a five step approach in accordance with IFRS&#160;15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognised when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognised as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognised as revenue within the 12 months following the balance sheet date are classified within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated entity recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues, including milestone revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the consolidated entity&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the licence is transferred to the customer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Finance Income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other revenue </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue is recognised when it is received or when the right to receive payment is established. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Grant income </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The R&amp;D Tax Incentive is a government program which helps to offset some of the incurred costs of R&amp;D. Eligible expenditure incurred under the scheme in a financial year attracts an additional 43.5% tax deduction, and for a group earning income of less than $20&#160;million, the cash value of the additional deduction is remitted to the taxpayer. In accordance with IAS&#160;20, as the compensation relates to expenses already incurred, it is recognised in profit or loss of the period in which it becomes receivable. Accordingly the group accounts for the R&amp;D Tax Incentive in the same year as the expenses to which it relates. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax expense or benefit for the period is the tax payable on that period&#8217;s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amount of recognised and unrecognised deferred tax assets are reviewed each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Limited (the &#8216;parent entity&#8217;) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the &#8216;separate taxpayer in the group&#8217; allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interpretation 23 Uncertain tax positions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interpretation 23 clarified the application of the recognition and measurement criteria IAS&#160;12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Judgments are reassessed as and when new facts and circumstances are presented. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory', window );">Current and non-current classification</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assets and liabilities are presented in the statement of financial position based on current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred tax assets and liabilities are always classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under IFRS&#160;16, leases are accounted for as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Depreciation on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and interest on lease liabilities are recognised in the consolidated statement of profit or loss; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total amount of cash paid under lease arrangements is separated into a principal portion (presented within financing activities) and interest (presented within operating activities) in the consolidated cash flow statement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lease incentives under IFRS 16 are recognised as part of the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;">Under IFRS&#160;16, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are tested for impairment in accordance with IAS 36 Impairment of assets. This replaces the previous requirement to recognise a provision for onerous lease contracts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For short-term leases (lease term of 12 months or less) and leases of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-value</div> assets, the consolidated entity has opted to recognise a lease expense on a straight-line basis as permitted by IFRS&#160;16 Leases. This expense is presented within other expenses in the consolidated statement of profit or loss. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing agreement for paxalisib </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Licensing Agreement asset was initially brought to account at fair value, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 15 years from the date of acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing agreement for EVT801 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Licensing agreement asset was initially brought to account at cost and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which was 12.5 years from the date of acquisition. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-financial</div> assets with finite useful lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-in-use.</div></div> The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-in-use</div></div> is the present value of the estimated future cash flows relating to the asset using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Compound financial instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compound financial instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortised cost using the effective interest rate method, whereas the equity component is not remeasured. Interest, gains and losses relating to the financial liability are recognised in profit or loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognised on conversion. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Short-term employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Liabilities for wages and salaries, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other long-term employee benefits </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined contribution superannuation expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based payments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (&#8216;ESOP&#8217;) and consultants as compensation for services performed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vesting</div> conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cumulative charge to profit or loss until settlement of the liability is calculated as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vesting</div> condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory', window );">Finance costs</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">When an asset or liability, financial or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial,</div> is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For recurring and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Issued capital</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued capital </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares are classified as equity. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted earnings per share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Goods and Services Tax ('GST') and other similar taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goods and Services Tax (&#8216;GST&#8217;) and other similar taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for finance costs. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 46<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoingConcernExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoingConcernExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for current and noncurrent classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for new accounting standards and interpretations not yet mandatory or early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for new, revised or amending accounting standards and interpretations adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DescriptionOfParentEntityInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description Of Parent Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DescriptionOfParentEntityInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304373672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesExplanatory', window );">Summary of licensing revenue</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of disaggregation of revenue from contracts with customers</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The disaggregation of revenue from contracts with customers is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Geographical regions</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">China</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sweden</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Timing of revenue recognition</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing revenue at a point in time</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProductsAndServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's products and services. [Refer: Products and services [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProductsAndServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305114616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory', window );">Summary of other income</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gain</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payroll tax rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidies and grants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reimbursement of expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development rebate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305978360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Summary of expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax includes the following specific</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amortisation</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib licensing agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evotech licensing agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">181</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net foreign exchange loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rental expense relating to operating leases</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimum lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Superannuation expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined contribution superannuation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee benefits expense excluding superannuation</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits expense excluding superannuation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chinese With-Holding Tax incurred on license transaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chinese Value Added Tax incurred on license transaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305737608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory', window );">Summary of income tax benefit</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerical reconciliation of income tax benefit and tax at the statutory rate</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income tax benefi<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,765</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax at the statutory tax rate of 26% (2020 &amp; 2019 27.5%)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,511</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax effect amounts which are not deductible/(taxable) in calculating taxable income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development claim</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation of intangibles</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee option plan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain/loss on revaluation of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to deferred tax balances as a result of change in statutory tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(186</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax losses and timing differences not recognised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,432</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(484</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax losses not recognised</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unused tax losses for which no deferred tax asset has been recognised-Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67,430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential tax benefit @ 26.0% (2020 27.5%)- Australia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Unused tax losses for which no deferred tax asset has been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">recognised-US</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,366</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Potential tax benefit at statutory tax <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rates@21%-US</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">497</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304302856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current assets - cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory', window );">Summary of cash and cash equivalents</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash at bank and on hand</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term deposits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure for detailed information about cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305633256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory', window );">Summary of current assets - trade and other receivables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D tax rebate receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deposits held</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">567</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Provision for impairment of deposits held</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deposit paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304570408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory', window );">Summary of current assets - other</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current assets </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305627752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Summary of non-current assets - intangibles</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreement - at acquired fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,082</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing agreement - at cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated amortisation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory', window );">Summary of reconciliations of intangibles</a></td>
<td class="text">Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 63%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EVT801&#160;licensing</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Paxalisib&#160;licensing</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortisation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of changes in intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304992872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">1 year or less [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory', window );">Summary of trade and other payables</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305813416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">1 year or less [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory', window );">Summary of provisions</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">229</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div> Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long service leave</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073315809928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory', window );">Summary of liabilities - contingent consideration</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration &#8211; EVT801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> Liabilities</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration - paxalisib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">458</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration &#8211; EVT801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,927</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">458</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303473992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory', window );">Summary of non-current liabilities - deferred tax</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> Liabilities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability associated with Licensing Agreement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073302691208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - contributed equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory', window );">Summary of equity - contributed equity</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 47%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares - fully paid</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,012,209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,598,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,290,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48,781,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory', window );">Summary of movements in ordinary share capital</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Movements in Ordinary share capital </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Details</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue&#160;price</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1&#160;July 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,166,673</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36,641,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1&#160;November&#160;2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">16&#160;April 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,041,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,216,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued under the Share Purchase Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">11&#160;May 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,390,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,756,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(833,052</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">30&#160;June 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,598,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48,781,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">28 August 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Institutional placement under ANREO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">12 October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,525,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,420,656</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retail placement under ANREO</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">26 October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,017,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,813,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">2&#160;March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">391,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.635</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">248,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on conversion of options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">15&#160;March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">28&#160;April 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,037,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,274,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued on achievement of a milestone</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">21&#160;May 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,391,865</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: share issue transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,673,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">30&#160;June 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,012,209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,290,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about issued capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about movement in ordinary share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307185032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Other contributed equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory', window );">Summary of equity - other contributed equity</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible note - Triaxial</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305780344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory', window );">Summary of foreign currency risk</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amount of the consolidated entity&#8217;s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euros</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk', window );">Summary of foreign currency risk sensitivity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the AUD had strengthened against the USD by 10% (2020: 10%) then this would have had the following impact: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD strengthened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD weakened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect&#160;on<br/> profit&#160;before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect&#160;on<br/> profit&#160;before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect&#160;on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euros</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD strengthened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUD weakened</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect on<br/> profit before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect on<br/> profit before<br/> tax</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect on<br/> equity<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US dollars</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(192</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(192</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory', window );">Summary of variable interest rate balances</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at the reporting date, the consolidated entity had the following variable interest rate balances: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">interest&#160;rate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">interest&#160;rate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash at bank and in hand</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short term deposits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net exposure to cash flow interest rate risk</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Summary of remaining contractual maturities of financial instrument liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 53%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted&#160;average<br/> interest&#160;rate</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;year&#160;or&#160;less</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Between</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;and&#160;2&#160;years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Between</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2&#160;and&#160;5&#160;years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Over</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">5 years</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">maturities</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-derivatives</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interest</div> bearing</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,097</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted average<br/> interest&#160;rate<br/> %</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">1 year or less<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Between<br/> 1&#160;and&#160;2&#160;years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Between<br/> 2 and 5 years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Over<br/> 5&#160;years<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Remaining<br/> contractual<br/> maturities<br/> A$&#8217;000</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-derivatives</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interest</div> bearing</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-derivatives</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial instruments by type of interest rate. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 39<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304994792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory', window );">Summary of assets and liabilities, measured or disclosed at fair value</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables detail the consolidated entity&#8217;s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs for the asset or liability </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;1<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;2<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;3<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated - 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock', window );">Summary of movements in level 3 assets and liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Movements in level 3 assets and liabilities during the current and previous financial year are set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Level&#160;3<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Available<br/> for sale<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Total<br/> A$&#8217;000</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidate<div style="display:inline;">d</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 1&#160;July 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses recognised in profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">475</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">475</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses recognised in profit or loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payout of milestone</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at 30&#160;June 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about movements in level 3 assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304809480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key management personnel disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory', window );">Summary of compensation made to directors and other members of key management personnel</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate compensation made to directors and other members of key management personnel (&#8216;KMP&#8217;) of the consolidated entity is set out below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term employee benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment benefits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about key management personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305735064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of auditors (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory', window );">Summary of remuneration of auditors</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the consolidated entity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit services - Grant Thornton Audit Pty Ltd</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit or review of the financial statements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">151</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">124</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">120</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about auditors remuneration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304998424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent entity information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfParentEntityFinancialInformationExplanatory', window );">Parent entity financial information</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set out below is the supplementary information about the parent entity. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of profit or loss and other comprehensive income</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020<br/> A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt; white-space: nowrap;">&#160;</td>
<td colspan="4" style="height: 6pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Statement of financial position</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current asset<div style="display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,522</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other contributed equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserves</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated losses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,012</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfParentEntityFinancialInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of parent entity financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfParentEntityFinancialInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073302647176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests in subsidiaries (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract', window );"><strong>Investments accounted for using equity method [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Summary of interest in subsidiaries</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements incorporate the assets, liabilities and results of the following sub<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>idiaries in ac<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ordance with the accounting policy described in note 2: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ownership&#160;interest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal&#160;place&#160;of&#160;business&#160;/</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country of incorporation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Laboratories Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Australia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Research Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Australia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">United States of America</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Glioblast Pty Ltd</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Australia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kazia Therapeutics (Hong Kong) Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Hong Kong</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305954984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of loss after income tax to net cash used in operating activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock', window );">Disclosure of reconciliation of profit or loss to operating cash flows</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A$&#8217;000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax expense from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments for:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation&#160;&amp; amortisatio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of property, plant&#160;&amp; equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net fair value loss on financial assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share based payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange difference<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in operating assets&#160;&amp; liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in trade and other receivables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">825</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in accrued revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease/(increase) in prepayment<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease/(increase) in trade and other payables</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(484</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase/(decrease) in other provisions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(6,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Reconciliation Of Profit Or Loss To Operating Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304426040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of earnings per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">A$&#8217;000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of ordinary shares used in calculating basic earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,674,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73,053,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,503,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of ordinary shares used in calculating Diluted earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,674,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73,053,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,503,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303286856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Summary of share-based payments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $636,383 was recognised. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">A$</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at&#160;the<br/> start&#160;of&#160;the</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">year</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired/<br/> lapsed on<br/> termination<br/> of<br/> employment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;the<br/> end&#160;of&#160;the&#160;year</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16/11/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941373">16/11/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/09/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941591">05/09/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941375">17/10/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941376">01/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21/11/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941377">23/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">07/08/2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941378">07/08/2022</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">224,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(121,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(15,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">87,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/02/2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941379">05/02/2023</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">440,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(120,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">320,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941380">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/11/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941381">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941382">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">200,000</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941383">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">09/11/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941384">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941385">04/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,775,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(441,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(314,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,219,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average exercise price</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.620</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">$0.826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No options were forfeited during the year. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of the period the following outstanding options were vested and exercisable: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 1 have expired during the year </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">- Options in tranches <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-</div> 8 were vested and exercisable except for tranche 6 which was vested as to 53% </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 9 were vested as to 1million of the 1.2million options on issue </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">- Options in tranches <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-12</div> were 25% vested </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 13 were unvested at year end </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining contractual life of options outstanding at the 30&#160;June 2021 is 2.6 years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tranche</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">A$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;at&#160;the<br/> start&#160;of&#160;the</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">year</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Modified</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expired</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;the<br/> end&#160;of&#160;the&#160;year</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/03/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941600">16/12/2019</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(46,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/03/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941602">18/12/2019</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,952</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,952</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24/06/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941603">30/06/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4.000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">519,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(519,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16/11/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941605">16/11/2020</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18/03/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941606">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18/03/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941607">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18/03/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941608">01/02/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/09/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941609">05/09/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941610">17/10/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31/10/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941611">01/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21/11/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941612">23/11/2021</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">07/08/2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941613">07/08/2022</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">224,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">224,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">05/02/2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941585">05/02/2023</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">440,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">440,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">04/01/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941586">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/11/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941587">04/01/2024</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13/01/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941588">13/01/2025</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,660,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">450,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(585,599</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,775,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average exercise price</div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3.716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of the period the following outstanding options were vested and exercisable: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranches 4, 8, 10, 11 and 13 were vested and exercisable </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in tranche 16 were unvested </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Options in the other tranches were vested as follows: 9: 75%, 12: 50% 14: 50% and 15: 67%. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All remaining options are expected to vest in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining contractual life of options outstanding at the 30&#160;June 2020 is 2.78 years. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of valuation for each tranche of options</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the above assumptions, the table below sets out the valuation for each tranche of options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 10%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 12%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 11%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share&#160;price<br/> at<br/> Grant&#160;Date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Volatility<br/> (%)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Life<br/> (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk&#160;free<br/> Rate&#160;(%)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value<br/> per&#160;option</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">05/09/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941445">05/09/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.105</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.630</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.60%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.840</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12/10/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941446">17/10/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.098</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.560</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.29</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.89%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.780</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31/10/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941447">01/11/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.090</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.380</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.87%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.720</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21/11/2016</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941448">23/11/2021</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.092</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.380</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.730</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">07/08/2017</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941449">07/08/2022</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.430</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.670</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.08</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.206</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">05/02/2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941592">05/02/2023</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.500</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.780</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.58</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.200</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941451">04/01/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.340</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<span style="-sec-ix-hidden:hidden26941594">0.493</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.140</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13/11/2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941452">04/01/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.410</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$<span style="-sec-ix-hidden:hidden26941595">0.493</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.180</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13/01/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941453">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.620</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;74.50%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.95%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.340</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941454">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.379</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941455">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.30</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.403</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941456">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.60</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.425</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941457">09/11/2024</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.132</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.446</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941458">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.450</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941459">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.70</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.490</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941460">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.520</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">09/11/2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941461">13/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.890</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.881</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.70</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.550</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941368">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.520</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941369">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.576</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941371">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.627</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">04/01/2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><span style="-sec-ix-hidden:hidden26941372">04/01/2025</span></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.185</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$1.169</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;90.00%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.19%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">$0.671</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303118632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Additional Information (Detail) - AUD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Consolidated loss after income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,421,960<span></span>
</td>
<td class="nump">$ 12,467,466<span></span>
</td>
<td class="nump">$ 10,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsLiabilities', window );">Net current asset position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,064,264<span></span>
</td>
<td class="nump">5,586,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash outflows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,111,000<span></span>
</td>
<td class="nump">8,810,000<span></span>
</td>
<td class="nump">6,714,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Consolidated cash in hand and at bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,586,760<span></span>
</td>
<td class="nump">$ 8,764,044<span></span>
</td>
<td class="nump">$ 5,434,000<span></span>
</td>
<td class="nump">$ 5,956,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_FundingPurposeAxis=kzia_ClinicalTrialsMember', window );">Clinical Trials [Member] | Covid Ninteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from funding for project purpose</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=kzia_ResearchAndDevelopmentTaxIncentiveProgramMember', window );">Research and development tax incentive program [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdditionalTaxDeductionPercentage', window );">Additional tax deduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Research and development tax incentive program [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_InterestIncomeLoss', window );">Earning income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicenseAgreementForPaxalisibMember', window );">Licensing agreement for paxalisib [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife', window );">Remaining useful life,licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementForEvtEightZeroOneMember', window );">Licensing agreement for EVT801 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife', window );">Remaining useful life,licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12.5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets less the amount of current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdditionalTaxDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional tax deduction percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdditionalTaxDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing the disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets with indefinite remaining useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_InterestIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_InterestIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_FundingPurposeAxis=kzia_ClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_FundingPurposeAxis=kzia_ClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_UncertainityAxis=kzia_CovidNinteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_UncertainityAxis=kzia_CovidNinteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=kzia_ResearchAndDevelopmentTaxIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=kzia_ResearchAndDevelopmentTaxIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicenseAgreementForPaxalisibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicenseAgreementForPaxalisibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementForEvtEightZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementForEvtEightZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303483608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract', window );"><strong>Disclosure of significant accounting judgments assumptions and estimates [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement', window );">Percentage milestone trigger to account cost of asset conferred under license agreement</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Abstract represents significant accounting judgments, assumptions and estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage milestone trigger to account cost of asset conferred under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305539832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating segments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>Major_Customer </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOperatingSegments1', window );">Number of operating segments | Segments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfMajorCustomers', window );">Number of major customers | Major_Customer</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ConcentrationRiskMajorCustomerPercentage', window );">Concentration risk major customer percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ConcentrationRiskMajorCustomerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk major customer percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ConcentrationRiskMajorCustomerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306318360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of licensing revenue (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 15,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember', window );">Licensing revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfProductsAndServicesLineItems', window );"><strong>Disclosure of products and services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 15,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProductsAndServicesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProductsAndServicesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307161704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of disaggregation of revenue from contracts with customers  (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 15,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember', window );">Licensing revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">15,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember', window );">Licensing revenue [Member] | Timing of revenue recognition [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">15,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CN', window );">China [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">10,006<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=kzia_SwedanMember', window );">Swedan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 5,177<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=kzia_LicensingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=kzia_SwedanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=kzia_SwedanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305140216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income - Summary of other income (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaterialIncomeAndExpenseAbstract', window );"><strong>Material income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Net foreign exchange gain</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxRebatesOnPayroll', window );">Payroll tax rebate</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SubsidiesAndGrants', window );">Subsidies and grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RebateIncomeOnResearchAndDevelopment', window );">Research and development rebate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 995<span></span>
</td>
<td class="nump">$ 1,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaterialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaterialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_RebateIncomeOnResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rebate income on research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_RebateIncomeOnResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SubsidiesAndGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidies and grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SubsidiesAndGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxRebatesOnPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax rebates on payroll.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxRebatesOnPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307173048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses - Summary of expenses (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Loss before income tax includes the following specific</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation</a></td>
<td class="nump">$ 1,265<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign exchange loss</a></td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MinimumOperatingLeasePayment', window );">Minimum lease payments</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Defined contribution superannuation expense</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Employee benefits expense excluding superannuation</a></td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction', window );">Chinese With-Holding Tax incurred on license transaction</a></td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction', window );">Chinese Value Added Tax incurred on license transaction</a></td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total Expenses</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_PaxalisibLicensingAgreementMember', window );">Paxalisib licensing agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Loss before income tax includes the following specific</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_EvotechLicensingAgreementMember', window );">Evotech Licensing Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Loss before income tax includes the following specific</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined benefit plans. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 5<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Chinese value added tax incurred on license transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Chinese withholding tax incurred on license transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_MinimumOperatingLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Operating Lease Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_MinimumOperatingLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_PaxalisibLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_PaxalisibLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_EvotechLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_EvotechLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073366016360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit - Summary of Income tax benefit (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Numerical reconciliation of income tax benefit and tax at the statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax benefit</a></td>
<td class="num">$ (8,906)<span></span>
</td>
<td class="num">$ (12,765)<span></span>
</td>
<td class="num">$ (10,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Tax at the statutory tax rate of 26% (2020 &amp; 2019 27.5%)</a></td>
<td class="num">(2,316)<span></span>
</td>
<td class="num">(3,511)<span></span>
</td>
<td class="num">(2,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract', window );"><strong>Tax effect amounts which are not deductible/(taxable) in calculating taxable income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim', window );">Research and Development claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfAmortisationOfIntangibles', window );">Amortisation of intangibles</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfExpenseEmployeeOptionPlan', window );">Employee option plan</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable', window );">Gain/loss on revaluation of contingent consideration</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped', window );">Prior year tax losses not recognised now recouped</a></td>
<td class="num">(1,086)<span></span>
</td>
<td class="num">(2,730)<span></span>
</td>
<td class="num">(2,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate', window );">Adjustment to deferred tax balances as a result of change in statutory tax rate</a></td>
<td class="num">(186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised', window );">Tax losses and timing differences not recognised</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AU', window );">Australia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxLossesNotRecognisedAbstract', window );"><strong>Tax losses not recognised</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset has been recognised</a></td>
<td class="nump">70,896<span></span>
</td>
<td class="nump">67,430<span></span>
</td>
<td class="nump">57,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes', window );">Potential tax benefit</a></td>
<td class="nump">18,433<span></span>
</td>
<td class="nump">17,531<span></span>
</td>
<td class="nump">15,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TaxLossesNotRecognisedAbstract', window );"><strong>Tax losses not recognised</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset has been recognised</a></td>
<td class="nump">2,038<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes', window );">Potential tax benefit</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax expense or income relating to tax rate changes or the imposition of new taxes. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect amounts which are not deductible/(taxable) in calculating taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of adjustment to deferred tax balances as a result of change in statutory tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfAmortisationOfIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of amortisation of intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfAmortisationOfIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfExpenseEmployeeOptionPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of expense employee option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfExpenseEmployeeOptionPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of expense research and development claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect of Gain loss on revaluation of contingent consideration payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of prior year tax losses not recognised now recouped.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of tax losses and timing differences not recognised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TaxLossesNotRecognisedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax losses not recognised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TaxLossesNotRecognisedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073309940216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit - Summary of Income tax benefit (Parenthetical) (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfIncomeTaxBenefitLineItems', window );"><strong>Disclosure Of Income Tax Benefit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AU', window );">Australia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfIncomeTaxBenefitLineItems', window );"><strong>Disclosure Of Income Tax Benefit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfIncomeTaxBenefitLineItems', window );"><strong>Disclosure Of Income Tax Benefit [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfIncomeTaxBenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax benefit [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfIncomeTaxBenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305499208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at bank and on hand</a></td>
<td class="nump">$ 21,087,000<span></span>
</td>
<td class="nump">$ 1,264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,586,760<span></span>
</td>
<td class="nump">$ 8,764,044<span></span>
</td>
<td class="nump">$ 5,434,000<span></span>
</td>
<td class="nump">$ 5,956,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303074680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables - Summary of current assets - trade and other receivables (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">R&amp;D tax rebate receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other current receivables</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DepositPaidNonCurrent', window );">Deposit paid</a></td>
<td class="nump">6,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Provision for impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=kzia_ResearchAndDevelopmentTaxRebateReceivableMember', window );">R&amp;D tax rebate receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">R&amp;D tax rebate receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=kzia_DepositsHeldMember', window );">Deposits held [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DepositPaidNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposit paid non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DepositPaidNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=kzia_ResearchAndDevelopmentTaxRebateReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=kzia_ResearchAndDevelopmentTaxRebateReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=kzia_DepositsHeldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=kzia_DepositsHeldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305808856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DepositPaidAsAdvance', window );">Deposit paid as advance</a></td>
<td class="nump">$ 6,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DepositPaidAsAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposit paid as advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DepositPaidAsAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305697160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other assets - Summary of current assets - other (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Prepayments</a></td>
<td class="nump">$ 1,720<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306295064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Summary of non-current assets - intangibles (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">$ 22,003<span></span>
</td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="nump">$ 13,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">GDC licensing agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">11,326<span></span>
</td>
<td class="nump">12,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">GDC licensing agreement [member] | Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">16,408<span></span>
</td>
<td class="nump">16,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">GDC licensing agreement [member] | Accumulated depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="num">(5,082)<span></span>
</td>
<td class="num">(3,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementMember', window );">Licensing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">10,677<span></span>
</td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementMember', window );">Licensing Agreement [Member] | Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">10,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementMember', window );">Licensing Agreement [Member] | Accumulated depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="num">$ (181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304065576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles - Summary of reconciliations of intangibles (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="nump">$ 13,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">10,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation expense</a></td>
<td class="num">(1,265)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
<td class="num">$ (1,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">22,003<span></span>
</td>
<td class="nump">12,410<span></span>
</td>
<td class="nump">13,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_PaxalisibLicensingAgreementMember', window );">Paxalisib licensing agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">12,410<span></span>
</td>
<td class="nump">13,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation expense</a></td>
<td class="num">(1,084)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">11,326<span></span>
</td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="nump">$ 13,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_EVT801LicensingAgreementMember', window );">EVT801 licensing agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">10,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation expense</a></td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 10,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_PaxalisibLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_PaxalisibLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_EVT801LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=kzia_EVT801LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305959880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables - Summary of current liabilities - trade and other payables (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and other payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 1,893<span></span>
</td>
<td class="nump">$ 1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued payables</a></td>
<td class="nump">3,040<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total trade and other payables</a></td>
<td class="nump">$ 4,933<span></span>
</td>
<td class="nump">$ 3,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304170088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee benefits - Summary of provision (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Long service leave</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsForEmployeeBenefits', window );">Provisions for employee benefits</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions for employee benefits. [Refer: Employee benefits expense; Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306645784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingent consideration - Summary of liabilities - contingent consideration (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationCurrent', window );">Contingent Consideration Current</a></td>
<td class="nump">$ 3,165<span></span>
</td>
<td class="nump">$ 1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">8,927<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsideration', window );">Contingent Consideration</a></td>
<td class="nump">12,091<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_ContingentConsiderationPaxalisibMember', window );">Contingent consideration - paxalisib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationCurrent', window );">Contingent Consideration Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_ContingentConsiderationEvt801Member', window );">Contingent consideration &#8211; EVT801</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationCurrent', window );">Contingent Consideration Current</a></td>
<td class="nump">3,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 7,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_ContingentConsiderationPaxalisibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_ContingentConsiderationPaxalisibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_ContingentConsiderationEvt801Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_ContingentConsiderationEvt801Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307572808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;) </div>
<div>Milestone</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MilestonePaymentPayable', window );">Milestone payment payable | $</a></td>
<td class="nump">$ 1,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MilestonePaymentsNotBooked', window );">Milestone payments not booked</a></td>
<td class="nump">$ 475,474,684<span></span>
</td>
<td class="nump">&#8364; 300,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MilestonePaymentDiscountRate', window );">Milestone payment discount rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=kzia_GlioblastPtyLtdMember', window );">Glioblast Pty Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of equity interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfContingentMilestonePayments', window );">Number of contingent milestone payments | Milestone</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=kzia_GenentechAgreementMember', window );">Genentech agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfContingentMilestonePayments', window );">Number of contingent milestone payments | Milestone</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_MilestoneTwoMember', window );">Milestone Two [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PaymentsForContingentConsideration', window );">Contingent consideration | $</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_MilestonePaymentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_MilestonePaymentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_MilestonePaymentsNotBooked">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments not booked.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_MilestonePaymentsNotBooked</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfContingentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of contingent milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfContingentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=kzia_GlioblastPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=kzia_GlioblastPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=kzia_GenentechAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=kzia_GenentechAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=kzia_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305129960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred tax - Summary of non-current liabilities - deferred tax (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets and liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability associated with Licensing Agreement - Non-current liabilities</a></td>
<td class="nump">$ 2,928<span></span>
</td>
<td class="nump">$ 3,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073295429816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - contributed equity - Summary of movements in ordinary share capital (Detail)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 21, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 15, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 02, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 26, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 12, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 28, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 11, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 16, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>AUD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>AUD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,125,000<span></span>
</td>
<td class="nump">$ 14,195,000<span></span>
</td>
<td class="nump">$ 19,242,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="nump">12,972,000<span></span>
</td>
<td class="nump">5,406,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance</a></td>
<td class="nump">$ 37,851,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,851,000<span></span>
</td>
<td class="nump">$ 14,125,000<span></span>
</td>
<td class="nump">$ 14,195,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning Balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,598,369<span></span>
</td>
<td class="nump">62,166,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance | shares</a></td>
<td class="nump">132,012,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,012,209<span></span>
</td>
<td class="nump">94,598,369<span></span>
</td>
<td class="nump">62,166,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,781,214<span></span>
</td>
<td class="nump">$ 36,641,519<span></span>
</td>
<td class="nump">$ 31,576,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="nump">12,972,000<span></span>
</td>
<td class="nump">5,406,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance</a></td>
<td class="nump">$ 80,290,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,290,062<span></span>
</td>
<td class="nump">$ 48,781,214<span></span>
</td>
<td class="nump">$ 36,641,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePlacementMember', window );">Share Placement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.400<span></span>
</td>
<td class="nump">$ 0.400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePlacementMember', window );">Share Placement [member] | Contributed equity [member] | 1 November 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePlacementMember', window );">Share Placement [member] | Contributed equity [member] | 16 April 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,041,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,216,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePlacementMember', window );">Share Placement [member] | Contributed equity [member] | 28 April 2021 {Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,037,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,274,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePurchasePlanMember', window );">Share purchase plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePurchasePlanMember', window );">Share purchase plan [member] | Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,390,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,756,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ShareIssueTransactionCostsMember', window );">Share issue transaction costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | (per share)</a></td>
<td class="nump">$ 0.000<span></span>
</td>
<td class="nump">$ 0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ShareIssueTransactionCostsMember', window );">Share issue transaction costs [member] | Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,673,388)<span></span>
</td>
<td class="num">$ (833,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember', window );">Conversion of options [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | (per share)</a></td>
<td class="nump">$ 4.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.493<span></span>
</td>
<td class="nump">$ 0.635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember', window );">Conversion of options [member] | Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember', window );">Conversion of options [member] | Contributed equity [member] | 2&#160;March 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember', window );">Conversion of options [member] | Contributed equity [member] | 15&#160;March 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember', window );">Conversion of options [member] | Contributed equity [member] | 28 August 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_InstitutionalPlacementUnderAnreoMember', window );">Institutional placement under ANREO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_InstitutionalPlacementUnderAnreoMember', window );">Institutional placement under ANREO [Member] | Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,525,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,420,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_RetailPlacementUnderAnreoMember', window );">Retail placement under ANREO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_RetailPlacementUnderAnreoMember', window );">Retail placement under ANREO [Member] | Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,017,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,813,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_IssuedOnAchievementOfAMilestoneMember', window );">Issued on achievement of a milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharesIssuedPricePerShare1', window );">Issue price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_IssuedOnAchievementOfAMilestoneMember', window );">Issued on achievement of a milestone [Member] | Contributed equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,391,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_SharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ShareIssueTransactionCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ShareIssueTransactionCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_ConversionOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePurchasePlanIssueDateAxis=kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_InstitutionalPlacementUnderAnreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_InstitutionalPlacementUnderAnreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_RetailPlacementUnderAnreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_RetailPlacementUnderAnreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_IssuedOnAchievementOfAMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_IssuedOnAchievementOfAMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306906120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - contributed equity - Summary of equity - contributed equity (Detail) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 14, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Ordinary shares - fully paid, shares</a></td>
<td class="nump">132,012,209<span></span>
</td>
<td class="nump">94,598,369<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Ordinary shares - fully paid</a></td>
<td class="nump">$ 80,290,062<span></span>
</td>
<td class="nump">$ 48,781,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073367367448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - contributed equity - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Fully paid ordinary shares par value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303475112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Other contributed equity - Summary of equity -Other contributed equity (Detail) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Convertible note - Triaxial</a></td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303686936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Other contributed equity - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Sep. 14, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of ordinary shares issued</a></td>
<td class="nump">132,012,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,598,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOrdinarySharesAvailableForConversion', window );">Number of ordinary shares available for conversion</a></td>
<td class="nump">1,865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes', window );">Percentage of capital acquired by third party for early conversion of convertibles notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ConvertibleNoteRepresentsOrdinaryShares', window );">Number of convertible note may be converted into ordinary shares</a></td>
<td class="nump">1,856,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ConvertibleNoteRepresentsOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>convertible note represents ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ConvertibleNoteRepresentsOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfOrdinarySharesAvailableForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares available for conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfOrdinarySharesAvailableForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital acquired by third party for early conversion of convertibles notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303065272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of foreign currency risk (Detail) - Foreign currency risk [member] - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Assets</a></td>
<td class="nump">$ 21,073<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Liabilities</a></td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Assets</a></td>
<td class="nump">21,073<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Liabilities</a></td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Liabilities</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304641560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Additional Information (Detail) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Net assets denominated in foreign currencies</a></td>
<td class="nump">$ 58,088,000<span></span>
</td>
<td class="nump">$ 23,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Net Liabilities denominated in foreign currencies</a></td>
<td class="nump">20,237,000<span></span>
</td>
<td class="nump">8,938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">27,586,760<span></span>
</td>
<td class="nump">8,764,044<span></span>
</td>
<td class="nump">$ 5,434,000<span></span>
</td>
<td class="nump">$ 5,956,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Foreign currency risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Net assets denominated in foreign currencies</a></td>
<td class="nump">$ 17,608,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Net Liabilities denominated in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,923,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Foreign currency risk [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">Hypothetical percentage change in risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">Hypothetical percentage change in risk</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Favourable/adverse effect on profit before tax and equity</a></td>
<td class="nump">$ 275,867<span></span>
</td>
<td class="nump">$ 87,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph B8<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk exposure associated with instruments sharing characteristic, percentage change in risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073315720024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of foreign currency risk sensitivity (Detail) - Foreign currency risk [member] - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">% change</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_IncreaseInMarketRiskMember', window );">Increase in market risk [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">% change</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_IncreaseInMarketRiskMember', window );">Increase in market risk [member] | Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">% change</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember', window );">Effect of increase in market risk on profit (loss) before tax [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="num">$ (1,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember', window );">Effect of increase in market risk on profit (loss) before tax [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="num">(1,762)<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember', window );">Effect of increase in market risk on profit (loss) before tax [member] | Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnEquityMember', window );">Effect of increase in market risk on equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="num">(1,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnEquityMember', window );">Effect of increase in market risk on equity [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="num">(1,762)<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnEquityMember', window );">Effect of increase in market risk on equity [member] | Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_DecreaseInMarketRiskMember', window );">Decrease in market risk [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">% change</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_DecreaseInMarketRiskMember', window );">Decrease in market risk [member] | Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk', window );">% change</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember', window );">Effect of decrease in market risk on profit (loss) before tax [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="nump">$ 1,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember', window );">Effect of decrease in market risk on profit (loss) before tax [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="num">$ (192)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember', window );">Effect of decrease in market risk on profit (loss) before tax [member] | Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnEquityMember', window );">Effect of decrease in market risk on equity [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnEquityMember', window );">Effect of decrease in market risk on equity [member] | US dollars [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="num">$ (192)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnEquityMember', window );">Effect of decrease in market risk on equity [member] | Euros [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Effect on profit before tax/equity</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph B8<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk exposure associated with instruments sharing characteristic, percentage change in risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=kzia_IncreaseInMarketRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=kzia_IncreaseInMarketRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=kzia_EffectOfIncreaseInMarketRiskOnEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=kzia_DecreaseInMarketRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=kzia_DecreaseInMarketRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=kzia_EffectOfDecreaseInMarketRiskOnEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303244424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Summary of variable interest rate balances (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at bank and in hand</a></td>
<td class="nump">$ 21,087<span></span>
</td>
<td class="nump">$ 1,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk [member] | Variable interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at bank and in hand</a></td>
<td class="nump">21,087<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Net exposure to cash flow interest rate risk</a></td>
<td class="nump">$ 27,587<span></span>
</td>
<td class="nump">$ 8,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk [member] | Variable interest rate [member] | Weighted average [member] | Cash at bank and in hand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_InterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk [member] | Variable interest rate [member] | Weighted average [member] | Short term deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_InterestRate', window );">Interest rate</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=kzia_CashAtBankAndInHandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=kzia_CashAtBankAndInHandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=kzia_ShortTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=kzia_ShortTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304618696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TradePayablesUndiscountedCashFlows', window );">Trade payables</a></td>
<td class="nump">$ 1,893<span></span>
</td>
<td class="nump">$ 1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AccruedPayablesUndiscountedCashFlows', window );">Accrued payables</a></td>
<td class="nump">3,039<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationUndiscountedCashFlows', window );">Contingent consideration</a></td>
<td class="nump">12,471<span></span>
</td>
<td class="nump">4,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total non-derivatives</a></td>
<td class="nump">17,403<span></span>
</td>
<td class="nump">7,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">1 year or less [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_TradePayablesUndiscountedCashFlows', window );">Trade payables</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AccruedPayablesUndiscountedCashFlows', window );">Accrued payables</a></td>
<td class="nump">3,039<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationUndiscountedCashFlows', window );">Contingent consideration</a></td>
<td class="nump">3,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total non-derivatives</a></td>
<td class="nump">8,097<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Between 1 and 2 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationUndiscountedCashFlows', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total non-derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember', window );">Between 2 and 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationUndiscountedCashFlows', window );">Contingent consideration</a></td>
<td class="nump">9,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total non-derivatives</a></td>
<td class="nump">$ 9,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AccruedPayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payables undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AccruedPayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsiderationUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsiderationUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_TradePayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade payables undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_TradePayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303021928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">$ 8,927<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">8,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">At fair value [member] | Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ContingentConsiderationNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 1,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303217720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail) - At fair value [member] - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_FairValueOfAssetsAndLiabilities', window );">Balance Beginning</a></td>
<td class="nump">$ 1,845<span></span>
</td>
<td class="nump">$ 1,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Losses recognised in profit or loss</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PayoutOfMilestone', window );">Payout of milestone</a></td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_FairValueOfAssetsAndLiabilities', window );">Balance Ending</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Available for sale [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Losses recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_FairValueOfAssetsAndLiabilities', window );">Balance Ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_FairValueOfAssetsAndLiabilities', window );">Balance Beginning</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Losses recognised in profit or loss</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PayoutOfMilestone', window );">Payout of milestone</a></td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_FairValueOfAssetsAndLiabilities', window );">Balance Ending</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 1,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of assets. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_FairValueOfAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_FairValueOfAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_PayoutOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payout of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_PayoutOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAvailableforsaleCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAvailableforsaleCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304843208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MilestonePaymentDiscountRate', window );">Milestone payment discount rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MilestonePaymentDiscountRate', window );">Milestone payment discount rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_MilestonePaymentDiscountRate', window );">Milestone payment discount rate</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_MilestonePaymentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_MilestonePaymentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305902008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">$ 1,574<span></span>
</td>
<td class="nump">$ 1,324<span></span>
</td>
<td class="nump">$ 1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">$ 2,303<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304400856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of auditors - Summary of remuneration of auditors (Detail) - AUD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditor's remuneration [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Audit or review of the financial statements</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Auditors remuneration</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073295375144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related party transactions - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Trade receivables from related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Trade payables to related parties</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions', window );">Loan to related parties</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions', window );">Loan from related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding commitments made by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding commitments made on behalf of the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073303843320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent entity information - Statement of profit or loss and other comprehensive income (Detail) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfParentEntityInformationLineItems', window );"><strong>Disclosure of parent entity information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax</a></td>
<td class="num">$ (8,421,960)<span></span>
</td>
<td class="num">$ (12,467,466)<span></span>
</td>
<td class="num">$ (10,270,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="num">(8,420,000)<span></span>
</td>
<td class="num">(12,471,000)<span></span>
</td>
<td class="num">$ (10,359,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfParentEntityInformationLineItems', window );"><strong>Disclosure of parent entity information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax</a></td>
<td class="num">(16,854,000)<span></span>
</td>
<td class="num">(11,064,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="num">$ (16,854,000)<span></span>
</td>
<td class="num">$ (11,064,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfParentEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item related to disclosure of parent entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfParentEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307205128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Parent entity information - Statement of financial position (Detail) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfParentEntityInformationLineItems', window );"><strong>Disclosure of parent entity information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">$ 29,391,000<span></span>
</td>
<td class="nump">$ 10,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">58,088,000<span></span>
</td>
<td class="nump">23,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">8,327,000<span></span>
</td>
<td class="nump">5,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,237,000<span></span>
</td>
<td class="nump">8,938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Contributed equity</a></td>
<td class="nump">80,290,062<span></span>
</td>
<td class="nump">48,781,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Other contributed equity</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,301,000<span></span>
</td>
<td class="nump">1,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(44,204,000)<span></span>
</td>
<td class="num">(36,186,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">37,851,000<span></span>
</td>
<td class="nump">14,125,000<span></span>
</td>
<td class="nump">$ 14,195,000<span></span>
</td>
<td class="nump">$ 19,242,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfParentEntityInformationLineItems', window );"><strong>Disclosure of parent entity information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">25,042,000<span></span>
</td>
<td class="nump">9,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">47,044,000<span></span>
</td>
<td class="nump">22,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">3,177,000<span></span>
</td>
<td class="nump">1,522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,032,000<span></span>
</td>
<td class="nump">5,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Contributed equity</a></td>
<td class="nump">80,290,000<span></span>
</td>
<td class="nump">48,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Other contributed equity</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,754,000<span></span>
</td>
<td class="nump">1,521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(50,496,000)<span></span>
</td>
<td class="num">(34,046,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">$ 32,012,000<span></span>
</td>
<td class="nump">$ 16,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfParentEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item related to disclosure of parent entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfParentEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305015656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests in subsidiaries - Summary of interest in subsidiaries (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaLaboratoriesPtyLtdMember', window );">Kazia Laboratories Pty Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaResearchPtyLtdMember', window );">Kazia Research Pty Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaTherapeuticsIncMember', window );">Kazia Therapeutics Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business</a></td>
<td class="text">United States of America<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">United States of America<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_GlioblastPtyLtdMember', window );">Glioblast Pty Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaTherapeuticsHongKongLimitedMember', window );">Kazia Therapeutics (Hong Kong) Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business</a></td>
<td class="text">Hong Kong<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaLaboratoriesPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaLaboratoriesPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaResearchPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaResearchPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_GlioblastPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_GlioblastPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaTherapeuticsHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=kzia_KaziaTherapeuticsHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073306438520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems', window );"><strong>Disclosure of reconciliation of profit or loss to operating cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense from continuing operations</a></td>
<td class="num">$ (8,421,960)<span></span>
</td>
<td class="num">$ (12,467,466)<span></span>
</td>
<td class="num">$ (10,270,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation &amp; amortisation</a></td>
<td class="nump">1,265,000<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant &amp; equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets', window );">Net fair value loss on financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">1,809,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based payments</a></td>
<td class="nump">637,000<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange differences</a></td>
<td class="nump">430,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Loss on contingent consideration</a></td>
<td class="nump">2,570,000<span></span>
</td>
<td class="nump">474,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Change in operating assets &amp; liabilities:</a></td>
<td class="num">(3,521,000)<span></span>
</td>
<td class="num">(10,479,000)<span></span>
</td>
<td class="num">(7,067,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease in trade and other receivables</a></td>
<td class="num">(5,027,000)<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Increase/(decrease) in accrued revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdjustmentsForDecreaseIncreaseInPrepayments', window );">Decrease/(increase) in prepayments</a></td>
<td class="num">(1,182,000)<span></span>
</td>
<td class="num">(168,000)<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables', window );">Decrease/(increase) in trade and other payables</a></td>
<td class="nump">1,010,000<span></span>
</td>
<td class="nump">1,722,000<span></span>
</td>
<td class="num">(409,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities', window );">Decrease in deferred tax liability</a></td>
<td class="num">(484,000)<span></span>
</td>
<td class="num">(298,000)<span></span>
</td>
<td class="num">(298,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Increase/(decrease) in other provisions</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (9,111,000)<span></span>
</td>
<td class="num">$ (8,810,000)<span></span>
</td>
<td class="num">$ (6,714,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_a_ii&amp;doctype=Standard&amp;book=b<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for increase decrease in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdjustmentsForDecreaseIncreaseInPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdjustmentsForDecreaseIncreaseInPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of profit or loss to operating cash flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073305904312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Summary of earnings per share (Detail) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</a></td>
<td class="num">$ (8,421,960)<span></span>
</td>
<td class="num">$ (12,467,466)<span></span>
</td>
<td class="num">$ (10,270,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Loss after income tax attributable to the owners of Kazia Therapeutics Limited</a></td>
<td class="num">$ (8,422,000)<span></span>
</td>
<td class="num">$ (12,467,000)<span></span>
</td>
<td class="num">$ (10,270,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating basic earnings per share</a></td>
<td class="nump">117,674,543<span></span>
</td>
<td class="nump">73,053,514<span></span>
</td>
<td class="nump">57,503,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in calculating diluted earnings per share</a></td>
<td class="nump">117,674,543<span></span>
</td>
<td class="nump">73,053,514<span></span>
</td>
<td class="nump">57,503,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share</a></td>
<td class="num">$ (7.16)<span></span>
</td>
<td class="num">$ (17.07)<span></span>
</td>
<td class="num">$ (17.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share</a></td>
<td class="num">$ (7.16)<span></span>
</td>
<td class="num">$ (17.07)<span></span>
</td>
<td class="num">$ (17.86)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073307395192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Additional Information (Detail) - AUD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOrdinarySharesAvailableForConversion', window );">Number of unlisted convertible notes</a></td>
<td class="nump">1,865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Face value of convertible notes</a></td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=kzia_UnlistedOptionsMember', window );">Unlisted options [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare', window );">Number of options that have been excluded from the calculations as they were antidilutive</a></td>
<td class="nump">4,446,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of antidilutive share options excluded from calculation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfOrdinarySharesAvailableForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares available for conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfOrdinarySharesAvailableForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=kzia_UnlistedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=kzia_UnlistedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073304522136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Employee remuneration expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 636,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options issued to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember', window );">Tranche 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOptionsVested', window );">Number of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOptionsIssued', window );">Number of options issued</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheOneMember', window );">Other Tranche One [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOptionsVested', window );">Number of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheOneMember', window );">Other Tranche One [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfOptionsVested', window );">Percentage of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheTwoMember', window );">Other Tranche Two [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOptionsVested', window );">Number of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheTwoMember', window );">Other Tranche Two [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfOptionsVested', window );">Percentage of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheThreeMember', window );">Other Tranche Three [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOptionsVested', window );">Number of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheThreeMember', window );">Other Tranche Three [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfOptionsVested', window );">Percentage of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheFourMember', window );">Other Tranche Four [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfOptionsVested', window );">Number of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheFourMember', window );">Other Tranche Four [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfOptionsVested', window );">Percentage of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TranchesTwoAndEightMember', window );">Tranches 2 and 8 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfOptionsVested', window );">Percentage of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TranchesTenAndTwelveMember', window );">Tranches 10 and 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_PercentageOfOptionsVested', window );">Percentage of Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfOptionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfOptionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_PercentageOfOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_PercentageOfOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_OtherTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TranchesTwoAndEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TranchesTwoAndEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TranchesTenAndTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TranchesTenAndTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073296873048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Summary of share-based payments (Detail)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>AUD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,660,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(314,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(585,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Balance at the start of the year, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement', window );">Modified, Weighted average exercise price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Balance at the end of the year, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheOneMember', window );">Tranche 1 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">04/03/2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 16,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,647)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwoMember', window );">Tranche 2 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">04/03/2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 18,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,952)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThreeMember', window );">Tranche 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24/06/2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(519,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourMember', window );">Tranche 4 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">16/11/2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16/11/2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov. 16,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 16,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFiveMember', window );">Tranche 5 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18/03/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixMember', window );">Tranche 6 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18/03/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSevenMember', window );">Tranche 7 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18/03/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEightMember', window );">Tranche 8 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">05/09/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">05/09/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Sep.  05,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  05,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember', window );">Tranche 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">12/10/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12/10/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Oct. 17,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 17,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTenMember', window );">Tranche 10 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">31/10/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31/10/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheElevenMember', window );">Tranche 11 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">21/11/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21/11/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov. 23,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 23,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwelveMember', window );">Tranche 12 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">07/08/2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">07/08/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Aug.  07,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  07,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirteenMember', window );">Tranche 13 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">05/02/2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">05/02/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Feb.  05,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  05,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourteenMember', window );">Tranche 14 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">04/01/2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  04,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFifteenMember', window );">Tranche 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">13/11/2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13/11/2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement', window );">Exercised and modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixteenMember', window );">Tranche 16 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">13/01/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13/01/2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the start of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired /lapsed on termination of employment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSeventeenMember', window );">Tranche 17 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEighteenMember', window );">Tranche 18 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineteenMember', window );">Tranche 19 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Balance at the end of the year, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph IG23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options modified in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangement options expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ShareBasedPaymentArrangementOptionsExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price modified in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140073296637000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Summary of valuation for each tranche of options (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEightMember', window );">Tranche 8 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">05/09/2016<span></span>
</td>
<td class="text">05/09/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Sep.  05,  2021<span></span>
</td>
<td class="text">Sep.  05,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.630<span></span>
</td>
<td class="nump">$ 1.630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">122.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember', window );">Tranche 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">12/10/2016<span></span>
</td>
<td class="text">12/10/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Oct. 17,  2021<span></span>
</td>
<td class="text">Oct. 17,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.560<span></span>
</td>
<td class="nump">$ 1.560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">122.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTenMember', window );">Tranche 10 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">31/10/2016<span></span>
</td>
<td class="text">31/10/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov.  01,  2021<span></span>
</td>
<td class="text">Nov.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.380<span></span>
</td>
<td class="nump">$ 1.380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">122.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheElevenMember', window );">Tranche 11 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">21/11/2016<span></span>
</td>
<td class="text">21/11/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov. 23,  2021<span></span>
</td>
<td class="text">Nov. 23,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.380<span></span>
</td>
<td class="nump">$ 1.380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">122.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwelveMember', window );">Tranche 12 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">07/08/2017<span></span>
</td>
<td class="text">07/08/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Aug.  07,  2022<span></span>
</td>
<td class="text">Aug.  07,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.670<span></span>
</td>
<td class="nump">$ 0.670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirteenMember', window );">Tranche 13 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">05/02/2018<span></span>
</td>
<td class="text">05/02/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Feb.  05,  2023<span></span>
</td>
<td class="text">Feb.  05,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.780<span></span>
</td>
<td class="nump">$ 0.780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourteenMember', window );">Tranche 14 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2019<span></span>
</td>
<td class="text">04/01/2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2024<span></span>
</td>
<td class="text">Jan.  04,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.492<span></span>
</td>
<td class="nump">$ 0.492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFifteenMember', window );">Tranche 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">13/11/2019<span></span>
</td>
<td class="text">13/11/2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2024<span></span>
</td>
<td class="text">Jan.  04,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.492<span></span>
</td>
<td class="nump">$ 0.492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixteenMember', window );">Tranche 16 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">13/01/2020<span></span>
</td>
<td class="text">13/01/2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">Jan. 13,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.881<span></span>
</td>
<td class="nump">$ 0.881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyMember', window );">Tranche 20 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov.  09,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyOneMember', window );">Tranche 21 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov.  09,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyTwoMember', window );">Tranche 22 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov.  09,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyThreeMember', window );">Tranche 23 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Nov.  09,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyFourMember', window );">Tranche 24 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyFiveMember', window );">Tranche 25 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentySixMember', window );">Tranche 26 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentySevenMember', window );">Tranche 27 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">09/11/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 0.890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 0.881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyEightMember', window );">Tranche 28 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 1.185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyNineMember', window );">Tranche 29 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 1.185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirtyMember', window );">Tranche 30 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 1.185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirtyOneMember', window );">Tranche 31 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="text">04/01/2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate', window );">Expiry date</a></td>
<td class="text">Jan.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kzia_SharePricePerShare', window );">Share price at Grant Date</a></td>
<td class="nump">$ 1.185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="nump">$ 1.169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility (%)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Remaining Option Life | yr</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free Rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value per option | $</a></td>
<td class="nump">$ 0.671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph IG23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_ShareBasedPaymentArrangementOptionsExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangement options expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_ShareBasedPaymentArrangementOptionsExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kzia_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kzia_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kzia_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=kzia_TrancheThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>123
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML&O%VL 8)@&^H[JC\_+^QO4PBCP*J_P]6S'M>0D4?7*&;^LZSK%+"VP@B5!
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MN#*6[($%E"( ]=GN9 ]WR!F0;^C;KGF.8DK] !"X!UM&]KS&L(FE4F !I0A
M?38[E<*UJQ16A=ON.^;Q RSQ @LHQ@)*L(!2!*!^#9P\W&)7-\8KW'; ,86!
M]F *VI,I6%()%E"* -0OC$XJ<;\AE7RGPFV''5,>6/H)%E",!91@ :4(0/WR
MZ.07URZ_#%2X75/-\('C7DM[M#%D8QUY&9AY@A4P10#J<]FI.:Y=S1F@<+NF
M6L' '=TPN\B>T1B:(!D%4#0!.\ L1<BK3T*GM;AVK66 -&U'&'-IQ9):L(!B
M%WCNQ67 X\* (627(F36)[(34UR[F&(7IBE([ &Q]_!U$,Z!@V. 9>BH!MCQ
MV>L59EJ"PC1@1UW'#)T AE//8XZ)F=IG:,3DSTY^<D'_9L=_LNH^+VM2\#N%
M[+P+5!U4AY_!.+R18M?\"L.MD%)LFY<;GJUYI0W4YW="[6K;-_J''8X_1G+S
M#U!+ P04    " "3.4=3'$A61I4&  #('   &    'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;*U9;6_;-A#^*X2Q#RE0UR+UZB QD%@=UF$=@A;=/C,2;7.5
M1)>DG>3?CY1DR;9.C ,D'V)9/A[YW OO.?+F2<B?:L.81L]E4:G;R4;K[?5L
MIK(-*ZGZ)+:L,K^LA"RI-E_E>J:VDM&\'E06,^)YT:RDO)HL;NIW#W)Q(W:Z
MX!5[D$CMRI+*EWM6B*?;"9X<7GSCZXVV+V:+FRU=L^],_]@^2/-MUFG)><DJ
MQ46%)%O=3N[P=>K7 VJ)?SA[4D?/R$)Y%.*G_?(EOYUX=D6L8)FV*JCYV+,E
M*PJKR:SC5ZMTTLUI!QX_'[3_7H,W8!ZI8DM1_,MSO;F=)!.4LQ7=%?J;>/J#
MM8!"JR\3A:K_HZ=&-II/4+936I3M8+."DE?-)WUN#7$T $<C T@[@)P/"$8&
M^.T _](!03L@J"W30*GMD%)-%S=2/"%II8TV^U ;LQYMX//*^OV[EN97;L;I
MQ5)42A0\IYKE2&GS89RJ%1(KE%&U02L3& I-T=V/%%W]]N%FILVD=N@L:R>X
M;R8@(Q-@@KZ*2F\4^ESE+#]5,#.K[99,#DN^)TZ-?^ZJ3\CW/B+B$0PL:'GY
M< \8GEX\',\=:/S. 7ZMSQ]S0&_EE10E,ADMJ>;5NDD)KCE3CFF";IJ@GB88
MF>8OH11Z9&:C8(A7F2@9TO09L6>S@2B&S'ND-PR],"HA'S?*HUJYW4KVBVD2
M$#R/C 7WQ[8'!#$)HCB(HE/)%)+T2.R9OT[R!&K800V=%KW+_S-YTX2QP77M
ML%[4J8R<UDN9V50S3INMJLH1+8747-4O('LUZL(C<)A$X3&TQER G)<$ [GT
M=;D37'&'*W;B^ML4EL)&AH&5<[45BA8V]2M13;.=E,:&B"K%M() .G7;@G6M
MMC1CMQ-C/,7DGDT6R.&,I%MTXESTEW)+N;3^M4O=2ILQ^N4CVA;4+M=XA_W:
M\:T5@%;M5'[1JAO7O9.>- %<.^;7>6>BN=-$WS=4LJFMASG:TI<Z%R!;S =S
M1WX\C-*A&(G(,$@!L2 :Q8*]OD1Y3C2FP)OR79G-*MO0:LU,J*Y6S 1G=KXU
MM@7)&RPD\+TA+/>T;W#A.R@Z-<U1]<:O;NNSJ[7A=Q]L#F>FTIK285/#/"J>
MU[4$WJ):S2?N"F/(3$/!( ;V*$ N\L?=3WJ,Q.U^D^UH3XL=Z_:J%:]H9?;C
MPK$[N;6^(=%;12<9&B4 ?D N\>;C%N@I O:=%CCG"#N;U[PZ< 7CZ4-I;Q)$
MV1\MW[8T(J-;KFD!FL@?K'CJAP0#,0!(8B^(YX 9 -'8B^)Q._0<!@=NKM2D
M?X_<LJ0Z .IMO^#TD1<U8W(5?=P3"1RZ*TV5F5Y*U3-J27-63R,,49*FY\D8
MW]/'8F0/"H=6"!MZ<V[:H:0?0N$UE$M(.&[5GMM@-[DYH)Q=Y:QY^F !FZQP
ME0X\I"13C)-A65B"DF "#07]>3*.L&<YV$US1A">N]3 '?=G#)1I#.V6@&!,
M@&H)"$X#UW;1\R/\"D&"X;8@I=ASV[7#,(=L9.X#((=BX9#=IH#8U!6R/;W!
M;GZ3LCXQ39//#%/-ZW[FL 6\@."&!&4: &Q["0F2.12QKPN>MK@]YR%NSC/B
M0YIE<F>P2K9GU8Z![>N0_4RQ[UA33S:(FVS8;J$^%#BK/XY>M>WGA\Q@.L<8
MJ#.09)( >99"DE&,QWLBTA,.0M[4DO-JS]3E+3GIZSIQU_4'*3+&\G::XP9,
M60(/V]*I\@VTYKT4I618\(D?CF]DI*_WQ'UH,0BXUSW1&LFI]RU&>B=%::OH
M<B/U)(6XCSO.H[7EQA=':\\3B)LGG$8K5\H0<G>H#NLY,;D\Y(Q+0!(3[ /L
M$I#T$SS>99*>))#7ST*:(\_+K-AB'%;Q,8P ,1C!.)1T8^R9 7$S XLQ/ZJ=
M-5Y+@.H'>VQB^JPQQD> DXID#I3%)2#I^P1""A"$T'=D1<\0B)LA+,>0(:KK
MD\Y'MN9591UL8MB^Z'O*L4-0,JSV21P%7A"<XQ\*AH$/M,R0X#P<][3?\P??
MS1\^KU8L:\[QNV,34ZO[#E$TWH=P^A"#B('32_<:WK [ C/B\8;1[QF+[V8L
MKT8!L^3_4O^WDQT?69,X3*)X< H.2(*1D@*"YY'20)\=7?&43*[KJS*%,K&K
M='-UTKWMKN/NZDNHL_?W^#IM+M5Z-<T=WU<J34HH5+"54>E]BHT[9'-MUGS1
M8EM?)#T*K459/VZ8::&D%3"_KX30AR]V@N[R<O$_4$L#!!0    ( ),Y1U/>
MZ41W_P(  (L&   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULI55-;^-&
M#/TKA KT%%BVXNT&J6T@WGZEVUT$F[1[*'J@1I1%9#2C<D9VW%]?CJ2X:;'Q
MI1=IAD,^OD<-J=7!RV-HB"(\M=:%==;$V%WG>3 -M1AFOB.G)[67%J-N99>'
M3@BK(:BU>3&??Y.WR"[;K ;;G6Q6OH^6'=T)A+YM48Y;LOZPSA;9L^$3[YJ8
M#/EFU>&.[BG^VMV)[O(32L4MN<#>@5"]SFX6U]ME\A\<?F,ZA!=K2$I*[Q_3
MYK9:9_-$B"R9F!!07WMZ1]8F(*7QYX29G5*FP)?K9_0?!NVJI<1 [[S]S%5L
MUME5!A75V-OXR1]^HDG/FX1GO W#$PZC;U%D8/H0?3L%*X.6W?C&IZD.+P*N
MYJ\$%%- ,? >$PTLO\.(FY7X TCR5K2T&*0.T4J.7?HH]U'TE#4N;GXD1X(6
MV(T?6"NURJ,"I^/<3"#;$:1X!611P ?O8A/@>U=1]6^ 7!F=:!7/M+;%6<2?
M>S>#R_D%%/-B<0;O\B3S<L"[? 7O@9XBE-:;1_@=RQ!%;\,?9W"7)]SE@+O\
M?^4["Y+Z[CIT:&B=:6,%DCUEFX\^$BQF\(4,\- 0U.S0&=:3$#&2]DD,8/R>
M!-[C7XS)2;"C/K()\ NW'*D"#(#JY8*W7&&R:!S'XV#C$-GMP-=G$5P%K*E"
M7P:N&(4IS%YGA$(PB'(IF!W<]*GZEM%!Y:U%"1=P:-@TP.%,WJ^_NBH6;[\-
M4/=NZ&=-DZA,V&-=3"]"SAQGYP1P*H%5K;KN^M*R4?%MA^ZHUM&E/$)HE+E2
M8V>\=%[P67OE6S9L_R-F!K<J5FB7<$4/?5VSH8FB@G"GA#NK'SG5M^R#WH$0
ME,RULA0BN-4"B<-)VH,_D"AGVI.%8GFAO3"'+0JZ'8KW<+,GUQ/<'RM'1_AX
M_UD;13T>@.!+MSI_,2!:DMTP!M-UZ5T<9\7)>IJT-^. ^<=]'-,?4';L EBJ
M-70^>_LF QE'W[B)OAO&3>FC#J]AV>C?@B0YZ'GM]69/FY3@]/_9_ U02P,$
M%     @ DSE'4Z3)26>3)P  "H8  !@   !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6S-/=N2&\=U[_F**49)4558<'=)491(L8HB*8>.9*E(VGY(Y:$!-( 1
M!S/P],PNX:_/N7:?G@MV)3NI/-CB C/=IT^?^PTO;IOV4]A[WQ6?#U4=OGNP
M[[KCMX\>A?7>'UQ8-D=?PS?;ICVX#OYL=X_"L?5N0R\=JD?7EY=/'QU<63]X
M^8(^^Z5]^:+INZJL_2]M$?K#P;6G[WW5W'[WX.J!?O"^W.T[_.#1RQ='M_,?
M?/?GXR\M_/4HKK(I#[X.95,7K=]^]^#5U;??/\'GZ8&_E/XVF'\7>))5TWS"
M/]YMOGMPB0#YRJ\[7,'!?V[\:U]5N!" \3=9\T'<$E^T_];5?Z"SPUE6+OC7
M3?77<M/MOWOP[$&Q\5O75]W[YO8_O)SG*UQOW52!_K^XY6<?7S\HUGWHFH.\
M#! <RIK_ZSX+'LP+SRYG7KB6%ZX);MZ(H'SC.O?R1=O<%BT^#:OA/^BH]#8
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M>DWCP\[CN^F(FP]A=#^A%8FI.I-BJ$.>MNBF.,6^&N87J@@JZG4^U[)A1YC
M#$4Q^96O/'C1L==<41":AG_R$\:@LVK?GR&LL\>[T_CCWO/)U^[UYJ.+5 S\
M*[XN#H++,=VI#F^'&^GWZ2)VMSQ=9W^6?H691AA58>OIR4\7,QRI^(HX/437
M\K7LTD6<+OAGK=""/"W ]\JA;^4'4C#<TU__!U!+ P04    " "3.4=3Z%E^
M6;P#  !""   &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*56VX[;-A#]
M%4)%BP986+;6218;VT"\;M$4V&:12_M0](&6QA:[$JEP*&O]]SU#R5XG&^]+
M7RQ>9LZ<.3,D/>N<O^>2**B'NK(\3\H0FNLTY;RD6O/(-62QLW&^U@%3OTVY
M\:2+Z%17:38>OTIK;6RRF,6U.[^8N394QM*=5]S6M?;[)56NFR>3Y+#PP6S+
M( OI8M;H+7VD\+FY\YBE1Y3"U&39.*L\;>;)V\GU<BKVT>!/0QV?C)5DLG;N
M7B;OBGDR%D)441X$0>.SHQNJ*@$"C2\#9G(,*8ZGXP/ZKS%WY++63#>N^LL4
MH9PG5XDJ:*/;*GQPW6\TY/-2\')7<?Q576^;98G*6PZN'IS!H#:V_^J'08<3
MAZOQ&8=L<,@B[SY09+G202]FWG7*BS709!!3C=X@9ZP4Y6/PV#7P"XOW#7D=
MC-TJIBW$#CQ+ W!E-\T'C&6/D9W!F&3JUME0LOK%%E1\#9""T)%5=F"US)Y%
M_+VU(W4YOE#9.)L\@W=YS/(RXEV>P?M$#T&M*Y??J[_UFH-',_SS#.[TB#N-
MN-/_I=ZS&'+JKKG1.<T3'"LFOZ-D\8<+I*8C]32 >E?@8S8FU[&MW09GHW$^
MZ'5%RCVU_U22RIUE5YE"!RJ4N(?]3S]<99/7;_BIBS(<&[U0@ _P-C:0M[H:
M C$6=5#:$Q9V.":PU+90K;BL]]%EZ;0OA-O*>)P_YUG]O"8)(KLWI:'-26XK
MRDT\Y;?ZGL0TDGOUYN;]ZG;@^>(%:"C-3,SB M]X(]F<8G!L%@2:."*'*+I"
MP4]$8M?ZG'AT3I%!"6(!$X"FU(B04QL@MF3/I'U>QG@%[7"A-5&O=0M*X!61
MH8HH8]WW:@'*JBL-, K#N0=AM3$621C@&]O?L4*8'@R'@>KI>E\!4 ZN5Q(*
M74B=4)"*-*,LZDNK8>*KO531\(74,WR;,I+!O<505''I.GO(F0.V8U;0K/%N
M8S#RJG+,,6\'(P^H&KU:RMV\$X*8]V7XROTQM<:Q$?XC5/A?P/47FY1ZU?I#
MO?90]RG1H38XLI9Q:K'2F5"JT+E'E(L8&\U(MH6BWM6*-$0^&"A=N]8.LAE1
M%WW 0G$R_E$^$C6X$(M\ A*;@+QQQ0@=C:B2M[8&+4)R)DCZ#I"5R2$%%-AZ
MHL=*G\GE>/(*WVYC2TNEOW<;I2?W.M+8QM>+@8ED^BO^N'I\(-_V[\*C>?^Z
MWFJ_-9;1)!NXCD>O7R;*]R]6/PFNB:_$V@5H%H<E'GGR8H#]C<.5-$PDP/%O
MP^(_4$L#!!0    ( ),Y1U/#/-*2D (   @&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;*U436_;, R]YU<0WK!3$7\D6;(V"=!DWUB'HNVVP["#
M8M.V4%GR)+GI_OTHV?'2M0DP8!=+I/B>^&B1\ZW2MZ9$M'!?"6D606EM?1J&
M)BVQ8F:H:I1TDBM=,4NF+D)3:V29!U4B3*+H95@Q+H/EW/LN]7*N&BNXQ$L-
MIJDJIG^M4*CM(HB#G>.*%Z5UCG YKUF!UVB_U)>:K+!GR7B%TG E06.^",[C
MT]78Q?N KQRW9F\/3LE&J5MG?,@60>020H&I=0R,ECM<HQ".B-+XV7$&_94.
MN+_?L;_UVDG+AAE<*_&-9[9<!+, ,LQ9(^R5VK['3L_$\:5*&/^%;1N;) &D
MC;&JZL"40<5EN[+[K@Y[@%ET )!T@,3GW5[DLWS-+%O.M=J"=M'$YC9>JD=3
M<ERZGW)M-9URPMGE%=ZA;' >6B)SKC#M@*L6F!P Q@E<*&E+ V]DAME#@I"R
MZ%-)=JFLDJ.,'QLYA%%T DF4Q$?X1KVTD><;'>"[P7L+&Z'26_C.-L9J>@$_
MCO".>]ZQYQW_>\F. S\KBS 90D<P6"MIE. 9LY@-G&@X?_[BV2R)IV=1%+DR
M1'][XE<//(-//'4-(@MJ$$\*\>0DGHW QR1GNW7PFAM6%!H+YIM!Y3W@ID3(
M#I[F6E60TH]VU3/T.&W9/4O4!K@!9B!7@GK;G/X/0>]0%9K5)4^9H"0*2L<,
MUB67#.+HA";-(V776\Q0 LF>3A\='JC&#:]<S?9T:DQ5(;F3_T11F04&M>+2
M I=@:2H=J/-3SRO<ZTZJ6N%GD*&B-M*VC=I[^S%WWG;WG_!V1EXP77!I0&!.
MT&@XG02@V[G3&E;5OM<WRM(O\MN21C5J%T#GN:(WV!GN@G[X+W\#4$L#!!0
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MRA[ _:U$ \>)57#\%5K]#5!+ P04    " "3.4=3%X:GY$4"   4!0  &0
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MIK:4C[Z=@J#!Y)+ZK;J9[PPC&S=G&VEH:MVQI#6)R@:0OY!46F_8!,/B3?\
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M+*UVJ\SI[/165%SM$6&%$M?,FG%B'=8O)GF+F#<(<@*1$;A7TI8&;F6!Q9^
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MHGQR!E\5]-S5FS\&Y0[TDDK=.:,V@Y,52;]X,7<PP&+S<@2["6#I$V!)2N\
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MC!1'2Z 5:4 K.$]YM,!ROLPG'SUSGH!*\\=028)TKZ)XM3Q!%5&19*A?_.,
M43F4,NR3; VRC?'EV9)29"K/DQ_7;7F.\OTD?<U!SNR1@[ <Q=DJ6A:LEH U
M*_ H72VB/,O.K(NR5C+L.S8O<$8T$J<&U_A$03@0<2!%O@Q@'GXQ;H5_2FM?
MC?OT_Z96PKLQRHKB^^1*'K6.AW[Q3;OY^AUQ*-=(OZ]JW?@MIM&,C%.EZKEK
MH+E4:J\JV5661%=YT=[H4DHLP&-^OU<=<'<T])P57BEUVXONP.H0[K7QT0&;
M/W:#;QN<0 "*5@_<QGP+' %']VK95#/ZC(6S+JF_BJ$6>T!ZKVDO&B3TZ.;1
MB4I#K-,NB IJ5*NXC0?+WH_!U=HHB\6Q=\[H \H-&SB9(% +CA^EA]TV=#U_
M6$!=..8!)@+. ,<+>C([,;\<./@OWM.F"=:9*GL^7-C)H6=.4:_Q58);(RV^
M(SX;V]YF.+S<")RG2(HG$$=>#L9X1G8O,>K=8;8\BLWH=0B'$-P=)ID.HY]G
M[V>?GX?S*U#AX)FW^AF5W?PN_0AGZ;Z675#E",?\$'N#>EJQE;M!F(H4:B@V
MJN'C$A_XO%0=5P/+M-->5X.XIHO(,A&0..6 YRG"%,/8Z0:#[8SI-Z0B<#(0
M;R,[N64C_%6COI!QXNZ1#.SR:(S>A;QVOCVT0WOR&1/(4,*$]]S(:BCE2!3K
M:7"J_3%KR*^1.T3';+'0XL5P^D>\8&2I=YWGC1J9ZY#-8W_8@JA=J;@G:ZMX
M"T1H0 .*AAI5<N-F]'Y\8E.E:,JA\=4X&=MH@^$(R;.$3L,RMO:A^@=V!9SG
M,2#LDV\C/6W(;VKMUQ3W&Q_Z$[A^,80,JH<12&P:G\)Q>:Q \ !#@6'Z\K3G
MY.[PG /*/F(*%[<RPPX)V>/^TOLT@AL[(UH;@8<*6Z22O>]%?$L1RC*M[+#=
MHE^Q]!;G%$1=;?2P0T#H"$9)Y[VP&C.#Y'FI; ;?K[C_\B]W@*I2X_GY:(;R
M96[1V#=,3\0+VM#6Z)9 +9\$_GV<_*_W&O:W*@]09VY:'*687+K="<<W5 52
M'Z0P,_K>?#P_NW*TTNS\Q0IDX/X5;A^GU=/=[3I<61[$P\4/Y^2.O6CD%JKQ
M;+6<PF%_F0HO3O?^ K/1#M<A_UCC_BD-"^#[5J,?C2]LX'2CO?H?4$L#!!0
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M/%P_T3_&W#F7M?!X:=4/65"]2-XE4& I6D6W=OL)^WS. B^WRL=/V':V699
MWGJRNA=S!%J:[EOL^CH<"-Z-7Q%DO2"+<7>.8I0?!(GEW-DMN&#-M+"(J48U
M!R=-^%'NR/&M9!TMKQY;27LXY0)[=!OT\Y08&R[3O$>L.D3V"F*2P;4U5'NX
M,@46SP$IQS,$E3T%M<J.$K^T9@33\0EDXVQRA#<=DIQ&WO05WCWN"-;*Y@_P
M4ZP].7X+OXYP9P-W%KFS_RG>443HN7/?B!P72=-3DN572PB3]R/XRP'P4^2'
M9OAI.(<FWP,G8[P2U#5)M(+[&H>U]-!Z+( L'^6V,M(CX"ZOA:D0"EF6&$",
M%DYZ:2HHG=7/L+8$8F(IC3"Y% H\"4+N3/+AKNQ#XD'AHL '9Q=MJ+.2PD!A
ME1+.C^"N%@Y/0Q,5T(A]1_CGH$,,&Z%:#$ZQJ\P:#9:2*8VS&UET$M2-LGL,
M*9F"<\6\#:W/R3*,K.-S%@A'?6;2L1?=FC[\DRBS?.&BE<07!+G5/!=]5R"N
M (3 )9=Q!"\]K/2@0S6Z*LXASY364->LP^DPZBZZ#O]CWLW):^$JR3566+)T
M/'I[EH#K9D^W(=O$?E];XND1ES6/:W3!@.]+R\^KWP0'PQ_ \C=02P,$%
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MM.S[7+)?E<8SEP<AM*K*-"BLW4+$2]A"EPA"'^(51&OE!7T3<T-QS[XW'0E
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M3L%\N\'?#G+1 -\+"WTT#S% ]T=F^0]02P,$%     @ DSE'4_/!&//T @
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MKAWI4YA6]$- XPWH?*$I\7;A'6Q_,=/?4$L#!!0    ( ),Y1U/!1+-^D (
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MU@-X/S?\+CK#)^A']NP/4$L#!!0    ( ),Y1U,I$ U6-P(  /P$   9
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M9ZM% &9HBH8/ISO?B&RUH[;&#VOJ(]'P OI?:;IYQ@]V<.A,-_\!4$L#!!0
M   ( ),Y1U-Y4&7I/P,  *T'   9    >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;+U52X_;-A"^^U<,U*#8 (+UL&2Y6]O >I.BCR18)&ER*'J@I+%%+$4J
M)+5V^NL[I+RJMZE]:(!<1')FOF\>(F>6>Z7O38-HX= *:59!8VUW'46F:K!E
M9JHZE*39*MTR2T>]BTRGD=4>U(HHC>-YU#(N@_72R^[T>JEZ*[C$.PVF;UNF
M/V]0J/TJ2()'P5N^:ZP31.MEQW;X#NWOW9VF4S2RU+Q%:;B2H'&["FZ2ZTWF
M[+W!!XY[<[('ETFIU+T[_%*O@M@%A (KZQ@8+0]XBT(X(@KCTY$S&%TZX.G^
MD?TGGSOE4C*#MTI\Y+5M5L$B@!JWK!?VK=K_C,=\<L=7*6'\%_:#;9H&4/7&
MJO8(I@A:+H>5'8YU. $LXC. ] A(?=R#(Q_E"V;9>JG5'K2S)C:W\:EZ- 7'
MI?LI[ZPF+2><7;]D6G*Y,] A_:J&:5Q&EGB=-JJ.')N!(SW#D:3P6DG;&'@I
M:ZR?$D04T!A5^AC5)KW(^&LOIS"+0TCC-+G -QNSG'F^V1F^]WBP4 I5W<,?
MK#16TV7X\P)O-O)FGC?[JNI=Y'"O[MITK,)50,_*H'[ 8 UOE$68)5/XTL7$
M%05NGGW_W2)-BA_C.'9EBO\M27YX(IF\4L8 VUJBX;)2+8)E!V#6:E[VEI6"
M! IL@Z#V$K4!M87?V%^<P?L&->NPM[PR\(JWW&(-5XLP2U-X#E=)&F;SPN_B
M,"UB>/Y-?;WIVY+\/%DF'_UK)"A[(+X=@AS4Y$?IFDOJ/T,Q#?2&S+B$BHFJ
M%\Q2L=T[YQ7@%Z6')"G">9&%>3:#8A;&^2S,DPSR(LQCVN;YUWI^P47OT/_+
M]RU*:^#D.]F<2^2JF"9S7\=B&A?'S8(DDPL1G 5!$B[F>>@N7D\7W#A\I215
MP'+WLR7=9D.=S3; 8$MW'1Z8Z-$5Y>99-L\\DLD:LC#+YI3/"8_J7/LVT%!!
MH424@(=*]-1H8*M5ZV\1*Q4IQSHZ<V:<YC/LD0)GTO+:Y4438 K_]?"CDQ;:
MHM[Y06$HB5[:H9N.TG$6W0PM^!_S89"]9GK'*0*!6X+&TR(/0 _#83A8U?F&
M7"I+[=UO&YJGJ)T!Z;>*RG4\. ?CA%[_#5!+ P04    " "3.4=3DG4J]XH*
M   #(0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R]6EMSV[H1?M>O
MP+A)QYF1*1*\RG$R8Y\DI^?,)/'$:<Y#IP^0"%EL2$*'%ROZ]]U=@"!%24[<
MIGV("1'8;W>!O8*YVJKJ:[V6LF'?BKRL7YVMFV9S.9O5R[4L1.VHC2QA9J6J
M0C3PL[J?U9M*BI2(BGS&73>:%2(KSUY?T;O;ZO65:IL\*^5MQ>JV*$2UNY&Y
MVKXZ\\ZZ%Y^R^W6#+V:OKS;B7M[)YN^;VPI^S2Q*FA6RK#-5LDJN7IU=>Y<W
M :ZG!5\RN:T'8X::+)3ZBC]^2U^=N2B0S.6R000!CP?YB\QS! (Q_C289Y8E
M$@[''?H[TAUT68A:_J+R/[*T6;\Z2\Y8*E>BS9M/:OLW:?0)$6^I\IK^LJU>
MR_D96[9UHPI##!(46:F?XIO9AP%!XIX@X(: D]R:$4GY1C3B]56EMJS"U8"&
M U*5J$&XK,1#N6LJF,V KGE]MQ:5O$"]4K81.]CNIKZ:-8",\[.E0;G1*/P$
MBL?9>U4VZYJ]+5.9[@/,0"0K%^_DNN&/(O[>E@[SW2GC+O<>P?.MGC[A^2?P
M/LMO#5OD:OF5_4,LZJ8"<_CG([B!Q0T(-_@O]^]QE ^JD<SG#CL&QZ[SG*D5
M:]:2J0W:<LUJ<%=P,;9 KV)K\2!A*$N6U74+I(UBLMCD:B=ES429LC2KP U4
M5;,6#J@BK+=W'V\=]J:MLO*>7JRR4I3+3.1L)T4%=$Q^ ^>O)7)_%OG1U$]\
MMA4U>.-2W9<92.G0 4T^5T )$+_"LV&I '7>?MMDU4Z/KY_!3UDM@8)MJFPI
MV8W(@4(RT1!K8DC$('VW--48,IV-ED\\YD4SSX/0XX5VR%WVC'$'PA'C(&L4
MQ>RO?TFXQU_:YWDW\:)[->',#6?N'*$B.^0>0'E.Y+LL=*<N((Z1NJ>>GOC,
MXS//U2A>K(<&)8Q<%O%'4?3T)&"^9U%<SZBE4?S$!1[3\!$4/3T)&3>D@,+]
M Y0?TP@$B&=N@BBQ'7(.**X3Q;#%/-B#.?>X1]*]@&%H1DE,6#%M+$>LQ ZY
M3U@Q2!0$[AA+O[#'!,ZAQ0+Z8.:2<G,[Y %!!7/.^$B[<S ' W5NMN\%\V/:
MJ#GSS.X<Q_*F'?')'>]63#P7P5QCAW88$EB2> >"60'#3CX+Y3$P0N\8E.=X
M/C_D_IA<_"28EJLC24Y )1V0WV^1UP^U5-&\)SPE4R<1G\9Q./7 ";F5_SP(
MK/'X7F!<-)AR;TXT?U!RA8  @:Z"6@$"TUXT(4.:QR2+.W>UD5(\\)PDQ.<S
MT)9'DP_*AM"MK"#DJ6HE,T1.^SB(P<AAUSHR28B>)OAN9)6I5(=*E4/@10*(
MPG4#(9;&0^@'69/$0&^D%8M<7K(+]M$LRTK6F+CIZ1@N=;P;"W.4IF;\XCC8
M?%^ &M.!5V1YCF60T<5SN'UC$)1)'R>X>>X%&--QZ7W-L2T[GHV6&S?O,RS8
MCL^ODE@PHHY+J!LP&;>0=O)L1;G&2C386Y,H(")#:2 IZX"X$.\C8E53(G)_
M;B)ZK])LE?5YZ# -H1_X?1KB.I90U =K#B#9!$>RD'F_EX0&0,D!$+C!/.2'
M0.9]#^0S#D"1!O)=/21'"!QTM% [U)$H9"9ZJ. _S+'6W_7\A!32NE%2T\%?
MIZ,Y^*H_BA?GOCL._IU(T7>@QJ%G$/S'4/%)*+ H".:'>20\!97\E IB_E,J
M")#\9Y00D()^1@V!R>=)1<2!#>EY2CY/JB#&3S,_\8(GU@\'$G6JA=\I'DZF
MY&-).OI.\3#B?E(J#A[G3N,HLBL#\SP/$RC*YG.L,[H$_ -I%?PJ<HT8VO7]
M((&G[\0@M$F[D_]GJJRA+&#)%-(1_/.(IDL_QV%.I*QHE++V5V&K!7^JGNLH
MI6JMZDLVOV1Q^!QDX9=@]L^9%^@G"19>LBA^[E 'UZ>\3G=H]:C#6C:Z94-T
MY+YJF[;J]A 2V_\L@[HZ@\9)ET+?FJ:1U=B'6I0WHW)$8I._EXJG@V*NHSK6
ME9*9V,YTL:,7H$"M\@P3-)Q<V63-CFW:JFXQA1NB7U2Q$>6.##Y^6?>24L=L
MSH[=0GIV)KB(1R]95PN F>#6TLFN5 OR_XE[%5T4>&>1[PX)^%$"49;T*%2+
M;?FJ4@7:WN\"7D.!08WP 93_&)2U+L(*AE#<VN,V:]9 +?+!^FV&=P)EOC-&
M,[P=8&N58X^/=I&5K:3Z;P%%"QA6GE\T6=&? 8$/-Y@I:OROZUHM,SJ0;F)0
MDR)/'!LOKV0NZ+<Y*RV& Y1@>%J'E88U FIYNF"37O:[UBM1M* 7F9!VNOY8
M/^YIV:_;5.HA0\,<JD/Z 6=;]7U0#88V=$]-)3)-85?<4NQ#B0?*[(DX!B,9
M%CV-#:/@B>!UN12U]KWWX+%%6[ /;;$ V6':'/++[^/W[M0KNN<;I--("])N
M(4$P:22C6A@8A]KGM>7A%-7'.##["Z%!^ZUC+?&+R%M!D[_!659TD00-U:(1
M:)]L);**/=@U.A74-HQ,1^E  'IQ$"L*D4+DQUVXR<7R*[M;PD&##1NSZ.$+
MV:Q5JG)UOP/R6E.W>&MD;5H'5[V\69OX5XA_J0I#S%@^ME5MGNY9)JBW%55:
MC]-;9\>R*AS8BTU+#FZ.8U_N0J4RA\EEWJ92 ^G@JE,L"'5O6Y7I* %/V8-"
MU\I!W"D=+Y)76?T5C@V<M\(C0QMCJ^S!Q.;K%B\W\PQL_E<%N:+$.T1VHU#X
M<L#+89\ YZ+'0?A^FKU#CQV$G*GE?7&$]\4CO!<'O.D.L:7;PUMT#LQF*VU,
MR*2AM*VO-M&E4@D&EM?.,$-_MFTI=;>^"14" E);CP)4/2P)3,8T@8F2Z\ $
M!)4$>=:E>3B>89ISP"-9FJ'WE>EA @?32>4R%]@J@MS:^4[GN$%$14NJ1Y>\
M.O'3?6V^PX6656\5M).P/T">E9*XT59*[%)!HC5H M:^A%P#K$7'89Q-R2*!
M/YP9'*@)Z[@6<@7I7 -GO!A>28&U"1[!&KDT^S&_UH>,/HCE$EB]JC:J(J7)
M/PHX;: GNP!\&S& RPU=>BM=?(D%R#*,$-,#RZAE0_6-SD@V+*#!2+%<VTJO
MKX8N)R=N!>X&#FD#Z)=^DS_96NN3];UW5O3)B?;/=3P72GC=!'J<0P/^'&_P
M(NP+88A74@$V24?;/M=QYPE28_/74_,Y7FG-B1H:G\F);L_5UV!=SV>I7:2.
M-36'?N%XDX?4_"@U!YTTM>].3O1VT/^ PL]TAQ<'#E;# )%@,Q$2,7>CR8E^
MSJ7[#JU<3QSN$0/GXSV<"]V):SHPOZ/VX6]/[>&.'V_<@,H[H [TGG74"5$?
MZ]3,A:/NURSQD#7(-AG<Q=HAL4[T<>'U[MRE_<:M9FZWWWX\?QJQ/R .7/]I
MQ-&0F(=/(TZ&Q$$T.7'_;(CUAEEB/B0.W:<1QT/B^9.(_3W.(7\B\9!S&/8&
M.KHJAYU*]".:]V*'1#SO.?\XL0]_!\1Q]#3B(>>(QT\A#O8X1_'1C[2SP8?I
M0E;W]/F]AF0(#93^1FW?VB_\U_K#=K]<__> ]Z*ZSR#!Y'(%I! ?PC.H1NB3
MN_[1J U]YEZHIE$%#=<2BLD*%\#\2JFF^X$,[/][>/UO4$L#!!0    ( ),Y
M1U, W9&R&0(  *T$   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;*64
M46^;,!#'O\K)SU,@D&Y519":;M,VJ5/4M-O#M <'#K "-K6/D'W[V8:03%OR
MLA?;9]__YSNX<](KO3,5(L&AJ:59LHJHO0L"DU78<#-3+4I[4BC=<+*F+@/3
M:N2Y%S5U$(7AVZ#A0K(T\7MKG2:JHUI(7&LP7=-P_6N%M>J7;,Z.&T^BK,AM
M!&G2\A(W2"_M6ELKF"BY:% :H21H+);L?GZW6CA_[_!-8&_.UN RV2JU<\;G
M?,E"%Q#6F)$C<#OM\0'KVH%L&*\CDTU7.N'Y^DC_Z'.WN6RYP0=5?Q<Y54MV
MRR#'@G<U/:G^$X[YW#A>IFKC1^@'WRABD'6&5#.*;02-D,/,#^-W.!/<AA<$
MT2B(?-S#13[*]YQXFFC5@W;>EN86/E6OML$)Z7[*AK0]%59'Z:;;&GSM4!+@
MWHXF"<ABW6&0C8C5@(@N(.81/"I)E8$/,L?\3T!@XYF"BHY!K:*KQ"^=G$$<
MOH$HC.97>/&49.QY\07>,QX(MK7*=O"#;PUI6PL_KW 7$W?AN8O_^7A7$:[G
M[DS+,UPRVU0&]1Y9^E410AS/X*\+X+E"C="[02HPHI2B$!D_.9B3A!10A;9U
M6J5)R!)R;KDS^%?FP5D)-:A+WR@&,M5)&JIIVIUZ\7XHP9/[T,B/7)="&JBQ
ML-)P]NZ&@1Z:8S!(M;X@MXIL>?ME9=\3U,[!GA?*YC\:[H+IA4I_ U!+ P04
M    " "3.4=3^&D0WU4I  !-E   &0   'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6S-/=N2VT9V[_D*E.)DI2H.-4-9LF39KM+-&R5VK+*TNP^I/#3))@D+
M!+AH8$;<K\^Y=?=IH($9SVY2>=BUA@2Z3Y\^]QN_NVG:S^Y@;5=\.5:U^_[!
MH>M.WSY^[#8'>S1NV9QL#=_LFO9H.OBSW3]VI]::+;UTK!ZO+B^?/3Z:LG[P
MPW?TV8?VA^^:OJO*VGYH"]<?CZ8]O[95<_/]@ZL'_H-?R_VAPP\>__#=R>SM
M1]O]Z?2AA;\>AU6VY='6KFSJHK6[[Q^\NOKV]>H;?(&>^'-I;YSZ=X%'63?-
M9_SC_?;[!Y<(D:WLIL,E#/SGVKZQ584K 1Q_E44?A#WQ1?UOO_J/='@XS-HX
M^Z:I_E)NN\/W#YX_*+9V9_JJ^[6Y^3<K!WJ*ZVV:RM'_%S?R[.6#8M.[KCG*
MRP#!L:SYO^:+(.(N+ZSDA17!S1L1E&]-9W[XKFUNBA:?AM7P'W14>AN *VN\
ME8]="]^6\%[WP\=R7Y>[<F/J#C"T:?JZ*^M]<6JJ<E-:5SS\(/]Z]-WC#O;#
MMQYO9.W7O/9J8NVK5?%S4W<'5[RKMW:;+O 8  W0KCRTKU>S*_Y[7R^+)Y>+
M8G6YNII9[TDX_1-:[\G$>I_LEZY85\WF<_%?9NVZ%HCDOV?6_3JL^S6M^_7$
MNO\)U-BTA0'RA8,7KR)B/W:FWIIVZPKX;_&^[FP+W-09)%'X;-N<NB&F&#&S
M&R+O?NM.9F._?P#+.=M>VP=_+Q3%IX,M-O !4,#6X <6WN[.Q<'$9TQ5%<VN
MZ.#1VMXL@%&O2P>?^WUQMSMO7#K7P[OK,ZU'W];TE:GRB[QNX#_%PW_]Y^>K
MJV<OW[_Z^)K^^<W+1["" 8IN+3 +/-PU[;D &48+;_JVA:, K*>F97*W;=EL
MEW1B.AD*##Z6LW>'?UMNB[KI $'7L$Y]+ISBKO((]],5L##"L"MK4V]*.!CL
M3<*UWEC$VJEQI=H^=P'+XA6L_?O0#0\,H0T80I#/H  BIN@ ^/':VKJPIJW.
M_L:7Q0Q_/ W\\?16_K@S5L?@P6$2F'+\,@O -+_\ Z$J7O4H4:K2U'=?EBZ%
MT-_:#5PW+$=W(*RAV'G=3]S>8N[Z/'/E^-KSAZGK'@ASR!X%[_ODL@ Q;$D$
M+Z=DA+ AG-$YZ]P1V4T(VO.!YZ[ZGE*J%&35#0"#B-A:>X0%ND;X#S ";R"+
MI:SGF6B&CI\%.GXV2\=_;!!../\&)%6."F=?SU-ALN:D#"YKDF(@@(NJ<8"A
M'9P5/VV.MNC,%\3O5\\77Z^N%B^>718/X;8NORV^NEHMOG[V#?SOV:-%<0-R
MO 3#"*Z@"T(1+ZQ+I-!7L,;ELZ\7JV=?RS*W//]T\?3YL\75ZODCNKB#V?(;
MQAT*, QW8 FZ8M<VQP*,R];079-U!DN R8%+%"\65U>7BZ=7SXKGB^>7+^!?
M+XI7<,PNH;])4L8]:3\XWP&!H/\!0YCZ,Y_I&P+RFV>73,-1'CL@,(L$ZYB.
MB(?@>DX&T8V&9+%/K@B,PM(!-@_EYH ?PMNG"M9P]$=9]P@0[%FCE*_T21$H
M,*6KTAF//$(G?P/_Z"KK60?$R+JL^+V2"5D6!'YI@8_@F77O@,*<6R*J2L1D
M9_E1P(4%R[([%-NVWP.K7(,]?J*U@6).IH9E%\S\M,MY1OT@A\G)@)L!6+V:
M/IT;H:K$AT_(Z/!H?X(CEQU\TL(K\)3K=SNT-6NA%2*1LKZV8 6W ![]#=8H
M^@1(,H CN)2NAO<3"EK05TQ@< ;P00!#&Z8L4)@6X78]7!9 N&]1-^]Z4IU,
M"ML21"_NR/>/&"@!1A0MC$F #$@8Q:6%O^2V2*GS,K#)7WM8A(E($.GOAAX.
MZ -4VB^G"E9*(5FH<S8GE,-]'6D&ER<9@*AA DF>$?IX0S<+DNY]38@J-WUE
M6K[F^4-&&?WFES^_?WMQ]>*?4**OGKTL_L/\K31!O'^VYV(#8@U,G*KH4-BZ
M@?;AI5CQC!8#P/86[L]4B[@,2D+3;HAWS?8:#2-D9J0@)*#6 G.!)P<Z[=0V
MG:7%Z;+AL%M[+#=P.-?V;,1M&<EXJ*9F8J3; L_R8M,"NG#'VN(2:'S!RDQ^
M<"&PO3M9E ED8NW,QO,?Z1V " ]I@?M)2:.^[%L0A';[,ASP4[P&A!U? /A+
MO&GD=X'($R6=@IT^VPH9.V VD&![OE;_)>P':"Z!KHOFVK9B?X,SXV I0"=8
M! ;N5DY_ZM= 3L4!1 U( , OW-1&;'T20=L><6R!"AK$G["2V(%P:)!#N$[=
M*%6*G,]2T[K\@5&_F#6_ZBPHC,@A*.E.<'U?2E32@+^O7H!W6U7DJ'=TG ,Y
MU,%J0-*&<]T@1#FZ?&T<B^=UO]U[$1I8=*$9@AR8H; !&!$XIA162X@?I KC
M#2"$NBLJN/*N .?VR,XMW1KQ%!R%X24R18Y\B6 $&%&!$:L! UNT]U-.W#9$
M( BTL^Q L/QBI#MOP,@QHHTE(AN.T!J@5>":;2ENDT<X"6-8MZ\2MEZ2O=7B
M(]4Y)QB"XNNFE.241EP6'P]-7VU%JS1HDH$1>SQ%^QD(X)JH [B'R.$$$J2S
M=%G(@"Z:<#VNW)FRAG/>'"RA94H_W0 A11&;44,BKUN+J [+@2JB-UDCLVI3
MZABX"];H2S0JX*/?HX^]]4&8.*)YZQB#6WG5Y7$[:Z-^$VS4;V9MU-=X&0@-
M7R71=<Y4G5TE;ZKFED8) ,<1L5Z(2+RS?84RGRB2_&&R6.[C1J61A-M62,,(
MQ:M7'U\C%UX 1>Z *GZO?4A':'O4A<0)!"'PH9 L2 ?@+U(\F\:A 09ZO":X
M%T!E&WLB&0 4YHBHA\K>B:F).@H455M:(JZ=*=OBVE2]719OO&93(3UXFX2M
MH_/H&Q,1FSVBF#*.GNB9K(43B\W<+F!U@#58@?H*2X"':O9LT)+=8]N-Y[/?
M4&C3-\)+@/H-<@XKBNJ,:T_P>Y2#X_BEA'2 I9%+KYN*#$T#=[!'EM_:?6OI
M3!$ P#R:Q)7] FLOR#6EUV]()FD11E(A8!6O0\=[Q.K(877!_FKI-A6:"WAF
M$(>V>#++\,\#PS^?9?@/AARSX"ARZ'Z"ZV>7RG/]Y/IHS@V9E_45R "O4%^!
M];"ZO+Q:S,B]@C:K66"RTG)S#DE35V#E?NR!4&@!TZ9P@?;I>;%3"KO+7,+J
M^>PMO BW\&+^%L IV90 $$$>H9ZXAWLO-HX09#&*D0&^!;8ZE&+3F@S9#52@
MZ]?@#I2FE<_(Z,>=6G.R/3"]*WXJCR7NYJ7F)C%*D&WDBP3E(3QKQKZ\]Z+4
MA8]@\2$J-&_Q'S4'I99S$.*Z*&.2A;IFSUH?.1$, 4O!%.#9686,8./VX<Q3
MP@BI4>V&F^!9N@/J0GJ2,(NF.POSZ4 &AQ':IIH,MOD'\#J##73PGG\N>.30
MZR2J[QH2<;A-B_:VHT^N 6RRW$&C]FTM-F[9>2'*DC(PN"S+P1Z7A!$ HV:W
M XM2SNX7[ YMT^_9E#HU-Z@:&[$]^?TD'J3#=B/$[OJJ.@]8(#7):Q6< 3Q1
MZ!"\;1=O?3+2#B@_2W3Q(GF + XA>E[-;$2'KTU%7I'H?;$GM\4>E"8;\>IQ
ML!^Z&PK3>JHHIR\. 0'W\0BD2:'X/\7%,0H8* VT;GP,0*A0E>*B:F>ROL'G
M!UK _U#Z(49HRU;';#G(IW"VU(942!;"TPF31?N(7=BM*-':HFY'*8UV0.W0
M,Z0(!!@\]>8<"2NL?'OT6C3]!FR-&(I,H"F#A2#>?N^\5:%?.X)<$%\O'!&.
M*T? VVENP+9UA_($?P 1@ FP()"]DJ& +,MI)+?%>&?#K,J6G;J3A2"('3'@
MFY;NI8Q4XD^/P1J6_YJ2O0C%++BW!?\25LQ1%.J^(&%8()F(-K!_.$!G-PU8
M-D[L0%$>H%.JGKS+?=-LT7=:),H$H:F;^D)6!Z6VGU&L5Y<Q97TYJPU_"5%C
M9_<DE[.YZ=E%\J;->.4B\Q'RF%@HR%V!BD0K*#.7G%JS.8A6T->K[9.X6!F<
M?&>.UKL/3MZ@?*A/S#C/P$& O3F4=J< ?FO!OL;U?S:?@6"#JG[SR]N?O2)F
MML%/.+;F3DA<*/I#-JBJFDUP%. )":;"IDT&-^CI4LY'L ).B<IPIMOIJ",%
M 7 _=L9@J[<^$C%KCUVI2H>K6;+Y$9Q]L,\E<[$1QJLF3;+YY?($-+?'M!^9
M$A1(&.6P;H%Q3!OR"Z6[U0W:]?5&HC\4(N>%&00/U[+(0^J5TORW"*\_& $,
MMS<&67$&>+4L/5MRE0"D:U-6Y(IU04\'3:_WBH"&-5B-DN7*.H\-1EPMZ/TT
M=T+!_O0$M3(2]!VA(QVN"*W,"S P PPJ,/AIUHC>C5_X>Y%FO#ODL[*(,^8G
MB1_[.-4)5.H_#@R# >7]$!Q/CRJ*R^#A/]2E9NYT$42++[MX15&W<(G#"X^:
MT(FY+MJ(>(5#I&B)M?: *9-K&_*@8F22'SZD:.%97((5L20")Y]S@XTE.H21
M&E3XP>(>(5W\3#:XF]VR>)<_6<GI'HRG'IO:LAL+,H+S#2A"'>5QR#91A##@
M?\RUJM0097C',+D#.B3K 38IR%Z=;\$K)PTV%=!_N2N]O>W-F6:(&4S#T/&-
MJA72,,X+^%44\*MY 1\8%P1$U_;3IL'L.A.2/2S^/BY>_,K(8]$!6 FF$GT2
MWU&2(HJ7Q%9*Z3H0TQ^!@D]P38AW#&3C_9^5QT(E:UBM0<: (Q8?Q?,B.E@_
M8U64-6AVZSM/8HA@<?_6.V]R:]&),<LT4,F>7384&5@P)8F%"F'>!@E[?)0Q
MZ?S#7K#O?A^"P=G9M.4:#X7EJ,O,!=%3N8O0N Z><IH15JF@ 6 HE,&:(5<[
MRHG!,Y3M@Z-VIO9XH) !$$;I/OM4W0W'O+T4#^Y8YM@<X!J=!JZ! @ ^G6&W
M"PJ#'4R[QW]3JK6JN-J( 0<U_$:X74Q!"JI(3NZV2WDW)!6 ?,L%3N4UAADD
MHRKY+\2T(:FEPZFR*F5QCF"D9HE9%$_JY98;FTLKO/_QUX_%U=,%87E,2*U5
M!*DWR/$('4UM2CQ2/)20\>D$7BR>\]'OHN4?O9:4%(KXL^.W%WGPE7PF+<^Z
M":SY&\(B*.=]0XXQ%V+(92KY]6U(7([7[S"1!>H'J0I/._OHK?*@>/CCGS_\
M]&A 9)X=P>TY@H@F4;0&M?1MDFT>:+^0<SLV6UO1S9!#YLV9 7S)4IK'8YT'
M,@:6,  74EQQ)%[EH&C%* 49[# N6,#MF_%+H0ASUK9('00D7WA&DN]>(/L_
M!01XE36X4@-@2Z22>Q#I&;%E\#E&F_/:_HPY23JDD+RPU9PU>+Y4L2>X3FQ1
M&)!P4W.>&^C'BP(4("#F07"0>0NN,U%6))G.!_0.M@JG,4.RN2$YU:Q_L]0U
M0&Y74QR::I@(5WIG X!A^!)#FEE*<AJ(Y!&D\&G"VB,$+:;*L/(J:IM .^ *
M4CF,.8>2HQ-G#,0']'$J'UQ0WU(Z&LOR4.]P_;"4$H[D@4_9W')ORH.AR"\;
MC@( 1]>6X-R[$#_$H,>Q[+H0'XSOXE&VZ:/ET1<%L,%.%E)@?T(/W0;^ TU2
MD#N<<V/RQN^.""93L*;VG2$.)E&)T0F6D.=4."O3,D_U=Q9VHY?#?<Z29B.U
M#^"L23R'R;+Q!#A.P0P>D.K"JO)/<B:9]8&[S83SCC><OF\1ED51MA@XDJO6
M=0\$<48],7OEF22P\=VIFH+>:8"U([[/48A.I ??3U^K-^2!+/! 0A<^?Z\(
M8UF\3^3GZ)AD8KQ0CMF-EKA\G3VJB"/6H0#<:-P!<IO/1.LJ0HBE/<R(?[,D
M=:GJ;0,,"#?"81#:9O52!2+SSQ4/W[T!ZJ/=0[:*HAELI^B2@"S$7,'I.*T2
M*G&0;(WC:']JN<&580*=C#"!! U:=3<A$(@>SKIM#**Z)0\9 -%X( ,VQA?5
M<LS8))7()\Z>?:%BUB>LXL+ "<H&7\T<50KV5AC7U)0&8].<:BR-Q$:E])-Y
MUF>X]-TPKPW*:7=]1\F.2.VAOLW3'Y5KJIJ'TGG*N/"4X</*8+NB= 3)N/%Q
MAB/*.$D6Y.PW3>>QUX"U)DI5RA!O]?UQ-$#0^%?@53P.8']C<SJB(*/5KTOF
MD[HC'X'^V&%$Z2IF@U61W&VP_H/@Q"L5,:0 E!I-A#N%=14#YLGG3[P,O:%:
MMPUE4/)6'D$?30J==5,\-A'FDTVO5A=4=9ASQR;]">T&C^5A_CF*^Y3!5\/U
M6?& ."9MJ97?T,^^S7&BRE:?#(GNT>(VATHE,EEN:$LOZP#?11]KIZPZ+V;B
M!W^OT<,> G]X06X!ODY^MV.4E+L$'ZKRU]2*'^+EZ<,%3P))9]*/8 DXX4;@
MDZDCL2Q^3:J316<[=J)#L7)X"F70P!U70*HBGIC!9!N,XPW1'@-T2:EDK-'!
M*@79AZP$VW%.BFH*@H6'_@$EX%&&KSEXCNZ!+">26:J%[<%4.ZG:;;FA@.K&
MU'F4:\;7C+0&]PN4>@JR>";$D&+P38K!-P&#6 !A3^5&Q3!VP'!D]H!]C-MC
M++*4Y%M$/5.'6/)$!JW=X1%=!MGP9JPX82YBG>4D!T?^=,7D$T+P,7;C02 3
MGC2/!\]YBM+>#9,<]GMP) )N,&EX7%?EWDBFYU,V=!-)AA?4!+;V1=]=J*SU
M!5+JQ!.I[XECHY?NPWBAW'Z(BXB%'PU72_N&DJ3WPP!^@?)".4T"V.*V^!;0
M;]W49"L,7J1^.:9FD<<I15 %2 B<Y&-B8WQS;K'V&5_&A>,Z43MU;<7PPL.=
M^$:-@CQ+4V&?'GH=9'RUC+T\EZ&5QX<$%$SM2XXO_-LA7:GT*)F(H:!A)_YN
MRD!3%4""P"AZ@F@ZH<E!^* M0SVJ%T?:M,"Z6'100URGW3+E;WV=F;P5]PEF
M(Q.CPH42>8J]5/=!"(=0X0>7'A4\T8$2<(-0H"SB#5ZEXB(TU-?R?PT158H(
M5%.%;JH.)=";5M([*M[-ZI:R+L1)1:+HZT ZTP1&\78NM9# A^ ',,#&T* )
M0"(_$>R0XT\-,M\M"99'>2PK[,]=^'!7[M@>5L>M*!EHX8JHEP'M6#YQ1O8O
M)C=0>+4EG<PH"4[9">J#B=K9'_>6$R[$6Y3$IO<778,F$7T8HQG$J+"98;</
M6[18+I! W?HCCE5:28U.R^*GT#+G$^+:WP-$8R-A'7DV4<O<;V?M7*&QBB%T
MEHP(R;S!I1 6E=;5^MMPQ@A9"4OH?3'/> 6L4D?6*UT7$OZGII2R>$)(K=0W
MP7P':1818[#>/1:=V"^&(^N=5A?*JS_';$SL*9I@F(64CZ&I1>T^G+JZR\%!
M%S7B/G?6&S&W[\B86DSD?.Z@]X57XF0(960D6I!K2N8UH:_%@"5/Q Z1XD(,
M*S3E<GO2WG(C( :W2?7[S@KIA40#=M]78;X F 9'[)K D#%Z#9TT";+FEGXF
M5565-SSN8&D):/$$F#&45@==\D:1U*K\C($ZL;^\L_.7J!M&6RU\%'I#\?UF
M4QJ?6Q#)DP,@>"Y8[^]O15,,9S:QMX.;0]=L&1$Q)<862H#648AA:#KVQU[,
MEH%J_QL!"!X<:L=F ZIJ6?P\ON%DJL;0((X6"5G>"V4UAFLFAP*\)>D2D8RH
MO]'AX3#::KG]^5#::ZKV[4I?:1[6DA I/^)==QRQ0KFB]]Y1;;/FF'$JU(J=
M3=;=S=_]A,$K9"555 M4O>E]0HQ1K_UHDI:YS+@O0Y37PEX^W>6[8,'JM-=X
MQ]*S.0MH2]V&266==$@8%,- LH!KGW_0'*#C>,+QL:8]B0-6Y2YPUO!<0L(\
M'*%MR:B,I)AY8UG\(ED+OJ?TK[$1+1RA'>Q0?A DLQ>"0L+"ZD!=5!NP!%*5
M*"[B&27'K_]JCJ>7;XM/Y@M2$(I53I%AGR7<0TW+ .7M6W,4[!YL=>*:T=T.
MC^[HTGSL4V992 ABYW=8%N] NE(U*F4:01_TK7H^]M31M#(KM4Y)_1ZH47&W
M3:+$OGZR?/HO-"ECB^W/;*Q(SS >A#UCT]8<BM\(O!* @K6^6EWZEN5%K -)
MPAQJN[ )WX>DNX0   I /FKJ3 ?5^U<?B]7EPE<!HW=H:^>M6QXTP6,$.-UL
M*IS.%B>$+"(13">8O9_$/!.,C+(+I4=)8&;0,\S(D@Q,;-*9H!-5W\P7Y +'
MT %"A(*,V8J;"><*Q.*TKZLGLP5B[\-XE&Q5V.S+^:JPN")QAIJ_(L=!#*]M
M;1'9:=FC%SCXL'?B*5IAO.P*YB8\(C8W+9]&/4*X4.].4FQ'$XD D;_U;>FV
MI2=R5=FE HS!.<7W)RI;D9?*==_YB ...FE:K%-4E8P+X,O>R4*^+44:$WAO
MD@^*'FGT CG8?' WC@TOB[=W@2\MI""$YT ,A4*"JM0!I^1+%)2J6@'7OB8]
MW+2CC;GF>+O0]T/53F&38!O8FF=B8"3)5WS11 OY0A=IQ"S.7SQ$X:K4C0<O
M306_6_+H0C0KFZ[9A>8-<O'JW$(D5K41Q]86!PI4@AJ 69=US$C@8XN Z_*8
MKP;F[!FF1TOO=NA6WAHO41B I9;#W/88*_ZAW(V3=AH8FMX*(.K7G4*+^"@%
MQ'\C#PPSA:!]Q.*6$\DL"Q\)(IL2+$R,F/BN%^L[$+F.1ANEM$@.VF!G\J)!
M:,IH",Y!D@DRP1=C/A %-(4@WZPV9%PRM<M=%GPQ@CS>?72$@,>)#ECC[R5%
M#T8II9.8)28AX&VEU7%L$VFK5)KKP@=9 4:(N"[M#?I_* N'B;4<^O0NM #/
M1YGT..H&X 8YVLXC2*@W@Z#@?PY.'&-O)'66Q0<\3-,[N)0[GCT\,@G]B"9;
M*WV56>B3:Q70HIR\NYP60Y (+)3]M&)'5G9/^4.+N?\-$WPP6.5-'RS4^U!O
M2/K5L",MBRIY+_E.O?C2\_Q9+)(0$S!'Q0 ]4'?+#>F%$F;)0[YEO0VDWZ7?
ME;'N#@14+4%X&L'C2G!.05E8HH#9IN>'J@YDH@-;VJ)O#B"DSA?8U)B,+%3R
M*\!%*6R,?1#_:?63!%K8'HS6>?H &Z[[$G.+<VW;3B*"NF/?IP*='CR:NU&O
M:/*@E3X[P0DQ)>]\%;LOQGG(@_5\-ZVH3%(=%[R6+HZ7=KJ)76EN*EHTEO6'
M7$^(*WDWP$O[O<K3ZS8\G7+T4;O@3L<Q.MJ5-%_8L/9!+?SWT1[7F"R:116-
MDLO?X=Z7[M"<'5J>I[[P43Q&N[0VJ&ZDL$8%W:2)&GN!.XH]X^MA<I$/6;+6
MGH4Z@+4<3(0I5D^*/_D10FQR2X3:99[<5& '[/PU9>JBAH4DNO0B9'_0<;M:
M^1C+)[J"@:#34XU(CBJ.Z@!-72Q("U-4C"^ \E%W4FM]]G#$1(V><#22]X1L
MH:L@OTA#@0V&)BC'H'W"@KN)RV#]^<46*L3BL:1/1P[H3O+N&;H-89M4W<2&
M$3P6&M:3[H7ZE"MZR'8+QK?4N#%+4%]$*"LW+I'6Z-=F(YM"KZX_JKSBVAO)
M-S2OS,8Z [*:0Q4;H)#[:IN^(X]:XDYHX&'!5D?6@T4O30)1%HBZUU2G\+DL
M_KW?JG9D9"FD"3X-US8AL]D;G%OG"Y3+=M,?T=OPG72AK'O>P8YCKZ_FYUZ_
M\4-!?>>W+ZM+JI6RSO?]%GXU;5\D#;5T;_.IJNBV;:8V\\X1UH#*9XCF;T-+
MS2!E*J,9L-">5'GXRF%!KN0J^Z.5X3,T/2SV5&_.F\J^]$%M+ D&N7X$R53%
M4;VJ-P2+7^"UE[< (R'IF*YE!=<E-6?LAK_T%!]/32-<VV%QM2_,\I,%K70$
M<F3:%T[0B7MGM45CE)<I=;O#\7K3\'%!%6<0\WTOQND+Q"ZII#?J#I<H3OW_
MP@7);$:UQSVNAM4(Z%20#;YTU3>H<5)OY\5:TA'-V<-_".:'?#>#_KNZ!J:Z
M,6<WL]*<L(HSR*_FAY"_F6H5R,JG>\P3G]R@F/Y&<ER>U7AZ,67144P)F='T
MT:IB@RBMERV[WB=C.=,.&KV[0%6W\+FCJH3]MNE .5P(5/^^1.HY&G#\U.P=
M')$F)('J6"+@OM@0B)K'[X BD_A"4WRNP9\(FI#2/G+BV/CI>JJ%);.4BAMU
M@@Z+<?&U&)^49M"YJX]CNZ_FYW;_ZD?,LD,8QA=G;_X>,[RGUB_>J33&EBO5
M1=?S\Z>#86%AT+8@](QR<3@Y1H++G..10#_REQ[K[+P\-*>R\ZJH#I%-NSGP
MO-T=CK 52>"Z?DO%+%RQ=XYQ*@\.F89;\(>HT)E#!&%PK$2Z0[S7V?B1A,5"
M[1[-P5U7\X/8K^*4RZOY,9<_88M!GG7O\B)X!^BM<L7FLP7)0B^-AJ-[N,#)
MQ< L_9;-1;.[ .T6/GQK@1XPB$@67,TR>?@0>8M-IQJQA%5.IO3Y+0(%("%3
M,I01>*]1FCN-ZHTA60T[/IQH&4RG93]*>VG&+^6&M#_*3JF*/9/!UEH6/TGO
MA^1_G)Q*,#V,4IDXXH#J"]*:=HW#X8TEWV'O;!1]_C8?,BKI(U@M:CH1:XP*
M>1B3?<W-!8F=.0J-8QFOYN<R@I\)-T@2DG5?EECO,9!QM' Q_H0F7+4I@O.1
M^X6NR8J#G:;K^CL:\J/;HL?C/]2 K>4<=)ZJJ_-@0TTB+-QP'3!O\!'+6?9R
MO*X44,0B ]\GZE3)?W(:JD*H>&CO635F4-'$+5O=95&&).9(AKN@1)!!<6T<
M<#/;&\QS0\CB3N=/<*0J VB$C7U-E7KP@\:P*"%,[:!IK'8;\W@3Y0K#W?@X
M4OQ!3KJSNQX;*ZYE0,VM. W1>_Y5$M07;Z)1D)1:G QZT;6O )<YK>)U\+8[
MFQ'I<#K?O8B3W"4K.BA0,<EPN#8:POIKKY=UL1(7GN;- 575D*W2DZ'T7U![
MEVM"9GSJ57B*_3/^.0_/,&NJ16'KBD^;Z<'AR7)RC\(A-'\&H\ D3U$ R1BR
M$.B/T]!+7;HLFGXA*[)=@S\,AW_I,ABX)YI:P*8@@GWU5 ;6CV:I)X)C"D/O
M_OSI^>75 #WF'N@A/OW_A)?5\FZ8F5-0<6+MU?R4V;2;%?VM82-;5F/=?]'_
M3/[ZE7-)*I?H2R1D6C,>6D(PN0:HBA69E! %V66H 0,>N"AKM V6R5\8)KH8
M%82D/TX7!Q.NY@<3XF!^:OC(]C#FD#>_X(1;.;N+GC!"XVSS;?S*^X_S5,@F
MV,PM/VSO^CU=<)088 $J]1V^\H=;L",<X9<R_%;+4**XR(U_B_,UTIHY70HQ
M/V%C6?Q2BP_K HHF)NHDDZ\P:4'@O\0H#,(6%'/JN#5Z_5F&7<6)AJOYB88?
MPLRG+&W=]>5"_7-J#M7D[P"&6=T/*6?KHYI +W3]CW23PN!'*(SJP5Z,DQ,S
M/^Y  4TQ&6,P$5^)N[&",][/M*%Z,WBBV"SH[=/$C(F+)%F#@1L>1VYY.;5&
M,@_;3/0Z9L'V2-3(RC4"8QY$A@,HS47/A1E1,4V GCSP#S6A><;49WN_BY4Y
MH7 11\^=]6]O+/1L,3^X7LPGWP_I(ZEWD*9QG-MJ?IS;N^.I:LXVAA"R1'Z/
M46ZCA?&72KRK:$=?_C1H,+HQTJY;@'J1@J'89H(:+DSOX_I<K V96OS3.!#+
MO[X'7NBU%3%' U:Y<8T_SC1H30:10\I2TU$JQUU"@X$2P@X2YHDU[DW@G[2M
M*O2GAM&T8$W[0^.@*2^C!]!$O2%A)BKN+3O?F^\+RM\,^WYP-$[MRU\UK'A)
M\8[.@#>PNFGX$5IION\^W,<6_4XJ[^*9J5R&J(ZTI-!=%AM9ECB:]C,8G>?2
M5MN)V9T4W07+)@PKB!/ZUPT.V. QV#0:"-/U')7E,>MQ+BO&Y^ K&@:!(?/&
MD?/L0L)1,K/9TG7_:WP4FJ=<*%5]8(DGS8CL,?2#])AX-V_4,]*V?/O+I\K4
MONF(E@EYN6'1<><G-,7 YL<#_'W!";J ]W>D=R\\X3OU3%(D'8.2E!6,,Y,5
M8<92%3V)*0@*VK_XA?W)#W"2,!WBW<=?/B0E->1Y8I$.]PDFD.C.8=]%A,<;
MG&0T:]?PT#^D1@3$46]L([]"0NX'?Q[#\OECCCNZD2;Q[%+'&-N:J?Y.&C+L
M+>!-3,>C6@P,YG.AW8_Q&W*/PP\!8HM%3,9'4?"Z,IO/%Q\WAX9^]^(4VH>(
MOV@4#4>GS6<ZVT AAM^741U'/O)'BO 4C>'X>W?;DG/N_#FAU?<I=>HX8<(;
M!Q[H@>L&[5 ][87(BN>XT$J+-%ZQ+6D$R):E1/S]"\Q][##IDIK._L:RA_ _
M9T$R W40)G=PX]]SD=-Y!M^8U?*$\*TT182Y/F+"!U?8[ZY_6%FU5O',B\RH
M6,HQ<X.0';3W*^2/!TH0ARRFC;"ZQZHA,CJ9EP*G2(D'@')MQ?F72R(SS<?2
M99W<N<;6X3A(ER_]5QB11=3AL0-I7+ :HHC<B"R]'L.]N4C4J[&[HY][Q^92
MQ>D%Y9(A*JV58FOH=TX<4' S<<>L2HT0 I9#EEQ0)[\,<;=[B\.&?%0%V3#[
M["1.%,DEZ"'@>YPI.CI!<O:Q0; L?F:K00TVI$&O(.!J%G"#QN>TCDK/S/T4
MVD$QP"Q$KS*NQ^Q.Z4!^8HCA;#=?2P8D@U:HV!_I8K':#PRW151&)A0-#/8-
MS?CDDPS$E(DC;T'JESSN@1PP//>Q/VI)->Y<E$02O2E5? ?CX@^4HAF[I-J>
MV*V576VAFPQ]_&Y(XFS!G]/]N-A:Q*644U+2;TPBMUDQ\L-).A"HMPH^G58!
MLR@-TWZ]!TYUAP%W94?8PJ6B*/8[R[O:W:[/"CGY2RF/8/24E.0A< V5J0$K
M@+Z7@"UQ>LD_V40E#1*IY]2#'T^L.%!]B$5;L%Y8(ST/&9<W5.(^0-R<SQH[
MS%;S'68_ZF%*67_U'DUFR:)%^M>P(XM\"1Y/HDNB5 G (,,J>9I8SY/.@[J7
MP:[]83UZ5&5DO6/+?ZW!L*"1(?.=?JM8B+B:KQ=4QJ9*(6<OY#X+<=-1MEE*
MSP\C&:E"W(N!$1P,9_5K"^KW!;5LY=]O+D_D5_"LN=X7@'B;.);JI0#1FO+
MN:#Q!K5D;57E!O52\UW1CVX,8O43E993D[&30K!%(5-5T:CUGG@8I17?.I2@
MV=K-0=S:9)Y&K Y2/U15GWH<"R>T>>30V*!N8#2[_/:N(+8"9:)&_.TEAGPT
ME-J$[)"OPDU,I^;&4O(7WF6 "]\]E_NUR"RY\7VT^!/*_%/G4I@:/IGCF5@/
MMYJOAWO/OYDJLB++*_<H@DM7+7[!OF$,R(C'.JX8]#_&\1[U)?V:8R6RB'\>
MCGX?8-"&BK2 ^U"*"82_+!Z]9"V1V*D;!!.&282P7(1S@?+KIE;N#ADAJGU<
MYM%UYLLB6I8^=SXOV6+IVFJ^=.T=MZ23<<_ 96_J'D5KXY7Q1[5!-MC?\<7
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M:G<):P(,250S XD?GR5!]=KWX>2[3[UH3')MBA!@PT4RW_7CISCG(^2#8X%
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MT2R$*$Z]ZZ85Z@F1<B4)04<=M"@D2E6?G6>8_V%"5SE?)&Z,%S0FRX7W!ST
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MN-]OT?_V>Z>]+)C!:R5^\L*N)T$60(%+5@E[J[;_8+,?'V"NA/'_L*UMTS2
MO#)6E8TS15!R6;=LU^1ASR&+#C@DC4/BXZZ)?)0?F673L59;T,Z:T%S';]5[
M4W!<NJ+<64VKG/SL]+.T3*[X0J"!DWOFVM-Q: G9K8=Y@S*O49(#*'$"WY2T
M:P.?9('%2X"00NKB2MJXYLE1Q"^5/(=!U(<D2N(C>(-NGP./-SB =X\["PNA
M\@?XERV,U22'_X[@IAUNZG'3 [AWM9A!+4$J>9976J.TP(Q!:^ ,^'-^7TOK
M<?!K)8T2O& 6BYY+A,M&U)N]>_]7EL07'Z(H@OU![RO/W7F1*V KC5BZ4,Z
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MMR!'B5\:>0+#Y"V0A*1'>,,^VV'@C0XIA"U2#4J#R]# @T"1H?YUA#SJR:-
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MQKU0K5&UK#B"#)P&<+_D6ABG1[0SIG 4IHX&-[J2K>-BPM=/,._J^AE67%9
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MMP"_SY6RVQ?GH+^83?\%4$L#!!0    ( ),Y1U,@?.C )0(  *8$   9
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MA]H)T'ZAJ%,U$V>@?1XN_@%02P,$%     @ DSE'4W3KZ="Z @  \04  !D
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M[LTPO&.FY,J"P#E!D[-^-P+3#)CFX'0=FGJF'8V(L*UH)J/Q#O1_KK7;'GR
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M_W%UO#Q/^SOC:7M_\W[F>B>(<HTEF4:'RW0*NK_-^HE5K;]!MLK2?>2'%?T
MH'8;Z'NIE'V<. ?C+\7F?U!+ P04    " "3.4=35#W#X=X"  #W!@  &0
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MCJ)V9%!?+\,$BK(T-75&(\ OD%785Q&NW7!;GP4)7-DL!J=KV?7^GU*IH"Q
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MIP:CU]H>X7J&FRA>VW>ZYTJ79(>E;K,@3(#>SSE7IXDAZ!MW\@=02P,$%
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M.ZYQ@G>X^)VSA#WY?:)RR;A".2R,++@9&K"R.DQ5 RW6[G@Q%]H<5MSERAQ
M0=H <W\AA'X>V!-+<Z2=_@%02P,$%     @ DSE'4R]KJ>-_ P  4PT  !D
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M4,'(-KWLGH5NHD7C.FLIM.E3-ZS,2XK2!IC]4@B]G=AF'=[F[!]02P,$%
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M9I)K_T3K<F[:#="LT$;F%=@JR)DHW_1;Y8@=0(Q/ *(*$)T+B"M ?  @R0E
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ML<6H;R[M'PDH-\%^GTMI-AUGH/['&?P/4$L#!!0    ( ),Y1U.-KX+-+0(
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MZ^X3#OE<>'^%EC9\H1MLXPB*UI)N!K!CT C5__GS4(<=P.3\#4 R ))# >D
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M]1K:%^S/!:OF4; H]CTN?(1Z]81D0$)"O=9!^V)7AN<F#0OB]&QE2E-YLN@
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M)OG9.<@U#?F0-.2:AGR .TE3WG$G"7J0>YP:'*19R8^]DS3E[?,!WX>8,0,
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M$/XK%MI#*W4Q&)(F%4%JRZ9MTK2H4;>':0\.',&JP=0V2?/O9QO"TC:IJO$
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M=F9IQC-(&V#V"R'T?F$O]##PD[]02P,$%     @ DSE'4\[WP$T% @   00
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MM#6@_96BH^@FUD'_Q;/X!5!+ P04    " "3.4=32L? 1[H"  #I"   &0
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M+TNJ8"KRGUFBTY%SXY $UK3,]:/8?H;:3]_HK42N["_9UEC/(:M2:<%J,NZ
M9;SZIZ]U'@X(?GR"$-2$H$V(3A#"FA"^EQ#5A,AFIK)B\S"CFHZ'4FR)-&A4
M,P.;3,M&^QDW95]HB4\SY.GQ-]BA',<*8RTU*4 JP3GD),G4*A>JE*!(CRRJ
M4T'$FJP$PS.GJ"T;HPD0+1 ML9!"*D)Y0H1.01(&;(ERAO-\*LKE##3-\BL,
M<?\T(Y<75^2"9)Q\3T6I4$H-78TNS5[=5>UH4CD*3CCR _(@N$X5^<@32-X*
MN)B>)D?!/D>3X*SBUY)?D]#[0 (O\#LV-'T_W>N@S]Y-]V_/N F;BH=6+SRA
M]P@YU9"0@DJ](UI2K*5]!Q7Y19<*%U;Z]YDX41,GLG&B$W$6J9"ZIT$R JS(
MQ0Z +('#.M.=5:W48JMF+JN7L=\?1$/WY3#3': P:(%F'2!_$#>@-V[ZC9O^
M63=SH72O\F&/\#DGE5+_3?R@9>08<SMHV3B&W$3=)N+&1/R?DE )/7--FO);
M(YT&XJ/(L=_:W?08$X1>R\$QQ@_ZW18&C87!60LG[ZO#:ZG+T^#H4.!^PY:I
M8Y ?]_V6JPY0>-.VY1Y<R0SDQK8VA;LLN:YNGF:UZ9[WMFFTUB?85:LF^$^F
M:LD/5&XR?&MS6*.D=SW 1,NJS543+0I[\2^%QC9BARE^&8 T 'R^%D+O)R9
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M!)0%F/U<2MQ/;(#VQY3\ 5!+ P04    " "3.4=3M<B!;S "  "-!0  &0
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M!H*))YB>(/BN60[6) .^9UMA#0JMY'/7EPK6Z<9>UW70/@T3NG\!93J@3"]
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MP66Z^I=\,Q/AGL:AL3?'!XQ[I'$>>\1Y;,1Y8)DH$&N>QUR>QT90A^ADSWX
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MB_ 1J>UR] BC;(&)2B QBA0F\.DP@5EBBA+K5?H11QT]IL#)8P(D,L$IF4R
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MP\/;(E\6=;] ]_YU5;6/3_H/.-S;]_+_4$L#!!0    ( ),Y1U,6WR0/,P,
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M&?=5.[SFB^4?R#<_ 5!+ 0(4 Q0    ( ),Y1U,'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ DSE'
M4QNDR8ON    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ DSE'4YE<G",0!@  G"<  !,              ( !
MS $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "3.4=32?J( UT&
M  #U'   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ DSE'4T!2ST0S!@  $AL  !@              ("!
MH X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ),Y1U-H
M% @NT00  ,,4   8              " @0D5  !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"% ,4    " "3.4=3!:.#'EP(  "81   &
M    @($0&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MDSE'4QQ(5D:5!@  R!P  !@              ("!HB(  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ),Y1U/>Z41W_P(  (L&   8
M          " @6TI  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "3.4=3I,E)9Y,G   *A@  &               @(&B+   >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ DSE'4S#HJ:'2"   LQ<
M !@              ("!:U0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( ),Y1U/H67Y9O ,  $((   8              " @7-=  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "3.4=3PSS2DI "
M   (!@  &0              @(%E80  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( ),Y1U.3FKMR?P(  &L%   9              "
M@2QD  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ DSE'
M4X\%JKL] P  6 <  !D              ("!XF8  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "3.4=3L>HDQQ0$   6"0  &0
M        @(%6:@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( ),Y1U,7AJ?D10(  !0%   9              " @:%N  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ DSE'4S3S[,LV P  N08
M !D              ("!'7$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "3.4=3JLX^I1P"  "7!   &0              @(&*=
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ),Y1U,!:'4+
MP ,  $4(   9              " @=UV  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ DSE'4^<UU<1W @  A 4  !D
M ("!U'H  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "3
M.4=3\7W6ID("   9!0  &0              @(&"?0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ),Y1U/5A_"VZ04  +X-   9
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M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ DSE'4^N
M&K.Y @  # 8  !D              ("!8I0  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " "3.4=3R9?1)3<"  #;!   &0
M    @(%2EP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M ),Y1U.B20+6)0P  )LA   9              " @<"9  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ DSE'4_/TWHM4!0  U P  !D
M             ("!'*8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "3.4=3\\$8\_0"  !N!@  &0              @(&GJP  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ),Y1U/!1+-^D (
M +X%   9              " @=*N  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ DSE'4RD0#58W @  _ 0  !D              ("!
MF;$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "3.4=3
MY6]2W3\"  #G!   &0              @($'M   >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ),Y1U-.:>0@-@,  )H'   9
M      " @7VV  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ DSE'4P\Z0(EG!   &0H  !D              ("!ZKD  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "3.4=38H?M;?,"  "-!@
M&0              @(&(O@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( ),Y1U-J).,6LP0  *4*   9              " @;+!  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ DSE'4WE09>D_
M P  K0<  !D              ("!G,8  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " "3.4=3DG4J]XH*   #(0  &0
M@($2R@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ),Y
M1U, W9&R&0(  *T$   9              " @=/4  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ DSE'4_AI$-]5*0  390  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( ),Y1U,V1Y1[2@(  .0$   9
M  " @1\. 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MDSE'4XH4[[N* @  ?P4  !D              ("!H! ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " "3.4=3K/FX-B("  "5!   &0
M            @(%A$P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( ),Y1U-2'=3E:0,   T(   9              " @;H5 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ DSE'4W MH45$ @
M'04  !D              ("!6AD! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " "3.4=3>@R,;E0"   D!0  &0              @('5
M&P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ),Y1U/
M4P=$A@(  /T%   9              " @6 > 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ DSE'4Y]0<U=" @  TP0  !D
M     ("!'2$! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ),Y1U-TZ^G0N@(  /$%   9              "
M@:\S 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ DSE'
M4]D=]-&7 @  L 4  !D              ("!H#8! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " "3.4=3-S0LA P#  "5!@  &0
M        @(%N.0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( ),Y1U.@X:]J^P(  'T&   9              " @;$\ 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ DSE'4VH(0YSM P  7@@
M !D              ("!XS\! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " "3.4=35#W#X=X"  #W!@  &0              @($'1 $
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ),Y1U,I#EKC
MCP<  #<9   9              " @1Q' 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ DSE'4X3S. R9!   ]!$  !D
M ("!XDX! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "3
M.4=3N] ZREX"   -!0  &0              @(&R4P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ),Y1U,7%RX'70(  ,0%   9
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M970V.2YX;6Q02P$"% ,4    " "3.4=3[0+XQ"L%  #$$@  &0
M    @(&@9@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M ),Y1U/A5M^GI (  'T)   9              " @0)L 0!X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ DSE'4SB$P9UX @  )P<  !D
M             ("!W6X! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"
M% ,4    " "3.4=3.D[1^"X#  #J"P  &0              @(&,<0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( ),Y1U-H4!(H^@$
M /@#   9              " @?%T 0!X;"]W;W)K<VAE971S+W-H965T-S0N
M>&UL4$L! A0#%     @ DSE'4W=;\RX1 @  @P0  !D              ("!
M(G<! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " "3.4=3
M5(QP-5L#  #>#@  &0              @(%J>0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<V+GAM;%!+ 0(4 Q0    ( ),Y1U,O:ZGC?P,  %,-   9
M      " @?Q\ 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%
M  @ DSE'4^\I-2=' @  [ 4  !D              ("!LH ! 'AL+W=O<FMS
M:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " "3.4=3-53$J4<"  "G!0
M&0              @($P@P$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+
M 0(4 Q0    ( ),Y1U,H%B"8T (  /X)   9              " @:Z% 0!X
M;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ DSE'4VQX:7Z/
M P  [PP  !D              ("!M8@! 'AL+W=O<FMS:&5E=',O<VAE970X
M,2YX;6Q02P$"% ,4    " "3.4=3C:^"S2T"  #A!   &0
M@(%[C $ >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( ),Y
M1U-)6^RC4 @  .HU   9              " @=^. 0!X;"]W;W)K<VAE971S
M+W-H965T.#,N>&UL4$L! A0#%     @ DSE'4]-+W49C @  _ 4  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " "3.4=32L?
M1[H"  #I"   &0              @('EH0$ >&PO=V]R:W-H965T<R]S:&5E
M=#@X+GAM;%!+ 0(4 Q0    ( ),Y1U,G5&X<K ,   4.   9
M  " @=:D 0!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @
MDSE'4\':\@VV!   FB   !D              ("!N:@! 'AL+W=O<FMS:&5E
M=',O<VAE970Y,"YX;6Q02P$"% ,4    " "3.4=3P:<:)&\#   X#0  &0
M            @(&FK0$ >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4
M Q0    ( ),Y1U->=\&OA@,  "<.   9              " @4RQ 0!X;"]W
M;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ DSE'4Q$T\H31 @
MP0D  !D              ("!";4! 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX
M;6Q02P$"% ,4    " "3.4=3-YKE#G$#  #6#   &0              @($1
MN $ >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( ),Y1U.U
M0S@LAP(  $$(   9              " @;F[ 0!X;"]W;W)K<VAE971S+W-H
M965T.34N>&UL4$L! A0#%     @ DSE'4V#R_.?] @  =P@  !D
M     ("!=[X! 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4
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M,"YX;6Q02P$"% ,4    " "3.4=3BW4 HJ #   ,$@  &@
M@(% S@$ >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " "3
M.4=3VNC>'B0%  !\$P  &@              @($8T@$ >&PO=V]R:W-H965T
M<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " "3.4=3JK3_?4$#  #1"@  &@
M            @(%TUP$ >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"
M% ,4    " "3.4=32>$+1LP"  "T!P  &@              @('MV@$ >&PO
M=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " "3.4=3YW0JS^,$
M   6&P  &@              @('QW0$ >&PO=V]R:W-H965T<R]S:&5E=#$P
M-2YX;6Q02P$"% ,4    " "3.4=3(?*ET9D,  #*8@  &@
M@($,XP$ >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " "3
M.4=3<Y,0>(P,  #G=P  &@              @('=[P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$P-RYX;6Q02P$"% ,4    " "3.4=3%M\D#S,#   0$P  #0
M            @ &A_ $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ),Y1U.7
MBKL<P    !,"   +              "  ?__ 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( ),Y1U/)\5HY-@<  *-%   /              "  >@  @!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "3.4=3F-"7[@4#  #:/@  &@
M        @ %+" ( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "3.4=3\GX#[W$"  ")/   $P              @ &("P( 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     <P!S *0?   J#@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>314</ContextCount>
  <ElementCount>369</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>114</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated statements of profit or loss and other comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated statements of profit or loss and other comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated statements of financial position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated statements of financial position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Statements of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Statements of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated statements of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Disclosure - General information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/GeneralInformation</Role>
      <ShortName>General information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Critical accounting judgements, estimates and assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions</Role>
      <ShortName>Critical accounting judgements, estimates and assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Operating segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OperatingSegments</Role>
      <ShortName>Operating segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OtherIncome</Role>
      <ShortName>Other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/Expenses</Role>
      <ShortName>Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Income tax benefit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IncomeTaxBenefit</Role>
      <ShortName>Income tax benefit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Current assets - cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents</Role>
      <ShortName>Current assets - cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Trade and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables</Role>
      <ShortName>Trade and other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OtherAssets</Role>
      <ShortName>Other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Employee benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EmployeeBenefits</Role>
      <ShortName>Employee benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Contingent consideration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ContingentConsideration</Role>
      <ShortName>Contingent consideration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Deferred tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/DeferredTax</Role>
      <ShortName>Deferred tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Equity - contributed equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityContributedEquity</Role>
      <ShortName>Equity - contributed equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Equity - Other contributed equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity</Role>
      <ShortName>Equity - Other contributed equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Equity - reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityReserves</Role>
      <ShortName>Equity - reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Equity - dividends</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityDividends</Role>
      <ShortName>Equity - dividends</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FairValueMeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Key management personnel disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures</Role>
      <ShortName>Key management personnel disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Remuneration of auditors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RemunerationOfAuditors</Role>
      <ShortName>Remuneration of auditors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Contingent liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ContingentLiabilities</Role>
      <ShortName>Contingent liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Parent entity information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ParentEntityInformation</Role>
      <ShortName>Parent entity information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Interests in subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries</Role>
      <ShortName>Interests in subsidiaries</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities</Role>
      <ShortName>Reconciliation of loss after income tax to net cash used in operating activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/Revenue</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OtherIncomeTables</Role>
      <ShortName>Other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/OtherIncome</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ExpensesTables</Role>
      <ShortName>Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/Expenses</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Income tax benefit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables</Role>
      <ShortName>Income tax benefit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/IncomeTaxBenefit</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Current assets - cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables</Role>
      <ShortName>Current assets - cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Trade and other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables</Role>
      <ShortName>Trade and other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/Intangibles</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/TradeAndOtherPayables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Employee benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables</Role>
      <ShortName>Employee benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/EmployeeBenefits</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Contingent consideration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ContingentConsiderationTables</Role>
      <ShortName>Contingent consideration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/ContingentConsideration</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Deferred tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/DeferredTaxTables</Role>
      <ShortName>Deferred tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/DeferredTax</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Equity - contributed equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityContributedEquityTables</Role>
      <ShortName>Equity - contributed equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/EquityContributedEquity</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Equity - Other contributed equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables</Role>
      <ShortName>Equity - Other contributed equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/FinancialInstruments</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Fair value measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair value measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/FairValueMeasurement</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Key management personnel disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables</Role>
      <ShortName>Key management personnel disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Remuneration of auditors (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables</Role>
      <ShortName>Remuneration of auditors (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/RemunerationOfAuditors</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Parent entity information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ParentEntityInformationTables</Role>
      <ShortName>Parent entity information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/ParentEntityInformation</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Interests in subsidiaries (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables</Role>
      <ShortName>Interests in subsidiaries (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables</Role>
      <ShortName>Reconciliation of loss after income tax to net cash used in operating activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/EarningsPerShare</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kaziatherapeutics.com/role/ShareBasedPayments</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Significant accounting policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant accounting policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail</Role>
      <ShortName>Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Operating segments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail</Role>
      <ShortName>Operating segments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Revenue - Summary of licensing revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail</Role>
      <ShortName>Revenue - Summary of licensing revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Revenue - Summary of disaggregation of revenue from contracts with customers  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail</Role>
      <ShortName>Revenue - Summary of disaggregation of revenue from contracts with customers  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Other income - Summary of other income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail</Role>
      <ShortName>Other income - Summary of other income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Expenses - Summary of expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail</Role>
      <ShortName>Expenses - Summary of expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Income tax benefit - Summary of Income tax benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail</Role>
      <ShortName>Income tax benefit - Summary of Income tax benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Income tax benefit - Summary of Income tax benefit (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail</Role>
      <ShortName>Income tax benefit - Summary of Income tax benefit (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail</Role>
      <ShortName>Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Trade and other receivables - Summary of current assets - trade and other receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail</Role>
      <ShortName>Trade and other receivables - Summary of current assets - trade and other receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Trade and other receivables - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail</Role>
      <ShortName>Trade and other receivables - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Other assets - Summary of current assets - other (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail</Role>
      <ShortName>Other assets - Summary of current assets - other (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Intangibles - Summary of non-current assets - intangibles (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail</Role>
      <ShortName>Intangibles - Summary of non-current assets - intangibles (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Intangibles - Summary of reconciliations of intangibles (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail</Role>
      <ShortName>Intangibles - Summary of reconciliations of intangibles (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Trade and other payables - Summary of current liabilities - trade and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and other payables - Summary of current liabilities - trade and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Employee benefits - Summary of provision (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail</Role>
      <ShortName>Employee benefits - Summary of provision (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Contingent consideration - Summary of liabilities - contingent consideration (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail</Role>
      <ShortName>Contingent consideration - Summary of liabilities - contingent consideration (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Contingent consideration - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail</Role>
      <ShortName>Contingent consideration - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Deferred tax - Summary of non-current liabilities - deferred tax (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail</Role>
      <ShortName>Deferred tax - Summary of non-current liabilities - deferred tax (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Equity - contributed equity - Summary of movements in ordinary share capital (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail</Role>
      <ShortName>Equity - contributed equity - Summary of movements in ordinary share capital (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Equity - contributed equity - Summary of equity - contributed equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail</Role>
      <ShortName>Equity - contributed equity - Summary of equity - contributed equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Equity - contributed equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail</Role>
      <ShortName>Equity - contributed equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Equity - Other contributed equity - Summary of equity -Other contributed equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail</Role>
      <ShortName>Equity - Other contributed equity - Summary of equity -Other contributed equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Equity - Other contributed equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail</Role>
      <ShortName>Equity - Other contributed equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Financial instruments - Summary of foreign currency risk (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail</Role>
      <ShortName>Financial instruments - Summary of foreign currency risk (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Financial instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Financial instruments - Summary of foreign currency risk sensitivity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail</Role>
      <ShortName>Financial instruments - Summary of foreign currency risk sensitivity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Financial instruments - Summary of variable interest rate balances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail</Role>
      <ShortName>Financial instruments - Summary of variable interest rate balances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail</Role>
      <ShortName>Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail</Role>
      <ShortName>Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail</Role>
      <ShortName>Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Fair value measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair value measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail</Role>
      <ShortName>Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Remuneration of auditors - Summary of remuneration of auditors (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail</Role>
      <ShortName>Remuneration of auditors - Summary of remuneration of auditors (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Related party transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related party transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Parent entity information - Statement of profit or loss and other comprehensive income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail</Role>
      <ShortName>Parent entity information - Statement of profit or loss and other comprehensive income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Parent entity information - Statement of financial position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail</Role>
      <ShortName>Parent entity information - Statement of financial position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Interests in subsidiaries - Summary of interest in subsidiaries (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail</Role>
      <ShortName>Interests in subsidiaries - Summary of interest in subsidiaries (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail</Role>
      <ShortName>Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Earnings per share - Summary of earnings per share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail</Role>
      <ShortName>Earnings per share - Summary of earnings per share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Earnings per share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail</Role>
      <ShortName>Earnings per share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Share-based payments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail</Role>
      <ShortName>Share-based payments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Share-based payments - Summary of share-based payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail</Role>
      <ShortName>Share-based payments - Summary of share-based payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d185056d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Share-based payments - Summary of valuation for each tranche of options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail</Role>
      <ShortName>Share-based payments - Summary of valuation for each tranche of options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="d185056d20f.htm">d185056d20f.htm</File>
    <File>d185056dex121.htm</File>
    <File>d185056dex122.htm</File>
    <File>d185056dex131.htm</File>
    <File>d185056dex151.htm</File>
    <File>d185056dex418.htm</File>
    <File>d185056dex419.htm</File>
    <File>d185056dex420.htm</File>
    <File>kzia-20210630.xsd</File>
    <File>kzia-20210630_cal.xml</File>
    <File>kzia-20210630_def.xml</File>
    <File>kzia-20210630_lab.xml</File>
    <File>kzia-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g185056g185056g48n95.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d185056d20f.htm": {
   "axisCustom": 3,
   "axisStandard": 24,
   "contextCount": 314,
   "dts": {
    "calculationLink": {
     "local": [
      "kzia-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kzia-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d185056d20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kzia-20210630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kzia-20210630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kzia-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 587,
   "entityCount": 1,
   "hidden": {
    "http://www.kaziatherapeutics.com/20210630": 50,
    "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 58
   },
   "keyCustom": 83,
   "keyStandard": 286,
   "memberCustom": 81,
   "memberStandard": 32,
   "nsprefix": "kzia",
   "nsuri": "http://www.kaziatherapeutics.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover",
     "role": "http://www.kaziatherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Revenue",
     "role": "http://www.kaziatherapeutics.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentAssets",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1100 - Disclosure - Parent entity information - Statement of financial position (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
     "shortName": "Parent entity information - Statement of financial position (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfParentEntityFinancialInformationExplanatory",
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1101 - Disclosure - Interests in subsidiaries - Summary of interest in subsidiaries (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail",
     "shortName": "Interests in subsidiaries - Summary of interest in subsidiaries (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_KaziaLaboratoriesPtyLtdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1102 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail",
     "shortName": "Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock",
       "kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "kzia:AdjustmentForIncreaseDecreaseInTradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1103 - Disclosure - Earnings per share - Summary of earnings per share (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail",
     "shortName": "Earnings per share - Summary of earnings per share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "kzia:NumberOfOrdinarySharesAvailableForConversion",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1104 - Disclosure - Earnings per share - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail",
     "shortName": "Earnings per share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_UnlistedOptionsMemberifrsfullClassesOfFinancialAssetsAxis",
      "decimals": "INF",
      "lang": null,
      "name": "kzia:NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1105 - Disclosure - Share-based payments - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
     "shortName": "Share-based payments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1106 - Disclosure - Share-based payments - Summary of share-based payments (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
     "shortName": "Share-based payments - Summary of share-based payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2019",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DateOfGrantOfSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1107 - Disclosure - Share-based payments - Summary of valuation for each tranche of options (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail",
     "shortName": "Share-based payments - Summary of valuation for each tranche of options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_TrancheEightMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "3",
      "lang": null,
      "name": "kzia:SharePricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD_per_Share",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Other income",
     "role": "http://www.kaziatherapeutics.com/role/OtherIncome",
     "shortName": "Other income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Expenses",
     "role": "http://www.kaziatherapeutics.com/role/Expenses",
     "shortName": "Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Income tax benefit",
     "role": "http://www.kaziatherapeutics.com/role/IncomeTaxBenefit",
     "shortName": "Income tax benefit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Current assets - cash and cash equivalents",
     "role": "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents",
     "shortName": "Current assets - cash and cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Trade and other receivables",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables",
     "shortName": "Trade and other receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Other assets",
     "role": "http://www.kaziatherapeutics.com/role/OtherAssets",
     "shortName": "Other assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Intangibles",
     "role": "http://www.kaziatherapeutics.com/role/Intangibles",
     "shortName": "Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Trade and other payables",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Employee benefits",
     "role": "http://www.kaziatherapeutics.com/role/EmployeeBenefits",
     "shortName": "Employee benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated statements of profit or loss and other comprehensive income",
     "role": "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
     "shortName": "Consolidated statements of profit or loss and other comprehensive income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Contingent consideration",
     "role": "http://www.kaziatherapeutics.com/role/ContingentConsideration",
     "shortName": "Contingent consideration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Deferred tax",
     "role": "http://www.kaziatherapeutics.com/role/DeferredTax",
     "shortName": "Deferred tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Equity - contributed equity",
     "role": "http://www.kaziatherapeutics.com/role/EquityContributedEquity",
     "shortName": "Equity - contributed equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfOtherEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Equity - Other contributed equity",
     "role": "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity",
     "shortName": "Equity - Other contributed equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfOtherEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Equity - reserves",
     "role": "http://www.kaziatherapeutics.com/role/EquityReserves",
     "shortName": "Equity - reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDividendsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Equity - dividends",
     "role": "http://www.kaziatherapeutics.com/role/EquityDividends",
     "shortName": "Equity - dividends",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDividendsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Financial instruments",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstruments",
     "shortName": "Financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Fair value measurement",
     "role": "http://www.kaziatherapeutics.com/role/FairValueMeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Key management personnel disclosures",
     "role": "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures",
     "shortName": "Key management personnel disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Remuneration of auditors",
     "role": "http://www.kaziatherapeutics.com/role/RemunerationOfAuditors",
     "shortName": "Remuneration of auditors",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated statements of financial position",
     "role": "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
     "shortName": "Consolidated statements of financial position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:NoncurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Contingent liabilities",
     "role": "http://www.kaziatherapeutics.com/role/ContingentLiabilities",
     "shortName": "Contingent liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Commitments",
     "role": "http://www.kaziatherapeutics.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Related party transactions",
     "role": "http://www.kaziatherapeutics.com/role/RelatedPartyTransactions",
     "shortName": "Related party transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Parent entity information",
     "role": "http://www.kaziatherapeutics.com/role/ParentEntityInformation",
     "shortName": "Parent entity information",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Interests in subsidiaries",
     "role": "http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries",
     "shortName": "Interests in subsidiaries",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities",
     "role": "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities",
     "shortName": "Reconciliation of loss after income tax to net cash used in operating activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Earnings per share",
     "role": "http://www.kaziatherapeutics.com/role/EarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Share-based payments",
     "role": "http://www.kaziatherapeutics.com/role/ShareBasedPayments",
     "shortName": "Share-based payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Subsequent events",
     "role": "http://www.kaziatherapeutics.com/role/SubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Significant accounting policies (Policies)",
     "role": "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Statements of changes in equity",
     "role": "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity",
     "shortName": "Statements of changes in equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2018_PreviouslyStatedMemberifrsfullRetrospectiveApplicationAndRetrospectiveRestatementAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProductsAndServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Revenue (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProductsAndServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Other income (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/OtherIncomeTables",
     "shortName": "Other income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Expenses (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/ExpensesTables",
     "shortName": "Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Income tax benefit (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables",
     "shortName": "Income tax benefit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Current assets - cash and cash equivalents (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables",
     "shortName": "Current assets - cash and cash equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Trade and other receivables (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables",
     "shortName": "Trade and other receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Other Assets (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/OtherAssetsTables",
     "shortName": "Other Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Intangibles (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/IntangiblesTables",
     "shortName": "Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Trade and other payables (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables",
     "shortName": "Trade and other payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Employee benefits (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables",
     "shortName": "Employee benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated statements of cash flows",
     "role": "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated statements of cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "lang": null,
      "name": "kzia:NetLossOnDisposalOfNonCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "true"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Contingent consideration (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables",
     "shortName": "Contingent consideration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_LaterThanOneYearMemberifrsfullMaturityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Deferred tax (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/DeferredTaxTables",
     "shortName": "Deferred tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Equity - contributed equity (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/EquityContributedEquityTables",
     "shortName": "Equity - contributed equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "kzia:DisclosureOfOtherEquityExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutOtherEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Equity - Other contributed equity (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables",
     "shortName": "Equity - Other contributed equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "kzia:DisclosureOfOtherEquityExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutOtherEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Financial instruments (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables",
     "shortName": "Financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Fair value measurement (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/FairValueMeasurementTables",
     "shortName": "Fair value measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Key management personnel disclosures (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables",
     "shortName": "Key management personnel disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Remuneration of auditors (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables",
     "shortName": "Remuneration of auditors (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfParentEntityFinancialInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Parent entity information (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/ParentEntityInformationTables",
     "shortName": "Parent entity information (Tables)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfParentEntityFinancialInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Interests in subsidiaries (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables",
     "shortName": "Interests in subsidiaries (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1006 - Disclosure - General information",
     "role": "http://www.kaziatherapeutics.com/role/GeneralInformation",
     "shortName": "General information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Reconciliation of loss after income tax to net cash used in operating activities (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables",
     "shortName": "Reconciliation of loss after income tax to net cash used in operating activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "kzia:DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kzia:DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Earnings per share (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/EarningsPerShareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Share-based payments (Tables)",
     "role": "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-based payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Significant accounting policies - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Significant accounting policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:CurrentAssetsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "kzia:PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail",
     "shortName": "Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "kzia:PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "kzia:NumberOfOperatingSegments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Operating segments - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail",
     "shortName": "Operating segments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "kzia:NumberOfOperatingSegments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segments",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Revenue - Summary of licensing revenue (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail",
     "shortName": "Revenue - Summary of licensing revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Revenue - Summary of disaggregation of revenue from contracts with customers  (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail",
     "shortName": "Revenue - Summary of disaggregation of revenue from contracts with customers  (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_GoodsOrServicesTransferredAtPointInTimeMemberifrsfullTimingOfTransferOfGoodsOrServicesAxis_LicensingRevenueMemberifrsfullProductsAndServicesAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "ifrs-full:NetForeignExchangeGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "true"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Other income - Summary of other income (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail",
     "shortName": "Other income - Summary of other income (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "ifrs-full:NetForeignExchangeGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "true"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Expenses - Summary of expenses (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
     "shortName": "Expenses - Summary of expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:NetForeignExchangeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Significant accounting policies",
     "role": "http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies",
     "shortName": "Significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Income tax benefit - Summary of Income tax benefit (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
     "shortName": "Income tax benefit - Summary of Income tax benefit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Income tax benefit - Summary of Income tax benefit (Parenthetical) (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail",
     "shortName": "Income tax benefit - Summary of Income tax benefit (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutIncomeTaxExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail",
     "shortName": "Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Trade and other receivables - Summary of current assets - trade and other receivables (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail",
     "shortName": "Trade and other receivables - Summary of current assets - trade and other receivables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "kzia:DepositPaidAsAdvance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Trade and other receivables - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail",
     "shortName": "Trade and other receivables - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "kzia:DepositPaidAsAdvance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherCurrentAssets",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Other assets - Summary of current assets - other (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail",
     "shortName": "Other assets - Summary of current assets - other (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Intangibles - Summary of non-current assets - intangibles (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
     "shortName": "Intangibles - Summary of non-current assets - intangibles (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_LicencesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Intangibles - Summary of reconciliations of intangibles (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail",
     "shortName": "Intangibles - Summary of reconciliations of intangibles (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Trade and other payables - Summary of current liabilities - trade and other payables (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail",
     "shortName": "Trade and other payables - Summary of current liabilities - trade and other payables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentProvisionsForEmployeeBenefits",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Employee benefits - Summary of provision (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail",
     "shortName": "Employee benefits - Summary of provision (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutProvisionsExplanatory",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ProvisionsForEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Critical accounting judgements, estimates and assumptions",
     "role": "http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions",
     "shortName": "Critical accounting judgements, estimates and assumptions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kzia:ContingentConsiderationCurrent",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Contingent consideration - Summary of liabilities - contingent consideration (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail",
     "shortName": "Contingent consideration - Summary of liabilities - contingent consideration (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory",
       "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "kzia:ContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "kzia:MilestonePaymentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Contingent consideration - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
     "shortName": "Contingent consideration - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "kzia:DisclosureOfContingentConsiderationLiabilitiesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "kzia:MilestonePaymentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Deferred tax - Summary of non-current liabilities - deferred tax (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail",
     "shortName": "Deferred tax - Summary of non-current liabilities - deferred tax (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Equity - contributed equity - Summary of movements in ordinary share capital (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
     "shortName": "Equity - contributed equity - Summary of movements in ordinary share capital (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P04_28_2021To04_28_2021_SharePlacementMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis",
      "decimals": "INF",
      "lang": null,
      "name": "kzia:SharesIssuedPricePerShare1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD_per_Share",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure - Equity - contributed equity - Summary of equity - contributed equity (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail",
     "shortName": "Equity - contributed equity - Summary of equity - contributed equity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure - Equity - contributed equity - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail",
     "shortName": "Equity - contributed equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD_per_Share",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherEquityInterest",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure - Equity - Other contributed equity - Summary of equity -Other contributed equity (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail",
     "shortName": "Equity - Other contributed equity - Summary of equity -Other contributed equity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure - Equity - Other contributed equity - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail",
     "shortName": "Equity - Other contributed equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2016To06_30_2017",
      "decimals": "INF",
      "lang": null,
      "name": "kzia:PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Financial instruments - Summary of foreign currency risk (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
     "shortName": "Financial instruments - Summary of foreign currency risk (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Assets",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Financial instruments - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Operating segments",
     "role": "http://www.kaziatherapeutics.com/role/OperatingSegments",
     "shortName": "Operating segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_USDsrtCurrencyAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1090 - Disclosure - Financial instruments - Summary of foreign currency risk sensitivity (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail",
     "shortName": "Financial instruments - Summary of foreign currency risk sensitivity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_CurrencyRiskMemberifrsfullTypesOfRisksAxis_IncreaseInMarketRiskMemberifrsfullRangeAxis_USDsrtCurrencyAxis",
      "decimals": "INF",
      "lang": null,
      "name": "kzia:RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1091 - Disclosure - Financial instruments - Summary of variable interest rate balances (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail",
     "shortName": "Financial instruments - Summary of variable interest rate balances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_InterestRateRiskMemberifrsfullTypesOfRisksAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kzia:TradePayablesUndiscountedCashFlows",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1092 - Disclosure - Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail",
     "shortName": "Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kzia:TradePayablesUndiscountedCashFlows",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kzia:ContingentConsiderationNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1093 - Disclosure - Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
     "shortName": "Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021_AtFairValueMemberifrsfullMeasurementAxis",
      "decimals": "-3",
      "lang": null,
      "name": "kzia:ContingentConsiderationNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2020_AtFairValueMemberifrsfullMeasurementAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kzia:FairValueOfAssetsAndLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1094 - Disclosure - Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail",
     "shortName": "Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2019_AtFairValueMemberifrsfullMeasurementAxis",
      "decimals": "-3",
      "lang": null,
      "name": "kzia:FairValueOfAssetsAndLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "kzia:MilestonePaymentDiscountRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1095 - Disclosure - Fair value measurement - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
     "shortName": "Fair value measurement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_BottomOfRangeMemberifrsfullRangeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "kzia:MilestonePaymentDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1096 - Disclosure - Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail",
     "shortName": "Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1097 - Disclosure - Remuneration of auditors - Summary of remuneration of auditors (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail",
     "shortName": "Remuneration of auditors - Summary of remuneration of auditors (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1098 - Disclosure - Related party transactions - Additional Information (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related party transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1099 - Disclosure - Parent entity information - Statement of profit or loss and other comprehensive income (Detail)",
     "role": "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail",
     "shortName": "Parent entity information - Statement of profit or loss and other comprehensive income (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "kzia:DisclosureOfParentEntityFinancialInformationExplanatory",
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d185056d20f.htm",
      "contextRef": "P07_01_2020To06_30_2021_ParentMemberifrsfullCategoriesOfRelatedPartiesAxis",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_AUD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 114,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia [member]"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US [member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euros [member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "US dollars [member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Contact Person Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Contact Personnel, Contact Person Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued payables"
       }
      }
     },
     "localname": "AccrualsClassifiedAsCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r62",
      "r66",
      "r96",
      "r106",
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Accumulated depreciation and amortisation [member]"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "auth_ref": [
      "r62",
      "r96",
      "r106",
      "r109",
      "r180",
      "r190",
      "r194",
      "r235",
      "r239"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated impairment [member]",
        "terseLabel": "Provision for impairment [member]"
       }
      }
     },
     "localname": "AccumulatedImpairmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Increase in trade and other receivables",
        "verboseLabel": "Decrease in trade and other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and amortisation",
        "verboseLabel": "Depreciation &amp; amortisation"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in deferred income",
        "terseLabel": "Increase/(decrease) in accrued revenue"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Increase/(decrease) in trade and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Increase/(decrease) in other provisions",
        "verboseLabel": "Increase/(decrease) in other provisions"
       }
      }
     },
     "localname": "AdjustmentsForProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments for:",
        "verboseLabel": "Adjustments for:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based payments",
        "verboseLabel": "Share based payments"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Foreign exchange differences"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r104",
      "r108",
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]",
        "terseLabel": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r26",
      "r158",
      "r163",
      "r164",
      "r185",
      "r204",
      "r205",
      "r220",
      "r222",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsideration",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefits",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r68",
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "negatedLabel": "Amortisation expense",
        "terseLabel": "Amortisation"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "auth_ref": [
      "r76",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amounts payable, related party transactions",
        "verboseLabel": "Trade payables to related parties"
       }
      }
     },
     "localname": "AmountsPayableRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "auth_ref": [
      "r76",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amounts receivable, related party transactions",
        "terseLabel": "Trade receivables from related parties"
       }
      }
     },
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r22",
      "r147",
      "r148",
      "r150",
      "r212",
      "r214"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 15.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "Net assets denominated in foreign currencies",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AtFairValueMember": {
     "auth_ref": [
      "r104",
      "r108",
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "At fair value [member]",
        "terseLabel": "At fair value [member]"
       }
      }
     },
     "localname": "AtFairValueMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AuditorsRemuneration": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor's remuneration",
        "totalLabel": "Auditors remuneration"
       }
      }
     },
     "localname": "AuditorsRemuneration",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AuditorsRemunerationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor's remuneration [abstract]"
       }
      }
     },
     "localname": "AuditorsRemunerationAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor's remuneration for audit services",
        "terseLabel": "Audit or review of the financial statements"
       }
      }
     },
     "localname": "AuditorsRemunerationForAuditServices",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsSummaryOfRemunerationOfAuditorsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share from continuing operations",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r172",
      "r202",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]",
        "terseLabel": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r62",
      "r64",
      "r96",
      "r99",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r180",
      "r190",
      "r191",
      "r235",
      "r240"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r64",
      "r99",
      "r105",
      "r107",
      "r108",
      "r180",
      "r190",
      "r191",
      "r235",
      "r238"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash at bank and in hand",
        "verboseLabel": "Cash at bank and on hand"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r18",
      "r120",
      "r143"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 17.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the financial year",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the financial year",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents",
        "verboseLabel": "Consolidated cash in hand and at bank"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r110",
      "r122"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r110",
      "r122"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r110",
      "r122"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "negatedLabel": "Net cash outflows from operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "auth_ref": [
      "r116",
      "r123"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations before changes in working capital",
        "totalLabel": "Cash flows from used in operations before changes in working capital",
        "verboseLabel": "Change in operating assets &amp; liabilities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]",
        "terseLabel": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]",
        "terseLabel": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail",
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "auth_ref": [
      "r94",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of contingent liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r219",
      "r230",
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]",
        "terseLabel": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]",
        "terseLabel": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]",
        "terseLabel": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]",
        "terseLabel": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]",
        "terseLabel": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that may be reclassified subsequently to profit or loss"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r3",
      "r43",
      "r128",
      "r130",
      "r136",
      "r141"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income",
        "totalLabel": "Total comprehensive income for the year",
        "verboseLabel": "Total comprehensive income for the year"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income attributable to [abstract]",
        "terseLabel": "Total comprehensive income for the year is attributable to:"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r3",
      "r45"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1": {
       "order": 15.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "terseLabel": "Owners of Kazia Therapeutics Limited"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration paid (received)",
        "negatedLabel": "Loss/(gain) on contingent consideration",
        "negatedTerseLabel": "Loss on contingent consideration"
       }
      }
     },
     "localname": "ConsiderationPaidReceived",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "auth_ref": [
      "r95",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities [member]"
       }
      }
     },
     "localname": "ContingentLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
     "auth_ref": [
      "r83",
      "r86",
      "r132",
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Country of incorporation of subsidiary",
        "terseLabel": "Country of incorporation"
       }
      }
     },
     "localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r208",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Foreign currency risk [member]"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r27",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 16.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets",
        "verboseLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssetsLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets less the amount of current liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets (liabilities)",
        "terseLabel": "Net current asset position"
       }
      }
     },
     "localname": "CurrentAssetsLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r29",
      "r136",
      "r139"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 7.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "terseLabel": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 10.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProvisionsForEmployeeBenefits",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current provisions for employee benefits",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "CurrentProvisionsForEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r28",
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "verboseLabel": "R&amp;D tax rebate receivable"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DateOfGrantOfSharebasedPaymentArrangement": {
     "auth_ref": [
      "r166",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Date of grant of share-based payment arrangement",
        "terseLabel": "Grant date"
       }
      }
     },
     "localname": "DateOfGrantOfSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets and liabilities [abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax expense or income relating to tax rate changes or the imposition of new taxes. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) relating to tax rate changes or imposition of new taxes",
        "terseLabel": "Potential tax benefit"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncomeRelatingToTaxRateChangesOrImpositionOfNewTaxes",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "auth_ref": [
      "r20",
      "r23",
      "r59"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 12.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "terseLabel": "Deferred tax",
        "verboseLabel": "Deferred tax liability associated with Licensing Agreement - Non-current liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/DeferredTaxSummaryOfNonCurrentLiabilitiesDeferredTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for finance costs. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for finance costs [text block]",
        "terseLabel": "Finance costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinanceCostsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "terseLabel": "Compound financial instruments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of non-financial assets [text block]",
        "terseLabel": "Impairment of non-financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for issued capital [text block]",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for taxes other than income tax [text block]",
        "terseLabel": "Goods and Services Tax ('GST') and other similar taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Volatility (%)"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Remaining Option Life"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk free Rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from continuing operations",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Critical accounting judgements, estimates and assumptions"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of auditors' remuneration [text block]",
        "terseLabel": "Remuneration of auditors"
       }
      }
     },
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RemunerationOfAuditors"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of consolidation [text block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Current assets - cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [text block]",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "terseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/DeferredTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [text block]",
        "terseLabel": "Summary of non-current assets - intangibles"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Summary of disaggregation of revenue from contracts with customers"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDividendsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of dividends [text block]",
        "terseLabel": "Equity - dividends"
       }
      }
     },
     "localname": "DisclosureOfDividendsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityDividends"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Summary of expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses [text block]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Expenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [line items]",
        "terseLabel": "Disclosure of fair value measurement of assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]",
        "terseLabel": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [line items]",
        "terseLabel": "Disclosure of financial assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]",
        "terseLabel": "Disclosure of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial instruments by type of interest rate. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [text block]",
        "terseLabel": "Summary of variable interest rate balances"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [line items]",
        "terseLabel": "Disclosure of financial instruments by type of interest rate [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial instruments, by type of interest rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [table]",
        "terseLabel": "Disclosure of financial instruments by type of interest rate [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r187",
      "r192",
      "r202"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "General information"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/GeneralInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGoingConcernExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's ability to continue as a going concern."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of going concern [text block]",
        "terseLabel": "Going concern"
       }
      }
     },
     "localname": "DisclosureOfGoingConcernExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Summary of valuation for each tranche of options"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information about key management personnel [text block]",
        "terseLabel": "Key management personnel disclosures"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Intangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]",
        "terseLabel": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interests in subsidiaries [text block]",
        "terseLabel": "Interests in subsidiaries"
       }
      }
     },
     "localname": "DisclosureOfInterestsInSubsidiariesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiaries"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInterimFinancialReportingExplanatory": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for interim financial reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interim financial reporting [text block]",
        "terseLabel": "Parent entity information"
       }
      }
     },
     "localname": "DisclosureOfInterimFinancialReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of issued capital [text block]",
        "terseLabel": "Equity - contributed equity"
       }
      }
     },
     "localname": "DisclosureOfIssuedCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]",
        "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]",
        "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [text block]",
        "terseLabel": "Summary of foreign currency risk"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Summary of share-based payments"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OperatingSegments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other current assets [text block]",
        "terseLabel": "Current assets - other"
       }
      }
     },
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [abstract]"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesExplanatory": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's products and services. [Refer: Products and services [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [text block]",
        "terseLabel": "Summary of licensing revenue"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [line items]"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProductsAndServicesTable": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the entity's products and services."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of products and services [table]"
       }
      }
     },
     "localname": "DisclosureOfProductsAndServicesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of provisions [text block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DisclosureOfProvisionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [text block]",
        "terseLabel": "Equity - reserves"
       }
      }
     },
     "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisclosureOfRevenueExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "auth_ref": [
      "r85",
      "r88",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [text block]",
        "terseLabel": "Summary of interest in subsidiaries"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]",
        "terseLabel": "Disclosure of subsidiaries [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "auth_ref": [
      "r85",
      "r88",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]",
        "terseLabel": "Disclosure of subsidiaries [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Significant accounting policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other receivables [text block]",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]",
        "terseLabel": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Summary of earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]",
        "terseLabel": "Earnings per share [line items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [table]",
        "terseLabel": "Earnings per share [table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effects of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r178",
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]",
        "terseLabel": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]",
        "terseLabel": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail",
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r85",
      "r88",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]",
        "terseLabel": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r22",
      "r34",
      "r127",
      "r129",
      "r147",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "totalLabel": "Equity attributable to the owners of Kazia Therapeutics Limited"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Exercise price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpenseByNature": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Expenses, by nature",
        "totalLabel": "Total Expenses"
       }
      }
     },
     "localname": "ExpenseByNature",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "ExpenseByNatureAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Employee remuneration expense"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 11.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income - bank interest"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r186",
      "r190",
      "r191",
      "r193",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Assets",
        "totalLabel": "Net exposure to cash flow interest rate risk"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAvailableforsaleCategoryMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets available-for-sale category. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets available-for-sale, category [member]",
        "verboseLabel": "Available for sale [member]"
       }
      }
     },
     "localname": "FinancialAssetsAvailableforsaleCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]",
        "terseLabel": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r219",
      "r230",
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]",
        "terseLabel": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember": {
     "auth_ref": [
      "r124",
      "r125"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy [member]",
        "terseLabel": "Increase (decrease) due to changes in accounting policy [member]"
       }
      }
     },
     "localname": "FinancialEffectOfChangesInAccountingPolicyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]",
        "terseLabel": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FloatingInterestRateMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Floating interest rate [member]",
        "terseLabel": "Variable interest rate [member]"
       }
      }
     },
     "localname": "FloatingInterestRateMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on available-for-sale financial assets",
        "negatedLabel": "Fair value loss on financial assets",
        "negatedTerseLabel": "Net fair value loss on financial assets"
       }
      }
     },
     "localname": "GainsLossesOnAvailableforsaleFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnDisposalsOfNoncurrentAssets": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on disposals of non-current assets. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on disposals of non-current assets",
        "terseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainsLossesOnDisposalsOfNoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on financial assets at fair value through profit or loss",
        "terseLabel": "Fair value losses on financial assets at fair value through profit or loss"
       }
      }
     },
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of assets. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets",
        "terseLabel": "Losses recognised in profit or loss"
       }
      }
     },
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r67",
      "r160",
      "r218",
      "r229"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]",
        "terseLabel": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail",
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r67",
      "r160",
      "r218",
      "r229"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail",
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goods or services transferred at point in time [member]",
        "terseLabel": "Timing of revenue recognition [member]"
       }
      }
     },
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r62",
      "r96",
      "r106",
      "r109",
      "r180",
      "r191",
      "r193",
      "r194",
      "r235",
      "r240"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Gross carrying amount [member]"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r63"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "disclosureGuidance": "Impairment of property, plant &amp; equipment",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment of property, plant and equipment"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r46",
      "r54",
      "r56",
      "r57",
      "r82",
      "r145",
      "r211"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      },
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax benefit",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in number of shares outstanding",
        "terseLabel": "Increase (decrease) in shares outstanding"
       }
      }
     },
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through conversion of convertible instruments, equity",
        "terseLabel": "Conversion of convertible note"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through other contributions by owners, equity",
        "terseLabel": "Contributions of equity, net of transaction costs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughOtherContributionsByOwners",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share based payment"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, equity",
        "terseLabel": "Transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r16",
      "r99"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 21.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r93",
      "r100",
      "r162"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible assets other than goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestRateRiskMember": {
     "auth_ref": [
      "r208",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate risk [member]",
        "terseLabel": "Interest rate risk [member]"
       }
      }
     },
     "localname": "InterestRateRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestRateTypesMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate types [member]",
        "terseLabel": "Interest rate types [member]"
       }
      }
     },
     "localname": "InterestRateTypesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method [abstract]"
       }
      }
     },
     "localname": "InvestmentsAccountedForUsingEquityMethodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issue of shares"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Contributed equity",
        "verboseLabel": "Ordinary shares - fully paid"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Contributed equity [member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Key management personnel compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Post-employment benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresSummaryOfCompensationMadeToDirectorsAndOtherMembersOfKeyManagementPersonnelDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r11",
      "r163",
      "r164",
      "r204",
      "r207",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than two years [member]",
        "terseLabel": "Between 1 and 2 years [member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearMember": {
     "auth_ref": [
      "r25",
      "r234",
      "r237"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year [member]",
        "terseLabel": "Later than one year [member]"
       }
      }
     },
     "localname": "LaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsideration",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two years and not later than five years [member]",
        "terseLabel": "Between 2 and 5 years [member]"
       }
      }
     },
     "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]",
        "terseLabel": "Level 3 [member]",
        "verboseLabel": "Level 3 [member]"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r68",
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r22",
      "r147",
      "r148",
      "r150",
      "r212",
      "r215"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities",
        "verboseLabel": "Net Liabilities denominated in foreign currencies"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LicencesMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Licences [member]",
        "terseLabel": "GDC licensing agreement [member]"
       }
      }
     },
     "localname": "LicencesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaterialIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material income and expense [abstract]"
       }
      }
     },
     "localname": "MaterialIncomeAndExpenseAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]",
        "terseLabel": "Summary of remaining contractual maturities of financial instrument liabilities"
       }
      }
     },
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r26",
      "r158",
      "r163",
      "r164",
      "r185",
      "r199",
      "r204",
      "r220",
      "r222",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsideration",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefits",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r104",
      "r108",
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]",
        "terseLabel": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetAssetsLiabilities": {
     "auth_ref": [
      "r11",
      "r131"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets (liabilities)",
        "totalLabel": "Net assets"
       }
      }
     },
     "localname": "NetAssetsLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeGain": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Net foreign exchange gain"
       }
      }
     },
     "localname": "NetForeignExchangeGain",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss"
       }
      }
     },
     "localname": "NetForeignExchangeLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]",
        "terseLabel": "Non-controlling interests [member]"
       }
      }
     },
     "localname": "NoncontrollingInterestsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r27",
      "r136",
      "r138"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 20.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r29",
      "r136",
      "r140"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 11.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-Current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 14.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProvisionsForEmployeeBenefits",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions for employee benefits",
        "terseLabel": "Employee benefits",
        "verboseLabel": "Long service leave"
       }
      }
     },
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentReceivables": {
     "auth_ref": [
      "r17",
      "r32"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 22.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other non-current receivables",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "NoncurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-derivative financial liabilities, undiscounted cash flows",
        "totalLabel": "Total non-derivatives"
       }
      }
     },
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r24",
      "r163",
      "r164",
      "r204",
      "r207",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "1 year or less [member]"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EmployeeBenefits",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r167",
      "r170",
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Balance at the end of the year, share options",
        "periodStartLabel": "Balance at the start of the year, share options"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "negatedTerseLabel": "Expired /lapsed on termination of employment"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Granted, share options",
        "verboseLabel": "Number of options issued to employees"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued and fully paid",
        "terseLabel": "Number of ordinary shares issued",
        "verboseLabel": "Ordinary shares - fully paid, shares"
       }
      }
     },
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfEquityContributedEquityDetail",
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r6",
      "r42",
      "r48",
      "r142"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 12.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income for the year, net of tax",
        "totalLabel": "Other comprehensive income for the year, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r30",
      "r48"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 13.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Net exchange difference on translation of financial statements of foreign controlled entities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 19.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other",
        "verboseLabel": "Prepayments"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/OtherAssetsSummaryOfCurrentAssetsOtherDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEquityInterest": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other equity interest",
        "positiveLabel": "Other contributed equity",
        "terseLabel": "Convertible note - Triaxial",
        "verboseLabel": "Face value of convertible notes"
       }
      }
     },
     "localname": "OtherEquityInterest",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquitySummaryOfEquityOtherContributedEquityDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEquityInterestMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other equity interest [member]",
        "terseLabel": "Other Contributed equity [member]"
       }
      }
     },
     "localname": "OtherEquityInterestMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r1",
      "r2",
      "r81"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income",
        "totalLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r9",
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "terseLabel": "Reserves [member]"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherRevenue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 10.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other revenue",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherRevenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding commitments made by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Outstanding commitments made by entity, related party transactions",
        "terseLabel": "Loan from related parties"
       }
      }
     },
     "localname": "OutstandingCommitmentsMadeByEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding commitments made on behalf of the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Outstanding commitments made on behalf of entity, related party transactions",
        "terseLabel": "Loan to related parties"
       }
      }
     },
     "localname": "OutstandingCommitmentsMadeOnBehalfOfEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Fully paid ordinary shares par value"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ParentMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      },
      "en-us": {
       "role": {
        "label": "Parent [member]",
        "terseLabel": "Parent [member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired",
        "verboseLabel": "Percentage of equity interests acquired"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined benefit plans",
        "terseLabel": "Employee benefits expense excluding superannuation"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined contribution plans",
        "terseLabel": "Defined contribution superannuation expense"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r4",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated [member]",
        "terseLabel": "Previously stated [member]"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary": {
     "auth_ref": [
      "r83",
      "r86",
      "r132",
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Principal place of business of subsidiary",
        "terseLabel": "Principal place of business"
       }
      }
     },
     "localname": "PrincipalPlaceOfBusinessOfSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from issue of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from non-current borrowings",
        "terseLabel": "Proceeds from funding for project purpose"
       }
      }
     },
     "localname": "ProceedsFromNoncurrentBorrowings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInterestsInAssociates": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of interests in associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of interests in associates",
        "terseLabel": "Proceeds from disposal of shares"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInterestsInAssociates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r159",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail",
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r159",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail",
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r41",
      "r114",
      "r128",
      "r130",
      "r136",
      "r212",
      "r213",
      "r221",
      "r232"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "disclosureGuidance": "Loss after income tax expense from continuing operations",
        "label": "Profit (loss)",
        "negatedLabel": "Consolidated loss after income tax",
        "positiveLabel": "Loss after income tax expense for the year",
        "positiveTerseLabel": "Loss before income tax expense for the year",
        "terseLabel": "Loss after income tax",
        "totalLabel": "Loss after income tax expense for the year",
        "verboseLabel": "Loss after income tax attributable to the owners of Kazia Therapeutics Limited"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) [abstract]",
        "terseLabel": "Loss before income tax includes the following specific"
       }
      }
     },
     "localname": "ProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "terseLabel": "Loss for the year is attributable to:"
       }
      }
     },
     "localname": "ProfitLossAttributableToAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeAlternate1": {
       "order": 14.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Loss after income tax attributable to the owners of Kazia Therapeutics Limited",
        "verboseLabel": "Owners of Kazia Therapeutics Limited"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r182",
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss before income tax benefit",
        "totalLabel": "Loss before income tax expense from continuing operations"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r65",
      "r93",
      "r162"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r84",
      "r87",
      "r134"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provisions for employee benefits. [Refer: Employee benefits expense; Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Provisions for employee benefits",
        "totalLabel": "Provisions for employee benefits"
       }
      }
     },
     "localname": "ProvisionsForEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsSummaryOfProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r172",
      "r202",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r172",
      "r202",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]",
        "terseLabel": "Numerical reconciliation of income tax benefit and tax at the statutory rate"
       }
      }
     },
     "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r4",
      "r14",
      "r124",
      "r125",
      "r126",
      "r221"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]",
        "terseLabel": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r34",
      "r51"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated losses"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r9",
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Losses [member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r4",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]",
        "terseLabel": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail",
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromInterest": {
     "auth_ref": [
      "r11",
      "r144",
      "r210",
      "r216"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 9.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income",
        "verboseLabel": "Revenue from continuing operations"
       }
      }
     },
     "localname": "RevenueFromInterest",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk exposure associated with instruments sharing characteristic",
        "terseLabel": "Effect on profit before tax/equity",
        "verboseLabel": "Favourable/adverse effect on profit before tax and equity"
       }
      }
     },
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedLabel": "General and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sensitivity analysis for types of market risk [text block]",
        "terseLabel": "Summary of foreign currency risk sensitivity"
       }
      }
     },
     "localname": "SensitivityAnalysisForEachTypeOfMarketRisk",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, classified as cash equivalents",
        "terseLabel": "Short term deposits",
        "verboseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r85",
      "r88",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]",
        "terseLabel": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Tax at the statutory tax rate of 26% (2020 &amp; 2019 27.5%)"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [member]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodsOrServicesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r172",
      "r202",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 8.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables",
        "totalLabel": "Total trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r31",
      "r35"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesSummaryOfCurrentLiabilitiesTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r17",
      "r32"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 18.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      },
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade and other receivables",
        "totalLabel": "Trade and other current receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherPayablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherReceivables": {
     "auth_ref": [
      "r17",
      "r32"
     ],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other receivables",
        "totalLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]",
        "terseLabel": "Types of interest rates [axis]"
       }
      }
     },
     "localname": "TypesOfInterestRatesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r184",
      "r188",
      "r189",
      "r223",
      "r224",
      "r225",
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r184",
      "r188",
      "r189",
      "r223",
      "r224",
      "r225",
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses for which no deferred tax asset has been recognised"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Expired, Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Granted, Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r167",
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Balance at the end of the year, Weighted average exercise price",
        "periodStartLabel": "Balance at the start of the year, Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, share options granted",
        "terseLabel": "Fair value per option"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r202",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted average [member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kzia_AccruedPayablesUndiscountedCashFlows": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payables undiscounted cash flows.",
        "label": "Accrued payables undiscounted cash flows",
        "terseLabel": "Accrued payables"
       }
      }
     },
     "localname": "AccruedPayablesUndiscountedCashFlows",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_AdditionalTaxDeductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tax deduction percentage.",
        "label": "Additional Tax Deduction Percentage",
        "terseLabel": "Additional tax deduction percentage"
       }
      }
     },
     "localname": "AdditionalTaxDeductionPercentage",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_AdjustmentForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Decrease/(increase) in trade and other payables",
        "documentation": "Adjustment for increase decrease in trade and other payables.",
        "label": "Adjustment For Increase Decrease In Trade And Other Payables"
       }
      }
     },
     "localname": "AdjustmentForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_AdjustmentsForDecreaseIncreaseInPrepayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease increase in prepayments.",
        "label": "Adjustments For Decrease Increase In Prepayments",
        "terseLabel": "Decrease/(increase) in prepayments",
        "verboseLabel": "Increase/(decrease) in prepayments"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInPrepayments",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in deferred tax liability.",
        "label": "Adjustments for increase (decrease) in deferred tax liabilities",
        "terseLabel": "Decrease in deferred tax liability"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredTaxLiabilities",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for net changes in operating assets &amp; liabilities.",
        "label": "Adjustments for net changes in operating assets and liabilities [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "AdjustmentsForNetChangesInOperatingAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_AwardTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award Types [axis]",
        "label": "Award Types [Axis]"
       }
      }
     },
     "localname": "AwardTypesAxis",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_AwardTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award Types [member]",
        "label": "Award types [member]"
       }
      }
     },
     "localname": "AwardTypesMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_BasicAndDilutedEarningsPerShareContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Earnings Per Share Continuing Operations [abstract]",
        "label": "Basic and Diluted Earnings Per Share Continuing Operations [abstract]",
        "terseLabel": "Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareContinuingOperationsAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_CashAtBankAndInHandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash at bank and in hand.",
        "label": "Cash at bank and in hand [member]",
        "terseLabel": "Cash at bank and in hand [member]"
       }
      }
     },
     "localname": "CashAtBankAndInHandMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_ChineseValueAddedTaxIncurredOnLicenseTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese value added tax incurred on license transaction.",
        "label": "Chinese Value Added Tax Incurred on License Transaction",
        "terseLabel": "Chinese Value Added Tax incurred on license transaction"
       }
      }
     },
     "localname": "ChineseValueAddedTaxIncurredOnLicenseTransaction",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ChineseWithholdingTaxIncurredOnLicenseTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese withholding tax incurred on license transaction.",
        "label": "Chinese Withholding Tax Incurred on License Transaction",
        "terseLabel": "Chinese With-Holding Tax incurred on license transaction"
       }
      }
     },
     "localname": "ChineseWithholdingTaxIncurredOnLicenseTransaction",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trials",
        "label": "Clinical Trials [Member]"
       }
      }
     },
     "localname": "ClinicalTrialsMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_ConcentrationRiskMajorCustomerPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk major customer percentage.",
        "label": "Concentration Risk Major Customer Percentage",
        "terseLabel": "Concentration risk major customer percentage"
       }
      }
     },
     "localname": "ConcentrationRiskMajorCustomerPercentage",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_ContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration",
        "totalLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsideration",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ContingentConsiderationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 9.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration current.",
        "label": "Contingent Consideration Current",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationCurrent",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ContingentConsiderationEvt801Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration EVT801 [Member]",
        "terseLabel": "Contingent consideration \u2013 EVT801"
       }
      }
     },
     "localname": "ContingentConsiderationEvt801Member",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_ContingentConsiderationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "order": 13.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration noncurrent.",
        "label": "Contingent Consideration Noncurrent",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationNoncurrent",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfAssetsAndLiabilitiesMeasuredOrDisclosedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ContingentConsiderationPaxalisibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration paxalisib [Member]",
        "terseLabel": "Contingent consideration - paxalisib"
       }
      }
     },
     "localname": "ContingentConsiderationPaxalisibMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationSummaryOfLiabilitiesContingentConsiderationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_ContingentConsiderationUndiscountedCashFlows": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration undiscounted cash flows.",
        "label": "Contingent consideration undiscounted cash flows",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationUndiscountedCashFlows",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ConversionOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of options.",
        "label": "Conversion Of Options [Member]",
        "terseLabel": "Conversion of options [member]"
       }
      }
     },
     "localname": "ConversionOfOptionsMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_ConvertibleNoteRepresentsOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "convertible note represents ordinary shares.",
        "label": "convertible note represents ordinary shares",
        "terseLabel": "Number of convertible note may be converted into ordinary shares"
       }
      }
     },
     "localname": "ConvertibleNoteRepresentsOrdinaryShares",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kzia_CovidNinteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covid ninteen",
        "label": "Covid Ninteen [Member]"
       }
      }
     },
     "localname": "CovidNinteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_DecreaseInMarketRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in market risk.",
        "label": "Decrease in market risk [member]",
        "terseLabel": "Decrease in market risk [member]"
       }
      }
     },
     "localname": "DecreaseInMarketRiskMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_DepositPaidAsAdvance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit paid as advance.",
        "label": "Deposit Paid as Advance",
        "totalLabel": "Deposit paid as advance"
       }
      }
     },
     "localname": "DepositPaidAsAdvance",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_DepositPaidNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit paid non current.",
        "label": "Deposit Paid Non Current",
        "terseLabel": "Deposit paid"
       }
      }
     },
     "localname": "DepositPaidNonCurrent",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_DepositsHeldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposits held.",
        "label": "Deposits held [member]",
        "terseLabel": "Deposits held [member]"
       }
      }
     },
     "localname": "DepositsHeldMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for current and noncurrent classification.",
        "label": "Description Of Accounting Policy For Current And Noncurrent Classification Explanatory",
        "terseLabel": "Current and non-current classification"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCurrentAndNoncurrentClassificationExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for new accounting standards and interpretations not yet mandatory or early adopted.",
        "label": "Description of accounting policy for new Accounting Standards and Interpretations not yet mandatory or early adopted [text block]",
        "terseLabel": "New Accounting Standards and Interpretations not yet mandatory or early adopted"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for new, revised or amending accounting standards and interpretations adopted.",
        "label": "Description of accounting policy for new, revised or amending Accounting Standards and Interpretations adopted [text block]",
        "terseLabel": "New or amended Accounting Standards and Interpretations adopted"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForNewRevisedOrAmendingAccountingStandardsAndInterpretationsAdoptedExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DescriptionOfParentEntityInformationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Parent Entity Information",
        "label": "Description Of Parent Entity Information [policy text block]",
        "terseLabel": "Parent entity information"
       }
      }
     },
     "localname": "DescriptionOfParentEntityInformationExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Adjustments For Reconcile Profit Loss Explanatory.",
        "label": "Disclosure Of Adjustments For Reconcile Profit Loss Explanatory [Text Block]",
        "verboseLabel": "Reconciliation of loss after income tax to net cash used in operating activities"
       }
      }
     },
     "localname": "DisclosureOfAdjustmentsForReconcileProfitLossExplanatoryTextBlock",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfContingentConsiderationLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of contingent consideration liabilities.",
        "label": "Disclosure Of Contingent Consideration Liabilities [text block]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "DisclosureOfContingentConsiderationLiabilitiesExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsideration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about auditors remuneration.",
        "label": "Disclosure of detailed information about auditors remuneration [text block]",
        "terseLabel": "Summary of remuneration of auditors"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutAuditorsRemunerationExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RemunerationOfAuditorsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure for detailed information about cash and cash equivalent.",
        "label": "Disclosure of detailed information about cash and cash equivalents [text block]",
        "terseLabel": "Summary of cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/CurrentAssetsCashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about contingent consideration liabilities.",
        "label": "Disclosure of detailed information about contingent consideration liabilities explanatory",
        "terseLabel": "Summary of liabilities - contingent consideration"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutContingentConsiderationLiabilitiesExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about deferred taxes.",
        "label": "Disclosure Of Detailed Information About Deferred Taxes Explanatory [text block]",
        "terseLabel": "Summary of non-current liabilities - deferred tax"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutDeferredTaxesExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/DeferredTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about fair value measurement.",
        "label": "Disclosure Of Detailed Information About Fair Value Measurement Explanatory [text block]",
        "terseLabel": "Summary of assets and liabilities, measured or disclosed at fair value"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutIncomeTaxExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about income tax.",
        "label": "Disclosure of detailed information about income tax [text block]",
        "terseLabel": "Summary of income tax benefit"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about issued capital.",
        "label": "Disclosure of Detailed Information About Issued Capital Explanatory",
        "terseLabel": "Summary of equity - contributed equity"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutIssuedCapitalExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about key management personnel.",
        "label": "Disclosure of detailed information about key management personnel [text block]",
        "terseLabel": "Summary of compensation made to directors and other members of key management personnel"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutKeyManagementPersonnelExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/KeyManagementPersonnelDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about movement in ordinary share capital.",
        "label": "Disclosure of detailed information about movement in ordinary share capital explanatory",
        "terseLabel": "Summary of movements in ordinary share capital"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutMovementInOrdinaryShareCapitalExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about movements in level 3 assets and liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about movements in level 3 assets and liabilities.",
        "label": "Disclosure of Detailed Information about Movements in level 3 Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of movements in level 3 assets and liabilities"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutMovementsInLevel3AssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other current assets.",
        "label": "Disclosure of Detailed Information About Other Current Assets [text block]",
        "terseLabel": "Summary of current assets - other"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutOtherEquityExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other equity.",
        "label": "Disclosure of detailed information about other equity explanatory",
        "terseLabel": "Summary of equity - other contributed equity"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherEquityExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about other income.",
        "label": "Disclosure Of Detailed Information About Other Income [Text block]",
        "terseLabel": "Summary of other income"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutProvisionsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about provisions.",
        "label": "Disclosure Of Detailed Information About Provisions [text block]",
        "terseLabel": "Summary of provisions"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutProvisionsExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about trade and other payables.",
        "label": "Disclosure of detailed information about trade and other payables [text block]",
        "terseLabel": "Summary of trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about trade and other receivables.",
        "label": "Disclosure of detailed information about trade and other receivables [text block]",
        "terseLabel": "Summary of current assets - trade and other receivables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfExpensesByNatureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expenses by nature.",
        "label": "Disclosure Of Expenses By Nature [line items]",
        "terseLabel": "Disclosure of expenses by nature [line items]"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfExpensesByNatureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to expenses by nature.",
        "label": "Disclosure Of Expenses By Nature [table]",
        "terseLabel": "Disclosure of expenses by nature [table]"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfIncomeTaxBenefitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of income tax benefit [line items]",
        "label": "Disclosure Of Income Tax Benefit [line items]",
        "terseLabel": "Disclosure Of Income Tax Benefit [line items]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxBenefitLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfIncomeTaxBenefitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information about income tax benefits.",
        "label": "Disclosure of income tax benefits [table]",
        "terseLabel": "Disclosure of income tax benefits [table]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxBenefitsTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail",
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfOtherEquityExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other equity.",
        "label": "Disclosure Of Other Equity Explanatory",
        "terseLabel": "Equity - Other contributed equity"
       }
      }
     },
     "localname": "DisclosureOfOtherEquityExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfParentEntityFinancialInformationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of parent entity financial information.",
        "label": "Disclosure of Parent Entity Financial Information [text block]",
        "terseLabel": "Parent entity financial information"
       }
      }
     },
     "localname": "DisclosureOfParentEntityFinancialInformationExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfParentEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about parent entity information.",
        "label": "Disclosure Of Parent Entity Information [abstract]"
       }
      }
     },
     "localname": "DisclosureOfParentEntityInformationAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfParentEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line item related to disclosure of parent entity information.",
        "label": "Disclosure Of Parent Entity Information [line items]",
        "terseLabel": "Disclosure of parent entity information [line items]"
       }
      }
     },
     "localname": "DisclosureOfParentEntityInformationLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfParentEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of parent entity information.",
        "label": "Disclosure Of Parent Entity Information [table]",
        "terseLabel": "Disclosure Of Parent Entity Information [table]"
       }
      }
     },
     "localname": "DisclosureOfParentEntityInformationTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfFinancialPositionDetail",
      "http://www.kaziatherapeutics.com/role/ParentEntityInformationStatementOfProfitOrLossAndOtherComprehensiveIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reconciliation of changes in intangible assets other than goodwill.",
        "label": "Disclosure of reconciliation of changes in intangible assets other than goodwill [text block]",
        "terseLabel": "Summary of reconciliations of intangibles"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reconciliation of profit or loss to operating cash flows",
        "label": "Disclosure of reconciliation of profit or loss to operating cash flows [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reconciliation of profit or loss to operating cash flows",
        "label": "Disclosure of reconciliation of profit or loss to operating cash flows [Table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesDisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Reconciliation Of Profit Or Loss To Operating Cash Flows",
        "label": "Disclosure Of Reconciliation Of Profit Or Loss To Operating Cash Flows [Text Block]",
        "terseLabel": "Disclosure of reconciliation of profit or loss to operating cash flows"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfProfitOrLossToOperatingCashFlowsTextBlock",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ReconciliationOfLossAfterIncomeTaxToNetCashUsedInOperatingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kzia_DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abstract represents significant accounting judgments, assumptions and estimates.",
        "label": "Disclosure of significant accounting judgments assumptions and estimates [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantAccountingJudgmentsAssumptionsAndEstimatesAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of summary of significant accounting policies.",
        "label": "Disclosure of summary of significant accounting policies [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items representing the disclosure of summary of significant accounting policies.",
        "label": "Disclosure Of Summary Of Significant Accounting Policies [line items]",
        "terseLabel": "Disclosure of summary of significant accounting policies [line items]"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_DisclosureOfSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of summary of significant accounting policies.",
        "label": "Disclosure of summary of significant accounting policies [table]",
        "terseLabel": "Disclosure of summary of significant accounting policies [table]"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_EVT801LicensingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EVT801 licensing agreement.",
        "label": "EVT801 Licensing Agreement [Member]",
        "verboseLabel": "EVT801 licensing agreement [Member]"
       }
      }
     },
     "localname": "EVT801LicensingAgreementMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_EffectOfDecreaseInMarketRiskOnEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of decrease in market risk on equity.",
        "label": "Effect of decrease in market risk on equity [member]",
        "terseLabel": "Effect of decrease in market risk on equity [member]"
       }
      }
     },
     "localname": "EffectOfDecreaseInMarketRiskOnEquityMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of decrease in market risk on profit (loss) before tax.",
        "label": "Effect of decrease in market risk on profit (loss) before tax [member]",
        "terseLabel": "Effect of decrease in market risk on profit (loss) before tax [member]"
       }
      }
     },
     "localname": "EffectOfDecreaseInMarketRiskOnProfitLossBeforeTaxMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_EffectOfIncreaseInMarketRiskOnEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of increase in market risk on equity.",
        "label": "Effect of increase in market risk on equity [member]",
        "terseLabel": "Effect of increase in market risk on equity [member]"
       }
      }
     },
     "localname": "EffectOfIncreaseInMarketRiskOnEquityMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of increase in market risk on profit (loss) before tax.",
        "label": "Effect of increase in market risk on profit (loss) before tax [member]",
        "terseLabel": "Effect of increase in market risk on profit (loss) before tax [member]"
       }
      }
     },
     "localname": "EffectOfIncreaseInMarketRiskOnProfitLossBeforeTaxMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_EquityTransactionsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Transactions [axis]",
        "label": "Equity Transactions [axis]",
        "terseLabel": "Equity Transactions [axis]"
       }
      }
     },
     "localname": "EquityTransactionsAxis",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_EquityTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Transactions [member]",
        "label": "Equity Transactions [member]",
        "terseLabel": "Equity Transactions [member]"
       }
      }
     },
     "localname": "EquityTransactionsMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_EvotechLicensingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evotech licensing agreement.",
        "label": "Evotech Licensing Agreement [Member]",
        "terseLabel": "Evotech Licensing Agreement [member]"
       }
      }
     },
     "localname": "EvotechLicensingAgreementMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_FairValueOfAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of assets and liabilities.",
        "label": "Fair Value Of Assets and Liabilities",
        "periodEndLabel": "Balance Ending",
        "periodStartLabel": "Balance Beginning"
       }
      }
     },
     "localname": "FairValueOfAssetsAndLiabilities",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_FundingPurposeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding purpose",
        "label": "Funding Purpose [Axis]"
       }
      }
     },
     "localname": "FundingPurposeAxis",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_FundingPurposeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding purpose",
        "label": "Funding Purpose [Member]"
       }
      }
     },
     "localname": "FundingPurposeMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_GainLossOnRevaluationOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome": {
       "order": 8.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on revaluation of contingent consideration.",
        "label": "Gain loss on revaluation of contingent consideration",
        "terseLabel": "Loss on revaluation of contingent consideration"
       }
      }
     },
     "localname": "GainLossOnRevaluationOfContingentConsideration",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_GenentechAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech agreement.",
        "label": "Genentech agreement [member]"
       }
      }
     },
     "localname": "GenentechAgreementMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_GlioblastPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glioblast Pty Ltd.",
        "label": "Glioblast Pty Ltd [member]",
        "terseLabel": "Glioblast Pty Ltd [member]"
       }
      }
     },
     "localname": "GlioblastPtyLtdMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through employee share-based payment options.",
        "label": "Increase (decrease) through employee share-based payment options",
        "terseLabel": "Employee share-based payment options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughEmployeeSharebasedPaymentOptions",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_IncreaseDecreaseThroughExpireOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through expire of Options",
        "label": "Increase Decrease Through Expire Of Options",
        "verboseLabel": "Expired options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExpireOfOptions",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_IncreaseInMarketRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in market risk.",
        "label": "Increase in market risk [member]",
        "terseLabel": "Increase in market risk [member]"
       }
      }
     },
     "localname": "IncreaseInMarketRiskMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_InstitutionalPlacementUnderAnreoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Institutional placement under ANREO [Member]"
       }
      }
     },
     "localname": "InstitutionalPlacementUnderAnreoMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IntangibleAssetsWithIndefiniteRemainingUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets with indefinite remaining useful life.",
        "label": "Intangible assets with indefinite remaining useful life",
        "terseLabel": "Remaining useful life,licensing agreement"
       }
      }
     },
     "localname": "IntangibleAssetsWithIndefiniteRemainingUsefulLife",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_InterestIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income loss.",
        "label": "Interest Income loss",
        "terseLabel": "Earning income"
       }
      }
     },
     "localname": "InterestIncomeLoss",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_InterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate.",
        "label": "Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "InterestRate",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_IssueDateSixteenthAprilTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue date sixteenth april two thousand and twenty.",
        "label": "Issue Date Sixteenth April Two Thousand And Twenty [Member]",
        "terseLabel": "16 April 2020 [Member]"
       }
      }
     },
     "localname": "IssueDateSixteenthAprilTwoThousandAndTwentyMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Date Twenty Eight April Two Thousand And Twenty One.",
        "label": "Issue Date Twenty Eight April Two Thousand And Twenty One [Member]",
        "verboseLabel": "28 April 2021 {Member]"
       }
      }
     },
     "localname": "IssueDateTwentyEightAprilTwoThousandAndTwentyOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IssueDateTwentyEightAugustTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Date Twenty Eight August Two Thousand And Twenty.",
        "label": "Issue Date Twenty Eight August Two Thousand And Twenty [Member]",
        "verboseLabel": "28 August 2020 [Member]"
       }
      }
     },
     "localname": "IssueDateTwentyEightAugustTwoThousandAndTwentyMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IssueDatedFifteenthMarchTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Dated Fifteenth March Two Thousand Twenty One [Member]",
        "terseLabel": "15\u00a0March 2021 [Member]"
       }
      }
     },
     "localname": "IssueDatedFifteenthMarchTwoThousandTwentyOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IssueDatedNovemberOneTwoThousandAndNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue dated november One two thousand and nineteen.",
        "label": "Issue Dated November One Two Thousand And Nineteen [Member]",
        "terseLabel": "1 November 2019 [Member]"
       }
      }
     },
     "localname": "IssueDatedNovemberOneTwoThousandAndNineteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IssueDatedSecondMarchTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Dated Second March Two Thousand Twenty One [Member]",
        "terseLabel": "2\u00a0March 2021 [Member]"
       }
      }
     },
     "localname": "IssueDatedSecondMarchTwoThousandTwentyOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_IssuedOnAchievementOfAMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued on achievement of a milestone [Member]"
       }
      }
     },
     "localname": "IssuedOnAchievementOfAMilestoneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_KaziaLaboratoriesPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kazia Laboratories Pty Ltd.",
        "label": "Kazia Laboratories Pty Ltd [member]",
        "terseLabel": "Kazia Laboratories Pty Ltd [member]"
       }
      }
     },
     "localname": "KaziaLaboratoriesPtyLtdMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_KaziaResearchPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kazia Research Pty Ltd.",
        "label": "Kazia Research Pty Ltd [member]",
        "terseLabel": "Kazia Research Pty Ltd [member]"
       }
      }
     },
     "localname": "KaziaResearchPtyLtdMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_KaziaTherapeuticsHongKongLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kazia Therapeutics (Hong Kong) Limited [Member]",
        "verboseLabel": "Kazia Therapeutics (Hong Kong) Limited [Member]"
       }
      }
     },
     "localname": "KaziaTherapeuticsHongKongLimitedMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_KaziaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kazia Therapeutics Inc.",
        "label": "Kazia Therapeutics Inc [member]",
        "terseLabel": "Kazia Therapeutics Inc [member]"
       }
      }
     },
     "localname": "KaziaTherapeuticsIncMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/InterestsInSubsidiariesSummaryOfInterestInSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_LicenseAgreementForPaxalisibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement for paxalisib.",
        "label": "License Agreement For Paxalisib [Member]",
        "terseLabel": "Licensing agreement for paxalisib [member]"
       }
      }
     },
     "localname": "LicenseAgreementForPaxalisibMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_LicensingAgreementForEvtEightZeroOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement for EVT801.",
        "label": "Licensing Agreement For EVT Eight Zero One [Member]",
        "terseLabel": "Licensing agreement for EVT801 [member]"
       }
      }
     },
     "localname": "LicensingAgreementForEvtEightZeroOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_LicensingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreement [Member]"
       }
      }
     },
     "localname": "LicensingAgreementMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfNonCurrentAssetsIntangiblesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_LicensingRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing revenue.",
        "label": "Licensing Revenue [Member]",
        "terseLabel": "Licensing revenue [Member]"
       }
      }
     },
     "localname": "LicensingRevenueMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail",
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfLicensingRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_MilestonePaymentDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment discount rate.",
        "label": "Milestone Payment Discount Rate",
        "terseLabel": "Milestone payment discount rate",
        "verboseLabel": "Milestone payment discount rate"
       }
      }
     },
     "localname": "MilestonePaymentDiscountRate",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_MilestonePaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment payable.",
        "label": "Milestone Payment Payable",
        "terseLabel": "Milestone payment payable"
       }
      }
     },
     "localname": "MilestonePaymentPayable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_MilestonePaymentsNotBooked": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments not booked.",
        "label": "Milestone Payments not Booked",
        "terseLabel": "Milestone payments not booked"
       }
      }
     },
     "localname": "MilestonePaymentsNotBooked",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two.",
        "label": "Milestone Two [member]"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_MinimumOperatingLeasePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Operating Lease Payment.",
        "label": "Minimum Operating Lease Payment",
        "terseLabel": "Minimum lease payments"
       }
      }
     },
     "localname": "MinimumOperatingLeasePayment",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_NetLossOnDisposalOfNonCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss on disposal of non current assets.",
        "label": "Net Loss On Disposal Of Non Current Assets",
        "negatedLabel": "Net loss on disposal of non-current assets"
       }
      }
     },
     "localname": "NetLossOnDisposalOfNonCurrentAssets",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of antidilutive share options excluded from calculation of earnings per share.",
        "label": "Number Of Antidilutive Share Options Excluded From Calculation Of Earnings Per Share",
        "terseLabel": "Number of options that have been excluded from the calculations as they were antidilutive"
       }
      }
     },
     "localname": "NumberOfAntidilutiveShareOptionsExcludedFromCalculationOfEarningsPerShare",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kzia_NumberOfContingentMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of contingent milestone payments.",
        "label": "Number of contingent milestone payments",
        "verboseLabel": "Number of contingent milestone payments"
       }
      }
     },
     "localname": "NumberOfContingentMilestonePayments",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "kzia_NumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers.",
        "label": "Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "localname": "NumberOfMajorCustomers",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "kzia_NumberOfOperatingSegments1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments.",
        "label": "Number Of Operating Segments1",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments1",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OperatingSegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "kzia_NumberOfOptionsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options issued.",
        "label": "Number of Options Issued",
        "terseLabel": "Number of options issued"
       }
      }
     },
     "localname": "NumberOfOptionsIssued",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kzia_NumberOfOptionsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of Options vested",
        "terseLabel": "Number of Options vested"
       }
      }
     },
     "localname": "NumberOfOptionsVested",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "kzia_NumberOfOrdinarySharesAvailableForConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares available for conversion.",
        "label": "Number of ordinary shares available for conversion",
        "terseLabel": "Number of ordinary shares available for conversion",
        "verboseLabel": "Number of unlisted convertible notes"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesAvailableForConversion",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kzia_NumberOfShareOptionsModifiedInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options modified in sharebased payment arrangement.",
        "label": "Number Of Share Options Modified In Sharebased Payment Arrangement",
        "terseLabel": "Exercised and modified"
       }
      }
     },
     "localname": "NumberOfShareOptionsModifiedInSharebasedPaymentArrangement",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "kzia_OtherTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tranche four.",
        "label": "Other Tranche Four [Member]"
       }
      }
     },
     "localname": "OtherTrancheFourMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_OtherTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tranche one.",
        "label": "Other Tranche One [Member]"
       }
      }
     },
     "localname": "OtherTrancheOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_OtherTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tranche three.",
        "label": "Other Tranche Three [Member]"
       }
      }
     },
     "localname": "OtherTrancheThreeMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_OtherTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tranche two.",
        "label": "Other Tranche Two [Member]"
       }
      }
     },
     "localname": "OtherTrancheTwoMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_PaxalisibLicensingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Paxalisib licensing agreement [member]",
        "documentation": "Paxalisib Licensing Agreement.",
        "label": "Paxalisib Licensing Agreement [Member]"
       }
      }
     },
     "localname": "PaxalisibLicensingAgreementMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ExpensesSummaryOfExpensesDetail",
      "http://www.kaziatherapeutics.com/role/IntangiblesSummaryOfReconciliationsOfIntangiblesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for contingent consideration.",
        "label": "Payments For Contingent Consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_PayoutOfMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payout of milestone.",
        "label": "Payout of Milestone",
        "terseLabel": "Payout of milestone"
       }
      }
     },
     "localname": "PayoutOfMilestone",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FairValueMeasurementSummaryOfMovementsInLevel3AssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage milestone trigger to account cost of asset conferred under license agreement.",
        "label": "Percentage Milestone Trigger to Account Cost of Asset Conferred Under License Agreement",
        "terseLabel": "Percentage milestone trigger to account cost of asset conferred under license agreement"
       }
      }
     },
     "localname": "PercentageMilestoneTriggerToAccountCostOfAssetConferredUnderLicenseAgreement",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/CriticalAccountingJudgementsEstimatesAndAssumptionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of capital acquired by third party for early conversion of convertibles notes.",
        "label": "Percentage of capital acquired by third party for early conversion of Convertibles notes",
        "terseLabel": "Percentage of capital acquired by third party for early conversion of convertibles notes"
       }
      }
     },
     "localname": "PercentageOfCapitalAcquiredByThirdPartyForEarlyConversionOfConvertiblesNotes",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityOtherContributedEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_PercentageOfOptionsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of options vested.",
        "label": "Percentage of options vested",
        "terseLabel": "Percentage of Options vested"
       }
      }
     },
     "localname": "PercentageOfOptionsVested",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_RebateIncomeOnResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebate income on research and development.",
        "label": "Rebate income on research and development",
        "terseLabel": "Research and development rebate"
       }
      }
     },
     "localname": "RebateIncomeOnResearchAndDevelopment",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation",
        "label": "Reconciliation [Abstract]"
       }
      }
     },
     "localname": "ReconciliationAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "kzia_ReimbursementOfExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_ResearchAndDevelopmentTaxIncentiveProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax incentive program.",
        "label": "Research and development tax incentive program [member]",
        "terseLabel": "Research and development tax incentive program [member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveProgramMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_ResearchAndDevelopmentTaxRebateReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax rebate receivable.",
        "label": "Research and development tax rebate receivable [member]",
        "terseLabel": "R&amp;D tax rebate receivable [member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxRebateReceivableMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesSummaryOfCurrentAssetsTradeAndOtherReceivablesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_RetailPlacementUnderAnreoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retail placement under ANREO [Member]"
       }
      }
     },
     "localname": "RetailPlacementUnderAnreoMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk exposure associated with instruments sharing characteristic, percentage change in risk.",
        "label": "Risk exposure associated with instruments sharing characteristic, percentage change in risk",
        "terseLabel": "% change",
        "verboseLabel": "Hypothetical percentage change in risk"
       }
      }
     },
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristicPercentageChangeInRisk",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kzia_ShareBasedPaymentArrangementOptionsExpiryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date on which share-based payment arrangement options expire.",
        "label": "Share Based Payment Arrangement Options expiry Date",
        "terseLabel": "Expiry date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionsExpiryDate",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "kzia_ShareIssueTransactionCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issue transaction costs.",
        "label": "Share issue transaction costs [member]",
        "terseLabel": "Share issue transaction costs [member]"
       }
      }
     },
     "localname": "ShareIssueTransactionCostsMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_SharePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share placement.",
        "label": "Share Placement [member]",
        "terseLabel": "Share Placement [member]"
       }
      }
     },
     "localname": "SharePlacementMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_SharePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price per share.",
        "label": "Share price per share",
        "terseLabel": "Share price at Grant Date"
       }
      }
     },
     "localname": "SharePricePerShare",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "kzia_SharePurchasePlanIssueDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Plan Issue Date",
        "label": "Share Purchase Plan Issue Date [Axis]"
       }
      }
     },
     "localname": "SharePurchasePlanIssueDateAxis",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_SharePurchasePlanIssueDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Plan Issue Date",
        "label": "Share Purchase Plan Issue Date [Domain]"
       }
      }
     },
     "localname": "SharePurchasePlanIssueDateDomain",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_SharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase plan.",
        "label": "Share purchase plan [member]",
        "terseLabel": "Share purchase plan [member]"
       }
      }
     },
     "localname": "SharePurchasePlanMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_SharesIssuedPricePerShare1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued price per share.",
        "label": "Shares Issued Price Per Share 1",
        "terseLabel": "Issue price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare1",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EquityContributedEquitySummaryOfMovementsInOrdinaryShareCapitalDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "kzia_ShortTermDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deposits.",
        "label": "Short term deposits [member]",
        "terseLabel": "Short term deposits [member]"
       }
      }
     },
     "localname": "ShortTermDepositsMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfVariableInterestRateBalancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [line items]",
        "terseLabel": "Statement [line items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsideration",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefits",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [table]",
        "terseLabel": "Statement [table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ContingentConsideration",
      "http://www.kaziatherapeutics.com/role/ContingentConsiderationTables",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefits",
      "http://www.kaziatherapeutics.com/role/EmployeeBenefitsTables",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsTables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherPayablesTables",
      "http://www.kaziatherapeutics.com/role/TradeAndOtherReceivablesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_SubsidiesAndGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidies and grants.",
        "label": "Subsidies and grants",
        "terseLabel": "Subsidies and grants"
       }
      }
     },
     "localname": "SubsidiesAndGrants",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_SwedanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swedan.",
        "label": "Swedan [Member]",
        "terseLabel": "Swedan [member]"
       }
      }
     },
     "localname": "SwedanMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/RevenueSummaryOfDisaggregationOfRevenueFromContractsWithCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect amounts which are not deductible/(taxable) in calculating taxable income.",
        "label": "Tax effect amounts which are not deductible/(taxable) in calculating taxable income [abstract]",
        "terseLabel": "Tax effect amounts which are not deductible/(taxable) in calculating taxable income:"
       }
      }
     },
     "localname": "TaxEffectAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of adjustment to deferred tax balances as a result of change in statutory tax rate.",
        "label": "Tax Effect of Adjustment to Deferred Tax Balances as a Result of Change in Statutory Tax Rate",
        "terseLabel": "Adjustment to deferred tax balances as a result of change in statutory tax rate"
       }
      }
     },
     "localname": "TaxEffectOfAdjustmentToDeferredTaxBalancesAsAResultOfChangeInStatutoryTaxRate",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxEffectOfAmortisationOfIntangibles": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of amortisation of intangibles.",
        "label": "Tax Effect Of Amortisation Of Intangibles",
        "terseLabel": "Amortisation of intangibles"
       }
      }
     },
     "localname": "TaxEffectOfAmortisationOfIntangibles",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxEffectOfExpenseEmployeeOptionPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of expense employee option plan.",
        "label": "Tax effect of expense employee option plan",
        "terseLabel": "Employee option plan"
       }
      }
     },
     "localname": "TaxEffectOfExpenseEmployeeOptionPlan",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxEffectOfExpenseResearchAndDevelopmentClaim": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of expense research and development claim.",
        "label": "Tax effect of expense research and development claim",
        "terseLabel": "Research and Development claim"
       }
      }
     },
     "localname": "TaxEffectOfExpenseResearchAndDevelopmentClaim",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect of Gain loss on revaluation of contingent consideration payable",
        "label": "Tax Effect of Gain loss on revaluation of contingent consideration payable",
        "terseLabel": "Gain/loss on revaluation of contingent consideration"
       }
      }
     },
     "localname": "TaxEffectOfGainLossOnRevaluationOfContingentConsiderationPayable",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of prior year tax losses not recognised now recouped.",
        "label": "Tax effect of prior year tax losses not recognised now recouped",
        "terseLabel": "Prior year tax losses not recognised now recouped"
       }
      }
     },
     "localname": "TaxEffectOfPriorYearTaxLossesNotRecognisedNowRecouped",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax effect of tax losses and timing differences not recognised.",
        "label": "Tax effect of Tax losses and timing differences not recognised",
        "terseLabel": "Tax losses and timing differences not recognised"
       }
      }
     },
     "localname": "TaxEffectOfTaxLossesAndTimingDifferencesNotRecognised",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TaxLossesNotRecognisedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax losses not recognised.",
        "label": "Tax losses not recognised [abstract]",
        "terseLabel": "Tax losses not recognised"
       }
      }
     },
     "localname": "TaxLossesNotRecognisedAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/IncomeTaxBenefitSummaryOfIncomeTaxBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_TaxRebatesOnPayroll": {
     "auth_ref": [],
     "calculation": {
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rebates on payroll.",
        "label": "Tax rebates on payroll",
        "terseLabel": "Payroll tax rebate"
       }
      }
     },
     "localname": "TaxRebatesOnPayroll",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/OtherIncomeSummaryOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Text block [abstract]",
        "label": "Text block [abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "kzia_TradePayablesUndiscountedCashFlows": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade payables undiscounted cash flows.",
        "label": "Trade payables undiscounted cash flows",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradePayablesUndiscountedCashFlows",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfRemainingContractualMaturitiesOfFinancialInstrumentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kzia_TrancheEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche eight.",
        "label": "Tranche Eight [member]",
        "terseLabel": "Tranche 8 [member]"
       }
      }
     },
     "localname": "TrancheEightMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche eighteen.",
        "label": "Tranche Eighteen [Member]",
        "terseLabel": "Tranche 18 [member]"
       }
      }
     },
     "localname": "TrancheEighteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche eleven.",
        "label": "Tranche eleven [member]",
        "terseLabel": "Tranche 11 [member]"
       }
      }
     },
     "localname": "TrancheElevenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Fifteen",
        "label": "Tranche Fifteen [Member]",
        "verboseLabel": "Tranche 15 [member]"
       }
      }
     },
     "localname": "TrancheFifteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche five.",
        "label": "Tranche Five [member]",
        "terseLabel": "Tranche 5 [member]"
       }
      }
     },
     "localname": "TrancheFiveMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche four.",
        "label": "Tranche Four [member]",
        "terseLabel": "Tranche 4 [member]"
       }
      }
     },
     "localname": "TrancheFourMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Fourteen.",
        "label": "Tranche Fourteen [member]",
        "terseLabel": "Tranche 14 [member]"
       }
      }
     },
     "localname": "TrancheFourteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche nine.",
        "label": "Tranche nine [member]",
        "terseLabel": "Tranche 9 [member]"
       }
      }
     },
     "localname": "TrancheNineMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche nineteen.",
        "label": "Tranche Nineteen [Member]",
        "terseLabel": "Tranche 19 [member]"
       }
      }
     },
     "localname": "TrancheNineteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one.",
        "label": "Tranche One [member]",
        "terseLabel": "Tranche 1 [member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche seven.",
        "label": "Tranche Seven [member]",
        "terseLabel": "Tranche 7 [member]"
       }
      }
     },
     "localname": "TrancheSevenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheSeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche seventeen.",
        "label": "Tranche Seventeen [Member]",
        "terseLabel": "Tranche 17 [member]"
       }
      }
     },
     "localname": "TrancheSeventeenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche six.",
        "label": "Tranche Six [member]",
        "terseLabel": "Tranche 6 [member]"
       }
      }
     },
     "localname": "TrancheSixMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Sixteen",
        "label": "Tranche Sixteen [Member]",
        "verboseLabel": "Tranche 16 [member]"
       }
      }
     },
     "localname": "TrancheSixteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche ten.",
        "label": "Tranche ten [member]",
        "terseLabel": "Tranche 10 [member]"
       }
      }
     },
     "localname": "TrancheTenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche thirteen.",
        "label": "Tranche Thirteen [member]",
        "terseLabel": "Tranche 13 [member]"
       }
      }
     },
     "localname": "TrancheThirteenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche thirty.",
        "label": "Tranche Thirty [Member]",
        "terseLabel": "Tranche 30 [member]"
       }
      }
     },
     "localname": "TrancheThirtyMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheThirtyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche thirty one.",
        "label": "Tranche Thirty One [Member]",
        "terseLabel": "Tranche 31 [member]"
       }
      }
     },
     "localname": "TrancheThirtyOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three.",
        "label": "Tranche Three [member]",
        "terseLabel": "Tranche 3 [member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twelve.",
        "label": "Tranche Twelve [member]",
        "terseLabel": "Tranche 12 [member]"
       }
      }
     },
     "localname": "TrancheTwelveMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail",
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty eight.",
        "label": "Tranche Twenty Eight [Member]",
        "terseLabel": "Tranche 28 [member]"
       }
      }
     },
     "localname": "TrancheTwentyEightMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty five.",
        "label": "Tranche Twenty Five [Member]",
        "terseLabel": "Tranche 25 [member]"
       }
      }
     },
     "localname": "TrancheTwentyFiveMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty four.",
        "label": "Tranche Twenty Four [Member]",
        "terseLabel": "Tranche 24 [member]"
       }
      }
     },
     "localname": "TrancheTwentyFourMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty.",
        "label": "Tranche Twenty [Member]",
        "terseLabel": "Tranche 20 [member]"
       }
      }
     },
     "localname": "TrancheTwentyMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty nine.",
        "label": "Tranche Twenty Nine [Member]",
        "terseLabel": "Tranche 29 [member]"
       }
      }
     },
     "localname": "TrancheTwentyNineMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty one.",
        "label": "Tranche Twenty One [Member]",
        "terseLabel": "Tranche 21 [member]"
       }
      }
     },
     "localname": "TrancheTwentyOneMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty seven.",
        "label": "Tranche Twenty Seven [Member]",
        "terseLabel": "Tranche 27 [member]"
       }
      }
     },
     "localname": "TrancheTwentySevenMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty six.",
        "label": "Tranche Twenty Six [Member]",
        "terseLabel": "Tranche 26 [member]"
       }
      }
     },
     "localname": "TrancheTwentySixMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty three.",
        "label": "Tranche Twenty Three [Member]",
        "terseLabel": "Tranche 23 [member]"
       }
      }
     },
     "localname": "TrancheTwentyThreeMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche twenty two.",
        "label": "Tranche Twenty Two [Member]",
        "terseLabel": "Tranche 22 [member]"
       }
      }
     },
     "localname": "TrancheTwentyTwoMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfValuationForEachTrancheOfOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two.",
        "label": "Tranche Two [member]",
        "terseLabel": "Tranche 2 [member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TranchesTenAndTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranches Ten and Twelve [Member]",
        "terseLabel": "Tranches 10 and 12 [Member]"
       }
      }
     },
     "localname": "TranchesTenAndTwelveMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TranchesTwoAndEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranches Two and Eight [Member]",
        "terseLabel": "Tranches 2 and 8 [Member]"
       }
      }
     },
     "localname": "TranchesTwoAndEightMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transactions with owners in their capacity as owners.",
        "label": "Transactions with Owners in Their Capacity as Owners [abstract]",
        "terseLabel": "Transactions with owners in their capacity as owners:"
       }
      }
     },
     "localname": "TransactionsWithOwnersInTheirCapacityAsOwnersAbstract",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_UncertainityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertainity",
        "label": "Uncertainity [Axis]"
       }
      }
     },
     "localname": "UncertainityAxis",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kzia_UncertainityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertainity",
        "label": "Uncertainity [Member]"
       }
      }
     },
     "localname": "UncertainityMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_UnlistedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unlisted options.",
        "label": "Unlisted Options [member]",
        "terseLabel": "Unlisted options [member]"
       }
      }
     },
     "localname": "UnlistedOptionsMember",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/EarningsPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kzia_WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price modified in sharebased payment arrangement.",
        "label": "Weighted Average Exercise Price Modified In Sharebased Payment Arrangement",
        "terseLabel": "Modified, Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceModifiedInSharebasedPaymentArrangement",
     "nsuri": "http://www.kaziatherapeutics.com/20210630",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/ShareBasedPaymentsSummaryOfShareBasedPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskDetail",
      "http://www.kaziatherapeutics.com/role/FinancialInstrumentsSummaryOfForeignCurrencyRiskSensitivityDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r1": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r10": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r100": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r101": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r102": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r103": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2020-01-01"
  },
  "r104": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r105": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r106": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r107": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r108": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2020-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r109": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2020-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r11": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r110": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r111": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r112": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r113": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r114": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r115": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r116": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r117": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r118": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r119": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r12": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r120": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r121": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "46",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r122": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r123": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2020-01-01"
  },
  "r124": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r125": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r126": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r127": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r128": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r129": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r13": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r130": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r131": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "IG63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r132": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_12_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r133": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_19B_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r134": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r135": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "2",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_2_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r136": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r137": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r138": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r139": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r14": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r140": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r141": {
   "Clause": "ix",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r142": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r143": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r144": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r145": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r146": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r147": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r148": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r149": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r15": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r150": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r151": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r152": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r153": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r154": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI",
   "URIDate": "2020-01-01"
  },
  "r155": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2020-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r156": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r157": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r158": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r159": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r16": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r160": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r161": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r162": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r163": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r164": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r165": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r166": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r167": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r168": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r169": {
   "Clause": "v",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r17": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r170": {
   "Clause": "vi",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r171": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r172": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r173": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r174": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r175": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r176": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r177": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r178": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r179": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r18": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r180": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r181": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r182": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r183": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r184": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r185": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r186": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r187": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r188": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r189": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r19": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r190": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r191": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r192": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r193": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r194": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r195": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r196": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r197": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r198": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r199": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r2": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r20": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r200": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r201": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r202": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r203": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r204": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r205": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r206": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B8",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r207": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r208": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2020-01-01"
  },
  "r209": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2020-01-01"
  },
  "r21": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r210": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r211": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r212": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r213": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r214": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r215": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r216": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r217": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r218": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r219": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2020-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r22": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r220": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r221": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r222": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r223": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r224": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r225": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r226": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r227": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r228": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r229": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r23": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r230": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2020-01-01"
  },
  "r231": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r232": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r233": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r234": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r235": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r236": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r237": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r238": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r239": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r24": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r240": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r241": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r242": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r243": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r244": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r245": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r246": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r247": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r248": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r249": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r25": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r26": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r27": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r28": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r29": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r3": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r30": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r31": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r32": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r33": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r34": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r35": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r36": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r37": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r38": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r39": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r4": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r40": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r41": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r42": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r43": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r44": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r45": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r46": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r47": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r48": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r49": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r50": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r51": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r52": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r53": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2020-01-01"
  },
  "r54": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r55": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_80_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r56": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r57": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r58": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r59": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r6": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r60": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r61": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2020-01-01"
  },
  "r62": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r63": {
   "Clause": "v",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r64": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r65": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r66": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r67": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r68": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r69": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r7": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r70": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r71": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2020-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r72": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r73": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r74": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r75": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r76": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r77": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r78": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r79": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r8": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r80": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2020-01-01"
  },
  "r81": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2020-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r82": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2020-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r83": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r84": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r85": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r86": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r87": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r88": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r89": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r9": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r90": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r91": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2020-01-01"
  },
  "r92": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "34",
   "Section": "Content of an interim financial report",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=34&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS34_g5-25_TI",
   "URIDate": "2020-01-01"
  },
  "r93": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r94": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2020-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r95": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "88",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2020-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r96": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r97": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r98": {
   "Clause": "vi",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r99": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2020-01-01"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0001193125-21-293688-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-293688-xbrl.zip
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M3FBOT>+U#^:+TSC\!#O<E&_<W6T>[1Y,]SI4=MY?PX)GOP),A9?^" 6[+0"
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M6_OX+->36Y>^& ==V'!ZB> T>T;;#URV+N<9CPW>.I^VYKZ>W+,4A$*Y<!Z
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M5Y>?[QP_7X*?"ZPPY1!V*0B[0 XZ_6;->>=LC.78& ODH[/SUY=W>?G.SSQ
M2L2]=D^PFNSHO% H2*P?]W@G8FWX FB$PGS3]^/?DB2\XU&T#AR>=3*4._0H
MK=90!/:;3@360P0P/VQ1(N 0?$UY!PBN:ZV[TO.ETO-+*#J_R&TY+Z#O>NQ5
M.@HLH;O>$ACK^NJ--QW?!+:Z7GJ5;N.+[Z*W!+:Z_GG5-N.;P%37,Z_"UF5T
MRUN&TN0Z3Y=4IL7WG%X"4UWSPPI;E]+V< F,=0T/RWQ=1JO#98"PVUM+(+P1
M.^MIY'2F"@I'&Z,TL<C9KF6]J:#(>K,6NW RMV[+?D2;)FO-7G2=.?:.NQ/7
MFKW[3><I?CE/\2*/6IT]^X+V[!(8Z^S9Y=NS2V"KLV>7;<\N X2=/?LB]NPR
MUJNS9U_$GET&:YT]^V+V[!+8Z^S9E[-GE\%>WG7<K4;)=#>$N=?\WC%W+%AF
MW9GKLEZ7G_6Z2'ZZG,DUYYW+F5Q*SN0B^>@RSY>1>;[(O)MV>N9S\7<_RBIN
MAB_,EYE8EW)FXZ,M?AN;XAJ>I,W J>^?V2V+#BZZ^>6_ WE]$?0KA>WH.EEW
MW1HP_-'!5RY]@!Z3Q<$)8 'VK>^G?[\Y;K9<>NVCZ;4/$VJ!^T1K<<QWZ=7K
MD5Z]0!%PZ=7KRSL[.<;YMFHRAI;BW5H\@RG^Q/%W/"9G,]B+82B.O>.A.>O.
M7N>;?@'?] +YZ?QB2_&++9"#[G1AS7GG3A>6<[JP0#Y.[?',&U$HX[Q]Z_/(
M!UN]FPCI1^S$3UDO$17WI_Z6H\Y1?< :2,.CHR^NG8D\F^0-?:YP9C%7DOD-
M/GQO?_MD"<5 3?$CE\F;_=;;]_"K>8KY*7\L/J?^F1*575GS6#US^OD)SQW"
M=1.?BC\^X9G_8+ZH>6:6BO?XTQ.>^.WZ(8K"KT]XYNFWJP>>";\^X9G72@#K
M^$26B/G]"8\&L?D.4OB=K![K^2&_!:C(_\2;OF8#)OPT$4^6P?$GX+>?6)P,
M "+JGCRU&)8?\KHRB4?)\,7_9R*^GV0R36"(D^A<ONII C<_:C\FGRM,;1Z!
M:@#*Q$1"FPN> A.3,.*19[WF]^]AWDDF B;5GWWFA[ 1_/P:IO;Q9_S'PW\]
MF8XBV'6[@-:[DO^+O?=:!WO[Q\/[#][ %ST>[Z;)\+W7'*;Y%YTD!:&!"_>.
MWK+!AP]T[QU#U]![KY-$X8>=CS_[7E^P[B\[_Y8FP<['&]PCO:3KG>"N0,O;
MUV,I#0-WC%T_XKWXO1>@)U' LTI7W/$P[;_WCO<.>?S!LZ^'3;@8HU"C\;,T
MR;_#"_17E8>"L<QV^WH&+6NJ$^=.WW42 335W^T&292(]Y[H=5XU&Q[^[Z?J
M)7KP+:1N^1<:R'M/)A$G\MF#8RG085<._0 L07PUW*T'=O_A0\CE,/)'L"'C
M+.#>O_U;ZZCY03-ZG,2EN1Y,,]?]M9UKC3AY)*U=?\"CT7OO;W]E2?KA!O0N
MZ7UE=]Y5,O!C]:6^4J^)XRJAWDP0BO)\[*5!*V-L!F-7/VUHLQ+NV]?SF]-/
MWO5-^^;TVK,)N%PR3EI;:T+&Z].3;U?G-^= P_;73][I?Y[\WO[ZVZEW<O'E
MR_GU]?G%U^71=G]U:;O_%-K^V;[^_?SK;S<77QO>I[V3/6^_>?CFW6/TG!=%
MGC/RV5&ILA^I(=+8:+]2$*P1=;_U[^6-SXA-"=F/G@?:8S<O&+27"CHEP7C.
MRCB[N/I2UD[Z/&5$"7AQG-P)?SB[^/P,ZEJ<Q*3S\L"+?72+A(R__Y0$&1I'
M>+JSXVD#^PJUK,OFV^_-%@62WB2%VV<'#/?=,]+_B@>6:>Z6T.8NH:<ME^;"
MELN<QC8KL5Y]\<4/[R)F/]5M'O_]O_V<DG42L"@:^F$(S_QEI[E#?^MWT-]Z
MX(JG]"XOR(0 R2&I>-:VK04%'A3Y0PE?FT_Y3Z79?E!"UFHV_QWE'J<@S/B&
M?H_M=@3S?^SR6((5"R;/;4(21Q>&%4OJ#2R%6R92'OB160Y S \?K/5!IM44
MP'3%>ERF@KH?7YM>Q],A%=!$#/STEQU^C^*31,R/NWXD&0K[N[=OWGP8A[$T
MK$QIRGE,A!)E0BY8_2J#3(S3CM9%)[LZ_>W\^N:J?8.:+1D/7TZ_WGB7WZZN
MO[7AP\V%!RHQ_=K:?]7YR;NX\E[U?E)P=7'FW?Q^ZEDZ<ZXOMT]N//BY]>[@
M3:V"1ZR&?\E%0\NUS,0 Q$6@\R'M(\WO<_+B-'86JW=O'%X"S]93R790/C\H
M;\=QYD=7;)B(9R!X*C(#X$<.P%< P-M?OWYK?_:N3B\OKB;@]@&"=NOP5?B3
MYQ![/1#[+!%>VF=>ETM8/-X(2.NQ.&2A]^@ZOZ1CV],X_ 3JVA,6>HA:'MS4
M#_T1OI?%.Q__(XN9=P#6T:-O/Z,!XY'G&7PCIS9J]UOC8%+^>WE^MXV3)K?_
MN_T_Q8A@R=&0>ZX.X*RX55,"P(#[>GU.N[U3!!QT.^C>+.B^[C,5E^O'(P?>
MFP;>U[^??OZ,!\R7[:__</B](/Q&:PCCE2B?T1/LKXP+8 ]865QZ$A<8+"E:
M8? C+K'Q&88L2)0K_+V7@3$FZ-%/!,OQ?XM(KLU_ZVJ-YK'STW60;^,Q2',U
MWU,!W%Y7)(,M$>;5&LV+"G.:.)YO&\_7&L! OQUPB<DR7I>#W1!GE$*SO&"<
M4TJ<.8-W?Z573^F[;.[NOWMWM.]B<K8T)F=N:VO_S>HZ+]38YKS43'!)G'Z%
M7Z9<;G_X_^*^=]-GL/A9!I:I]#[S >!"^'('!IL6J-L^^>HUCPZ\_<-WWMO#
M>BMR.;O+ZA#R:8%JI_=^D)+@H^U9"+SG@]$Y9 $FNX8>CSV>2B_H^P(>7QO4
MYK8.MW5LD]_[:Y)Z[2&F/),3>5D(M+KI+$_*9GE%AWX1&1YE /K;OQWOM]Y^
MD J;> P+\#3N15SV'X4?)[63I1:>>)UD:=_[TX^8?"!>0FE YS&8A</$BJ\]
M2;(X%:.3)'Q"[,:N9,%[%O9\,13);: >A?$;[0RY'G'_Q72D35M8_Y$)+D,>
MF)7%;4YZB8#_]?R8_XO^=DOJZ4OJD174#D/!I-3_^0SWM*8T)&[Z@C&/2L'$
MQ"4_\FZ2.R; H,"BR&#S-+R#9M/[U<<2:[Y($J]]R^*,51?1H\M<C^X$/EX(
M>$<\Y1"O1V',1N.OJ\#,E*^_3&3J1__%A].#R\?]9K/YY.DJ_'DBC&GTPF<[
M!%L$@FDN(7@-!< 7'\("8/<L */Z%LV5+@^8=-"U .C"F@E@%UX"UB1QS**I
MW1_??\TD/!O7%CU!%0."1Y86'C-PB&F%5&+HXV]^1W 6@2;]._/3)%ZAX,IY
M+:-7[*>I"7XZ\'FDB;0DPN\IPO^?'^B_2BWWU5Z0#,;8\2K]:0&>[WD_\/]Y
M@."$WFAO)-/M=D^F\-%8Y/#NY&'ADP3SI]X!GSRJL?. R8/ZG 1^=-E/XEG.
M'9X\L'=OWN[OOFDU:^*MQYP5ZPD$JX;VSU-4G\SHE==OGSRSEU:+GPX*2]*F
MGSK +5;"7Z$.UO!N6,2&",6-^6^_I[NH=6CJ^''X.A'>F1](/K".N^%[S]+,
M=="GIQGI*0WFI_4^Z7\A@+X&TT;PE,/#!?E!F6 ANFK2Q.LP^[MA)F2&IS3P
M"]R%X*D<^BH%&OB"D5;M(-U;TZ.:68.SB\.:>UV!;<[AVL=SCM:V'JVB5FMC
MM \P2'OJ\>Y,$QVM^/C<IYKQ':SX^%I/&9\*/1YGEWE&Y>YQ.9DZ%'_2Y.O@
MW YIKS^Q7/XF5CZ?I#-+=3I9.> T2]Y3:WZW$R7!CQ6)B7^2<^J&IZJZ)/.#
MOA=@HZF)D>S3<+P P:D7B).159<1X>.VY5V/!C"L5_(G)R%.0LJGL3KLAD"$
MW0=][)3C)3%R#KXI%+Y'LF2>ME4I)?7)>Q6F64TO8L^)59F1E9.L5:U>CUK[
M'8+O*4^8VO0</_8^L6$B>>J+D4<5J&5#,4ZP(?R!5>TQ6X?%/W?$ZX_>A8#%
M7US[OQ[R9BT$!:II<*O$"@V-"AFGC:O\K_.V(V*-/)]JX)@^1G4\) ,>87PH
M-V Y?FU??VK_7^\Z!8#UL)8=2Q\G_=9E[*VUFZ WDYO >=4GQP'&CT;_K:B3
MQ<7#/JF\Z>HQ\J5+&=A*_$N4,MB?OI3!_UJQ @)3P^&T9L[RHI^[N.4H1:[A
M=;(4#)=HA*D" 88PJ,##.Y[V:9,15IU6W'@F:]5[WD0[9TZZQ8P6TE-UAZ5K
M \@093EB^ ;SN/1\72L 39.D ^*J&#!9,:#:#9,4 U?J^;EY !LE>N=Q"+-.
M&0F+/AX$T4FR%!NUD>]+=4/*?1Q:L#@V9A=YA#^Y3]55@6K6CMILD P&(*J2
M;!!?FGN#*)',_*$+" 3)+>F[G1%]ZU,A42WY3H(?]5-.Y%[%AU%F'_+$3SVL
MO*BP \LOHGG9\.[\/+;A3/AJ)ZA&#9P0>\G"5$^_*%Y<L6++C25W/.PX1;^4
MFO"%+."P)\I?=LZ_GH&J QLZ(Z7'KC$$\PR35%^Z\[%UL-]HMO8;^\UWQKXU
M _XXW='I0M?RLQT+2\8!6']!G\%R'6#Y>]XM[?RPV]"&= <ZZ>Z/.+F#M<U\
M">93J"6J@2(5LBZ/5<KA50: ^J9Y:.3.VNKF8K-N#\^4:<9C;%\Z:2#_8+)<
MMX'J;\U:U.*1LA/JWX?CB?X$ ?D#Y>-:B\<Y2<>4;L*OR9BG:H+U];0@NJJ
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ML/HM4"ZN?M=A$6>WK/HU-BK#%-=T[!=V/V1!.O:M3/F@YNJA8"$?OWR8(/R
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MWI N&46T)8%O4*NN!!NP:B.?J\Q"8%V*#%5MHO";2\%O,0S/RF;Y#/_ID03
MZ+'1JM<.:,FWWKT[I$E+_8S]MVWS'.M^O%JED]-52H':;YV:2T_O PK.Q@OW
MX!4^%82F'U\$?5$D >)PK ![*+5IH@0&\#3,F"< :3! $4?SF P:G :A\'_
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MZ8XA.L0QJ? ,L[=QN_F$K??:X0!,6TII)4&$J9Y]:C<*,;3=7CT6!]2:+4R
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MM3[);$_XM 5BMS]8=/X]L$KRCO<*48,)F/O<*U[\]NEDM]D\?O-30U/ ]^0
M&]P/DH@%683%.OJ\PU-$/%6)Y/+\X(_7[1_IZ\$-YDCY:?_.'ZGTAM._WQPW
M6PWSD-W\(9)%JG=K^7&WO@RHOR.+0\3!"/G4$\D=B D&>R2"SA>&^.' >_7W
MT]_.K@Y^VO-^5TU9&YCKC84!J-\?$1!9W_<E2!+\,/!#I@N'^%()C)%@8W.H
M8(V)TU*%GE)@)$N5SS(.5'_=7'@;)3?% WLFHB9AK9?%18@W$*N+95],;JH:
M4&6E-4R[2%R=7;VL<)'HX!;\6JT=DG2-H@C >(0C\L6TYYVGN+J'B91<E2F
MG44?*)OUB?M8JH:+K\H7IU4$P*Q319W\;(<T ?5&N$GO':5:!/HXJ-K1U@'S
M=,",DIW$O:0.C&$35CMK/1PKW4"K,TRHS;N? 36QM>(_U69YWJ6M/LGB4+=<
M55H3=GKUNRREW0#8&ZO'Y46+*+Q@7&A!0E"*-@:[7T@U_\3DD&.A.H!E'VO/
M![2(=(4X6N9]7P!< I75MFJX17I;E"ORU$W:CEXK'>:JKJE^S =61ZY"0QTP
M+)'/Y4"W[548H@ILP/,?$!7!,*9/B5=%$2CU498IGAA98[H#R?*4-!*>C)D-
MDX0U3>X!J3!^[P__7]PG*>Q8NCZ2C&R#4GMGH]H6NFQD+!A% @ZKD N%\[IW
M;RZS18]>P8:9LC,P5M ?P*2<&OH$M,O5H[J.P;3S:"!4<H;[6A[A1$F5:>E6
M5<DF # D7"SB.O&ZJ[^!(?GA4ZZ$;2/,5#<:TR$[\&7?ZI">=X%6E=)PY4;:
M'*P8@5)57U+AO HS(C^.L6D[+CM<_X;NNG;0B+H"EQH2RPQU"!P"-?Q6JW&&
M/MM:\3,3,P(D/2MK@5/5)*W8$4A6^V3CRE=V:0TUC!VJNJA76EG?^F)D I1Q
M:JF)&DZ!O*K\DZD!6MH^+5%4S=<Y:6YHE!?:&Y+W!Y9P JJ@J:\;I*M6UOF#
M"W+ID=I-S=D]Z .TC R-Z0,B)>C(!'4TCTZI"A26QE(EI529J,G-7TO!TD6I
M*5 ;>*2<#_<<%81(N5]PRX\P_%J@4HR:, XB!!-AO[F_ORU=N;$+?>K]!^QH
MRN]\T&S@_%L-U;Y>\P@65=_7FQ]<WO'C'TBQ]O_8?[MWI&Z$P4:D-=UHVBIU
M2F)Q6K6/D0>&K"40GJ&/NR-(>15;.[[DENL&=#ZP5FB/+JMQ:I>P&:T6"!JR
MN;4%NSC+ _'3-&*FV!N8?X37VA&&\J ?"'HFNH?@&K/AD@^0HYBG3%T:X(9.
M*VU<SZ'53\9:I7?\U!M*-BR7O<.;0T# V]*Z(+X0#O#XEDFP6]%YA7\7+FQR
M4*D@7?JS3"L%(LHGJ#$&9FU*I!E;EIK4&T^;XFX(F@U:S)JE")U@&I*VT]<(
MVHW C$.,A+],@3F4"^VPT^I1;L>6]!L2,JI4''?I $_9CJ1LZHI_BFL@%X'V
M1.+J'@IJV5JJ.EBN)J=]A;"-P.@J<#+.E<<@P"4EOQQL';BDY/5+2I[3)KIR
MPGC>+2E^''4.<S92?VA!I3.K!Y+8$"Y%<,K=&;6&)'DJPRQ@2IG,E4 LMBD3
MRL2P1T/&B%2G;.K5G1$Z22/:$8IA20::'6T.RNA.[K"$:I\/J60,*%H*J?L@
M;-2=KDNO+^[*=;>01QDH\\X0G=80_<IZJF)K+THZZ%.%_2<94%5;[8K2'ET\
MH OZ(" L[K'<+U"U8?-]5&^6(Z-,"18AGU#G4I5$R6NKC-3\P$[%PY$P%B?C
ML-479RR%4-?LKOKAP]22:_O\+??0/7H.-_G(;=5\=3G_+'YIG;+$T5'#<MT$
M:#^E.;ES!:E0G$WB*(_##%@)=Q,)E6Z#AC">.9#UE(ZT_=-)S0,POP)7?,B1
M14#(@FT-ZV!5#1Q]3\KJK).GD@JKJ] 5;Z'D>C_0"'268'4J2>D<"D;TZ=[\
MCY-.+OY^_FFW]4ZS65,:RV0Q7#OH5K#FI[S!6D,M<X7(@9>K)AWHW0/M#REE
M6P<%8VR6W2:8'$SDP?4 &^\/\[M9=28X0#D'!)<_E*VIUAVB,TP73Y&0FO9Q
M#;D:J$2_T DPY/D8JXH,C^661]O>$$A9SW15;&4$P:+CIN 7GHS:,BN+J3=0
M'^;2]B3D<2_PW4A[+VD)EYWM$^'(B'@QTFXN'?9).JZD6SRE$U*G.)9@"#;;
M> K !"J '9E2K7"XC\6-TJZH=]=BGZ:-C$T(+M"5)BH;+CY;\2$LJG&71DO&
M1GA+;.(J> C+<Q<>%WVL"%LV@#M/57:3PCTR:U1Q=&VJ371V:/?\XT=<Z^ZL
M.,]#3PK&U98-G[ 5Y0$G)=;G)B!")'&7T=*!UY ;#+T(L(C46E/A,86?*E^M
M(!Y%>HH]G!PJZ_9&)>"YU*(X9>HK<G7@758\"V;TDX:HBHYW']N19>T[[_H@
M<H@EZ'%=]MZ\7HK@<L3Z"C8%Z5UAH0FEZ"-S?S4P>5%0>!;UYNGD/-H,M?K/
M(K:L5*D;E&<\_*/]VO2/L+48U2.'^N-@K"?&B9<KXI7CRL8VP3'/'0'U6+8^
MJZ_9H;W_>%B)?C2U+6 (6AYD6 I 5!LG; S89L**?:1D>C,AQ ?J@A/[*HSU
M1=7E,S(UX&EDP,!_<U0VCL2265K+HR+4ILH:ZN>J:(9_H?_7&V:P:Y(*AGTS
MJ+?&W-71N3\0.*M\?$F6[NI/0OTW[RL+#]*_=$M,K D)0EW%:C!+?3.H@HV*
MBC)[&KOU(VJ2!'?2?I/37P55I$JJ;C'823>RMM:*Q;<J7PK+A_SF _^?>#;/
MDWQ0(QSBL.\#-@0LHT#WPIFN5%F=QT7:;+=JH.)>;:V 1JYOYC'@29S7^T+-
M%B1O5YWZ6<4TP+RYW_/:\6A\W1O% <-E:1]5':($(XC!9',\/L!Q95*]O13=
MFD?+YL>4OGX+XDU^-%9Z(^\VZ(%Y\'&I98THTM_QJ&.<Z^I8 :2* 2^5W%,H
M[@/QSJ9]RH"QM!S'K,\];9HCRA2GG.5?:>-'.M)"K039YS'-M:N[050K-X>9
M^_*BXUVU>.(DWA6H_HMB/0F]DM0P,>BEQV0="(/ @PH&/Y%WQH9@5/9[(N_7
MPY&#%"I%WUA^'$5(D0W3"DQ3^$I^"+7IROV-BM2U=^([VF&19CSRX@SVSB2S
M+# =UE[HG&A=E[ &6)1(K2)G\0\0EM@^^FNH4W[!=/4)F770=Y%R*KW5215K
MHDR%DX(5H&K@PI7:[6*Y/RF0>&2//]_/<AF@C(2&UP>E"0,7^[ 4\T"BRA*Q
M]C&2'DN8]%/N!"Z#$*8DK:-.N!:[PA&8)W8<T;@0AUB&#'8 TP94ZQ2-PFDT
MTK H49HQ3!;IIL[WQU:[FM^@HPP@\B!7(N5!34KB6$5C4#Y 8/(A<L/"&BX=
M18Z57OO!1JI4&Z?^7E;#+:%\EF"I)P/MH*Y]B8EOQ1"SGO+O6"N.@M!RS[?9
M0K#(9!'=PPB]<21X-)V,&)O\MJT)(PB"1."2BZA+FXZ33LF(QMIX'?: (0V6
M*GJ=?C#5UZRN7QL1M] NROJZ.O"(?0I!"9D,!.^@=&,?RP;=6KK>O#NT')IZ
M;]?QJ<:UCD>!ZDBXR,(A6TVY#.=@--?FFU032TZ26-L8C6I8ME*^QO+8'MEA
M-0D(73O,CN=&G#0>>U(=M+,8>$/^9 42"(?5#GHTY@0]A6HN4Q<JM(F9>_:*
M**C45OQNF?$<UA8*,G6"_*!/4?#HB%UG]\-R#>8V=9:VD$YK^SJPAE"/JE5V
M.:RN'^0$+@$GZ?*DN!=8KX1,X7K5-,Y5HG),-H;N;6-4Y(75Y"_"O3HJ-<*T
M(ME97E<4ET(-)_3:!_Q0O@9K]U6F%$8S6ME2M+8';-#1.V=%#TV9/R@@I;+S
MH;E^RR6:8#9ND-*BM64U=)E:K6WK/=EY9I)"G3R8'\W"N>7IW5!W3UNU(-C
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MLI9<2O1[&EJIUNB1SP=ZK+J59/U6/$.]X8J15Y21[&4^58=F14_&8C!@6=(
MB_IK>>?RO -G'9FQ'0_9W8DP-@?M0YE\T%&-C25,$7_COZ"2]*9Q$!7FQ5,=
MNTTE$4</F<2J9D#Y<5,7W0CD-]:UO,P3V3V7J6Z;B@ZW^!:66:C[-*@G6II/
M_AT1!FF4ET'S<QJ-#Z1PAY@!AQ4_M2(W]:W55ZIQZLL?$H=&Y6 *-3V.;>>5
M\U@5>T3FSUWPJ80F.0@"IM4;P7:QM:M6K_27,(1TEXJ1Z_4 U.3LKJ%J<-+
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MTA+B(?'ZV=SW9S[KQ1]M.I5N"A<IXABAS2UGV*&1@2RC$2"I:)J2_9?W(OM
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MBK//4.I_MD2/J<QRH@$F*_J87*3Q)[(.!F4P*(-!&3P"9:#=:MCFF.1FJ>9
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M*G5W'=TON@1,W^/O3%=3P,^$A(P/[$@),SLS-Q'A'-6,_)DLK2Q-:-68Q>]
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MLA- ZH/@0PSGTA=E)XJ&'09O%>&+<'U-^8114:X7[?TZ:QR^^F@M<>\2.O6
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M7TK!S=<EU72V!>.FD )DL#)NT<%?4FV5D%YWJE^Y #V:M!5]IT(J :Y\MWP
MXW)NB\B/.FT_(V37,O6U"S:'IK%3YFX]=72J3[)_[,BCO0U1T*;,B8(I!4+5
M0ZQ06*TY&$V+:(WLL<V?3D[IAZV?GD4,?#E=2/$]KBIAAF*;3E+7A!"-99Y2
M@"@GQQ%&R_N$4S=/+I% @JI!\Q)Y2;3[1]BX)U(LCHT6<)1@S*@Y/79<;#/%
M:EE^MQ2K\L/M4*E%/)DKVA+Q>,#WSPLN][8$)]*<B@VPV,^>&^KSZM+QUJ[-
MR+[+4@"G;65BJ@ZFJMLR*D<-YE"T7TDUBZD9Y C1VF3U$%FI$*(0[.W#^NUY
M-C>XC3PO(D>LQN=,*ZB38[UQ<AJA8IJ #5;2&+$J]D)6CWDC;(GP&#'*\<HL
M"\%^XOI? A>TF_,/OS^+FTRH/VN-"7)- C</#J,EB,(ZTI8_98&CASR+A5U&
MNE04T9"?8IG'A3X968VE@<[_K,*+(6943=V%>5DOO4F1L^5E+1($G(HT)53T
M/YIEC0>ER[#M5$!=<V^Q1YC#F\ 4=%O;0@ZIS01*7^<WG"7R,CAK>'K84_Z
M'=?N')T>?; 'R7O74ZE*/B:*9FD.7?SH=Z_"Q4BM$LS^@WF&4=OH$8+CK0=!
M;ER$6Z,;M.<8UTR[G,+G+_C./L\: 7-)Y%S99MF:X'J9 D,0':6/%/OA+HP
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M()\55X.1U\ 1;&O6'C(,1.3)$S:NK"SRUM12[*2[(]52]E/=72^+[L@8R9Q
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M9D)U,+:ZY^B0<>^XK(.OM<X794ZU#T5'&KJ[TIVIT09WYU<6')M&2P"_$C,
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M(A_K!#^>_7TWG!^E#UV<)HE@*&/;\GF6S> ",K?8-7V")E %JI''[6\2%LV
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MP!M\NK]O=BYHM%S![EW(BO0\!B7DMC.,"?(T-]>5.,1AX)%1CO?:W$B9- X
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MW@>R#XK *UL-<2=5@;,^D/7N",45,?-N+?J09=RZ2>,\/']QLC.4X27Z#X#
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M__0D/#GSJ0]>,L_U0J1&B#LIEWO=L_"D?VCXU3_=J*/=1U,^BD?@@'=I8VK
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M1U0;RYA@[XV,Y&0@LZ#?[7<[ 8XO)H"1N1EZ*&%^V$Q@&,!@@C SDS@R NM
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M>(<.W'\7.&Y;M>!#W9'78R5'0=5>XO-H!-IR%G*M1G2LV(83?K]PO][)05:
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MTKD3/#VI(5.X%#3US\/S_CDC73.ZY(=&[#"@V,H0C@* HI7N3]$)4R0W4J.
MM\LUZ=4CJ:@:0"2U42)K*=IF]"]86H"^ BH_& &4EYW47A=RA02=EW8<ZOS&
M!U0:>V]I9"D#TF&#SS29X#(629 5L=0A*R!@$V8@":E>"2DH8^ 44#+F1.0N
M&PWK(?'/=?(>%IDML=+0T9;1F7V._+;FR)^<_W1G8GI;9;G2S^_6&USB9S_T
M6H;^D2OXLQ^Z@2\G^[X4.:NX-FH)4EBBKT"IVGQ*><AT])=!]O-_&T&VCN87
M*U_*/T 6 _/SN-^WO5NPBK??ILKZ?7=X$3*+E)9$4],,="A^Q9]V<C7O0&/D
M04EMY!]%3HLC_;$ZK1]<YB,&" 4#$7V]SK .YW/',.MWC\.@?W0&_SDY>;8\
MB'7/?^[U?D9M<6=:J+#OX\ :Q_2.?N[2.1U:"ZQRX2<[M/ ' $?;FKN=L[-=
M.N<?7N[QR6KY>8,!FAY9=Q5@^H>Z<(^L^[O<XQ4W%O2:K<??1X*AHT-=N,??
M_5WNR4/@QVNV'ED? V".#W7A'EGW=[DGN^,S.'C-]N@@\1<PZ#!]MB6![I+@
M^4% ZG5Z1[OD0?IA_#UZ<;XK^.N1=8L(;U7(^L(CZXXLW"/K WVVW=6ZPKQF
MZ_'WD33;7>)+C[\>?Y?#WQ7[C;QFZY'UP9KM+G&<1U:/K,LAZ_'IKB#KJC7;
MXX?[ C=\9W9RB/![?*B*[?'A79GU.J<KCH[:ZN7N:3""!]9=6'1Y3(<6Y>6!
M=>^7"\#ZPNNUN\*0APV_NV1=>_CU\+L4_)[V7^P*_'I@W1ZZ.UA\.=B%>V!]
M(+"^6&V S2)@M?U?YBOX+%S;.O9O8<F]A07#3?TB+HXU_1;H-%9#4K"[88#_
M>[9,4?%5E$T\N&6ND:^VX5D_=S_WZMG=<1CLBG[3#WL[%X"P#<_ZN?NYWX]+
M>ZGP'8$F-$P+++BYUQK?UJS30ZN?^\'._2^^*<]=)9UMSXY(9-D,*W/#=$"K
M38;8;^,FQ0JC >EZNA.\Q58@7#(5NS%%:4)[CP"7IT&:R$9'D*"8PI/2%,?L
M!&^JNM%8+3H,SD_#$[<] Q8(MX\/ZSVA395S+'W>/SZI=W68^UI99]V7]KZW
M6YH$*P8V=B 3.5+YP;6]L0T&IT(-J0U:/^R?=VV)\Y'2@"Q<Q!\[34E;>EX7
M4YE1![:\MGM(G]/FEF8RIN9CV '@XZ7V1'EOU\=.\"H5V3"XQ,YO*CJ\;DQ9
MRNT[$"MY*P!PA8;!XSB]U;\LU9WFM+G4!Y?8/]U0A?UMKZ>_]+VEK:S_TUT.
M#O/044O)=VR'Z[I=J.<*#G76[Y_>,59OP5@/<+,L>/7"]C'<#N:@6HUF<II)
MC>T+058@]&OLH&)4'(7EM*7.==E3SC8@ 0T%^Z=I*>WWL%>)4-I^5>?8F/-:
M82^3:1JK"'XRHJ5JFV+0P0@P;):IL+=)%!=#R0W:L%'H?*,.'&=<3+!;BM1I
MD2&Z.@,%8T$M4F"E$>EU$RGS ,58.OB7!#2^,7/![W S4IQ*O<&CG>3+9J.F
M1]#(/=9YK/-8]^A8-\W2'-G?(!8:7Q-&K%*%=L )'QD4*D;B!V59YP+P!YF"
M.U&A+MWLR22B""B3OLVMJV#(89%;Z$L'L/7"]"&:3%/;++E4D !58W%;0E.S
M:]1K^&*N\J)LCXPOP=<&HTQ,)/9;1AR;9@"?24Y/R-&( 8^;$*>QYEY8DI>2
M*?W5-&466DNMJ2GST$#AT&.?QSZ/?7N!?: H3;$Q'5(V0A?B"RI8(HX!5[)I
M2GW4W^-'B=7-N,DX-KT34PFH$^G@-T#,W( $*E2Z& !-*9&1HL>J&^+E)$U4
MGF9-;3 *AM1%US38<W4V!CW 1.ZE3>,A%A>Q(,2^3D6LN5=VI:<15M5?):*Q
MDC?\9WH%#DE?]FCFT<RCV5Z@F8;GX<'06&]6HY.)9J<GMH./5:6(M6E3I,;I
MX&D%6O@46+O +TJ/2WQ)!V@26TP<PP8$$M0N=*K"L\D0%#?]["4]ZO'%XXO'
MESW EQ)(:A8>W@=^E=,<]!S43-!Z&[5"2].,G(A_@=XR!+4D3J<(+# 6&V;P
M"E*C<M/.&#X6*IN[7_'7P(O/ZG>KV:J8U,:?1T42L9%=OWU@OZ*_=_ (ZQ%V
MXPBK9<SX%^+-0:JJ"PB)BAG;?*,LG00YS !]5/POL'/]!B$$7(4W3U1B5;A,
M3HH$;%9C989\[1"+A)ZPQJ\N(FSV#K_A(X3B;S][$]$#C >8O0"8RC*<9FDD
MAT4FG4M!1 &#.]93I&6B[O0NP3.HJSGPP]!"-P&,)H@X%FF:UYD(2*-9Z:9R
M7EY=14Y2 +^F9^Q*1IG,13;SZ.31R:/37J"3$SSAL+KK04>H,7=V'%\116F1
M "^@F3,+]$SG<N)]VAX2/"3L!R2H9%J@:PE,'=(J5(*13E/07HQ.X&@FCBL)
M_Q*5%WCFHJV&),997K>;ZH%0_!I2<J9D.<%/@V)X+?,U(LS9#R/,V8H09A%5
M1A(#XAIT^3#_V0/6M!ZR.^HV#[CVCS.IFAM03N:7@9\Y8#:00&X(9O&MF&GG
M^,=9$V 0%@/+B$<X8R?_N'=R% ;V/\]>/OEY(07UCCK],_QV;:J=TQ<MLS4?
MOW0CR ,*(8>)BF"<R=%?G_Q7GD9/:I2@$HRMX<U\\M]?2 X!![Z&4="O^Y>?
M17,CEZ&H!A*:;3GKG"B@IWE<-$O)>-*BR-/R,WS ?/3$BTHO*O=25-9O?:\+
MQ7*.56)D1XIK:UCR%,R,,M75JNU-+OX<RVOZJ[TZGC/@[_0H@-C&I#.T\4FE
MGPCX$\X#DQYT&BG*GUEX&STH-*P-8_!*=X""B=#TK2>3Q?0T4R3IS6HQO)D6
MBM_1'-+GS0*/=1[K]@/K&FD6CC^R/<AE:/6181&9 !;X0^;8"-=5D)_-S/!X
MX?'"X\5>X$4-("S+-P-2YE4+ZSC@RU*$!7_=X$'!@\)^@$+EW^-0M$A,50[&
MCOPVE<E0Y6#*A(&(_ETHK3AT"F%@B/[!G/ZJPSGMPPQ165D>+SQ>>+S8"[QP
M^!S9OO)\N#G2Z 0AAT7I Q$*@V(IO5!7A7+0\7*=X:4EZ!GU)&XV33():@K>
M.7@$\0CB$62_$:1>#&(>0ZC2$$%'&J115$S)1 &\&$L14TXU'(L8R7P6SGE
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MLNN>9UF^F:L#$-(%7C'%=$4D-F1^Q@JE$<S2+ ^![X'AAW!F>4"7TD#,\#C
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M493\6L8[6:RW8:9T%2X&*N;K$#.YNM3 A^#U_X:%@U#D2"F\<T&AD,F<"A\
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MYY#\AQSGV>*73X;N/2KJA":(AV('."Q339CL*^5O/E[FJ3&P9U-,*XMG)O9
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MKO@:]R7AC\W,54VOH"73X(=1R>S+?78F6JS3C*-G1:MA9?4V!HD(MO$Z)=+
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MGE-B'/^*OKSTUMHA5 EAC1UW+W@KN:7\B"$ED],TPZ*QB<.MY,2DR\XA7V/
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MP7BA^6-]WRFR^>,]]HLX-Q\W)83/@6O"^4*XR@^8*ICU2[E4M4(\YWP<(Y0
MUA.B)X.)(X29X,Y-TX\IN+@?__OVM-4FV %LV-U3&>2&.W.J@ZCDU2VB,>39
M8CGG70).%EP1#Z\I!"14&"+7="Y00#3&%H9Q(MP)O2'D45.P. RU@E" /X:$
M*DI/"JMZ*ZA5'X_V2(D4@Y!P(*"5#XX/?RT)WIUBE Y;9HX=^<O=S?<AL\9
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MP 5Y"$70DYM+#: 3$\U,=S_>?+Q0)0T*L:E02D?EQ.<T(4%"T>N@L'@<!-V
MBK43D<6NAO>)*#$NN%DT'F<(,93<,>8*N&,!MXGJ=CKXI^PHSF1X%N>%&'7=
M?2"WD*O:BC!Z\@7PBV"9.Y] _"1"P"E]W?^X[SI_]P@X-T/XELO]"_A)IW5T
M>+;O?*/2;JR\#<TUEAZWJO^"[;W35FL/WG^O=7#0JF Q!)7C *])/C(JP+6"
M!@;.Q-4E<3P$K3"FDF5)7H3WIR 7>'&F"'D5VD%_$-T4WK%\->2-^*(G1[G\
M(N$=\(6>_?X/#P_[J>CMW\7W_,+-#+ZM&0H6;Q2NQ@_07#>!8:VFGQ\]:K\^
M?-1>5OSH[<U8#'P0('&O?7K4.CK^1_M0OYJ.\"P^4=&\G5>SW$R&OP*C6G9:
MM_>+[+7=,QGK&,#YKS%"OF(6]YYMFO]"" KY;[!9<:+3F"HYNVC\_,XM:=^#
M]$=ED*<^HQ&?(5W7K'!4FR&5IR333G)+=8SAA&C3"%QK(C*CYS$P#TE!I:)?
M,>01<])IR=$SR5/I@8WL=+U0IN1-AP?15^C7F,!,[E4E:[YB4"C4\%%J)S)^
M%'H8A,.1%N3)^8(*KMCMJ$;6Y.%]Y+VD1M4<-6<]8A<1>R-@W\O.]A4!LS[#
M1ELO$UQPG\8;IGY%5NAS2HJ2H\$&(!-5(PL! F73,-8)W<A%YW$4PS$_N5R2
MDY:Z:.5:)IO10#O8<BB+GN EL CSJ<@T6%$%&ICSEL JL(.1[-XDSA 1ZP;N
M"^@+"7\\8A[3SA1!JQ.G8EDXL1%LF;:*?."+OH<@J$@,KA( 1!G<OV= Y.)/
MBUO$->Y(1IC+X/KR4/$)_$PZ7*H(4OM-V?_' \>_+W3F](TN(>L07'J(A\]U
MD#3-"-X5 PM]N)"8^Y/248Q-V/FD')9?'ES 740=601NK_IDJ<98;B5AP'LY
M%*AR0VN'=*X!ZZ PC^*BDLC)V^?)H_3#GIPOB?(8!U+L854=D$87& .\^SM/
MSBHH,*;6"91-1-K%JN72=Q@R?T1!)%62H&:R"@,],(\^J;0_1I(CN-VQ;)!Q
M'N+DA_F!"-M,BWO2]1$*W)>#5H3TE'))@GD6P_A>QN]4\:!&,"?V0' I'#&K
M"0H[*(.W1$Z?L(LCGS?F:TO7*(T.)BVU%#0V^B^@6O7XD7Q0C$X8I-Q;V?[5
M 9]:PDIUVOJ'^3>N@)$3#A++TNRW9@FH<3OL@?>>WK1-H/$H QZNR-09/BFX
M;))Q,D NSTUU3$N-"?\EC8>]0O?PKWB<YD>K1&3J&D*N/&%'X]VQ#;RO!R)-
M/DG(9G@UVC?ORM:#PF-0<02EF$]>5L5./'$^BFF:L6JNT7NE)(/$6,B;K?-Q
M*..H)WE7?P47C\AYR+V"(,K!XE6 =_UC$#957T>JX3_'D11!!RW,&G3:Q<R+
M'W"7#O5Y@&K!W UZ_T5S0THIAR##(N].&3O]$O^6RMJUG>8]23P$!/E",L,_
M2<&R?AT(G]:D3M$[*46Y0Z10:4V))Q\Q,PLV55%=CI'D:)@T[%ZM3,88]BS1
MQLK[EN:GPL^YCT-$)2#0!T8.^./F,I_A2Z]"_J0:C@2_SEDE51%E:G,A6+1*
MBBU"^5P2P^5(%']<:B0*+HLT#'B"08M[I<6X,KWP= 8 4G-L#?::^"0U!3N+
M=[\TG3L6,0%,;^1%NM]9DMJWQ9H;+-8\ML6:S2O6?//IH*.)=%"[YNF@CDT'
M;;JO4Z2])!BIR-U-#L%TG3?+?OQSC/$QXY?K3@75<-S+>KWF\WWG$@-2,^]@
MRQUG6YCX(M+YL._\7<'QH'/PG='JWSCYV/KZA5-W^U(76-EC9<\S:>=RWSD?
MB@137J"_*&^&57<2ZFVSI=%^OA\TTBFQ0@$N(?-'O@@#,$ YSEAHQ)[Q3CJ8
M<WF3ZFB.QH*F,%(^&])(6>9S6_63:&JJ&O)F0#_@#C#&Y"?>@P3-YV4QUR5T
M'(@QG.5WA[*IM>*=]?L./<I*^3A\->B.==8KWR]E62EO2>4,N!?^M@(^Y1QT
MFJ^!N)\)?D^!9GKF<!C],6(J#?I"@U4Y:XO+3VR=P!MY^W1C'E=XPV?EO>E/
MZHZJ?.=4K:&C><67Y:WJV^H&O.?\ /@#5!&N$$"[<?QC3] 8(#D^2H]-AS?D
M ;'!B+7OG"O!]\J+1\#;'JM,/$]*67H!-9S8GI=E"6],,I\^,WB'("RR!-^Y
M_@2&9G&JU<P;HF!D/U_'O J^"?S$Q&V88ZR>XG'>A"!SLIP583I1A+C]@%&?
MRB%UCKJ7CAXX6>2Q:_CD..5H>##LCA,"!Y3 D HD27,P79&\.@5I#,=/2+P/
M'J4)A(PR4UX[E92A:4)!3[@%4@ZYL(%&X*99Z?LJB84%AT IQ5%%^$EJG!"1
M:N"7.!CXJ+O$&])4() <6,FMLA2,(&  U*DB+CU_J_+@D.$82I@@^[Q0) :F
MJ7Q']8I):G3&]/M!2%-0]$CK?&7N.8%/XB/ "8[R\Z?#9*3 84 #JN<FJR3Y
M=,K$^OQ"[,Z&"K%YDQQYXX!>W6-QQMKXT7>E,)6,MQUAR';A#;^K"GBIR%U%
MX([O=(D/:,9.#T]>LE6.0TW>X2)Z@&SO^='7*2%*]?)5"GH9D (+IX04D>OH
M_BASTC@,?,H@M%P'_[?[JZ,XW"$>WD.>K4E(\T6YJV\$Z5*PK>-$V\N&J3T<
MIQDJR5^F!C,7N6<E$)58?.[W5O\D2XD;HL1/<3*=MEXCH%B]O5A"81+EW7_\
M<?/3T7ZK1?#&.#QB%TTHZD0EGQ-_;'AJZN>[*Z37<G)'YPO)CSY>):OPD5RE
MZ5C9F/BR9C%G('^'O0GI.,QTT957]%K@J[DK+P>#:@-2>;BS24!>,IENQ6TK
M-CB629/\O<"T ;J,_OJN\VYI']XXB6XSK5T@,86AKIF?'^@I4&._VJEQ&$04
M_1!+8XN*P?W644D*PF5L,^V=5\9;$)4(G.I$W,%/"0528J5:2EKL5"D B9 6
M]UXHAPC)B I[_QI25T6V@(N-F4=FS%3&O 8>?EY$QG0-$\Q3_UK* 3F$(2BI
ML6TFY<NR[IUZG@KX%\/.^KB,C\O1Y(DH?%'B=!C!',LFJQ&X*?VEAZSC>PE-
M^MUJPIU,4E@"6NCDOA/G*>B6)(=,QECJ-I/,K8$-+>5/#F"33XDRJO"+P+9:
M9A$N3I+'_"-O*"K"UJA*,%2/.'I8F1^13E(VIQ%4D0^W]+O0-7Y4:8^)$]]F
MXKU B\<%_R04CT3 ?:^7!D-$_2(&5MD/G&@LL/<(FXI3;+954.82$WG"Y]FU
M=&>]:9P[D:CL>K'/!X2=T=YFI=1BU'+K/0H3?^\NAL]%R&_8@D20>&F%PJ!Y
M4N,TBWUL<.*Q@IREEZ.?T';6V4_&/F.TU@A_Y9:&%]*,6*W@,]P3_E2/=)!*
M2,W:I0]L,YV?ITXDL$%-:PM+R(L$.R2]!A%)A2JWSC1VS(H&5>93Y3.^14K;
M,,I3_2IRL/+I<F;EDRZK>6;EDSNK=(X 7?+H!<,^&)$+UXQY/*=VRC8DUK A
M\<0V)#:O(9$6+?7H';];F&;?[(R);^??;YVKJX4P09I?#%?WTK=GMZ&>-*X-
M]<"VH6Z\#96PW,"YNY2C/)QS8 4O\>ZD%WHIX*-_CL&CWT3_:<.[EVX1!S_
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M&$F9GF.G46U48Y\<OW08U>GALD8\':YLQ%-SOVV/IE;3MI8Y3:D"V'#*&I4
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M1WEP^<7MXF\JGL$DJ$^0JY&EG9";\D0_YWR@?%;ZJ"GXH<X[MT46.,L"^9+
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ME-5'Z0+'M#?W%K WB;!F&)O:(^QT%&>!9GT!9QTUDK,ZR%F=EN6L^9SU@HK
M#7/6\<M<M'DL4ZY\ .9IG_(+ZRP#4=7BT93&%=M;OEF8;UY0P[=AOI&YN,]A
MW 7:PRYJ'J^,3M6Y[XVHFU,Y9JZS(^%</U^<?Y=PK;LY=V7$7938[<;&-+64
M?3BO@IF.R@&-15E)*Z/%LW56&362J4[_';8)5'RP"*^\FKM\!ETT\V"7XEZ$
M\6BH!KGC1$"1(,9G( <-4:%<3SP_]G?MI4/X_;>!EPSAQ<<\[O'\@PI%E/-G
MG?:^I9BY%'.V,8J1*9O)PLD%Z>$F&((#(,H$<1'ON[(8>H(N.F>6,!8DC$YK
M4X2ANK-?3!@?[^-,])R=3PFZB+O.S?F-HH7S41*$4D9(6K"D,)L43E^"D;/.
M$-[I0>OH].S@O7\,Q'K2 A(ZU5AULO9IW(7#"#P*N"WF?)PV#]>&>R1/;2:W
M=BS4[NRW_WV]4K2M$.$N\!M]^(Y"K)@&/S,:)SA?C_IW<0#?"BBH?>#MM0\)
M0)?I1@X4O\F'^7U\[ V\Z ZD?H_ WX''#TT@2:NYY]-:9^VTUIE":POBJ%C2
MVP[2.UB_F#MXKIA38VQ?0)J@6__8O]F_V$>JP=]*0_+@J$5DXL<C&G)J?"65
M0W_/6L>:XKRDZT4BW;M^#,63(K9.J]6Q!#:/P([63V!'!NZQG*]\!=)@)&BJ
M.EB!=P&FB1'>8MP-@QY<*$W'Q135IR 9VDN==ZFM]O[5UYM5WNO_?/C^!6Z-
M1S@[EW%OC.ZDO9.9=W)S\=O*[^36>XRC>/ADE.3>] 9BZ-E+6NR2+LZ_;.*2
M+KRP-PY5/#?ZT4446GME"UW9Y<=/F[BR2QRW'M@;>\&-?3G_L(D;^^)U16@O
MZYF7]>W[QTU<UK=$H'EH1>+S[VR5%:(7,?S<^88# J^P3LSKD3-XB0@Z%";=
MP;(4WY?!U2 B%^V*H@8.W;4OKW#7/,2_V,%$O(7:]\*O<!#8(F+&C@&;7Q="
MJ0T<"4+I#3L,S/+<=,9Y1DK:LMY<8L2@J0<ZKQ='_0##65B2%D1]W!89,J0/
M@]01,BOZ@"VRPR"3F=.A\"+JF84W_8$!KW3<&Q06();N@MK](;)45\3]WW__
M]W__?[HDKBMZWAB,)=2\O(M^(/P9FTKAX#)X)A:"P^\P:@L_PZ]G3R-<Q\OH
M7PG%YA(*Q0(UP@9PJG 2W&/#1)P4GK"_-L%CH:$V @W5L=!0%AIJ\<>N6 \T
M9##RS=7GK^>W?WS_>%,Y&GD=,^(-(8XV(FB='J?Z1,J2'M324*!V\<)0Y=@2
M\><X2-1 >1#U?<1-O<N+=98]+)YK=>A4.,'(&QN PO&Q<8@T'%>G ;4-X@3.
M@O.0- <O!7+%?\<._JUJXCWJ/7B7KAAX87^_2FZ99]QYM8[A)>IHW1[6$ERM
M2L;7!!IMG6/M_W;^_UV=.[>_??Q^_NWC'[=7%S?.EZO?KVX_7D[.N']Y.(R)
M<V$:J%48;'UZIFU0>_ZS1R>-P\ G6Z/E.OB_W9JY)>_3]\Y_>KCV9R^)1#+5
M,G]I*+6QI'.9E ZF%KOZW8N\.U2ONJ:&.C^J"W"6POMUNQ9P*'\I5N.><'&Y
M]2.WS8\\L'ZD]2,7>&S@__5= +;]X[N%6>/-NIE84/>(W@\78A+:0P8RE?VW
M13S/YOL]VX,S7>*GL^/<$ZITE1;$GI[S]]<8 :>OL@'D9AUYR07[^QD)ZT66
M6:@"8-K"!5=@SU 5N1M0_(BZH D_8H^>] M[$H4DBY:LZW,Y,;D_Z5PNZ<8V
M;EI.ZK" "H]_<?;(J%AUOJJ@X.B)M7(5L2H;B9!Z^2JU!T;_$!6+;_6@Q78Y
M(PJ0GT*8/JHKX FL<4HE10[U?/Q2X7L^IU#EV=S_0L^TJ6M;_C+YZZ!V_)5;
M\/T@XJ:(?[01?9*#TL_LA<CM_;4QU/-)V51G9.N73G\Y8"A[G6=KJUD3+BPW
M-96;.B4EIE47<M>W).X'&=8J?(G3E%%00#DEU).>B $6G]X3Z'$\%):[<NXZ
ML-QEN0NXZV 6=^7VXK<XI=8(RT(Y"QU9%K(L!"QT.(N%+JACGC#$/_XY#K(G
MRT$Y!QU;#K(<!!QT-).#O'3@? KCA]2R3LXZIY9U+.L ZQPC[%2&I7ZQ,S?6
M9QDH9Z"SE3&0+6/8@C*&3WMV5+*M8YCU6*>@H&1^5U<VF-'@-90RTL\J-M2(
MZH;O'[]=?[]UKC\Y5U\O/W[["/_Y>NM\__CYZN;VX_>/E\ZW/SY\N;IPSB\N
MKO_X>GOU];/SZ>K[[\^JN'_Y<;=/7W/>ZSG!#[&7^":>'(=";P9>(@9PU3@$
M;M7G]"JR7,\QS8#%K3<5U9%KKT=!1%!R# G0U_9F^KS*I->?[;3^F!I1WM^%
M,_#N!6@.G\@-3\SK]1@X%[-_/=-V-TX0>#H_V9&,PN)/YT \IP5$7WR<;"TU
MP'JIN91GNDX6 ,C4?P?^R0U#(6UMQCY'.A<3JEQ,3+F87B$7$U NQG5Z>60L
M->241!%V!$7+7%JFAR& /H8 J%I!>+V!:F3*P.Y050D2G&(DDB#VN3RALK)!
MU3*H=XK(@=K!VBY!\!>AQ#Q.N.7(X]Y9>8!5A*Y.<]^Y@LL9)T[,S.%.9XT1
MXZ$X?2](0GA/V#SV9^FF7?CU"':3EI<P:<  7U[D'O/W3L<AWQFV3,5P8!Y/
M Z9.8?C1D@]<=E"#^PQ7RBW/!#82T6/AI7)GE1/GR!'@MD8^J+64($:#-!US
M3S7CCYC?-I+H^DL.J<1RTW*-Y/IJ:[X^>&G =R<IL=*7>9.B&$1F.H4G<3ZN
M9) 1L$/0#4(DV"*G:9CS(79UT#?WG6O@^=*W HK)B$=D=.0L=1-*89:7J]P1
M@B3Y^ T4*J0\TGT'E GNU'-&7$3BY?3?#Y*A[ BE,A,-B"[K392T,%CF^I[:
M*P<9LXRS\T<4Z"!LNJLQ";Y=G%]_R-4&-FHFNI&4Y&07A7M>[4+/EF*L!!5/
MT@ZVD/@$.*EWB>BQ3E^ 'L!CR)&'0^\AU>++&XW@5<C%3,:AX%_ .TN\O;0"
MN9B&'BCT8IRX N)$S1.BT\%W6X.PZ-2?/8"X0%;[XQ[20$YUTVXLU0)7GKH\
MRMM!G)J_E73"C;\/H#-"CX\?E <J!KY9?!222MPEV(U$>"E(>+QI#^1_PAC$
MW7@,2PP$V193]2L29Q]5%:%O2*6*]ZX^XNHU_#%--@!]C_(R@:_!1O 5#'IE
M2 V3VM&><S$F#*\#SX)W$M$=" 3ZI7PKU+GRK:2R#5ASX6"K*$OBT"'\K?P-
M$J7_]IUS,!(\+B(S[N%!3/"=/"UX%/=*XZ%3,W=_\<<Y73A4?$74&:34Q\D(
MKQ 6D3*,ARB7Q9CH]]EHBE#,31&5SWEK(C+X*QI%>*A2@$8Q@Z?(QUMF)1_,
MY,]>.$8#3)(>WA98Y#WACQ-.#P +X4&2@@O2'^E4SE"W6,57<[C&-7FZO 5D
M?5:2/NL#I"_:RKYS@W=K?%B_CGCT$&\\NG.1XCPX_#1#M1C 5L0]HM. 3,"9
M<)*.28X,4;FQV(<SZX$_(A>=^EZLPN59>F$:&SNX]\*QER^>J\Y1 A\*1JB#
M-'H!XA,0SCJ<(TZ/Q!-&6\$7! BD;0:R:A\$F/SP9^D1R!WH#(Q,S,09ET(F
M05>$@;B7$M80&'"H>$QP=(8X[>;V8>ZMU-A:KFT4Y (M#)RJQ5(>;CLK!]O>
MNK7M]*K/J =VV!AG/1)8E@!ODS2;^K4'DH%,VB1FZT"V>"EW4ZO5J2: M#42
M47Q4G)2MUL*OI:7*R^-O$,U+:-227YR=]JX,'9!497&0XK*FK*&'R_=A$2L7
MKK968/6=SBX(G?LXO)>6%YG.\$&$1QG 'V!?D!Q,Q]U_LLYU&:5K""+HT?GG
MV+^3XH!.7;^4E!Y3KL&/!1LW7HASHLF0 "?=>S)%PZPHG^MDW@\1T80'T YQ
M*%@+2$L%EG91]!G[D6)NRH:(%%PIMP@T38 =1)!DO)E4[6;* BC5(E-63UY.
MC-G<'IFP3_(RZR[]9$N9+$)X?O% ]7I!YH$S5=5Q"E;D72!-;Y$Y 5ATX%P2
M5J\AVS:[2Z=&>]G!.@RGXSKTYX'\L]W9M:$74QDHCZKG)12;#ABWJ6!\5D0[
M@Q(]ILRU)$KB7^:P[C,!31=C1PMQ6GS?BFSXJT!/CWZ>53PD/W3P'&34TT[G
M>,9:57W67)?V+$QM"ZDZD_A1+?/@4N3=?'0IZ^,[Q+%+"Z%"]E<Q/@E:V^?I
MR1RA\![A&-.@ZPS!YNB-0R!-M#M>@E/J4&668Y1F39<$5LA8(6.%S!L1,A__
M^_:TU=82YF4HR$N0+F\CGGE;$.M5-S@@+Q.-1RJ;P+@9Q:A_:K?W#X8ZH2.O
M[7DKM/9/AN0[I]K(1 >V*RCR/<0 (V7C[F7>(1%#CT*30/Q]H4(1%(,/:>V1
ME[%W#\YU[\]Q(&U9+)YPY;+M(^9[3JCC]MN=_<+/9 :-RA)J%O6^.K]Q#HXK
M5.%Z757MF>(5G-/%%8Y)1GLH"8M@YMF3$0Z74.@BHOHYJG3(DR(RU&0DFX >
M@M3A%*:O@BL<ZXFDISSTGB@52MO"J:A7_?(7Q&.0JM(.N:,4(SPZ8BSIJT>1
M8')Z**2M:(P>-!WD]JT(BR"ERZB. ZD$!9Z7BL');+[*#X#O^><8C]Q(!0]
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M4HR'9^8I1(S,>U0%L'7#_FRJ(5A/(W-S,7..@B/M?2#2N_4>-Q.;.77/6BL
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MQM=N]EG:]AU[M'7936..UMI8C;1XMLK&LBUTZZN;>8A$0JUP?_/^%7C.[4#
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MM*9A=J2%O-D\Y(U%35O\V"TFU!MD$(N:9CG$<HA%3=LT:IJ-OV[9VIN*OQZ
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M_@:@OP3V;0A"\-N"DC^T4/*K@9)?A)96BB0?^' Z0=0^/6H=@>1YMP3RVB*
M\QG0\G!H7M0+O- 9Q6E "L!BQB]PI.>8NWP53'QA(,O+M  OL8U \6USXL\:
MD>(/?GY65J7"UI@/H?[*!S3WV_9H[-$L].TW6LIJ!P>\_KB>Y]$LJHX6=MCJ
M4:?U(N]PLA?K^1[B4L^SW>SS//_I?_W;::=]\FNKU5I*N=I&JXHM7[V"KRKO
MW_)5K?CJY37HA_M'JRRW?LO+VU3QVRL7/T]346XKL07>&R^GK=.>FKIVO793
MQ[5M)UB-%K=UXMND5R\X*N]X5K_6:6U[EE:_;EZ_6H>J2;6W%UXZH"GP/?R+
M^',<W'MAN1F_,:6W9UM<>5OUOO,*[O!VSR,?__B87VVIUNX\O8YFEM6:E75[
M![JT[F!F15WGQ#TZ74$QY?H@6NIV-56%KR^ZFE/WY/APM3=C[?UZB_W;Q/,%
MR?TX&XC$241/  UV0]%,P=]N6<E?$"]TP2!?KO%ZI;_V/;_DM:B TQ4+F2:+
M_U?<S]+T0-L]..HT5@]8)V%MVH*(M)EZ89M[\5XB=TQYP^FQM:B"MGN"I0M6
M&RSC5I:F (X.5NR@S<O!3%9/V[!IH]=^N?";VC0U56G*NGUN5QH].M270C9
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MLDI#K%$4[;6;HC=_)K_NU;MNMUM&U[6%T&;?8(&U(SZ@8&"C#E;+"<HW -\
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MG,G6J$RV]0*EU>5+7W4NKLO<&YS;N3<G8M^8OW:4 //^WO#^(=P&]:,K]NI
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MG!L8>SVF@@=F9VOX *<\A8LDYP=: 'Y,EP?<#7AK2+Z>52=7T>16O1%6N@!
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MCG.=![0I(^*S<1(_).Y(68I#$8Y)]8D' S3C4C) =98^Q4Q]#;L:Z#><.!]
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MS54X3"#\GU\@M_:D2!\2KK&9!/[C6SR^'WQ!0$YQ1/JH; MN?G]O[\#QI=F
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MJG:Y"K&0L# M&Q(5H0G% ]5<$%C_V9.2WL0*U3=UII[]G@<74^X+ORJ\-UK
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M^ZP:(Y2F[,XH,>M=V2B5XEO\7CNR;DTAV_O!+4@P4'?PKP]YI_FFJ#9M3[!
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MDP>85 DFLT,S;FUS!!3=9_>D;N+;+"*OTKQJ/^8N#:U2&<4R9'A=X>XX8Q
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MOO^6W7GND^7C?<#Q-=:< )D[FK?B.(<,(&=TT?SQ52X,,L'X%MRMA)S2!U#
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MM-OA@QL&9:2#\LV[1-.A-A,L^[UC)UBJV9<I5F/T]\[F"8-+C^WS<SY+GQ)
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M 9J%Y\ WX$J@.SGRAB1\?D/# ',-MF#/M+G?9($,/IW:EKI=HS  *H EI\#
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M>MD;S^I:K]_1.H,!M9ZMAW2I1?O()IRQ^A1:S:7I7M7[C-1ZME%K4XRCQ+Z
M4C25K4<<XZBFLD=8+)E6,'?:6DMO:^T6=96MR=)EOB*[N\IF<!^.+=EM:6V<
M*MW+?L8+V=D5M <ZH"N;;OA@BQH;!"4Y9/5IM)I+T\VJ^R'79 _\PV%3O\5"
M#K16$+#&^N^K]H@248-]#9\4BR:Q0@9'7#7K(NP9H!X(;^72[+8QCSQ2,4;:
MIXOV%5O&;SH@DJ>0MN;J*?"SA#G]($ A0G/:?N8S'P^HEAS/M9-GRPS&N._6
MRQL64VT']YL(T>M7'8W%_[R^>?%F$^[USF5[@ \O;?2RUT_9:_3QC7S\.7KS
M@VNCV?\K9V,/%;Y? M=X\=L]4C0FYKU'O=+!\#7?CTR641H==G!Y90&-)+^.
MYOM\AY[:"P\#=\6^EQ]E1B9'TF0$*PFJ-5(Z$P5_=0-8-W!9,!9L9#G<,2QN
MPT9XH")G:>1-4%QYK?27=$".H*%T",0.XW_Z8"\P';K[PT",%,/T_B53AAZ[
MD$:C9SV$@3"94!]N.GR^6WN%.[$<L%)?)S? -B"A;((3Y'QT "Z-=,O\^XM[
MX'7?A2VDO?NCW;ONZMU.:PNAYR91Y<]SQ>C@\VY8#WT)EK'^]5O/!&;DS50V
MU$%<Z# (],JF4ZR>')BP%8 4108]!K(7'K+K*4?=V)H"FV:6PV"KEBD<TV?<
M,>57IYYK" $? "'A[\^6='FR<(KR&#\QW,F4.S-\'+X\=3U)=)$H<*3/5.;4
MPX)\XH8H"Z;<,N,%H^V-A6U>LGN4'J%MSZ*OK)QAS)\$V^6#NN/>O[@=SA.*
MMGJC]JY@VN1ENO"%@9ZF9]BK+YP7OSDN6_,O 939$^YI#M88:*8+QW+<0!V-
M@_$PL9#_*4A)N(7!V/4L'SXTE,_L<B-;/$4FM$M'P [ PQ^[SPB%,4>B%&#*
MS=A$^@R!V(2/]1H\P'H-(0(D2R1"X?G8.L1C#S.DR)^2?&Q;@=@%"?N$H@<Q
M$4ZQ]H--7?BKX,8XRIE,^7H^,-]/#I^!;:JZX275.<7Q>? N'L+9!28!+\O3
M(IDQ,!B9% M'8$;H>4A F1_3=2[@Y7^)J-XZHJK<H'FY73VI&VU&D0,&//$O
MV*##56Y>@T3[O10@CDSTX%);1MD^DVG&_1L0U0__@XK>$[S\>2P<!23DCI$
M84B.(*!]/A*/(?=,9H%0Y@^6C3HW_"'6?QF'C]FC*Y]U'4-XCL9\E.S =*T
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MS+W8?-M*PRJ_E-H*TS@5*!RKHQR5,/]?<DNKY:OGK4&H.$@Y$"Y?K?4AB)X
MT5CU55P#]=\R ;?B)3,OZU,G0Y?J +R_4Q8DW:3:%)_1U2H)(9!214I5Z2%*
M2A4I5<3Y2:DJ.43S4*JH$+WV:U-!=^4+NM]CL)T' &_G+QDLMQPVAO_6J;P[
M&4;?*W;^ Z$R#-X!3(:.^=GY3P#(<A')>YO[/E:BI(7O97'))]OE&(M.OCRU
MEB7YA;CJ>_')'B4PL2$T5-K[GM,/5HOLNON6@K<N6U0,GEX/A62S?=)%8521
M51UN6]=:@WY92G'+@_1]&8M^G6 L+6(LVQE+EQC+48RE53W&HFOM7O;H+D0Y
M);7S9+7S^]CU @:/3.)LS%HU%#I<XRR.JTO0WP/D/T2 /U0 D5@HBUB0J P2
MJ)3(LT86(,='F8'U[T\ 9$!=S?32GG:5@QG25+64N,]F[G-]1=PG5^Y30>6U
MGS?WH;X>A^^HFDL777$,Q,-D14R-"X[+<4:Z472CZ$85/.R-8H_5<0)]%<%2
M%;4L_!W9[O-*&286GA?I':HFVRL71RW _IB;B$,P&6OGX&B#C5'9P%LUR9QN
M4*V,]('6/TN$B8STVBU-;<'J>TBZ4W2GZ$Z5H-6>80ONO86CC6\F_&>\V:AA
M3L/;86%FKOQ!+&(JL&# ;1O[%_UMGP2BH6,>$A/>H8:UYEI8:[<=TP-5;#U>
MPEZA8ODVC]VW,MJ]U"&U5G==CWQ]R88.<T<C*VH>IOK/OS&C1O282+W2#\X=
ML9(,]]!/5,E/FB250@@/W+=\-G4M).N(*DH"JE:)0?6:/;NA;0*;>!*,LQ%_
M<D,/^>P;;H)\ 2(4\=C)Y:FH.!!5\A0UAQ(I<^<ES&?8PZF4>#17NM(&O77W
MBB*^<P'C5%H[ELGUM5YWG=1>8P-$H!+X]B5#"36=7YYHTC+V3@5Z!'D%(,*.
M>N+G%,@-?G]R;1Y8=D1;*WPP]%%F13TS0=YQ28K<X?;,#V3K10&R+MBW%^;Q
MCO-#.J\>5K4G?RZL3^M[3YAPMS<U:*UUF];DV3TQ JX7MUF5'P5C'@!K--P0
M:7#*/:#(9\NVX9J,>&A+UF@!T>&E1,(/09:[#Z"2<]4'%,@6OH7T"O)\T2O4
M=OWY>U(4-W5?-C883C87-A+[A[T Z0M0<("'KY(_7D_<I>6$7'FRUHCDL K@
MC6THCRHA33$'#JG&/8P*#SA2,53XZ:(]V.OJ+;$?C,BMG@(_2X0FE;Q^R[C]
MS&?^PA(:SWV.42]'4!9>WK#8PNO@?A/!2_VJH['XG]<W+]YL;$':N6P/\.&E
MC5[V^BE[C3Z^2?)')ADD;).SL8>"Z9? -5XLD4$< U6].^]EHU(0$N]1+#J8
M!\Z7H,=^G?^[A9I>+'\C LK@\LH"6DI^'X.A\Y-X:L^JY^E2M%1^M+)HSN':
MPDO%CXS:NBC#(]ZWX(@^]EU6/:W7;P"!<>VU_P@=P3HMC:$2?!#(<NDNGV\?
M3J09UM8OV:>E;MN1GKQ1S<MW4Z\B:2K,U\N WP#_DHE7:2 G%0)FF7]_<0^L
M[KNPA53AA].I<,P?[=YU5^^"J:5O8V@5E\#;7&C<=*?X$6>V-1(![&!AJ4A-
MCF,C<.PI@EH>&"I@%TF=;_ZM2$O#+T?,S^.F2&IKV W>#1_'DBV&OA1I'*WN
M)\N7FB0LZ5D_(^-G9/V$5>=NH<3RBT?@>U*/]$5R&>ZI<UHFF%0F]CS'5OE@
ME046.@$,+SH/,T(?L(+Z,+Q@4ROTN?6&)P%MU.=X%#RV9PF A\;&8+6Z'GJJ
M9;]N15C1SM%L _7DF7OFA>VZ?RDU65F:EC0)0?D&]9<_<<M&*"VKM)FQN,KX
M<Z-)!-+@0&]N7/NF1A&,@5G%I/!O,$3PB0WC"1#R#[ >O,"8:4#6$UP%L<PG
M:.HDB"J98:4FFSB/V!I>6407TB12]LJ&Z2A<N9+@\:EGP5ZFL?TC'4@.KJU>
M[7.X7#,U<D'-;U!D@!X V)T:>P%+JT$,L'VY;=FO/S+&T K28L^ ^@57\\1B
M9$8TAV73?G'!1S4!(K$FO@R_'8#%92/8 .CJALF=X=B $:SDXB%AYU,7_1%3
MN'5P8EA,C>[@2W8; #=4=P%8!I^;<8IOX-UW-B"O*7?@]WAJAI;"+)&+/7L6
MK"A]Z.QY+*0'R1/*7&;H0W<=:1LH)CPG)5C&!8H$FOWLF( +X$X1B[.0Q@P[
MA'=)W128#M*]9,2F>( O(AJ%\X@>+(DUX)Y\)JD*AVMH^&)T?CVA[0YLS) *
MK?K(BBB;S]>5<U_^$DNN@V@Y-3^$1Q-$V".<!F"'_-!A.IL)[C6%"NXE3A'=
MSHK?PW50XGB1GV7!K^1]17YH.=O=*RN>$]OZ=VC%S 5(03(7%/I^M(SD=PSY
MG151(#:]2>&]ZA+[34%1TH-FH9[BP/TPE_CST8)%WH,E4;<O5,FK^T42-/*=
MK8[=K ASLV=WHZR5E.)'-V^^T0?\BP4:J24%++!^4&; _EN>ZQ1I,)$!XX8^
M"-D)B&14-O$IQ4\C#5/& Q;YX>II4#*-<4R=\$OH214+XURV4JL7\I?+!$?Y
MF&WQ!XQ,6.AA_>PHAF"$-O>T:#>/0O$GJ6,KN3/AH"NCAA-8/A8X,F&AM)(Z
M6"1!XDE>KOS4\OU0BAY_#)S&U^(918!EN#ZQ+ OF7N++%'NS4&K[)B81PI+R
M+ (K,LR];.2:!!7NEZ9#!4IG,060M+U))LWGPGG; *D8(NJ<HQ1/R#)MXB:B
M5\L [X, '<GT^+/#PNERW UD'M"59+QF\IHLW8'$XBM1.^[9%H;G\#SXX?/8
M,L8K_KWDTR@[/0P=>RJ> 3=CRBUS:<NQ)H;Y/(L H+(-8BLBL5-3C413\GHK
M"*V(>4AM406SI8TLLV%\>5--:S2"RSGRW G^T4(1Y'DSR5>4%(MTB[G3<AE2
ML7VP2U:5;O 7VS%X[H^("H<RUFKYGUSO*]@Z\-TGZ3^8N^>^++!]U+0YS (K
MU00R/9DJ=^ (,AE:>?$;VY3JK0(9+'5P5^?E03F4,F,N=:7.YEE=)[Z@ND\3
M: @T!!H"#8&FZ*=E4G>*0,QB)AX[/$_^#!,7]]SE6JT(RV1VP*YTB)(,#RAT
M$(P"<CS#Y,%[\]O<[D@?OW%&(!XR+Z#X61KL< JG.U$J=.H*NAAI4#^YT7_!
M-/?I#APV!8.N0]6OPSL1/ OAE(3P2P>>B%MP)Y*A[07W(&9!S*)AMX&8Q5;P
MM%>8Q14Q"V(6C;T-MP"XDE!]Z6!SQ8@I$%-H(.'/<RE*0OJE U BK$\@2@?1
M(MNA)!"J/__<%-1(CBQ=7C:#&9JKW#?3 9VT>-T6/R7PEE'?X^TW2S4^7N=3
M%>E\O'="<%IWR"-J:9V+1?;5R@BL(WG9H1KA:61>S[4)E@3+,JY-L"18EG%M
M@N79M;>:ZV7RY\**87)1].)DI$BS>Q"R.QSI?"59FV!)L"SCV@1+@F49UR98
MGEWG(X_=T7LZN")8MC"9\IFL;BU:7=LYBN;X9=+F!LFX2OOFK)L]%E:'O^G
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MDL%/Y@F;1\,^Y5@-X]^AY5OR3_#8[[;E/MC<#]A=,&-?X+[AW" YW<<RA&/
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M79H>7IHYF)MT4[[(4G C<7B<5.Q9OKHU:+S!%> 3-\2_806I+!Z7\XFGGIC
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MDI'Z 7[Z; 5C^)8+^D'T=?PC^@YEN%(]I"'EFFI ,7QHX<!KG'ZL,?'3$--
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MOCN/R,OI=ZM?;<CX#1^[^\[+9*YXUTRRD9])3H;\WO#E2;/'^7F/Y$(VN8Z
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MJGO: Y\-P%<D-?Y,I%6ZNF=U3 -XKV!UKT?WB^(" ]Z3RWL5C%H&[O4<71E
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M-*AK[JY4T6OC *.L+Z1[)0DL>-7F.1%Y<#)2GL>%H/"E"/E>FI2@/*@V$#H
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M7C F@X/OSMPX")\+F?D5(@[DSBFLA LLC NRK&):^V!E@X\H,.SX_"4GEX?
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M3W"Y<&'L3'S N7-#?N?^_Z=I..F@2*./K2,8P88%Q+/]#.B!7W<21<B9BF=
M.D7B4KG/F=I'$DC26"T G\ZGRL4.OD8KI $)K6KE2S3*?0[ZSE36'D;Y9P#=
MQ,TFKHJWC3 JP^])<=VEDUH.HUU_T5L'\&H=5E4+&^X!,_M,&_RP]X'SX8--
M+2H:HT,"O2JZ87;[D7UW8/\^\VA0TS37S@:MP^&;+<&Z"=]\^'N.HI7Q< <S
MGOR<5@_]0YM=HM8:(UU_](=I_/&P9F_P 8WQ)PT=/)MT*A$+[6'&OP%02P,$
M%     @ DSE'4_:(30W@!P  $BH  !$   !D,3@U,#4V9&5X,3(R+FAT;>U:
M77,BMQ)]IXK_H"*U*;L*#'CMW!N,J<*&79.0M<M+;6X>Q4P/J'9F1"0-F/SZ
M=$L:&/ 7>]=[KY.P#UYF1A_=FG.Z3VO4OAK],NRTK_K=7J=<:H\&HV&_T_]/
MK7E\=-RNNTN\7_<-6/OBNO<;NWA_>3V\OCVO_'HU&/4K]("52]CN$E(#JM/N
M#3ZQCZ/?AOWSRD*$9MKZ]]&I2"N,QV*2GE=BB(SMU;[)FR5<341:,W+6:LS,
M&?/78VF,3-RM2*:FIL4?T&JNKR.>B'C9&HD$-/L "W8K$XXS=8>#]Q_.*TI,
MICA5^Z+3OYN*L3",/&/M^D6G7;\AUQZRH'G\@B8$=DVL#9>@C(A$P(V0*9,1
M,U-@/:$@,%+1]3N1\C0 QM.0=<-$I$(;Y5ISS13\GF'CD(V7SWGPDFM8<*#]
M[OK#:/5FI\) 3<]X *U4+A2?53JW60S?IV,].VN^Y;7FR0$_=)<R:M>I<\?Z
M_!&"3 DC<+[^73#EZ018-S"T!,T?WY[\3]Y/9U!E[_E8"8AC8%? C4RK++"O
M:(E6<M-B9$,!I.OA?\#1MY;[GCF5CG/=#D+DZEX,^_E0%]>WO?YM#7DT[-Y\
M[+?R'T_:O.U@A;EASBN-"KOL#X<WW5YO\.']ZOKC3?<RO_YUT!M=G5>:C<:;
MBK/GEFFS1-_/667&)U ;*^"?:R+5(H06GTL1^H:]O//)FPK[Y&&!?J\@X@C=
M/,*0T<N[%!]M="JN*-M<1/:U;_6,;=DT8%,^!Z3.7, "J6.F0K-NFF8\9K<P
MDPI!E[)G<?U.JL2]S>-&[9W[%4E5P'2Y% D=X*A+X(I!&N)D/V6I9\/;1I4=
M-XZ;[.#[[YHGIV=N:OK]P]DAP?YG_H?@;#0%G XR(P+-AB)!0T)V0(QQW2YE
M,N/ITO<[L_BT:XY_;ND/06R/V)T1>_P*$7O!-;YT!&6R9)\1?S&$$Z@ZX'K$
MAA)'2*5A 8[+!2:'=,FRU*@,<(&X@01#-J&*HW$8NP7",N(47S'+(*B8D:X=
MX^729HL4 M":JR6U2?AGL/%Z-:C&>R%:@W/&E%KS)!8(%60)-L/LI=&4$!1#
M'@53IC/ZL^Z_  5^$/(@$3H&'HITPA;"3)&H>H;ID&:G<6=HF@S1SSGXQ%=8
MA\?P7\P:>P(\28"W?R4" (NL/B*PKA%5M6I)XF-5>"Y2#,^)DTXB#>*,XC&B
MM@"?*H9L+E2\9#-$'3&&F!3':\YX,.JMN9%UH:"1J]0BB[$!TD B5NU\VAH4
M<#UE42P7.N>(#]ZDY&3DK$8;JP6<Z]R2>[;NH?[54#]YA5 ?K6'A<KKV0/8R
ME,*BC+!B '6@#RUD!HPKL,A$I(DQ+A""B 'R81P+/:4>U"S!M$"I :_+I1"5
M22QUAATI8R@9.XS.E P@Q-N:'2 J0T",.^AMJ/)GU=%.98$NU 6G!^#K C3#
MWS\-B_</O;3*%1:9*Z@.21T!R0E&6:' 2V6I0BN WJ#7:W>(8M_<I>@1EZ+#
MPVW!6*R%5F$!/22MVMI3_7FJ__AF[=2:U#O% 2Q)7U\@"$&+"8'5RJ7G^5HE
M*1?P3._>A235&(@6?BJGTF2F< 3,/W.A;4K#9I#:@:@&7B?#8D95$'-+-"_3
M/(:K/M72$X%9$2W1,A8A-];,,;Y/P;'@1O.%4Y(VP:<T3*9)W=GHIZT4M+25
M&M :8[<*JFS&D=Y!%G-*VNB4M6"M$K&'TYPV<;IH0!.-P49!S*TX (3[LNG;
M\FO\ZOFU<R*Y1[-G>I9+ZQQDZ<9V8!M2=(XO F?E6J:<4CK72$"[$ZA@PE68
M QUY)_A8Q,(L254^E/J(])83%NVKG<:'E+-3#G?>HUFF9D@W;55P$$@56@-L
M53:!%,5MC*S#)S C.E,3+#D]LY#W8H8)<<^M;\NMX!5R"^8\SFR()]Q!%&')
M).:(&+U=^N0:=X=DY2ZWBJ&<7I9&V!-SC78%UUAFYO'I=\FG?-4:J)R,GMI^
M\%:,\T+5A@:_#&C/F1U\K^*^*1/"5\@$C[-"]>Z10OK>5Q^^&MEBQ.ZE#8FR
M<DD&0:8(DO=5T 98Z5.2W>OVAEA)-^5Z)>LHI%O*0&B3G;79YZ$EB\5GB/U6
MX%;[K_)BSY 7V=(X_;ML:=AO-"OV5->1E0)](K5!Z-!GR$*0Q4'*I2\0<IN5
M2FX:QV+%2*57LLG>P.&21!@#\$@"NY HRNA9_O%6LP,D#S)04SK"_ZE6RHE)
MGVW1;K(_RM+ [A$>'NWA_\\K\VEWF>H!>P@ X4!;5($ !*N7/*MJ>X%+0Q+&
MZ7$K8FPE83_AY#O-A, '*4 ?(^^G#E<<N^W#!T(\#[&GAB<C?%Y\8',$/M8(
M52>B-"HHG26X7+@PUA.?<![<D=^'_W]H&4XZ*%(88ZL(1K!I ?%LOP-ZX%>=
M1!'I7,9S()V2XE*Y[YG*9Q)(9K%< CY=3*7+'7R#5D@#$EKETM=HE,<"](.E
MK#V1\M\!=!LWV[C*WS;"J B_%\5UATYO.8QV_(_>)H#7Z[!NFMOP")C9%]K@
MIWT,G$^?;FK2K3$&)%#K6W?,;C^R[QKVWQ>>#ZKK^KT#0IN0^'\LPTX<];>(
M=*WF4:,!R1DS<&?0L!"IU*KE-[]H0?:+45B,W8[M;2X1G:2\%T1>_%Q;#T-I
MBUVC<6.,;/_R!X_\<;IZ;_ )C?$'-1V3ZW2H$V_:LZ!_ E!+ P04    " "3
M.4=39(F-Z@ &  #_%P  $0   &0Q.#4P-39D97@Q,S$N:'1M[5AM;]LV$/YN
MP/_AH**#,_A->6W]!CBV$KOS8L-1V_4C+5$6,5G2**I.^NMW%"5;5IPT7M-V
MP.8/AD21=\>[YSG>L3,R?Y_T.B.C/^R52QUS;$Z,GO%'33^IZYV&>L7Q1CH!
M.I?3X2>XO!Y,)]-Y5_LX&IN&)C] N83S!M07E/<ZP_$'N#4_38RNMF:V<%MO
MZF?,UX!X;.EW-8\Z(EG5F6735H0OF5\30=AJAJ(-Z?LB$")8J2$G\$4M8E]H
M2]^^.V3%O/N6R58T@ANZAGFP(JBI/QE?WW0USI8NJNI<]HP[ERV8 +DSZ#0N
M>YW&3&YMGP7Z\0N:8"4^26P84"Z8PRPB6.!#X(!P*0Q<1ATP[J@5"_:9PM3!
M&90#\>WD^Y!Q:HF R_E7S">^19-O?7O%?!8)KJ21"#C]*\;)-BSN<6-7TQMS
M$P27"5J+0F+1EA^L.0FUWCSVZ"_^(@K;^@FIZ:>5Q9%Z#9Q.0R[N)>IOT2[.
M!,.]&7>62_PEA;XEI#7ZVY/3C2MSL<QY23JR$-H';M5Z2F\Q(![S:<VE,H(M
MO=[\FB2I:A%PF_)L!!?A-(@"C]GPJIG\\LKVP^]%@M^;Q3R*B2] !(D;T]BL
M$ P048&+N7"!^:#B5"Y]]TA5)40(&F C0BIRP2^O]-.+=GZN''G3/JHF $-Y
M$EF9YK.FE#1P28APAO,3^68RX5'0WV18?N^C];A2$(%6# *;0@6_OJ_?U@=U
MJ>_\(I&$&MZA*5&Y=$VX3WGU,18H2Z[)@C/JH:H1)2+PJ\\D155^_HU\801,
MEZ(O*0JW(IBPE;13"H=^+&=[#!^M@(=!2J>-@\[:@V 5$O]>OIQ+WZ DNK@'
M2Y$9]RE<(EI0A.\6+N<'D@!D)NY?3HQ,U.5T/C3F-4RZD_[LUFAE#T]BL A8
M#928KM;48&!,)K/^<#B^N=Z\W\[Z@^S]XWAHCKJ:WFR^UI0]<XC$/4:@"UI(
MEK2VX)3\66-^Q&S:(I\#9J<3A]GBT]?;39G#PL>SUQI\2#,D.F63+=714-&/
M\FORWW96Y2D,NRZ&;^5P&PI&F3)9Y[$004@Y"VQF(;T1.4BUC,]/L/DJX"OE
MEN-F[4H]83;(,;E<4G)!<?5=[*?T/VE6X;AYK"MT?E63@F]!GT)QJC;VO/M,
ML85;\R2<UPPS4R%G19))D4H(>(16R!$@^78SQ%G%/LH2P==.C6TJ:DO>RA)C
MUDM"CG]S^2?QO_]0^9].!]/I^%]*)^8C\E<JXUJXEN"1;\M3\5GXWLLDPO@6
MTR&GD41OM5Q"H<3S<!-X>C'B(;BC$.$;51-=3G*&R'$TPV:JHL+S!&?%GD)_
M@*1,+(TVE9M*!G78#]X?65S^JG;__/_#%SQQP!U<YFTI661*D4EYYN09]Z)4
M[LGF1=&RESYL:7>!O$N"N_F244;M;6MC-O$A;[]I_<: !%U;4S,?/)(_X$ ?
M%(Q+\L$C55G>RL)F]J2H'8G?L/1Y-=_64[M>RFTWM]N1,;X>F>C[\UW3<N.
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MEK&+=4I64;PFT1K<O[R P(;<0DB\\U3@GRZB_[3?MZ=4L--+Q**[-<?._,4
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M;8/__K:H7EZODM<ULT@=W8L5:3*ADA%,)MQ?F,J+\=V+\9J%6>?$^'X+*[T
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M3O(RCN-<DD>S'>S7IY-&)"ROC0D,T+FBDQ--$<ZE-V#?R#P0#AA>&3T%_MX
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M.2IA_C(1)2HCZG;^70JZ%ERB5!A ^LU^8ZLDFY>5T3BC"U7\&!0T*#"\%5$
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M65YS4A(12!UY(080%5Q0+SR>,>64/E%\"7Q;H>*;94Z\X['"\7C<6L?C#Y2
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MEJ5V%ER=;L>YL-@*5GI/"%GBQ8<\FJD=O+W!_(J\4^=I^Q)^)K\^5Z[/]O8
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M1)YX2M1L(7X4U)&CBT2/I;[R!L'B]5=?'7^-XZ0F<84+WW"Y+P4>5ZUO68F
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M$M5D<BA+:6K(C;(\ ]F3%]@X5%7-MKN="-;0B'?W[))E$'S3*O "O'EFI"/
M(:,&E(QD,J6$C)54E"9PFHGQS;!R66&W4MI0GM4*:/;@Y+C[;4DK6ZG@&.7H
MV^NJ]57S<I6IN\3,O8EQNMQ$\=;I*NNTO5#G$XF-T0S[9@F^NC=,;^VEMQ@*
M:U^[ASUOHA/2R&A^D7):]7-N]&_&S8^DQ(0RZ*"D#F1?)[R!.4G3&][^5Y<#
MV\K0XBD0AJ?#JH>5YA@WLY\Q2ZO))"]I/1)DL$5KC8%VRR >B129M6U.V?1
MU&9#)5JR:E/&U"<-W,>N-]=CX95064?DTEKAMT*%EA6V1QNN0F)[0;DU+%@+
M)>4RD/]@1@YH$V?Q"GU5+RD;B!I\',RG".37:6*15:!-L!]$Y@"MKI4/\"#O
M#0-Y[S[R(&\/\FZ;NKZ.W]M>M-=5(0[O]:ZOU\O^WD3, NX10D9<& S*HM%6
MR09508S!90DMFE1^C9!;>Y(37I9J0R-./00[N_!U!@XQVX?@\F8Y;?"2X5AU
M^S83%R;L&#K!Z&HCS%=POQS;DJ'J^Q$\0!0-(ERG"MOB; 7(3M!_\X#D.%?P
M-W&(O'US,<XG#:1R2&#>.M6X\RAX6^HDPVY1^YA^L7VE+?BK3L 0M%C@W'#G
M*GQ\XAZ'T>+I\\@UZRIU.Z:7;?/7#!$1*<RSN?LX+U7M5DU+A4U8\+[G,'W#
M&8'3P!NKO';RUY?%%K@DKO^F3[-@0&YN@*(YCJM"%?QN#?(HG?EXP ;& SX3
M$MYD=01W8*XAY*@G*.]MZ.YMN@A4"H.,<,*X)873J7VYW#6Z-M>JR?B4#M8=
M5)-9@PBGH_T+M4Z$2ZX6=5=KB2U<S/@UP>Y-=VDEZ0:\D%,8:(RCEJC()*55
M4?KI^MKM2:UD*L]1/\UI.;\\-C _^MF6BP1F [*ZE>522>P9#?M/?L$KQ(?*
M-C%4UMRYZ]0U=@?!JJLH<5O5<^P5SJE:N#E'V7I(TS6P@9?J=I;9+Y5QXEHR
ME\3BO,6_SJ&X&@;1V)VOE;EB\U1P[QTJ2 ,[?#(ML+.-E+PCX\%8OHL%1''"
M@81I*DP*P78CM'>NEX(Q&?@T;$]XI7 Z,W6=7D3P*F\8(3$8%A@+J&\)MGC(
MX^=5:7YUC']\:&,8R4 Z$->&U3!,R #![ML%$ES8DLU+]@_?(.@VS8BXA:L2
MT?I1K@MM+65^_<XJ=,S9"L0_R%4FZU:?99:2,WJY,'4[5ULC7M0VW1CQN3IO
M('R#@7#K'01OOFO#J+GN/1*:/;-*L3;V8=:)MJR^4J7\^+[1Y;?D.9ZV-LMQ
M0EL?1G!\IF,3,QV?EWC+I YD1N@5TG+_668,]]N7D9P,$&E71_V0V[+RT$EK
ME-,8$QK+D>RH+L%#&&'C3R3^(+@?EC%QR[+ET/)3=)'XLI8.B=J6,A6FFI!Q
MZ*#N*;84RT(D*0S3&W,;:,RA:%R2R?^_!GG1 E"T-OX<29]BA0?%R)\UXMNO
M$&?A!6S3[,&*5HE]4P[ZD%YCTHR8PCM(MU%Q8^D";"NJV\%T*[=?'EM->0Q?
M90;\W-,ZCS"-&W<[_:R0:2J9J/78,)>Z1*Z8G$XQ86I(:4"3BHH>R9:<L[!3
MK&E^.)<2AGH1OBT1;J,,"Y"("3'/@' T<^ HO'7N_6I0U"I5:J)XF?Q:=#M&
M<?J2WPU,F"-'$IMFVL:(EW*U79*R?HH):QODT^70Q&32F3'VX((HL'2=;@>C
M[AIQ-()<7TF0F=J++TE/UX(,5SFIP]0'PR&-%"YB9']![N52@?>BO7G)[L-%
M#$4PI.)?I$&H BS6U;Y"PIM4#DE&'HZ1Z63"V2.9.ESEX*,E(*.DG,D3@D%+
M72!: \2T8 K-TV@LXQ)>T^IR=8\;WS3<^(['C7O<> MWAROBJ<]:&T^M.KV<
M.94[OD[^MMY[B^ODZ<W[(/HF!M'/K!L02=/EJ0$6)[+*C#BLLZ7,7<)&A,C=
ML(G%A<A0V.T0T[\!]J/ ;6U;5+_W.C;.H7YG8C/TL)9(,L[+@0&D42GIK!&8
M00'5 4%>*GDC_'DFEXH<)W2RO.AV!/<)N/I2?!DN4%F,;+KGT\5UJ<YQ*>"Y
M%)XTPZ;8J"C@S\)S7][>!MK>@CO78D+BWX0DB(N;KF=!W1!"\?RF"(I3I_2K
M$58G('*BIR4QH8##5S*\4^58!56E-8V3O[L3-I\.(9ZN8V^KON7\3H)Q+)5@
M#"&$*>IV1LFY#3?DSO6:1'EAW;K!''6,1[WTV,DU-TM(Z$:Y)';M?@9B>4[Q
MJ(-SE*4'R'&L8D)&(F6=B8^2SETX&'&6<.<D*T'>MA #YW.>FV=PH"%+>(V*
M6-/!P<TCWAS0K3D(A4A,*;H.QQ.@G?*8\[ T4E+=3JT;5^O#886\GV%?HF L
MF!L>]5_,LCP_5#P$"W4MH)X;U<P=M*R()!A(KO&KVQ(998P;0IP'.C=(E3FB
M4@:L(+H]XF>0 3P,=A0V6X>Y*1%J9;.J1" E8$R>S=,\(O0E\P;1+1E$[24#
MGS.(3%)@[4PAI\[E6D803(596/4*[':2H3=HUMV@68*542AEY_D7["*F C$
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M-'3\8X^.]^CXGV^3>]':+6XOSX;8G[? UWYMXCWO5%S]REOL5!PUH;C1-\G
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M>A0;LT"=?P:WO\6Z4W;1F?O:SKM==A5K ?W.K?\'I4T>O,?%(%@ [P#!91O
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MV'\$N6.:+\8_CA;\SRD8,N54?J]" ;CQR4>*L.AP(:&)HAT9T!@C#Y5,>K@
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M]UED*4>6BT56-OP^M<=\N7/)-+P:[U'$^Z/9K$8B#ZAR!"ITO"4T)CBI)?%
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M( <<JQTWUP=F-9995<E'$Y1]X>Z6"+6B6?QC<.XC8O A^'9$7]E%XH@BG4Q
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M-6R!8H]YB=D6_"V3U KX=9:+E1[H\:W)Y69(SQ;456.-.PE48DO%I=6'A__
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M,=2:#D@MN-X16_>BP;$]0J7!O"KCIA$5:?G!GJPRF1BQU*[-=#HTRHY'4YN
M+R8K\+J&J<-;2&>%8[D!]!0O!@TZI0%2!0I?7SA[ZY<HT5)QSB N!O:-F&LC
MV#NNNJ%R!=.N%I*P>7;0M[7UA&W+;'O>9;+5.[2XOI#:6Y +.EY9>MX>3]37
M$^4 U\4179AN1[K$8:2\;E*+1+%S0#_ODAL4.'W7ESF>PLD4 P=UI_ZREFE!
M1(9K]1[V*\<&A@8;(9+4.%P]NEB723$#YP/N\A%=0NI:F877"D,,0@'BKJN[
M*LQ(QIK=D1GO2#N (;1"FGUVG W"0<?Z!\IZW1@=T"*="6*MP@'1/K2#(;PB
MH6/JT1;X70.W1\+0SGJ#NM6C\8@,OMJG^36=7FP0/.,U"T'BMFXP@&_$/M]O
MOX'N03+,Q:YNF9 %[O#]!G)B>/;AD[FJQ)@/C%W"XK<2+&-R!P@^G9%6MQG0
MAO&N$0-Y<0&6];]EQ%[<W!K@#Y*:1T?@(S\>7EO,<2*U29=L)!5)6M+@BKPL
M'_%AX0Z4\BN;:H0GL?BQYL)XPG0I>9R5<?GZWJ'S%/K KIBM ?[^*H/+^P_!
MY;M ;C[;$D'-X=$_CMZ\>_\6U@QL_\');[\,#LY_.SV*!B>'T<&[MV^/3@^.
MX6O_,S@_?G>R-1Z;9VOAG:_Y5FJ@.3=/)G-6FZM*4+,Y:S_VE3/.X99Z\K:2
MOT_$ W57-U5U !+&E$=Y:4<\MT4QV]B7==B$0U#?%T9:HP<[PR8J.5=+!^&N
MFZ8>:]?P7!V8#S2L1O.5BSD\$1>YU6OP0#Y?L;<C2 $L]:G ]Y@PGI9+)AJ,
M1C44VPU\I)7.61"ZWXP@J-_388M[Y?^V5UXZSAQ+)!4P&Y'G8DF+@F/D+2H!
M0U'S<;M]B/&<)G,6$?59;QFQY^5S6DGI^@VK8UYC5NHV\+%!RFAW)TT;#!M2
M[B]L ;)\&?,(H&O7,:NPWMV6=;MYJ/EQC7AAIN8J"9^Q>G9;@2X]6UNP>^XA
MN>=RB!FP]+OVG?J]UB!J848FO6*O1!(.E!:R6X*9'<)=5*W8WS@(^MD\AJ_J
M1F&"/[@Z*R(CBGX%*YPS(1_3LG( B="1<SV]YVBSYHN2, HVXZ,TD ;1YB7:
ME&8FQFLN,%&ZO>*P1S.%6JEW=73 ZW7,L,'$=XC^=)8E./!TI*V2MO>.K2<;
M+PI[H(F'K7F5UE(XXZ1"?Q33.&344^E92[6P.AW]'I&NK HV>H&W*.VXIJQ7
MHH_#[1?76E/968D8Y7-IH(TMWS427-+8&1R3J!Q=FO$"824Z9;TC!@5)#"T#
M@U$805Q;"$$.:?RY>AEZ=W-,^>](7&%"%>S/];E [P76FV $NZ"#?\/2I09\
M^5\+*FS5TT^F9=Y^!%2FALX0^?8>,8^O;*,'L@7-=@=UM:)<%B'NG*/<;1NM
M3XD:33(:$8"N)J3)59).:\-E)$!FL,;C"C,*[BZUU>OTO@V!\&229;D^:V2-
MJ;VJ,Q,6)IT-%T5I[+/5/#: 4JT]P7!_/\HGC^;YZ(.IY!C[TUQ6N]LR#Y]U
MZ7ZUUO>68VO@DH'U,!T?G=1=NA(98[*#^64"FOQ)]&WT=&U8N=^[F*9@\(+=
M!Z/2-S=^[K7^VV"<S&D(PJEPG&7Y%<?VWH ,9SB&H^PJ+?*,DX/HF>2%K\JR
M7 PYX@=L_,8]]=2>A!T71^..?3Y_M\-8II:9<!S:?]$WIE.1MT%WV)/7<Z49
MCH/!GS7EDZ*HN:$9_DDV;60#ZZL=,:U7/Q@S]^XCA^Z,O=M1X5X0"I@O!;P?
MG<B%]R,_S2;$<6@J3UXN+L!\]M6M%%O%6*4N8[*J*8Q56N,TJ%EH^J!!K8\@
MI<23Y;42YUJQQD55DV!#6:-HWR'1QA2QZRWN 4/+=4R:LBB7)B-(.KR1Z ;T
M6@L 2%E_'M5D[-7HH7F^P(<6CFXN$K)/6*%@T_N]UHM4S C,D\!@_;,:5D'W
M]:[,7@Q2D/4@Q\(I&MJ/KSC ^.0AP/@ET:LK;.!TXM*(Y:4IM2^;]'NMS#Y1
MM_:+&LH//7DZZUUJ$,]K^VO6JD2F\;H-M>@'T>_51K%*3];#534C?)Y70H'
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M@P^!^XL]MCQ3KVA>V$_RY]31$>TC<^C0/='&<Z"+JV,P)^]^/QV\O[$V&1(
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M)LL.QG8WZN4!=?2G1AW]0A))';%\H+@A\#NI0T[ONB")B#]";QK"SQ'CEP_
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MU?M]\FB2A%(BJQ,?M,Z[-VC:YG(%?]^;[ZFO,U$9C"D;A41V80T<6&JL,!7
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MZV\/LALIYEG@G.L$;>=\&<&\X;WA"XI6-QY7J9S8A8=0U(.Y ]=&P>9<0Y7
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M< XG)Z]@8OOPZK^.XZ(B7%9TL0JPA7!8A$>'DQ_QX-F]2 <Y32D((8')D&D
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M="0=REDJX[0\>!9;=?48=+*8,QQ>(?L&QL*F NKMLS.,%F. >6[H?!@]B_&
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M )N>,Z>K*R!A8-4H);/=?<%9DO6Q@L3&H[#\M'6'N%)\_0,@N%_][YKJLT\
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MU]XN?:U7#<'2CK[CG?9W/P7_^8K^<U;%7)P+O\\>$9D%^[N_G@0?*PDN3%^
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M8 @6Q9I>"L7/(10A%7S C*6#*X=YD7PY$(MO$=$#$-TB9SF6$O%GE(C=+$7
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M#S8.SM\?!V]>G^P";0!/R%6$+ )FF<,6I\0NX/LQS&5!GV&!2OP&Y@S;513
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MBE.*X8W5",0/R\"_YN-SEI<C-L]HE$D43\&L5C!K$*_12"O[HT@\#/+5A&(
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M&4SU&S&8GDTS_CA6942\&KW98/[$PSG_$$]G6<X?"Y4(-Q_;6>*T\8?*>*P
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MU^&L@C\&9R&[Q8(2+PC923J?SOA8X7=.R9RN5N?OS6$#]IM$5P(AX.0SIW*
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M:CI+LH52U$8A1<]\1.T1J#\%J&]9#G^ _2GQ]9#Z5XN#G?1=:2:\B9(CQJ"
MFKJZ8Y J#%IB2X5:FH';?4E/Q.GMM(YST1%+U&"2VE;&.9U*HWN+F?!A")\B
M0;BN.)PJ_(:X3$AM6 Q_0)=(KJ0Q:F,X&F,B8!?@6<+>Q#&>.'?-ARK!T$JA
M'5BP-1,8.2O[A8P7WS<V8\[LF!O; V[M-B!H-_6G=3O;^^&\D4G-K&TUJ+R!
M\;RT0E X_A<*4E66P7U&._ZG>8AL!69F&,!P)]@NT2W<).G (GH1W*3.%?FO
M$N.DO>#>=)2B8,;UUQQTSHEI^B@G%9DG=7WB-ZBQO%5ZSUUE\V1LVM4+9]5M
M/?@2NZN\ES'YC487S=O)"5[&3<QA1Z5*BR,?8]KCQJZG]$:34G&?.;V\U,R)
MG76^"\]W?5(G[5S:B'IN-^+_A,[NQ^DJZ5V1S:&HJ+).J+G2[M4+0A/!;<!D
MR4\7NE.I.QZ)X V/Y97-%1I>'A>;8+\5JR_C>S7K"U!19-!ZL@"J!ZG:"'.E
MD[2L,5TE_8;'/,XDSHDM"Z53HJ'EHE2SPNV@#F_(<5# !NC),@6AB#1.%5+$
M;PT4@91C3'I9C-D\+S#PP/L4%[49/\)\ V13]#)]<$91RDT79"RQ[6W =,?#
MZ.Q(@^.\#T/4^<N<&D0F365MR-V+QR,:\08M7P?Z2A*-I!4*_$[+(">M!-*@
MV2L=%. ';U)?PK2+Z0L/MNP>3;WN"7=>((1S?[BX;P(?M#9ZB891 >07%?ID
M:4JKDB%[W6D=6K@R<#),5LB9J#9BH1AIDD'Y#,3\'2M7^GLQAZ"UL,W)&D3/
MTZWMK6T*PL#]36RAVAC/Z:ZG7]DF#JAK">)F:6TIO53"=3M'B4D8[M0:!DUA
M.FM2F$?"P+$O:=-/68J1#PGG-8TA(@]_A47H)GYZV27OAN?#3: C7IA1!'HH
MQ_Q"F]T1E;K3GI"B#6G1N^$2I=T!H*E,L?L>1W3FF+.''6XHO\<R2-PK7SP;
MAP=NG@ C<AL/>)JD46KN6@2*.GJQ3U-]1ME0J-:4.> P/VZ^QO;#?_^$C>_7
MJ?-Q5Z*6H\(+M77I\!3F[/?<[& DZ8FV =SCX"0LT<G(3>E^5#T/Q!RD6CI7
MYU%N^J95-4QOJ*NJ[WBT_%IL'=QL0\MV@YO$7/C"?J_./;')IV=O  ?A=H82
M4,!9C#0; HYD>O!H#0LM3=V#NTVV<'-?#LQ6&2PJ%=([DABB3JL-@XOL"OLF
MAB(/M.Z$?,^T3&*A;M.RX:KJT_L]RQW'J,EKM8D2V^J/<E10D4NBU8P,.[;A
M$NUB;=F)UBW<"C1N5'.?HCM';(,C]DF'(_9X\$\LXSF]Q?[7M7M9GW1Y66N5
MRMKOP8G-E/+@]42OJ%0>CV-^T)1/+;D4^G#.(G/;"GHSZEQP?N&Y$8'SL"X\
M470>M\.'#Q_B_V\]?!AL?$A!2XJ3! :\&1S,\TS;/Z"+C.8M#<504VHSJE^!
MGI>BVW/?VE(D'&8E=\"C+GK4.Q83]HV X-F)PP.&VN]13@UV6$Y-[V-I(ZK5
M1EX;L:VT)BQ<.9M,@.F%P0BQN4H,'E/..3,H#&G3]IGL$V;R 3:C+3)FJ[HA
MJBEDF!"+KRX&]TO]>M?M;]<E5:^=G'::D3T<3X=S#H 3Q6Q$)?OBYS-<'2IU
MV@QT<^@9==)E7CWB1JQ+\FB&BKI(RCT..?=[M(T1402V?O1*3(L8YA#1\G$V
MN+@4(C)PR$*;B2#X%U:K>A)+EQ#MDW%49FMPDS_I"B2\CQ-5E)CZ;2&A= #F
MNU/&DZW.^LBJ8\H)LYJI.$[=4WNX//T!42L>53/]/RGV>MJVAIT<"]YV'[6,
MT-1F7X_'7>\^Y@DN;Q1VX-0<?3&#Z_>6<CC=)=4N#OE*XQQC95PIX-8HC;*<
MPW*D-$\-E5%G>>N>1\X$H[<M:_$;I\5XL=:FCVQCW0*4U\?;*W=]]%%>C0+V
M5'__W>%#J].L\AW*=FI2[:X+GK+*RQSMQP=4_2%P:W:^!**&Q.;7 M/0T->P
M6E\]9IE]\\"=$3@#>'N Q1!PE)X 8_B ?.((W3%KF+[_>I^4T=_A4'*;U/SW
M^[??NPVC6/W?+V1!RVGSJ7\T[->69';6<F!?BW9.#]0EI>-L/BQ#+R&?:@=$
M/6<[D?68-@\RJ8:DR<.EW',;'?$8RPSA)DI849]GF."".0V@L8RWOAG#Z^0;
MC9OC\9/U[ ZN8H=!<!K!6E9TZ5H;<.U!LWJ=V4#,2\&<E4B<!O5=;%:['<72
M*-5!15D.?"6X7?O%C">C_@9?9]JO2_&]0>K]D7M/;&__^T=?[NR2[R "OV/#
MA*\^NM_O>'588]?!X]N^]EB\<^#;*5^'?'DM ^E;JBP[S2K+FGQK'2FSG'*!
MLV\2_U^ [>D.>'OWNB,V25\-XVT<K!1.D??/TS%TAJ:C(^!WTUE9C?E23!@W
M79)FF!KZ/<HZJ@IS+S.Q>?\Q5"MO-3F?Z+:G,$#U>9@P:))UT+F)7V"4@(/4
M^&5UO##](IJ*OJ++PDN=.9E5XN V]FUS(FOE+F.WL*7?,S@RG%4>V2Q'28$L
M2)&AV4VV@@%,#COQS,OV;! B1=A=C422D/Y#V4P<N>#0!"*6+%LA$_[%O&D-
MH!2-L!#+8OEX+]Y^M+6[%B=\Q\$3DQ!W\R1;1 FRF^?R<1&<X/(\#P8C2B_4
MNR=X-M;5_97G\PL82B=(0].\FNL[O#AA+A./ICAAS+D;I.D\2N#M9<#V">RT
M5Y30[U%5@NC@#./S77/U0IV[:'(O<2"OR4JPR;,T>CJTE?11-Q.[L6! L3UA
M^%,2P8/'T8(2E<T7FF2H.&&2Y94<-,DBLY8,5OUK%_N/:!OLW-D&M[4QW:]/
M5S4-'C<UINNZZ5%K-SLGMO'J#>W0[_?^-AHI-9G<^[:ZOU;QO\;%OWMCT/0"
M&%#EG!(>9/_%SJ-@"L^X*%B!(';E*O\W@67?_8RE=W.Y&_,UOASE(7_:^&5S
M/9&<F]CIQUN_;E<W=>OQBMM:$2FW;,^J>_$-S^'V-]J=FVL1,< 42-)D;JS;
ME@UJW< >-1K9WS/*?B>Q[B36,HEUF(YR)4EO6G$U@NN6<;ZU2ZL5^>$*BOF-
MR2JK6E0MH:_P,WX;7GTCN1+?A$O?2=(?8'?N]N+V[,7=2;F5N_/%(9VO]E5V
M(:J(ZVQ M40FQ]YM/'0(*F2"Q46HGQSGV4SE+E[-X437/C0&]\L+%?LA_AH:
M_%AQ?2C^),7'3I'X7_/Q.9=8."!P'GJ'@,]&NBZ5K7KT+;K3<&$8&AL#6@0&
M]N#C _Z@%(F])(JG7E\2.CO]GL4&C=,)8J28&H-I7%CP>BG+(*^D^\3A@AR3
M\10#"H+&4$2X)"YN*#QMSOG^42W37^JYJ7!%=E*72CBH#;; :ZB"\5QIUZO!
MMOG/.2P%UDXX%?.UQ/%M$WKH]Z@\ ZO:R-MLGO/U;F<9";J=]5,K?F<]5O$_
MPQI.X@G.&S0LG/?&XX>_;&I$_XI/74<DE^>CU$E6E^OU>[4ETQ7/+DG%U=HB
MXY-N(#P#P"'1M9;+D.J9T!U,U-KXFX>_A67EZ '#G@ECD\N3Y>H\(Z3(Y?0#
M)[M*0#;SJ(-DFJ!8L-@D'LVQP*2VG%Z-D% 93G<*@V5HIJ;=A@N0+45> 51M
M-#MKB3]W(A@WL&"@B#VI[=ESFUU8KOOA&E&>I4WV.N,\&(;Y^G,M41Y\C7QL
M#B<A9E +<W)0J"H!'VT>QX@@:.K&J+CCC4I5'H^\H),).5E497W9 8_,B@+"
MUB")DWFLVY2;.$B&#,1>A46Q'-HIQ74.FR[-E?/4@#3A,U_W5#2<A:W@->+!
M2JG8+"LTW'+3B=@-@]H2&"K0BQ!,59068?THFT7E*K,B2QS.1%BKJ[!68HU#
M#]>KHA\0S[B(\BD0U+SD-D+R9KQ-8&VIAHFR NHHU()A)%=SR-R+16X(C@JG
M%4@'&4:9A&=CZB4L\ ;BIU3&)C0PBK2$!EM_J*$NY.F;NC4/HMKGGY2DB (O
M0^4!-I#?1]SMVHL'<ZZLG@_12]-<ON"4K".0N#P?>,TH@O.+@Z/JS:6WF_+Y
MFC0UZ_,Z5LEX3>QW&7::61CN;@02>"Y-\8Q>Z\R^"3U0ZH5%M#D+'58C_7 H
MS2G'-0&RPKI*AB\N*W!5-<0U"V'C)2 3 HLON8LFF5P$3S K"ZY^@J?>@Y>!
M/4IB-==I!,2O$(!=*PL=;_,X5N4]P(&%.X'YJ94RJ@EV4\E,HL\2O8PQ:R(-
M^^,L]!)URV[==\^+B I=45DOYELA1\4UD*]-]4M2R,BJU1LQE^)XK?+5]\&N
MNKO@W.K.?F.JY1D;&^$A#].XM);/,54L[U0:=1@HZ.#;CHI3WU<?T0^;%[+[
M$^6%_-# (+_]TN0^6@DUQ(#<MYQM_IA-;A]:" &>K5+'ONJ)MZ=U.0B)'?23
MGQ.'YFO(;?PCDUNUJNN.LFX19:G-VT<T'DUS3U"=P;LJ[6Q=#WS^V]D]'8!S
M.DMYG]1K9L:5UB G557?^""FT=CQHE8] VZ_#P0&6AV90_#)OJI&4:5CTV6N
MYD0R+;LB\K37DI(IS;XEK;G]84U)S_U>8]8SO\!T]MAYV%BGV36/L+'0(Y*>
M._ U+X<Q!/!Y-K5$/]7X;Q9!N9C16-UN?&V9V:$%^25[,2NCQ&2M3_J]L<9N
M$JOM/,^*@I:;[&03[K$C"FWOGA9'6<Y&(*CXCB>/)M&>/TXK23!\&L'0&9FM
M8HF&V:5P?"/MH@!L@I%I%2P(VWJ*9E2>*SP$ S_Z)'[(C$HRYJ3F.&$(X^)M
M,)MWMW9"^L^NMI\-?.AWYAQ/.AS6NJ?P8#Z.X8#;!I1-'87<DIO1/%<ZC.=9
M]WB5YZ1":*PP^*34S.M?)3!86)&VL2M[M5!1+I1&8+$4!A$*G]E2C-PP<G3I
M\NIW=C=FTI4\1LV"N$H)B)>/>+'4Z5F;6>7PA<W=BY& D*DYPX:OALJ>'CO@
M9+&U#-$YJ':F;UP_IS[\4A^7:DC(5C95H+2!:&C$LUD6(\GS_DH?$71T(C7"
M'TB2A%K&J-HS6A=]4J+4:Q; 72VU=]RT-8B0YD1.).J2;S+[M?HVP*,N844F
M@O#KGV]&V)997T4%E[>/2NPY9C=@JU;1_\7DSC=SY)LG8ULJT?;1K(=20;?J
M:DK$A)N>Y\%0"YJ+;(X[+L[A61)QXW3Z4& Y6JYT:PX9# )JCX!U 8_(@6U0
MV^U0E^4TX?0W@<IZF($\(R90+^BG495=[$4;_:/&+-4($1=!Y=7+:N#U6OA%
M;@C2BPPYW_-YV>KW!@32QPM!>D_3UAC-"!N-,"3K$!NKI)-X+"D"ATXEH295
M@I>PP5^NLDWYH&GZ,]S%\JT8>!$]EC:>6G4R=*T157-"4:PH"=,9 L-O#.>F
M^(I?FV9!$I4Z!,$;VN\U=E[P.B>XFAHZ[E(I@1SKW15M)*/N"]S999.A+TR4
M.7.0N:E$] )NF<" 6]%1&U<,1/A-+!CZOOL]OAO1R*EK 4-O6*^R^Z[H'%LR
ML)2?S"E?PVC+?J!\(Y[@0OL7X<#@LB98?K-?C 3"KQ86I1GB9H7Q#_$@4&Q_
M3BU="[,WO"&"&%/8 X@AAB1C+/=^CQ;+]FVT[OA),,%8F(TT8HI%[H0P>!'/
MSQ$QNJRK2BB_=*RSZ?2&5I>F4)I+N#6 3-WVV4D2PJFB?)8:6:\A!M!>RL**
M.8*=_9H"4K\N5Z\^ 'DAZ=21*0=NT 39I6^&.7 P2$WXC&:L6EK7?H^HA?IA
M8G<8/$>D9F,KI8@T$+$@O5U'W$_4&!R%:RY*%Y;IX@!CBJ\2"68YA?21ZCC+
M9!I]CJ?SJ7TMO7&&$K4L&QN)<G&U.7CX-GUX1,6DV>)2A(2*/4*M+DIC>AI+
M9#[!:"FBD8:!N##@EF$RBH+T]7RNQNO1N)\N)XFSZ+.E@C.3K$.-KZ;6NX53
ME=BU:*Q.PA.!IW%*D42(^5+^JMHKQ4',M5D2EB*KW8HJ"3M9:LP?X3\P U5H
M_M/>-A;X&>G&-*8HP9BC6^_._>Y$\,+<##*]1!3Y+1LVGL[>AXLLX:PG^KG]
M[2*UB8+UJ=H$XKV,JW.B".H4^,\\YVR"JPL,V#+B,"H1>#\USR8L!:0WRO1+
M@38=GP!.<TU,Z+>5O$-@Y!V"5$?=EQ?79T;Z*LH@L%U#8'[^711-QXWROQ:]
M\@*FI[1HT/J:T(U^ Z^?;#F3ARVAI\6L/KJLY=P@I_'?(+L@DW *Q%FQ"447
M=A,^:%S5EVG?E&W[))F?W%9+^ZDXWQ.S)[659?(%G4&5%R"/S:B:VF31X_1+
M"R,/JX>^B?ESI+R@U!"2ANY,]-&0/44K*I>!R;9JJ KN93,MI&5+D"KBWJ0B
MP<>$'M'OZ0RD=EUNXNHU19URB+)8 S(+Z&YJ0_?FA>EI .R^P-AN9'[Q6S:+
M'+%X-PO' !8#B'4O6O8RC])BHGMV656L2IGM+D_=MU?HR]]; =K)7"-XE'%>
MHW([[N&Y<&%)7(9F9T(<G3M\R"SJBXN<[@?N4//HWS_>_<4=:KX,V.3A<JGP
MIR-,/9T$SG%%;=-4Z4M@;$8G,E"?41;*F ./-C^Y%#A)6+ARFXZ[I V#G%>3
M,D46)QU:=RSF#9%A8_HDA4YV%+ ,RG1;\@!2A5V?41&"^1R[C\!NIZY8@$^P
M%O!_CH<2SVY=7:E!G$>NX>-X]0@ZDKS8\:6\V-B035!0W!\,_8Y1HCE2M5>W
M1O#W[3%:>7F4'4N_A^W$.5/9+Y8@1Z9MHR'U&CC=H4K5)#;2'H%,I8!"[.02
M+<R%,;,1GPP=@M%G:<=()B/NGM]_;&:DYUJ4J^T.A*#7P%RP\?H>@VV!M?H9
MM*#TW)2&M@I,SP1D=77I 2%(4%?^^R$\;-? 7412!UE**\##*/T$!$';(*(/
MZW.<OE*.*PQ>5YCUISM-!,2<+Z?5HX/*9:UUMBFQ?1&*5?@O=\ILR0@/G9 6
MJ@EZ1G M>BME:9WD6IIJR".TMYII2YL]&APN(R^,U@N+9\'&X,&K3:T4#H+?
MJ80"]]%#:*+'UV*%@M+KY![KF_5(.03U"AY;T7'TA4J(Q.F?1TIMZ#V\WTLR
M5'KL DQ,N0>]3N)E:,CC%+'K<@T_C/SKG'<\L>_5/4B,YYV*T>EK63NC./&J
MFS$X"SHOG!"Z]B22(4[]8BS<5[$ -75:Z!Z"N,..XSL1GY989BFV/:0*>LJ_
MW*R9\<X9ONM&U9".\>O6BW8X=71!G!P,SK ?U2UN1\7NL]?!WH>CUX?[,-;#
MP;O@\.CUAY/W@[/##T?/@^./K]X=[AV>_5//XGK)&M^DA]6O[7AR@8:]L6&$
MV*V]_-[@=[]B^]#EHJTRUFK3<1ZWT\*3I19%1#'(<IYB!W83DG-<5,(J^KW6
MH H^[I@T+%5B:>A[W02>C-XR+A&=\2(^OP#><1DE<V*NH+,H-CP=OB6.F>9A
MDIU6:##(:J.=(L!%XA1X_+0;NH5+5+"$/W$C*X,L#C,A!_O&XWI0%D2XWSX5
MN'U<J76S\MW$HDSN!_KFM)O?#5".(BPK[8I,4N_FS'O 8FE<J[)M3K((/FJ^
MVACZO:9!S+_H_2"^U(RT$(N4;QW.M0YAHD.;?)36OM68Z)06)L1+^BM(98:)
MO[H 3<:+K[2.N:D;-U$.IR?$[,PB!P2=1R.@30?*>G'7KSC=>,(C.^9179$K
M"Q$T7>?3&C1D.B#+N<@![9EF&MQ>$GTE;C]1;(!6838-Q7/$LL!N8&A5;220
MBMBZ([1JYOQ$A28KG5HBFTJM0&'E/Z79E>D-4%G>ADJ6"%N>3Y$CY;I;@'0/
MR$#+5MF\X'@%4IH.HWOHM*&KT\+=EW%>SJ7\C"LPW'5Q1JO5\WZO,DKGD"Z;
M+851V7"39(-QAIDY(<_2\:[!*I.CHZA?C.DGV?S\@H*AD1."K8])GT&N^7>K
MGYM66AK:N;73%Y'TN$VBJ\D\Z?<XWP"6P;H$G.E-T %GP ,LK361FFSW/M_M
MCGKLC=I76<><_\Z30"M7-.KJ7/",8SL]-X3@ @&LP /MR'38YR8(+P\VE)Z?
M$TJ1W"1A=K4(N^\;J@9["1]<NN+::8AICVV-O4>[G@5BD+Q:U5!.<<&EZ_ZP
MTK$VWV990:$D=OYZ!P8D+>$NR#%PWFQ'I\=%Z@02%2^"Y*_&L]CQZ30^8:6:
M_"7L+EG"[22^ZW*[H*#T,NS["X]6HPNJ>G*!)L@]AR[S%,Q @;1P:2H2TM3M
M[)U59>$W5:H4'Y^+'P_/M)?JLX^JCY,B0D7+01L:/:,$V[):^*65^&7J$H_4
M98%:SE=9D>X0RN0 JH%S?JI'<@J/H9[2HK/ IEW&8[0X52(1$ZU$MFNHN?KZ
M@4@0E<G6K@II32AJ0 3 !LZT5^1KW_<#QP<>W\4';E9KZT"R>!=/R2&S;T1J
ME\G'MA0Z*:/2E<08)RB7Z,SB3]2NSYI6J[D>MF3*%HK"#<@,0!Y%3HJGFP'1
M" 53!1'R*M]!Q3D'DN!B?OM>)49"]07XD^0VXIM$&>'*?A!E40XF*[70I2Q0
MR76 L1 7;8IV/'>ZR^,"AK;'@K.4;&B1C-4K!J]CFP"3/3-N%)QAA! FH@5_
MAZ9=#2-ST-H84YA%"6OPJ]<^*S2]AY=8U/6MQ+W6$@1^KFI<VH782BM&D;^A
M"O!4J3$<L_NH]C?5?M<L =&_]$ 3=2Z-L:VLC<:7<4'H#:XB[@2"+>!50T8;
M2E.&Y\*T&(-)9>)?UMJU!?'F#%26V^1V,G&:%$HW)#960XK1H/:'BC=/@T6_
M_TRM>C+>@(G'J?P<GQB-X &%T 925): \!<<K O)*6'7LPD7ZM;4%)&(>!$P
M$R*Q0?LJ 5%VD'^0W8*3K';*M8KCG.\F08PA>953@D>A\DO*Q4#_>W5[^-Y"
M13ERA-PK@K4E-QKBHP%CPKTHJH"?N=S&FX,S.()"D!&&?J&+;JC.BROY&G;8
M=?\;[1.Y242#YS_[/2\1;)XZM$LQ3<+_>#W/\8&8IQVNX%U#I)[9PG@X(NOD
M*FR;=W2]16DVB0TF#W"OC6TOY<+D*AY,)I+,@F5O7K;9A,=V'69$R3S7YD=9
M;KO/-%B0^OYF3^;&H(,]L)$(QBXN#(@R6&AX6Z%&<T8',Y4TQQ%Q;R[>"44*
M-=PP!A,4M@CET+G.-Z$VAX1G4GE*8RC)EUD;KZXS XD5GV/J9RIP$";CAP+J
MEYRK*H<JA+4RT'DA<PFT,&B"[LE2%K_H.;&G/7=8;1F"Q?-^SU(>FZR!!P"4
M+ESARV(;GATV<A#QU&YKBWH"2X\\37+-EI&)#M0;IR2($%ITVR*)^5Z04;^B
M>2I>"ZYL+ /)LY T)YFP,W1B$SN;03S!A+5_S5516E98=WO83"6D =]?*ND$
MCNNRC>C59$*]E>S.>Y8Y90-HB$5T=B$'X=PT<@DTH<U5]"'3#J9%[DG1$J5F
MU?QDR'A .32E'_!XM >0K4\JF@\C/"VT\]5Q"6,W)]<B;E^-=@=EUN;?;:*R
M6(ZLT\&T[<G]GAG9]T^$1@MC&5@3^H5%G^= Q9[1Z#MC2ZC'4$JNI)AH!D\Y
M,*R.*^_9UEH0D2F74NE)VY7:;G$1L%##IH(\+&@KB+27B89FME^/:Y#6GN4Z
M!UXC[VB7)Z<HTALI*WZ9?D^,W,B%Y1Z,UA$Z1W7D"U8M4#,;_"%[IR'RHZ]Q
M>(?#$12.8Z0M*\<^D4<".[@ BTF*#UOWB)2!.3M&I9S.SF]YL,AHP]X$30*)
ML 8OO5[S"=>X)7A8G#[LAS_69:ZM:Q#'&KJ]_=H5TCDFT\,+7S>MH5ULW%&Z
M!U,]TA0(>(3V*\]:>]+9\5;A^VA@+NHP@+9X'!45J4?CI7/;'K(SL]*"3^,#
MVL(F_RJ_1+;:]\^8(+Q'_,@ZGN*2$>MPLUDP1W4R+1:Q+E<OT// TU-"-U3-
M<<5*MH^;^EUSV6/RDPM -ZYJ(Y6NBA5>Q59J,,ZCB9/KEW'*)V^R.#%+,(^Q
MI5MSZK3A<EQ,46)<!6&8[1.DCM]BVTT:G2*QIWLF\2<EGG*R#WBGR?>RJ+JS
M-546%ZS(<\(B6*UU&(SE&ZHM6H+53:.I*NJAZ_:E[O><+,H&*XU72C-[,=+T
MRE'4A_\4]0\7755,NJ#;HD/L[B1:8 X6^=?8SZ-N .GQ"_A/5[=)2R2%I(K0
MWM5R4U@"^"B:2RP"OUNN$W_09.)'7[AP:,PHINZ0L)R2-%DM-CBVK_T=VG_O
M*+(LXV$RPX(\DH5#D?S04!0_9',\GR:*M$"N3EQYF0O V%T;DIB!D."-!+))
MJ>$J=HFZ(O%R3SA?X8IY\=G(8Q"5&0HHO,N#@")A&7-?"HLFXO@3E&5 ^I14
MWA,1"F:"0"5<])/E?C0]*ON]E;@5Y7]SC(4*U]KGP[@PZ 4&,9*=\]:1PH*K
M=HX0O>@MU.M/3CJ![\8JM:LJ0ZX@05!Q"5$R<F,\NCBU^0Q_2&&B.(??O#G$
MU65!^]>.UXO&BBMJQBX!26!EXM:6&@Q/&:%?<35JW3/V#1W@/>B58- -5=48
MZA,T6J ?3B#IVQ%5B!V36%.')UWJVW68ZL0?T5J67.W$"<(EWK4RCX=S&\QD
MR'6J Y?TN#$KT2M@;M_GRJ?B(IYI%[4#5&" 1.I>&XOV ,N! >HH'Q<_<"3P
MR5TD\"9%;8>5_I%]84>HU-0$JV=: 6TY27C]7DLE#X@9-VO03;OKRE^T2@SE
MSB#$S3D&KMC7GD9<CFN=!@_@$O$G;W !,HJ"@HMZB8_PJ<4[-XUUIQWG8CX:
MX>FK889O$^1SRMGZ57\IUJ/GL>22.GI'V#A(]%.1,FMN<F;L)8"T50Q6Z[:J
MJ3QR>U.A95W-N\NR7YYE_W3KMJ;-OSL$#G1Z$+PY&1R=G3X/#OYK[]W'T\,_
M;E>N_-.M[>5E"J+?%NO+D7_:G2-_8"KE=7.7-[GOQ#RUQKK-]!5'%AM9-O'7
MX9G53'-$XZM>(UQ$'**$D5U8A*TH=>KX3:B8(/_OZS]U+H)C39QA1EF69.<+
MXRFQED8U1.1Z7HS:1@/QL/8C)\@' L+SJ3Q%K#RX2X=50Q/_Z?>< )!XB=VH
M3]4 TK:@_.'V*ZA!"FXYN$)#X]CD;;D$[=>XE1ME%T+:70\5S'G G,.-RU:\
MWZLLN=&L$<Q?NV4*,(%,;F,5*=V0@9-N4EEW(&[.UG.[BXS 0HVU5FLV\'I/
MM9IIX1-_KB3O5\_&%=<(P4?"&ALF)!+@2LF8-2%W KQ">>@%WO-ZH'VSYL+Y
M.FI9Y@1Y^FW88U>[-WW<+)VMDU/N=''**E[X>R]==8"Q/\J/:@2?;# .ZUS&
M,#.PY1L(-VYTZ3+!BF94B_GH>$0UK<1))XG+)DH-:_CH_GPC,]_J&:&V-:[F
M&,(Q!(O4<7>Y 1.WVE[#G=4*8;Y_ ! )HH. ER;'7(L*J'%.G0P:V=<-4D'%
M+V^STUP0P<C*>8.+Y_<SJ<N97%%FKXN29&O!I<X <Y.,ZQ\?C$5%7A61+21S
M"I!-T'A98E(-?U>C5?II5SJ]K0F_N (:6<<&=!TS[F+8S*!* *&&8NCXY.!9
MZC.FN>C:03T,D)"Q![R@(5NK>V!?VYYZ)'1AWE0I+ZMH"@Q"0>&<L;[5/;A+
M8+K\D@L);38-=AWGNL,W?Y0%'\BJ7@(ES.<XS9R.2V+1FS!*OZ<^SY(,3E*3
MF@17MNFD35%?"Q#=PAF_:\W<T\[,"-':)<#*)7.#UM0W<:?X4J2F^5LFV%2D
M2/PO]!$H25GU:YX:[!0)" !UJV3">8^F+L3K9>GUTXJY@P\#('7I<HZP# UL
MU422O+%>SX"YV2JL"AJ)R[CZO:IMU91KM#S>%]:1F*\RS+%R2WY]+/OJIC6V
MTY07X,,M'#TP.O+>3A5FT,;%E&8UT@E\5)F3!L64H(M!=Q[-"7^-7.?,VON]
MRZA@+%S82SQD"3K,S_/L"D$?. 4><6-F^&'7P0G\X^#-ZY-=!R7P!_8<_WKG
M.?[BQ7Q9+7$#<D4Y::*17$N1+YS.C&A;QVE8Q;7EVDRXK=WC^).V8.GHLA+?
MPBXKVN[![H8J)4;$+&.CV'1!FR>A58^]%%2_RC<S8%16=I!KP"B;XAQH @.F
M(0A)VLX46F!$A*_.>:A@,V$.':9O=H;>LLGD?HFPEJ5IH\OB:+$5O%H$5QQX
M59\C[#] $+E\=3# U!1>#$F5X^]?X?>@":E9Q'" ]+6/&\W-OE%-XOZOQM[A
M29HIF.1VKV<UZ#X$BL$A9ZDU;EBQ,S,@TTI7Y??-*TP_5IY$8)?>XH&56'-<
M-J^XM,[5(^79?,5Z&^@P'L_S%B=V(U+0'4=IY"@_ DL1>P[9 =<E69(RW.8+
M6$V%K1"M5A@$5]T:(U\2YCT/P!T)?C4)WD8:M,QL&&>SBT6A6U7/%">';?QC
M' ;_B,/@$_H!/@'3"H/]M_#_IYMNB-F(&BN</'+N]T8@-R)0XHH[6OIZ6KJ\
MU:0D\I\2J+ A<'S.\294'#[#6N1SBG11$Z).,?E?]T^BA4A(H*)\ 9HYF)M@
MY .Y$I%);1>8C>5%-J8:$^)R_-[BP1V7^WZ4>1L)4\O9B31<EK)239\AB,,D
M*:AT;>AU)(#%.$=?C7@KR!.J46ZH&(-\&9CAR&AM2-<:& !)S8.+%)YZ1V0W
M0&2W49)J*@,Y"D_^I!A"!FM %Z%;^<$6$NAJ5/*D:["M@B>I4IJIP>. V;%4
MCLH+M,+((]?ON3K>*-'@/1:R&'L4@$6A<DPA&.?S\T:_&F6H(J)R-,)QQM%Y
MBDEA,'9,K^=D-W&\(@03-A^#<>#;BF4=9^^H^1K4?)O)F5M0.M1KX[DV*^;P
M:)\SJ8FF2_@2/=A[[_?(?3S5/2F17 ;'APZ $P)IH6J8CF.";M->7<JD<;I?
MU8P:!L2B/"-6-J;D.!@J0;:C?F$,PN@"?FEX 2^KY"K+/[5UP+U#XUV9D']K
M!0#G:,_AT1F,Z6#O[./@W6T'Y#T^^7!\<'+VS^#D\,W;L]-;E$WX6V>B'@N
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M@OEJC:?R9JF6VJ&#"O+IY4TRT1Q9NK9DJ;X"[YAI-GFD@8IN)DXK<.T>(6]
MM)'E7,,4,QLK+!]N2NJ,8G:2#D$T6JB!6=J)O34U]QQE;L,6&V.9+/X5LYB$
M3HT#5.1<6UH5\=:+TH'O+<*KBO6>>0=<RGM L&4[I:*Y9Z<$E2Z89IJ&[3(>
MQ5>ZT(.!DPS1DDPM+VX:SDS.+)*%6RJ;.Z7"HJDHG6,\V1,R/%/1V&<0M#\R
MC0O0VU$<%4%;;%6CF%Y*1CI(K\@ JF2$/*""IS!=&E1U%0BK:SN!+B7UIOLI
M\XQ2+DD$4BN;O))-MA J3>GX0(=S=XM9!DFE!GX7EN@\N9D.X3J*TVE.=25
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MU7;ZF[>=/I\D;+:1R95X:2^0%+=SZ'K_60&(""@53A]+'-NKP]Y>%&APBJ8
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M(U>4_R_FC)>GUB\&F_<_76LX>;C^D8@? 0)0'0U-[ ?>\;$S".3LC794\UX
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MY;Y,LWD9!^'AL@(V[T'3+=FWCM(DC%63FF<B9"N?6.EJ/I!/'"T8\FTM$ K
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M,;X1GS9>1.2DS4N?--<+5A": R9.FN:*3 <V, 43ZU4CJP!7+_GX.@9]KZ*
MY39_VC';V*]FTK87PXE79CTH">B3OZ.2<D-2H*1G-;?0(EQ"*;?!:??0UZD4
M[4A\$.&U:4LIQ+,V9ID!O*D0Y<*E3M^ GA[$,,=$[UQ!KXC*]$!3X)39=$ H
MY*D-/Z[,]E3<\-CG^0;4]B/^)J^T\@N(LL<->Z3VXSHC\3,V]L\G7K\MD8YC
MAKNMQ^B<V?)O7*AAJ=^QF0GM,MZO&?!-L"IO2^K3[ 4+%S#C9_.FTH739ZVZ
M?^ASKM^X%^^KSQ(ZONQ?!4N;\ZH!(?NVD!BAH XA7S(R8W6+/4RZ@O2EE4BI
MF[;=50%5AX#ZWMI43VP CP+%P/0#IKGQ!VFVAMP3J-$TPR(XH91R7BX+=TV+
M33;:D/,1F-[6P[2<3?Z[X,8%"MG<'?-;&PXW"CH_ME34O\TIU;6A99RV-W#K
MB;V/B]G;M)!32-$NUBN]2]E3J^EHB[3U=Z[N$GG%84"*[HSH>[&RT.%&I)]F
MIH<7*EIL/K%%M_RA;XDP<MFE>CS=:.A\4[N<74*U5="FPT23Q;O&(&14D4T\
M!YUZ_H0(2<7=YXG#SK>B>4,K^!)6\VZY58'FB(I+A/W*"PA6]"]K)O#10;_8
M^=^Q&&&)/3\O:-,GT=!_\8"%M8R9+<_HS-K8J*?T<$JMP2N#/LK&S2]%OA3?
MD[6*99+((^NSDX;0'B;6@G)T5;&1G?GN2DHHG^C4+]VHMS><^C7;U%YEY074
MGK_X<;5R8^",[;X2= MS 2'8,@@/$EA=_S_LO&<P'%S\][T)$B6$5:*'6&&U
M)**7A-76ZHO%KA*]K]XB142O:RV")=IBL0C6ZDGT+D&(WD/4($B(*_?U?_4\
M][OGU3WW,W/->7'FG/G..3.?.7/.[_N;.;\=A&*)$%?C#RG.=^GJ:UR:)]4,
M&&OO9K\W[C]]P$8R404=T4Z":N28S%>15[&*E' \6Z[0-2JG/E2E%RYY&K$]
M.4.K#2PX3XPW46,8C##%%^'A^"7ZZK?D/F>[N?;=DS4.XM>S2Z.@C3(5L@'"
M_X!4-<'.\Y!1F602%CYW@WM$324YPP!<WKVZNMB@=>$$LFP.[%G.JQLL]2*-
M-(:'G1G'LG S5, X<%6W\)W<('$UUHHZ]=YK ! +4*\I:4Y=,=C4OI,@";J?
M1.P1\B7 ;%^!#7\8!9HMH]Q1GM5S#';HCJ?!74>M^GW^N2^VI!X<WDM^>M-Z
M5RSS%9EHFC;3J+JQ.SH6P!1=JWYL$R"U0EW\U0HM^Z;A5'DV"?9S*WO[CU?N
M65B IPM?J?)@7->1,_1Y[\(SGVN?/JS_!8S\!93BL?",?/V:%E$3-9(Y8<!"
MYU-\:D,W=%ANUP6#(Z"A5H'B6: 5ZQQ@QK5/6<S15_F@(8']"XGW X*4;[JC
M.RKLY"0G$L[#\:;GJ&2O1JU]'^=^\U3UBKXL'QWU^=TQ82]@T$8UO.ICD8_P
M4E%N3+6%X*N=;!K\2J BQPF)5C/67GCS#(BCB>70$X8:WB?-X].P6'R(PM5?
MB9#A#[.9I;-O&J^86%WI'<?\@&3^ZQ'^ K0U0B&(Z$A%X]6,W--T[X69VF;6
MKL7A1<4]J\LKGAMIP?RCB\I'9<NHQ9,SGI\3=SH:+,A>V&0[[MM/=IL%5?VB
MLV5,$ V1@!:QOX QG'D'L_&0U^!;P9*.-ZW)=8.I_LU,:2V4*]3@Q@^#:3V:
M2<QJ526W<(U"==7ZJH.W\L"+\\YTG9C(K!P4NB:46!81)$E\-RA34GE=K/#'
MT^29VN>'@S8/.L)$UQ#PIKYW7HA1!6^#9ONYG-DO+PH[VYM9?0=&O<H:E54D
M2PYK-9A72#8G+Q3M>/SWG)DFUS@4%,$!S9P'#V_CK&/&L^;<)9MP$OM'NK0
MMO4M\_3%Q?V*;KFX/Y6%: R/&-PZ"*8VOV2%8 N!FYDO\+H!HTH*Z18>J4UJ
MN+OO=^</>5M5U%AX6W5<:(01BO/G]B8]03U"SBHZ&)3#E^93F7G92,GY9]T.
M8I.<:ETP58_#0@Y2TP\T[J%\96G9W6J#N?:!/N89EQLZ/V;'LWAX7^LZTX$M
MC>&429B_]*V%&RREKTS02S2"Z'ZS@0=]$K.9$[DU51VV].ZZ<![OA@.T#RYS
MG%MY>;_B<&_[T=IFK->CB\]D*8,CJM0VS]588,/)[6"M+4_[G>I&K;G0&9=&
M(:5<<:K(QZY594M?TE*U7YR9)QDY5)K&V%8R/J0>MSI>]9!N+$1F!_E9OM D
M&BH,+ND::W@)-!8WW;<V/.R'Q?L\(V@",30IC>NYV*Z ?.>XS]B)PS<?Q(/.
M@-MF96RTWNJT"T.AH8*N#%ZB8/.^I'#(QZX7_,&_;-RR+O/<UOHX*(:;4WA3
M[=^U97)L)TJ'!E^JEJOI/B[LW7.NDEI)K-^3C=7_.%S_^4Z2>7!$4B(EL:5#
M Z)9*<:GX?943Z)5Q*^A!$Q00D2#&]",J[-F01_!8$#4_BN)]G/QG.(,Y7Z5
M8V_AGIJ0+.^2Z,:,FF?7NJ($CMS7QVOKX-8;;%6?]6Z+R G;U:76O:CI7YA&
M4?93A#2.6O-52K6GQ3;3I&0: O5DETR(K=+=Y)BG[2Y?<Z5L3A1'WFF.R%ZW
MB8GS^#AN,J2KH=05K,0>T,S! ^?.=(2D&-_P/<+Y6JO-J].Z^40M$V"+_=>#
M("%3U9-1",S..X9Q7.R"][H<3I@>Q<6DU!";R9+Q*)J2B2OCO^(M-3TO$]RQ
M:S_^I_M;?OGLL\26;60JO_J\':M<Z43]WHB'S==QYW1:QC0NAXYAV*+]AA3V
M0$!\JM'+92)96W)]-]%EE.V40T[(1JHY\*F$#LJ>"7QT(P:IA\Z$@AKA$4#2
M)^FD'0Q^&T&P+IC7S@\31I5[E1,V\:;A'S9 ).=1 ^7N#5UMB%E!"#;F4ZKL
M[Y"ND;=]^\,,!VZC<]]N2;X-SM3=.5?]>-I7>E IJYW(ZK_$H;0!D]>8"*)B
ME9D>#@KR$/N5X<LM_5J[V]4$O?L.^"[V4.Y&R"H4K=73Q*B=/$O39XQ3^ !O
MEH.3L^9]@9M@'/MFZ#(PO4UA6V\X5#SS.+4(9CQ@G/);\7EG3!>C_QP)L]KO
M!<P<1Y!./PWB@+EY+>4^^0%GM>'1B.:P(52^_#:).*A:^0 L*^CX)J?)@T^=
M0:UX;A<+KVA]<3FTET-^M8T]6*Q>V4T\H7GT?8)%KEB/CQ"6"=#%[)C,PB#&
MF"P;TQ0 :U0$S\(5,"=O*'U[MP)HSI)&_-^((NBDJ8A"R7&7K"M T _ )\F2
M\]&,"Q/M@_APFJ%T':$>M,Z /NK C/,-HTB=MW^(C6L@;MKB?$(L&0'[U$9"
MG#'\>]M78(G4.GZ*;W[<,H";V^OL#U_E#7QVVNV+*W1JFP7&,O-"$B:9@25\
M;,K5US4Z&S-U[JZ8@*'>'O!("ALN"FN6D0S7D8XAKBW5C!E=D=&_>2V<Q[45
M4G5AE/:C57ODX\(,9?&S"X7QW;><:IO&<R,O6>41>1,%*[&?4GT-7-RT"LW@
M-7B=%,BVW;<H!:1/5,P>J_#^!&'49KSK:4!SS3B+P@V29 @#+YFZ#Q[A'=5?
M126LV=?>^0C4J'-J<9"<SUHT11,_L+'-,2D@(7BP]G<%."PCX^H:(5@Y^IGR
M^ZU]4;='+P*$LO#E2W..*?,F>8N8G"(+%^AT@XT2^VGAFZ], E)FO9*ZJA2Y
M&\;#_>+*=7*26 <'F#=M:;^<-Q4R)M7(UKIT ?L'FN9X?^)(@^;#XO&0X&1Q
M&(,0HUR(]HXW01 L-DG4S%V5WI&0^]E\3VF;BXDDK"XIWQ*=-WYET4^7P=C/
M$]EL3DU20\OQ5,U>O#CZG>I"<3;B%^>9<*[?J/&4FZI3K#^2&['/^JK,"OTN
MSHOO_?JU41))2CLB]@R9DC4SM.NUW%I?)54TAH".Z.2 6HF8Y*]^<0OO Y[K
MBY!)R64LXS@"DU+>%$IOKN JV^FAU8+RH  ;;D/6])["G3F3H<;CB:PV/G%3
MZV(8;)VD+\)@TB6H #&+O@;!91D7L%OECZTDZ0 OM,,E&FZR*PH/7RUKE<O;
M]/=_;+W["+;+&&_TE4U*]@N#:T#M?I6$D>;6U_WZ<=@TH?C.O$RI%7T%B:U"
M_J%<GB_:).W:^L_,.\ZE<^[11<IN?DQ06RIO7*I_5 1I51K/T@%K):+LB;[<
MW@'0P!9"Q/94[WKP@#@&42!-EA * A&_B+(+0MTR-_C@WAM-OU_-?1DRO*>E
M5=DAVP,O^X@6PPX'.UJ'U_U,J7_N2"D-<D+=D!ZG:G"R-V(;=;M*74?M>-O!
M'P]/P6/+- RTZK73VON;S.4,I6^"CE^)"@ ,J>S5<!LZ\&N1U9!YO[G$9$ER
M9G]2)QQ#$/PVRX!$F!ECB\@"4>S4$5?$:6 ]+W=G*_QTO/;SF&;>BBEK-]QV
M/ZVQE7<X*C8[JCZN?X+&5WBS?6";_:G(%_8N*X0HF4,2%Y,R8%9*426D-!LD
M/"1_+2UZ--*S) O/=1YW_!"\^%VR+UB)&YQD])L<+7]N5D,#(G;""7F?VLW2
MHWP[%SBM2V!T&J,R:W7R_X97U/L*9-G735N,S#:,^TT-/OY2-R<:N]MT/ U>
MULI9?RC :;<5S]_#QEKV"CDY;LM^%V>HK_*]SQEW-RJL^]L! !?QZ$7S1VIV
MG)P"":KV71A&=_2-<G3-+)".WF0+</69FL7Z]>2\M^:*ACUZ(8IG-<*_C71F
M3)6R,&V?IKS X:4OX3LC(B_>#<WLGZ D9)%%+.ZVWLKTVM(-#3]/>_V<GOXC
M;9_LW[C8IJUOD^J<+G.^'_=NK<]4-UA%-HM;KUHEBD!KB<RDA9@N\'4#</@,
M]J2$E>*^0%3FSVPFXAEWNHA$4\&<2E%>$.\KUR!#'$$79BTNCM@RU:HS35R"
M+K;%: 3\!0QL+LUU_@6$)FJDXWWFN,N>3WS*Q<42K!I!![>+@E6I'&S$!7YS
M7D\?KZQ+RPX\7+O#+1QD3>*^,9O> Q]'L?P67Y,@*"8+4H3* 77,MTT](;R]
M/SX(77]%)Y !I)OU'J _(?1$PB\8@/$T!.$>';UR9.[2 E0<-M[ 1G1'?FZ!
MXVKD<NNW%^K"AOK;9V8U%/W:M ^?O%;L8[JRK;DI8@\.;G<TSC1)&=RP*<J/
M>)!4.[:'JG2'>H<(JR1F_<#U]\6]AEQ9O>W,"IQ$6$7B2@;VG0Q#KFA)B3J7
M#P@K]S,*_(,1UA)'T*IXG)JMI2@<4;!39L/!D]AH-H(E:@B,V4%?IX=DB[DH
MCQ \-<H143H+]7C*[.R13T*;S"=IY2.IXT$&YX3IYLU?!-WP6D5)L]7%:JVB
MW"NJLG8>_4,-K;9.H,_1CCXISW1^-C7%-T>HA0^(HKS]<GQU<;^<BJ2!F:;"
MDPV=!*67VC9B_2CO"!A&C7Z1*A1XE;P)]2OFR^SZC2ECJ'10KB&QS$&9J,%E
M/*;W1*O\I9C,HD7",7YTMGLO=D_C&W>8/I6FA!Z4A$,;;E,+-[4^SUB/LGN\
M<KJ#3&T-@C_E6M!Y B<TGE2LK_ D#;,L98[M2@RY&#JR8(T%/VF5_R+53V8)
MK)QYCQD X9QF[#+6ZV9Y7^1J^V%A]X.@ N7EZUA=$<Z(X/%$R'(,@PA.L[LE
M,\S6Q)"&,@=HXA.$T=,:.\DP8]*:,&(I9>/!B\:G]OX'#19OVKHVBG)R1H2'
MT?I^2SJF(<()T0:$AU%Y33V>.Z!A@C=\H1J=!S,O*"9_X=#V4$9-./28I%0T
M!SB$W,D?VB],3(*RW-'2Z]=7J.,'PR97<;BC-V-;<_TF&XBKF<5$*X"KK9CU
M_8V1%]9]2&3I0,J KE?MZ%$",X[QC \N_U*-;F'!N ML]:&A\?G L'=\;T>O
MX1@GWV^/PB-'/-+E^A/_@#1VK=EBRE8;>JIE5&S',[URAH^L517<TU2?EEC.
MO4RO^([;4,QJMO,;Q/B =T>P*;F_9=14UU]%WBRNJE*P#$0:F73F!#7BV3/[
M81 SY1+,E1GDDE_Y VP9,ABEUO%M4[0Q6T^MB6$@K%KWN+UE8BWK4NR*!(EG
M1QLL_V$$51+N&"[;]+OTU Y4)?/4_''@<8"3YUY[D\1%9AD27_(A/'L\6,L[
MO#X>O'U9Z8CBE^0*O';D-LTOS,?=H*\AXA8?(#/B-V?>LXE\HD"N9RQ#NLE
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M?+),4 !L@ %$33PC^WY,X'KM8-G<^X'(*<HB=NWR$R,'ES%LX Q$A-'"V-1
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M5IK-$%@VK4^:B[)@#$I<2MP/E+=1=0A/*6':$'CB"@]P)LMP<'P/,E0HHZ?
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M2@^LB"5$O\PLCBCMQ2[=#QH1!8*"&M0K_-^%0@':1!$:Q5C&IG#97F_R:/*
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MECDF40;1P(\:S4\V'&KT0%6\X<$I<T4+(7%\Z@^=4K(;5MN$^AT@X]8WFOC
M_?3P7JARGY 6WZIA0"J?[3;P&"U3A6[!SKX:H*DOPH9 +0+S-P75DM+SQ J/
MWM8/>5J)M^>?5O-ZVX17A=2XG 7SF%S4FF^ZG'!\*!SV%&6T""RU<_R>RC4G
MA!Q1FUK#>9U>.4ANO%/'.&Y>3)Z%U<ZFRM(^3 =3;%Q6*C\2"%*%]N/;B,@&
M(B@2JLCK:W@4@B&YKAZ<5JQEY@9S_ 5X9AG7?65PUM\G,BHLOA; A*0WL0%Q
M"JBP]VV>R_= %?,_[JG\#ALXMQ.4ZEG3C,FI-'%7RO-V-QA//TT<]BX:X:O
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M:VRH.C":+ER&-T5K/;^A,([ %4YUI<W3&VZ'.944SLLOL!$H2% EC::[]:*
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MR3_,CSQ3@_>\"TJ_'HN]-.]]0/NF7-C9N72R\,MNQ0>!*9KP*+$A0QFUXCM
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M)*6SW34DJ4M Z']?30#>PR]]U)#&O3=1,@+3[*40,F5MF;+E!T55!C9F\;^
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M'98=C>)!;W>+FX<)/$?38N_F3-QV4X0J/"E&?;(7':T=@U.PXN48S!\ PH>
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MJ-TXWWQ1T=A_AW&];"X<,.="4^ EALQ;!"#[!>VA>97(9]%&+?W% BX[HTY
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MZPG[#MDR(!"+5,&247:%:HZK?/;_M!%)#OQBT$-(4C]#WJ<&E3V]UE9AT@%
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M%/8,$.5BQWE.G#Q%QTXAGW,KXOSN[BU("58/0$./'BRE7; O^M%BYQ 8='I
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MI0D4G(ZEDD:VG15H:NV,V \1!M2W:3@TE" U]G9<3]#V)[M*6,0LBE73K3Q
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MUDICPG@>U3HG$&BOQ"18A!CK5[C@8%+_&?QNKC:!LF!%>]>#";PB-A_(@DT
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MNY"^VT";WFGP&L\4".-S5FS=;%#;?*\WR599+?>7D)_XD</55&<4\*OO<P
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MKO^<1.2!0:P[!HH=F$\!S9A]!QD#MQF]R+$=Z35;8FR;[E+E"ZAN"1#W^[\
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M[/G5)"0MD*_8]G?X  WT2NO$Z_F&BK[F(AVS$/7:((;Y9*<B(O&P513^4C-
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M @H.LN^1I9*J/!,;:V\??OVY%W+SS>/7<ONZ(^;-"R;F;X)[%H>M1A]KS[]
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MP/'N^ ,';TQ^#$1+D>@BTL0DFI<FJ>\32NA\N*XR[?;072TH?+^$BJ_]P5:
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M-6%BZ][!WDW[&B[4ZYZ823HV1+B^2/Q.]+'S63Y>H_H61,]YEJ:;A_3>]>[
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MZF0MO2F0OG1))H/LL@[!Y?Y@U'7TM_5K>6(.&%#,-Q,>A(#!;YY-.]^F]=\
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MAHR?[O>E)X&^#_?9A6(\$7[M!IEPGN!Q*91QAF/ 'U(ITV/*L'Z75@T (/P
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M"%@!;?&K7YU3>[L6L>@5BWP-#WL;/JF%)6OMH<>Y10!XSCW1E*0%2+S'UT)
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MW+8WMC,\9T+.XS4A\:B04#^N'7OD*:C>SW''K(#I+LKM=%C@E\<',M?N\S=
M>6 [#&7SHDH5"216TFV1:'G+C6"F_D&B;_V2(?<KO30\%LI</KEPL'S0UNLV
M*SH@6+X=412 7@#]6)T$QL>[F&G:8([]+M-8/?Y-!P9O?-4'9[,_[<<;X"!2
MG5^OJ^$\((RT"^,SC[QQ>HG\5_P_5.D+*6K+P_%G1M< >FQCJKFP^.&8O 2*
M;O:P;0E,^&.ZY@_"!3H2A$D5\RK"+'/"V>%CI@'OXM=N8F*$P!N0Q6@%*PH_
M)"Q"BM4N3NL?%,NU[IG,RS5D%&2)[H?Y:714T!1D:>+D ''Q=P?#(VX\^/R*
MD@J,Y_]62<DLQ]GH%D)SA9]>?@,?^UF\WP#C.-= 3YAB+V QT# +R.:@@?E9
M\I!(BBBM^QL"<%*U\#^MYV L3<@"AO#2CTB3#4O19Z@CUMC0,=#\?,&?^ (;
MF U0BW7U#A>7ND#TNH:C@PG*X&5_S<VGRA"^BH#XMLV]&I@=GKT!3(8VE"[=
MLF2+G Q(5 Z*&M.R1LO;B3=///].3H\XO(H5$/B_Q >N_"/+G]37M*22O(Y.
M]XNN()^D/)Y)N!)?#"QF"G=:^/,FE1PXA%)UO/DZER[;LG8@@LE<V--[)-X^
M7B4O+:/3ZZ^#T;MO %R=FY*FREBZZ]G5<:6]!<.8\SM^!]J'ELD"A7Y7+ZG,
MS UK?^::&P__:K"74/^"+X,]8]X(_\W=M=JC6VI>Z^]8PN%7YMHCM?\#^_\]
MV+?%J=:E0 I3D*E)J3/53Y'6[ ]T.0'!=(BU "B6*  T!0!:T EP_:]'RO*.
M2Z?;9%6OB@(!+NBE. =#7>3O/W;M?W8Z&T& AC[#=#:B%Q;?H C*^RXLX9P/
M]%4.R9#Z9K57/IO1?U^;P1;-Z]59H3?64/IW$W?@>MY&@R2\ :*:D;>^(1R7
M*&%LDQHH3XR] 1!>(NK]O[.@9C4:2GK(_UPF"GH#;+,T/J^C$.VMBJ!S*7,%
M.;I !8@8%S8QQ']VR+J<U10X>Q%VL])J_/A//Z*^Z?T@M&?1I7@9AG"W/OP%
M'I[M,P_P46#2HYNU<IM6$OW3.F&?LO-7.L0F!FF/9":Y'7[2N?GB-P!G)Y?/
M\ .V,^M*Z=]1[VV;Y\%"E7*OK+N,WR](2POXI8)]W21:.5]PKYCF,F&',X0L
M&CV3AG_&#PEX0=4%_X41S/('XV>JK7T80&"_PE<5BJ^;0N!0;T8NW\U@F,6'
M-T"((7]-V=_%H!PCYBFT-[]<O\'[-5MHGRY?C#A<7>@-X%@.>$6,(::Z%:&7
M*ND1J*VF]SN:(@N#;E;+//3D_9/'0(54D_9KT^'U#3BSJD/OGZ:C,?WW!?!V
MV'] /\11$.96O2CL(K:R1,@"&/0J^>30C0=4:J]Y+I0?BQ)Y YQ'&KD=LIP1
MUY*$'L-LZ=-/"8LH[F0[X^+\GHQ]0A[?=-O!NW!!0Y^IL(M8&?GE+L-G?KK4
M(6.6R&9DJRQ?3*<>I?;@!(,410.#VSK7SGM[*/@HA9"5E]7FE<3KS>^+%YS8
M%?LIK7K23=H_@5H0Y \9\P#*7#VY\0'SO;[-W:L#'RG4C@9?VQQ0$_=NCIJ\
MI5+'E?Y#=N#B2/"+8OK_$?W_L>A\_*)=5/F!MV34>AT.E80$W'!Z&-V['[MT
M'[H08U7#814VKUW1SUZ)AAF&#P917*84,V9:4#U=G(KI*6.!2HBD"S7Z$]7_
MO@4I5[W?:\ ;P+S]]05?]O?TI:]HI50SB5#YG-:/!?7_'-C"T. <F;*B!>1
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ML8A/QUF./+GEW#]+=)ESYC7(E[Z:H;K-L;0^&S_D>&?,!>>"IXKHQ3H>_0(
ML!?BT+F93!>"'W[_H7R+ 5#S!7)Z6N?%:+>T;X"-A#&MP0&__.D.?]S;XKS/
M9?_)*3%N_0!X(SZ^ =X G6]_C5!<DR5CQ"5(MEQ;/;S8:..B)X8PD=U\J/!]
MH8#91\> @KI&1/39(A-T1'_Y<QK[1A:+V&^*2$D6R#=?+/L5&C&I"QE!%3$@
M@(CWWCM.7/"0;]-ECA?XA:LS/KXR3Y'WXN)&?:%:XBO/!RP-."PZ?%9D"QA0
M+C29,998FW$8( Q)6%@8(?NQN@WTH>TS*M)0EP#LS4Q#5R%F>$ N-5T 7A<T
M-5U8& #QN8N"C Q >8!.\F-H@I5M>G)>UA7].@P1 <1[\T)^#GPU$*NZ-MUU
MG>GX2T>B)GUKWJL2H6^=RULEZFEE9/$U>A]G$/N[16MYAQLDM*JTT.GHCF:&
MZDRG,<LOK^L3K,=;(*"2&$8].W;P.7>HMAFY8MOVNI@5%95I@ R#"I(L)E9]
M\38]K>Q:HUXE;F2PG$+N^[*"&9^0'YH/'TL>G4&R6#N]=D6_<=)D,[SFDUA'
MK9AY=S#9M#N*UIZ WQ:)].HR1XM.>5?I64+BD@M'8,,I]J%8R[6'S:WS5V29
M=@[Q*@FH?B?Z$]M_-<A)E8;MUO?"V&L<%?=M9G*PQV[ 0=:JQ&Q8$[//+G/3
M*Y!&,CQNE*'GWNP\F9BVS1\X?58R:=8V;^M*)(Y,)(I/)/5Q;,>?HQ^Z(A0+
M:#@RVTL!P:'"$L'00EOCJ4''#5QD4Z2ZPG858XD78O7Q?N\JI(^@4$&'^E/1
M :$&TYO;FQ>NBTAQ;(E13N>>-EM8 U#H4.B <\0WP&?$@#^-Y@8#'?#J1*0:
M((:4\$GD_-,V/Y+4F%D;FA+*EJP W!>X.?Y/CBA;3T#_(N5!*7_N<W ,K]/D
MM&+B&$OB=";^X227 K(8Z4O7!Z\Q4I>#0V/<#N-8I6MY55>6" %89#(*8EB6
MP= 6\ !W+&(.-_AA>'#Q"Z 0 P =%O;<!:"@G!.&R4;HG!.'>0,4A]*+0$&A
M_SG^M%!7=-)]=%(?K)(OZF^ Q26A>? ;X#YE;'IP0+! \]WVCI"N]==_[8#S
MK\]!S$?K_!#MSF;SO#NI:IT4=XYAUR<>_#0NX15M]C_$*K?MGY)-K86MJ_#3
M-SG%_!1>:D4+!]W,@>H2LVU]\U<51 T8='?B:[(-%Y:^9"S:V>72F!8P3=-3
ME$ZQPHJDQK3CQ,)5A7-[O0%(8VGE7;( ^Q</S4\NDX;>BG>^U\<P7R!Z^FX?
M8M/5XA855X;\E@S%9R&$NT^#JI#0FU GE?E,(8B/PD;<WN\K^T&"Q(!?)\+A
MMA,D9C^!?7;R^K6)"*@Q;9#?4B3W8;,\$\&>3=^WNA'Z,UPJ&;Y,_XZ#AE@Y
M?[%Q]K>WVXMOO#[_"2H%9X9DGW(CD;#-*G22Y1][-\9S1B"KFVL>Z$>5B>B>
M,F>*<R]U?PE)D/GYLUJZAK4@P8GJ8G@B R'?]<:3[T;)&0!N8>F"%'$!#0EV
M;Q9(>SH(W3..44Z["3:FZH0A@A\OE,3T/&]KE.?6NAMT;QQXCJ=ORY(D0YH'
M'7_174A;"U2K)U;W3=B]6W^R T/TAN!CM(/,EFJ-KZ3\ _:/)F/[E#CYH8$(
M 3R\%@CR[TT/0C\[Q5 =Y5#Y0.+5_H>*:7[_^FKT.F7T^_+]/WJDJFW/IZON
MET6D-ULU_A3=&AXM5A'5-6@FFKR2Y:,8ZG,&X=/JPQ$6+-_9>*0[L,)+53^6
MRB +H-5('M5((/]IWZD-Y>B((T;CJHJ(<R&P-T=QDD<:OKUO %K(Q_;ERH=P
MC%Q92W>>E1"<O;Y8IE]U<C4ER'+.>FY(FA=(#$BP.7*BX:(+R7[F_,YZ'0P^
M)@WW?7RY_O8X,0^I58:'Z<M^N<3??O/>0#*)VU^87A(-0_S:W2LZ\6XS>R1=
M@FKO5-EF@V#P!WZ"HQF5HH;OQ3.7['R[22X25]VR6F@@BVW4=WK9L5^$##.\
M'R\[?"&^I/MI-T((AAP"53!\&W7:'@%=6N4X^N!0MA7\ ?;!]U91FCD>'VE@
MHF-6:.D0H08V+<\!:!T ![.G +1M $E0]/FVPV[:#0.?YF9@EDXY8?YNT97?
M<* 4M)3EU_@QZ:']JDPV^G46@5^K?$",#ZE_H3 B_2;_Q:P%3RK;#0,*X^A@
MX'+"0V_R#>"ZF-JT4%1?\8BPX(,J&?X7C'Q4 ,G4T" GXB 'W%Q):SL$^Y=/
M )EBPS/WO;!8]G?O4=\A1*]@F"+E:Y^EC5><5YDJT6S)QJB=R:^$&Q!"(=-%
M?<BK2&4+9%(O0NBG]C%=1=I6:224B 96LZZBFW P[ @RT<R.R7<U>C4Z/*D<
M9#C4$,![!_]WWOZE-E/%&$S#2-*UV@"I)AB+DQ^*BHJ'IZ@'M&I1IKL9BC8.
M P6"6P+5>KRT!TJOJ<NO6]ZNQTJO=O>"#EQK-]<FWYX7_@)3<VKC[^IK\>O>
M$/+ZM>9>__?B(WP+I-*M>Q_[?F#/^\?&TFD[. !J<-4WKZ0+)AL*N.Q7"$#[
M#+@%H'%R=89T)OR!<:KG![C-[ X&Y?LI+3NBNL3QB<EG<H/UW@56SF"1MB4D
M"ZNQ"B?UY2<U?Y!^=?L@3K7.>^E,)P GFK/5M4__WKZ0'+8"# I( ATTRZI5
MO0%:X'2'[-F^+\7G='OX,N,R7>1TJ2YD8!;)<^+M14B*RK4^Y\C"0%G#OSKA
M)DOF5M<<GJ;7F=8+UJW.T@FL@I+O9(>-5J=;CANA@VC24K)8;\R55!45X"NU
MI70(X]6_4A /-P8'>#@D&)$1SXQZVQV>Z^Y/W%8U&E@JMA>@M?.X#TW/K=C9
MI@1&2OA45.-(@@-YB9R8<Q829L5V#<=_AR23?$,=(42H5KG;,!R6<,(AZ9D^
MO4OW&^A;*>N?/E+SH1IIE$+W]0G'L*]GOJZE[TTX8,/9.KFS=:(5J?I*I&/2
M'Q-6PS^?&&T35AFL9;X(14X]#TQ;_O15A\N]-XX_W+$&TAAN]8ZD5DY'K:E%
METN]BXF:S80CT4@;KMF'(,6C(J8=[F[5RHB/L(9.-^$F56?*\!,SM2+*R:<&
MK%V@G,H*<Q,XIF(8;>A1E[IN2'-3+*@!YZ<+]2 7FOI]J: ^C3W.>GJXJU>?
MP-)!=82.U3O07H^H0=WY4IIX=%53+A7AUWK;^<84+>OQ=UAN9<Y=O7:YK1N8
MCGN^DZ\V961GC 9.AL'#0>%  MH8N$3NFJ#J;JG*A_G,^QHT^BTS3IP^]]>9
M-GDL4SA!*GWM6&?9LY!WFHMVLNH[1DL[#;GZ=3I!(4;-=++OO)3<5U8_,3%U
M)'$X+'II_N2,!C:-+_T:Z!9/T[[E<4>RI_S F5ZS/]U)7<QT)W*261RV=X:S
M&I7T.;V!3R=]&6FYXJ>Q0$Y)*A*36QWXEEJUK*9^G5=-_Y >DW5A37).H0QU
MOYE\G-'TI$=U0:#*P8HA3P9OB%%5],KOUU57*]+@F*'@LD<XM^4R(N]SC.:\
M5ZQ)['OR1A/;ZQRGCYJA>>20^2>3F.H1PYGR@KY?.XBZ>OQ9=G!U5P/'.:QO
M *V3Z*41]XW-2O?'QF??ZUJF:C0[4G.#AF1W^\VE]%^OX[K;E4R-U6L61M0/
MLS2ZF@0-HP;5)2Q,; 2QM81<.#YCZ[2T"RW].<D_<_?E@2:,!$V_,H-<37_'
M!R93F*I8WN_*#](&TV,IJ*=('W,YKXN#N#3$-<@'9ZY8A575I8CGX: R'*6I
MX  BJBY)NTZP'RXUL0,*R"TWAJ6=D$648?-+^+JI%9*AT;< =##9Y#**"O_%
M?GCB6Z6P=OT&EA&6&-5RGQJ",12:=>-R?:=_S7T.A L+I(?=YRXVNF-J*C:)
M"/0P=O($PS^^?%FH]5CW!-X^/;E.$B$W-)MI_>VLBGPJFK'V%N%PV5SG^"Q
M.9C,YGLJDANX"FSR/8G?0[Z9YQ;[)PHY6\/TXI:\]R)#P_IK^C(2(@"^)?AK
M G/Z#8!Z#P0YE86GS*O_S_;V*.@Q1=R,7*G'))/<HVW<""L,X"+G6Q4]<T(7
MKU8.,'SXH4AY8F+_&$6+H2_/K-G_C]G(\4V/'=+%WKW%(B(&R95.7V'_$J'7
MFQ3C#D&V6YKHZX?."@G\O]9__O?;,!=:&]51LK:Y:XR%)U^([>S!E"I#AX\Y
MDH6+;RD#H.BE.@2VCLXM]%=\2^MMO]$U,O:JD80S6%@%=]DU[I*%JE_'XA Y
M5>HTQ,%?VY5SY^:#*2F:RW FUMS3Y']P-E(T4H?UR+ 1Z<E7,+A]+,B^0M^R
M&L3*Q6S$U).685C$?G<B]WZ@IXPOSXKIO/*F8;@:1)EF<#Y_P#91-CU*44)"
MKUG%[875=W<;14^+04VVO:K=>5499UY[8>EZNO0ZUAYB;KA- :EK@/S <VI/
M_>E&R.B41<T 5TC%L#_"8[D5:!".M"= VRSY!J#21".M_QWI\['6+"U2(M<L
MYS8[[RI%H.RJ\#W\7#*U,YXY['=@ %D]C8TQ&Y4#]\H<ETWCC&[C-ZNT"%>[
MV]8M+QB:+G3-$G\;M82RM?;@SY4:N>>Q)-*==@ZNR\+"QA_)TG6,;-]Q)O/U
M))?FWYR69]5Z1 (=;/<GAY8;UD746YT+&YDW1^_Y8O7TQ)@J/]A3?6S']1K:
MDT#]C)$<=/!,:K\B1]PDO"*09V&U;C;S8Y'<7J/#*4J]G,VQ#YB6\LPW+$M-
MWH!31P54+LBX#A_]I?X,_<V&*-E.WY?)/E5VN:*0&GF]B5<DW]74S1 Q@B']
MD![OJUIODP^JD<MGM)_9Z49?W7"Y<&8&K09/H[/4#JT99:,%"AN36W+!D7%W
MF,H0^Z,68"A8 IE:[T'Z%%GI2*N9G:K$E*F $89;6E8M0SG_IDC# F\[$].M
M*7^K4H5TA%Y'=^QPL,$5G15Y3">W7(FI'#>>GX!C,*'&N883$..E&6W:3ZU5
M#@VT[4X[Q#XDF'DN.*Q\ZDG9K>W(OSH-S6OJH6A*<NZ_:0B-&V0(?Z<[)!\(
MG5)7YH*)F0#\L.HE&C:QT[@F.QKD6>3A):OZ2SFIJ,4A -;APU2SD9D'P8Y"
M)YO1=TV,=_')66^ Y&8/;!QF.4JJ[5T7"Q3M! U+%M-E6@?*A60%80\\)+IP
MH6%]G!Y-0LT1OI9&50VBJW"Y2OLD3LQZ:EDF8..<<DCH+\PS$;"*[(C,;3>E
M&S>J!VPPV$L'$!QB'\ JHNJL5H6<8,7PC$]MP/8J*FFHJDJ@TGNH0_C>N7(?
MIFN0*SS!U $5%'&:,_MM*B9W;PHF0?7KC+&+-$,$[-2/=]$=&";.2'O*H>MV
M(<'U"?7<(=%3*^I'HB,&EN!$AP0R,DP'V^ 2GJ14$1EJ.)D1H$L(BD?,X8 (
MW@9?;TM7R9*PL#CLGT/X#\L* /X0%O[VI_MN!'5?"P3W-$#VZ0U1_$=0?)F!
MN'4V\(DJY=NF'E%ILXZR8Y$\)8LJ-T5BR*?!Z$BBS@2(!D-I!MM=VPCD] CK
M= 3RJ(HPEMTLIT%>?*&FR17U= [<._BFK'4<_5T#SP6*I-=P?7%2]"&^9L=\
MUHSI_O6?!+ /S*26+4O"Z23W*"7$[H6I&G8K9E=F=E/ I7S"^</&[/6F=[^P
M9?@0V%^G?5QWX2\D->:88X/FW8G=/$)4Z(.ES!4FQ#M^1$5_=^\;E]T0#4M2
M.4&CR<MXYD/WPELZG$&_AC"'1B?PE:6RJJ+NNE.TDN@B:JO7"XXL]*![>#@1
M*X0CNR$SHRHP>? =T<X*:/-)U1[6VFZ,-!-C-J093+>.(2']-_;>,KBM=MGS
ME1D2R^R8F1TS,X-DBID=,S-3S!2#S,S,S! G9F9F9F;'3NS)?M_9Y]:N>\Z>
M\^5^N#,C?5"M5:VUNKI4_72OY]\_J7@O6+#,K7DJ#B$P8>D1)):R+@^2/J^Z
M'JJ^I\SS??[!]S5QH06_?E4!RI2+E=PP3ZT>7Q_'B\5($7X]O% *WEG?D;A0
MG'L"*R><G<;MIUN-"2&WW5[\"<UHGHRJ>P8;P1N %E'6M*>P-;HGRH"R[-N,
M/TC;H00+N19X[T.Y]>E+":QK<%U7TXTAO5A+X$BH @ZBD@):9^B, Q)!4PN;
MEO2Q5.EE8N-.!R3-X.$[[7;1DH"4:G]"B%(W%L@?N7Q),^G.N6D-W2SI4,*1
M#&C,E&]%6%^$GI' WRW27$]\@<4])4-&\6M'%#96W,2>\OU!O=010_^W-2Q:
MGJAZZ#"G3H.*0" 6M P#')DG(9NL5RQ;TOA8'>. 3^ %I[R7[NP8(_'J_?')
MS30GYYX!(7VF3HE#\E>5H$MS3,1E59*V5'>^;K6A"#+K(F2)'L(-O(B5R*^?
MZ2>I"QN+FD$@6E=I*@^Q ,HJ*DWHYIZ9U@)G=Q"0DDQF+VL?HT0YA04KMI#4
M+ABZ<8O&4:>- E9 YVOQ3->H$W7E\EQ45@!2(HUR0QX[?:=@5F:2YTTU^>SE
M-^?/^MB67./Q:AILU_7ALJ,-H%0.NJ.U#?!C26,2'?@=T"G/FDY3&?B)!8R,
M'.C<69M;M"NN@6V'92?F"@)_4FK55L; F@;_0.:%,A2EW*+$2LS3HERT2]@O
MSJ)[KR]/>Z^*H3>;IF%78QKANSRG"[56G\9K!,56 ;SVI H9[9OVN*&?)8RH
M3%;@Y88?]?-)?-Y1=5 MHNW"Z,R#+3)WYA7=F!?!'(E&E.&$0 ,^6T#%*V.V
M#]P@JW9BN6O# ;+@152L>"_JU+WU*ALBB-1,]S,G&7: J\2VIZPQWK2LMQB.
MN?NKK&J&\MVB.9%X]DCK/JKO2%6G&.IS4\B[J4*_*GUVDGH./58_6<B,&^\E
M=!UX2/LQY6%X*'4DA<7O[X292*6) "/OQ#'+,Q>5@5GN=WI&<G+]!G@9->OA
M>1J<*\_S$9 ^E9?#LU7[E_6\U-[J]V^HUW'OWT]L22\%.\\ANC%. GY:I36L
ME14@2+HIZ[P:E@HI$J3^E#J0+A%FPA1'<P_$]@K S,REQDB$E3/R+]-!%C)*
M*!Y3\^VF0\AMK8>HW4KLZ<.HRNQO1DAG&74Z?5PI3VCQ#T1^)Q5)?CQ$N6XR
MQU9 <?TTTY6U2YG%;5!Q0"<C !H-52K_9I69<##F@RCD,B)PDG0Z4 DWJOS=
M91E.IXZ].<0MG]IE#4OU59ADMKB)]+@B5U.;W^RJ:JUZ>#BMP^ZL*H=#.,BC
M>SB#ODSGNTF-JGZ=ILQQ^I8)$7E\$09TVB_7GQ7>__/1CV/W+CN_LD"-%KXD
MSK"@-D<- 3X(GJ&\'&6SAEA-<N<C877@^:J@&C2GPW9',+KF26X98NE$ZV+I
M;DU8<AMN6548,)V##GB]RP4J;T=14CHM/IO56BT"!TE9E.Y+A#<L5F/)=U!;
MID[H\RIQG<>K&2<&%CDFI83:'>'RI(?8DS+466DN8J*7@O#F\O2(Z?(HDEVD
M2]P_9N#!&6G'03G21KE$5&(Z9'KWDO[/N^+>+':G!R%!A>,=H:7"S5JQ=(WW
M>W, YV,$>N0&2 8%XQ'*Q2@+C_&>:J+Q8<,R84,I\Z^P>9^O=W]YNNSJ0>AT
MF/0X3=;-8[(:#(;KI?5FCQ%LE^HL @VHE7I;JN<E*]2/$V%'F+959^3RY@YI
M/:_!JQ_&H(XI4,B(M=2TRL@303D<']NGPRL33/?1(]BZ22N5@2EVXWWIME'=
M"-4$#5K=A*V2%&6ZE<JMX]GU7D"XR /FD>G5\,=0H^N&F88X"P.&H<50J_+<
M&5#<F+(@Q(%.T,P9"Q(K,T"+G#:Y.[I)](H]_&^>Z-R<[[+ ^\_L$Q^NVR=V
M[E!=!:Q7#\6HCM# A",%%VFTIOO#H6%&&$[)3_-3O 'FZOS.A]X K1-O@/#%
M<$+K"\6?0HYGZ]Z+2DN;UBRL>7]R<D-0PGCP)?J,%._I+6_VA\\U_[I-Z/WZ
M0-<;;1T86+MIXUHNSU3_?&_7\5V;.J0F?_&:ES&&?NW;(R5'&B0>^^2]%O_H
M\@5S)D<,SC']>$??+$_E;H?-PMC#L=67[I .=/L;M-PBW8Q%3PME\3CE+E;#
MQO@BQ38&U](A\++MEZ;.TN]<#^YG%Y!!VS4W%9-JEAW;3@O6XG/UA=$H)G6%
M7AR&K\KD^A>U,(KY;X"6%M'@,[?NYA1JQD'\;^L%;I%R TG/ M.-D0]- 1V?
M\KDJR5>'JQPC[9R=;4_.M>=XHBNW\K'3(Z;2)3M[1L0XZOKZZ3X"HI1/J!2]
MRFI>6" ?:TZOI[/JQ1+;XG=6-BW3JFKGOA2N2"12,TWH+%O :E:V\0#95LGB
MFT<RQ</%ZU5-@G%)D'M8"S4?Q':;O 5=,NJ9=$U&SM"7>*B6^<672VR8,>/P
M]Y=)ZK'"&;EYG[@94JQY=O;8IKZQP8_;1&@V2K8.)R7$WA4=/4^(CN.8D82S
M/$BA/%GV%]LE<8V<PZ_9A:W"&=N>=R?)+@]X/8M]ZC:1>F<BW6C1WF-;T@RQ
MX*AP8+"T%[=[+]%F[\A%V46P/ J\Z?M=V5ID1X99;>':R!..3%8&U8:2G!S2
M>'NL(U@#E+8F?UY_ UCE-S6BF3U895C''IH#1V,: ^HWBL_#S5]M.VS,!A C
MSQ$>XCE$3XTN")BI#C.D+H9LK"2[W64C6)A$G("K@\/>A&,AD";G<[@ND7Z-
M$D*QXIENV:V)UA8N5P:%1?RN//(X0^84$#..BS318$ARAA=,+7.P937NP*#<
M#<NNGH;S1B\&5]:#CMJ 4[R:U=*J<I8!-:5ZA*Z9W"!^;.V<6Z;*9"7/;>'
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M4=&!1>B5$S&" QV0%_(Q$O=V/27>W\X5TEF+6XBMN<[;<<S*Z%2W=YH[%F>
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MP$=4&&//^%T;6Z0)U:66#(_GY>K&A>==Z_ZD[,(4D0R>*HZU@_)E5ASI^:K
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M_J5UQ<'C(237M60KY9[*AKKT["AK2E0D =?M'YFW68Y/W?W BR YNTRH;%)
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MS== 2E9!)U'#0N/\WC7<U757 C!-M0*J;X#M>^)\X1'L224 ,'N^@DB@A^(
MU< +\//7#@":[."Q[C^NX3NK:$M2S@[PYCB_R'QM'YR,>FCNXO.[>O9L]Z/5
MT..[?P.TWV=WO0$^WWX+/)W]3>3E,KC7//D+;7)4X7CR]/-VA+>EH)+G9(/"
MQM6 H&L,I'IA5[=8^,9G->N6K7./?<K"G!9]*D^E(NN3C:G,NPC0>WH)OA^Q
M&=V)JHJ=OO[TF#4>)/$OPI,6YOO%OTM55J5/H@8$T]U>5#*?3P:<M]$;( ^H
M@14M.!V8&_;RJ)]6, 3\W3;$NGD;R=<+SL'5L=1860V>^0U7(N!=@PMBON9Q
M41;RU*]COE?E=A45?ZXLX*&M)3!X-^NE^ :H\@@#WIO4J'TH9Z5_ QR7V'/
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M3CHZ)YK^N8-8%*WRIS0R> -HQ+P!-G38I4EPGY,TF</"?UN6!?T3C_3/C<:
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M-!R#Q5, N+=;#"_0EQ(PV[&SA;1W45%P<G!T=*UJ3X/;/2BM^*+]J"]PMRC
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MIZ)/H^?7#T!_9>(+(6_0K4#2_OMJS?O+\-[GB1_5++\7?XS*V7*4R3U4?_\
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ML*Z3E\ZY/2I\!U6I30\V]F4TNXUP-UKP'_-!F?,*\:/RWM?_%Z+N2U9+R?T
MMS?0D'.T4G[Y,8R?8T6':(U/]CQ+$X89$WX>R6/@" )D^+2RA[B'\_\B>Z+*
M:GB);_[M_/A@Y+/*U.+]=$H4^0\:H/]1!NL_:(IX?)+U?$PXWO+Q_[;Y_DY'
MU(RV8$96AP"Y!H)'R&G!-)(',.:48H&'//6$@ 5FSJ""H8*= #C7C]7YSJ*/
MH/XFX81P8Y2ZF_J)?0\= @T_FPQ3_AT2\XH?7W %5C<<4:M7I,/(E:>7')D6
M\,2DL@U;IZK**'@$\3Q?K+K.ST\<85_^/5GEOTT@T*TT;8AW,"]2T\:0Y=IX
M!3,6P6+5 .A&^5I*87J2R" ++Q.V[1G%FJ$@^XH#73>OEW XIG;?&].[3OGX
M^1TG6>>D.U+_Q6V W]FZL&\*D40KZ,#>Y" X1K,M)"2)-8T1BBFD$.9&[?K+
MYM"-(O>52@^:EN]TUT+Y\"]N@[^W5N( =8(&M08QR J8+3"14WND'7"X$P:)
MO2 %8%%V$)LCE33QFVT6R/)6,-/S=#OG8TF59#J]0!LT@@"!#5^FIUOYC'?>
M^\[_VDZAE>D_=K(OP/ZQTP%X4<NL[Z<%YO7Y9>4$TPO.D$0:> V$1H-M>KOF
M\.DZD@5%,?Z5X?'"2N^Z'#P\HOC!B8SEXO!/YB#1WX 5,??NE<GM4K YBY?D
MOK*\]3)X?GS16IG,3SAJ0]8[2//Y&ZG^5SV$O;@D*)CT#'\]89]\BH-3UJ/M
MNH?%,U! *;>ZO]I*_YY-L>5XV4$YC?L 1+3^+4 I_1-6$NLH(4\-'5KVO_'Z
MAX)3R;@(N).(5O9TGK?[<#J)UC+Z G/T.=+HFSVK?<K]."(JP_[&;5"Q\:A+
MPFLDLE_N<J++S"><\ZR0CA4EJ!S2:@=;XC0@FE,JS6]/DI*G^]@Y#\F8%^.,
M>PTQI^Z;QSK)R_G>./PP#O9;Y--QX<BF1.<-?,;7[J5WUG]>&[KANXQ10KB\
M_P!$\M7U_) ??#:W[XCVW,/L>WGS <E9U1 G,/U(T[8EW_P-Q?@7\>[3W-H7
MF'U$O:)D_)''+B&9_SO=_U;3L?VR)!L2+<,->)@:"PT3DUG15R_)%,1 +8/U
M23%*R#/T_3T 3WX);1P7GX'HYOM<CHXBL)0]C+=OHH+Y'S*!8>S*&1F.RXH2
M(YV&8BD\"H:L=D[2I2-7L"(ED*B7. 4O<2$O/61_09J6\H&1M/-@ONX?@(%Y
MV_.HP9N[[N*O#_5XDUG+9WI?OST[?  L,8N;>#Z-S[YG=*\.TOQK3*VTIU&M
M5^?7X_&W"L5_/[KRX-:EV+)HI:#CM)@VQ%]VK=6I[B14^C/CYSCO?602Q90^
M*.H03$B)7^"<A3:\B<W#9; "<36UV@-0\.&#6>S*2FCH_KYI/2*AD(.,8#V=
M,ZA_SF"(,&/+:F2^2R1[[]KE0$%P#[V2$ !,]-=#-")?XL,?:(-T"F?8HI/&
M4SP,,"2/,H W)0#*,Z)2J SXGY<"*BI1#AE.,=X&T&*QCH& DIZWW.6[S.22
M['A^WGQ9BF1L!JUN@6 9 61I6!$U00\E=<CO6NFGBHU2< X%<_=Y)9>8J@4Q
M'6Z9* 4(5RB3 P'ABAC\"S'1@0$(]T"//T/GSLYST&#(6=B1!@UL$)[6LL$9
MP!B5Y:$\'J'T)?^<MTA;D /(E!?1VLK&IKBX0_9341E.JEO_MJBR-HCW.6CD
M?JGIT">T3K M[0ZPF4XC*IBB82&/B*487,A./7T.,?M,OO#Z:(I-;[7+7;K)
M=_OOBS1R5BY?DPO?N'P:PY36",/WCWV >N>&"0_#AK\]].:27]0+^?X_#M8Z
MMU+%X#46 8[C%'N-!--D55 R(1^3$12!<0C1A!E0^[YLD^'"",H)LE:WAX3Z
MT! 1.BN@X_*X/$,J<5LCYOE=D/,J84%4DJR,&0I[SPS&TY"G,J)7B9? 922S
M^>2_C[PWA@R=ICEFN 9E[ZCJ,?QW[?N4IWPAI?@_6^;EU2$486]<4*K46<V*
M]MD(69,3P&=X1=3+,R%_)O.7."EQAG=LD2WW4RGCY)AZ.BXG?-3A1O)P?./F
MKU?#_V=!L(JE'1;37C6"C#,:;6"][;5DL&QNHK*$Q+A?[S_4C787,AZ3'"*!
M4R-7%IV44GR*ALFJ%'K#&Y953R=,:Y<+<C9L HJI;N.4C7Z:<[25CPPS=O\T
M <()&+Z(2C<I="8Y+V=-T!&=^X2,+@,$M_ME/!8)ERB5]**0GRM;.+RI;ETT
M7D59]%L"*S"'9C 7[!LI28FQ7Z7UZCG'M[V#RB1+K_'*T3M)^Q#LIPOI5%(T
M\G8&.5+<A,JEA%\F1-YFUO!ZGV?GT85E746Y,*EQ61+VB=T&&''R/P#3@VA@
M*'W@$-,BDT16W?*2)/[(L+Q"1P+14/8]_F"0J.)">/X"A!) MG(LUO\"1IUU
MQ1@:'_H\4%+F/QHXM(E>LL)N3D9FO5(;89C(CLY<*4W!&(J)N55A1*V4:LBN
MKFP5]<_VCM=(W-PPX7YS:94'_R0K*DVZ(A,_0 &/<DZ/5=Z\R>XIR+.*V#%@
M3S)1 :LK'VWTBBG2:]=:?EHQX.*&B#&.@? K_7'DQK-!5?Q.R&8A,%'=>; S
M?!W6VOK/ALC_.5JDU(N(]OON4!FM-%DIQ-H'0 R_:(9"AKSA$ER?%%=2FNVK
M4Q\E1X!72VC/D#RZ,M#?K;GG2>YN0OVQ_1I^RB4$,"5Q#R!^!V9O?P">$F\:
M/:L_O3N[_T3[&]CBL#=Z%V6&>"%68ZXWNC?ZS[LPM=ZO<EZ=?'\\&F[/S0_
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M$8POF,(YR3W7-HJZRX O9[EU0:EF'%"YW%X!EQO<,S8P$LJ$_W_"M.)$4)9
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MI?W[5,D& #)JZE/ON+M/F#,JPEX/1+<\\W+93:A(D(7BWV(JMJ6TF+(IJ*[
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M[A_VB-C4^V28BV#\SA,Y_) @-FOD2XE%& 3D'<07WT0M9P!A_1"6N5,$3-]
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M*BL"B;4N@')>%N2]JC6KIN.0X6/?9USW?MGD@J4Q&(S\[Q$1D)#CWCT;@9%
MKV>%I:#ZU%T2#=.>@8WY!'[&(%']&%@ZQ:S21[\&O54N][E@BN9?DWD!GIW1
M'[%UJ]1_)L6P%;:1=BSX8&93#_>7#C*:$>3Y^]M;*UY^CT=BB'.9%J\';[I\
M#^(NQ\L3>2Z!BU=BI+;G3M+M-J\E'\7%?UVXJ7X2V87K.HZ%&F5E-N#7G"Z_
M@.@,&6S8>SP9:I(;W2*[7J1**%N&BI[6"XV6C'IUIII?:4<\>'7<4+'D4XKM
M'<3%D0F.+C+DT*#Y!F!<(GG_IYQ]957'2G*1P97;"!F?ON!M]1M."ASHLHY\
MJU6_U-B.VUYQ3IO,4-G823:>(%.N3-FT#':6?,5BMZ:&%7:?YJN!4Z(4X].#
M $M2SX1O>3K<JX+8K<_R'ULFN(LK_<1JP(0QB E*/C0F_M]XNE"A*W=GS-\E
M5\+]3+N7L*LLAY[U4;KZS5'&>(IEDLZNZ?D//O(+2K;7@&>24LN'6KH8.Q2E
M-.C%F8ND!*.R@C8HBPH!_2C@%+H8E',T\;/[V-EZ2'$NJSMW['=/&@'A^\1?
M+MI+[W.<3Y\SEK^6D4R*O-]I:=E)V=7N&_.W8KCG4FZ(,0Y#FYQZ@2M/";J_
M?+/_.?MJ?[GR?QHA&F/VZ^T[!X]S<G_81-N9N=7O#.-WD\J,Y>Q?@ K7W#0=
ML!-SDJW :Y>OGK/7<89?72@$;OH?[VQW/Y]$[RJ,?,O,^)Z=NMIZ&M,Y-I!(
MB-DY**NE 4>GE9Q%BIR"(2"F%-$CS5(/<_N3_8MN['OP[NH]=Y,_9_T7ZZ'?
M\K9T,WZYE"GKG9T=S2;3SCG0*.ESRBA.9< I8VK)SU-"%A..9AOFM7'6L\^=
M1X3Q:83?*A)V[ O(JMX*DPX]F%/!'9QRKH^X,) )*GZ8F. 75P;^ ;#.[R*Y
M^86U0N7)F(Q3%YMW\&5)3QUOQ#&^O^-Q [$],@EJ7C@;9T:\3"3_AV9SO_^/
M=/?Z'S+BS4F_8N%DYSX/Y__'+'QO4A]C&Z\/3OKU3>;,P.<O4Q/?M?,-OE_P
M=,>UX<F7MU_\LCXKO+%*9[(3Z!&5\&0/2=M,7L9K$&MLN3%H>]=94._C;)'-
M/M1Y)N*%C#7]GMB&EM:,E1VO$I-+ :TAQO[0\SO6I\DS8,X.12!C[EO4,V!)
M8NE[\/Q.0N&2G56_&N3A5]T7JI,8X'%+W('<61S"%'<!XR*+J;OUE:.N6@W)
M&&MD95G+7D7MB3"__9I(BO/E"MXW70'Q$$&JG.,O[FMA/#*LM FY_647<JQ(
M(T8^- (.+1.YU-Y[7T;L2C/L]==QQITEVR_59M_O3B7M'T;-"()V:(,[<RI%
M9QN^5W\[;5T[V1C_V45]\F5XJ>YJI^BV)1[JUJ=X<MM(U H=UIR<4[;)B%:0
M#>]HOZX$L@T6]NQKK!"Q.]DU;6^U<Y7F?I6II$+ .B%(%@H%%U CP%"VERH8
M#XH 118D')&8)4&'J6[RV:X933:K=\H66<MW@YGBP(T\.>!KPMHN%UM &D.N
M^FH 41N7NAV;O'RQM*I]]TU\6H]Z7N5QO%574*NU%1'_]%+>[&M15*2^T73L
MYKS^M+2[<!N]#Q/*M8?O2Y>?D0**"&P5QR*=-P\Y_:L^ILAO=-;)S!]=CLI(
MC[0I(>(1CGY@960%5%1&J-U_,P5>1';&&YQMT6(!'4>,^/X L#EV-%DKDB!R
MO]Q<,;\YV_[71_=B[YQR-+;2R@3CI)"MVSS4RZHM(T0%[J:! <4R5TJ3ZX"S
M>-A1&6M JD1!!56GSK\.2-:LW_N_OMTOP:FJN_OW0WL5CK133/MOK!$ ARG
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M-3&(5VRZ];42*T%FLQITW&^5O,<:V9JKR?64= ;Q=(]#"8EP?$5R5H""6W\
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MH93[6WOMN_=:9XQ[_KEWWW7.&?N_+V-\F=_S/N^<SSOG_&9&8*T/@+-PJP=
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MS.W&+H>(K@U/[U+WU D?2.RYQ."X=Y-#)RO"?FF%BGE&.S"H9!LMBE  LN5
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M(3.E\U%ORABPA0WQLL"M1!3U!>1"]ZYP8.YQ4D-)Q6.L6B-BP7Y6>L!C>BD
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MLW,50:!C:$^J++X<2SH3)A")RXM^!\VA\&'2Y9B(-6^7YL@<-FP51D9"$PM
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M2I#.R$]0:HS^"T<MEAE69L*1>8WD3T.<KCCI/ XKCD[IL(;I5KZ I(QLO/I
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M7G?1N=J+%M;E1VQ=E@#Z#2<U&@<FF!PK)T8['@ \H "L/PUX4Z\(SL?C/,O
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MR71U32=H$QB7\4/0XU_9HX],?R:; FI<S5L-P0B117KE5L'-:52T&,E=7$X
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M@ EL8)0:D:*7C<+&P8W<$MV,>L^)^13$*DW'%+#-QM!PS(T&VRYE]J0N(D[
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MOYH!#?3FR<(5E#F]"?M^I(\)^\Q;8BE*?YK\-;D,+6K.'V+G(ZGBX>9\=J^
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MBJIJU\2^D#H)?QK4)T;')VD;0K,8;;]'WQ$$85S]9&-"8PU 8[2^>R-F5FM
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M4ZPNK]DSU-Q/0XY'FN(0J'#[\S-_N'\"]Y(':DV)2N8U]#F)Z?F% !G'-5@
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M=<OZMDOC&WL.7IO@KN$V)!Y0*I8/0]\C+@<6Z8S1L7! W0K1?W8@1'?>](T
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M52T$;9?:9T*^NE/5JAH:I< :!@$<OV:_P'4_8OVQ" M#R'T'Z!(C_^<'>ZA
M1G2TT$A8PW68GN;2D#-K- GH'3HA'(1%==V;.Y(X[*^X._YRKG9SP"@X ^5D
M-0I^7X.@Q>3L_;H9.LAI$I*9?1V1E>V3DQ=)(;SX?<.0J\J%B<Q#[J885V&(
MOSU Y*_.&XGWS!A#YNCN,Z_5TF'A,'X2F3($+ZZUT#V-<"CO* KA Y@8K3NG
M.9!7^G-B/DYT>-JGR[566BOQ.<[QO.;&8:H%GV2:GI3/(;A^\Q 5D9- V,ES
M.I^+\-OY1 :):9"ZK[_%%SMS2?4NSAF=G$Q5'6OCW"D>U#6W([P_8J"/DN?
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M Q*'V#L+>_.W2][^BR;[7\'D[T=UPMO3"^9PB*/.C!U'D.[+@\IBMWKK6TK
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MI$F //-4<;_@^(0K+F+Y%FLPWG%//>?4PU4-LN65L+;0?A OX@_J2;$V&P?
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M"ME;4WH=P>@R%IWJVZ'X=4(5>:$2#W%W@SW90G0B]K %  !C+$XB2)I.#,(
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MQ*]1 E]G#O@<S)8.E/C%5KG!:%.:@H(1^1EF@<GWC5@H.1=(Y+W&I,.%8+Q
MIC?"NXV-^*;.I?M;_G=Y=F0L-PF2BMREM&QA4MTP(R#X4=$P4WVR/#J&M7GL
M^&M,B5E.$EFH)LI)<+G.J"87KO-8BQ&!BBPH$_@\M',==QU-V'RY^WX,+T<+
MW[:U+!W& >"_0(ODU\ATZ2])DS*\+A";"Q*,>@?M)>(K!S3&ML?@KXI&(R,:
M@=!9&SP(1'4Y\5E=1CCD$J&-Q$R$2\T+M@.O$ICY>G:)^&+ ?=5K8HM;A9D
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M7V>6$EO/@"I\Z2XEGTZ=@/*L-%CU7_B^V_'[6.$SE&O<Y'C#%NIP*4G3J^.
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MT5V!-=W#Y,PZE=&>:U'J#C8XAJD$^XP?SAWRU+_O )E&A2D&MB24[%^9R%_
M*IH?&"4C<%1\-WO&__4@RMQA20197V7)!2N_XZ&W%K2&MX]>OB#-GOQK<C4T
M>0<),[K<C*)>UF-@)(4KA_EKRUG?HF(WA.[>M3*9_0H(6 ]J68&<R0G8IOH9
M!TSJ'BX\TC2L.Y,CT(,3R-GWQ^#9%"U=ET/'B7EFMP^<3HJ&\P/*/<BV,I1\
MEJ4[NH"#J2SF1^[63'K5'VS&-%Q N()8YN?!!P;;(+O?DMS]<HOG_-1\U9&@
M';&D 1[75EVIR#*LC0@+\+#OKH2Z]D<^,)HN=L3OA4!IN-<@YL:V1JI82>F=
MC4Q?-S L%$,#IGVW&M(2&,R)JN9N0*;B7(.2?1L@I6X)6G<;L @:TXM^%_9M
M7/1Q"/ 4<:>/69=6-IX!_($0_PD%!=D5Q;T/'0QJ#$]5":%0%@VJ]NUP;*4V
M?:YI>CB#GH9_#6**G0T;CH*W%1<ML*$^]B@$#/9@_'\?JP._^#+1^\D$>J&H
M9AC?*!AQJ:[EI\)"*DV-8H/C;1 4EPX_,>CW<1\O(1-[/ETO1$N#@TY#$@=V
MS<;-0[W0,-&$*UF+0TH\"'TIS@/7#A-%,^.4,-;'?(8C'I\Q"LS#G,BAP]I2
MKJ"\46$HJ"NID J-),D_=28')8EO<G)0:L*55,NTN8M47R[&PPS0$K/!3B_[
MW#_'V//=?T<R5U(R%2I(BJK5\7<EB6_2WY6:,,[]//1YBO^OB(4R\+\A=*NX
M]?^Z4LKY)S"5B=HW6^2XBN(4I[+@S99DTAQ]%[$WI' !5G/-P8$\."Y%PDDT
MRXOI2AYE5JC]R5)9*[R$HQM3=-(N:DOM2H&FK'C;Q($2EI#N=%1@IP5K-NO3
M:,K>MS7C)#+%M&9.S4D,:TGL3,JGJ8 &%0C*DG+2*JJ+ZTQBJ5XQ?-Z*US[)
M.J>/?R?T"]>7R1WF.F0=-Y4ZHCM3]<K!%P34-O1*[Q&P;]=N=[FRH%#L2@M$
ML-^=$QJB^+TP)G6PRQ,[0C,HKP1G4FC[\P5 5(@FK'P$/3+%2&HM76>)?^8Z
M#%?# ."0RRRVSV1M^/QSU+JTC]"4:NO$F9S@K-/(?7+QME!_J-]4*M/Y"&VC
M6&AG$I"SHGS"/(H.A)GS/SBC>+W+'M<CEZ7)2YB#&;FC-Q S-3B3 9VY>S0$
MR(^WQ+?93)H:<MI>1V@ .=(6)T?;4F0A\R:"[A*@0.R)<GTP$,"=-Q/D8E^.
MT!&:0SD%%"=FE[,0S2;E/0SC-Q6LWSHB7SI2E TO]^>,NAX-CN8B%V=NMP^1
M,FKVLFL+9IP44\47,6RJMLJM8^?9+EP^/VE:T\6&.N%%-5-UO#>;3*F9M\;@
M><3C[5#,I3SBYO*I=D"ETRJ;VJM@/<_-9BEJ%/L0/?*@!4%1K?D#!3GY!*J6
MEJM5Q7*SZ7T:K8X@FC]&E,D\?9&W)'>>M*K5-K=<OUJ^FTVXTRI9>$S,GGCU
MDNKUB'J-F_2U7OTF0EA9VW!M*IO09/V%/7%)PM&[U3T((YH?F^RUK5_[9(8P
M!_1W%,YF)/!YH,J?$?WXRI(_X&!X8D#YY@W@"7ATEEZ!T*%+>ZH5GZV*4EZJ
M%XE3$K[DV_JZOB^S%6J@5H*..Z"5$,HX!'K1RWCI]9\Z;7DSK:E_MF>2:[H6
MA07B%#)_<%_)5[HZI\&=2VL/,T+#$-)Y#RY$@6)V'0#&T 1!O\O*&%HY0HYA
M6DXX*^=!78K\=O)+3Y2ZUO;,A94N4!1<D+!)I",K7%,$5W,U;)H-$1.'%P=$
M]X55>36-'5%]G@CV3VGK^P"[\UDJ^UC9WM(9K>%RW!:+-B;RUX=HL0@0I-5%
MW2=DD^-I "U7DWQ?1%?BS*[GT0@$V<!).YL:]G,2WUR)K)QG=\N:;J;8S:T=
M>R;1ZJ5J30K4'GK!_$W4F3<2K^&2\];-E]]2\>6*@-<LPGS@2?4C7-T!#*;R
M-&[(G^4$8QCT$/,"PB*:#F3)7.S62A;N^!-G3'J(0H\;X^:EO7=P_BA?IJ6A
M:LWTK.8O+6&N19MTM\%[B_G<["B5\NA:= _LY>;0[[MZ+;E=F?*+A1P2QI4L
MY!--&K(8'=&C-A>=T*[4&C-QB)T[#[4GECUZ1VTA"GF-DY%>,HX8P7F$DZ39
MP:0;^4@$!IO@0?VS/0'!FJ,TG_D; LH.-OBDBC,>C\JO'R!=(J^HZHL1@4,7
MR\X!3+'98222\1/Z)1TKSM0:@^?DZ;!QJ=T?['&F#6=)?D?\-B)16V^;5Y]K
M@68$FL@/7A>)&U)$Z-\@H*)0B+Q^<4_"[5W.>_(D_H@6RKM+ZVS<*L0.7U+/
M&*K=Y.,JXKY4WO>:MPU+?(DZ1G,N5P_QG_AJW=MATP#7,L2. -<RXKY(VGF*
MM^V]R3%)U?AY!P(@N.NR[@BR*. MXZL[?2PJH$=\I)5(FP>A*C5S5P%-#'($
M=M"$&FK%K!W!GHB!?_D_4$L#!!0    ( ),Y1U.Q&+++\$@  ).]!  5
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MBF3&TL V,:'.4LMIE;GS5AL"+E?^>B:7N<+8H!MU,IJV//!8'30%8S3GC/7
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M24#\?JI2=$9EH-'I&?)2-!+28YT5ZHQ '0VEPZGF073,48'W* /K&DR8AKS
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M#TA=5']W@>EF] SCU,W0<0;US]%.Z5NE13U!N]'3# E6T#^2)ZGK"[A]+.@
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M9'2Q\H"C,L]P<E.6!UQHL:ZLXQ3L:LT5:&$5+GYC-5!;!=5U?.%]01/<0MZ
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MV!5JE2 8/+Z@0L!BV'Q_*$G&3^)XDWW"FNF>HJPCC*HT/>_\MESGN7ZMBWK
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M%-+^H&P'!U=.6:]@O6V0+J@F>-O:/&CT'8+[R%M[/S&FO;UY"9!W",,K-"<
MMN.>KIJ/4V;8B-(>.:=!C89330CB@-=JC#2C9\*[A8KGT)IO2E -JN7J74*C
M]I*HH?;5MD$-U%3Q\.;@%!O">$P0AJ'!XX$. 01Z+'"V3FBC!0)Z!E 6ZWL7
M'<<%U)\J>H^F[]D #=S>-U5"BJ.W,&,Y]<='T.O4YU/."FB$_\CY<U+ PN;/
M&1':#-5R9NI]1CIN&N>* B!]AX&%BVH]=M(\16O?4V:;J7)0K+PK\A=2LA0<
M'_+B>K=/\R/&[^ND(R">&@3X8*[))A67]UT]GA .-S7;'"R^J6)KUK5)?R^D
M 0%.22,0VD(Y9[;=DS'4]'3N#-O6Z,>'A;4[,\:2X#9I0*#2'4,[W:HY?=9R
MMZ9?T?.&S< &\)[-J58XVS902[0[-TL??<S>%:%M/8F<@.P^+42(*1M0H^#$
MXI'"VX:ZPAM,=4H>HZ_0U:FJBM/!6:GW>7>T!7DJP0 6?:,4]W<*.ZV=CRRP
M)X\)/Y;]0JIG=$MB]D!3MD6K;8'K]'H72#%U\COAT%-#G&GH>1'@C-Q^)A["
M#!P^\_9_/0.RM9.%B'TM7H"3[-"0/WZ?!RS#$SMLMT7Z? EUQV>\=<9-'W>C
MYW@C;G,Z1):X>*'C)4IQ].+Y<H0EC70NXA5L8+%T&=41M&-U7M2I"Q#T%+C
M"P2P!074U"_(Y=TN8EG>YT% =NSK(9#J/J!M]_Q$ W?GKX4 )X9SVO0ZWM"
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MD EAH?()[YYPH<7]L*"'14NGHRHH8,<+> X)&*NECQGXL-=5\_!AEX=U7@+
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M>[K@[9NLK(K#Z*QZ1CG>.&6V4$^O4VP).0D(CFKV5GZ0V14.\8# U',0B,J
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M%$1@H:0G- &%\[,SKZ+4/(HLHWT8,9#J$<4$G7F&E%6Y2EY8!DK B-(KZV%
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M.C?,+<LLD"A2S0*&,Z6$H[+IJ%E_=Y!*2QE\9B_"1Q(WLUV:$XGU!M7U42T
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MM/=.C4@87RZ-!P/X#=))<.@&B9I_?:E?T/Q5_T->(?W'_P%02P,$%     @
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M5C^<9-HSV1V@Z3J<)PD(&2P!DJ5L@X3UP/Y@F_O"#XTD6&G,AO,>)7Y EBK
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M&;>MU\?C&Y<'NZP2SIO/KE.'V<798$!W('=P%1;MEK(NWNFA[)5U*/BL/#L
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MV\$[/JB;?@T0 2]=MMV4 2&K7!^)X9O7U#NH6Z$(@8!O+IMGMJ'<SGP:EL%
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M=:6$@])6W4'W LGT[3_YAHH>AV*)\RLTUNH0.G8\\*ZJ^N>$\BC>*;I3P.3
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M0"3T6 D;BWL'DK4D6L=T/U5N5PERB7XSU]7KMF>/FQ;;XBHFI>-(>1%S.H#
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MQ9.*U7/:^.8N&@6 NW55R1FA?&^7P^K&"KF#0:,IQ3Y5+EWTZ*]I8[X^)&,
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M?BZ^JY;3Z*5"HT&2^-'R*6"3)Z05!V3T<,UDKOK6FB;&CJPF4%W)O^?,&++
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M;SY-V!8_G(#V.UG>P0NZ69-$U:\ ,]Q*CFTFAGJP!3+8>8_ RO!C4K6CV=A
M>+?>);-C09.!%4A9Y]T#!L\OFHP(1'8^/- *1($<==[>O_ULNRUIDHP+!.^0
M8;86J$"R.F_D+[9O<AVGMCU(.V,"H9VWW5H"*0CUW).U'U&:FE2\;38V$+XK
M1EE5L (IZ[9#@%UQC)XT,AP42'U( 6&-4 H$JO.F?>,\;O-Q@> =,N#7 A5(
M5N=M]OD+?"M+H/6(BOKAO8NS#EGU5?$*Q*VYF7_?56X6))J3_ %<W)S-U4O
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M4+__2N=]J!< U4);S08$&CEA7-MBFJ&J+X'8#?V>)1[2: ICLT>1*&#(O^&
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M!C.ENI6MOB$Q!))W\*9-([*H[#[FXP+!D>(HK$F+52&L4D4@AGNRD KN(4_
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MDO%OTWCQ.?<_)P7OE__X5'"Y]^FDEW.Y_+%W_<!AY_J7)4+T.TPM S8YQP.
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MBO9K"::?(>3UH:5]]Z)>UPQ4YGD53<=#R"_0(X6DU-]DV?;$.QY"?H&>EV7
MF^7$_ZHAY'U7(Z3$IY\NO(Z&D.O%87)"#2]<*8Y4PS_1.2B U%:,]GYOG=<L
M$3_*BB)@UW[*@K;8'ZR6],(/V9UA=1'E_]J=&RA_?DK73GE78/BI&XN13; 6
M"$P7O3:="D%%"VZ-P=*=<D&2E]BI3?7Y-4XR6/JS&Y*;M=*\/#.=4!(,TBVB
M2?FM,Q#0%/UIO"9RH8_5TMW4/?GAD]%@BP,ZH=NHFNX5(E2V[JBXU41&B1^P
M]Y?R"IU/9$P )(NB71_+U2-<U-J=4UHT0Z5SNJXS,/[2C15:53R_T,B/QA0N
MBP6/!&9E]<[>,7X1<C56"!U 2@@[:E.^]I/D@]5=S^,\!N/Q?,8B.4@ !UM"
MQD5R6#5\'LA\-WOS:9(_#,->L8S3=&N4VF=.6OHH< H](U--FL1G2)N4Z:A]
M?!.N@G&<UP$HA&YH;9?[:C)7I0:Z9;TE?\HNE50\*J)>0"OTLCQB'@I=*G(X
MZ(;[EBR(ZS6U7C@*S)?T WHY8.+097\M(!>] _QLSM'RY?.UYB=_6D=S&*"'
M [8*-0:;XT-U&8B\0:5QY3](&,A9NML24#E@3=#@F@A"1PNP2/1DF:-/;P"@
M(+J'MMF%0!UE1ZNQE":E_(I?N=K+]7M^'Z 3>CD^=7X*U749.$MU5-RS,N>F
MG1*ZJA@(^@"ET&.@FHN!%%Q7WTK:,/1I2D--7^_DR&7;D:)4*(&T5O/$9AI5
MJ?X\^C1XB*-RZC7JWF;C(F/UW.4#7\I%%61=?3Y)9,$W\L"4Y$)W2UA>SER$
MUJJ6N.E9' 0!+;#=19,XF>5?_JLX$ LF6TDM6>\J Z#IHGC:N'9O7;4MIX)N
M!E$GF7QKY0"SY=_#74<Y88HMAN^4SQNXLX!8U8G\N>?*#OE8)M<I+2*5 ;R3
M7M^-8ZZJEA7\4+[ %,T!"OH55IWD*G>7*J[V8NSVG3^Y*C"W6H5K;:Y 7&GC
MSG+<#%'>?)97:3FJ#."=G#D8&+,]6[W(&&YO[P2KS*()0U0LD!*878V/87&=
M)-V%OO-*=7W4B]900%6G;K(2U@LME0: .QJB4DL!!1^TXAA 1WQ_M 'G15*D
M!;NC$2OYVY1CHI+XN]G4.\$J4F;(0)$4\&"AQJ@(;MK%*Z+,YSM-")%&ETC;
MEQ=3=!=V ^8IXK,4:!*ZLUJ[%5-[@O_*25,]I%72=#37UDY0[0G^.R?M<E]-
MYJK4Z&@\C^V@VA-\:[.8AR*NU\#I:(B.:$U%0759Z479U@X$%$57CO0%1!\A
MZLM(.*:W>^WX/^$(0$.GW, &VHL&SJZ&_=1>0IK938!XZ$X5#2X;&TH*G*V]
M>(3O8]E\TF[#_/37<[*LJ@ [#->*DZ6/;NY49T@#)TO?7A$2U_9W1"<+5MEB
M;=;;<K)(RA0?NACMU<F"546N&><;.UG$U>5P'TI[]-_]D*;T1=< 7]O1.[E
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M^5NRA+V:N\TXN<=488 ",GXJB3:'A%Y3+= =/>4?XFC<5'H4QRAIZ=35KY$
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M6'2_HPE[U+>*';"6(N]:YNS:3*;)W'7'$C*Z\[!=_O+PHL:JZ?%9D[LE1O3
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M?>@U/;RS4_18UEVJ<ZYX=1!08R5$SS5/)F2<,1/X[MR'T6,23VAV'Z?I%9F
M&C3RWVM><S8;#NB#;O538G$C?*BQ$T;\+RJ%-&%Y=02@ KH*98'+NY!08RL$
MC%T_":.Z XM[ $IT!4B)<7404",H:E8@;^X-=F#-X;RS,_2()ZVU:80/-43#
MB/\Z.W#]"+ *W-!SFW%Y%U)'T_\:9@^<HB]I"]=6/JRN9O]92!\X18^;X+-,
MA<%5#%V-A;"0/X#_.*J(:4+7E0"%.X$1+0>4GZ#;,(SW8CX86U$.AQU1?H*4
MJ\7GR2;?ZF=N*WS [9#R4R<+UISL9.#LSAK?J;^'BC6]H\O>V1&2JFK,HXV9
MVW*$NZ:J[#WF]P3=#&SAQJ*)5R \N%:IPPT6/'4^97Z+_QSS1SM4$0C:P6<H
M.1@B=HJ>PM](".T102!SS2US#@6(_0[HV:E030JZ\D/H )K$P82'77VP._UF
M,I25D#'9P-[9V8&$D?%0- \M$XX*A$'WE39GK*F&5$.6CH:E-;3VXZ=3-F2K
MN@= G&)Y\/%K%AP Y^@:,)]C.@Z <Z&^>O#U@RS6ENFC+WD1[T2\EB'I:"TA
MNP44SMROGM!LFQ= =J;P4'N;0=.:"F=GZ%%:<AZJ; H[@- +%[54YC>,@3W1
MM(I=@??B;K"'HH=[2!DIXGX=)/2R1XXDH9RAAVZUM/%O8>QH'27#Q)1S]$6]
MQ1XI%S>FW=&@O#\(G;YF)!@L2.)/539M;@_8W- UN5V>B;@K@=#54+SKT$]3
MILUP4RWK-N[:WK":G'<2&&[HBM@[&^ G@Z\2\5??'PB('D^FR&4C(:FBQ T1
M%+T@S4IQ9%=^].<@"NZB__"C0!ZD+^P ^R[Z/J#,"XZON@88;IB@@'O/KW&2
MC4@RNR%O<4HEJU+6' "ZO0AK.">%A1\:Z(Z?[]Y*F)-T9&"2\Z%/AMJ !;K@
MQD$*<]S7\Q7M'-4VL*X.DL5;O.!L)+LHNQH0R0X[N>X&#8 $!^F[ES*:!Q$W
M<K$]+N<'8U8Y&/-3EDXHW']3G8IT.@,!2='-]RU*C3XINAJNV.A-Q_.#- (K
MR@@7K;4(PCCS0T<C")\(RS=@(91QE(=/S?WPFY_-D[RP+)?.E<*S;L88EO/_
M& #;/E*:?HF3AQBHE\ JS^B"\-YUU(XW;/(1[ZQ_ZL:.T!217ARB\1> 8$Z=
M4,V9KW)E:4BNCL8JKJA29P>O-O3.+M"]6199*Y*>7<@=C54<3*<)F;*$@!&=
MD2L_"E3,V\)>0%5T>]HN[T1<KH'1T>#%ASB[!\S)Z-6/AA'Y)_$3!98+>P&)
MT9V@-8P4\;\&4T>#&;<A#Z*@2HC1CYC]5&4;T!J)I=J>G^!7(3.4%4.L'8UY
MW,&]18XO</1J2Y':6+ VT4.FF\J0#M*.!D_N>KVJ*KY^:,96;V"$4Y;ZEO14
M13IT-/Z2!UHE %?8#:B%;IQ39&FM 4X KJ.AF4W7FKY_N-%7@!=.^9=:VIXL
MTPLU&E7@0AXE?D >_0]&C/1[% #B>!Z!9L <(E_"^ =/HA1[@@* ?INVS$*.
MZUF5#KA!J@+V#\;C9$X"(P%0Z0O0#UZ/J1<!=4K@!IR*(@GCB&6_ #'A;RF%
M*>5,TA(&G3& % =_>M0+A3Y%W*E$:=MB5T-,54EK.B20&=U^TZK@V2&0M8!9
M9'^W3Y/?_7!.OA&?T9OYK%?^[L*_/XB"C7M&WBX8)B632##(5J.XZ>/F@5RA
MTZZ=HS"8=W;I8KT<R<PU:^34C00$<&H346>:RC5'$7Y7?<IKT/5NY<VVWOD1
MNA_)@)%"#S(/7>>=R!746F[DG7Y 7/24&BX+ZWW) BP=]297#G@5CF^W!J(Z
MY,T1L$[(<SZ:KOJ-R8*$:65C_ \*6F,R?JV/())W!:HY%5/4<.=7 =M1M_ @
M#,7H5;:'^OY >W2;J J'A7N&*L2.^GUS\">&\E'7&4B/KC4H,UBZ?]2"[*A+
M]QJ.X6F<;(;,EW>QVJ  >5^@NE.F](;'C!+:CGI[M_"6I%#90:0]@6;X[G\5
MMM8Z_\7H.EK11W5AZ?OYE48#VCKED6FXMQCB=])#*W C/<11\1 ,S[JKUA$.
MXH,Q9&YQ2MW=M@W7E@-V09*7V*DMI.+(D"NAZW9 $O0#PXH$2-"UYE1UR)GU
M+5[D/TCOHD+[YGFW=/U7HH A0'$%'?Z4>)?X#5E4^=E9KV=A4ZP*38&+!'?1
M)$YFA0"_Q/-,B2@BWU +7RGA(YD+ZUC"V5';@F_)=Q2ZL_4V<1OU>C JUD'<
M*I]574LK"EAR+SDD&&UXE@IRH9_;0BZ:>)A6F"QYF5P2@88.IIPT/70'@Q+W
MU!U-*U0_G4V:UGFVO9X?(]W64<X+58)8<DJYM'?LP1]5D _].%%E<A._U JJ
M)=^40Y+2KELJ)]P)_AFDPV-C]]0*K"47E7N6HC:=5 7UD"+A4(XG98I8<F8Y
MM.NTY<<J2(8>6*7,63-_U@JE)9^6NX(Q6, J9*L)5F'JA\1<4.0CE21%CZ%0
MY+NBV*ABMN6^,CVPVK;5RGR?+7VIW/V17K/<XW'6.OUL^=VT-SF!5*[4/WXJ
MD$C$:KJ5BQ$IPJ]U)G)D1ID@MOQP;R2A<?"<^4GFD$K]U:=1>A^SRA=/9!Q/
M(YHRLC\F\81FPX3]AN?!4ZB_VVCDDOQ(<6-[ED?K-'/RX9!'_P,H-IQ\ T*F
M61P)O9<[#4M@G7 UJ6U.$A+@/BZ"<2@AF?C</93$P2':-N/B4+J- K<"1 9!
M0 ML%6+_S&,N0A_.>W_Q/.;S'GHFBAG31,>^ ?R.YC'KONQ[WCNPU(*<>2(Y
MV,+5T:QEL]=\SWOH@=Y;[)%R<6/:'4U!OHJS+)X-)SE@!7YRVGOGQT@V*AF_
M1)P5 NAH,,@H?E/G[G9CH RZ/5N=M?S9=S1=&#MIY[R'+AD63VU#_*AYQH)[
M_,K>\.A_L*G?E)6V9.\TROK *D)WAAJRAW,[KT?:5G+P?F_D_R ?W_S(G^;D
M>82YQ%%$PC4=UX]O7<>S-Q*E^12^^0$9Q3<T(6,0-V:Y&++AB^TT'4X$HSIS
MJ7\B(8L2??23[&.4^(!JS&"I7>+K.H-XG+NQ]_/94&7DZKG!V]E;&'\0<D4B
M,J$UYOX&XWIH8:&Z#!0= 8W!=_0Z7T^7QSB%/9>1A#6Q)&G\08'2Z&FC;8N9
M#'E'S0DJ:P^X\^*G>:'C&3_SN-%X'EK@X#XW,"[HCIHVZNG14(8\!\($VQ89
M3Q(DJ&\;P:W)^T1F\ZA,S8<;PSR@3,FMOD++^;4[RNUR1M5Y*BFVLH[>.F+1
M07A?XB3_\3-)%G1<4UM 90 /+3Y*AQVBY:J.L*.Z*(\ VC+AH86AM"4#GB2J
M1%\WQ-ZD!0>:V^$$+5L>SH[=6(!50UQUIE<D^T%(5 &B_2ZWVG! "O0-7(U=
M*J9F'<P=W=*K>2Z;V+72P7:[ M70W9*FO!;)C@KBCIH(;J.,9A_IB)U.H/-L
MHE=P;2KT!_JA1Z*H<%@D'<H0.WKAUUIM^GY1]2&!RDXY1VUL/4THT='0BL&,
M>0Y9E#^A"T9!D6(@OZ*HC@*T1'>Q-)$"X8U&CP =C><HJ5 ^X]=$DFJ& "JB
M7W];%",E]);B-MRKKC"<9VGF1P&-IM?Q;$:S/*F!N?6'T15Y]</)<%*H"482
MUGQXH#]ZN9<VI,\693I:FEY,GJN/5N2Q;ECO_!R]I,Q^Y5"-(FT5O=^O$?$Q
MYT"!MV(N?(9/E?%BU73,99@3\WLEY)5$*5V0NPA&TWYW4:$,@6!N=15M-88
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MDP$)G(Z^J%&H+2309[VT)] ,/2'(3 048*&6&&E/%*[\E(Z71,L#L4K"2<5
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M_P%02P$"% ,4    " "3.4=3&,#SO'38 @"MV"H #P              @ $
M    9#$X-3 U-F0R,&8N:'1M4$L! A0#%     @ DSE'4P0D"7RR!P  TR@
M !$              ( !H=@" &0Q.#4P-39D97@Q,C$N:'1M4$L! A0#%
M  @ DSE'4_:(30W@!P  $BH  !$              ( !@N " &0Q.#4P-39D
M97@Q,C(N:'1M4$L! A0#%     @ DSE'4V2)C>H !@  _Q<  !$
M     ( !D>@" &0Q.#4P-39D97@Q,S$N:'1M4$L! A0#%     @ DSE'4[PY
MVDH= P  ^@<  !$              ( !P.X" &0Q.#4P-39D97@Q-3$N:'1M
M4$L! A0#%     @ DSE'4X+:#OZNB   :Q0& !$              ( !#/("
M &0Q.#4P-39D97@T,3@N:'1M4$L! A0#%     @ DSE'4VL-88%GPP  ITT$
M !$              ( !Z7H# &0Q.#4P-39D97@T,3DN:'1M4$L! A0#%
M  @ DSE'4_,KML9DCP  KY@# !$              ( !?SX$ &0Q.#4P-39D
M97@T,C N:'1M4$L! A0#%     @ DSE'4[BDM><3I ( D%X# !@
M     ( !$LX$ &<Q.#4P-39G,3@U,#4V9S0X;CDU+FIP9U!+ 0(4 Q0    (
M ),Y1U.0X;7.<!X  'AY 0 1              "  5MR!P!K>FEA+3(P,C$P
M-C,P+GAS9%!+ 0(4 Q0    ( ),Y1U.-9?].+0T  #>T   5
M  "  ?J0!P!K>FEA+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4    " "3.4=3
ML1BRR_!(  "3O00 %0              @ %:G@< :WII82TR,#(Q,#8S,%]D
M968N>&UL4$L! A0#%     @ DSE'4Y9[Z!COA   <RP( !4
M ( !?><' &MZ:6$M,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( ),Y1U/M
M7"-WO&<  (P<!P 5              "  9]L" !K>FEA+3(P,C$P-C,P7W!R
;92YX;6Q02P4&      X #@"' P  CM0(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
